[{"path":"index.html","id":"about","chapter":"About","heading":"About","text":"Information intended assist preparation Clinical Chemistry content ASCP BOC’s MLS, C, SC certification exams Content Guidelines MLS, C, SC certification examsYou recommend use information supplement “Reading List” cited ASCP BOC certificationMedical Laboratory Scientist, MLS(ASCP)Technologist Chemistry, C(ASCP)Specialist Chemistry, SC(ASCP)","code":""},{"path":"content-areas.html","id":"content-areas","chapter":"Content Areas","heading":"Content Areas","text":"Major content areas covered:","code":""},{"path":"content-areas.html","id":"general-chemistry","chapter":"Content Areas","heading":"General Chemistry","text":"CarbohydratesLipidsHeme Derivatives","code":""},{"path":"content-areas.html","id":"proteins-and-enzymes","chapter":"Content Areas","heading":"Proteins and Enzymes","text":"EnzymesProteins","code":""},{"path":"content-areas.html","id":"acid-base-blood-gases-and-electrolytes","chapter":"Content Areas","heading":"Acid-Base, Blood Gases, and Electrolytes","text":"Acid-BaseElectrolytes","code":""},{"path":"content-areas.html","id":"special-chemistry","chapter":"Content Areas","heading":"Special Chemistry","text":"EndocrinologyVitamins, NutritionTherapeutic Drug MonitoringToxicology","code":""},{"path":"content-areas.html","id":"last-updated","chapter":"Content Areas","heading":"Last Updated","text":"Last edit pushed site 2025-03-28","code":""},{"path":"author.html","id":"author","chapter":"Author","heading":"Author","text":"Author: Brett M. Rice, MLS(ASCP)SH,SCYMHe graduate Augusta University’s Clinical Laboratory Science program. worked Clinical Hematology bench Wellstar MCG Health’s Core Laboratory full time 2013-18. 2016, earned Specialist Hematology (ASCP). time, gained experience Bone Marrow Flow Cytometry bench successful Specialist Cytometry (ASCP) 2018Since September 2018, teaching full time Augusta University’s Clinical Laboratory Science (BS-CLS | MHS-CLS) program primary teaching focus Clinical Hematology. still practices Clinical Hematology, Bone Marrow, Flow Cytometry Laboratory one day week","code":""},{"path":"author.html","id":"disclaimer","chapter":"Author","heading":"Disclaimer","text":"AI used creation site. AI makes mistakes, double-check informationIf see mistakes omissions, please let know edits need made using “Edit page” feature displayed right column (desktop view). hoping time can build project reliable resource . Along line, considering project perpetual state “-progress”","code":""},{"path":"author.html","id":"license","chapter":"Author","heading":"License","text":"work licensed CC -NC-SA 4.0","code":""},{"path":"author.html","id":"contribute","chapter":"Author","heading":"Contribute","text":"author appreciates help maintain reference material. use resource, please consider using “Edit page” feature right side page (desktop view) suggest changes content. Another way can contribute keep author caffeinated!","code":""},{"path":"ascp-boc.html","id":"ascp-boc","chapter":"ASCP BOC","heading":"ASCP BOC","text":"ASCP BOC’s Content Guideline Technologist Chemistry, C(ASCP), Specialist Chemistry, SH(ASCP), certification exams consists five major content areas. information last revised ASCP’s website March 2022","code":""},{"path":"ascp-boc.html","id":"general-chemistry-1","chapter":"ASCP BOC","heading":"General Chemistry","text":"Exam Percentage: 15% - 25%Description: Biochemical theory physiology, test procedures, test result interpretation, disease state correlation carbohydrates, lipids, heme derivatives","code":""},{"path":"ascp-boc.html","id":"proteins-and-enzymes-1","chapter":"ASCP BOC","heading":"Proteins and Enzymes","text":"Exam Percentage: 15% - 25%Description: Biochemical theory physiology, test procedures, test result interpretation, disease state correlation enzymes, proteins nitrogen-containing compounds","code":""},{"path":"ascp-boc.html","id":"acid-base-blood-gases-and-electrolytes-1","chapter":"ASCP BOC","heading":"Acid-Base, Blood Gases, and Electrolytes","text":"Exam Percentage: 15% - 25%Description: Biochemical theory physiology, test procedures, test result interpretation, disease state correlation acid-base determinations, blood gases, electrolytes","code":""},{"path":"ascp-boc.html","id":"special-chemistry-1","chapter":"ASCP BOC","heading":"Special Chemistry","text":"Exam Percentage: 15% - 20%Description: Biochemical theory physiology, test procedures, test result interpretation, disease state correlation endocrinology, vitamins, therapeutic drug monitoring, toxicology","code":""},{"path":"ascp-boc.html","id":"laboratory-operations","chapter":"ASCP BOC","heading":"Laboratory Operations","text":"Exam Percentage: C(ASCP): 15% - 20% | SC(ASCP): 20% - 25%Description: Quality assessment/troubleshooting, compliance, regulations, safety, laboratory mathematics, instrumentation, laboratory administration (SC EXAM )","code":""},{"path":"reading-list.html","id":"reading-list","chapter":"Reading List","heading":"Reading List","text":"ASCP makes clear suggested reading/reference list Technologist Chemistry, C(ASCP), Specialist Chemistry, SH(ASCP), certification exams “intended partial reference source”. suggested reading/reference list last revised ASCP’s website January 2025","code":""},{"path":"reading-list.html","id":"journals","chapter":"Reading List","heading":"Journals","text":"Clinical Laboratory Science. Published American Society Clinical Laboratory ScienceClinical Chemistry. Published Oxford Universtiy PressLaboratory Medicine. Published Oxford University PressMedical Laboratory Observer. Published Endeavor Business Media, LLC","code":""},{"path":"reading-list.html","id":"texts","chapter":"Reading List","heading":"Texts","text":"Clarke, W. & Marzinke, M. (Eds.). (2020). Contemporary Practice Clinical Chemistry (4th ed.). Washington D.C.: AACC\nPressBishop, M.L., et al. (2022). Clinical Chemistry: Principles, Techniques, Correlations (9th ed.). Jones & Bartlett LearningRifai, N., et al. (2023). Tietz Fundamentals Clinical Chemistry Molecular Diagnostics (9th ed.). St. Louis, Missouri: ElsevierRifai, N., et al. (2022). Tietz Textbook Laboratory Medicine (7th ed.). Elsevier Health Sciences. reference appropriate Specialist (SC) level","code":""},{"path":"reading-list.html","id":"laboratory-safety","chapter":"Reading List","heading":"Laboratory Safety","text":"Davis, D.L. (2016). Laboratory Safety: Self-Assessment Workbook (2nd ed.). Chicago: ASCP Press","code":""},{"path":"reading-list.html","id":"laboratory-management","chapter":"Reading List","heading":"Laboratory Management","text":"texts appropriate SC LevelGarcia, L.S., et al. (Eds.). (2024). Clinical Laboratory Management (3rd ed.). Washington D.C.: ASM PressHarmening, D.M. (2020). Laboratory Management, Principles Processes (4th ed.). St. Petersburg, FL: D. H. Publishing & Consulting IncMcPherson, R.. & Pincus, M.R. (2021). Henry’s Clinical Diagnosis Management Laboratory Methods (24th ed.). Philadelphia: Elsevier","code":""},{"path":"reading-list.html","id":"online","chapter":"Reading List","heading":"Online","text":"Association Diagnostics & Laboratory Medicine (ADLM) (formerly AACC)Clinical Laboratory Standards Institute (CLSI)College American Pathologists (CAP)Medical Training Solutions (MTS)Joint Commission (TJC)Westgard QC","code":""},{"path":"carbohydrates.html","id":"carbohydrates","chapter":"Carbohydrates","heading":"Carbohydrates","text":"overview connects biochemical understanding carbohydrates clinical assessment laboratory","code":""},{"path":"carbohydrates.html","id":"biochemical-theory-and-physiology","chapter":"Carbohydrates","heading":"Biochemical Theory and Physiology","text":"Carbohydrates Fuel: Carbohydrates, primarily glucose, main energy sourceMetabolic Pathways\nGlycolysis: Glucose breakdown energy\nGluconeogenesis: Glucose synthesis non-carb sources\nGlycogenesis: Glucose storage glycogen\nGlycogenolysis: Glycogen breakdown release glucose\nPentose Phosphate Pathway: NADPH nucleotide precursor production\nGlycolysis: Glucose breakdown energyGluconeogenesis: Glucose synthesis non-carb sourcesGlycogenesis: Glucose storage glycogenGlycogenolysis: Glycogen breakdown release glucosePentose Phosphate Pathway: NADPH nucleotide precursor productionHormonal Control: Insulin (lowers glucose) glucagon (raises glucose) key regulatorsNormal State: Tight blood glucose control consistent energy, especially brainAbnormal States: Hyper/hypoglycemia, insulin resistance, genetic metabolic disorders","code":""},{"path":"carbohydrates.html","id":"laboratory-test-procedures","chapter":"Carbohydrates","heading":"Laboratory Test Procedures","text":"Glucose Measurement\nPrinciple: Enzymatic methods like glucose oxidase hexokinase\nSpecimen plasma, serum, whole blood\nPrinciple: Enzymatic methods like glucose oxidase hexokinaseSpecimen plasma, serum, whole bloodGlucose Tolerance Test (GTT)\nPrinciple: Assesses glucose clearance glucose load\nSerial glucose measurements timed intervals\nPrinciple: Assesses glucose clearance glucose loadSerial glucose measurements timed intervalsGlycated Hemoglobin (HbA1c)\nPrinciple: Measures average glucose 2-3 months\nImmunoassay HPLC methods\nWhole blood specimen\nPrinciple: Measures average glucose 2-3 monthsImmunoassay HPLC methodsWhole blood specimenUrine Glucose\nPrinciple: Detects glucose urine\nDipstick enzymatic methods\nPrinciple: Detects glucose urineDipstick enzymatic methodsKetone Measurement\nPrinciple: Detects ketones blood/urine, indicating fat breakdown\nImmunoassay enzymatic methods\nPrinciple: Detects ketones blood/urine, indicating fat breakdownImmunoassay enzymatic methodsSpecialized Testing: galactose, fructose, etc., using enzymatic chromatographic methods","code":""},{"path":"carbohydrates.html","id":"test-result-interpretation","chapter":"Carbohydrates","heading":"Test Result Interpretation","text":"Normoglycemia: Fasting 70-99 mg/dL, postprandial < 140 mg/dLDiabetes Diagnosis\nFasting glucose ≥ 126 mg/dL\n2-hour GTT glucose ≥ 200 mg/dL\nHbA1c ≥ 6.5%\nRandom glucose ≥ 200 mg/dL + symptoms\nFasting glucose ≥ 126 mg/dL2-hour GTT glucose ≥ 200 mg/dLHbA1c ≥ 6.5%Random glucose ≥ 200 mg/dL + symptomsPrediabetes\nImpaired fasting glucose: 100-125 mg/dL\nImpaired glucose tolerance: 2-hour GTT 140-199 mg/dL\nHbA1c 5.7-6.4%\nImpaired fasting glucose: 100-125 mg/dLImpaired glucose tolerance: 2-hour GTT 140-199 mg/dLHbA1c 5.7-6.4%Gestational Diabetes: Specific OGTT criteriaHypoglycemia: Glucose < 70 mg/dLKetones: Positive indicates fat breakdown, DKA","code":""},{"path":"carbohydrates.html","id":"disease-state-correlation","chapter":"Carbohydrates","heading":"Disease State Correlation","text":"Diabetes Mellitus: Hyperglycemia due insulin issuesPrediabetes: Increased risk type 2 diabetes cardiovascular diseaseGestational Diabetes: Diabetes pregnancy, risks mother/babyHypoglycemia: Low glucose, various causesDiabetic Ketoacidosis (DKA): Hyperglycemia, ketosis, acidosis (life-threatening)Hyperosmolar Hyperglycemic State (HHS): Extreme hyperglycemia, dehydrationGenetic Disorders: Galactosemia, hereditary fructose intolerance, etc","code":""},{"path":"carbohydrates.html","id":"putting-it-together","chapter":"Carbohydrates","heading":"Putting It Together","text":"Comprehensive Picture: Lab results + clinical context + patient historyClinical Significance: Guiding diagnosis, treatment, monitoring metabolic disordersContinual Learning: Staying updated new guidelines testing methods key","code":""},{"path":"biochemicals.html","id":"biochemicals","chapter":"Biochemicals","heading":"Biochemicals","text":"Carbohydrates body’s primary fuel source, metabolism vital process. ’s break , build, store sugars keep energy levels stable","code":""},{"path":"biochemicals.html","id":"key-metabolic-pathways","chapter":"Biochemicals","heading":"Key Metabolic Pathways:","text":"Core Concept: Carbohydrates body’s primary energy source, glucose central player. metabolism carefully orchestrated series pathways ensuring constant energy supply building blocks molecules\nGlycolysis: breakdown glucose pyruvate, yielding ATP NADH. Occurs cytoplasm. fate pyruvate depends oxygen availability (aerobic vs. anaerobic)\nGluconeogenesis: synthesis glucose non-carbohydrate precursors (lactate, glycerol, amino acids). Primarily occurs liver fasting. helps maintain blood glucose levels\nGlycogenesis: conversion glucose glycogen storage, primarily liver muscles. way store excess glucose\nGlycogenolysis: breakdown glycogen release glucose needed\nPentose Phosphate Pathway (PPP): Produces NADPH (reductive biosynthesis antioxidant defense) ribose-5-phosphate (nucleotide synthesis)\nCore Concept: Carbohydrates body’s primary energy source, glucose central player. metabolism carefully orchestrated series pathways ensuring constant energy supply building blocks moleculesGlycolysis: breakdown glucose pyruvate, yielding ATP NADH. Occurs cytoplasm. fate pyruvate depends oxygen availability (aerobic vs. anaerobic)Gluconeogenesis: synthesis glucose non-carbohydrate precursors (lactate, glycerol, amino acids). Primarily occurs liver fasting. helps maintain blood glucose levelsGlycogenesis: conversion glucose glycogen storage, primarily liver muscles. way store excess glucoseGlycogenolysis: breakdown glycogen release glucose neededPentose Phosphate Pathway (PPP): Produces NADPH (reductive biosynthesis antioxidant defense) ribose-5-phosphate (nucleotide synthesis)Regulation: pathways tightly regulated hormones (insulin, glucagon, epinephrine, cortisol) allosteric effectors (ATP, AMP, etc.) maintain glucose homeostasisRegulation: pathways tightly regulated hormones (insulin, glucagon, epinephrine, cortisol) allosteric effectors (ATP, AMP, etc.) maintain glucose homeostasis","code":""},{"path":"biochemicals.html","id":"normal-and-abnormal-states","chapter":"Biochemicals","heading":"Normal and Abnormal States","text":"Core Concept: Disruptions carbohydrate metabolism lead range diseases, notably diabetes mellitus\nNormal State: Normoglycemia\nFasting glucose: 70-99 mg/dL (3.9-5.5 mmol/L)\nPostprandial glucose: <140 mg/dL (7.8 mmol/L)\nMaintained hormonal balance efficient metabolic pathways\n\nAbnormal States:\nHyperglycemia: Elevated blood glucose\nCauses: Diabetes mellitus (Type 1, Type 2, gestational), endocrine disorders, medications, stress\nComplications: Acute (DKA, HHS) chronic (retinopathy, nephropathy, neuropathy, cardiovascular disease)\n\nHypoglycemia: Low blood glucose\nCauses: Excess insulin, liver disease, kidney disease, hormone deficiencies, alcohol consumption\nComplications: Neurological symptoms, seizures, coma, brain damage\n\nInsulin Resistance: Cells don’t respond properly insulin\nConsequences: Hyperinsulinemia, prediabetes, type 2 diabetes, metabolic syndrome\n\nGenetic Disorders:\nGlycogen Storage Diseases (GSDs): Enzyme deficiencies glycogen metabolism\nGalactosemia: Impaired galactose metabolism\nHereditary Fructose Intolerance: Impaired fructose metabolism\nPentosuria: Excess excretion pentoses urine\n\n\nCore Concept: Disruptions carbohydrate metabolism lead range diseases, notably diabetes mellitusNormal State: Normoglycemia\nFasting glucose: 70-99 mg/dL (3.9-5.5 mmol/L)\nPostprandial glucose: <140 mg/dL (7.8 mmol/L)\nMaintained hormonal balance efficient metabolic pathways\nNormal State: NormoglycemiaFasting glucose: 70-99 mg/dL (3.9-5.5 mmol/L)Postprandial glucose: <140 mg/dL (7.8 mmol/L)Maintained hormonal balance efficient metabolic pathwaysAbnormal States:\nHyperglycemia: Elevated blood glucose\nCauses: Diabetes mellitus (Type 1, Type 2, gestational), endocrine disorders, medications, stress\nComplications: Acute (DKA, HHS) chronic (retinopathy, nephropathy, neuropathy, cardiovascular disease)\n\nHypoglycemia: Low blood glucose\nCauses: Excess insulin, liver disease, kidney disease, hormone deficiencies, alcohol consumption\nComplications: Neurological symptoms, seizures, coma, brain damage\n\nInsulin Resistance: Cells don’t respond properly insulin\nConsequences: Hyperinsulinemia, prediabetes, type 2 diabetes, metabolic syndrome\n\nGenetic Disorders:\nGlycogen Storage Diseases (GSDs): Enzyme deficiencies glycogen metabolism\nGalactosemia: Impaired galactose metabolism\nHereditary Fructose Intolerance: Impaired fructose metabolism\nPentosuria: Excess excretion pentoses urine\n\nAbnormal States:Hyperglycemia: Elevated blood glucose\nCauses: Diabetes mellitus (Type 1, Type 2, gestational), endocrine disorders, medications, stress\nComplications: Acute (DKA, HHS) chronic (retinopathy, nephropathy, neuropathy, cardiovascular disease)\nCauses: Diabetes mellitus (Type 1, Type 2, gestational), endocrine disorders, medications, stressComplications: Acute (DKA, HHS) chronic (retinopathy, nephropathy, neuropathy, cardiovascular disease)Hypoglycemia: Low blood glucose\nCauses: Excess insulin, liver disease, kidney disease, hormone deficiencies, alcohol consumption\nComplications: Neurological symptoms, seizures, coma, brain damage\nCauses: Excess insulin, liver disease, kidney disease, hormone deficiencies, alcohol consumptionComplications: Neurological symptoms, seizures, coma, brain damageInsulin Resistance: Cells don’t respond properly insulin\nConsequences: Hyperinsulinemia, prediabetes, type 2 diabetes, metabolic syndrome\nConsequences: Hyperinsulinemia, prediabetes, type 2 diabetes, metabolic syndromeGenetic Disorders:\nGlycogen Storage Diseases (GSDs): Enzyme deficiencies glycogen metabolism\nGalactosemia: Impaired galactose metabolism\nHereditary Fructose Intolerance: Impaired fructose metabolism\nPentosuria: Excess excretion pentoses urine\nGlycogen Storage Diseases (GSDs): Enzyme deficiencies glycogen metabolismGalactosemia: Impaired galactose metabolismHereditary Fructose Intolerance: Impaired fructose metabolismPentosuria: Excess excretion pentoses urine","code":""},{"path":"biochemicals.html","id":"physical-and-chemical-properties","chapter":"Biochemicals","heading":"Physical and Chemical Properties","text":"Core Concept: structure carbohydrates dictates physical properties (solubility, taste) chemical reactivity (oxidation, hydrolysis)\nMonosaccharides:\nCrystalline solids, water-soluble, sweet\nCyclization (anomers), oxidation (reducing sugars), esterification, glycoside formation\nExamples: Glucose, fructose, galactose, ribose\n\nDisaccharides:\nCrystalline solids, water-soluble, sweet\nHydrolyzed enzymes acid\nCan reducing (lactose, maltose) non-reducing (sucrose)\n\nPolysaccharides:\nAmorphous fibrous, mostly insoluble, generally tasteless\nHydrolyzed enzymes acid\nVary structure (linear vs. branched) composition (homo- vs. heteropolysaccharides)\nExamples: Starch, glycogen, cellulose\n\nCore Concept: structure carbohydrates dictates physical properties (solubility, taste) chemical reactivity (oxidation, hydrolysis)Monosaccharides:\nCrystalline solids, water-soluble, sweet\nCyclization (anomers), oxidation (reducing sugars), esterification, glycoside formation\nExamples: Glucose, fructose, galactose, ribose\nCrystalline solids, water-soluble, sweetCyclization (anomers), oxidation (reducing sugars), esterification, glycoside formationExamples: Glucose, fructose, galactose, riboseDisaccharides:\nCrystalline solids, water-soluble, sweet\nHydrolyzed enzymes acid\nCan reducing (lactose, maltose) non-reducing (sucrose)\nCrystalline solids, water-soluble, sweetHydrolyzed enzymes acidCan reducing (lactose, maltose) non-reducing (sucrose)Polysaccharides:\nAmorphous fibrous, mostly insoluble, generally tasteless\nHydrolyzed enzymes acid\nVary structure (linear vs. branched) composition (homo- vs. heteropolysaccharides)\nExamples: Starch, glycogen, cellulose\nAmorphous fibrous, mostly insoluble, generally tastelessHydrolyzed enzymes acidVary structure (linear vs. branched) composition (homo- vs. heteropolysaccharides)Examples: Starch, glycogen, cellulose","code":""},{"path":"metabolic.html","id":"metabolic","chapter":"Metabolic","heading":"Metabolic","text":"","code":""},{"path":"metabolic.html","id":"carbohydrate-metabolic-pathways","chapter":"Metabolic","heading":"Carbohydrate Metabolic Pathways","text":"Glycolysis: Glucose breakdown pyruvate, yielding bit ATP NADHGluconeogenesis: Making glucose non-carb sources glucose lowGlycogenesis: Storing excess glucose glycogenGlycogenolysis: Breaking glycogen release glucose neededPentose Phosphate Pathway: Produces NADPH (building stuff) ribose-5-phosphate (DNA/RNA)","code":""},{"path":"metabolic.html","id":"glycolysis","chapter":"Metabolic","heading":"Glycolysis","text":"Purpose: central pathway break glucose pyruvate, generating ATP NADH processLocation: Cytoplasm cellsOverview:\nInvestment Phase (Energy Requiring):\nGlucose phosphorylated twice, consuming 2 ATP\nGlucose converted fructose-1,6-bisphosphate\n\nPayoff Phase (Energy Releasing):\nFructose-1,6-bisphosphate split two 3-carbon molecules\nmolecules converted pyruvate, generating 4 ATP 2 NADH\n\nNet Yield: 2 ATP, 2 NADH, 2 pyruvate molecules per glucose molecule\nInvestment Phase (Energy Requiring):\nGlucose phosphorylated twice, consuming 2 ATP\nGlucose converted fructose-1,6-bisphosphate\nGlucose phosphorylated twice, consuming 2 ATPGlucose converted fructose-1,6-bisphosphatePayoff Phase (Energy Releasing):\nFructose-1,6-bisphosphate split two 3-carbon molecules\nmolecules converted pyruvate, generating 4 ATP 2 NADH\nFructose-1,6-bisphosphate split two 3-carbon moleculesThese molecules converted pyruvate, generating 4 ATP 2 NADHNet Yield: 2 ATP, 2 NADH, 2 pyruvate molecules per glucose moleculeRegulation:\nKey Regulatory Enzymes:\nHexokinase/Glucokinase: Inhibited glucose-6-phosphate (product inhibition). Glucokinase (liver) higher Km glucose inhibited glucose-6-phosphate, allowing liver continue taking glucose even cellular glucose levels high\nPhosphofructokinase-1 (PFK-1): important regulatory enzyme\nActivated AMP, ADP, fructose-2,6-bisphosphate\nInhibited ATP citrate\n\nPyruvate Kinase:\nActivated fructose-1,6-bisphosphate (feedforward activation)\nInhibited ATP alanine\n\n\nKey Regulatory Enzymes:\nHexokinase/Glucokinase: Inhibited glucose-6-phosphate (product inhibition). Glucokinase (liver) higher Km glucose inhibited glucose-6-phosphate, allowing liver continue taking glucose even cellular glucose levels high\nPhosphofructokinase-1 (PFK-1): important regulatory enzyme\nActivated AMP, ADP, fructose-2,6-bisphosphate\nInhibited ATP citrate\n\nPyruvate Kinase:\nActivated fructose-1,6-bisphosphate (feedforward activation)\nInhibited ATP alanine\n\nHexokinase/Glucokinase: Inhibited glucose-6-phosphate (product inhibition). Glucokinase (liver) higher Km glucose inhibited glucose-6-phosphate, allowing liver continue taking glucose even cellular glucose levels highPhosphofructokinase-1 (PFK-1): important regulatory enzyme\nActivated AMP, ADP, fructose-2,6-bisphosphate\nInhibited ATP citrate\nActivated AMP, ADP, fructose-2,6-bisphosphateInhibited ATP citratePyruvate Kinase:\nActivated fructose-1,6-bisphosphate (feedforward activation)\nInhibited ATP alanine\nActivated fructose-1,6-bisphosphate (feedforward activation)Inhibited ATP alanineFate Pyruvate:\nAerobic Conditions: Pyruvate converted acetyl-CoA, enters citric acid cycle\nAnaerobic Conditions: Pyruvate converted lactate (lactic acid fermentation) regenerate NAD+ glycolysis continue\nAerobic Conditions: Pyruvate converted acetyl-CoA, enters citric acid cycleAnaerobic Conditions: Pyruvate converted lactate (lactic acid fermentation) regenerate NAD+ glycolysis continue","code":""},{"path":"metabolic.html","id":"gluconeogenesis","chapter":"Metabolic","heading":"Gluconeogenesis","text":"Purpose: synthesize glucose non-carbohydrate precursors, primarily liver kidneysLocation: Primarily liver kidneysOverview:\nReversal glycolysis bypass reactions overcome irreversible steps\nPrecursors: Pyruvate, lactate, glycerol, glucogenic amino acids\nKey Bypass Reactions:\nPyruvate Phosphoenolpyruvate (PEP):\nPyruvate carboxylase converts pyruvate oxaloacetate (mitochondria)\nPEP carboxykinase converts oxaloacetate PEP (cytoplasm)\n\nFructose-1,6-bisphosphate Fructose-6-phosphate:\nFructose-1,6-bisphosphatase catalyzes reaction\n\nGlucose-6-phosphate Glucose:\nGlucose-6-phosphatase catalyzes reaction (primarily liver kidneys)\n\n\nEnergy Cost: Gluconeogenesis energy-intensive, requiring 6 ATP equivalents per glucose molecule\nReversal glycolysis bypass reactions overcome irreversible stepsPrecursors: Pyruvate, lactate, glycerol, glucogenic amino acidsKey Bypass Reactions:\nPyruvate Phosphoenolpyruvate (PEP):\nPyruvate carboxylase converts pyruvate oxaloacetate (mitochondria)\nPEP carboxykinase converts oxaloacetate PEP (cytoplasm)\n\nFructose-1,6-bisphosphate Fructose-6-phosphate:\nFructose-1,6-bisphosphatase catalyzes reaction\n\nGlucose-6-phosphate Glucose:\nGlucose-6-phosphatase catalyzes reaction (primarily liver kidneys)\n\nPyruvate Phosphoenolpyruvate (PEP):\nPyruvate carboxylase converts pyruvate oxaloacetate (mitochondria)\nPEP carboxykinase converts oxaloacetate PEP (cytoplasm)\nPyruvate carboxylase converts pyruvate oxaloacetate (mitochondria)PEP carboxykinase converts oxaloacetate PEP (cytoplasm)Fructose-1,6-bisphosphate Fructose-6-phosphate:\nFructose-1,6-bisphosphatase catalyzes reaction\nFructose-1,6-bisphosphatase catalyzes reactionGlucose-6-phosphate Glucose:\nGlucose-6-phosphatase catalyzes reaction (primarily liver kidneys)\nGlucose-6-phosphatase catalyzes reaction (primarily liver kidneys)Energy Cost: Gluconeogenesis energy-intensive, requiring 6 ATP equivalents per glucose moleculeRegulation:\nKey Regulatory Enzymes:\nPyruvate Carboxylase: Activated acetyl-CoA\nFructose-1,6-bisphosphatase:\nInhibited AMP fructose-2,6-bisphosphate\n\nGlucose-6-phosphatase: Regulated substrate availability (glucose-6-phosphate)\n\nHormonal Regulation:\nInsulin: Inhibits gluconeogenesis\nGlucagon: Stimulates gluconeogenesis\nCortisol: Stimulates gluconeogenesis\n\nKey Regulatory Enzymes:\nPyruvate Carboxylase: Activated acetyl-CoA\nFructose-1,6-bisphosphatase:\nInhibited AMP fructose-2,6-bisphosphate\n\nGlucose-6-phosphatase: Regulated substrate availability (glucose-6-phosphate)\nPyruvate Carboxylase: Activated acetyl-CoAFructose-1,6-bisphosphatase:\nInhibited AMP fructose-2,6-bisphosphate\nInhibited AMP fructose-2,6-bisphosphateGlucose-6-phosphatase: Regulated substrate availability (glucose-6-phosphate)Hormonal Regulation:\nInsulin: Inhibits gluconeogenesis\nGlucagon: Stimulates gluconeogenesis\nCortisol: Stimulates gluconeogenesis\nInsulin: Inhibits gluconeogenesisGlucagon: Stimulates gluconeogenesisCortisol: Stimulates gluconeogenesis","code":""},{"path":"metabolic.html","id":"glycogenesis","chapter":"Metabolic","heading":"Glycogenesis","text":"Purpose: synthesize glycogen glucose storage, primarily liver musclesLocation: Cytoplasm liver muscle cellsOverview:\nGlucose converted glucose-6-phosphate\nGlucose-6-phosphate converted glucose-1-phosphate\nGlucose-1-phosphate activated UTP form UDP-glucose\nUDP-glucose added growing glycogen chain glycogen synthase\nBranching enzyme creates α-1,6-glycosidic branches\nGlucose converted glucose-6-phosphateGlucose-6-phosphate converted glucose-1-phosphateGlucose-1-phosphate activated UTP form UDP-glucoseUDP-glucose added growing glycogen chain glycogen synthaseBranching enzyme creates α-1,6-glycosidic branchesRegulation:\nKey Regulatory Enzyme:\nGlycogen Synthase:\nActivated glucose-6-phosphate insulin\nInhibited glucagon epinephrine (via phosphorylation)\n\n\nKey Regulatory Enzyme:\nGlycogen Synthase:\nActivated glucose-6-phosphate insulin\nInhibited glucagon epinephrine (via phosphorylation)\n\nGlycogen Synthase:\nActivated glucose-6-phosphate insulin\nInhibited glucagon epinephrine (via phosphorylation)\nActivated glucose-6-phosphate insulinInhibited glucagon epinephrine (via phosphorylation)","code":""},{"path":"metabolic.html","id":"glycogenolysis","chapter":"Metabolic","heading":"Glycogenolysis","text":"Purpose: break glycogen glucose energy, primarily liver musclesLocation: Cytoplasm liver muscle cellsOverview:\nGlycogen phosphorylase cleaves α-1,4-glycosidic bonds, releasing glucose-1-phosphate\nDebranching enzyme removes α-1,6-glycosidic branches\nGlucose-1-phosphate converted glucose-6-phosphate\nliver, glucose-6-phosphatase converts glucose-6-phosphate glucose, released bloodstream. (Muscle lacks glucose-6-phosphatase, glucose-6-phosphate enters glycolysis)\nGlycogen phosphorylase cleaves α-1,4-glycosidic bonds, releasing glucose-1-phosphateDebranching enzyme removes α-1,6-glycosidic branchesGlucose-1-phosphate converted glucose-6-phosphateIn liver, glucose-6-phosphatase converts glucose-6-phosphate glucose, released bloodstream. (Muscle lacks glucose-6-phosphatase, glucose-6-phosphate enters glycolysis)Regulation:\nKey Regulatory Enzyme:\nGlycogen Phosphorylase:\nActivated AMP, epinephrine, glucagon (via phosphorylation)\nInhibited ATP, glucose-6-phosphate, insulin\n\n\nKey Regulatory Enzyme:\nGlycogen Phosphorylase:\nActivated AMP, epinephrine, glucagon (via phosphorylation)\nInhibited ATP, glucose-6-phosphate, insulin\n\nGlycogen Phosphorylase:\nActivated AMP, epinephrine, glucagon (via phosphorylation)\nInhibited ATP, glucose-6-phosphate, insulin\nActivated AMP, epinephrine, glucagon (via phosphorylation)Inhibited ATP, glucose-6-phosphate, insulin","code":""},{"path":"metabolic.html","id":"hexose-monophosphate-shunt","chapter":"Metabolic","heading":"Hexose Monophosphate Shunt","text":"Nomenclature: Pentose Phosphate Pathway (PPP) Hexose Monophosphate Shunt (HMP Shunt)Purpose:\nProduction NADPH: Important reducing power anabolic reactions, detoxification reactive oxygen species, synthesis fatty acids steroids\nProduction Ribose-5-phosphate: precursor nucleotide biosynthesis\nProduction NADPH: Important reducing power anabolic reactions, detoxification reactive oxygen species, synthesis fatty acids steroidsProduction Ribose-5-phosphate: precursor nucleotide biosynthesisLocation: Cytoplasm various cells, particularly involved lipid synthesis (e.g., liver, adipose tissue, adrenal cortex)Overview:\nOxidative Phase:\nGlucose-6-phosphate converted ribulose-5-phosphate, producing NADPH\nphase irreversible\n\nNon-Oxidative Phase:\nRibulose-5-phosphate converted various sugar phosphates (e.g., ribose-5-phosphate, fructose-6-phosphate, glyceraldehyde-3-phosphate)\nphase reversible allows pathway adapt cell’s needs\n\nOxidative Phase:\nGlucose-6-phosphate converted ribulose-5-phosphate, producing NADPH\nphase irreversible\nGlucose-6-phosphate converted ribulose-5-phosphate, producing NADPHThis phase irreversibleNon-Oxidative Phase:\nRibulose-5-phosphate converted various sugar phosphates (e.g., ribose-5-phosphate, fructose-6-phosphate, glyceraldehyde-3-phosphate)\nphase reversible allows pathway adapt cell’s needs\nRibulose-5-phosphate converted various sugar phosphates (e.g., ribose-5-phosphate, fructose-6-phosphate, glyceraldehyde-3-phosphate)phase reversible allows pathway adapt cell’s needsRegulation:\nKey Regulatory Enzyme:\nGlucose-6-phosphate dehydrogenase (G6PD):\nInhibited NADPH (product inhibition)\n\n\nKey Regulatory Enzyme:\nGlucose-6-phosphate dehydrogenase (G6PD):\nInhibited NADPH (product inhibition)\n\nGlucose-6-phosphate dehydrogenase (G6PD):\nInhibited NADPH (product inhibition)\nInhibited NADPH (product inhibition)","code":""},{"path":"metabolic.html","id":"importance-and-clinical-relevance","chapter":"Metabolic","heading":"Importance and Clinical Relevance","text":"Understanding pathways crucial :Diabetes Mellitus: Disruptions glucose metabolism central pathophysiology diabetesMetabolic Disorders: Genetic defects enzymes pathways can lead various metabolic disorders (e.g., glycogen storage diseases, G6PD deficiency)Nutritional Status: pathways highly responsive dietary intake hormonal signals, reflecting body’s adaptation different nutritional states","code":""},{"path":"metabolic.html","id":"key-terms","chapter":"Metabolic","heading":"Key Terms","text":"Glycolysis: breakdown glucose pyruvate, yielding ATP NADH. ’s foundation cellular energy productionGluconeogenesis: synthesis glucose non-carbohydrate precursors. vital maintaining blood glucose levels fasting starvationGlycogenesis: process converting glucose glycogen storage liver musclesGlycogenolysis: breakdown glycogen release glucose, providing quick source energyInsulin: hormone promotes glucose uptake, glycogenesis, glycolysis, effectively lowering blood glucoseGlucagon: hormone stimulates glycogenolysis gluconeogenesis, raising blood glucose levelsATP (Adenosine Triphosphate): primary energy currency cell. Many pathways geared toward producing consuming ATPNADPH (Nicotinamide Adenine Dinucleotide Phosphate): crucial reducing agent anabolic reactions, like fatty acid steroid synthesis. ’s key product pentose phosphate pathway","code":""},{"path":"physiology.html","id":"physiology","chapter":"Physiology","heading":"Physiology","text":"","code":""},{"path":"physiology.html","id":"physiologic-states-in-carbohydrate-metabolism","chapter":"Physiology","heading":"Physiologic States in Carbohydrate Metabolism","text":"Normal State:\nNormoglycemia:\nMaintained within tight range hormones like insulin glucagon\nProvides constant energy supply, especially brain\n\nNormoglycemia:\nMaintained within tight range hormones like insulin glucagon\nProvides constant energy supply, especially brain\nMaintained within tight range hormones like insulin glucagonProvides constant energy supply, especially brainAbnormal States:\nHyperglycemia: High blood glucose, often due diabetes (lack insulin insulin resistance). Can cause acute (DKA, HHS) chronic (retinopathy, nephropathy, neuropathy, cardiovascular disease) complications\nHypoglycemia: Low blood glucose, due excess insulin, liver/kidney disease, factors. Can cause neurological symptoms, seizures, coma, brain damage\nInsulin Resistance: Cells don’t respond insulin, leading high insulin levels increased risk type 2 diabetes\nGenetic Disorders:\nGlycogen Storage Diseases (GSDs): Enzyme deficiencies glycogen metabolism leading glycogen accumulation hypoglycemia\nGalactosemia: Enzyme deficiencies galactose metabolism leading accumulation galactose organ damage\nFructose Intolerance: Enzyme deficiencies fructose metabolism leading accumulation fructose-1-phosphate organ damage\nPentosuria: Benign condition, deficiency L-xylulose reductase required metabolism L-xylulose\n\nHyperglycemia: High blood glucose, often due diabetes (lack insulin insulin resistance). Can cause acute (DKA, HHS) chronic (retinopathy, nephropathy, neuropathy, cardiovascular disease) complicationsHypoglycemia: Low blood glucose, due excess insulin, liver/kidney disease, factors. Can cause neurological symptoms, seizures, coma, brain damageInsulin Resistance: Cells don’t respond insulin, leading high insulin levels increased risk type 2 diabetesGenetic Disorders:\nGlycogen Storage Diseases (GSDs): Enzyme deficiencies glycogen metabolism leading glycogen accumulation hypoglycemia\nGalactosemia: Enzyme deficiencies galactose metabolism leading accumulation galactose organ damage\nFructose Intolerance: Enzyme deficiencies fructose metabolism leading accumulation fructose-1-phosphate organ damage\nPentosuria: Benign condition, deficiency L-xylulose reductase required metabolism L-xylulose\nGlycogen Storage Diseases (GSDs): Enzyme deficiencies glycogen metabolism leading glycogen accumulation hypoglycemiaGalactosemia: Enzyme deficiencies galactose metabolism leading accumulation galactose organ damageFructose Intolerance: Enzyme deficiencies fructose metabolism leading accumulation fructose-1-phosphate organ damagePentosuria: Benign condition, deficiency L-xylulose reductase required metabolism L-xylulose","code":""},{"path":"physiology.html","id":"normal-sate","chapter":"Physiology","heading":"Normal Sate","text":"","code":""},{"path":"physiology.html","id":"normoglycemia","chapter":"Physiology","heading":"Normoglycemia","text":"Definition: Normal blood glucose levelsFasting: 70-99 mg/dL (3.9-5.5 mmol/L)Postprandial (2 hours eating): < 140 mg/dL (7.8 mmol/L)Maintenance: complex interplay hormones (insulin, glucagon, epinephrine, cortisol), liver function, cellular glucose uptake maintains normoglycemiaImportance: Provides constant supply glucose energy, especially brain, relies heavily glucose","code":""},{"path":"physiology.html","id":"abnormal-states","chapter":"Physiology","heading":"Abnormal States","text":"","code":""},{"path":"physiology.html","id":"hyperglycemia","chapter":"Physiology","heading":"Hyperglycemia","text":"Definition: Abnormally high blood glucose levelsCauses:\nDiabetes Mellitus (Type 1 Type 2):\nType 1: Autoimmune destruction pancreatic beta cells, leading absolute insulin deficiency\nType 2: Insulin resistance (cells don’t respond properly insulin) relative insulin deficiency (pancreas can’t produce enough insulin overcome resistance)\n\nGestational Diabetes: Insulin resistance pregnancy\nEndocrine Disorders: Cushing’s syndrome (excess cortisol), acromegaly (excess growth hormone), hyperthyroidism\nPancreatic Diseases: Pancreatitis, cystic fibrosis (affecting pancreatic function)\nMedications: Corticosteroids, diuretics\nStress/Illness: Stress hormones (cortisol, epinephrine) can raise blood glucose\nDiabetes Mellitus (Type 1 Type 2):\nType 1: Autoimmune destruction pancreatic beta cells, leading absolute insulin deficiency\nType 2: Insulin resistance (cells don’t respond properly insulin) relative insulin deficiency (pancreas can’t produce enough insulin overcome resistance)\nType 1: Autoimmune destruction pancreatic beta cells, leading absolute insulin deficiencyType 2: Insulin resistance (cells don’t respond properly insulin) relative insulin deficiency (pancreas can’t produce enough insulin overcome resistance)Gestational Diabetes: Insulin resistance pregnancyOther Endocrine Disorders: Cushing’s syndrome (excess cortisol), acromegaly (excess growth hormone), hyperthyroidismPancreatic Diseases: Pancreatitis, cystic fibrosis (affecting pancreatic function)Medications: Corticosteroids, diureticsStress/Illness: Stress hormones (cortisol, epinephrine) can raise blood glucoseSymptoms:\nClassic Symptoms: Polyuria (frequent urination), polydipsia (excessive thirst), polyphagia (increased hunger), unexplained weight loss\nSymptoms: Fatigue, blurred vision, slow-healing sores, frequent infections\nClassic Symptoms: Polyuria (frequent urination), polydipsia (excessive thirst), polyphagia (increased hunger), unexplained weight lossOther Symptoms: Fatigue, blurred vision, slow-healing sores, frequent infectionsComplications:\nAcute:\nDiabetic Ketoacidosis (DKA): Primarily Type 1 diabetes. Insulin deficiency leads increased lipolysis, ketone body production, metabolic acidosis\nHyperosmolar Hyperglycemic State (HHS): Primarily Type 2 diabetes. Severe hyperglycemia leads dehydration hyperosmolarity, less ketosis DKA\n\nChronic:\nMicrovascular Complications:\nRetinopathy: Damage blood vessels retina, leading vision loss\nNephropathy: Damage blood vessels kidneys, leading kidney failure\nNeuropathy: Damage nerves, leading pain, numbness, loss sensation\n\nMacrovascular Complications:\nCardiovascular Disease: Increased risk heart attacks strokes\nPeripheral Artery Disease: Reduced blood flow limbs, increasing risk amputation\n\n\nAcute:\nDiabetic Ketoacidosis (DKA): Primarily Type 1 diabetes. Insulin deficiency leads increased lipolysis, ketone body production, metabolic acidosis\nHyperosmolar Hyperglycemic State (HHS): Primarily Type 2 diabetes. Severe hyperglycemia leads dehydration hyperosmolarity, less ketosis DKA\nDiabetic Ketoacidosis (DKA): Primarily Type 1 diabetes. Insulin deficiency leads increased lipolysis, ketone body production, metabolic acidosisHyperosmolar Hyperglycemic State (HHS): Primarily Type 2 diabetes. Severe hyperglycemia leads dehydration hyperosmolarity, less ketosis DKAChronic:\nMicrovascular Complications:\nRetinopathy: Damage blood vessels retina, leading vision loss\nNephropathy: Damage blood vessels kidneys, leading kidney failure\nNeuropathy: Damage nerves, leading pain, numbness, loss sensation\n\nMacrovascular Complications:\nCardiovascular Disease: Increased risk heart attacks strokes\nPeripheral Artery Disease: Reduced blood flow limbs, increasing risk amputation\n\nMicrovascular Complications:\nRetinopathy: Damage blood vessels retina, leading vision loss\nNephropathy: Damage blood vessels kidneys, leading kidney failure\nNeuropathy: Damage nerves, leading pain, numbness, loss sensation\nRetinopathy: Damage blood vessels retina, leading vision lossNephropathy: Damage blood vessels kidneys, leading kidney failureNeuropathy: Damage nerves, leading pain, numbness, loss sensationMacrovascular Complications:\nCardiovascular Disease: Increased risk heart attacks strokes\nPeripheral Artery Disease: Reduced blood flow limbs, increasing risk amputation\nCardiovascular Disease: Increased risk heart attacks strokesPeripheral Artery Disease: Reduced blood flow limbs, increasing risk amputation","code":""},{"path":"physiology.html","id":"hypoglycemia","chapter":"Physiology","heading":"Hypoglycemia","text":"Definition: Abnormally low blood glucose levelsThreshold: Generally defined < 70 mg/dL (3.9 mmol/L), symptoms can varyCauses:\nExcess Insulin:\nInsulin Overdose: diabetic patients\nInsulinoma: Insulin-secreting tumor pancreas\n\nReactive Hypoglycemia: Exaggerated insulin release meal\nFasting Hypoglycemia:\nLiver Disease: Impaired gluconeogenesis glycogen storage\nKidney Disease: Impaired gluconeogenesis\nHormone Deficiencies: Adrenal insufficiency (low cortisol), growth hormone deficiency\nCertain Tumors: Non-islet cell tumors can secrete insulin-like substances\n\nAlcohol Consumption: Inhibits gluconeogenesis\nIntense Exercise: Can deplete glycogen stores\nExcess Insulin:\nInsulin Overdose: diabetic patients\nInsulinoma: Insulin-secreting tumor pancreas\nInsulin Overdose: diabetic patientsInsulinoma: Insulin-secreting tumor pancreasReactive Hypoglycemia: Exaggerated insulin release mealFasting Hypoglycemia:\nLiver Disease: Impaired gluconeogenesis glycogen storage\nKidney Disease: Impaired gluconeogenesis\nHormone Deficiencies: Adrenal insufficiency (low cortisol), growth hormone deficiency\nCertain Tumors: Non-islet cell tumors can secrete insulin-like substances\nLiver Disease: Impaired gluconeogenesis glycogen storageKidney Disease: Impaired gluconeogenesisHormone Deficiencies: Adrenal insufficiency (low cortisol), growth hormone deficiencyCertain Tumors: Non-islet cell tumors can secrete insulin-like substancesAlcohol Consumption: Inhibits gluconeogenesisIntense Exercise: Can deplete glycogen storesSymptoms:\nAdrenergic Symptoms (Early): Sweating, shakiness, anxiety, palpitations, hunger\nNeuroglycopenic Symptoms (Later): Confusion, dizziness, blurred vision, difficulty speaking, seizures, loss consciousness\nAdrenergic Symptoms (Early): Sweating, shakiness, anxiety, palpitations, hungerNeuroglycopenic Symptoms (Later): Confusion, dizziness, blurred vision, difficulty speaking, seizures, loss consciousnessComplications:\nBrain Damage: Prolonged severe hypoglycemia can lead irreversible brain damage\nSeizures\nComa\nDeath\nBrain Damage: Prolonged severe hypoglycemia can lead irreversible brain damageSeizuresComaDeath","code":""},{"path":"physiology.html","id":"insulin-resistance","chapter":"Physiology","heading":"Insulin Resistance","text":"Definition: Cells don’t respond normally insulin, requiring higher levels insulin achieve effect glucose uptakeCauses:\nObesity: Excess adipose tissue releases factors interfere insulin signaling\nGenetics: individuals genetically predisposed insulin resistance\nPhysical Inactivity\nInflammation\nAging\nObesity: Excess adipose tissue releases factors interfere insulin signalingGenetics: individuals genetically predisposed insulin resistancePhysical InactivityInflammationAgingConsequences:\nHyperinsulinemia: Elevated insulin levels pancreas tries compensate resistance\nPrediabetes: Impaired fasting glucose impaired glucose tolerance\nType 2 Diabetes: Eventually, pancreas may able produce enough insulin overcome resistance\nMetabolic Syndrome: cluster conditions including insulin resistance, abdominal obesity, high blood pressure, high triglycerides, low HDL cholesterol, increasing risk cardiovascular disease type 2 diabetes\nHyperinsulinemia: Elevated insulin levels pancreas tries compensate resistancePrediabetes: Impaired fasting glucose impaired glucose toleranceType 2 Diabetes: Eventually, pancreas may able produce enough insulin overcome resistanceMetabolic Syndrome: cluster conditions including insulin resistance, abdominal obesity, high blood pressure, high triglycerides, low HDL cholesterol, increasing risk cardiovascular disease type 2 diabetes","code":""},{"path":"physiology.html","id":"genetic-defects-in-glycogen-metabolism","chapter":"Physiology","heading":"Genetic Defects in Glycogen Metabolism","text":"","code":""},{"path":"physiology.html","id":"glycogen-storage-diseases-gsds","chapter":"Physiology","heading":"Glycogen Storage Diseases (GSDs)","text":"Definition: group inherited disorders caused deficiencies enzymes involved glycogen synthesis breakdownTypes:\nVon Gierke Disease (Type Ia): Deficiency glucose-6-phosphatase. Causes severe hypoglycemia, hepatomegaly, lactic acidosis, hyperlipidemia\nPompe Disease (Type II): Deficiency lysosomal α-glucosidase (acid maltase). Causes glycogen accumulation lysosomes, affecting various organs, especially heart muscles\nCori Disease (Type III): Deficiency debranching enzyme. Causes milder hypoglycemia hepatomegaly Von Gierke disease\nMcArdle Disease (Type V): Deficiency muscle glycogen phosphorylase. Causes muscle cramps fatigue exercise\nVon Gierke Disease (Type Ia): Deficiency glucose-6-phosphatase. Causes severe hypoglycemia, hepatomegaly, lactic acidosis, hyperlipidemiaPompe Disease (Type II): Deficiency lysosomal α-glucosidase (acid maltase). Causes glycogen accumulation lysosomes, affecting various organs, especially heart musclesCori Disease (Type III): Deficiency debranching enzyme. Causes milder hypoglycemia hepatomegaly Von Gierke diseaseMcArdle Disease (Type V): Deficiency muscle glycogen phosphorylase. Causes muscle cramps fatigue exerciseSymptoms: Depend specific enzyme deficiency tissues affected","code":""},{"path":"physiology.html","id":"galactosemia","chapter":"Physiology","heading":"Galactosemia","text":"Definition: inherited disorder caused deficiency enzymes needed convert galactose glucoseCause: commonly deficiency galactose-1-phosphate uridyltransferase (GALT)Symptoms:\nEarly: Feeding difficulties, vomiting, diarrhea, lethargy, jaundice, hepatomegaly\nLater: Cataracts, intellectual disability, liver damage, kidney damage\nEarly: Feeding difficulties, vomiting, diarrhea, lethargy, jaundice, hepatomegalyLater: Cataracts, intellectual disability, liver damage, kidney damageTreatment: Strict galactose-free diet","code":""},{"path":"physiology.html","id":"fructose-intolerance","chapter":"Physiology","heading":"Fructose Intolerance","text":"Definition: Impaired Fructose Metabolism\nHereditary Fructose Intolerance (HFI): Deficiency aldolase B. Causes accumulation fructose-1-phosphate, inhibiting gluconeogenesis glycogenolysis\nFructose Malabsorption: Impaired absorption fructose small intestine\nHereditary Fructose Intolerance (HFI): Deficiency aldolase B. Causes accumulation fructose-1-phosphate, inhibiting gluconeogenesis glycogenolysisFructose Malabsorption: Impaired absorption fructose small intestineSymptoms:\nHFI: Vomiting, abdominal pain, hypoglycemia, liver damage, kidney damage\nFructose Malabsorption: Bloating, gas, diarrhea\nHFI: Vomiting, abdominal pain, hypoglycemia, liver damage, kidney damageFructose Malabsorption: Bloating, gas, diarrheaTreatment:\nHFI: Strict fructose-free sucrose-free diet\nFructose Malabsorption: Limiting fructose intake\nHFI: Strict fructose-free sucrose-free dietFructose Malabsorption: Limiting fructose intake","code":""},{"path":"physiology.html","id":"pentosuria","chapter":"Physiology","heading":"Pentosuria","text":"Definition: Excess excretion pentoses urine\nEssential Pentosuria: Deficiency L-xylulose reductase required metabolism L-xylulose, pentose sugar\nEssential Pentosuria: Deficiency L-xylulose reductase required metabolism L-xylulose, pentose sugarSymptoms:\nEssential Pentosuria: Benign condition L-xylulose accumulates excreted urine, thus clinical symptoms\nEssential Pentosuria: Benign condition L-xylulose accumulates excreted urine, thus clinical symptoms","code":""},{"path":"physiology.html","id":"key-terms-1","chapter":"Physiology","heading":"Key Terms","text":"Normoglycemia: Normal blood glucose levelsHyperglycemia: Elevated blood glucose levelsHypoglycemia: Reduced blood glucose levelsInsulin Resistance: Impaired cellular response insulinGlycogen Storage Diseases (GSDs): Genetic defects glycogen metabolismGalactosemia: Impaired galactose metabolismFructose Intolerance: Impaired fructose metabolismPentosuria: Excess excretion pentoses urine","code":""},{"path":"properties.html","id":"properties","chapter":"Properties","heading":"Properties","text":"","code":""},{"path":"properties.html","id":"physical-and-chemical","chapter":"Properties","heading":"Physical and Chemical","text":"Physical Properties:\nMonosaccharides/Disaccharides: Crystalline solids, water-soluble, sweet\nPolysaccharides: Amorphous solids fibrous, mostly insoluble, generally tasteless\nMonosaccharides/Disaccharides: Crystalline solids, water-soluble, sweetPolysaccharides: Amorphous solids fibrous, mostly insoluble, generally tastelessChemical Properties:\nMonosaccharides:\nCyclization (forming α β anomers)\nOxidation (reducing sugars can reduce compounds)\nEsterification, Glycoside Formation\n\nDisaccharides:\nHydrolyzed enzymes acid monosaccharides\nCan reducing non-reducing\n\nPolysaccharides:\nHydrolyzed enzymes acid smaller sugars\nVary structure (linear vs. branched) composition (homo- vs. heteropolysaccharides)\n\nMonosaccharides:\nCyclization (forming α β anomers)\nOxidation (reducing sugars can reduce compounds)\nEsterification, Glycoside Formation\nCyclization (forming α β anomers)Oxidation (reducing sugars can reduce compounds)Esterification, Glycoside FormationDisaccharides:\nHydrolyzed enzymes acid monosaccharides\nCan reducing non-reducing\nHydrolyzed enzymes acid monosaccharidesCan reducing non-reducingPolysaccharides:\nHydrolyzed enzymes acid smaller sugars\nVary structure (linear vs. branched) composition (homo- vs. heteropolysaccharides)\nHydrolyzed enzymes acid smaller sugarsVary structure (linear vs. branched) composition (homo- vs. heteropolysaccharides)","code":""},{"path":"properties.html","id":"monosaccharides","chapter":"Properties","heading":"Monosaccharides","text":"Definition: basic building blocks carbohydrates; hydrolyzed smaller units (also known simple sugars)Examples: Glucose, fructose, galactose, ribose","code":""},{"path":"properties.html","id":"physical","chapter":"Properties","heading":"Physical","text":"State: Crystalline solids room temperatureSolubility: Highly soluble water due numerous hydroxyl (-OH) groups form hydrogen bonds water moleculesTaste: Generally sweet, although degree sweetness varies (fructose > sucrose > glucose > galactose)Optical Activity: Chiral molecules rotate plane-polarized light; classified either dextrorotatory (+) levorotatory (-)","code":""},{"path":"properties.html","id":"chemical","chapter":"Properties","heading":"Chemical","text":"Cyclization:\nMonosaccharides five carbon atoms can cyclize aqueous solution, forming cyclic hemiacetals (aldehydes) hemiketals (ketones)\nAnomers: cyclization process creates new chiral center carbonyl carbon (anomeric carbon), resulting α β anomers\nMutarotation: spontaneous interconversion α β anomers solution equilibrium mixture reached\nMonosaccharides five carbon atoms can cyclize aqueous solution, forming cyclic hemiacetals (aldehydes) hemiketals (ketones)Anomers: cyclization process creates new chiral center carbonyl carbon (anomeric carbon), resulting α β anomersMutarotation: spontaneous interconversion α β anomers solution equilibrium mixture reachedOxidation:\nMonosaccharides free aldehyde ketone group can oxidized (reducing sugars)\nReducing Sugars: Glucose, fructose, galactose, lactose, maltose\nTests Reducing Sugars:\nBenedict’s Test: Reducing sugars react copper(II) sulfate alkaline solution, reducing copper() oxide, forming red-brown precipitate\nFehling’s Test: Similar Benedict’s test, uses copper(II) tartrate complex\n\nMonosaccharides free aldehyde ketone group can oxidized (reducing sugars)Reducing Sugars: Glucose, fructose, galactose, lactose, maltoseTests Reducing Sugars:\nBenedict’s Test: Reducing sugars react copper(II) sulfate alkaline solution, reducing copper() oxide, forming red-brown precipitate\nFehling’s Test: Similar Benedict’s test, uses copper(II) tartrate complex\nBenedict’s Test: Reducing sugars react copper(II) sulfate alkaline solution, reducing copper() oxide, forming red-brown precipitateFehling’s Test: Similar Benedict’s test, uses copper(II) tartrate complexReduction: aldehyde ketone group monosaccharide can reduced form sugar alcohol (alditol)\nExamples\nGlucose reduced sorbitol (glucitol)\nXylose reduced xylitol (sugar substitute)\n\nExamples\nGlucose reduced sorbitol (glucitol)\nXylose reduced xylitol (sugar substitute)\nGlucose reduced sorbitol (glucitol)Xylose reduced xylitol (sugar substitute)Esterification: Hydroxyl groups (-OH) can react acids form esters\nExample: Phosphorylation glucose (e.g., glucose-6-phosphate) essential metabolism\nExample: Phosphorylation glucose (e.g., glucose-6-phosphate) essential metabolismGlycoside Formation: anomeric hydroxyl group can react another alcohol form glycoside O-glycosidic bond\nGlycosidic Bond: bond links monosaccharides together form disaccharides, oligosaccharides, polysaccharides\nGlycosidic Bond: bond links monosaccharides together form disaccharides, oligosaccharides, polysaccharidesIsomerization: Monosaccharides can converted isomers\nExample: Glucose can converted fructose via enediol intermediate\nExample: Glucose can converted fructose via enediol intermediate","code":""},{"path":"properties.html","id":"examples","chapter":"Properties","heading":"Examples","text":"Glucose (D-Glucose):\nAlso Known : Dextrose, blood sugar\nSignificance:\nPrimary Energy Source: main energy source cells body\nCentral Metabolism: Central molecule carbohydrate metabolism; glycolysis, gluconeogenesis, glycogenesis, glycogenolysis revolve around glucose\nRegulation: Blood glucose levels tightly regulated insulin glucagon\n\nAlso Known : Dextrose, blood sugarSignificance:\nPrimary Energy Source: main energy source cells body\nCentral Metabolism: Central molecule carbohydrate metabolism; glycolysis, gluconeogenesis, glycogenesis, glycogenolysis revolve around glucose\nRegulation: Blood glucose levels tightly regulated insulin glucagon\nPrimary Energy Source: main energy source cells bodyCentral Metabolism: Central molecule carbohydrate metabolism; glycolysis, gluconeogenesis, glycogenesis, glycogenolysis revolve around glucoseRegulation: Blood glucose levels tightly regulated insulin glucagonFructose (D-Fructose):\nAlso Known : Fruit sugar, levulose\nSignificance:\nSweetest Natural Sugar: Found fruits, honey, high-fructose corn syrup\nMetabolism: Metabolized primarily liver\nDietary Concerns: High intake fructose linked metabolic issues\n\nAlso Known : Fruit sugar, levuloseSignificance:\nSweetest Natural Sugar: Found fruits, honey, high-fructose corn syrup\nMetabolism: Metabolized primarily liver\nDietary Concerns: High intake fructose linked metabolic issues\nSweetest Natural Sugar: Found fruits, honey, high-fructose corn syrupMetabolism: Metabolized primarily liverDietary Concerns: High intake fructose linked metabolic issuesGalactose (D-Galactose):\nSignificance:\nPart Lactose: Found milk part disaccharide lactose\nMetabolism: Converted glucose liver\nGalactosemia: Deficiency enzymes metabolize galactose leads galactosemia\n\nSignificance:\nPart Lactose: Found milk part disaccharide lactose\nMetabolism: Converted glucose liver\nGalactosemia: Deficiency enzymes metabolize galactose leads galactosemia\nPart Lactose: Found milk part disaccharide lactoseMetabolism: Converted glucose liverGalactosemia: Deficiency enzymes metabolize galactose leads galactosemiaRibose (D-Ribose):\nSignificance:\nComponent RNA: crucial component ribonucleic acid (RNA)\nComponent ATP: Also found ATP, NADH, important coenzymes\nPentose Phosphate Pathway: Synthesized pentose phosphate pathway\n\nSignificance:\nComponent RNA: crucial component ribonucleic acid (RNA)\nComponent ATP: Also found ATP, NADH, important coenzymes\nPentose Phosphate Pathway: Synthesized pentose phosphate pathway\nComponent RNA: crucial component ribonucleic acid (RNA)Component ATP: Also found ATP, NADH, important coenzymesPentose Phosphate Pathway: Synthesized pentose phosphate pathwayDeoxyribose (2-Deoxy-D-Ribose):\nSignificance:\nComponent DNA: crucial component deoxyribonucleic acid (DNA). derivative ribose, one fewer oxygen atom\n\nSignificance:\nComponent DNA: crucial component deoxyribonucleic acid (DNA). derivative ribose, one fewer oxygen atom\nComponent DNA: crucial component deoxyribonucleic acid (DNA). derivative ribose, one fewer oxygen atom","code":""},{"path":"properties.html","id":"disaccharides","chapter":"Properties","heading":"Disaccharides","text":"Definition: Two monosaccharides linked together glycosidic bondExamples: Sucrose, lactose, maltose","code":""},{"path":"properties.html","id":"physical-1","chapter":"Properties","heading":"Physical","text":"State: Crystalline solids room temperatureSolubility: Soluble water due presence hydroxyl groupsTaste: Sweet, although degree sweetness variesOptical Activity: Chiral optically active","code":""},{"path":"properties.html","id":"chemical-1","chapter":"Properties","heading":"Chemical","text":"Hydrolysis: Disaccharides can hydrolyzed (broken ) constituent monosaccharides :\nEnzymes: Specific disaccharidases (e.g., sucrase, lactase, maltase)\nAcid: Heating dilute acid\nEnzymes: Specific disaccharidases (e.g., sucrase, lactase, maltase)Acid: Heating dilute acidReducing/Non-Reducing:\nReducing Disaccharides: free anomeric carbon can undergo oxidation (e.g., maltose, lactose)\nNon-Reducing Disaccharides: anomeric carbons involved glycosidic bond oxidized (e.g., sucrose)\nReducing Disaccharides: free anomeric carbon can undergo oxidation (e.g., maltose, lactose)Non-Reducing Disaccharides: anomeric carbons involved glycosidic bond oxidized (e.g., sucrose)Glycosidic Bond Specificity: properties disaccharide depend type glycosidic bond (α β) specific monosaccharides involved","code":""},{"path":"properties.html","id":"examples-1","chapter":"Properties","heading":"Examples","text":"Sucrose (Table Sugar):\nComposition: Glucose + Fructose (α-1,2-glycosidic bond)\nNon-reducing: anomeric carbons involved glycosidic bond\nComposition: Glucose + Fructose (α-1,2-glycosidic bond)Non-reducing: anomeric carbons involved glycosidic bondLactose (Milk Sugar):\nComposition: Galactose + Glucose (β-1,4-glycosidic bond)\nReducing: Glucose free anomeric carbon\nComposition: Galactose + Glucose (β-1,4-glycosidic bond)Reducing: Glucose free anomeric carbonMaltose (Malt Sugar):\nComposition: Glucose + Glucose (α-1,4-glycosidic bond)\nReducing: One glucose free anomeric carbon\nComposition: Glucose + Glucose (α-1,4-glycosidic bond)Reducing: One glucose free anomeric carbon","code":""},{"path":"properties.html","id":"polysaccharides","chapter":"Properties","heading":"Polysaccharides","text":"Definition: Polymers consisting many monosaccharide units linked together glycosidic bondsExamples: Starch, glycogen, cellulose","code":""},{"path":"properties.html","id":"physical-2","chapter":"Properties","heading":"Physical","text":"State: Amorphous solids fibrous materialsSolubility: Generally insoluble form colloidal dispersions waterTaste: Generally tastelessMolecular Weight: High molecular weights","code":""},{"path":"properties.html","id":"chemical-2","chapter":"Properties","heading":"Chemical","text":"Hydrolysis: Polysaccharides can hydrolyzed smaller oligosaccharides monosaccharides :\nEnzymes: Amylases, cellulases, etc\nAcid: Heating dilute acid\nEnzymes: Amylases, cellulases, etcAcid: Heating dilute acidStructure:\nHomopolysaccharides: Composed one type monosaccharide (e.g., starch, glycogen, cellulose)\nHeteropolysaccharides: Composed two types monosaccharides (e.g., hyaluronic acid)\nHomopolysaccharides: Composed one type monosaccharide (e.g., starch, glycogen, cellulose)Heteropolysaccharides: Composed two types monosaccharides (e.g., hyaluronic acid)Branching:\nLinear Polysaccharides: Monosaccharides linked straight chain (e.g., cellulose)\nBranched Polysaccharides: Chains branch points (e.g., glycogen, amylopectin)\nLinear Polysaccharides: Monosaccharides linked straight chain (e.g., cellulose)Branched Polysaccharides: Chains branch points (e.g., glycogen, amylopectin)","code":""},{"path":"properties.html","id":"examples-2","chapter":"Properties","heading":"Examples","text":"Starch:\nComposition: Polymer glucose\nTypes:\nAmylose: Linear chain glucose α-1,4-glycosidic bonds\nAmylopectin: Branched chain glucose α-1,4-glycosidic bonds α-1,6-glycosidic bonds branch points\n\nHydrolysis: Hydrolyzed amylases produce glucose, maltose, dextrins\nComposition: Polymer glucoseTypes:\nAmylose: Linear chain glucose α-1,4-glycosidic bonds\nAmylopectin: Branched chain glucose α-1,4-glycosidic bonds α-1,6-glycosidic bonds branch points\nAmylose: Linear chain glucose α-1,4-glycosidic bondsAmylopectin: Branched chain glucose α-1,4-glycosidic bonds α-1,6-glycosidic bonds branch pointsHydrolysis: Hydrolyzed amylases produce glucose, maltose, dextrinsGlycogen:\nComposition: Polymer glucose\nStructure: Highly branched structure α-1,4-glycosidic bonds α-1,6-glycosidic bonds branch points (branched amylopectin)\nFunction: Storage form glucose animals\nComposition: Polymer glucoseStructure: Highly branched structure α-1,4-glycosidic bonds α-1,6-glycosidic bonds branch points (branched amylopectin)Function: Storage form glucose animalsCellulose:\nComposition: Polymer glucose\nStructure: Linear chain glucose β-1,4-glycosidic bonds\nProperties: Forms strong, rigid fibers due extensive hydrogen bonding chains. digestible humans (lacks cellulase enzyme)\nComposition: Polymer glucoseStructure: Linear chain glucose β-1,4-glycosidic bondsProperties: Forms strong, rigid fibers due extensive hydrogen bonding chains. digestible humans (lacks cellulase enzyme)","code":""},{"path":"properties.html","id":"key-terms-2","chapter":"Properties","heading":"Key Terms","text":"Monosaccharide: simple sugar hydrolyzed furtherDisaccharide: Two monosaccharides linked glycosidic bondPolysaccharide: polymer many monosaccharide unitsReducing Sugar: sugar can oxidized, reducing another substanceGlycosidic Bond: bond links monosaccharides togetherAnomers: Isomeric forms cyclic monosaccharides differ position hydroxyl group anomeric carbonMutarotation: change optical rotation resulting conversion one anomer anotherHydrolysis: cleavage chemical bond addition water","code":""},{"path":"procedures.html","id":"procedures","chapter":"Procedures","heading":"Procedures","text":"Carbohydrate testing assessing glucose levels diagnose monitor diabetes, also looking specific sugars tied metabolic disorders. use variety techniques get comprehensive picture body handling sugars","code":""},{"path":"procedures.html","id":"key-tests-principles","chapter":"Procedures","heading":"Key Tests & Principles","text":"Glucose Measurement\nPrinciple: Uses enzymatic reactions (glucose oxidase hexokinase) quantify glucose\n’re measuring products byproducts enzyme-catalyzed reactions\nPrinciple: Uses enzymatic reactions (glucose oxidase hexokinase) quantify glucoseWe’re measuring products byproducts enzyme-catalyzed reactionsGlucose Tolerance Testing (GTT)\nPrinciple: Measures body’s ability clear glucose blood challenge dose\nassesses insulin secretion insulin sensitivity\nPrinciple: Measures body’s ability clear glucose blood challenge doseThis assesses insulin secretion insulin sensitivityGlycated Hemoglobin (HbA1c)\nPrinciple: Quantifies percentage hemoglobin glucose attached, reflecting average glucose levels 2-3 months\nProvides long-term view glycemic control\nPrinciple: Quantifies percentage hemoglobin glucose attached, reflecting average glucose levels 2-3 monthsProvides long-term view glycemic controlUrine Glucose\nPrinciple: Detects presence glucose urine blood glucose exceeds kidney’s reabsorption capacity\nquick, less sensitive, way check high blood sugar\nPrinciple: Detects presence glucose urine blood glucose exceeds kidney’s reabsorption capacityA quick, less sensitive, way check high blood sugarKetone Measurement\nPrinciple: Detects ketones blood urine, indicating fat breakdown due insufficient glucose use\nImportant diagnosing monitoring diabetic ketoacidosis (DKA)\nPrinciple: Detects ketones blood urine, indicating fat breakdown due insufficient glucose useImportant diagnosing monitoring diabetic ketoacidosis (DKA)Carbohydrate Tests\nPrinciple: Uses specialized enzymatic chromatographic methods quantify sugars like galactose fructose\nUsed diagnosing specific metabolic disorders\nPrinciple: Uses specialized enzymatic chromatographic methods quantify sugars like galactose fructoseUsed diagnosing specific metabolic disorders","code":""},{"path":"procedures.html","id":"factors-affecting-results","chapter":"Procedures","heading":"Factors Affecting Results","text":"Special Precautions\nPatient Prep: Includes proper fasting, awareness medications, consideration acute illness\nSpecimen Handling: Involves prompt processing, appropriate temperature control, use correct anticoagulants\nReagent Quality: Proper storage awareness expiration dates essential\nPatient Prep: Includes proper fasting, awareness medications, consideration acute illnessSpecimen Handling: Involves prompt processing, appropriate temperature control, use correct anticoagulantsReagent Quality: Proper storage awareness expiration dates essentialTroubleshooting\nneed able identify source errors (pre-analytical, analytical) results unexpected\nneed able identify source errors (pre-analytical, analytical) results unexpectedInterfering Substances\nSubstances like ascorbic acid (vitamin C), bilirubin, lipids, hemoglobin can affect certain assays\nKnowing interferences helps us choose best methods interpret results correctly\nSubstances like ascorbic acid (vitamin C), bilirubin, lipids, hemoglobin can affect certain assaysKnowing interferences helps us choose best methods interpret results correctly","code":""},{"path":"procedures.html","id":"interpretation-disease-correlation","chapter":"Procedures","heading":"Interpretation & Disease Correlation","text":"Normoglycemia & Aberrations: Understanding normal ranges tests foundationalLinking Labs Disease: Recognizing specific test patterns correlate conditions like diabetes, prediabetes, gestational diabetes, hypoglycemia, DKA, metabolic disorders ultimate goalPutting Context: Remembering patient factors, medications, even ethnicity can influence lab results makes interpretation nuanced","code":""},{"path":"principles.html","id":"principles","chapter":"Principles","heading":"Principles","text":"Carbohydrate testing lab centers measuring glucose levels diagnose manage diabetes, also involves assessing sugars specific metabolic disordersGlucose Measurement:\nPrinciple: Enzymatic methods (glucose oxidase, hexokinase) common, measuring products glucose oxidation phosphorylation\nMethods: Glucose Oxidase, Hexokinase\nSpecimen: Plasma, serum, whole blood (point--care)\nPrinciple: Enzymatic methods (glucose oxidase, hexokinase) common, measuring products glucose oxidation phosphorylationMethods: Glucose Oxidase, HexokinaseSpecimen: Plasma, serum, whole blood (point--care)Glucose Tolerance Testing (GTT):\nPrinciple: Measures body’s ability clear glucose time standard glucose load\nMethod: Serial blood glucose measurements oral glucose administration\nSpecimen: Plasma serum timed intervals\nPrinciple: Measures body’s ability clear glucose time standard glucose loadMethod: Serial blood glucose measurements oral glucose administrationSpecimen: Plasma serum timed intervalsGlycated Hemoglobin (HbA1c):\nPrinciple: Measures average blood glucose past 2-3 months assessing percentage hemoglobin glycated\nMethods: Immunoassay, HPLC\nSpecimen: Whole blood (EDTA)\nPrinciple: Measures average blood glucose past 2-3 months assessing percentage hemoglobin glycatedMethods: Immunoassay, HPLCSpecimen: Whole blood (EDTA)Urine Glucose:\nPrinciple: Detects presence glucose urine, indicating hyperglycemia exceeding renal threshold\nMethods: Dipstick, enzymatic methods\nSpecimen: Urine\nPrinciple: Detects presence glucose urine, indicating hyperglycemia exceeding renal thresholdMethods: Dipstick, enzymatic methodsSpecimen: UrineKetone Measurement:\nPrinciple: Detects ketone bodies (acetone, acetoacetate, beta-hydroxybutyrate) blood urine, indicating fat breakdown due insufficient glucose utilization\nMethods: Immunoassay, enzymatic methods\nSpecimen: Serum, plasma, urine\nPrinciple: Detects ketone bodies (acetone, acetoacetate, beta-hydroxybutyrate) blood urine, indicating fat breakdown due insufficient glucose utilizationMethods: Immunoassay, enzymatic methodsSpecimen: Serum, plasma, urineOther Carbohydrates:\nPrinciple: Specialized tests galactose, fructose, etc., typically involve enzymatic chromatographic methods\nMethods: Enzymatic assays, chromatography\nSpecimen: Serum, urine\nPrinciple: Specialized tests galactose, fructose, etc., typically involve enzymatic chromatographic methodsMethods: Enzymatic assays, chromatographySpecimen: Serum, urine","code":""},{"path":"principles.html","id":"glucose-measurement","chapter":"Principles","heading":"Glucose Measurement","text":"Core Concept: Accurate measurement glucose central diagnosing managing diabetes mellitus","code":""},{"path":"principles.html","id":"glucose-oxidase-method-god","chapter":"Principles","heading":"Glucose Oxidase Method (GOD)","text":"Principle: Glucose oxidase catalyzes oxidation glucose gluconic acid hydrogen peroxide (H2O2). H2O2 reacted chromogen presence peroxidase (POD) produce colored product, measured spectrophotometricallyReactions:\nGlucose + O2 + H2O –(Glucose Oxidase)–> Gluconic Acid + H2O2\nH2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + H2O\nGlucose + O2 + H2O –(Glucose Oxidase)–> Gluconic Acid + H2O2H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + H2ODetection: intensity colored product directly proportional glucose concentration sampleAdvantages: Specific glucose, relatively inexpensiveDisadvantages: Susceptible interference reducing substances, oxygen availability can affect results","code":""},{"path":"principles.html","id":"hexokinase-method-hk","chapter":"Principles","heading":"Hexokinase Method (HK)","text":"Principle: Hexokinase catalyzes phosphorylation glucose ATP form glucose-6-phosphate (G6P) ADP. G6P oxidized glucose-6-phosphate dehydrogenase (G6PD) presence NAD+ form 6-phosphogluconate NADH. NADH produced measured spectrophotometricallyReactions:\nGlucose + ATP –(Hexokinase)–> Glucose-6-Phosphate + ADP\nGlucose-6-Phosphate + NAD+ –(G6PD)–> 6-Phosphogluconate + NADH + H+\nGlucose + ATP –(Hexokinase)–> Glucose-6-Phosphate + ADPGlucose-6-Phosphate + NAD+ –(G6PD)–> 6-Phosphogluconate + NADH + H+Detection: increase absorbance due NADH formation directly proportional glucose concentration sampleAdvantages: accurate precise glucose oxidase, less susceptible interferencesDisadvantages: expensive glucose oxidase, requires additional enzymes","code":""},{"path":"principles.html","id":"glucose-tolerance-testing-gtt","chapter":"Principles","heading":"Glucose Tolerance Testing (GTT)","text":"Core Concept: GTT assesses body’s response glucose challenge, providing insight insulin secretion sensitivity","code":""},{"path":"principles.html","id":"oral-glucose-tolerance-test-ogtt","chapter":"Principles","heading":"Oral Glucose Tolerance Test (OGTT)","text":"Principle: measured dose glucose administered orally, blood glucose levels measured specific intervals (e.g., 0, 30, 60, 90, 120 minutes) assess body processes glucoseProcedure:\nPatient Preparation: Overnight fasting (8-12 hours)\nGlucose Load: Adults typically receive 75 grams glucose liquid solution. Pregnant women may receive different dose (e.g., 50g gestational diabetes screening, 100g diagnostic testing). Children receive 1.75 g glucose per kg body weight, maximum 75 g\nBlood Collection: Blood samples collected timed intervals (e.g., fasting, 30 minutes, 1 hour, 2 hours, 3 hours)\nPatient Preparation: Overnight fasting (8-12 hours)Glucose Load: Adults typically receive 75 grams glucose liquid solution. Pregnant women may receive different dose (e.g., 50g gestational diabetes screening, 100g diagnostic testing). Children receive 1.75 g glucose per kg body weight, maximum 75 gBlood Collection: Blood samples collected timed intervals (e.g., fasting, 30 minutes, 1 hour, 2 hours, 3 hours)Detection: Plasma serum glucose concentrations measured time point using enzymatic methods (glucose oxidase hexokinase)Interpretation: Glucose levels plotted time generate glucose tolerance curve. shape curve glucose values different time points used diagnose diabetes, prediabetes, gestational diabetesClinical Significance: OGTT used diagnose diabetes mellitus, gestational diabetes (pregnancy), assess insulin resistance","code":""},{"path":"principles.html","id":"glycated-hemoglobin-hba1c","chapter":"Principles","heading":"Glycated Hemoglobin (HbA1c)","text":"Core Concept: HbA1c reflects long-term glycemic control, providing integrated measure average blood glucose levels several weeks","code":""},{"path":"principles.html","id":"immunoassay-methods","chapter":"Principles","heading":"Immunoassay Methods","text":"Principle: Antibodies specific glycated hemoglobin (HbA1c) used capture quantify HbA1c blood sampleProcedure:\nSample Preparation: Whole blood lysed release hemoglobin\nIncubation: sample incubated HbA1c-specific antibodies\nDetection: amount antibody-HbA1c complex formed measured, proportional HbA1c concentration\nSample Preparation: Whole blood lysed release hemoglobinIncubation: sample incubated HbA1c-specific antibodiesDetection: amount antibody-HbA1c complex formed measured, proportional HbA1c concentrationDetection Methods:\nEnzyme-Linked Immunosorbent Assay (ELISA): Enzyme-labeled antibodies used, enzyme activity measured quantify antibody-HbA1c complex\nTurbidimetric Inhibition Immunoassay (TINIA): Antibody-HbA1c complex formation measured change turbidity (light scattering)\nEnzyme-Linked Immunosorbent Assay (ELISA): Enzyme-labeled antibodies used, enzyme activity measured quantify antibody-HbA1c complexTurbidimetric Inhibition Immunoassay (TINIA): Antibody-HbA1c complex formation measured change turbidity (light scattering)Advantages: Automated, high-throughput, widely availableDisadvantages: Susceptible interferences hemoglobin variants factors affecting red blood cell turnover","code":""},{"path":"principles.html","id":"high-performance-liquid-chromatography-hplc","chapter":"Principles","heading":"High-Performance Liquid Chromatography (HPLC)","text":"Principle: HPLC separates different hemoglobin fractions (including HbA1c) based chemical properties. separated fractions quantified using spectrophotometric detectionProcedure:\nSample Preparation: Whole blood lysed release hemoglobin\nSeparation: hemolysate injected HPLC column separates hemoglobin fractions based charge affinity\nDetection: HbA1c hemoglobin fractions detected measuring absorbance specific wavelength\nSample Preparation: Whole blood lysed release hemoglobinSeparation: hemolysate injected HPLC column separates hemoglobin fractions based charge affinityDetection: HbA1c hemoglobin fractions detected measuring absorbance specific wavelengthAdvantages: Highly accurate, can detect hemoglobin variantsDisadvantages: complex, requires specialized equipment, labor-intensive immunoassay methods","code":""},{"path":"principles.html","id":"urine-glucose","chapter":"Principles","heading":"Urine Glucose","text":"Core Concept: Urine glucose quick indicator hyperglycemia less sensitive blood glucose measurements","code":""},{"path":"principles.html","id":"dipstick-method","chapter":"Principles","heading":"Dipstick Method","text":"Principle: reagent strip impregnated glucose oxidase, peroxidase, chromogen dipped urine sample. Glucose urine reacts glucose oxidase produce gluconic acid hydrogen peroxide. hydrogen peroxide reacts chromogen presence peroxidase produce colored productReactions: Glucose Oxidase MethodDetection: color change reagent strip compared color chart estimate glucose concentration urineAdvantages: Simple, rapid, inexpensiveDisadvantages: Semi-quantitative, less sensitive blood glucose measurements, susceptible interferences reducing substances ascorbic acid (Vitamin C)","code":""},{"path":"principles.html","id":"enzymatic-methods","chapter":"Principles","heading":"Enzymatic Methods","text":"Principle: Similar enzymatic methods used blood glucose measurement (glucose oxidase hexokinase). reaction products measured spectrophotometricallyAdvantages: quantitative dipstick method, sensitiveDisadvantages: complex, requires instrumentation","code":""},{"path":"principles.html","id":"ketone-measurement","chapter":"Principles","heading":"Ketone Measurement","text":"Core Concept: Ketone testing helps detect ketoacidosis, serious complication uncontrolled diabetes","code":""},{"path":"principles.html","id":"nitroprusside-reaction-ketostix","chapter":"Principles","heading":"Nitroprusside Reaction (Ketostix)","text":"Principle: Acetoacetate acetone react nitroprusside alkaline medium produce purple colorProcedure: reagent strip impregnated sodium nitroprusside, glycine, buffer dipped urine serum sampleDetection: color change reagent strip compared color chart estimate ketone concentrationSpecificity: Primarily detects acetoacetate; acetone reacts less strongly. Beta-hydroxybutyrate detectedAdvantages: Simple, rapid, inexpensiveDisadvantages: Semi-quantitative, detect beta-hydroxybutyrate (predominant ketone body DKA), susceptible false positives","code":""},{"path":"principles.html","id":"beta-hydroxybutyrate-bhb-measurement","chapter":"Principles","heading":"Beta-Hydroxybutyrate (BHB) Measurement","text":"Principle: Beta-hydroxybutyrate dehydrogenase (BHBDH) catalyzes oxidation beta-hydroxybutyrate acetoacetate, reduction NAD+ NADH. NADH produced measured spectrophotometricallyReaction:\nBeta-Hydroxybutyrate + NAD+ –(BHBDH)–> Acetoacetate + NADH + H+\nBeta-Hydroxybutyrate + NAD+ –(BHBDH)–> Acetoacetate + NADH + H+Detection: increase absorbance due NADH formation directly proportional beta-hydroxybutyrate concentration sampleAdvantages: Quantitative, specific beta-hydroxybutyrate, clinically relevant DKA managementDisadvantages: expensive, requires instrumentation","code":""},{"path":"principles.html","id":"other-carbohydrates","chapter":"Principles","heading":"Other Carbohydrates","text":"Core Concept: glucose primary focus, specific tests exist sugars investigating metabolic disorders","code":""},{"path":"principles.html","id":"galactose-measurement","chapter":"Principles","heading":"Galactose Measurement","text":"Principle: Galactose oxidase catalyzes oxidation galactose galactonolactone hydrogen peroxide. hydrogen peroxide reacted chromogen presence peroxidase produce colored productReaction:\nGalactose + O2 + H2O –(Galactose Oxidase)–> Galactonolactone + H2O2\nH2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + H2O\nGalactose + O2 + H2O –(Galactose Oxidase)–> Galactonolactone + H2O2H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + H2ODetection: intensity colored product directly proportional galactose concentration sampleClinical Significance: Used diagnose monitor galactosemia","code":""},{"path":"principles.html","id":"fructose-measurement","chapter":"Principles","heading":"Fructose Measurement","text":"Principle: Fructose can measured using enzymatic methods involving specific enzymes convert fructose measurable products (e.g., using fructokinase)Clinical Significance: Used diagnose monitor hereditary fructose intolerance","code":""},{"path":"principles.html","id":"chromatography","chapter":"Principles","heading":"Chromatography","text":"Principle: Chromatography (e.g., HPLC, gas chromatography) can used separate quantify various carbohydrates sample based physical chemical propertiesClinical Significance: Used research purposes specialized clinical settings identify quantify rare sugars carbohydrates","code":""},{"path":"principles.html","id":"key-terms-3","chapter":"Principles","heading":"Key Terms","text":"Glucose Oxidase: enzyme catalyzes oxidation glucoseHexokinase: enzyme catalyzes phosphorylation glucoseGlycated Hemoglobin (HbA1c): Hemoglobin glucose attached itOral Glucose Tolerance Test (OGTT): test assess body’s response glucoseKetones: Products fat breakdownSpectrophotometry: method measure absorbance light solutionChromogen: substance produces colored productEnzymatic Method: laboratory method uses enzymes catalyze reaction","code":""},{"path":"special-precautions.html","id":"special-precautions","chapter":"Special Precautions","heading":"Special Precautions","text":"Accurate carbohydrate testing hinges proper technique. starts moment specimen collection continues troubleshooting issues might pop ","code":""},{"path":"special-precautions.html","id":"special-precautions-1","chapter":"Special Precautions","heading":"Special Precautions","text":"Patient Preparation\nFasting: accurate glucose lipid measurements, patients typically need fast 8-12 hours specimen collection. ensures postprandial effects don’t skew results\nMedications: drugs can influence carbohydrate metabolism. ’s important know patient taking corticosteroids, diuretics, meds impact glucose levels\nInfection/Stress: Illness stress can elevate glucose. patient acutely ill, note request form, can influence interpretation\nFasting: accurate glucose lipid measurements, patients typically need fast 8-12 hours specimen collection. ensures postprandial effects don’t skew resultsMedications: drugs can influence carbohydrate metabolism. ’s important know patient taking corticosteroids, diuretics, meds impact glucose levelsInfection/Stress: Illness stress can elevate glucose. patient acutely ill, note request form, can influence interpretationSpecimen Collection\nTiming: Strict adherence collection times essential, especially glucose tolerance tests. Meticulously document time sample drawn\nOrder Draw: Follow correct order draw collecting multiple tubes. minimizes risk cross-contamination tube additives\nAnticoagulants: Use right anticoagulant test. glucose, fluoride oxalate tubes often used inhibit glycolysis\nTiming: Strict adherence collection times essential, especially glucose tolerance tests. Meticulously document time sample drawnOrder Draw: Follow correct order draw collecting multiple tubes. minimizes risk cross-contamination tube additivesAnticoagulants: Use right anticoagulant test. glucose, fluoride oxalate tubes often used inhibit glycolysisSpecimen Handling\nPrompt Processing: Glucose levels can change quickly unseparated samples cells continue metabolize glucose. Process sample soon possible\nTemperature Control: Keep samples refrigerated (2-8°C) testing delayed, avoid freezing whole blood\nPrompt Processing: Glucose levels can change quickly unseparated samples cells continue metabolize glucose. Process sample soon possibleTemperature Control: Keep samples refrigerated (2-8°C) testing delayed, avoid freezing whole bloodReagent Handling\nStorage: Store reagents according manufacturer’s instructions. Incorrect storage can degrade reagents, leading inaccurate results\nExpiration Dates: Always check expiration dates discard expired reagents\nContamination: Prevent contamination reagents. Use clean technique handling, avoid introducing bacteria substances interfere\nStorage: Store reagents according manufacturer’s instructions. Incorrect storage can degrade reagents, leading inaccurate resultsExpiration Dates: Always check expiration dates discard expired reagentsContamination: Prevent contamination reagents. Use clean technique handling, avoid introducing bacteria substances interfereInstrumentation\nCalibration: Regularly calibrate instruments using appropriate standards. ensures readings accurate consistent time\nMaintenance: Follow instrument’s maintenance schedule. Routine maintenance can prevent breakdowns maintain performance\nQuality Control: Run quality control samples regular intervals monitor accuracy precision instrument\nCalibration: Regularly calibrate instruments using appropriate standards. ensures readings accurate consistent timeMaintenance: Follow instrument’s maintenance schedule. Routine maintenance can prevent breakdowns maintain performanceQuality Control: Run quality control samples regular intervals monitor accuracy precision instrument","code":""},{"path":"special-precautions.html","id":"specimen-collection-and-processing","chapter":"Special Precautions","heading":"Specimen Collection and Processing","text":"Glucose\nSpecimen: Plasma (fluoride oxalate tube), serum\nCollection: Fasting sample preferred. Collect appropriate tube, invert gently mix anticoagulant\nProcessing: Centrifuge promptly (within 30 minutes collection) separate plasma serum. Analyze immediately refrigerate\nStorage: Stable several days refrigerated\nSpecimen: Plasma (fluoride oxalate tube), serumCollection: Fasting sample preferred. Collect appropriate tube, invert gently mix anticoagulantProcessing: Centrifuge promptly (within 30 minutes collection) separate plasma serum. Analyze immediately refrigerateStorage: Stable several days refrigeratedGlucose Tolerance Test (GTT)\nSpecimen: Plasma (fluoride oxalate tube)\nCollection\nPatient fasts 8-12 hours\nBaseline sample taken\nPatient drinks standard glucose solution\nSamples collected specific intervals (e.g., 30 min, 1 hr, 2 hr, 3 hr)\n\nProcessing: Centrifuge promptly, analyze immediately refrigerate\nSpecimen: Plasma (fluoride oxalate tube)Collection\nPatient fasts 8-12 hours\nBaseline sample taken\nPatient drinks standard glucose solution\nSamples collected specific intervals (e.g., 30 min, 1 hr, 2 hr, 3 hr)\nPatient fasts 8-12 hoursBaseline sample takenPatient drinks standard glucose solutionSamples collected specific intervals (e.g., 30 min, 1 hr, 2 hr, 3 hr)Processing: Centrifuge promptly, analyze immediately refrigerateGlycated Hemoglobin (HbA1c)\nSpecimen: Whole blood (EDTA)\nCollection: Routine venipuncture, fasting required\nProcessing: Analyze directly store refrigerated\nStorage: Stable week refrigerated\nSpecimen: Whole blood (EDTA)Collection: Routine venipuncture, fasting requiredProcessing: Analyze directly store refrigeratedStorage: Stable week refrigeratedUrine Glucose\nSpecimen: Random timed urine sample\nCollection: Collect clean container\nProcessing: Analyze immediately, glucose can consumed bacteria\nStorage: delay unavoidable, refrigerate, prompt analysis best\nSpecimen: Random timed urine sampleCollection: Collect clean containerProcessing: Analyze immediately, glucose can consumed bacteriaStorage: delay unavoidable, refrigerate, prompt analysis bestKetones\nSpecimen: Serum, plasma, urine\nCollection: Collect appropriate container\nProcessing: Analyze immediately refrigerate\nSpecimen: Serum, plasma, urineCollection: Collect appropriate containerProcessing: Analyze immediately refrigerate","code":""},{"path":"special-precautions.html","id":"troubleshooting","chapter":"Special Precautions","heading":"Troubleshooting","text":"High Glucose Results\nPre-Analytical\nPatient fasting\nDelayed processing\nContamination specimen\n\nAnalytical\nIncorrect calibration\nReagent deterioration\nInterfering substances\n\nPre-Analytical\nPatient fasting\nDelayed processing\nContamination specimen\nPatient fastingDelayed processingContamination specimenAnalytical\nIncorrect calibration\nReagent deterioration\nInterfering substances\nIncorrect calibrationReagent deteriorationInterfering substancesLow Glucose Results\nPre-Analytical\nProlonged storage without proper anticoagulant\nGlycolysis cells\n\nAnalytical\nIncorrect calibration\nReagent deterioration\n\nPre-Analytical\nProlonged storage without proper anticoagulant\nGlycolysis cells\nProlonged storage without proper anticoagulantGlycolysis cellsAnalytical\nIncorrect calibration\nReagent deterioration\nIncorrect calibrationReagent deteriorationHbA1c Discrepancies\nPre-Analytical\nImproper collection tube\nStorage issues\n\nAnalytical\nInterfering hemoglobin variants\nMethod-specific issues\n\nPre-Analytical\nImproper collection tube\nStorage issues\nImproper collection tubeStorage issuesAnalytical\nInterfering hemoglobin variants\nMethod-specific issues\nInterfering hemoglobin variantsMethod-specific issuesGTT Curve Abnormalities\nPre-Analytical\nIncorrect glucose dose\nMissed collection times\nPatient vomiting\n\nPre-Analytical\nIncorrect glucose dose\nMissed collection times\nPatient vomiting\nIncorrect glucose doseMissed collection timesPatient vomitingUrine Glucose Discrepancies\nPre-Analytical\nContamination\nImproper storage\n\nAnalytical\nInterfering substances affecting dipstick results\n\nPre-Analytical\nContamination\nImproper storage\nContaminationImproper storageAnalytical\nInterfering substances affecting dipstick results\nInterfering substances affecting dipstick results","code":""},{"path":"special-precautions.html","id":"interfering-substances","chapter":"Special Precautions","heading":"Interfering Substances","text":"Ascorbic Acid (Vitamin C)\nInterference: Can cause falsely low glucose results glucose oxidase methods\nMechanism: Ascorbic acid reducing agent interferes chromogenic reaction\nMitigation: Use glucose oxidase methods minimize ascorbic acid interference, hexokinase methods\nInterference: Can cause falsely low glucose results glucose oxidase methodsMechanism: Ascorbic acid reducing agent interferes chromogenic reactionMitigation: Use glucose oxidase methods minimize ascorbic acid interference, hexokinase methodsBilirubin\nInterference: High bilirubin levels can interfere spectrophotometric assays\nMechanism: Bilirubin absorbs light similar wavelengths, affecting absorbance readings\nMitigation: Use methods less susceptible bilirubin interference, employ bilirubin correction techniques\nInterference: High bilirubin levels can interfere spectrophotometric assaysMechanism: Bilirubin absorbs light similar wavelengths, affecting absorbance readingsMitigation: Use methods less susceptible bilirubin interference, employ bilirubin correction techniquesLipemia\nInterference: Turbidity high lipid concentrations can affect spectrophotometric readings\nMechanism: Lipids scatter light, leading inaccurate absorbance measurements\nMitigation: Use lipemia clearing techniques (ultracentrifugation, lipid clearing reagents), consider methods less affected turbidity\nInterference: Turbidity high lipid concentrations can affect spectrophotometric readingsMechanism: Lipids scatter light, leading inaccurate absorbance measurementsMitigation: Use lipemia clearing techniques (ultracentrifugation, lipid clearing reagents), consider methods less affected turbidityHemoglobin\nInterference: Hemolysis releases hemoglobin, can interfere enzymatic reactions\nMechanism: Hemoglobin can absorb light interfere enzyme activity\nMitigation: Avoid hemolysis collection processing\nInterference: Hemolysis releases hemoglobin, can interfere enzymatic reactionsMechanism: Hemoglobin can absorb light interfere enzyme activityMitigation: Avoid hemolysis collection processingUrea\nInterference: High urea concentrations can interfere enzymatic reactions\nMechanism: Urea can alter enzyme activity\nMitigation: Use methods less susceptible urea interference\nInterference: High urea concentrations can interfere enzymatic reactionsMechanism: Urea can alter enzyme activityMitigation: Use methods less susceptible urea interferenceDrugs\nInterference: Certain drugs can directly affect glucose levels\nExamples\nCorticosteroids: Increase glucose\nInsulin: Decreases glucose\nDiuretics: Can increase glucose\n\nMitigation: aware patient’s medication list\nInterference: Certain drugs can directly affect glucose levelsExamples\nCorticosteroids: Increase glucose\nInsulin: Decreases glucose\nDiuretics: Can increase glucose\nCorticosteroids: Increase glucoseInsulin: Decreases glucoseDiuretics: Can increase glucoseMitigation: aware patient’s medication listHemoglobin Variants\nInterference: Can affect HbA1c measurements\nMechanism: variants don’t glycate normally interfere antibody binding\nMitigation: Use HbA1c methods affected common variants\nInterference: Can affect HbA1c measurementsMechanism: variants don’t glycate normally interfere antibody bindingMitigation: Use HbA1c methods affected common variantsSalicylates\nInterference: High doses can cause hypoglycemia\nMechanism: Increased insulin secretion\nMitigation: Consider patient history\nInterference: High doses can cause hypoglycemiaMechanism: Increased insulin secretionMitigation: Consider patient history","code":""},{"path":"special-precautions.html","id":"key-terms-4","chapter":"Special Precautions","heading":"Key Terms","text":"Pre-analytical: Processes occur sample analyzedAnalytical: Processes involved analyzing sampleInterfering Substance: substance affects accuracy testGlycolysis: breakdown glucose cellsCalibration: Adjusting instrument ensure accurate readingsQuality Control: Samples used monitor accuracy precision testLipemia: presence excess lipids bloodHemolysis: breakdown red blood cellsFluoride Oxalate: anticoagulant inhibits glycolysis","code":""},{"path":"tolerance-testing.html","id":"tolerance-testing","chapter":"Tolerance Testing","heading":"Tolerance Testing","text":"Tolerance testing, particularly Oral Glucose Tolerance Test (OGTT), designed assess body handles glucose load. ’s dynamic test, meaning ’re just looking single snapshot rather glucose levels change time","code":""},{"path":"tolerance-testing.html","id":"oral-glucose-tolerance-test-ogtt-1","chapter":"Tolerance Testing","heading":"Oral Glucose Tolerance Test (OGTT)","text":"Principle: Measures body’s ability clear glucose blood set period ingesting specific amount glucose. assesses insulin secretion insulin sensitivityIndications:\nDiagnosis diabetes mellitus (especially fasting glucose borderline)\nScreening diagnosis gestational diabetes\nEvaluation insulin resistance\nAssessment reactive hypoglycemia\nDiagnosis diabetes mellitus (especially fasting glucose borderline)Screening diagnosis gestational diabetesEvaluation insulin resistanceAssessment reactive hypoglycemia","code":""},{"path":"tolerance-testing.html","id":"patient-preparation","chapter":"Tolerance Testing","heading":"Patient Preparation","text":"Dietary Instructions:\n3 Days Prior: patient consume diet containing least 150 grams carbohydrates per day. ensures body’s glucose handling mechanisms primed\nRationale: Carbohydrate restriction test can impair insulin secretion lead false-positive results\n3 Days Prior: patient consume diet containing least 150 grams carbohydrates per day. ensures body’s glucose handling mechanisms primedRationale: Carbohydrate restriction test can impair insulin secretion lead false-positive resultsFasting\n8-12 Hours: patient must fast 8-12 hours test. water allowed period\nRationale: Fasting ensures baseline glucose level stable influenced recent food intake\n8-12 Hours: patient must fast 8-12 hours test. water allowed periodRationale: Fasting ensures baseline glucose level stable influenced recent food intakeMedications\nHold Certain Medications: medications can affect glucose metabolism. physician advise patient whether withhold medications like corticosteroids, diuretics, oral contraceptives prior test\nRationale: medications can alter glucose levels interfere test results\nHold Certain Medications: medications can affect glucose metabolism. physician advise patient whether withhold medications like corticosteroids, diuretics, oral contraceptives prior testRationale: medications can alter glucose levels interfere test resultsActivity Level\nAvoid Strenuous Exercise: patient avoid strenuous exercise least 12 hours test\nRationale: Exercise can affect glucose metabolism influence test results\nAvoid Strenuous Exercise: patient avoid strenuous exercise least 12 hours testRationale: Exercise can affect glucose metabolism influence test resultsSmoking\nSmoking: patient smoke fasting period throughout test\nRationale: Nicotine can affect glucose levels hormonal responses\nSmoking: patient smoke fasting period throughout testRationale: Nicotine can affect glucose levels hormonal responses","code":""},{"path":"tolerance-testing.html","id":"procedure","chapter":"Tolerance Testing","heading":"Procedure","text":"Baseline Sample\nCollect fasting blood sample (plasma serum) measure baseline glucose level\nRationale: establishes starting point glucose metabolism\nCollect fasting blood sample (plasma serum) measure baseline glucose levelRationale: establishes starting point glucose metabolismGlucose Load Administration\nAdults: Administer 75 grams glucose liquid solution (usually 300 mL water). solution consumed within 5 minutes\nPregnant Women: 75-gram 100-gram glucose load may used, depending guidelines followed gestational diabetes screening\nChildren: Administer 1.75 grams glucose per kilogram body weight, maximum 75 grams\nRationale: glucose load challenges body’s ability regulate glucose levels\nAdults: Administer 75 grams glucose liquid solution (usually 300 mL water). solution consumed within 5 minutesPregnant Women: 75-gram 100-gram glucose load may used, depending guidelines followed gestational diabetes screeningChildren: Administer 1.75 grams glucose per kilogram body weight, maximum 75 gramsRationale: glucose load challenges body’s ability regulate glucose levelsBlood Sample Collection\nCollect blood samples (plasma serum) specific intervals glucose load. Common time points include:\n30 minutes\n60 minutes (1 hour)\n120 minutes (2 hours)\nAdditional time points (e.g., 3 hours) may required certain cases\n\nRationale: intervals capture dynamic changes glucose levels body responds glucose load\nCollect blood samples (plasma serum) specific intervals glucose load. Common time points include:\n30 minutes\n60 minutes (1 hour)\n120 minutes (2 hours)\nAdditional time points (e.g., 3 hours) may required certain cases\n30 minutes60 minutes (1 hour)120 minutes (2 hours)Additional time points (e.g., 3 hours) may required certain casesRationale: intervals capture dynamic changes glucose levels body responds glucose loadPatient Monitoring\nMonitor patient adverse reactions, nausea, vomiting, dizziness, sweating\nRationale: Adverse reactions can affect accuracy test may require medical intervention\nMonitor patient adverse reactions, nausea, vomiting, dizziness, sweatingRationale: Adverse reactions can affect accuracy test may require medical intervention","code":""},{"path":"tolerance-testing.html","id":"specimen-handling","chapter":"Tolerance Testing","heading":"Specimen Handling","text":"Collection Tubes\nUse appropriate collection tubes (e.g., fluoride oxalate tubes) prevent glycolysis\nRationale: Fluoride inhibits enzymatic breakdown glucose blood cells\nUse appropriate collection tubes (e.g., fluoride oxalate tubes) prevent glycolysisRationale: Fluoride inhibits enzymatic breakdown glucose blood cellsProcessing\nPromptly centrifuge blood samples separate plasma serum\nRationale: Delay processing can lead falsely low glucose values due continued glycolysis\nPromptly centrifuge blood samples separate plasma serumRationale: Delay processing can lead falsely low glucose values due continued glycolysisStorage\nAnalyze samples immediately refrigerate. samples analyzed within hours, freeze \nRationale: Proper storage minimizes changes glucose levels\nAnalyze samples immediately refrigerate. samples analyzed within hours, freeze themRationale: Proper storage minimizes changes glucose levels","code":""},{"path":"tolerance-testing.html","id":"analytical-considerations","chapter":"Tolerance Testing","heading":"Analytical Considerations","text":"Glucose Measurement Methods\nUse accurate reliable glucose measurement methods, glucose oxidase hexokinase assays\nRationale: Precise glucose measurement essential accurate OGTT interpretation\nUse accurate reliable glucose measurement methods, glucose oxidase hexokinase assaysRationale: Precise glucose measurement essential accurate OGTT interpretationQuality Control\nFollow strict quality control procedures ensure accuracy precision glucose measurements\nRationale: Quality control helps minimize errors ensure reliable test results\nFollow strict quality control procedures ensure accuracy precision glucose measurementsRationale: Quality control helps minimize errors ensure reliable test resultsInterfering Factors\naware potential interfering factors, medications, stress, acute illness, can affect glucose levels\nRationale: Recognizing accounting factors helps prevent misinterpretation test results\naware potential interfering factors, medications, stress, acute illness, can affect glucose levelsRationale: Recognizing accounting factors helps prevent misinterpretation test results","code":""},{"path":"tolerance-testing.html","id":"interpretation","chapter":"Tolerance Testing","heading":"Interpretation","text":"Diagnostic Criteria\nDiagnostic criteria diabetes mellitus based OGTT values (according American Diabetes Association):\nNormal: Fasting glucose < 100 mg/dL (5.6 mmol/L) 2-hour glucose < 140 mg/dL (7.8 mmol/L)\nPrediabetes: Fasting glucose 100-125 mg/dL (5.6-6.9 mmol/L) 2-hour glucose 140-199 mg/dL (7.8-11.0 mmol/L)\nDiabetes: Fasting glucose ≥ 126 mg/dL (7.0 mmol/L) 2-hour glucose ≥ 200 mg/dL (11.1 mmol/L)\n\nGestational Diabetes:\nSpecific criteria vary organization. One common set Carpenter-Coustan criteria, uses 100g load different cutoffs\n\nDiagnostic criteria diabetes mellitus based OGTT values (according American Diabetes Association):\nNormal: Fasting glucose < 100 mg/dL (5.6 mmol/L) 2-hour glucose < 140 mg/dL (7.8 mmol/L)\nPrediabetes: Fasting glucose 100-125 mg/dL (5.6-6.9 mmol/L) 2-hour glucose 140-199 mg/dL (7.8-11.0 mmol/L)\nDiabetes: Fasting glucose ≥ 126 mg/dL (7.0 mmol/L) 2-hour glucose ≥ 200 mg/dL (11.1 mmol/L)\nNormal: Fasting glucose < 100 mg/dL (5.6 mmol/L) 2-hour glucose < 140 mg/dL (7.8 mmol/L)Prediabetes: Fasting glucose 100-125 mg/dL (5.6-6.9 mmol/L) 2-hour glucose 140-199 mg/dL (7.8-11.0 mmol/L)Diabetes: Fasting glucose ≥ 126 mg/dL (7.0 mmol/L) 2-hour glucose ≥ 200 mg/dL (11.1 mmol/L)Gestational Diabetes:\nSpecific criteria vary organization. One common set Carpenter-Coustan criteria, uses 100g load different cutoffs\nSpecific criteria vary organization. One common set Carpenter-Coustan criteria, uses 100g load different cutoffsGlucose Tolerance Curve\nEvaluate glucose tolerance curve, plots glucose levels time\nRationale: shape curve provides insights glucose metabolism insulin response\nEvaluate glucose tolerance curve, plots glucose levels timeRationale: shape curve provides insights glucose metabolism insulin response","code":""},{"path":"tolerance-testing.html","id":"troubleshooting-1","chapter":"Tolerance Testing","heading":"Troubleshooting","text":"Unexpected Results\nOGTT results inconsistent patient’s clinical picture, repeat test consider alternative diagnostic methods\nRationale: OGTT results can influenced various factors, confirmation may needed\nOGTT results inconsistent patient’s clinical picture, repeat test consider alternative diagnostic methodsRationale: OGTT results can influenced various factors, confirmation may neededAdverse Reactions\npatient experiences severe adverse reactions (e.g., vomiting, fainting), discontinue test provide appropriate medical care\nRationale: Patient safety paramount\npatient experiences severe adverse reactions (e.g., vomiting, fainting), discontinue test provide appropriate medical careRationale: Patient safety paramountTechnical Errors\ntechnical errors occur test (e.g., incorrect glucose load, missed sample collection), repeat test different day\nRationale: Technical errors can compromise accuracy test results\ntechnical errors occur test (e.g., incorrect glucose load, missed sample collection), repeat test different dayRationale: Technical errors can compromise accuracy test results","code":""},{"path":"tolerance-testing.html","id":"special-considerations","chapter":"Tolerance Testing","heading":"Special Considerations","text":"Pregnancy\nGestational diabetes screening typically performed 24 28 weeks gestation\ndiagnostic criteria gestational diabetes may differ non-pregnant adults\n1-hour glucose challenge test (GCT) commonly used screening test. GCT positive, 3-hour OGTT performed diagnosis\nGestational diabetes screening typically performed 24 28 weeks gestationThe diagnostic criteria gestational diabetes may differ non-pregnant adultsThe 1-hour glucose challenge test (GCT) commonly used screening test. GCT positive, 3-hour OGTT performed diagnosisChildren\nOGTT rarely used children except specific cases, suspected insulin resistance impaired glucose tolerance\nglucose load adjusted based body weight\nOGTT rarely used children except specific cases, suspected insulin resistance impaired glucose toleranceThe glucose load adjusted based body weightElderly\nelderly may impaired glucose tolerance due age-related changes insulin sensitivity\nDiagnostic criteria diabetes younger adults, clinical judgment needed\nelderly may impaired glucose tolerance due age-related changes insulin sensitivityDiagnostic criteria diabetes younger adults, clinical judgment needed","code":""},{"path":"tolerance-testing.html","id":"key-terms-5","chapter":"Tolerance Testing","heading":"Key Terms","text":"Glucose Load: amount glucose given patient testBaseline Sample: blood sample taken administering glucose loadDiagnostic Criteria: specific glucose values used diagnose diabetesGlucose Tolerance Curve: graph plots glucose levels timeGestational Diabetes: Diabetes develops pregnancyInsulin Resistance: condition cells respond normally insulinReactive Hypoglycemia: Low blood glucose levels occur meal","code":""},{"path":"glycated-proteins.html","id":"glycated-proteins","chapter":"Glycated Proteins","heading":"Glycated Proteins","text":"Glycated proteins, particularly HbA1c, cornerstone diabetes monitoring. provide retrospective view glucose control, helping clinicians patients make informed decisions\n* Definition: Glycated proteins formed glucose non-enzymatically binds proteins, process known glycation Maillard reaction. extent glycation depends average glucose concentration time protein’s lifespan\n* Clinical Significance: Glycated proteins provide measure average glucose levels extended period, making valuable assessing glycemic control diabetes mellitus\n* Types Glycated Proteins\n* Glycated Hemoglobin (HbA1c): commonly measured glycated protein, reflecting average blood glucose levels past 2-3 months\n* Fructosamine: Represents glycated serum proteins, reflecting average glucose levels past 2-3 weeks\n* Glycated Albumin: Reflects average glucose levels past 2-3 weeks, similar fructosamine","code":""},{"path":"glycated-proteins.html","id":"glycated-hemoglobin-hba1c-1","chapter":"Glycated Proteins","heading":"Glycated Hemoglobin (HbA1c)","text":"Principle: HbA1c formed glucose binds hemoglobin red blood cells. percentage hemoglobin glycated proportional average blood glucose concentration lifespan red blood cell (approximately 120 days)Clinical Use\nDiagnosis diabetes mellitus\nMonitoring long-term glycemic control patients diabetes\nAssessment treatment effectiveness\nDiagnosis diabetes mellitusMonitoring long-term glycemic control patients diabetesAssessment treatment effectivenessSpecimen Requirements\nWhole Blood (EDTA): fasting required\nCollection: Routine venipuncture\nStorage: Stable week refrigerated\nWhole Blood (EDTA): fasting requiredCollection: Routine venipunctureStorage: Stable week refrigerated","code":""},{"path":"glycated-proteins.html","id":"analytical-methods","chapter":"Glycated Proteins","heading":"Analytical Methods","text":"Ion-Exchange Chromatography\nPrinciple: Separates hemoglobin fractions based charge differences. Glycated hemoglobin different charge non-glycated hemoglobin, allowing separation\nProcedure\nHemolysate applied ion-exchange column\nDifferent hemoglobin fractions eluted using gradient increasing ionic strength\nFractions detected spectrophotometrically\n\nAdvantages: Accurate precise\nDisadvantages: Labor-intensive, requires specialized equipment\nPrinciple: Separates hemoglobin fractions based charge differences. Glycated hemoglobin different charge non-glycated hemoglobin, allowing separationProcedure\nHemolysate applied ion-exchange column\nDifferent hemoglobin fractions eluted using gradient increasing ionic strength\nFractions detected spectrophotometrically\nHemolysate applied ion-exchange columnDifferent hemoglobin fractions eluted using gradient increasing ionic strengthFractions detected spectrophotometricallyAdvantages: Accurate preciseDisadvantages: Labor-intensive, requires specialized equipmentAffinity Chromatography\nPrinciple: Uses boronate affinity bind glycated hemoglobin. Boronate binds specifically cis-diol groups glycated hemoglobin\nProcedure\nHemolysate applied boronate affinity column\nGlycated hemoglobin binds boronate resin, non-glycated hemoglobin washed away\nGlycated hemoglobin eluted column\namount glycated hemoglobin quantified spectrophotometrically\n\nAdvantages: Specific glycated hemoglobin\nDisadvantages: Can affected interfering substances\nPrinciple: Uses boronate affinity bind glycated hemoglobin. Boronate binds specifically cis-diol groups glycated hemoglobinProcedure\nHemolysate applied boronate affinity column\nGlycated hemoglobin binds boronate resin, non-glycated hemoglobin washed away\nGlycated hemoglobin eluted column\namount glycated hemoglobin quantified spectrophotometrically\nHemolysate applied boronate affinity columnGlycated hemoglobin binds boronate resin, non-glycated hemoglobin washed awayGlycated hemoglobin eluted columnThe amount glycated hemoglobin quantified spectrophotometricallyAdvantages: Specific glycated hemoglobinDisadvantages: Can affected interfering substancesImmunoassay\nPrinciple: Uses antibodies specific glycated hemoglobin capture quantify HbA1c\nProcedure\nSample incubated HbA1c-specific antibodies\namount antibody-HbA1c complex formed measured\nDetection methods include enzyme-linked immunosorbent assay (ELISA) turbidimetric inhibition immunoassay (TINIA)\n\nAdvantages: Automated, high-throughput, widely available\nDisadvantages: Susceptible interferences hemoglobin variants factors affecting red blood cell turnover\nPrinciple: Uses antibodies specific glycated hemoglobin capture quantify HbA1cProcedure\nSample incubated HbA1c-specific antibodies\namount antibody-HbA1c complex formed measured\nDetection methods include enzyme-linked immunosorbent assay (ELISA) turbidimetric inhibition immunoassay (TINIA)\nSample incubated HbA1c-specific antibodiesThe amount antibody-HbA1c complex formed measuredDetection methods include enzyme-linked immunosorbent assay (ELISA) turbidimetric inhibition immunoassay (TINIA)Advantages: Automated, high-throughput, widely availableDisadvantages: Susceptible interferences hemoglobin variants factors affecting red blood cell turnoverCapillary Electrophoresis\nPrinciple: Separates hemoglobin fractions based electrophoretic mobility capillary tube. Glycated hemoglobin different mobility non-glycated hemoglobin\nProcedure\nHemolysate injected capillary tube filled electrolyte solution\nelectric field applied, causing hemoglobin fractions migrate different rates\nFractions detected spectrophotometrically\n\nAdvantages: High resolution, rapid analysis\nDisadvantages: Requires specialized equipment\nPrinciple: Separates hemoglobin fractions based electrophoretic mobility capillary tube. Glycated hemoglobin different mobility non-glycated hemoglobinProcedure\nHemolysate injected capillary tube filled electrolyte solution\nelectric field applied, causing hemoglobin fractions migrate different rates\nFractions detected spectrophotometrically\nHemolysate injected capillary tube filled electrolyte solutionAn electric field applied, causing hemoglobin fractions migrate different ratesFractions detected spectrophotometricallyAdvantages: High resolution, rapid analysisDisadvantages: Requires specialized equipment","code":""},{"path":"glycated-proteins.html","id":"interferences-and-limitations","chapter":"Glycated Proteins","heading":"Interferences and Limitations","text":"Hemoglobin Variants\nCertain hemoglobin variants (e.g., HbS, HbC, HbE, HbF) can interfere HbA1c measurements, leading inaccurate results. variants don’t glycate normally interfere antibody binding\nUse HbA1c methods affected common variants. interference suspected, use alternative method refer specialized laboratory\nCertain hemoglobin variants (e.g., HbS, HbC, HbE, HbF) can interfere HbA1c measurements, leading inaccurate results. variants don’t glycate normally interfere antibody bindingUse HbA1c methods affected common variants. interference suspected, use alternative method refer specialized laboratoryRed Blood Cell Turnover\nConditions affecting red blood cell turnover (e.g., anemia, hemolysis, hemoglobinopathies) can affect HbA1c levels\nIncreased red blood cell turnover can lead falsely low HbA1c results, decreased turnover can lead falsely high results\nConditions affecting red blood cell turnover (e.g., anemia, hemolysis, hemoglobinopathies) can affect HbA1c levelsIncreased red blood cell turnover can lead falsely low HbA1c results, decreased turnover can lead falsely high resultsEthnicity\nethnic groups (e.g., African Americans, Hispanics) may slightly different HbA1c levels compared Caucasians, even similar glucose control\nInterpret HbA1c results caution, considering individual factors clinical context\nethnic groups (e.g., African Americans, Hispanics) may slightly different HbA1c levels compared Caucasians, even similar glucose controlInterpret HbA1c results caution, considering individual factors clinical contextPregnancy\nHbA1c may accurately reflect glycemic control pregnancy due changes red blood cell turnover\nUse alternative methods, continuous glucose monitoring (CGM), assessing glycemic control pregnancy\nHbA1c may accurately reflect glycemic control pregnancy due changes red blood cell turnoverUse alternative methods, continuous glucose monitoring (CGM), assessing glycemic control pregnancyRenal Disease\nChronic kidney disease can affect HbA1c levels due changes red blood cell lifespan uremia\nUse HbA1c results caution, considering severity renal disease\nChronic kidney disease can affect HbA1c levels due changes red blood cell lifespan uremiaUse HbA1c results caution, considering severity renal disease","code":""},{"path":"glycated-proteins.html","id":"fructosamine","chapter":"Glycated Proteins","heading":"Fructosamine","text":"Principle: Fructosamine measures glycated serum proteins, primarily albumin. extent glycation reflects average glucose levels preceding 2-3 weeks (shorter-term marker compared HbA1c)Clinical Use\nMonitoring glycemic control shorter period HbA1c\nSituations HbA1c unreliable (e.g., hemoglobinopathies, hemolytic anemia)\nMonitoring glycemic control shorter period HbA1cSituations HbA1c unreliable (e.g., hemoglobinopathies, hemolytic anemia)Specimen Requirements\nSerum plasma\nFasting required\nSerum plasmaFasting requiredAnalytical Methods\nColorimetric Assay\nBased ability glycated proteins reduce nitroblue tetrazolium (NBT) formazan\namount formazan produced proportional fructosamine concentration\n\nColorimetric Assay\nBased ability glycated proteins reduce nitroblue tetrazolium (NBT) formazan\namount formazan produced proportional fructosamine concentration\nBased ability glycated proteins reduce nitroblue tetrazolium (NBT) formazanThe amount formazan produced proportional fructosamine concentrationInterferences Limitations\nSerum protein levels\nConditions affecting protein turnover (e.g., nephrotic syndrome, liver disease)\nAscorbic acid (Vitamin C)\nSerum protein levelsConditions affecting protein turnover (e.g., nephrotic syndrome, liver disease)Ascorbic acid (Vitamin C)","code":""},{"path":"glycated-proteins.html","id":"glycated-albumin","chapter":"Glycated Proteins","heading":"Glycated Albumin","text":"Principle: Glycated albumin measures percentage albumin glycated, reflecting average glucose levels preceding 2-3 weeks (another short-term option)Clinical Use\nSimilar fructosamine\nMay reliable fructosamine certain conditions\nSimilar fructosamineMay reliable fructosamine certain conditionsSpecimen Requirements\nSerum plasma\nFasting required\nSerum plasmaFasting requiredAnalytical Methods\nEnzymatic Assay\nGlycated albumin cleaved protease release glycated amino acids\nGlycated amino acids quantified using enzymatic reactions\n\nAffinity Chromatography\nGlycated albumin separated non-glycated albumin using affinity chromatography\namount glycated albumin quantified\n\nEnzymatic Assay\nGlycated albumin cleaved protease release glycated amino acids\nGlycated amino acids quantified using enzymatic reactions\nGlycated albumin cleaved protease release glycated amino acidsGlycated amino acids quantified using enzymatic reactionsAffinity Chromatography\nGlycated albumin separated non-glycated albumin using affinity chromatography\namount glycated albumin quantified\nGlycated albumin separated non-glycated albumin using affinity chromatographyThe amount glycated albumin quantifiedInterferences Limitations\nAlbumin levels\nConditions affecting albumin turnover\nAlbumin levelsConditions affecting albumin turnover","code":""},{"path":"glycated-proteins.html","id":"key-terms-6","chapter":"Glycated Proteins","heading":"Key Terms","text":"Glycation: non-enzymatic binding glucose proteinsGlycated Hemoglobin (HbA1c): Glycated hemoglobin red blood cellsFructosamine: Glycated serum proteins, primarily albuminGlycated Albumin: Glycated albumin serumHemoglobin Variant: abnormal form hemoglobinRed Blood Cell Turnover: rate red blood cells replacedInterference: substance condition affects accuracy testAnalytical Method: laboratory procedure used measure substance","code":""},{"path":"result-interpretation.html","id":"result-interpretation","chapter":"Result Interpretation","heading":"Result Interpretation","text":"Interpreting carbohydrate test results piecing together clinical picture, lab values, patient history. ’s just numbers, mean context","code":""},{"path":"result-interpretation.html","id":"glucose","chapter":"Result Interpretation","heading":"Glucose","text":"Fasting Glucose\nNormal: 70-99 mg/dL (3.9-5.5 mmol/L)\nImpaired Fasting Glucose (Prediabetes): 100-125 mg/dL (5.6-6.9 mmol/L)\nDiabetes: ≥ 126 mg/dL (7.0 mmol/L) one occasion\nInterpretation\nElevated fasting glucose suggests impaired insulin secretion insulin resistance\nPrediabetes indicates increased risk developing type 2 diabetes\n\nNormal: 70-99 mg/dL (3.9-5.5 mmol/L)Impaired Fasting Glucose (Prediabetes): 100-125 mg/dL (5.6-6.9 mmol/L)Diabetes: ≥ 126 mg/dL (7.0 mmol/L) one occasionInterpretation\nElevated fasting glucose suggests impaired insulin secretion insulin resistance\nPrediabetes indicates increased risk developing type 2 diabetes\nElevated fasting glucose suggests impaired insulin secretion insulin resistancePrediabetes indicates increased risk developing type 2 diabetesRandom Glucose\nDiabetes: ≥ 200 mg/dL (11.1 mmol/L) symptoms hyperglycemia\nInterpretation\nrandom glucose level 200 mg/dL higher patient classic symptoms diabetes (polyuria, polydipsia, unexplained weight loss) diagnostic diabetes\n\nDiabetes: ≥ 200 mg/dL (11.1 mmol/L) symptoms hyperglycemiaInterpretation\nrandom glucose level 200 mg/dL higher patient classic symptoms diabetes (polyuria, polydipsia, unexplained weight loss) diagnostic diabetes\nrandom glucose level 200 mg/dL higher patient classic symptoms diabetes (polyuria, polydipsia, unexplained weight loss) diagnostic diabetesPostprandial Glucose (2-hour postprandial)\nNormal: < 140 mg/dL (7.8 mmol/L)\nImpaired Glucose Tolerance (Prediabetes): 140-199 mg/dL (7.8-11.0 mmol/L)\nDiabetes: ≥ 200 mg/dL (11.1 mmol/L)\nInterpretation\nElevated postprandial glucose indicates impaired insulin sensitivity secretion\nImpaired glucose tolerance indicates increased risk developing type 2 diabetes\n\nNormal: < 140 mg/dL (7.8 mmol/L)Impaired Glucose Tolerance (Prediabetes): 140-199 mg/dL (7.8-11.0 mmol/L)Diabetes: ≥ 200 mg/dL (11.1 mmol/L)Interpretation\nElevated postprandial glucose indicates impaired insulin sensitivity secretion\nImpaired glucose tolerance indicates increased risk developing type 2 diabetes\nElevated postprandial glucose indicates impaired insulin sensitivity secretionImpaired glucose tolerance indicates increased risk developing type 2 diabetes","code":""},{"path":"result-interpretation.html","id":"oral-glucose-tolerance-test-ogtt-2","chapter":"Result Interpretation","heading":"Oral Glucose Tolerance Test (OGTT)","text":"Non-pregnant Adults\nNormal\nFasting glucose < 100 mg/dL (5.6 mmol/L)\n2-hour glucose < 140 mg/dL (7.8 mmol/L)\n\nImpaired Glucose Tolerance (Prediabetes)\nFasting glucose < 100 mg/dL (5.6 mmol/L)\n2-hour glucose 140-199 mg/dL (7.8-11.0 mmol/L)\n\nDiabetes\nFasting glucose ≥ 126 mg/dL (7.0 mmol/L)\n2-hour glucose ≥ 200 mg/dL (11.1 mmol/L)\n\nInterpretation\nOGTT provides dynamic assessment glucose metabolism, revealing fasting postprandial abnormalities\nImpaired glucose tolerance indicates increased risk developing type 2 diabetes\n\nNormal\nFasting glucose < 100 mg/dL (5.6 mmol/L)\n2-hour glucose < 140 mg/dL (7.8 mmol/L)\nFasting glucose < 100 mg/dL (5.6 mmol/L)2-hour glucose < 140 mg/dL (7.8 mmol/L)Impaired Glucose Tolerance (Prediabetes)\nFasting glucose < 100 mg/dL (5.6 mmol/L)\n2-hour glucose 140-199 mg/dL (7.8-11.0 mmol/L)\nFasting glucose < 100 mg/dL (5.6 mmol/L)2-hour glucose 140-199 mg/dL (7.8-11.0 mmol/L)Diabetes\nFasting glucose ≥ 126 mg/dL (7.0 mmol/L)\n2-hour glucose ≥ 200 mg/dL (11.1 mmol/L)\nFasting glucose ≥ 126 mg/dL (7.0 mmol/L)2-hour glucose ≥ 200 mg/dL (11.1 mmol/L)Interpretation\nOGTT provides dynamic assessment glucose metabolism, revealing fasting postprandial abnormalities\nImpaired glucose tolerance indicates increased risk developing type 2 diabetes\nOGTT provides dynamic assessment glucose metabolism, revealing fasting postprandial abnormalitiesImpaired glucose tolerance indicates increased risk developing type 2 diabetesGestational Diabetes\nDiagnostic criteria vary depending organization (e.g., ADA, , IADPSG). common approach Carpenter-Coustan criteria using 100-gram glucose load:\nFasting ≥ 95 mg/dL (5.3 mmol/L)\n1-hour ≥ 180 mg/dL (10.0 mmol/L)\n2-hour ≥ 155 mg/dL (8.6 mmol/L)\n3-hour ≥ 140 mg/dL (7.8 mmol/L)\nDiagnosis requires two values meeting exceeding criteria\n\nInterpretation\nGestational diabetes associated increased risks mother fetus, including macrosomia, hypoglycemia, preeclampsia\nManagement typically involves dietary modifications, exercise, sometimes insulin therapy\n\nDiagnostic criteria vary depending organization (e.g., ADA, , IADPSG). common approach Carpenter-Coustan criteria using 100-gram glucose load:\nFasting ≥ 95 mg/dL (5.3 mmol/L)\n1-hour ≥ 180 mg/dL (10.0 mmol/L)\n2-hour ≥ 155 mg/dL (8.6 mmol/L)\n3-hour ≥ 140 mg/dL (7.8 mmol/L)\nDiagnosis requires two values meeting exceeding criteria\nFasting ≥ 95 mg/dL (5.3 mmol/L)1-hour ≥ 180 mg/dL (10.0 mmol/L)2-hour ≥ 155 mg/dL (8.6 mmol/L)3-hour ≥ 140 mg/dL (7.8 mmol/L)Diagnosis requires two values meeting exceeding criteriaInterpretation\nGestational diabetes associated increased risks mother fetus, including macrosomia, hypoglycemia, preeclampsia\nManagement typically involves dietary modifications, exercise, sometimes insulin therapy\nGestational diabetes associated increased risks mother fetus, including macrosomia, hypoglycemia, preeclampsiaManagement typically involves dietary modifications, exercise, sometimes insulin therapy","code":""},{"path":"result-interpretation.html","id":"glycated-hemoglobin-hba1c-2","chapter":"Result Interpretation","heading":"Glycated Hemoglobin (HbA1c)","text":"Normal: < 5.7%Prediabetes: 5.7-6.4%Diabetes: ≥ 6.5%Target patients diabetes: < 7.0%Interpretation\nHbA1c reflects average glucose levels past 2-3 months\nused diagnosis monitoring diabetes\ntarget HbA1c patients diabetes < 7.0%, individualized goals may set based factors age, comorbidities, risk hypoglycemia\nHbA1c reflects average glucose levels past 2-3 monthsIt used diagnosis monitoring diabetesThe target HbA1c patients diabetes < 7.0%, individualized goals may set based factors age, comorbidities, risk hypoglycemiaLimitations\nHbA1c may unreliable conditions affecting red blood cell turnover (e.g., anemia, hemoglobinopathies)\nCertain ethnic groups may different HbA1c levels average glucose\nHbA1c may unreliable conditions affecting red blood cell turnover (e.g., anemia, hemoglobinopathies)Certain ethnic groups may different HbA1c levels average glucose","code":""},{"path":"result-interpretation.html","id":"urine-glucose-1","chapter":"Result Interpretation","heading":"Urine Glucose","text":"Normal: NegativePositive: Presence glucose urineInterpretation\nGlucose urine indicates renal threshold glucose (approximately 180 mg/dL) exceeded\nUrine glucose testing less sensitive specific blood glucose testing primarily used screening tool\npositive urine glucose test followed blood glucose testing\nGlucose urine indicates renal threshold glucose (approximately 180 mg/dL) exceededUrine glucose testing less sensitive specific blood glucose testing primarily used screening toolA positive urine glucose test followed blood glucose testing","code":""},{"path":"result-interpretation.html","id":"ketones","chapter":"Result Interpretation","heading":"Ketones","text":"Normal: NegativePositive: Presence ketones blood urineInterpretation\nKetones produced body breaks fat energy due insufficient glucose availability\nKetones urine blood indicate state ketosis, can occur conditions :\nDiabetic ketoacidosis (DKA)\nStarvation\nLow-carbohydrate diets\n\nElevated ketones, especially context hyperglycemia metabolic acidosis, suggestive DKA, medical emergency\nKetones produced body breaks fat energy due insufficient glucose availabilityKetones urine blood indicate state ketosis, can occur conditions :\nDiabetic ketoacidosis (DKA)\nStarvation\nLow-carbohydrate diets\nDiabetic ketoacidosis (DKA)StarvationLow-carbohydrate dietsElevated ketones, especially context hyperglycemia metabolic acidosis, suggestive DKA, medical emergency","code":""},{"path":"result-interpretation.html","id":"fructosamine-1","chapter":"Result Interpretation","heading":"Fructosamine","text":"Normal: Varies depending assayElevated: Indicates elevated average glucose levels past 2-3 weeksInterpretation\nFructosamine marker short-term glycemic control\nmay useful situations HbA1c unreliable, patients hemoglobinopathies altered red blood cell turnover\nFructosamine marker short-term glycemic controlIt may useful situations HbA1c unreliable, patients hemoglobinopathies altered red blood cell turnover","code":""},{"path":"result-interpretation.html","id":"factors-affecting-interpretation","chapter":"Result Interpretation","heading":"Factors Affecting Interpretation","text":"Medications\nCertain medications can affect glucose levels. Corticosteroids, diuretics, antipsychotics can increase glucose, insulin oral hypoglycemic agents decrease glucose\nConsider patient’s medication list interpreting carbohydrate test results\nCertain medications can affect glucose levels. Corticosteroids, diuretics, antipsychotics can increase glucose, insulin oral hypoglycemic agents decrease glucoseConsider patient’s medication list interpreting carbohydrate test resultsAcute Illness/Stress\nAcute illness stress can elevate glucose levels due hormonal changes\nAccount factors interpreting results, especially hospitalized patients\nAcute illness stress can elevate glucose levels due hormonal changesAccount factors interpreting results, especially hospitalized patientsPregnancy\nPregnancy affects glucose metabolism, specific diagnostic criteria used gestational diabetes\nInterpret glucose test results context pregnancy-specific guidelines\nPregnancy affects glucose metabolism, specific diagnostic criteria used gestational diabetesInterpret glucose test results context pregnancy-specific guidelinesRenal Disease\nRenal disease can affect glucose metabolism HbA1c levels\nUse caution interpreting carbohydrate test results patients renal disease\nRenal disease can affect glucose metabolism HbA1c levelsUse caution interpreting carbohydrate test results patients renal diseaseLiver Disease\nSevere liver disease can affect glucose metabolism due impaired gluconeogenesis glycogen storage\nUse caution interpreting carbohydrate test results patients liver disease\nSevere liver disease can affect glucose metabolism due impaired gluconeogenesis glycogen storageUse caution interpreting carbohydrate test results patients liver disease","code":""},{"path":"result-interpretation.html","id":"clinical-correlation","chapter":"Result Interpretation","heading":"Clinical Correlation","text":"Diabetes Mellitus\nCharacterized hyperglycemia due defects insulin secretion, insulin action, \nDiagnosis based fasting glucose, 2-hour glucose OGTT, HbA1c, random glucose symptoms\nManagement involves lifestyle modifications, oral hypoglycemic agents, /insulin therapy\nCharacterized hyperglycemia due defects insulin secretion, insulin action, bothDiagnosis based fasting glucose, 2-hour glucose OGTT, HbA1c, random glucose symptomsManagement involves lifestyle modifications, oral hypoglycemic agents, /insulin therapyPrediabetes\nCharacterized impaired fasting glucose impaired glucose tolerance\nIndicates increased risk developing type 2 diabetes\nManagement involves lifestyle modifications prevent progression diabetes\nCharacterized impaired fasting glucose impaired glucose toleranceIndicates increased risk developing type 2 diabetesManagement involves lifestyle modifications prevent progression diabetesGestational Diabetes\nDiabetes develops pregnancy\nDiagnosis based OGTT\nManagement involves dietary modifications, exercise, sometimes insulin therapy\nDiabetes develops pregnancyDiagnosis based OGTTManagement involves dietary modifications, exercise, sometimes insulin therapyHypoglycemia\nCharacterized low blood glucose levels\nSymptoms include sweating, shakiness, confusion, loss consciousness\nCauses include excess insulin, missed meals, exercise, certain medical conditions\nCharacterized low blood glucose levelsSymptoms include sweating, shakiness, confusion, loss consciousnessCauses include excess insulin, missed meals, exercise, certain medical conditionsDiabetic Ketoacidosis (DKA)\nlife-threatening complication diabetes characterized hyperglycemia, ketosis, metabolic acidosis\nManagement involves insulin therapy, fluid resuscitation, electrolyte replacement\nlife-threatening complication diabetes characterized hyperglycemia, ketosis, metabolic acidosisManagement involves insulin therapy, fluid resuscitation, electrolyte replacement","code":""},{"path":"result-interpretation.html","id":"key-terms-7","chapter":"Result Interpretation","heading":"Key Terms","text":"Fasting Glucose: Glucose level overnight fastPostprandial Glucose: Glucose level mealOral Glucose Tolerance Test (OGTT): test assess glucose metabolismGlycated Hemoglobin (HbA1c): measure average glucose levels 2-3 monthsRenal Threshold: glucose concentration glucose begins appear urineKetones: Products fat breakdownFructosamine: measure average glucose levels 2-3 weeksPrediabetes: condition impaired glucose metabolism increases risk developing diabetesGestational Diabetes: Diabetes develops pregnancyHypoglycemia: Low blood glucose levelsDiabetic Ketoacidosis (DKA): life-threatening complication diabetes characterized hyperglycemia, ketosis, metabolic acidosis","code":""},{"path":"disease-correlation.html","id":"disease-correlation","chapter":"Disease Correlation","heading":"Disease Correlation","text":"results carbohydrate tests paint picture patient’s metabolic health. Certain patterns results point specific disease states, understanding correlations key","code":""},{"path":"disease-correlation.html","id":"diabetes-mellitus-dm","chapter":"Disease Correlation","heading":"Diabetes Mellitus (DM)","text":"Definition: group metabolic disorders characterized hyperglycemia resulting defects insulin secretion, insulin action, bothTypes\nType 1 Diabetes (T1DM): Autoimmune destruction pancreatic beta cells, leading absolute insulin deficiency\nType 2 Diabetes (T2DM): Progressive insulin resistance relative insulin deficiency\nGestational Diabetes (GDM): Diabetes diagnosed pregnancy\nspecific types diabetes: Due genetic defects, medications, conditions\nType 1 Diabetes (T1DM): Autoimmune destruction pancreatic beta cells, leading absolute insulin deficiencyType 2 Diabetes (T2DM): Progressive insulin resistance relative insulin deficiencyGestational Diabetes (GDM): Diabetes diagnosed pregnancyOther specific types diabetes: Due genetic defects, medications, conditionsLaboratory Findings\nFasting Plasma Glucose (FPG): ≥ 126 mg/dL (7.0 mmol/L) one occasion\nOral Glucose Tolerance Test (OGTT): 2-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L)\nHbA1c: ≥ 6.5%\nRandom Plasma Glucose: ≥ 200 mg/dL (11.1 mmol/L) patient classic symptoms hyperglycemia (polyuria, polydipsia, unexplained weight loss)\nUrine Glucose: Positive (cases significant hyperglycemia)\nKetones: Positive (especially T1DM uncontrolled hyperglycemia)\nFasting Plasma Glucose (FPG): ≥ 126 mg/dL (7.0 mmol/L) one occasionOral Glucose Tolerance Test (OGTT): 2-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L)HbA1c: ≥ 6.5%Random Plasma Glucose: ≥ 200 mg/dL (11.1 mmol/L) patient classic symptoms hyperglycemia (polyuria, polydipsia, unexplained weight loss)Urine Glucose: Positive (cases significant hyperglycemia)Ketones: Positive (especially T1DM uncontrolled hyperglycemia)Disease State Correlation\nElevated FPG, OGTT, HbA1c levels diagnostic diabetes mellitus\nseverity hyperglycemia correlates risk developing long-term complications (e.g., retinopathy, nephropathy, neuropathy, cardiovascular disease)\nPresence ketones indicates uncontrolled diabetes increased risk diabetic ketoacidosis (DKA)\nElevated FPG, OGTT, HbA1c levels diagnostic diabetes mellitusThe severity hyperglycemia correlates risk developing long-term complications (e.g., retinopathy, nephropathy, neuropathy, cardiovascular disease)Presence ketones indicates uncontrolled diabetes increased risk diabetic ketoacidosis (DKA)Clinical Significance\nEarly diagnosis management diabetes essential prevent delay onset complications\nMonitoring glucose levels HbA1c crucial assessing treatment effectiveness adjusting therapy needed\nPatient education lifestyle modifications (diet, exercise) important components diabetes management\nEarly diagnosis management diabetes essential prevent delay onset complicationsMonitoring glucose levels HbA1c crucial assessing treatment effectiveness adjusting therapy neededPatient education lifestyle modifications (diet, exercise) important components diabetes management","code":""},{"path":"disease-correlation.html","id":"prediabetes","chapter":"Disease Correlation","heading":"Prediabetes","text":"Definition: state impaired glucose regulation characterized either impaired fasting glucose (IFG) impaired glucose tolerance (IGT)Laboratory Findings\nImpaired Fasting Glucose (IFG): FPG 100-125 mg/dL (5.6-6.9 mmol/L)\nImpaired Glucose Tolerance (IGT): 2-hour plasma glucose OGTT 140-199 mg/dL (7.8-11.0 mmol/L)\nHbA1c: 5.7-6.4%\nImpaired Fasting Glucose (IFG): FPG 100-125 mg/dL (5.6-6.9 mmol/L)Impaired Glucose Tolerance (IGT): 2-hour plasma glucose OGTT 140-199 mg/dL (7.8-11.0 mmol/L)HbA1c: 5.7-6.4%Disease State Correlation\nPrediabetes indicates increased risk developing type 2 diabetes, cardiovascular disease, complications\nhigher glucose levels, greater risk progression diabetes\nPrediabetes indicates increased risk developing type 2 diabetes, cardiovascular disease, complicationsThe higher glucose levels, greater risk progression diabetesClinical Significance\nEarly identification prediabetes allows intervention lifestyle modifications (diet, exercise) prevent delay onset type 2 diabetes\nRegular monitoring glucose levels HbA1c recommended\nEarly identification prediabetes allows intervention lifestyle modifications (diet, exercise) prevent delay onset type 2 diabetesRegular monitoring glucose levels HbA1c recommended","code":""},{"path":"disease-correlation.html","id":"gestational-diabetes-mellitus-gdm","chapter":"Disease Correlation","heading":"Gestational Diabetes Mellitus (GDM)","text":"Definition: Diabetes diagnosed pregnancyScreening\nTypically performed 24-28 weeks gestation\n1-hour Glucose Challenge Test (GCT): 50-gram glucose load, measure plasma glucose 1 hour. value ≥ 130-140 mg/dL (7.2-7.8 mmol/L) considered positive requires follow-OGTT\nTypically performed 24-28 weeks gestation1-hour Glucose Challenge Test (GCT): 50-gram glucose load, measure plasma glucose 1 hour. value ≥ 130-140 mg/dL (7.2-7.8 mmol/L) considered positive requires follow-OGTTDiagnosis\nOral Glucose Tolerance Test (OGTT) 75-gram 100-gram glucose load\nDiagnostic criteria vary depending organization (e.g., ADA, , IADPSG)\nCommon criteria (Carpenter-Coustan, 100-gram OGTT):\nFasting ≥ 95 mg/dL (5.3 mmol/L)\n1-hour ≥ 180 mg/dL (10.0 mmol/L)\n2-hour ≥ 155 mg/dL (8.6 mmol/L)\n3-hour ≥ 140 mg/dL (7.8 mmol/L)\nTwo values meeting exceeding criteria establish diagnosis\n\nOral Glucose Tolerance Test (OGTT) 75-gram 100-gram glucose loadDiagnostic criteria vary depending organization (e.g., ADA, , IADPSG)Common criteria (Carpenter-Coustan, 100-gram OGTT):\nFasting ≥ 95 mg/dL (5.3 mmol/L)\n1-hour ≥ 180 mg/dL (10.0 mmol/L)\n2-hour ≥ 155 mg/dL (8.6 mmol/L)\n3-hour ≥ 140 mg/dL (7.8 mmol/L)\nTwo values meeting exceeding criteria establish diagnosis\nFasting ≥ 95 mg/dL (5.3 mmol/L)1-hour ≥ 180 mg/dL (10.0 mmol/L)2-hour ≥ 155 mg/dL (8.6 mmol/L)3-hour ≥ 140 mg/dL (7.8 mmol/L)Two values meeting exceeding criteria establish diagnosisLaboratory Findings\nElevated glucose levels OGTT\nElevated glucose levels OGTTDisease State Correlation\nGDM associated increased risks mother fetus, including macrosomia (large baby), hypoglycemia, preeclampsia, increased risk developing type 2 diabetes later life\nGDM associated increased risks mother fetus, including macrosomia (large baby), hypoglycemia, preeclampsia, increased risk developing type 2 diabetes later lifeClinical Significance\nEarly diagnosis management GDM essential reduce risks mother fetus\nManagement typically involves dietary modifications, exercise, sometimes insulin therapy\nPostpartum glucose testing recommended assess persistent diabetes\nEarly diagnosis management GDM essential reduce risks mother fetusManagement typically involves dietary modifications, exercise, sometimes insulin therapyPostpartum glucose testing recommended assess persistent diabetes","code":""},{"path":"disease-correlation.html","id":"hypoglycemia-1","chapter":"Disease Correlation","heading":"Hypoglycemia","text":"Definition: Abnormally low blood glucose levelsCauses\nExcess insulin administration patients diabetes\nOral hypoglycemic agents\nMissed meals inadequate carbohydrate intake\nExcessive exercise\nAlcohol consumption\nCertain medical conditions (e.g., liver disease, kidney disease, hormone deficiencies, insulinoma)\nExcess insulin administration patients diabetesOral hypoglycemic agentsMissed meals inadequate carbohydrate intakeExcessive exerciseAlcohol consumptionCertain medical conditions (e.g., liver disease, kidney disease, hormone deficiencies, insulinoma)Laboratory Findings\nPlasma glucose < 70 mg/dL (3.9 mmol/L)\nsevere cases, glucose may < 50 mg/dL (2.8 mmol/L)\nPlasma glucose < 70 mg/dL (3.9 mmol/L)severe cases, glucose may < 50 mg/dL (2.8 mmol/L)Disease State Correlation\nSymptoms hypoglycemia include sweating, shakiness, anxiety, palpitations, confusion, dizziness, blurred vision, difficulty speaking, seizures, loss consciousness\nSevere hypoglycemia can lead brain damage death\nSymptoms hypoglycemia include sweating, shakiness, anxiety, palpitations, confusion, dizziness, blurred vision, difficulty speaking, seizures, loss consciousnessSevere hypoglycemia can lead brain damage deathClinical Significance\nPrompt recognition treatment hypoglycemia essential\nTreatment typically involves ingestion fast-acting carbohydrates (e.g., glucose tablets, juice)\nUnderlying causes hypoglycemia identified addressed\nPrompt recognition treatment hypoglycemia essentialTreatment typically involves ingestion fast-acting carbohydrates (e.g., glucose tablets, juice)Underlying causes hypoglycemia identified addressed","code":""},{"path":"disease-correlation.html","id":"diabetic-ketoacidosis-dka","chapter":"Disease Correlation","heading":"Diabetic Ketoacidosis (DKA)","text":"Definition: life-threatening complication diabetes characterized hyperglycemia, ketosis, metabolic acidosisEtiology\nPrimarily occurs patients type 1 diabetes due absolute insulin deficiency\nCan also occur patients type 2 diabetes conditions severe stress, infection, illness\nPrimarily occurs patients type 1 diabetes due absolute insulin deficiencyCan also occur patients type 2 diabetes conditions severe stress, infection, illnessLaboratory Findings\nPlasma Glucose: Elevated, typically > 250 mg/dL (13.9 mmol/L)\nKetones: Elevated serum urine\nBeta-hydroxybutyrate predominant ketone body\n\nArterial Blood Gases (ABG)\npH < 7.3\nBicarbonate (HCO3-) < 15 mEq/L\n\nElectrolytes\nAnion gap > 12 mEq/L\nPotassium may normal, elevated, decreased\n\nPlasma Glucose: Elevated, typically > 250 mg/dL (13.9 mmol/L)Ketones: Elevated serum urine\nBeta-hydroxybutyrate predominant ketone body\nBeta-hydroxybutyrate predominant ketone bodyArterial Blood Gases (ABG)\npH < 7.3\nBicarbonate (HCO3-) < 15 mEq/L\npH < 7.3Bicarbonate (HCO3-) < 15 mEq/LElectrolytes\nAnion gap > 12 mEq/L\nPotassium may normal, elevated, decreased\nAnion gap > 12 mEq/LPotassium may normal, elevated, decreasedDisease State Correlation\nDKA medical emergency requiring prompt treatment\nSymptoms include polyuria, polydipsia, nausea, vomiting, abdominal pain, weakness, fruity-smelling breath, altered mental status\nDKA medical emergency requiring prompt treatmentSymptoms include polyuria, polydipsia, nausea, vomiting, abdominal pain, weakness, fruity-smelling breath, altered mental statusClinical Significance\nPrompt diagnosis treatment DKA essential prevent complications cerebral edema, cardiac arrhythmias, death\nTreatment involves insulin therapy, fluid resuscitation, electrolyte replacement\nPrompt diagnosis treatment DKA essential prevent complications cerebral edema, cardiac arrhythmias, deathTreatment involves insulin therapy, fluid resuscitation, electrolyte replacement","code":""},{"path":"disease-correlation.html","id":"hyperosmolar-hyperglycemic-state-hhs","chapter":"Disease Correlation","heading":"Hyperosmolar Hyperglycemic State (HHS)","text":"Definition: life-threatening complication diabetes characterized severe hyperglycemia, hyperosmolarity, dehydration, without significant ketosisEtiology\nPrimarily occurs patients type 2 diabetes\nOften precipitated illness, infection, dehydration\nPrimarily occurs patients type 2 diabetesOften precipitated illness, infection, dehydrationLaboratory Findings\nPlasma Glucose: elevated, typically > 600 mg/dL (33.3 mmol/L)\nSerum Osmolality: > 320 mOsm/kg\nKetones: Absent mild\nArterial Blood Gases (ABG): pH > 7.3, bicarbonate > 15 mEq/L\nElectrolytes: May show electrolyte imbalances\nPlasma Glucose: elevated, typically > 600 mg/dL (33.3 mmol/L)Serum Osmolality: > 320 mOsm/kgKetones: Absent mildArterial Blood Gases (ABG): pH > 7.3, bicarbonate > 15 mEq/LElectrolytes: May show electrolyte imbalancesDisease State Correlation\nHHS medical emergency requiring prompt treatment\nSymptoms include severe dehydration, altered mental status, seizures, coma\nHHS medical emergency requiring prompt treatmentSymptoms include severe dehydration, altered mental status, seizures, comaClinical Significance\nPrompt diagnosis treatment HHS essential prevent complications cerebral edema, thromboembolic events, death\nTreatment involves fluid resuscitation, insulin therapy, electrolyte replacement\nPrompt diagnosis treatment HHS essential prevent complications cerebral edema, thromboembolic events, deathTreatment involves fluid resuscitation, insulin therapy, electrolyte replacement","code":""},{"path":"disease-correlation.html","id":"galactosemia-1","chapter":"Disease Correlation","heading":"Galactosemia","text":"Definition: rare genetic metabolic disorder characterized inability metabolize galactose due deficiency one enzymes involved galactose metabolismTypes\nClassic Galactosemia: Deficiency galactose-1-phosphate uridyltransferase (GALT)\nGalactokinase Deficiency: Deficiency galactokinase (GALK)\nUDP-Galactose-4-Epimerase Deficiency: Deficiency UDP-galactose-4-epimerase (GALE)\nClassic Galactosemia: Deficiency galactose-1-phosphate uridyltransferase (GALT)Galactokinase Deficiency: Deficiency galactokinase (GALK)UDP-Galactose-4-Epimerase Deficiency: Deficiency UDP-galactose-4-epimerase (GALE)Laboratory Findings\nElevated galactose levels blood urine\nDeficiency specific enzyme red blood cells\nUrine reducing substances positive (non-glucose)\nElevated galactose levels blood urineDeficiency specific enzyme red blood cellsUrine reducing substances positive (non-glucose)Disease State Correlation\nSymptoms galactosemia include feeding difficulties, vomiting, diarrhea, lethargy, jaundice, hepatomegaly, cataracts, intellectual disability\nEarly diagnosis treatment essential prevent long-term complications\nSymptoms galactosemia include feeding difficulties, vomiting, diarrhea, lethargy, jaundice, hepatomegaly, cataracts, intellectual disabilityEarly diagnosis treatment essential prevent long-term complicationsClinical Significance\nNewborn screening galactosemia performed many countries\nTreatment involves strict dietary restriction galactose\nNewborn screening galactosemia performed many countriesTreatment involves strict dietary restriction galactose","code":""},{"path":"disease-correlation.html","id":"hereditary-fructose-intolerance-hfi","chapter":"Disease Correlation","heading":"Hereditary Fructose Intolerance (HFI)","text":"Definition: rare genetic metabolic disorder caused deficiency aldolase B, leading accumulation fructose-1-phosphate liver, kidney, small intestineLaboratory Findings\nHypoglycemia fructose ingestion\nElevated liver enzymes (AST, ALT)\nElevated bilirubin\nProlonged prothrombin time (PT)\nUrine reducing substances positive (non-glucose)\nGenetic testing confirms diagnosis\nHypoglycemia fructose ingestionElevated liver enzymes (AST, ALT)Elevated bilirubinProlonged prothrombin time (PT)Urine reducing substances positive (non-glucose)Genetic testing confirms diagnosisDisease State Correlation\nSymptoms HFI include vomiting, abdominal pain, hypoglycemia, liver damage, kidney dysfunction\nRepeated fructose ingestion can lead liver failure death\nSymptoms HFI include vomiting, abdominal pain, hypoglycemia, liver damage, kidney dysfunctionRepeated fructose ingestion can lead liver failure deathClinical Significance\nEarly diagnosis treatment essential prevent long-term complications\nTreatment involves strict dietary restriction fructose, sucrose, sorbitol\nEarly diagnosis treatment essential prevent long-term complicationsTreatment involves strict dietary restriction fructose, sucrose, sorbitol","code":""},{"path":"disease-correlation.html","id":"key-terms-8","chapter":"Disease Correlation","heading":"Key Terms","text":"Diabetes Mellitus: group metabolic disorders characterized hyperglycemiaPrediabetes: state impaired glucose regulationGestational Diabetes: Diabetes diagnosed pregnancyHypoglycemia: Abnormally low blood glucose levelsDiabetic Ketoacidosis (DKA): life-threatening complication diabetes characterized hyperglycemia, ketosis, metabolic acidosisHyperosmolar Hyperglycemic State (HHS): life-threatening complication diabetes characterized severe hyperglycemia, hyperosmolarity, dehydration without significant ketosisGalactosemia: genetic disorder characterized inability metabolize galactoseHereditary Fructose Intolerance (HFI): genetic disorder caused deficiency aldolase B, leading accumulation fructose-1-phosphateFasting Plasma Glucose (FPG): Glucose level overnight fastOral Glucose Tolerance Test (OGTT): test assess glucose metabolismHbA1c: measure average glucose levels 2-3 monthsKetones: Products fat breakdown","code":""},{"path":"lipids.html","id":"lipids","chapter":"Lipids","heading":"Lipids","text":"Lipid testing fundamental assessing cardiovascular risk identifying metabolic disorders. comprehensive overview integrates underlying biochemical theory laboratory testing procedures, result interpretation, disease state correlation","code":""},{"path":"lipids.html","id":"biochemical-theory-and-physiology-1","chapter":"Lipids","heading":"Biochemical Theory and Physiology","text":"Lipid Functions\nEnergy Storage: Triglycerides primary form energy storage\nCell Structure: Phospholipids cholesterol essential components cell membranes\nHormone Synthesis: Cholesterol precursor steroid hormones bile acids\nEnergy Storage: Triglycerides primary form energy storageCell Structure: Phospholipids cholesterol essential components cell membranesHormone Synthesis: Cholesterol precursor steroid hormones bile acidsLipid Metabolic Pathways\nLipolysis: Breakdown triglycerides release fatty acids glycerol\nFatty Acid Oxidation: Breakdown fatty acids generate energy\nLipogenesis: Synthesis fatty acids acetyl-CoA\nCholesterol Synthesis: Complex process produce cholesterol\nLipoprotein Metabolism: Assembly, transport, breakdown lipoproteins\nLipolysis: Breakdown triglycerides release fatty acids glycerolFatty Acid Oxidation: Breakdown fatty acids generate energyLipogenesis: Synthesis fatty acids acetyl-CoACholesterol Synthesis: Complex process produce cholesterolLipoprotein Metabolism: Assembly, transport, breakdown lipoproteinsLipoproteins\nChylomicrons: Transport dietary triglycerides\nVLDL: Transport triglycerides liver\nLDL: Transport cholesterol tissues\nHDL: Transport cholesterol tissues back liver (reverse cholesterol transport)\nChylomicrons: Transport dietary triglyceridesVLDL: Transport triglycerides liverLDL: Transport cholesterol tissuesHDL: Transport cholesterol tissues back liver (reverse cholesterol transport)Key Enzymes\nLipoprotein Lipase (LPL): Hydrolyzes triglycerides lipoproteins\nHMG-CoA Reductase: Rate-limiting enzyme cholesterol synthesis\nLipoprotein Lipase (LPL): Hydrolyzes triglycerides lipoproteinsHMG-CoA Reductase: Rate-limiting enzyme cholesterol synthesisHormonal Regulation\nInsulin: Promotes lipid storage inhibits lipolysis\nGlucagon Epinephrine: Promote lipolysis\nCortisol: Affects lipid metabolism distribution\nInsulin: Promotes lipid storage inhibits lipolysisGlucagon Epinephrine: Promote lipolysisCortisol: Affects lipid metabolism distribution","code":""},{"path":"lipids.html","id":"laboratory-test-procedures-1","chapter":"Lipids","heading":"Laboratory Test Procedures","text":"Lipid Panel\nTotal Cholesterol (TC): Enzymatic methods\nTriglycerides (TG): Enzymatic methods\nHDL Cholesterol (HDL-C): Direct indirect methods\nLDL Cholesterol (LDL-C): Calculated (Friedewald equation) direct methods\nTotal Cholesterol (TC): Enzymatic methodsTriglycerides (TG): Enzymatic methodsHDL Cholesterol (HDL-C): Direct indirect methodsLDL Cholesterol (LDL-C): Calculated (Friedewald equation) direct methodsApolipoproteins\nApo -1 (HDL component): Immunochemical methods\nApo B (LDL, VLDL, IDL component): Immunochemical methods\nApo -1 (HDL component): Immunochemical methodsApo B (LDL, VLDL, IDL component): Immunochemical methodsLipoprotein () [Lp()]\nImmunochemical methods\nImmunochemical methodsLipid Electrophoresis\nSeparation lipoproteins based electrical charge size\nSeparation lipoproteins based electrical charge sizeSpecial Precautions\nPatient Preparation: Fasting (9-12 hours), medication considerations\nSpecimen Collection: Proper tube type, order draw, tourniquet time\nSpecimen Processing: Prompt centrifugation storage\nPatient Preparation: Fasting (9-12 hours), medication considerationsSpecimen Collection: Proper tube type, order draw, tourniquet timeSpecimen Processing: Prompt centrifugation storageInterfering Substances\nLipemia, bilirubin, hemoglobin, medications\nLipemia, bilirubin, hemoglobin, medications","code":""},{"path":"lipids.html","id":"test-result-interpretation-1","chapter":"Lipids","heading":"Test Result Interpretation","text":"Reference Intervals\nTotal Cholesterol: < 200 mg/dL\nTriglycerides: < 150 mg/dL\nHDL Cholesterol: > 40 mg/dL\nLDL Cholesterol: Varies depending risk factors\nTotal Cholesterol: < 200 mg/dLTriglycerides: < 150 mg/dLHDL Cholesterol: > 40 mg/dLLDL Cholesterol: Varies depending risk factorsClinical Significance\nElevated LDL-C non-HDL-C increase CVD risk\nLow HDL-C independent risk factor CVD\nElevated triglycerides increase CVD pancreatitis risk\nElevated LDL-C non-HDL-C increase CVD riskLow HDL-C independent risk factor CVDElevated triglycerides increase CVD pancreatitis riskFactors Affecting Interpretation\nFasting status, medications, medical conditions, ethnicity, age, gender, pregnancy\nFasting status, medications, medical conditions, ethnicity, age, gender, pregnancy","code":""},{"path":"lipids.html","id":"disease-state-correlation-1","chapter":"Lipids","heading":"Disease State Correlation","text":"Atherosclerosis\nElevated LDL-C, non-HDL-C, Apo B; low HDL-C\nElevated LDL-C, non-HDL-C, Apo B; low HDL-CCoronary Artery Disease (CAD)\nElevated LDL-C, triglycerides, Lp(); low HDL-C\nElevated LDL-C, triglycerides, Lp(); low HDL-CHyperlipidemia Dyslipidemia\nElevated total cholesterol, LDL-C, triglycerides; low HDL-C\nElevated total cholesterol, LDL-C, triglycerides; low HDL-CMetabolic Syndrome\nElevated triglycerides fasting glucose; low HDL-C\nElevated triglycerides fasting glucose; low HDL-CAcute Pancreatitis\nElevated triglycerides (> 500 mg/dL)\nElevated triglycerides (> 500 mg/dL)Lipoprotein Disorders (e.g., Familial Hypercholesterolemia, Tangier Disease)\nElevated LDL-C (FH), low HDL-C (Tangier)\nElevated LDL-C (FH), low HDL-C (Tangier)Non-Alcoholic Fatty Liver Disease (NAFLD)\nElevated liver enzymes, triglycerides, fasting glucose\nElevated liver enzymes, triglycerides, fasting glucoseClinical Management\nLifestyle Modifications: Diet, exercise, weight loss, smoking cessation\nMedications: Statins, fibrates, niacin, omega-3 fatty acids\nAssessment Cardiovascular Risk: Use risk assessment tools (e.g., Framingham Risk Score, ASCVD Risk Estimator)\nLifestyle Modifications: Diet, exercise, weight loss, smoking cessationMedications: Statins, fibrates, niacin, omega-3 fatty acidsAssessment Cardiovascular Risk: Use risk assessment tools (e.g., Framingham Risk Score, ASCVD Risk Estimator)","code":""},{"path":"biochemicals-1.html","id":"biochemicals-1","chapter":"Biochemicals","heading":"Biochemicals","text":"overview connects biochemical understanding lipids roles health disease, covering metabolic pathways, normal abnormal states, physical/chemical properties","code":""},{"path":"biochemicals-1.html","id":"biochemical-theory-and-metabolic-pathways","chapter":"Biochemicals","heading":"Biochemical Theory and Metabolic Pathways","text":"Lipids Versatile Molecules: Essential energy storage, cell structure, hormone synthesisKey Metabolic Pathways\nLipolysis: Triglyceride breakdown release fatty acids glycerol\nFatty Acid Oxidation (Beta-Oxidation): Fatty acid breakdown generate energy\nLipogenesis: Fatty acid synthesis acetyl-CoA\nTriglyceride Synthesis: Esterification fatty acids glycerol storage\nCholesterol Synthesis: Complex process produce cholesterol\nLipoprotein Metabolism: Assembly, transport, breakdown lipoproteins\nLipolysis: Triglyceride breakdown release fatty acids glycerolFatty Acid Oxidation (Beta-Oxidation): Fatty acid breakdown generate energyLipogenesis: Fatty acid synthesis acetyl-CoATriglyceride Synthesis: Esterification fatty acids glycerol storageCholesterol Synthesis: Complex process produce cholesterolLipoprotein Metabolism: Assembly, transport, breakdown lipoproteinsHormonal Regulation: Insulin, glucagon, epinephrine, cortisol","code":""},{"path":"biochemicals-1.html","id":"normal-and-abnormal-states-1","chapter":"Biochemicals","heading":"Normal and Abnormal States","text":"Normal Lipid Profile: Optimal levels cholesterol, triglycerides, LDL, HDLAbnormal Lipid States\nHyperlipidemia: Elevated total cholesterol, LDL cholesterol, /triglycerides\nDyslipidemia: Imbalances lipid levels (high LDL, low HDL, high triglycerides)\nAtherosclerosis: Plaque buildup arteries\nFatty Liver Disease (NAFLD/NASH): Excess fat accumulation liver\nLipoprotein Disorders: Genetic defects affecting lipoprotein metabolism\nLipodystrophy: Selective loss adipose tissue\nHyperlipidemia: Elevated total cholesterol, LDL cholesterol, /triglyceridesDyslipidemia: Imbalances lipid levels (high LDL, low HDL, high triglycerides)Atherosclerosis: Plaque buildup arteriesFatty Liver Disease (NAFLD/NASH): Excess fat accumulation liverLipoprotein Disorders: Genetic defects affecting lipoprotein metabolismLipodystrophy: Selective loss adipose tissue","code":""},{"path":"biochemicals-1.html","id":"physical-and-chemical-properties-1","chapter":"Biochemicals","heading":"Physical and Chemical Properties","text":"Lipoproteins\nSpherical particles hydrophobic core amphipathic shell\nTransport lipids blood\nSpherical particles hydrophobic core amphipathic shellTransport lipids bloodPhospholipids\nAmphipathic molecules polar head nonpolar tails\nForm cell membrane bilayers\nAmphipathic molecules polar head nonpolar tailsForm cell membrane bilayersTriglycerides\nNonpolar, hydrophobic molecules\nPrimary form energy storage\nNonpolar, hydrophobic moleculesPrimary form energy storageCholesterol\nRigid, hydrophobic steroid ring structure\nPrecursor hormones bile acids\nRigid, hydrophobic steroid ring structurePrecursor hormones bile acidsApolipoproteins\nProteins bind lipoproteins\nProvide structure, targeting signals, enzyme regulation\nProteins bind lipoproteinsProvide structure, targeting signals, enzyme regulation","code":""},{"path":"biochemicals-1.html","id":"interconnections","chapter":"Biochemicals","heading":"Interconnections","text":"Metabolic Pathways Impact Lipid Levels: Dysregulation lipid metabolism leads abnormal lipid profilesLipid Properties Influence Function: physical chemical properties lipids determine transported, stored, used bodyDisease States Arise Imbalances: Abnormal lipid states contribute cardiovascular disease, fatty liver disease, metabolic disorders","code":""},{"path":"biochemicals-1.html","id":"clinical-significance","chapter":"Biochemicals","heading":"Clinical Significance","text":"Diagnosis Risk Assessment: Lipid profiles used assess cardiovascular riskManagement Strategies: Lifestyle modifications medications target specific lipid abnormalitiesUnderstanding Interplay: Connecting lipid biochemistry disease states allows comprehensive patient care","code":""},{"path":"metabolic-1.html","id":"metabolic-1","chapter":"Metabolic","heading":"Metabolic","text":"Lipid metabolic pathways vital energy storage, cell structure, hormone synthesis. metabolism complex set processes breaking building moleculesKey Pathways\nLipolysis: Triglyceride breakdown release fatty acids glycerol\nFatty Acid Oxidation (Beta-Oxidation): Fatty acid breakdown generate energy\nLipogenesis: Fatty acid synthesis acetyl-CoA\nTriglyceride Synthesis: Esterification fatty acids glycerol form triglycerides\nCholesterol Synthesis: multi-step process produce cholesterol\nLipoprotein Metabolism: processes assembling, transporting, breaking lipoproteins deliver lipids throughout body\nLipolysis: Triglyceride breakdown release fatty acids glycerolFatty Acid Oxidation (Beta-Oxidation): Fatty acid breakdown generate energyLipogenesis: Fatty acid synthesis acetyl-CoATriglyceride Synthesis: Esterification fatty acids glycerol form triglyceridesCholesterol Synthesis: multi-step process produce cholesterolLipoprotein Metabolism: processes assembling, transporting, breaking lipoproteins deliver lipids throughout body","code":""},{"path":"metabolic-1.html","id":"lipolysis","chapter":"Metabolic","heading":"Lipolysis","text":"Purpose: break stored triglycerides (fats) glycerol fatty acidsLocation: Cytosol adipose (fat) tissue cellsRegulation\nHormone-sensitive lipase (HSL) rate-limiting enzyme\nActivated : Epinephrine, glucagon, cortisol (hormones signal low energy)\nInhibited : Insulin (hormone signals high energy)\nHormone-sensitive lipase (HSL) rate-limiting enzymeActivated : Epinephrine, glucagon, cortisol (hormones signal low energy)Inhibited : Insulin (hormone signals high energy)Process\nHormone binds receptor\nSignal cascade activates protein kinase (PKA)\nPKA phosphorylates activates HSL\nHSL hydrolyzes triglycerides diglycerides, monoglycerides, ultimately glycerol fatty acids\nHormone binds receptorSignal cascade activates protein kinase (PKA)PKA phosphorylates activates HSLHSL hydrolyzes triglycerides diglycerides, monoglycerides, ultimately glycerol fatty acidsFate Products\nFatty acids bind albumin blood transported tissues energy use (beta-oxidation)\nGlycerol transported liver gluconeogenesis glycolysis\nFatty acids bind albumin blood transported tissues energy use (beta-oxidation)Glycerol transported liver gluconeogenesis glycolysis","code":""},{"path":"metabolic-1.html","id":"fatty-acid-oxidation-beta-oxidation","chapter":"Metabolic","heading":"Fatty Acid Oxidation (Beta-Oxidation)","text":"Purpose: break fatty acids acetyl-CoA energy production (primarily mitochondria)Location: Mitochondrial matrixProcess\nActivation: Fatty acid activated coenzyme (CoA) form fatty acyl-CoA\nRequires ATP\n\nTransport: Fatty acyl-CoA transported mitochondrial matrix via carnitine shuttle\nBeta-Oxidation Cycle\ncycle shortens fatty acyl-CoA two carbon atoms, producing:\nOne molecule acetyl-CoA (enters Krebs Cycle)\nOne molecule FADH2 (enters electron transport chain)\nOne molecule NADH (enters electron transport chain)\n\n\nActivation: Fatty acid activated coenzyme (CoA) form fatty acyl-CoA\nRequires ATP\nRequires ATPTransport: Fatty acyl-CoA transported mitochondrial matrix via carnitine shuttleBeta-Oxidation Cycle\ncycle shortens fatty acyl-CoA two carbon atoms, producing:\nOne molecule acetyl-CoA (enters Krebs Cycle)\nOne molecule FADH2 (enters electron transport chain)\nOne molecule NADH (enters electron transport chain)\n\ncycle shortens fatty acyl-CoA two carbon atoms, producing:\nOne molecule acetyl-CoA (enters Krebs Cycle)\nOne molecule FADH2 (enters electron transport chain)\nOne molecule NADH (enters electron transport chain)\nOne molecule acetyl-CoA (enters Krebs Cycle)One molecule FADH2 (enters electron transport chain)One molecule NADH (enters electron transport chain)Regulation\nCarnitine palmitoyltransferase (CPT-) rate-limiting enzyme\nInhibited : Malonyl-CoA (product fatty acid synthesis)\nCarnitine palmitoyltransferase (CPT-) rate-limiting enzymeInhibited : Malonyl-CoA (product fatty acid synthesis)Energy Yield: efficient energy production\nExample: Palmitic acid (16 carbons) yields 129 ATP\nExample: Palmitic acid (16 carbons) yields 129 ATPOdd-Chain Fatty Acids\nOxidation proceeds normally last three carbons\nPropionyl-CoA formed, converted succinyl-CoA (enters Krebs Cycle)\nOxidation proceeds normally last three carbonsPropionyl-CoA formed, converted succinyl-CoA (enters Krebs Cycle)","code":""},{"path":"metabolic-1.html","id":"ketogenesis","chapter":"Metabolic","heading":"Ketogenesis","text":"Purpose: produce ketone bodies (acetone, acetoacetate, beta-hydroxybutyrate) acetyl-CoA periods prolonged fasting, starvation, uncontrolled diabetesLocation: Mitochondrial matrix liver cellsProcess\nAcetyl-CoA molecules combine form acetoacetyl-CoA\nAcetoacetyl-CoA converted HMG-CoA\nHMG-CoA cleaved form acetoacetate\nAcetoacetate can :\nReduced beta-hydroxybutyrate\nSpontaneously decarboxylated acetone\n\nAcetyl-CoA molecules combine form acetoacetyl-CoAAcetoacetyl-CoA converted HMG-CoAHMG-CoA cleaved form acetoacetateAcetoacetate can :\nReduced beta-hydroxybutyrate\nSpontaneously decarboxylated acetone\nReduced beta-hydroxybutyrateSpontaneously decarboxylated acetoneRegulation\nAvailability fatty acids acetyl-CoA\nAvailability fatty acids acetyl-CoAFate Ketone Bodies\nReleased blood transported tissues (brain, heart, muscle) energy use\nConverted back acetyl-CoA entry Krebs Cycle\nReleased blood transported tissues (brain, heart, muscle) energy useConverted back acetyl-CoA entry Krebs CycleClinical Significance\nKetone bodies provide alternative fuel source brain starvation\nExcessive production ketone bodies can lead ketoacidosis (dangerous lowering blood pH), especially uncontrolled diabetes\nKetone bodies provide alternative fuel source brain starvationExcessive production ketone bodies can lead ketoacidosis (dangerous lowering blood pH), especially uncontrolled diabetes","code":""},{"path":"metabolic-1.html","id":"lipogenesis","chapter":"Metabolic","heading":"Lipogenesis","text":"Purpose: synthesize fatty acids acetyl-CoALocation: Cytosol liver adipose tissue cellsProcess\nAcetyl-CoA Transport: Acetyl-CoA transported mitochondria cytosol via citrate shuttle\nActivation: Acetyl-CoA carboxylated form malonyl-CoA acetyl-CoA carboxylase (ACC)\nRequires ATP biotin\n\nFatty Acid Synthesis\nMalonyl-CoA acetyl-CoA repeatedly added growing fatty acid chain fatty acid synthase (FAS)\nRequires NADPH\nPalmitic acid (16 carbons) primary product\n\nAcetyl-CoA Transport: Acetyl-CoA transported mitochondria cytosol via citrate shuttleActivation: Acetyl-CoA carboxylated form malonyl-CoA acetyl-CoA carboxylase (ACC)\nRequires ATP biotin\nRequires ATP biotinFatty Acid Synthesis\nMalonyl-CoA acetyl-CoA repeatedly added growing fatty acid chain fatty acid synthase (FAS)\nRequires NADPH\nPalmitic acid (16 carbons) primary product\nMalonyl-CoA acetyl-CoA repeatedly added growing fatty acid chain fatty acid synthase (FAS)Requires NADPHPalmitic acid (16 carbons) primary productRegulation\nAcetyl-CoA carboxylase (ACC) rate-limiting enzyme\nActivated : Insulin, citrate\nInhibited : Glucagon, palmitoyl-CoA (feedback inhibition)\nAcetyl-CoA carboxylase (ACC) rate-limiting enzymeActivated : Insulin, citrateInhibited : Glucagon, palmitoyl-CoA (feedback inhibition)","code":""},{"path":"metabolic-1.html","id":"triglyceride-synthesis","chapter":"Metabolic","heading":"Triglyceride Synthesis","text":"Purpose: synthesize triglycerides (triacylglycerols) glycerol fatty acids storageLocation: Cytosol liver adipose tissue cellsProcess\nGlycerol-3-phosphate formed either:\nGlycerol (liver)\nDihydroxyacetone phosphate (DHAP) glycolysis (adipose tissue)\n\nFatty acids activated CoA form fatty acyl-CoA\nFatty acyl-CoA molecules sequentially added glycerol-3-phosphate form:\nLysophosphatidic acid\nPhosphatidic acid\nDiacylglycerol\nTriacylglycerol (triglyceride)\n\nGlycerol-3-phosphate formed either:\nGlycerol (liver)\nDihydroxyacetone phosphate (DHAP) glycolysis (adipose tissue)\nGlycerol (liver)Dihydroxyacetone phosphate (DHAP) glycolysis (adipose tissue)Fatty acids activated CoA form fatty acyl-CoAFatty acyl-CoA molecules sequentially added glycerol-3-phosphate form:\nLysophosphatidic acid\nPhosphatidic acid\nDiacylglycerol\nTriacylglycerol (triglyceride)\nLysophosphatidic acidPhosphatidic acidDiacylglycerolTriacylglycerol (triglyceride)Regulation\nAvailability glycerol-3-phosphate fatty acids\nInsulin promotes triglyceride synthesis\nAvailability glycerol-3-phosphate fatty acidsInsulin promotes triglyceride synthesis","code":""},{"path":"metabolic-1.html","id":"cholesterol-synthesis","chapter":"Metabolic","heading":"Cholesterol Synthesis","text":"Purpose: synthesize cholesterol, essential component cell membranes precursor steroid hormones bile acidsLocation: Cytosol endoplasmic reticulum liver cellsProcess: complex, multi-step pathway involving:\nAcetyl-CoA molecules combine form HMG-CoA\nHMG-CoA reduced mevalonate HMG-CoA reductase (rate-limiting enzyme)\nMevalonate converted isopentenyl pyrophosphate\nIsopentenyl pyrophosphate converted squalene\nSqualene cyclized modified form cholesterol\nAcetyl-CoA molecules combine form HMG-CoAHMG-CoA reduced mevalonate HMG-CoA reductase (rate-limiting enzyme)Mevalonate converted isopentenyl pyrophosphateIsopentenyl pyrophosphate converted squaleneSqualene cyclized modified form cholesterolRegulation\nHMG-CoA reductase rate-limiting enzyme\nInhibited : Cholesterol, statin drugs\nActivated : Insulin\nHMG-CoA reductase rate-limiting enzymeInhibited : Cholesterol, statin drugsActivated : InsulinFate Cholesterol\nIncorporated cell membranes\nUsed synthesize steroid hormones (cortisol, aldosterone, sex hormones)\nConverted bile acids liver (fat digestion)\nPackaged lipoproteins transport blood\nIncorporated cell membranesUsed synthesize steroid hormones (cortisol, aldosterone, sex hormones)Converted bile acids liver (fat digestion)Packaged lipoproteins transport blood","code":""},{"path":"metabolic-1.html","id":"lipoprotein-metabolism","chapter":"Metabolic","heading":"Lipoprotein Metabolism","text":"Purpose: transport lipids (triglycerides, cholesterol) bloodLipoprotein Classes\nChylomicrons: Transport dietary triglycerides intestine tissues\nVLDL (-Low-Density Lipoproteins): Transport triglycerides liver tissues\nLDL (Low-Density Lipoproteins): Transport cholesterol liver tissues\nHDL (High-Density Lipoproteins): Transport cholesterol tissues back liver\nChylomicrons: Transport dietary triglycerides intestine tissuesVLDL (-Low-Density Lipoproteins): Transport triglycerides liver tissuesLDL (Low-Density Lipoproteins): Transport cholesterol liver tissuesHDL (High-Density Lipoproteins): Transport cholesterol tissues back liverProcess\nAssembly: Lipoproteins assembled intestine (chylomicrons) liver (VLDL, HDL)\nSecretion: Lipoproteins secreted blood\nLipolysis: Triglycerides chylomicrons VLDL hydrolyzed lipoprotein lipase (LPL) capillaries, releasing fatty acids uptake tissues\nRemnant Uptake: Chylomicron remnants IDL (intermediate-density lipoproteins) taken liver\nLDL Formation: VLDL converted LDL triglycerides removed\nReceptor-Mediated Uptake: LDL taken cells via LDL receptors\nReverse Cholesterol Transport: HDL picks cholesterol tissues transports back liver excretion\nAssembly: Lipoproteins assembled intestine (chylomicrons) liver (VLDL, HDL)Secretion: Lipoproteins secreted bloodLipolysis: Triglycerides chylomicrons VLDL hydrolyzed lipoprotein lipase (LPL) capillaries, releasing fatty acids uptake tissuesRemnant Uptake: Chylomicron remnants IDL (intermediate-density lipoproteins) taken liverLDL Formation: VLDL converted LDL triglycerides removedReceptor-Mediated Uptake: LDL taken cells via LDL receptorsReverse Cholesterol Transport: HDL picks cholesterol tissues transports back liver excretionRegulation\nComplex hormonal enzymatic regulation\nComplex hormonal enzymatic regulation","code":""},{"path":"metabolic-1.html","id":"key-terms-9","chapter":"Metabolic","heading":"Key Terms","text":"Lipolysis: breakdown triglycerides glycerol fatty acidsBeta-Oxidation: breakdown fatty acids acetyl-CoAKetogenesis: production ketone bodies acetyl-CoALipogenesis: synthesis fatty acids acetyl-CoATriglyceride Synthesis: formation triglycerides glycerol fatty acidsCholesterol Synthesis: production cholesterol acetyl-CoALipoproteins: Particles transport lipids bloodHormone-Sensitive Lipase (HSL): enzyme hydrolyzes triglyceridesAcetyl-CoA Carboxylase (ACC): enzyme carboxylates acetyl-CoA form malonyl-CoAHMG-CoA Reductase: rate-limiting enzyme cholesterol synthesis","code":""},{"path":"physiology-1.html","id":"physiology-1","chapter":"Physiology","heading":"Physiology","text":"Lipid levels metabolism crucial health. Imbalances can lead range disorders, particularly cardiovascular disease","code":""},{"path":"physiology-1.html","id":"normal-states","chapter":"Physiology","heading":"Normal States","text":"Normal Lipid Profile: Optimal levels cholesterol, triglycerides, LDL, HDLBalanced Lipid Metabolism: Efficient breakdown synthesis lipids, appropriate energy storage utilization","code":""},{"path":"physiology-1.html","id":"normal-lipid-profile","chapter":"Physiology","heading":"Normal Lipid Profile","text":"Total Cholesterol: < 200 mg/dL (5.18 mmol/L)LDL Cholesterol: < 100 mg/dL (2.59 mmol/L)HDL Cholesterol: > 60 mg/dL (1.55 mmol/L)Triglycerides: < 150 mg/dL (1.7 mmol/L)Importance\nlevels associated lower risk cardiovascular disease\nOptimal lipid levels contribute overall health well-\nlevels associated lower risk cardiovascular diseaseOptimal lipid levels contribute overall health well-","code":""},{"path":"physiology-1.html","id":"abnormal-states-1","chapter":"Physiology","heading":"Abnormal States","text":"Hyperlipidemia (High Lipids): Elevated total cholesterol, LDL cholesterol, /triglyceridesDyslipidemia (Abnormal Lipids): Imbalances lipid levels, including high LDL, low HDL, high triglyceridesAtherosclerosis: Plaque buildup arteries due lipid depositionFatty Liver Disease (NAFLD/NASH): Excess fat accumulation liverLipoprotein Disorders: Genetic defects affecting lipoprotein synthesis metabolismLipodystrophy: Selective loss adipose tissue","code":""},{"path":"physiology-1.html","id":"hyperlipidemia","chapter":"Physiology","heading":"Hyperlipidemia","text":"Definition: Abnormally high levels lipids (fats) bloodTypes\nHypercholesterolemia: Elevated total cholesterol LDL cholesterol\nHypertriglyceridemia: Elevated triglycerides\nMixed Hyperlipidemia: Elevated cholesterol triglycerides\nHypercholesterolemia: Elevated total cholesterol LDL cholesterolHypertriglyceridemia: Elevated triglyceridesMixed Hyperlipidemia: Elevated cholesterol triglyceridesCauses\nPrimary (Genetic): Familial hypercholesterolemia, familial hypertriglyceridemia, etc\nSecondary (Acquired)\nDiet: High intake saturated trans fats, cholesterol, simple carbohydrates\nLifestyle: Sedentary behavior, smoking\nMedical Conditions: Diabetes, hypothyroidism, kidney disease, liver disease\nMedications: Diuretics, beta-blockers, corticosteroids\n\nPrimary (Genetic): Familial hypercholesterolemia, familial hypertriglyceridemia, etcSecondary (Acquired)\nDiet: High intake saturated trans fats, cholesterol, simple carbohydrates\nLifestyle: Sedentary behavior, smoking\nMedical Conditions: Diabetes, hypothyroidism, kidney disease, liver disease\nMedications: Diuretics, beta-blockers, corticosteroids\nDiet: High intake saturated trans fats, cholesterol, simple carbohydratesLifestyle: Sedentary behavior, smokingMedical Conditions: Diabetes, hypothyroidism, kidney disease, liver diseaseMedications: Diuretics, beta-blockers, corticosteroidsSymptoms\nOften asymptomatic\nSevere hypertriglyceridemia can cause eruptive xanthomas (small, yellow papules skin) lipemia retinalis (milky appearance retinal blood vessels)\nOften asymptomaticSevere hypertriglyceridemia can cause eruptive xanthomas (small, yellow papules skin) lipemia retinalis (milky appearance retinal blood vessels)Complications\nAtherosclerosis: Plaque buildup arteries, leading heart disease, stroke, peripheral artery disease\nPancreatitis: high triglycerides can cause inflammation pancreas\nFatty Liver Disease: Excess fat accumulation liver\nAtherosclerosis: Plaque buildup arteries, leading heart disease, stroke, peripheral artery diseasePancreatitis: high triglycerides can cause inflammation pancreasFatty Liver Disease: Excess fat accumulation liverClinical Significance\nHyperlipidemia major risk factor cardiovascular disease\nEarly detection management essential prevent delay onset complications\nManagement involves lifestyle modifications (diet, exercise), medications (statins, fibrates, etc.), addressing underlying causes\nHyperlipidemia major risk factor cardiovascular diseaseEarly detection management essential prevent delay onset complicationsManagement involves lifestyle modifications (diet, exercise), medications (statins, fibrates, etc.), addressing underlying causes","code":""},{"path":"physiology-1.html","id":"dyslipidemia","chapter":"Physiology","heading":"Dyslipidemia","text":"Definition: abnormal lipid profile characterized imbalances lipid levelsCommon Patterns\nHigh LDL cholesterol, low HDL cholesterol, high triglycerides\nHigh LDL cholesterol high triglycerides\nLow HDL cholesterol high triglycerides\nHigh LDL cholesterol, low HDL cholesterol, high triglyceridesHigh LDL cholesterol high triglyceridesLow HDL cholesterol high triglyceridesCauses\nSimilar hyperlipidemia\nSimilar hyperlipidemiaSymptoms\nOften asymptomatic\nOften asymptomaticComplications\nSimilar hyperlipidemia\nSimilar hyperlipidemiaClinical Significance\nDyslipidemia significant risk factor cardiovascular disease\nManagement involves lifestyle modifications (diet, exercise), medications, addressing underlying causes\nDyslipidemia significant risk factor cardiovascular diseaseManagement involves lifestyle modifications (diet, exercise), medications, addressing underlying causes","code":""},{"path":"physiology-1.html","id":"atherosclerosis","chapter":"Physiology","heading":"Atherosclerosis","text":"Definition: chronic inflammatory disease characterized buildup plaque (atheroma) arteriesProcess\nEndothelial Injury: Damage inner lining artery\nLipid Deposition: LDL cholesterol accumulates artery wall\nInflammation: Immune cells recruited, leading chronic inflammation\nPlaque Formation: Plaque consists lipids, cholesterol, calcium, cellular debris\nPlaque Rupture: Plaque can rupture, leading thrombus (blood clot) formation\nEndothelial Injury: Damage inner lining arteryLipid Deposition: LDL cholesterol accumulates artery wallInflammation: Immune cells recruited, leading chronic inflammationPlaque Formation: Plaque consists lipids, cholesterol, calcium, cellular debrisPlaque Rupture: Plaque can rupture, leading thrombus (blood clot) formationRisk Factors\nHyperlipidemia\nHypertension\nSmoking\nDiabetes\nObesity\nFamily history\nHyperlipidemiaHypertensionSmokingDiabetesObesityFamily historySymptoms\nOften asymptomatic significant narrowing arteries occurs\nAngina (chest pain)\nShortness breath\nLeg pain exercise (claudication)\nOften asymptomatic significant narrowing arteries occursAngina (chest pain)Shortness breathLeg pain exercise (claudication)Complications\nCoronary Artery Disease (CAD): Heart attack, heart failure\nStroke\nPeripheral Artery Disease (PAD)\nAneurysm\nCoronary Artery Disease (CAD): Heart attack, heart failureStrokePeripheral Artery Disease (PAD)AneurysmClinical Significance\nAtherosclerosis leading cause cardiovascular disease death\nManagement involves lifestyle modifications, medications (statins, antiplatelet agents), procedures (angioplasty, bypass surgery)\nAtherosclerosis leading cause cardiovascular disease deathManagement involves lifestyle modifications, medications (statins, antiplatelet agents), procedures (angioplasty, bypass surgery)","code":""},{"path":"physiology-1.html","id":"fatty-liver-disease","chapter":"Physiology","heading":"Fatty Liver Disease","text":"Definition: accumulation excess fat liverTypes\nNon-Alcoholic Fatty Liver Disease (NAFLD): Fatty liver caused excessive alcohol consumption\nNon-Alcoholic Steatohepatitis (NASH): severe form NAFLD characterized inflammation liver damage\nNon-Alcoholic Fatty Liver Disease (NAFLD): Fatty liver caused excessive alcohol consumptionNon-Alcoholic Steatohepatitis (NASH): severe form NAFLD characterized inflammation liver damageCauses\nObesity\nInsulin resistance\nMetabolic syndrome\nHigh-fat diet\nDiabetes\nObesityInsulin resistanceMetabolic syndromeHigh-fat dietDiabetesSymptoms\nOften asymptomatic\nFatigue\nRight upper quadrant abdominal pain\nHepatomegaly (enlarged liver)\nOften asymptomaticFatigueRight upper quadrant abdominal painHepatomegaly (enlarged liver)Complications\nCirrhosis: Scarring liver\nLiver failure\nHepatocellular carcinoma (liver cancer)\nCirrhosis: Scarring liverLiver failureHepatocellular carcinoma (liver cancer)Clinical Significance\nNAFLD common condition, especially developed countries\nNASH can progress cirrhosis liver failure\nManagement involves lifestyle modifications (weight loss, diet, exercise), medications, addressing underlying causes\nNAFLD common condition, especially developed countriesNASH can progress cirrhosis liver failureManagement involves lifestyle modifications (weight loss, diet, exercise), medications, addressing underlying causes","code":""},{"path":"physiology-1.html","id":"lipoprotein-disorders","chapter":"Physiology","heading":"Lipoprotein Disorders","text":"Definition: Genetic disorders affecting lipoprotein synthesis, structure, metabolismExamples\nFamilial Hypercholesterolemia: Mutations LDL receptor gene, leading high LDL cholesterol levels\nFamilial Hypertriglyceridemia: Increased VLDL production decreased triglyceride clearance, leading high triglyceride levels\nFamilial Combined Hyperlipidemia: Elevated cholesterol triglycerides\nTangier Disease: Deficiency ABCA1 transporter, leading low HDL cholesterol levels\nFamilial Hypercholesterolemia: Mutations LDL receptor gene, leading high LDL cholesterol levelsFamilial Hypertriglyceridemia: Increased VLDL production decreased triglyceride clearance, leading high triglyceride levelsFamilial Combined Hyperlipidemia: Elevated cholesterol triglyceridesTangier Disease: Deficiency ABCA1 transporter, leading low HDL cholesterol levelsSymptoms\nVary depending specific disorder\nVary depending specific disorderComplications\nPremature cardiovascular disease\nlipid-related complications\nPremature cardiovascular diseaseOther lipid-related complicationsClinical Significance\nEarly diagnosis management essential prevent delay onset complications\nTreatment involves lifestyle modifications, medications, sometimes specialized therapies\nEarly diagnosis management essential prevent delay onset complicationsTreatment involves lifestyle modifications, medications, sometimes specialized therapies","code":""},{"path":"physiology-1.html","id":"lipodystrophy","chapter":"Physiology","heading":"Lipodystrophy","text":"Definition: syndrome characterized selective loss adipose tissueTypes\nGenetic (Congenital): Rare, often associated mutations genes involved lipid metabolism\nAcquired: Can caused HIV medications (lipodystrophy syndrome), autoimmune diseases, factors\nGenetic (Congenital): Rare, often associated mutations genes involved lipid metabolismAcquired: Can caused HIV medications (lipodystrophy syndrome), autoimmune diseases, factorsSymptoms\nLoss subcutaneous fat certain areas body (e.g., face, limbs)\nAccumulation fat areas (e.g., abdomen)\nInsulin resistance\nHypertriglyceridemia\nFatty liver disease\nLoss subcutaneous fat certain areas body (e.g., face, limbs)Accumulation fat areas (e.g., abdomen)Insulin resistanceHypertriglyceridemiaFatty liver diseaseComplications\nDiabetes\nCardiovascular disease\nLiver disease\nDiabetesCardiovascular diseaseLiver diseaseClinical Significance\nManagement involves addressing underlying cause, managing metabolic complications, sometimes cosmetic procedures\nManagement involves addressing underlying cause, managing metabolic complications, sometimes cosmetic procedures","code":""},{"path":"physiology-1.html","id":"key-terms-10","chapter":"Physiology","heading":"Key Terms","text":"Hyperlipidemia: Elevated levels lipids bloodDyslipidemia: Abnormal lipid profileAtherosclerosis: Plaque buildup arteriesFatty Liver Disease (NAFLD/NASH): Excess fat accumulation liverLipoprotein Disorders: Genetic defects affecting lipoprotein metabolismLipodystrophy: Selective loss adipose tissueTotal Cholesterol: measure cholesterol bloodLDL Cholesterol: “Bad” cholesterol contributes plaque buildupHDL Cholesterol: “Good” cholesterol helps remove LDL arteriesTriglycerides: type fat blood","code":""},{"path":"properties-1.html","id":"properties-1","chapter":"Properties","heading":"Properties","text":"unique structures lipids dictate physical chemical behaviors. knowledge essential understanding lipids transported, stored, used body","code":""},{"path":"properties-1.html","id":"physical-and-chemical-properties-2","chapter":"Properties","heading":"Physical and Chemical Properties","text":"Lipoproteins\nPhysical: Spherical particles core triglycerides cholesterol esters, surrounded shell phospholipids, cholesterol, apolipoproteins\nChemical: Amphipathic nature allows transport hydrophobic lipids aqueous blood\nPhysical: Spherical particles core triglycerides cholesterol esters, surrounded shell phospholipids, cholesterol, apolipoproteinsChemical: Amphipathic nature allows transport hydrophobic lipids aqueous bloodPhospholipids\nPhysical: Amphipathic molecules polar head group nonpolar fatty acid tails. form bilayers aqueous solutions\nChemical: Hydrolyzed phospholipases. Participate cell signaling membrane structure\nPhysical: Amphipathic molecules polar head group nonpolar fatty acid tails. form bilayers aqueous solutionsChemical: Hydrolyzed phospholipases. Participate cell signaling membrane structureTriglycerides\nPhysical: Nonpolar, hydrophobic molecules liquid body temperature\nChemical: Ester bonds hydrolyzed lipases. Primary form energy storage\nPhysical: Nonpolar, hydrophobic molecules liquid body temperatureChemical: Ester bonds hydrolyzed lipases. Primary form energy storageCholesterol\nPhysical: rigid, hydrophobic steroid ring structure\nChemical: Precursor steroid hormones bile acids. Can form esters fatty acids\nPhysical: rigid, hydrophobic steroid ring structureChemical: Precursor steroid hormones bile acids. Can form esters fatty acidsApolipoproteins\nPhysical: Proteins bind lipoproteins, providing structure targeting signals\nChemical: Interact cell surface receptors enzymes. Activate inhibit enzymes lipid metabolism\nPhysical: Proteins bind lipoproteins, providing structure targeting signalsChemical: Interact cell surface receptors enzymes. Activate inhibit enzymes lipid metabolism","code":""},{"path":"properties-1.html","id":"lipoproteins","chapter":"Properties","heading":"Lipoproteins","text":"Definition: Complex particles transport lipids (triglycerides, cholesterol) aqueous environment blood. essential delivering lipids tissuesStructure\nCore: Hydrophobic core containing triglycerides cholesterol esters\nShell: Amphipathic shell containing phospholipids, free cholesterol, apolipoproteins\nCore: Hydrophobic core containing triglycerides cholesterol estersShell: Amphipathic shell containing phospholipids, free cholesterol, apolipoproteinsClasses\nChylomicrons: Transport dietary triglycerides intestine tissues\nVLDL (-Low-Density Lipoproteins): Transport triglycerides liver tissues\nLDL (Low-Density Lipoproteins): Transport cholesterol liver tissues\nHDL (High-Density Lipoproteins): Transport cholesterol tissues back liver (reverse cholesterol transport)\nChylomicrons: Transport dietary triglycerides intestine tissuesVLDL (-Low-Density Lipoproteins): Transport triglycerides liver tissuesLDL (Low-Density Lipoproteins): Transport cholesterol liver tissuesHDL (High-Density Lipoproteins): Transport cholesterol tissues back liver (reverse cholesterol transport)Physical Properties\nShape: Spherical\nSize: Varies depending class (chylomicrons > VLDL > LDL > HDL)\nDensity: Varies depending lipid protein content (HDL > LDL > VLDL > chylomicrons)\nSolubility: Amphipathic nature allows dispersed aqueous blood\nShape: SphericalSize: Varies depending class (chylomicrons > VLDL > LDL > HDL)Density: Varies depending lipid protein content (HDL > LDL > VLDL > chylomicrons)Solubility: Amphipathic nature allows dispersed aqueous bloodChemical Properties\nAmphipathic Nature: outer shell amphipathic, allowing hydrophobic lipids core transported blood\nApolipoprotein Interactions: Apolipoproteins surface interact cell surface receptors enzymes involved lipid metabolism\nLipolysis: Triglycerides chylomicrons VLDL hydrolyzed lipoprotein lipase (LPL), releasing fatty acids uptake tissues\nAmphipathic Nature: outer shell amphipathic, allowing hydrophobic lipids core transported bloodApolipoprotein Interactions: Apolipoproteins surface interact cell surface receptors enzymes involved lipid metabolismLipolysis: Triglycerides chylomicrons VLDL hydrolyzed lipoprotein lipase (LPL), releasing fatty acids uptake tissuesApolipoproteins Functions\nStructural Component\nLigands receptors\nEnzyme regulators\nStructural ComponentLigands receptorsEnzyme regulators","code":""},{"path":"properties-1.html","id":"phospholipids","chapter":"Properties","heading":"Phospholipids","text":"Definition: Amphipathic lipids major components cell membranes. consist glycerol backbone, two fatty acid tails, phosphate group attached polar head groupStructure\nGlycerol Backbone: three-carbon molecule\nFatty Acid Tails: Two fatty acids attached glycerol backbone via ester bonds. One saturated unsaturated\nPhosphate Group: phosphate group attached third carbon glycerol, linked polar head group\nPolar Head Group: Varies (e.g., choline, serine, ethanolamine, inositol)\nGlycerol Backbone: three-carbon moleculeFatty Acid Tails: Two fatty acids attached glycerol backbone via ester bonds. One saturated unsaturatedPhosphate Group: phosphate group attached third carbon glycerol, linked polar head groupPolar Head Group: Varies (e.g., choline, serine, ethanolamine, inositol)Physical Properties\nAmphipathic Nature: hydrophobic (fatty acid tails) hydrophilic (polar head group) regions\nBilayer Formation: aqueous solutions, phospholipids spontaneously form bilayers, hydrophobic tails facing inward hydrophilic head groups facing outward\nFluidity: fluidity bilayer depends saturation fatty acid tails presence cholesterol\nAmphipathic Nature: hydrophobic (fatty acid tails) hydrophilic (polar head group) regionsBilayer Formation: aqueous solutions, phospholipids spontaneously form bilayers, hydrophobic tails facing inward hydrophilic head groups facing outwardFluidity: fluidity bilayer depends saturation fatty acid tails presence cholesterolChemical Properties\nHydrolysis: Phospholipids can hydrolyzed phospholipases, releasing fatty acids molecules\nCell Signaling: phospholipids (e.g., phosphatidylinositol) play role cell signaling pathways\nMembrane Structure: essential components cell membranes, providing structure flexibility\nHydrolysis: Phospholipids can hydrolyzed phospholipases, releasing fatty acids moleculesCell Signaling: phospholipids (e.g., phosphatidylinositol) play role cell signaling pathwaysMembrane Structure: essential components cell membranes, providing structure flexibility","code":""},{"path":"properties-1.html","id":"triglycerides","chapter":"Properties","heading":"Triglycerides","text":"Definition: Neutral lipids consisting glycerol molecule esterified three fatty acids. primary form energy storage bodyStructure\nGlycerol Backbone: three-carbon molecule\nFatty Acids: Three fatty acids attached glycerol backbone via ester bonds. fatty acids can saturated, unsaturated, combination thereof\nGlycerol Backbone: three-carbon moleculeFatty Acids: Three fatty acids attached glycerol backbone via ester bonds. fatty acids can saturated, unsaturated, combination thereofPhysical Properties\nHydrophobic Nature: Nonpolar insoluble water\nLiquid Body Temperature: triglycerides liquid body temperature (fats solid room temperature higher proportion saturated fatty acids)\nEnergy Density: High energy density (9 kcal/gram)\nHydrophobic Nature: Nonpolar insoluble waterLiquid Body Temperature: triglycerides liquid body temperature (fats solid room temperature higher proportion saturated fatty acids)Energy Density: High energy density (9 kcal/gram)Chemical Properties\nEster Bonds: ester bonds linking fatty acids glycerol can hydrolyzed lipases, releasing fatty acids glycerol\nSaponification: Triglycerides can saponified (hydrolyzed strong base) produce glycerol soap (fatty acid salts)\nOxidation: Fatty acids can oxidized produce energy (beta-oxidation)\nEster Bonds: ester bonds linking fatty acids glycerol can hydrolyzed lipases, releasing fatty acids glycerolSaponification: Triglycerides can saponified (hydrolyzed strong base) produce glycerol soap (fatty acid salts)Oxidation: Fatty acids can oxidized produce energy (beta-oxidation)","code":""},{"path":"properties-1.html","id":"cholesterol","chapter":"Properties","heading":"Cholesterol","text":"Definition: sterol lipid essential component cell membranes precursor steroid hormones bile acidsStructure\nSteroid Ring Structure: Four fused hydrocarbon rings (, B, C, D)\nHydroxyl Group: hydroxyl (-OH) group carbon 3, making weakly amphipathic\nAlkyl Side Chain: alkyl side chain carbon 17\nSteroid Ring Structure: Four fused hydrocarbon rings (, B, C, D)Hydroxyl Group: hydroxyl (-OH) group carbon 3, making weakly amphipathicAlkyl Side Chain: alkyl side chain carbon 17Physical Properties\nHydrophobic Nature: Mostly nonpolar insoluble water\nRigid Structure: steroid ring structure rigid provides stability cell membranes\nCrystalline Solid: Cholesterol crystalline solid room temperature\nHydrophobic Nature: Mostly nonpolar insoluble waterRigid Structure: steroid ring structure rigid provides stability cell membranesCrystalline Solid: Cholesterol crystalline solid room temperatureChemical Properties\nPrecursor Steroid Hormones: Cholesterol precursor steroid hormones cortisol, aldosterone, testosterone, estrogen, progesterone\nPrecursor Bile Acids: Cholesterol converted bile acids liver, aid digestion absorption fats\nEsterification: hydroxyl group carbon 3 can esterified fatty acid, forming cholesterol esters, hydrophobic stored cells lipoproteins\nHydroxylation: Cholesterol can hydroxylated form various oxysterols, regulatory functions\nPrecursor Steroid Hormones: Cholesterol precursor steroid hormones cortisol, aldosterone, testosterone, estrogen, progesteronePrecursor Bile Acids: Cholesterol converted bile acids liver, aid digestion absorption fatsEsterification: hydroxyl group carbon 3 can esterified fatty acid, forming cholesterol esters, hydrophobic stored cells lipoproteinsHydroxylation: Cholesterol can hydroxylated form various oxysterols, regulatory functions","code":""},{"path":"properties-1.html","id":"apolipoproteins","chapter":"Properties","heading":"Apolipoproteins","text":"Definition: Proteins bind lipoproteins, providing structural support, targeting signals, enzyme regulationTypes\nApoA-: Major protein HDL; activates LCAT (lecithin-cholesterol acyltransferase)\nApoB-100: Major protein VLDL LDL; ligand LDL receptor\nApoC-II: Activates lipoprotein lipase (LPL)\nApoE: Ligand LDL receptor LDL receptor-related protein (LRP)\nApoA-: Major protein HDL; activates LCAT (lecithin-cholesterol acyltransferase)ApoB-100: Major protein VLDL LDL; ligand LDL receptorApoC-II: Activates lipoprotein lipase (LPL)ApoE: Ligand LDL receptor LDL receptor-related protein (LRP)Physical Properties\nSoluble Proteins: Soluble aqueous solutions\nAmphipathic Regions: Contain amphipathic regions allow interact lipids water\nSoluble Proteins: Soluble aqueous solutionsAmphipathic Regions: Contain amphipathic regions allow interact lipids waterChemical Properties\nLipid Binding: Bind lipids lipoproteins, stabilizing structure\nReceptor Binding: Interact cell surface receptors, mediating lipoprotein uptake\nEnzyme Activation: Activate inhibit enzymes involved lipid metabolism\nLipid Binding: Bind lipids lipoproteins, stabilizing structureReceptor Binding: Interact cell surface receptors, mediating lipoprotein uptakeEnzyme Activation: Activate inhibit enzymes involved lipid metabolismFunctions\nStructural Component\nLigands receptors\nEnzyme regulators\nStructural ComponentLigands receptorsEnzyme regulators","code":""},{"path":"properties-1.html","id":"key-terms-11","chapter":"Properties","heading":"Key Terms","text":"Lipoproteins: Particles transport lipids bloodPhospholipids: Amphipathic lipids major components cell membranesTriglycerides: Neutral lipids consisting glycerol molecule esterified three fatty acidsCholesterol: sterol lipid essential component cell membranes precursor steroid hormones bile acidsApolipoproteins: Proteins bind lipoproteins, providing structural support, targeting signals, enzyme regulationAmphipathic: hydrophobic hydrophilic regionsHydrophobic: Repelling waterHydrophilic: Attracted waterEster Bond: chemical bond formed alcohol carboxylic acidSaponification: hydrolysis triglyceride strong base produce glycerol soapSteroid Ring Structure: four fused hydrocarbon rings form basic structure cholesterol steroid hormonesLipoprotein Lipase (LPL): enzyme hydrolyzes triglycerides lipoproteinsLCAT (Lecithin-Cholesterol Acyltransferase): enzyme esterifies cholesterol HDL","code":""},{"path":"procedures-1.html","id":"procedures-1","chapter":"Procedures","heading":"Procedures","text":"Lipid testing plays critical role assessing cardiovascular risk diagnosing lipid disorders. ensure accuracy reliability tests, ’s essential understand principles behind method precautions necessary specimen collection, processing, analysis","code":""},{"path":"procedures-1.html","id":"key-principles-of-lipid-tests","chapter":"Procedures","heading":"Key Principles of Lipid Tests","text":"Total Cholesterol\nEnzymatic methods convert cholesterol esters cholesterol, oxidized produce hydrogen peroxide. hydrogen peroxide reacts chromogen form colored product, measured spectrophotometrically\nEnzymatic methods convert cholesterol esters cholesterol, oxidized produce hydrogen peroxide. hydrogen peroxide reacts chromogen form colored product, measured spectrophotometricallyTriglycerides\nEnzymatic methods hydrolyze triglycerides glycerol fatty acids. Glycerol phosphorylated oxidized produce hydrogen peroxide. hydrogen peroxide reacts chromogen form colored product, measured spectrophotometrically\nEnzymatic methods hydrolyze triglycerides glycerol fatty acids. Glycerol phosphorylated oxidized produce hydrogen peroxide. hydrogen peroxide reacts chromogen form colored product, measured spectrophotometricallyHDL Cholesterol\nDirect methods use selective detergents antibodies block non-HDL lipoproteins, allowing measurement HDL cholesterol. Indirect methods use precipitation reagents selectively precipitate non-HDL lipoproteins\nDirect methods use selective detergents antibodies block non-HDL lipoproteins, allowing measurement HDL cholesterol. Indirect methods use precipitation reagents selectively precipitate non-HDL lipoproteinsLDL Cholesterol\nCalculated using Friedewald equation (LDL-C = Total Cholesterol - HDL-C - Triglycerides/5) triglycerides < 400 mg/dL. Direct methods also available\nCalculated using Friedewald equation (LDL-C = Total Cholesterol - HDL-C - Triglycerides/5) triglycerides < 400 mg/dL. Direct methods also availableApolipoproteins\nImmunochemical methods, turbidimetry, nephelometry, ELISA, used measure specific apolipoproteins\nImmunochemical methods, turbidimetry, nephelometry, ELISA, used measure specific apolipoproteins","code":""},{"path":"procedures-1.html","id":"special-precautions-2","chapter":"Procedures","heading":"Special Precautions","text":"Patient Preparation\nFasting: Patients typically fast 9-12 hours lipid testing\nMedications: Certain medications can affect lipid levels\nRecent Illness/Surgery: Acute illness, surgery, trauma can affect lipid levels\nPosture: patient seated least 5 minutes blood collection\nFasting: Patients typically fast 9-12 hours lipid testingMedications: Certain medications can affect lipid levelsRecent Illness/Surgery: Acute illness, surgery, trauma can affect lipid levelsPosture: patient seated least 5 minutes blood collectionSpecimen Collection\nTube Type: Serum separator tubes (SST) plasma tubes EDTA commonly used\nOrder Draw: Follow correct order draw prevent cross-contamination\nTourniquet Time: Minimize tourniquet time prevent hemoconcentration\nTube Type: Serum separator tubes (SST) plasma tubes EDTA commonly usedOrder Draw: Follow correct order draw prevent cross-contaminationTourniquet Time: Minimize tourniquet time prevent hemoconcentrationSpecimen Processing\nTiming: Process specimen soon possible collection\nCentrifugation: Centrifuge sample according manufacturer’s instructions\nStorage: analysis delayed, store specimen refrigerated frozen\nTiming: Process specimen soon possible collectionCentrifugation: Centrifuge sample according manufacturer’s instructionsStorage: analysis delayed, store specimen refrigerated frozenAnalytical Considerations\nReagent Quality: Use high-quality reagents store according manufacturer’s instructions\nCalibration: Calibrate instrument regularly using appropriate standards\nQuality Control (QC): Run quality control samples regular intervals monitor accuracy precision assay\nReagent Quality: Use high-quality reagents store according manufacturer’s instructionsCalibration: Calibrate instrument regularly using appropriate standardsQuality Control (QC): Run quality control samples regular intervals monitor accuracy precision assay","code":""},{"path":"procedures-1.html","id":"troubleshooting-2","chapter":"Procedures","heading":"Troubleshooting","text":"High Lipid Results\nPre-Analytical: Patient fasting, prolonged tourniquet time, improper collection tube\nAnalytical: Incorrect calibration, reagent deterioration, interfering substances\nPre-Analytical: Patient fasting, prolonged tourniquet time, improper collection tubeAnalytical: Incorrect calibration, reagent deterioration, interfering substancesLow Lipid Results\nPre-Analytical: Improper storage, lipid degradation\nAnalytical: Incorrect calibration, reagent deterioration\nPre-Analytical: Improper storage, lipid degradationAnalytical: Incorrect calibration, reagent deteriorationInconsistent Results\nCheck patient preparation, review collection processing procedures, evaluate reagent quality calibration, consider interfering substances\nCheck patient preparation, review collection processing procedures, evaluate reagent quality calibration, consider interfering substances","code":""},{"path":"procedures-1.html","id":"interfering-substances-1","chapter":"Procedures","heading":"Interfering Substances","text":"Endogenous\nLipemia: Causes turbidity, affecting spectrophotometric readings\nBilirubin: Absorbs light similar wavelengths, affecting absorbance readings\nHemoglobin: Absorbs light can interfere enzymatic reactions\nLipemia: Causes turbidity, affecting spectrophotometric readingsBilirubin: Absorbs light similar wavelengths, affecting absorbance readingsHemoglobin: Absorbs light can interfere enzymatic reactionsExogenous\nAscorbic Acid (Vitamin C): Can interfere certain enzymatic reactions\nMedications: Certain drugs can directly affect lipid levels (e.g., statins, fibrates, beta-blockers, oral contraceptives)\nAscorbic Acid (Vitamin C): Can interfere certain enzymatic reactionsMedications: Certain drugs can directly affect lipid levels (e.g., statins, fibrates, beta-blockers, oral contraceptives)","code":""},{"path":"principles-1.html","id":"principles-1","chapter":"Principles","heading":"Principles","text":"Lipid testing lab helps assess cardiovascular risk, diagnose lipid disorders, monitor treatmentCore Lipid Tests\nTotal Cholesterol: Measures cholesterol blood\nTriglycerides: Measures amount triglycerides blood\nHDL Cholesterol: Measures high-density lipoprotein cholesterol\nLDL Cholesterol: Measures low-density lipoprotein cholesterol\nApolipoproteins: Measures specific apolipoproteins associated lipoproteins\nTotal Cholesterol: Measures cholesterol bloodTriglycerides: Measures amount triglycerides bloodHDL Cholesterol: Measures high-density lipoprotein cholesterolLDL Cholesterol: Measures low-density lipoprotein cholesterolApolipoproteins: Measures specific apolipoproteins associated lipoproteins","code":""},{"path":"principles-1.html","id":"total-cholesterol","chapter":"Principles","heading":"Total Cholesterol","text":"Principle: Enzymatic methods commonly used. Cholesterol esterase hydrolyzes cholesterol esters free cholesterol. Cholesterol oxidase oxidizes free cholesterol cholest-4-en-3-one hydrogen peroxide (H2O2). H2O2 reacted chromogen presence peroxidase (POD) produce colored product, measured spectrophotometricallyReactions\nCholesterol Esters –(Cholesterol Esterase)–> Cholesterol + Fatty Acids\nCholesterol + O2 –(Cholesterol Oxidase)–> Cholest-4-en-3-one + H2O2\n2 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2O\nCholesterol Esters –(Cholesterol Esterase)–> Cholesterol + Fatty AcidsCholesterol + O2 –(Cholesterol Oxidase)–> Cholest-4-en-3-one + H2O22 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2ODetection: intensity colored product directly proportional total cholesterol concentration sampleAdvantages: Accurate, precise, widely availableDisadvantages: Can affected interfering substances bilirubin hemoglobin","code":""},{"path":"principles-1.html","id":"triglycerides-1","chapter":"Principles","heading":"Triglycerides","text":"Principle: Enzymatic methods used. Lipoprotein lipase (LPL) hydrolyzes triglycerides glycerol free fatty acids. Glycerol phosphorylated glycerol kinase (GK) glycerol-3-phosphate (G-3-P). G-3-P oxidized glycerol-3-phosphate oxidase (GPO) dihydroxyacetone phosphate (DAP) H2O2. H2O2 reacted chromogen presence peroxidase (POD) produce colored product, measured spectrophotometricallyReactions\nTriglycerides –(Lipoprotein Lipase)–> Glycerol + 3 Fatty Acids\nGlycerol + ATP –(Glycerol Kinase)–> Glycerol-3-Phosphate + ADP\nGlycerol-3-Phosphate + O2 –(Glycerol-3-Phosphate Oxidase)–> Dihydroxyacetone Phosphate + H2O2\n2 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2O\nTriglycerides –(Lipoprotein Lipase)–> Glycerol + 3 Fatty AcidsGlycerol + ATP –(Glycerol Kinase)–> Glycerol-3-Phosphate + ADPGlycerol-3-Phosphate + O2 –(Glycerol-3-Phosphate Oxidase)–> Dihydroxyacetone Phosphate + H2O22 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2ODetection: intensity colored product directly proportional triglycerides concentration sampleAdvantages: Accurate, precise, widely availableDisadvantages: Can affected interfering substances bilirubin lipemia","code":""},{"path":"principles-1.html","id":"hdl-cholesterol","chapter":"Principles","heading":"HDL Cholesterol","text":"Principle\nDirect Methods: Use selective detergents antibodies block non-HDL lipoproteins (LDL, VLDL, chylomicrons), leaving HDL measured. HDL cholesterol measured using cholesterol oxidase-peroxidase method similar used total cholesterol\nIndirect Methods: Use precipitation reagents selectively precipitate non-HDL lipoproteins, followed measurement cholesterol supernatant containing HDL\nDirect Methods: Use selective detergents antibodies block non-HDL lipoproteins (LDL, VLDL, chylomicrons), leaving HDL measured. HDL cholesterol measured using cholesterol oxidase-peroxidase method similar used total cholesterolIndirect Methods: Use precipitation reagents selectively precipitate non-HDL lipoproteins, followed measurement cholesterol supernatant containing HDLReactions\nDirect Methods\nSelective Detergents/Antibodies block non-HDL lipoproteins\nHDL Cholesterol + O2 –(Cholesterol Oxidase)–> Cholest-4-en-3-one + H2O2\n2 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2O\n\nIndirect Methods\nNon-HDL lipoproteins precipitated\nHDL Cholesterol + O2 –(Cholesterol Oxidase)–> Cholest-4-en-3-one + H2O2\n2 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2O\n\nDirect Methods\nSelective Detergents/Antibodies block non-HDL lipoproteins\nHDL Cholesterol + O2 –(Cholesterol Oxidase)–> Cholest-4-en-3-one + H2O2\n2 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2O\nSelective Detergents/Antibodies block non-HDL lipoproteinsHDL Cholesterol + O2 –(Cholesterol Oxidase)–> Cholest-4-en-3-one + H2O22 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2OIndirect Methods\nNon-HDL lipoproteins precipitated\nHDL Cholesterol + O2 –(Cholesterol Oxidase)–> Cholest-4-en-3-one + H2O2\n2 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2O\nNon-HDL lipoproteins precipitatedHDL Cholesterol + O2 –(Cholesterol Oxidase)–> Cholest-4-en-3-one + H2O22 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2ODetection: intensity colored product directly proportional HDL cholesterol concentration sampleAdvantages\nDirect methods automated less susceptible interferences\nIndirect methods inexpensive labor-intensive\nDirect methods automated less susceptible interferencesIndirect methods inexpensive labor-intensiveDisadvantages\nIndirect methods can affected incomplete precipitation carryover non-HDL lipoproteins\nDirect methods can affected certain interfering substances\nIndirect methods can affected incomplete precipitation carryover non-HDL lipoproteinsDirect methods can affected certain interfering substances","code":""},{"path":"principles-1.html","id":"ldl-cholesterol","chapter":"Principles","heading":"LDL Cholesterol","text":"Principle\nFriedewald Equation (Calculation): LDL cholesterol estimated using Friedewald equation:\nLDL Cholesterol = Total Cholesterol - HDL Cholesterol - (Triglycerides / 5) (mg/dL)\nLDL Cholesterol = Total Cholesterol - HDL Cholesterol - (Triglycerides / 2.2) (mmol/L)\nequation valid triglycerides < 400 mg/dL (4.5 mmol/L)\nDirect Methods: Use selective detergents antibodies block non-LDL lipoproteins (HDL, VLDL, chylomicrons), leaving LDL measured. LDL cholesterol measured using cholesterol oxidase-peroxidase method similar used total cholesterol\nFriedewald Equation (Calculation): LDL cholesterol estimated using Friedewald equation:LDL Cholesterol = Total Cholesterol - HDL Cholesterol - (Triglycerides / 5) (mg/dL)LDL Cholesterol = Total Cholesterol - HDL Cholesterol - (Triglycerides / 2.2) (mmol/L)equation valid triglycerides < 400 mg/dL (4.5 mmol/L)Direct Methods: Use selective detergents antibodies block non-LDL lipoproteins (HDL, VLDL, chylomicrons), leaving LDL measured. LDL cholesterol measured using cholesterol oxidase-peroxidase method similar used total cholesterolReactions\nDirect Methods\nSelective Detergents/Antibodies block non-LDL lipoproteins\nLDL Cholesterol + O2 –(Cholesterol Oxidase)–> Cholest-4-en-3-one + H2O2\n2 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2O\n\nDirect Methods\nSelective Detergents/Antibodies block non-LDL lipoproteins\nLDL Cholesterol + O2 –(Cholesterol Oxidase)–> Cholest-4-en-3-one + H2O2\n2 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2O\nSelective Detergents/Antibodies block non-LDL lipoproteinsLDL Cholesterol + O2 –(Cholesterol Oxidase)–> Cholest-4-en-3-one + H2O22 H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + 2 H2ODetection: intensity colored product (direct methods) directly proportional LDL cholesterol concentration sampleAdvantages\nFriedewald equation inexpensive widely used\nDirect methods accurate can used triglycerides elevated\nFriedewald equation inexpensive widely usedDirect methods accurate can used triglycerides elevatedDisadvantages\nFriedewald equation accurate triglycerides > 400 mg/dL (4.5 mmol/L) certain dyslipidemia\nDirect methods expensive\nFriedewald equation accurate triglycerides > 400 mg/dL (4.5 mmol/L) certain dyslipidemiaDirect methods expensive","code":""},{"path":"principles-1.html","id":"apolipoproteins-1","chapter":"Principles","heading":"Apolipoproteins","text":"Principle: Immunochemical methods commonly used measure specific apolipoproteins. Antibodies specific apolipoprotein used capture quantify apolipoprotein blood sampleMethods\nTurbidimetric Immunoassay (TIA): Antibody-apolipoprotein complex formation measured change turbidity (light scattering)\nNephelometry: Antibody-apolipoprotein complex formation measured amount light scattered angle\nEnzyme-Linked Immunosorbent Assay (ELISA): Enzyme-labeled antibodies used, enzyme activity measured quantify antibody-apolipoprotein complex\nTurbidimetric Immunoassay (TIA): Antibody-apolipoprotein complex formation measured change turbidity (light scattering)Nephelometry: Antibody-apolipoprotein complex formation measured amount light scattered angleEnzyme-Linked Immunosorbent Assay (ELISA): Enzyme-labeled antibodies used, enzyme activity measured quantify antibody-apolipoprotein complexDetection: amount antibody-apolipoprotein complex formed measured, proportional apolipoprotein concentrationAdvantages: Specific automatedDisadvantages: Can affected interfering substances requires specialized equipment","code":""},{"path":"principles-1.html","id":"lipoprotein-a","chapter":"Principles","heading":"Lipoprotein (a)","text":"Principle: Immunochemical methods commonly used measure Lp(). Antibodies specific Lp() used capture quantify Lp() blood sampleMethods\nTurbidimetric Immunoassay (TIA): Antibody-Lp() complex formation measured change turbidity (light scattering)\nNephelometry: Antibody-Lp() complex formation measured amount light scattered angle\nEnzyme-Linked Immunosorbent Assay (ELISA): Enzyme-labeled antibodies used, enzyme activity measured quantify antibody-Lp() complex\nTurbidimetric Immunoassay (TIA): Antibody-Lp() complex formation measured change turbidity (light scattering)Nephelometry: Antibody-Lp() complex formation measured amount light scattered angleEnzyme-Linked Immunosorbent Assay (ELISA): Enzyme-labeled antibodies used, enzyme activity measured quantify antibody-Lp() complexDetection: amount antibody-Lp() complex formed measured, proportional Lp() concentrationAdvantages: Specific automatedDisadvantages: Can affected interfering substances requires specialized equipment","code":""},{"path":"principles-1.html","id":"lipid-electrophoresis","chapter":"Principles","heading":"Lipid Electrophoresis","text":"Principle: Separates lipoproteins based electrical charge sizeProcedure\nSerum applied support medium (e.g., agarose gel paper)\nelectric field applied, causing lipoproteins migrate different rates\nLipoproteins stained lipid-specific dye\nSerum applied support medium (e.g., agarose gel paper)electric field applied, causing lipoproteins migrate different ratesLipoproteins stained lipid-specific dyeDetection: separated lipoprotein bands visualized quantifiedClinical Significance\nHelps identify specific lipoprotein abnormalities, :\nElevated chylomicrons\nIncreased VLDL\nIncreased LDL\nDecreased HDL\n\nUsed diagnose classify hyperlipidemias\nHelps identify specific lipoprotein abnormalities, :\nElevated chylomicrons\nIncreased VLDL\nIncreased LDL\nDecreased HDL\nElevated chylomicronsIncreased VLDLIncreased LDLDecreased HDLUsed diagnose classify hyperlipidemias","code":""},{"path":"principles-1.html","id":"key-terms-12","chapter":"Principles","heading":"Key Terms","text":"Cholesterol Esterase: enzyme hydrolyzes cholesterol estersCholesterol Oxidase: enzyme oxidizes cholesterolPeroxidase: enzyme catalyzes reaction hydrogen peroxide chromogenLipoprotein Lipase (LPL): enzyme hydrolyzes triglycerides lipoproteinsGlycerol Kinase: enzyme phosphorylates glycerolGlycerol-3-Phosphate Oxidase: enzyme oxidizes glycerol-3-phosphateChromogen: substance produces colored productTurbidimetric Immunoassay (TIA): immunoassay measures change turbidityNephelometry: immunoassay measures amount light scatteredEnzyme-Linked Immunosorbent Assay (ELISA): immunoassay uses enzyme-labeled antibodiesFriedewald Equation: equation used estimate LDL cholesterolApolipoproteins: Proteins bind lipoproteins","code":""},{"path":"special-precautions-3.html","id":"special-precautions-3","chapter":"Special Precautions","heading":"Special Precautions","text":"Accurate lipid testing relies careful handling start finish. Pre-analytical steps key ensuring reliable resultsPatient Preparation\nFasting\nMedications\nRecent Illness/Surgery\nPosture\nFastingMedicationsRecent Illness/SurgeryPostureSpecimen Collection\nTube Type\nOrder Draw\nTourniquet Time\nTube TypeOrder DrawTourniquet TimeSpecimen Processing\nTiming\nCentrifugation\nStorage\nTimingCentrifugationStorageAnalytical Considerations\nReagent Quality\nCalibration\nQuality Control (QC)\nReagent QualityCalibrationQuality Control (QC)Interfering Substances\nEndogenous\nExogenous\nEndogenousExogenous","code":""},{"path":"special-precautions-3.html","id":"patient-preparation-1","chapter":"Special Precautions","heading":"Patient Preparation","text":"Fasting: Patients typically fast 9-12 hours lipid testingRationale: Fasting essential triglyceride levels significantly affected recent food intake. Non-fasting samples can lead falsely elevated triglyceride levels, affecting LDL cholesterol calculationsMedications: Certain medications can affect lipid levels\nExamples: Statins, fibrates, niacin, beta-blockers, oral contraceptives, corticosteroids\nAction: healthcare provider review patient’s medication list determine medications need temporarily discontinued testing. Document medications patient taking\nExamples: Statins, fibrates, niacin, beta-blockers, oral contraceptives, corticosteroidsAction: healthcare provider review patient’s medication list determine medications need temporarily discontinued testing. Document medications patient takingRecent Illness/Surgery: Acute illness, surgery, trauma can affect lipid levels\nRationale: Stress inflammation can temporarily alter lipid metabolism\nAction: Testing deferred patient recovered acute event. Note recent illnesses surgeries test request form\nRationale: Stress inflammation can temporarily alter lipid metabolismAction: Testing deferred patient recovered acute event. Note recent illnesses surgeries test request formPosture: patient seated least 5 minutes blood collection\nRationale: Prolonged standing can affect plasma volume lipid concentrations\nAction: Ensure patient comfortably seated venipuncture\nRationale: Prolonged standing can affect plasma volume lipid concentrationsAction: Ensure patient comfortably seated venipuncture","code":""},{"path":"special-precautions-3.html","id":"specimen-collection","chapter":"Special Precautions","heading":"Specimen Collection","text":"Tube Type: Serum separator tubes (SST) plasma tubes EDTA commonly usedRationale: SSTs allow easy separation serum, EDTA tubes provide plasma samples. choice depends laboratory’s standard operating procedures specific assays performedAction: Follow laboratory’s guidelines tube selection. Ensure tubes within expiration dateOrder Draw: Follow correct order draw collecting multiple tubes\nRationale: prevent cross-contamination tube additives. Lipid panels typically drawn blood culture tubes coagulation tubes\nAction: Follow CLSI guidelines order draw\nRationale: prevent cross-contamination tube additives. Lipid panels typically drawn blood culture tubes coagulation tubesAction: Follow CLSI guidelines order drawTourniquet Time: Minimize tourniquet time (ideally less 1 minute)\nRationale: Prolonged tourniquet time can cause hemoconcentration, leading falsely elevated lipid levels\nAction: Release tourniquet soon blood flow established, last tube filled\nRationale: Prolonged tourniquet time can cause hemoconcentration, leading falsely elevated lipid levelsAction: Release tourniquet soon blood flow established, last tube filled","code":""},{"path":"special-precautions-3.html","id":"specimen-processing","chapter":"Special Precautions","heading":"Specimen Processing","text":"Timing: Process specimen soon possible collection\nRationale: prevent degradation lipids cellular metabolism affecting results\nAction: Centrifuge sample within 1-2 hours collection\nRationale: prevent degradation lipids cellular metabolism affecting resultsAction: Centrifuge sample within 1-2 hours collectionCentrifugation: Centrifuge sample according manufacturer’s instructions specific tube type\nRationale: Proper centrifugation ensures complete separation serum plasma cells\nAction: Use correct speed duration centrifugation\nRationale: Proper centrifugation ensures complete separation serum plasma cellsAction: Use correct speed duration centrifugationStorage: analysis delayed, store specimen refrigerated (2-8°C) 7 days frozen (-20°C -70°C) longer storage\nRationale: prevent lipid degradation\nAction: Aliquot sample smaller portions avoid repeated freeze-thaw cycles, can degrade lipids\nRationale: prevent lipid degradationAction: Aliquot sample smaller portions avoid repeated freeze-thaw cycles, can degrade lipids","code":""},{"path":"special-precautions-3.html","id":"analytical-considerations-1","chapter":"Special Precautions","heading":"Analytical Considerations","text":"Reagent Quality: Use high-quality reagents store according manufacturer’s instructions\nRationale: ensure accurate reliable results\nAction: Check expiration dates discard expired reagents\nRationale: ensure accurate reliable resultsAction: Check expiration dates discard expired reagentsCalibration: Calibrate instrument regularly using appropriate standards\nRationale: ensure accurate precise measurements\nAction: Follow manufacturer’s calibration schedule procedures\nRationale: ensure accurate precise measurementsAction: Follow manufacturer’s calibration schedule proceduresQuality Control (QC): Run quality control samples regular intervals monitor accuracy precision assay\nRationale: detect shifts trends assay performance\nAction: Follow laboratory’s QC procedures. Evaluate QC results releasing patient results\nRationale: detect shifts trends assay performanceAction: Follow laboratory’s QC procedures. Evaluate QC results releasing patient results","code":""},{"path":"special-precautions-3.html","id":"interfering-substances-2","chapter":"Special Precautions","heading":"Interfering Substances","text":"Endogenous: Bilirubin, hemoglobin, lipemia\nRationale: substances can interfere spectrophotometric assays, leading inaccurate results\nAction: Use methods less susceptible interference, employ techniques remove correct interfering substance\nRationale: substances can interfere spectrophotometric assays, leading inaccurate resultsAction: Use methods less susceptible interference, employ techniques remove correct interfering substanceExogenous: Medications, contrast dyes\nRationale: Certain medications contrast dyes can affect lipid levels\nAction: aware potential interferences medications contrast dyes. Document substances patient taken\nRationale: Certain medications contrast dyes can affect lipid levelsAction: aware potential interferences medications contrast dyes. Document substances patient taken","code":""},{"path":"special-precautions-3.html","id":"troubleshooting-3","chapter":"Special Precautions","heading":"Troubleshooting","text":"High Lipid Results\nPre-Analytical:\nPatient fasting\nProlonged tourniquet time\nImproper collection tube\n\nAnalytical:\nIncorrect calibration\nReagent deterioration\nInterfering substances\n\nPre-Analytical:\nPatient fasting\nProlonged tourniquet time\nImproper collection tube\nPatient fastingProlonged tourniquet timeImproper collection tubeAnalytical:\nIncorrect calibration\nReagent deterioration\nInterfering substances\nIncorrect calibrationReagent deteriorationInterfering substancesLow Lipid Results\nPre-Analytical:\nImproper storage\nLipid degradation\n\nAnalytical:\nIncorrect calibration\nReagent deterioration\n\nPre-Analytical:\nImproper storage\nLipid degradation\nImproper storageLipid degradationAnalytical:\nIncorrect calibration\nReagent deterioration\nIncorrect calibrationReagent deteriorationInconsistent Results\nCheck patient preparation\nReview collection processing procedures\nEvaluate reagent quality calibration\nConsider interfering substances\nCheck patient preparationReview collection processing proceduresEvaluate reagent quality calibrationConsider interfering substances","code":""},{"path":"special-precautions-3.html","id":"interfering-substances-3","chapter":"Special Precautions","heading":"Interfering Substances","text":"Lipemia\nInterference: Causes turbidity, affecting spectrophotometric readings\nMechanism: Lipids scatter light, leading inaccurate absorbance measurements\nMitigation:\nUse lipemia clearing techniques (ultracentrifugation, lipid clearing reagents)\nConsider methods less affected turbidity\n\nInterference: Causes turbidity, affecting spectrophotometric readingsMechanism: Lipids scatter light, leading inaccurate absorbance measurementsMitigation:\nUse lipemia clearing techniques (ultracentrifugation, lipid clearing reagents)\nConsider methods less affected turbidity\nUse lipemia clearing techniques (ultracentrifugation, lipid clearing reagents)Consider methods less affected turbidityBilirubin\nInterference: Absorbs light similar wavelengths, affecting absorbance readings\nMechanism: Competes chromogen light absorption\nMitigation:\nUse methods less susceptible bilirubin interference\nEmploy bilirubin correction techniques\n\nInterference: Absorbs light similar wavelengths, affecting absorbance readingsMechanism: Competes chromogen light absorptionMitigation:\nUse methods less susceptible bilirubin interference\nEmploy bilirubin correction techniques\nUse methods less susceptible bilirubin interferenceEmploy bilirubin correction techniquesHemoglobin\nInterference: Absorbs light can interfere enzymatic reactions\nMechanism: Released hemolyzed red blood cells\nMitigation:\nAvoid hemolysis collection processing\nUse methods less susceptible hemoglobin interference\n\nInterference: Absorbs light can interfere enzymatic reactionsMechanism: Released hemolyzed red blood cellsMitigation:\nAvoid hemolysis collection processing\nUse methods less susceptible hemoglobin interference\nAvoid hemolysis collection processingUse methods less susceptible hemoglobin interferenceAscorbic Acid (Vitamin C)\nInterference: Can interfere certain enzymatic reactions\nMechanism: Acts reducing agent\nMitigation: Use methods less susceptible ascorbic acid interference\nInterference: Can interfere certain enzymatic reactionsMechanism: Acts reducing agentMitigation: Use methods less susceptible ascorbic acid interferenceMedications\nInterference: Certain drugs can directly affect lipid levels\nExamples:\nStatins: Decrease cholesterol\nFibrates: Decrease triglycerides, increase HDL\nBeta-blockers: Increase triglycerides, decrease HDL\nOral contraceptives: Increase triglycerides, decrease HDL\n\nMitigation: aware patient’s medication list\nInterference: Certain drugs can directly affect lipid levelsExamples:\nStatins: Decrease cholesterol\nFibrates: Decrease triglycerides, increase HDL\nBeta-blockers: Increase triglycerides, decrease HDL\nOral contraceptives: Increase triglycerides, decrease HDL\nStatins: Decrease cholesterolFibrates: Decrease triglycerides, increase HDLBeta-blockers: Increase triglycerides, decrease HDLOral contraceptives: Increase triglycerides, decrease HDLMitigation: aware patient’s medication list","code":""},{"path":"special-precautions-3.html","id":"key-terms-13","chapter":"Special Precautions","heading":"Key Terms","text":"Pre-analytical: Processes occur sample analyzedAnalytical: Processes involved analyzing sampleInterfering Substance: substance affects accuracy testLipemia: presence excess lipids bloodHemolysis: breakdown red blood cellsCalibration: Adjusting instrument ensure accurate readingsQuality Control: Samples used monitor accuracy precision testSpectrophotometry: method measure absorbance light solutionChromogen: substance produces colored productEnzymatic Method: laboratory method uses enzymes catalyze reactionImmunochemical Methods: Laboratory methods use antibodies measure substance","code":""},{"path":"result-interpretation-1.html","id":"result-interpretation-1","chapter":"Result Interpretation","heading":"Result Interpretation","text":"Accurate interpretation lipid test results crucial assessing cardiovascular risk guiding patient managementKey Analytes\nTotal Cholesterol (TC)\nTriglycerides (TG)\nHigh-Density Lipoprotein Cholesterol (HDL-C)\nLow-Density Lipoprotein Cholesterol (LDL-C)\nTotal Cholesterol (TC)Triglycerides (TG)High-Density Lipoprotein Cholesterol (HDL-C)Low-Density Lipoprotein Cholesterol (LDL-C)Additional Analytes\nNon-HDL Cholesterol\nApolipoproteins (Apo -1, Apo B)\nLipoprotein () [Lp()]\nNon-HDL CholesterolApolipoproteins (Apo -1, Apo B)Lipoprotein () [Lp()]","code":""},{"path":"result-interpretation-1.html","id":"total-cholesterol-1","chapter":"Result Interpretation","heading":"Total Cholesterol","text":"Reference Interval: < 200 mg/dL (5.18 mmol/L)Interpretation\nDesirable: < 200 mg/dL\nBorderline High: 200-239 mg/dL (5.18-6.18 mmol/L)\nHigh: ≥ 240 mg/dL (6.22 mmol/L)\nDesirable: < 200 mg/dLBorderline High: 200-239 mg/dL (5.18-6.18 mmol/L)High: ≥ 240 mg/dL (6.22 mmol/L)Clinical Significance\nElevated TC associated increased risk cardiovascular disease (CVD)\nTC component LDL-C calculation contributes overall risk assessment\nElevated TC associated increased risk cardiovascular disease (CVD)TC component LDL-C calculation contributes overall risk assessment","code":""},{"path":"result-interpretation-1.html","id":"triglycerides-2","chapter":"Result Interpretation","heading":"Triglycerides","text":"Reference Interval: < 150 mg/dL (1.7 mmol/L)Interpretation\nNormal: < 150 mg/dL\nBorderline High: 150-199 mg/dL (1.7-2.2 mmol/L)\nHigh: 200-499 mg/dL (2.3-5.6 mmol/L)\nHigh: ≥ 500 mg/dL (5.7 mmol/L)\nNormal: < 150 mg/dLBorderline High: 150-199 mg/dL (1.7-2.2 mmol/L)High: 200-499 mg/dL (2.3-5.6 mmol/L)High: ≥ 500 mg/dL (5.7 mmol/L)Clinical Significance\nElevated TG associated increased risk CVD, especially presence low HDL-C risk factors\nhigh TG levels (> 500 mg/dL) increase risk pancreatitis\nTG component LDL-C calculation (using Friedewald equation)\nElevated TG associated increased risk CVD, especially presence low HDL-C risk factorsVery high TG levels (> 500 mg/dL) increase risk pancreatitisTG component LDL-C calculation (using Friedewald equation)","code":""},{"path":"result-interpretation-1.html","id":"high-density-lipoprotein-cholesterol","chapter":"Result Interpretation","heading":"High-Density Lipoprotein Cholesterol","text":"Reference Interval: > 40 mg/dL (1.0 mmol/L)Interpretation\nLow: < 40 mg/dL\nOptimal: ≥ 60 mg/dL (1.55 mmol/L)\nLow: < 40 mg/dLOptimal: ≥ 60 mg/dL (1.55 mmol/L)Clinical Significance\nLow HDL-C independent risk factor CVD\nHigh HDL-C considered protective CVD\nHDL-C component LDL-C calculation\nLow HDL-C independent risk factor CVDHigh HDL-C considered protective CVDHDL-C component LDL-C calculation","code":""},{"path":"result-interpretation-1.html","id":"low-density-lipoprotein-cholesterol","chapter":"Result Interpretation","heading":"Low-Density Lipoprotein Cholesterol","text":"Reference Interval: Varies depending individual risk factorsInterpretation (ATP III Guidelines)\nOptimal: < 100 mg/dL (2.59 mmol/L)\nNear Optimal: 100-129 mg/dL (2.59-3.34 mmol/L)\nBorderline High: 130-159 mg/dL (3.37-4.11 mmol/L)\nHigh: 160-189 mg/dL (4.14-4.89 mmol/L)\nHigh: ≥ 190 mg/dL (4.91 mmol/L)\nOptimal: < 100 mg/dL (2.59 mmol/L)Near Optimal: 100-129 mg/dL (2.59-3.34 mmol/L)Borderline High: 130-159 mg/dL (3.37-4.11 mmol/L)High: 160-189 mg/dL (4.14-4.89 mmol/L)High: ≥ 190 mg/dL (4.91 mmol/L)Clinical Significance\nLDL-C primary target cholesterol-lowering therapy\nLower LDL-C levels associated reduced risk CVD events\nLDL-C goals individualized based patient’s overall CVD risk\nLDL-C primary target cholesterol-lowering therapyLower LDL-C levels associated reduced risk CVD eventsLDL-C goals individualized based patient’s overall CVD risk","code":""},{"path":"result-interpretation-1.html","id":"non-hdl-cholesterol","chapter":"Result Interpretation","heading":"Non-HDL Cholesterol","text":"Calculation: Non-HDL-C = Total Cholesterol - HDL-CInterpretation\nDesirable: < 130 mg/dL (3.37 mmol/L)\nBorderline High: 130-159 mg/dL (3.37-4.11 mmol/L)\nHigh: 160-189 mg/dL (4.14-4.89 mmol/L)\nHigh: ≥ 190 mg/dL (4.91 mmol/L)\nDesirable: < 130 mg/dL (3.37 mmol/L)Borderline High: 130-159 mg/dL (3.37-4.11 mmol/L)High: 160-189 mg/dL (4.14-4.89 mmol/L)High: ≥ 190 mg/dL (4.91 mmol/L)Clinical Significance\nNon-HDL-C includes atherogenic lipoproteins (LDL, VLDL, IDL, Lp())\nmay better predictor CVD risk LDL-C alone, especially patients high triglycerides\nNon-HDL-C includes atherogenic lipoproteins (LDL, VLDL, IDL, Lp())may better predictor CVD risk LDL-C alone, especially patients high triglycerides","code":""},{"path":"result-interpretation-1.html","id":"apolipoproteins-2","chapter":"Result Interpretation","heading":"Apolipoproteins","text":"Apo -1 (Major protein HDL)\nReference Interval:\nMales: 100-160 mg/dL\nFemales: 120-190 mg/dL\n\nClinical Significance:\nLow levels associated increased CVD risk\n\nReference Interval:\nMales: 100-160 mg/dL\nFemales: 120-190 mg/dL\nMales: 100-160 mg/dLFemales: 120-190 mg/dLClinical Significance:\nLow levels associated increased CVD risk\nLow levels associated increased CVD riskApo B (Major protein LDL, VLDL, IDL, Lp())\nReference Interval: 80-130 mg/dL\nClinical Significance:\nHigh levels associated increased CVD risk\nMay better predictor CVD risk LDL-C alone, especially patients metabolic syndrome diabetes\n\nReference Interval: 80-130 mg/dLClinical Significance:\nHigh levels associated increased CVD risk\nMay better predictor CVD risk LDL-C alone, especially patients metabolic syndrome diabetes\nHigh levels associated increased CVD riskMay better predictor CVD risk LDL-C alone, especially patients metabolic syndrome diabetes","code":""},{"path":"result-interpretation-1.html","id":"lipoprotein-a-1","chapter":"Result Interpretation","heading":"Lipoprotein (a)","text":"Reference Interval: < 30 mg/dL < 75 nmol/LClinical Significance\nElevated Lp() independent risk factor CVD\nLp() levels largely genetically determined less responsive lifestyle modifications\nConsider measuring Lp() patients premature CVD family history CVD\nElevated Lp() independent risk factor CVDLp() levels largely genetically determined less responsive lifestyle modificationsConsider measuring Lp() patients premature CVD family history CVD","code":""},{"path":"result-interpretation-1.html","id":"factors-affecting-interpretation-1","chapter":"Result Interpretation","heading":"Factors Affecting Interpretation","text":"Fasting Status: Triglyceride levels significantly affected fasting status. Non-fasting samples can lead falsely elevated triglyceride levelsMedications: Certain medications can affect lipid levels (e.g., statins, fibrates, niacin, beta-blockers, oral contraceptives, corticosteroids)Medical Conditions: Certain medical conditions can affect lipid levels (e.g., diabetes, hypothyroidism, kidney disease, liver disease, metabolic syndrome)Acute Illness/Stress: Acute illness, surgery, trauma can affect lipid levelsEthnicity: Certain ethnic groups may different lipid levels compared CaucasiansAge Gender: Lipid levels vary age genderPregnancy: Pregnancy affects lipid metabolism, specific reference intervals used pregnant women","code":""},{"path":"result-interpretation-1.html","id":"key-terms-14","chapter":"Result Interpretation","heading":"Key Terms","text":"Total Cholesterol (TC): measure cholesterol bloodTriglycerides (TG): type fat bloodHigh-Density Lipoprotein Cholesterol (HDL-C): “Good” cholesterol helps remove LDL arteriesLow-Density Lipoprotein Cholesterol (LDL-C): “Bad” cholesterol contributes plaque buildupNon-HDL Cholesterol: Total cholesterol minus HDL cholesterol, representing atherogenic lipoproteinsApolipoproteins (Apo -1, Apo B): Proteins bind lipoproteinsLipoprotein () [Lp()]: lipoprotein particle associated increased CVD riskAtherosclerosis: Plaque buildup arteriesCardiovascular Disease (CVD): Diseases heart blood vesselsFamilial Hypercholesterolemia (FH): genetic disorder characterized high LDL-C levelsFamilial Hypertriglyceridemia (FHTG): genetic disorder characterized elevated triglyceride levelsMetabolic Syndrome: cluster conditions increase risk heart disease, stroke, diabetesStatin Therapy: Medications lower LDL cholesterol levelsFibrates: Medications lower triglyceride levels increase HDL cholesterol levels","code":""},{"path":"disease-correlation-1.html","id":"disease-correlation-1","chapter":"Disease Correlation","heading":"Disease Correlation","text":"Understanding lipid tests connect specific disease states vital effective diagnosis management. Lipids, including cholesterol triglycerides, play critical role various physiological processes. Abnormal lipid levels associated several disease states\n* Key Conditions\n* Atherosclerosis\n* Coronary Artery Disease (CAD)\n* Hyperlipidemia Dyslipidemia\n* Metabolic Syndrome\n* Acute Pancreatitis\n* Lipoprotein Disorders (e.g., Familial Hypercholesterolemia, Tangier Disease)\n* Non-Alcoholic Fatty Liver Disease (NAFLD)","code":""},{"path":"disease-correlation-1.html","id":"atherosclerosis-1","chapter":"Disease Correlation","heading":"Atherosclerosis","text":"Definition: chronic inflammatory disease characterized accumulation lipids, cholesterol, calcium, cellular debris within walls arteries, leading plaque formation narrowing arterial lumenLaboratory Findings\nElevated LDL Cholesterol (LDL-C): > 130 mg/dL (3.37 mmol/L)\nElevated Non-HDL Cholesterol: > 160 mg/dL (4.14 mmol/L)\nElevated Apolipoprotein B (Apo B): > 130 mg/dL\nLow HDL Cholesterol (HDL-C): < 40 mg/dL (1.0 mmol/L)\nElevated Lipoprotein () [Lp()]: > 30 mg/dL > 75 nmol/L\nElevated LDL Cholesterol (LDL-C): > 130 mg/dL (3.37 mmol/L)Elevated Non-HDL Cholesterol: > 160 mg/dL (4.14 mmol/L)Elevated Apolipoprotein B (Apo B): > 130 mg/dLLow HDL Cholesterol (HDL-C): < 40 mg/dL (1.0 mmol/L)Elevated Lipoprotein () [Lp()]: > 30 mg/dL > 75 nmol/LDisease State Correlation\nElevated LDL-C non-HDL-C contribute lipid accumulation arterial wall\nLow HDL-C impairs reverse cholesterol transport, reducing removal cholesterol arterial wall\nElevated Apo B indicates increased number atherogenic particles\nElevated Lp() promotes thrombosis inflammation\nElevated LDL-C non-HDL-C contribute lipid accumulation arterial wallLow HDL-C impairs reverse cholesterol transport, reducing removal cholesterol arterial wallElevated Apo B indicates increased number atherogenic particlesElevated Lp() promotes thrombosis inflammationClinical Significance\nAtherosclerosis underlying cause cardiovascular diseases\nEarly detection management risk factors essential prevent slow disease progression\nAtherosclerosis underlying cause cardiovascular diseasesEarly detection management risk factors essential prevent slow disease progression","code":""},{"path":"disease-correlation-1.html","id":"coronary-artery-disease-cad","chapter":"Disease Correlation","heading":"Coronary Artery Disease (CAD)","text":"Definition: condition characterized narrowing blockage coronary arteries, usually due atherosclerosis, leading reduced blood flow heart muscleLaboratory Findings\nElevated LDL Cholesterol (LDL-C): > 100 mg/dL (2.59 mmol/L)\nElevated Non-HDL Cholesterol: > 130 mg/dL (3.37 mmol/L)\nLow HDL Cholesterol (HDL-C): < 40 mg/dL (1.0 mmol/L)\nElevated Triglycerides: > 150 mg/dL (1.7 mmol/L)\nElevated Lipoprotein () [Lp()]: > 30 mg/dL > 75 nmol/L\nElevated LDL Cholesterol (LDL-C): > 100 mg/dL (2.59 mmol/L)Elevated Non-HDL Cholesterol: > 130 mg/dL (3.37 mmol/L)Low HDL Cholesterol (HDL-C): < 40 mg/dL (1.0 mmol/L)Elevated Triglycerides: > 150 mg/dL (1.7 mmol/L)Elevated Lipoprotein () [Lp()]: > 30 mg/dL > 75 nmol/LDisease State Correlation\nAbnormal lipid levels contribute plaque formation narrowing coronary arteries\nElevated Lp() increases risk thrombosis acute coronary events\nAbnormal lipid levels contribute plaque formation narrowing coronary arteriesElevated Lp() increases risk thrombosis acute coronary eventsClinical Significance\nCAD can lead angina, myocardial infarction (heart attack), heart failure, sudden cardiac death\nManagement involves lifestyle modifications, medications (statins, antiplatelet agents), procedures (angioplasty, bypass surgery)\nCAD can lead angina, myocardial infarction (heart attack), heart failure, sudden cardiac deathManagement involves lifestyle modifications, medications (statins, antiplatelet agents), procedures (angioplasty, bypass surgery)","code":""},{"path":"disease-correlation-1.html","id":"hyperlipidemia-and-dyslipidemia","chapter":"Disease Correlation","heading":"Hyperlipidemia and Dyslipidemia","text":"Definitions\nHyperlipidemia: Elevated levels lipids (fats) blood\nDyslipidemia: Abnormal lipid profile, including high LDL cholesterol, low HDL cholesterol, /high triglycerides\nHyperlipidemia: Elevated levels lipids (fats) bloodDyslipidemia: Abnormal lipid profile, including high LDL cholesterol, low HDL cholesterol, /high triglyceridesLaboratory Findings\nElevated Total Cholesterol (TC): > 200 mg/dL (5.18 mmol/L)\nElevated LDL Cholesterol (LDL-C): > 130 mg/dL (3.37 mmol/L)\nElevated Triglycerides (TG): > 150 mg/dL (1.7 mmol/L)\nLow HDL Cholesterol (HDL-C): < 40 mg/dL (1.0 mmol/L)\nElevated Total Cholesterol (TC): > 200 mg/dL (5.18 mmol/L)Elevated LDL Cholesterol (LDL-C): > 130 mg/dL (3.37 mmol/L)Elevated Triglycerides (TG): > 150 mg/dL (1.7 mmol/L)Low HDL Cholesterol (HDL-C): < 40 mg/dL (1.0 mmol/L)Disease State Correlation\nconditions increase risk atherosclerosis, CAD, stroke, peripheral artery disease\nconditions increase risk atherosclerosis, CAD, stroke, peripheral artery diseaseClinical Significance\nManagement involves lifestyle modifications (diet, exercise) medications (statins, fibrates, niacin, omega-3 fatty acids)\nEarly detection treatment essential prevent cardiovascular complications\nManagement involves lifestyle modifications (diet, exercise) medications (statins, fibrates, niacin, omega-3 fatty acids)Early detection treatment essential prevent cardiovascular complications","code":""},{"path":"disease-correlation-1.html","id":"metabolic-syndrome","chapter":"Disease Correlation","heading":"Metabolic Syndrome","text":"Definition: cluster conditions occur together, increasing risk heart disease, stroke, type 2 diabetesDiagnostic Criteria (ATP III Guidelines)\nThree following:\nAbdominal Obesity: Waist circumference > 40 inches (102 cm) men > 35 inches (88 cm) women\nElevated Triglycerides: > 150 mg/dL (1.7 mmol/L)\nLow HDL Cholesterol: < 40 mg/dL (1.0 mmol/L) men < 50 mg/dL (1.3 mmol/L) women\nElevated Blood Pressure: ≥ 130/85 mmHg\nElevated Fasting Glucose: ≥ 100 mg/dL (5.6 mmol/L)\n\nThree following:\nAbdominal Obesity: Waist circumference > 40 inches (102 cm) men > 35 inches (88 cm) women\nElevated Triglycerides: > 150 mg/dL (1.7 mmol/L)\nLow HDL Cholesterol: < 40 mg/dL (1.0 mmol/L) men < 50 mg/dL (1.3 mmol/L) women\nElevated Blood Pressure: ≥ 130/85 mmHg\nElevated Fasting Glucose: ≥ 100 mg/dL (5.6 mmol/L)\nAbdominal Obesity: Waist circumference > 40 inches (102 cm) men > 35 inches (88 cm) womenElevated Triglycerides: > 150 mg/dL (1.7 mmol/L)Low HDL Cholesterol: < 40 mg/dL (1.0 mmol/L) men < 50 mg/dL (1.3 mmol/L) womenElevated Blood Pressure: ≥ 130/85 mmHgElevated Fasting Glucose: ≥ 100 mg/dL (5.6 mmol/L)Laboratory Findings\nElevated Triglycerides: > 150 mg/dL (1.7 mmol/L)\nLow HDL Cholesterol: < 40 mg/dL (1.0 mmol/L) men < 50 mg/dL (1.3 mmol/L) women\nElevated Fasting Glucose: ≥ 100 mg/dL (5.6 mmol/L)\nElevated Triglycerides: > 150 mg/dL (1.7 mmol/L)Low HDL Cholesterol: < 40 mg/dL (1.0 mmol/L) men < 50 mg/dL (1.3 mmol/L) womenElevated Fasting Glucose: ≥ 100 mg/dL (5.6 mmol/L)Disease State Correlation\nMetabolic syndrome increases risk cardiovascular disease, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), certain cancers\nMetabolic syndrome increases risk cardiovascular disease, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), certain cancersClinical Significance\nManagement involves lifestyle modifications (diet, exercise, weight loss) medications address individual components syndrome\nManagement involves lifestyle modifications (diet, exercise, weight loss) medications address individual components syndrome","code":""},{"path":"disease-correlation-1.html","id":"acute-pancreatitis","chapter":"Disease Correlation","heading":"Acute Pancreatitis","text":"Definition: Inflammation pancreas, can caused gallstones, alcohol abuse, medications, hypertriglyceridemiaLaboratory Findings\nElevated Triglycerides: > 500 mg/dL (5.7 mmol/L)\nElevated Amylase Lipase: Enzymes released damaged pancreas\nElevated Triglycerides: > 500 mg/dL (5.7 mmol/L)Elevated Amylase Lipase: Enzymes released damaged pancreasDisease State Correlation\nHypertriglyceridemia can cause pancreatic damage due formation toxic free fatty acids\nHypertriglyceridemia can cause pancreatic damage due formation toxic free fatty acidsClinical Significance\nManagement involves supportive care, including intravenous fluids, pain management, bowel rest\nsevere cases, treatment may include plasma exchange (apheresis) rapidly lower triglyceride levels\nManagement involves supportive care, including intravenous fluids, pain management, bowel restIn severe cases, treatment may include plasma exchange (apheresis) rapidly lower triglyceride levels","code":""},{"path":"disease-correlation-1.html","id":"lipoprotein-disorders-1","chapter":"Disease Correlation","heading":"Lipoprotein Disorders","text":"Definition: Genetic disorders affect lipoprotein synthesis, structure, metabolism, leading abnormal lipid levelsExamples\nFamilial Hypercholesterolemia (FH)\nElevated LDL Cholesterol (LDL-C): > 190 mg/dL (4.91 mmol/L) adults > 160 mg/dL (4.14 mmol/L) children\nGenetic testing reveals mutations LDL receptor gene, ApoB gene, PCSK9 gene\n\nFamilial Hypertriglyceridemia (FHTG)\nElevated Triglycerides: > 200 mg/dL (2.26 mmol/L)\nGenetic testing may reveal mutations genes involved triglyceride metabolism (e.g., LPL, ApoC2)\n\nTangier Disease\nLow HDL Cholesterol (HDL-C): < 5 mg/dL (0.13 mmol/L)\nGenetic testing reveals mutations ABCA1 gene\n\nFamilial Hypercholesterolemia (FH)\nElevated LDL Cholesterol (LDL-C): > 190 mg/dL (4.91 mmol/L) adults > 160 mg/dL (4.14 mmol/L) children\nGenetic testing reveals mutations LDL receptor gene, ApoB gene, PCSK9 gene\nElevated LDL Cholesterol (LDL-C): > 190 mg/dL (4.91 mmol/L) adults > 160 mg/dL (4.14 mmol/L) childrenGenetic testing reveals mutations LDL receptor gene, ApoB gene, PCSK9 geneFamilial Hypertriglyceridemia (FHTG)\nElevated Triglycerides: > 200 mg/dL (2.26 mmol/L)\nGenetic testing may reveal mutations genes involved triglyceride metabolism (e.g., LPL, ApoC2)\nElevated Triglycerides: > 200 mg/dL (2.26 mmol/L)Genetic testing may reveal mutations genes involved triglyceride metabolism (e.g., LPL, ApoC2)Tangier Disease\nLow HDL Cholesterol (HDL-C): < 5 mg/dL (0.13 mmol/L)\nGenetic testing reveals mutations ABCA1 gene\nLow HDL Cholesterol (HDL-C): < 5 mg/dL (0.13 mmol/L)Genetic testing reveals mutations ABCA1 geneDisease State Correlation\nFH increases risk premature cardiovascular disease\nFHTG increases risk pancreatitis cardiovascular disease\nTangier disease associated enlarged orange tonsils, neuropathy, premature cardiovascular disease\nFH increases risk premature cardiovascular diseaseFHTG increases risk pancreatitis cardiovascular diseaseTangier disease associated enlarged orange tonsils, neuropathy, premature cardiovascular diseaseClinical Significance\nEarly diagnosis management essential prevent complications\nTreatment involves lifestyle modifications, medications, sometimes specialized therapies\nEarly diagnosis management essential prevent complicationsTreatment involves lifestyle modifications, medications, sometimes specialized therapies","code":""},{"path":"disease-correlation-1.html","id":"non-alcoholic-fatty-liver-disease-nafld","chapter":"Disease Correlation","heading":"Non-Alcoholic Fatty Liver Disease (NAFLD)","text":"Definition: condition characterized accumulation excess fat liver individuals consume excessive alcoholLaboratory Findings\nElevated Liver Enzymes: ALT AST (indicators liver inflammation/damage)\nElevated Triglycerides: > 150 mg/dL (1.7 mmol/L)\nElevated Fasting Glucose: ≥ 100 mg/dL (5.6 mmol/L)\nElevated LDL Cholesterol (LDL-C): > 130 mg/dL (3.37 mmol/L)\nLow HDL Cholesterol (HDL-C): < 40 mg/dL (1.0 mmol/L) men < 50 mg/dL (1.3 mmol/L) women\nElevated Liver Enzymes: ALT AST (indicators liver inflammation/damage)Elevated Triglycerides: > 150 mg/dL (1.7 mmol/L)Elevated Fasting Glucose: ≥ 100 mg/dL (5.6 mmol/L)Elevated LDL Cholesterol (LDL-C): > 130 mg/dL (3.37 mmol/L)Low HDL Cholesterol (HDL-C): < 40 mg/dL (1.0 mmol/L) men < 50 mg/dL (1.3 mmol/L) womenDisease State Correlation\nNAFLD associated insulin resistance, obesity, metabolic syndrome, increased risk cardiovascular disease\nNon-Alcoholic Steatohepatitis (NASH): severe form NAFLD characterized inflammation liver damage\nNAFLD associated insulin resistance, obesity, metabolic syndrome, increased risk cardiovascular diseaseNon-Alcoholic Steatohepatitis (NASH): severe form NAFLD characterized inflammation liver damageClinical Significance\nManagement involves lifestyle modifications (weight loss, diet, exercise) medications address underlying conditions\nManagement involves lifestyle modifications (weight loss, diet, exercise) medications address underlying conditions","code":""},{"path":"disease-correlation-1.html","id":"key-terms-15","chapter":"Disease Correlation","heading":"Key Terms","text":"Atherosclerosis: Plaque buildup arteriesCoronary Artery Disease (CAD): Narrowing blockage coronary arteriesHyperlipidemia: Elevated levels lipids bloodDyslipidemia: Abnormal lipid profileMetabolic Syndrome: cluster conditions increase risk heart disease, stroke, diabetesAcute Pancreatitis: Inflammation pancreasFamilial Hypercholesterolemia (FH): genetic disorder characterized high LDL-C levelsFamilial Hypertriglyceridemia (FHTG): genetic disorder characterized elevated triglyceride levelsTangier Disease: genetic disorder characterized low HDL-C levelsNon-Alcoholic Fatty Liver Disease (NAFLD): Excess fat accumulation liver caused excessive alcohol consumptionLipoproteins: Particles transport lipids blood","code":""},{"path":"heme-derivatives.html","id":"heme-derivatives","chapter":"Heme Derivatives","heading":"Heme Derivatives","text":"Heme derivatives essential oxygen transport, electron transfer, various enzymatic processes. Accurate lab testing compounds critical diagnosing managing wide range conditions","code":""},{"path":"heme-derivatives.html","id":"biochemical-theory-and-physiology-2","chapter":"Heme Derivatives","heading":"Biochemical Theory and Physiology","text":"Heme Structure Function\nPorphyrin ring complex iron (Fe2+)\nEssential hemoglobin, myoglobin, cytochromes, heme proteins\nPorphyrin ring complex iron (Fe2+)Essential hemoglobin, myoglobin, cytochromes, heme proteinsHeme Synthesis\nComplex pathway producing heme, primarily bone marrow liver\nKey enzymes: ALA synthase, ALA dehydratase, ferrochelatase\nComplex pathway producing heme, primarily bone marrow liverKey enzymes: ALA synthase, ALA dehydratase, ferrochelataseHeme Degradation\nBreakdown heme biliverdin, bilirubin, eventually excreted products\nKey enzymes: Heme oxygenase, biliverdin reductase, UDP-glucuronosyltransferase (UGT)\nBreakdown heme biliverdin, bilirubin, eventually excreted productsKey enzymes: Heme oxygenase, biliverdin reductase, UDP-glucuronosyltransferase (UGT)Iron Metabolism\nIron crucial component heme tightly regulated\nAbsorption, transport (transferrin), storage (ferritin)\nIron crucial component heme tightly regulatedAbsorption, transport (transferrin), storage (ferritin)","code":""},{"path":"heme-derivatives.html","id":"laboratory-test-procedures-2","chapter":"Heme Derivatives","heading":"Laboratory Test Procedures","text":"Bilirubin\nDiazo Method: Total, Direct (Conjugated), Indirect (Unconjugated) Bilirubin\nJendrassik-Grof Method: Modification Diazo method reduce interference\nDiazo Method: Total, Direct (Conjugated), Indirect (Unconjugated) BilirubinJendrassik-Grof Method: Modification Diazo method reduce interferenceUrine Bilirubin\nDipstick Method: Qualitative detection conjugated bilirubin\nDipstick Method: Qualitative detection conjugated bilirubinUrine Urobilinogen\nEhrlich’s Reagent Method: Semi-quantitative detection urobilinogen\nEhrlich’s Reagent Method: Semi-quantitative detection urobilinogenIron Studies\nSerum Iron: Measurement iron serum\nTotal Iron-Binding Capacity (TIBC): Measurement blood’s capacity bind iron\nTransferrin Saturation: Calculated (Serum Iron / TIBC) x 100\nFerritin: Immunoassay measuring ferritin concentration\nSerum Iron: Measurement iron serumTotal Iron-Binding Capacity (TIBC): Measurement blood’s capacity bind ironTransferrin Saturation: Calculated (Serum Iron / TIBC) x 100Ferritin: Immunoassay measuring ferritin concentrationPorphyrin Analysis\nHPLC: Separation quantification porphyrins urine, blood, feces\nHPLC: Separation quantification porphyrins urine, blood, fecesFecal Occult Blood Test (FOBT)\nGuaiac-Based FOBT (gFOBT): Detection heme’s peroxidase activity\nFecal Immunochemical Test (FIT): Uses antibodies human hemoglobin\nGuaiac-Based FOBT (gFOBT): Detection heme’s peroxidase activityFecal Immunochemical Test (FIT): Uses antibodies human hemoglobin","code":""},{"path":"heme-derivatives.html","id":"test-result-interpretation-2","chapter":"Heme Derivatives","heading":"Test Result Interpretation","text":"Bilirubin\nElevated Total Bilirubin: Hyperbilirubinemia\nIncreased Direct Bilirubin: Biliary obstruction, liver disease\nIncreased Indirect Bilirubin: Hemolysis\nElevated Total Bilirubin: HyperbilirubinemiaIncreased Direct Bilirubin: Biliary obstruction, liver diseaseIncreased Indirect Bilirubin: HemolysisUrine Bilirubin\nPositive: Biliary obstruction, liver disease\nPositive: Biliary obstruction, liver diseaseUrine Urobilinogen\nIncreased: Hemolysis, liver disease\nDecreased: Biliary obstruction\nIncreased: Hemolysis, liver diseaseDecreased: Biliary obstructionIron Studies\nDecreased Serum Iron, Ferritin, Transferrin Saturation; Increased TIBC: Iron Deficiency Anemia\nIncreased Serum Iron, Ferritin, Transferrin Saturation; Decreased TIBC: Hemochromatosis\nDecreased Serum Iron, Ferritin, Transferrin Saturation; Increased TIBC: Iron Deficiency AnemiaIncreased Serum Iron, Ferritin, Transferrin Saturation; Decreased TIBC: HemochromatosisPorphyrin Analysis\nElevated levels specific porphyrins urine, blood, feces: Porphyria\nElevated levels specific porphyrins urine, blood, feces: PorphyriaFecal Occult Blood Test (FOBT)\nPositive: Gastrointestinal bleeding\nPositive: Gastrointestinal bleeding","code":""},{"path":"heme-derivatives.html","id":"disease-state-correlation-2","chapter":"Heme Derivatives","heading":"Disease State Correlation","text":"Liver Diseases\nHepatitis: Elevated Total Bilirubin, Direct Bilirubin, ALT, AST\nCirrhosis: Elevated Bilirubin, Decreased Albumin, Prolonged PT\nBiliary Obstruction: Elevated Total Bilirubin, Direct Bilirubin, Alkaline Phosphatase (ALP), Gamma-Glutamyl Transferase (GGT)\nHepatitis: Elevated Total Bilirubin, Direct Bilirubin, ALT, ASTCirrhosis: Elevated Bilirubin, Decreased Albumin, Prolonged PTBiliary Obstruction: Elevated Total Bilirubin, Direct Bilirubin, Alkaline Phosphatase (ALP), Gamma-Glutamyl Transferase (GGT)Hemolytic Anemias\nElevated Total Bilirubin (Indirect), Increased Reticulocyte Count, Decreased Haptoglobin\nElevated Total Bilirubin (Indirect), Increased Reticulocyte Count, Decreased HaptoglobinPorphyrias\nElevated levels specific porphyrins porphyrin precursors urine, blood, feces\nElevated levels specific porphyrins porphyrin precursors urine, blood, fecesIron Deficiency Anemia (IDA)\nDecreased Hemoglobin, Hematocrit, Serum Iron, Ferritin; Increased TIBC\nDecreased Hemoglobin, Hematocrit, Serum Iron, Ferritin; Increased TIBCHemochromatosis\nElevated Serum Iron, Transferrin Saturation, Ferritin\nElevated Serum Iron, Transferrin Saturation, FerritinLead Poisoning\nElevated Blood Lead Levels, Elevated Zinc Protoporphyrin (ZPP), Anemia\nElevated Blood Lead Levels, Elevated Zinc Protoporphyrin (ZPP), AnemiaAnemia Chronic Disease (ACD)\nDecreased Hemoglobin, Serum Iron, TIBC; Normal Increased Ferritin\nDecreased Hemoglobin, Serum Iron, TIBC; Normal Increased Ferritin","code":""},{"path":"heme-derivatives.html","id":"key-considerations-for-accurate-results","chapter":"Heme Derivatives","heading":"Key Considerations for Accurate Results","text":"Pre-analytical variablesInterfering substancesAnalytical limitationsReference ranges based patient’s age sex","code":""},{"path":"heme-derivatives.html","id":"overall-approach","chapter":"Heme Derivatives","heading":"Overall Approach","text":"Connect Dots: Integrate biochemical knowledge lab data, patient history, clinical examContinual Learning: Stay --date guidelines best practicesClinical Significance: Understanding heme metabolism relationship disease critical accurate diagnosis treatment","code":""},{"path":"biochemicals-2.html","id":"biochemicals-2","chapter":"Biochemicals","heading":"Biochemicals","text":"section connects biochemical basis heme derivatives clinical significance. covers heme metabolism, connection disease, chemical properties govern behavior","code":""},{"path":"biochemicals-2.html","id":"biochemical-theory-and-metabolic-pathways-1","chapter":"Biochemicals","heading":"Biochemical Theory and Metabolic Pathways","text":"Heme Functional Unit: Heme porphyrin ring complex iron, essential oxygen transport, electron transfer, detoxificationKey Metabolic Pathways\nHeme Synthesis: Complex pathway producing heme, primarily bone marrow liver\nHeme Degradation: Breakdown heme biliverdin, bilirubin, eventually excreted products\nHeme Synthesis: Complex pathway producing heme, primarily bone marrow liverHeme Degradation: Breakdown heme biliverdin, bilirubin, eventually excreted productsIron Metabolism: Important heme function, tightly regulatedEnzymes\nALA Synthase: Rate-limiting enzyme heme synthesis\nHeme Oxygenase: Breaks heme\nUDP-Glucuronosyltransferase (UGT): Conjugates bilirubin excretion\nALA Synthase: Rate-limiting enzyme heme synthesisHeme Oxygenase: Breaks hemeUDP-Glucuronosyltransferase (UGT): Conjugates bilirubin excretion","code":""},{"path":"biochemicals-2.html","id":"normal-and-abnormal-states-2","chapter":"Biochemicals","heading":"Normal and Abnormal States","text":"Normal State: Balanced heme synthesis degradation, appropriate bilirubin iron levelsAbnormal States\nPorphyrias: Genetic defects heme synthesis, leading porphyrin accumulation\nJaundice/Hyperbilirubinemia: Elevated bilirubin due increased production, impaired conjugation, excretion issues\nIron Deficiency Anemia: Low iron leading insufficient heme production\nHemochromatosis: Iron overload, damaging tissues\nLead Poisoning: Disrupts heme synthesis\nPorphyrias: Genetic defects heme synthesis, leading porphyrin accumulationJaundice/Hyperbilirubinemia: Elevated bilirubin due increased production, impaired conjugation, excretion issuesIron Deficiency Anemia: Low iron leading insufficient heme productionHemochromatosis: Iron overload, damaging tissuesLead Poisoning: Disrupts heme synthesis","code":""},{"path":"biochemicals-2.html","id":"physical-and-chemical-properties-3","chapter":"Biochemicals","heading":"Physical and Chemical Properties","text":"Hemoglobin\nTetrameric protein heme; carries oxygen\nRed color oxygenated, cooperative oxygen binding\nTetrameric protein heme; carries oxygenRed color oxygenated, cooperative oxygen bindingMyoglobin\nMonomeric protein heme; stores oxygen muscle\nHigher oxygen affinity hemoglobin\nMonomeric protein heme; stores oxygen muscleHigher oxygen affinity hemoglobinBilirubin\nYellow pigment heme breakdown\nInsoluble (unconjugated), soluble conjugated liver\nYellow pigment heme breakdownInsoluble (unconjugated), soluble conjugated liverUrobilinogen\nColorless product bacterial bilirubin reduction\nExcreted feces urine\nColorless product bacterial bilirubin reductionExcreted feces urinePorphyrins\nCyclic tetrapyrrole intermediates heme synthesis\nFluorescent, abnormal accumulation indicates porphyrias\nCyclic tetrapyrrole intermediates heme synthesisFluorescent, abnormal accumulation indicates porphyrias","code":""},{"path":"biochemicals-2.html","id":"interconnections-1","chapter":"Biochemicals","heading":"Interconnections","text":"Heme Synthesis & Iron: Iron critical building block hemeHeme Breakdown & Bilirubin: Heme source bilirubinStructure Determines Function: chemical properties (solubility, binding) heme derivatives determine act bodyDisease Arises Metabolic Imbalances: Genetic defects, toxins, disruptions heme metabolism lead disease","code":""},{"path":"biochemicals-2.html","id":"clinical-significance-1","chapter":"Biochemicals","heading":"Clinical Significance","text":"Diagnostic Markers: Bilirubin, iron, porphyrins used diagnose various conditionsUnderstanding Pathophysiology: Connecting heme biochemistry disease states allows targeted treatmentCritical Role Labs: Accurate measurement compounds essential effective patient management","code":""},{"path":"metabolic-2.html","id":"metabolic-2","chapter":"Metabolic","heading":"Metabolic","text":"Heme derivatives play critical roles oxygen transport, electron transfer, detoxification. Understanding heme metabolism essential interpreting various clinical conditions","code":""},{"path":"metabolic-2.html","id":"heme-derivatives-1","chapter":"Metabolic","heading":"Heme Derivatives","text":"Definition: Heme porphyrin ring complex central iron atom (usually Fe2+ ferrous state). ’s prosthetic group essential function various proteinsExamples\nHemoglobin: Oxygen transport red blood cells\nMyoglobin: Oxygen storage muscle cells\nCytochromes: Electron transport mitochondria\nCatalase Peroxidase: Detoxification hydrogen peroxide\nTryptophan Pyrrolase: Catalyzes first step catabolism tryptophan\nHemoglobin: Oxygen transport red blood cellsMyoglobin: Oxygen storage muscle cellsCytochromes: Electron transport mitochondriaCatalase Peroxidase: Detoxification hydrogen peroxideTryptophan Pyrrolase: Catalyzes first step catabolism tryptophanKey Metabolic Pathways\nHeme Synthesis: Production heme bone marrow liver\nHeme Degradation: Breakdown heme spleen liver, leading bilirubin formation\nHeme Synthesis: Production heme bone marrow liverHeme Degradation: Breakdown heme spleen liver, leading bilirubin formation","code":""},{"path":"metabolic-2.html","id":"heme-synthesis","chapter":"Metabolic","heading":"Heme Synthesis","text":"Purpose: produce heme, essential hemoglobin, myoglobin, cytochromes, heme-containing proteinsLocation: Bone marrow (primarily hemoglobin synthesis) liver (cytochromes heme proteins)Subcellular Location: Initial steps mitochondria, intermediate steps cytosol, final steps back mitochondriaProcess\nGlycine + Succinyl CoA → δ-Aminolevulinate (ALA)\nCatalyzed ALA synthase (rate-limiting enzyme) mitochondria\nRequires pyridoxal phosphate (vitamin B6) cofactor\n\n2 ALA → Porphobilinogen (PBG)\nCatalyzed ALA dehydratase (also known porphobilinogen synthase) cytosol\nInhibited lead\n\n4 PBG → Protoporphyrin\nseries enzymatic reactions cytosol convert four molecules PBG protoporphyrin\n\nProtoporphyrin + Fe2+ → Heme\nCatalyzed ferrochelatase mitochondria\nInhibited lead\n\nGlycine + Succinyl CoA → δ-Aminolevulinate (ALA)\nCatalyzed ALA synthase (rate-limiting enzyme) mitochondria\nRequires pyridoxal phosphate (vitamin B6) cofactor\nCatalyzed ALA synthase (rate-limiting enzyme) mitochondriaRequires pyridoxal phosphate (vitamin B6) cofactor2 ALA → Porphobilinogen (PBG)\nCatalyzed ALA dehydratase (also known porphobilinogen synthase) cytosol\nInhibited lead\nCatalyzed ALA dehydratase (also known porphobilinogen synthase) cytosolInhibited lead4 PBG → Protoporphyrin\nseries enzymatic reactions cytosol convert four molecules PBG protoporphyrin\nseries enzymatic reactions cytosol convert four molecules PBG protoporphyrinProtoporphyrin + Fe2+ → Heme\nCatalyzed ferrochelatase mitochondria\nInhibited lead\nCatalyzed ferrochelatase mitochondriaInhibited leadRegulation\nALA synthase rate-limiting enzyme regulated :\nHeme: Inhibits ALA synthase (feedback inhibition)\nErythropoietin: Stimulates ALA synthase (erythroid cells)\nDrugs Steroid Hormones: Can induce ALA synthase (liver)\n\nALA synthase rate-limiting enzyme regulated :\nHeme: Inhibits ALA synthase (feedback inhibition)\nErythropoietin: Stimulates ALA synthase (erythroid cells)\nDrugs Steroid Hormones: Can induce ALA synthase (liver)\nHeme: Inhibits ALA synthase (feedback inhibition)Erythropoietin: Stimulates ALA synthase (erythroid cells)Drugs Steroid Hormones: Can induce ALA synthase (liver)","code":""},{"path":"metabolic-2.html","id":"heme-degradation","chapter":"Metabolic","heading":"Heme Degradation","text":"Purpose: breakdown heme aged damaged red blood cells recycle componentsLocation: Primarily spleen liverProcess\nHeme → Biliverdin\nCatalyzed heme oxygenase macrophages\nHeme oxygenase opens porphyrin ring, releasing iron (Fe2+) carbon monoxide (CO)\n\nBiliverdin → Bilirubin\nCatalyzed biliverdin reductase macrophages\nBilirubin insoluble water (unconjugated bilirubin)\n\nBilirubin → Bilirubin-Albumin Complex\nBilirubin transported blood bound albumin\nAlbumin increases solubility bilirubin\n\nUptake Liver\nbilirubin-albumin complex taken hepatocytes\nBilirubin dissociates albumin transported hepatocyte\n\nConjugation Bilirubin\nBilirubin conjugated glucuronic acid bilirubin UDP-glucuronosyltransferase (UGT) endoplasmic reticulum\nConjugation makes bilirubin water-soluble (conjugated bilirubin)\n\nSecretion Bile\nConjugated bilirubin secreted bile transported small intestine\n\nConversion Urobilinogen\nintestine, bacteria convert conjugated bilirubin urobilinogen\n\nFate Urobilinogen\nurobilinogen excreted feces stercobilin (gives feces brown color)\nsmall amount urobilinogen reabsorbed blood excreted urine urobilin (gives urine yellow color)\n\nHeme → Biliverdin\nCatalyzed heme oxygenase macrophages\nHeme oxygenase opens porphyrin ring, releasing iron (Fe2+) carbon monoxide (CO)\nCatalyzed heme oxygenase macrophagesHeme oxygenase opens porphyrin ring, releasing iron (Fe2+) carbon monoxide (CO)Biliverdin → Bilirubin\nCatalyzed biliverdin reductase macrophages\nBilirubin insoluble water (unconjugated bilirubin)\nCatalyzed biliverdin reductase macrophagesBilirubin insoluble water (unconjugated bilirubin)Bilirubin → Bilirubin-Albumin Complex\nBilirubin transported blood bound albumin\nAlbumin increases solubility bilirubin\nBilirubin transported blood bound albuminAlbumin increases solubility bilirubinUptake Liver\nbilirubin-albumin complex taken hepatocytes\nBilirubin dissociates albumin transported hepatocyte\nbilirubin-albumin complex taken hepatocytesBilirubin dissociates albumin transported hepatocyteConjugation Bilirubin\nBilirubin conjugated glucuronic acid bilirubin UDP-glucuronosyltransferase (UGT) endoplasmic reticulum\nConjugation makes bilirubin water-soluble (conjugated bilirubin)\nBilirubin conjugated glucuronic acid bilirubin UDP-glucuronosyltransferase (UGT) endoplasmic reticulumConjugation makes bilirubin water-soluble (conjugated bilirubin)Secretion Bile\nConjugated bilirubin secreted bile transported small intestine\nConjugated bilirubin secreted bile transported small intestineConversion Urobilinogen\nintestine, bacteria convert conjugated bilirubin urobilinogen\nintestine, bacteria convert conjugated bilirubin urobilinogenFate Urobilinogen\nurobilinogen excreted feces stercobilin (gives feces brown color)\nsmall amount urobilinogen reabsorbed blood excreted urine urobilin (gives urine yellow color)\nurobilinogen excreted feces stercobilin (gives feces brown color)small amount urobilinogen reabsorbed blood excreted urine urobilin (gives urine yellow color)","code":""},{"path":"metabolic-2.html","id":"iron-metabolism","chapter":"Metabolic","heading":"Iron Metabolism","text":"Importance: Iron crucial component heme tightly regulatedDietary Iron: Absorbed small intestineTransport: Transported blood bound transferrinStorage: Stored cells ferritin hemosiderinRegulation: Hepcidin, hormone produced liver, regulates iron absorption release","code":""},{"path":"metabolic-2.html","id":"porphyrias","chapter":"Metabolic","heading":"Porphyrias","text":"Definition: group genetic disorders caused deficiencies enzymes heme synthesis pathwayTypes: Different types characterized specific enzyme deficiencySymptoms: Vary depending type porphyriaDiagnosis: Based elevated levels porphyrins porphyrin precursors urine, blood, feces","code":""},{"path":"metabolic-2.html","id":"key-terms-16","chapter":"Metabolic","heading":"Key Terms","text":"Heme: porphyrin ring complex central iron atomALA Synthase: rate-limiting enzyme heme synthesisALA Dehydratase: enzyme heme synthesis inhibited leadFerrochelatase: enzyme heme synthesis inserts iron protoporphyrin, inhibited leadHeme Oxygenase: enzyme breaks heme biliverdinBiliverdin Reductase: enzyme converts biliverdin bilirubinUDP-Glucuronosyltransferase (UGT): enzyme conjugates bilirubin glucuronic acidUrobilinogen: product bilirubin degradation intestinePorphyrias: Genetic disorders caused deficiencies enzymes heme synthesis pathwayHepcidin: hormone regulates iron absorption release","code":""},{"path":"physiology-2.html","id":"physiology-2","chapter":"Physiology","heading":"Physiology","text":"Maintaining proper levels heme breakdown products crucial overall health. Imbalances can lead variety disorders","code":""},{"path":"physiology-2.html","id":"normal-states-1","chapter":"Physiology","heading":"Normal States","text":"Normal Heme Synthesis: Balanced production heme meet body’s needsNormal Heme Degradation: Efficient breakdown excretion heme productsNormal Bilirubin Levels: Proper conjugation excretion bilirubin, preventing accumulation bodyNormal Iron Levels: Appropriate absorption, transport, storage iron support heme synthesis","code":""},{"path":"physiology-2.html","id":"normal-heme-synthesis","chapter":"Physiology","heading":"Normal Heme Synthesis","text":"Sufficient production hemoglobin red blood cells oxygen transportAdequate synthesis myoglobin muscle cells oxygen storageProper production cytochromes mitochondria electron transferBalanced synthesis heme-containing enzymes various metabolic processes","code":""},{"path":"physiology-2.html","id":"normal-heme-degradation","chapter":"Physiology","heading":"Normal Heme Degradation","text":"Efficient breakdown aged damaged red blood cellsEffective conversion heme biliverdin bilirubinAppropriate conjugation bilirubin liverProper excretion bilirubin bileBalanced production urobilinogen intestine excretion feces urine","code":""},{"path":"physiology-2.html","id":"normal-bilirubin-levels","chapter":"Physiology","heading":"Normal Bilirubin Levels","text":"Total Bilirubin: 0.3-1.0 mg/dL (5.1-17.1 μmol/L)Direct (Conjugated) Bilirubin: 0.0-0.3 mg/dL (0-5.1 μmol/L)Indirect (Unconjugated) Bilirubin: 0.2-0.8 mg/dL (3.4-13.7 μmol/L)levels indicate proper bilirubin production, conjugation, excretion","code":""},{"path":"physiology-2.html","id":"normal-iron-levels","chapter":"Physiology","heading":"Normal Iron Levels","text":"Serum Iron: 60-170 μg/dL (10.7-30.4 μmol/L)Total Iron-Binding Capacity (TIBC): 240-450 μg/dL (42.9-80.6 μmol/L)Transferrin Saturation: 20-50%Ferritin: 20-200 ng/mL women, 20-500 ng/mL menThese levels indicate proper iron absorption, transport, storage","code":""},{"path":"physiology-2.html","id":"abnormal-states-2","chapter":"Physiology","heading":"Abnormal States","text":"Porphyrias: Accumulation porphyrins porphyrin precursorsJaundice Hyperbilirubinemia: Accumulation bilirubinIron Deficiency Anemia: Insufficient iron levelsHemochromatosis: Excessive iron absorption accumulationLead Poisoning: Exposure leadAnemia Chronic Disease: Chronic inflammatory conditionsOther conditions","code":""},{"path":"physiology-2.html","id":"porphyrias-1","chapter":"Physiology","heading":"Porphyrias","text":"Definition: Genetic disorders caused deficiencies enzymes heme synthesis pathway, leading accumulation porphyrins porphyrin precursorsPathophysiology: Enzyme deficiencies result buildup specific porphyrins porphyrin precursors tissues body fluidsLaboratory Findings: Elevated levels porphyrins porphyrin precursors urine, blood, fecesSymptoms: Abdominal pain, neurological dysfunction, photosensitivitySpecific States\nAcute Intermittent Porphyria (AIP): Deficiency porphobilinogen deaminase (PBGD)\nElevated ALA PBG urine acute attacks\nAbdominal pain, neurological symptoms\n\nPorphyria Cutanea Tarda (PCT): Deficiency uroporphyrinogen decarboxylase (UROD)\nElevated uroporphyrins urine\nPhotosensitivity, skin lesions\n\nAcute Intermittent Porphyria (AIP): Deficiency porphobilinogen deaminase (PBGD)\nElevated ALA PBG urine acute attacks\nAbdominal pain, neurological symptoms\nElevated ALA PBG urine acute attacksAbdominal pain, neurological symptomsPorphyria Cutanea Tarda (PCT): Deficiency uroporphyrinogen decarboxylase (UROD)\nElevated uroporphyrins urine\nPhotosensitivity, skin lesions\nElevated uroporphyrins urinePhotosensitivity, skin lesions","code":""},{"path":"physiology-2.html","id":"jaundice-and-hyperbilirubinemia","chapter":"Physiology","heading":"Jaundice and Hyperbilirubinemia","text":"Definition: Yellowing skin mucous membranes due elevated bilirubin levelsPathophysiology\nPre-hepatic (hemolytic): Excessive red blood cell breakdown\nHepatic: Liver dysfunction affecting bilirubin conjugation excretion\nPost-hepatic (obstructive): Blockage bile ducts preventing bilirubin excretion\nPre-hepatic (hemolytic): Excessive red blood cell breakdownHepatic: Liver dysfunction affecting bilirubin conjugation excretionPost-hepatic (obstructive): Blockage bile ducts preventing bilirubin excretionLaboratory Findings: Elevated total bilirubin levels, varying proportions conjugated unconjugated bilirubinSymptoms: Yellowing skin eyes, dark urine, pale stoolsSpecific States\nPre-Hepatic (Hemolytic Jaundice): Excessive red blood cell breakdown\nElevated total bilirubin, primarily unconjugated\nNormal liver function tests\nCauses: Hemolytic anemia, transfusion reactions\n\nHepatic Jaundice: Liver dysfunction\nElevated total bilirubin, varying proportions conjugated unconjugated bilirubin\nAbnormal liver function tests (AST, ALT, alkaline phosphatase)\nCauses: Hepatitis, cirrhosis, drug-induced liver injury\n\nPost-Hepatic (Obstructive Jaundice): Blockage bile ducts\nElevated total bilirubin, primarily conjugated\nElevated alkaline phosphatase gamma-glutamyl transferase (GGT)\nCauses: Gallstones, tumors\n\nPre-Hepatic (Hemolytic Jaundice): Excessive red blood cell breakdown\nElevated total bilirubin, primarily unconjugated\nNormal liver function tests\nCauses: Hemolytic anemia, transfusion reactions\nElevated total bilirubin, primarily unconjugatedNormal liver function testsCauses: Hemolytic anemia, transfusion reactionsHepatic Jaundice: Liver dysfunction\nElevated total bilirubin, varying proportions conjugated unconjugated bilirubin\nAbnormal liver function tests (AST, ALT, alkaline phosphatase)\nCauses: Hepatitis, cirrhosis, drug-induced liver injury\nElevated total bilirubin, varying proportions conjugated unconjugated bilirubinAbnormal liver function tests (AST, ALT, alkaline phosphatase)Causes: Hepatitis, cirrhosis, drug-induced liver injuryPost-Hepatic (Obstructive Jaundice): Blockage bile ducts\nElevated total bilirubin, primarily conjugated\nElevated alkaline phosphatase gamma-glutamyl transferase (GGT)\nCauses: Gallstones, tumors\nElevated total bilirubin, primarily conjugatedElevated alkaline phosphatase gamma-glutamyl transferase (GGT)Causes: Gallstones, tumors","code":""},{"path":"physiology-2.html","id":"iron-deficiency-anemia","chapter":"Physiology","heading":"Iron Deficiency Anemia","text":"Definition: Anemia caused insufficient iron levels, leading impaired heme hemoglobin synthesisPathophysiology: Inadequate iron intake, absorption, increased iron loss leads reduced heme synthesisLaboratory Findings\nDecreased red blood cell count, hemoglobin, hematocrit\nLow serum iron ferritin levels\nElevated total iron-binding capacity (TIBC)\nDecreased transferrin saturation\nDecreased red blood cell count, hemoglobin, hematocritLow serum iron ferritin levelsElevated total iron-binding capacity (TIBC)Decreased transferrin saturationSymptoms: Fatigue, weakness, pale skin, shortness breath","code":""},{"path":"physiology-2.html","id":"hemochromatosis","chapter":"Physiology","heading":"Hemochromatosis","text":"Definition: genetic disorder characterized excessive iron absorption accumulation tissuesPathophysiology: Mutations genes regulating iron absorption lead iron overloadLaboratory Findings\nElevated serum iron ferritin levels\nDecreased total iron-binding capacity (TIBC)\nIncreased transferrin saturation\nElevated serum iron ferritin levelsDecreased total iron-binding capacity (TIBC)Increased transferrin saturationSymptoms: Fatigue, joint pain, abdominal pain, liver damage, diabetesSpecific States\nHereditary Hemochromatosis: Genetic mutations leading increased iron absorption\nElevated serum iron transferrin saturation\nElevated ferritin\nLiver damage, diabetes, skin pigmentation\n\nSecondary Iron Overload: Due transfusions causes\nElevated serum iron ferritin\nTransfusion history\n\nHereditary Hemochromatosis: Genetic mutations leading increased iron absorption\nElevated serum iron transferrin saturation\nElevated ferritin\nLiver damage, diabetes, skin pigmentation\nElevated serum iron transferrin saturationElevated ferritinLiver damage, diabetes, skin pigmentationSecondary Iron Overload: Due transfusions causes\nElevated serum iron ferritin\nTransfusion history\nElevated serum iron ferritinTransfusion history","code":""},{"path":"physiology-2.html","id":"lead-poisoning","chapter":"Physiology","heading":"Lead Poisoning","text":"Definition: Exposure lead, inhibits enzymes heme synthesis pathwayPathophysiology: Lead inhibits ALA dehydratase ferrochelatase, disrupting heme synthesisLaboratory Findings\nElevated blood lead levels\nElevated zinc protoporphyrin (ZPP) red blood cells\nAnemia\nElevated blood lead levelsElevated zinc protoporphyrin (ZPP) red blood cellsAnemiaSymptoms: Abdominal pain, constipation, neurological symptoms, developmental delays children","code":""},{"path":"physiology-2.html","id":"anemia-of-chronic-disease","chapter":"Physiology","heading":"Anemia of Chronic Disease","text":"Definition: Anemia associated chronic inflammatory conditionsPathophysiology: Inflammation leads increased hepcidin production, reduces iron absorption releaseLaboratory Findings\nDecreased red blood cell count, hemoglobin, hematocrit\nNormal elevated ferritin levels\nDecreased serum iron total iron-binding capacity (TIBC)\nDecreased transferrin saturation\nDecreased red blood cell count, hemoglobin, hematocritNormal elevated ferritin levelsDecreased serum iron total iron-binding capacity (TIBC)Decreased transferrin saturationSymptoms: Fatigue, weakness","code":""},{"path":"physiology-2.html","id":"other-conditions","chapter":"Physiology","heading":"Other Conditions","text":"Sideroblastic Anemia: Impaired heme synthesis bone marrow\nElevated serum iron ferritin\nRinged sideroblasts bone marrow\nElevated serum iron ferritinRinged sideroblasts bone marrowPlumbism (Lead Poisoning): Disruption heme synthesis lead\nElevated blood lead levels\nAbdominal pain, neurological symptoms\nElevated blood lead levelsAbdominal pain, neurological symptoms","code":""},{"path":"physiology-2.html","id":"key-terms-17","chapter":"Physiology","heading":"Key Terms","text":"Porphyrias: Genetic disorders heme synthesisJaundice: Yellowing skin eyes due elevated bilirubinHyperbilirubinemia: Elevated bilirubin levels bloodIron Deficiency Anemia: Anemia due insufficient ironHemochromatosis: genetic disorder iron overloadLead Poisoning: Disruption heme synthesis leadTotal Bilirubin: measure bilirubin bloodDirect (Conjugated) Bilirubin: Bilirubin conjugated liverIndirect (Unconjugated) Bilirubin: Bilirubin conjugated liverSerum Iron: measure iron bloodTotal Iron-Binding Capacity (TIBC): measure blood’s capacity bind ironTransferrin Saturation: percentage transferrin bound ironFerritin: protein stores ironPorphyrins: Intermediates heme synthesisALA (δ-Aminolevulinate): precursor heme synthesisPBG (Porphobilinogen): precursor heme synthesisZPP (Zinc Protoporphyrin): Accumulates red blood cells heme synthesis impaired","code":""},{"path":"properties-2.html","id":"properties-2","chapter":"Properties","heading":"Properties","text":"physical chemical properties heme derivatives essential function oxygen transport, electron transfer, detoxification","code":""},{"path":"properties-2.html","id":"hemoglobin","chapter":"Properties","heading":"Hemoglobin","text":"Definition: protein found red blood cells responsible transporting oxygen lungs tissues carbon dioxide tissues lungsStructure\nTetrameric Protein: Consists four polypeptide chains (globins)\nTwo α Chains Two β Chains: adult hemoglobin (HbA), chain linked heme group\nHeme Group: porphyrin ring central iron atom (Fe2+ functional state)\nTetrameric Protein: Consists four polypeptide chains (globins)Two α Chains Two β Chains: adult hemoglobin (HbA), chain linked heme groupHeme Group: porphyrin ring central iron atom (Fe2+ functional state)Physical Properties\nColor: Red oxygenated (oxyhemoglobin), bluish-red deoxygenated (deoxyhemoglobin)\nSolubility: Soluble water within red blood cells\nMolecular Weight: Approximately 64,000 Da\nQuaternary Structure: Tetrameric structure allows cooperative binding oxygen\nColor: Red oxygenated (oxyhemoglobin), bluish-red deoxygenated (deoxyhemoglobin)Solubility: Soluble water within red blood cellsMolecular Weight: Approximately 64,000 DaQuaternary Structure: Tetrameric structure allows cooperative binding oxygenChemical Properties\nOxygen Binding: Iron atom heme binds reversibly oxygen\nOxyhemoglobin: Hemoglobin bound oxygen\nDeoxyhemoglobin: Hemoglobin without oxygen\n\nCarbon Dioxide Binding: Hemoglobin can also bind carbon dioxide transport back lungs\nAllosteric Regulation: Oxygen binding affected pH, carbon dioxide, 2,3-bisphosphoglycerate (2,3-BPG)\nMethemoglobin Formation: Iron can oxidized Fe3+, forming methemoglobin, bind oxygen\nCarbaminohemoglobin Formation: Carbon dioxide can bind amino groups hemoglobin, forming carbaminohemoglobin\nOxygen Binding: Iron atom heme binds reversibly oxygen\nOxyhemoglobin: Hemoglobin bound oxygen\nDeoxyhemoglobin: Hemoglobin without oxygen\nOxyhemoglobin: Hemoglobin bound oxygenDeoxyhemoglobin: Hemoglobin without oxygenCarbon Dioxide Binding: Hemoglobin can also bind carbon dioxide transport back lungsAllosteric Regulation: Oxygen binding affected pH, carbon dioxide, 2,3-bisphosphoglycerate (2,3-BPG)Methemoglobin Formation: Iron can oxidized Fe3+, forming methemoglobin, bind oxygenCarbaminohemoglobin Formation: Carbon dioxide can bind amino groups hemoglobin, forming carbaminohemoglobin","code":""},{"path":"properties-2.html","id":"myoglobin","chapter":"Properties","heading":"Myoglobin","text":"Definition: protein found muscle cells stores oxygen facilitates oxygen diffusionStructure\nMonomeric Protein: Consists single polypeptide chain (globin)\nHeme Group: porphyrin ring central iron atom (Fe2+ functional state)\nMonomeric Protein: Consists single polypeptide chain (globin)Heme Group: porphyrin ring central iron atom (Fe2+ functional state)Physical Properties\nColor: Red\nSolubility: Soluble water within muscle cells\nMolecular Weight: Approximately 17,000 Da\nTertiary Structure: Globular protein hydrophobic pocket heme group\nColor: RedSolubility: Soluble water within muscle cellsMolecular Weight: Approximately 17,000 DaTertiary Structure: Globular protein hydrophobic pocket heme groupChemical Properties\nOxygen Binding: Iron atom heme binds reversibly oxygen\nOxymyoglobin: Myoglobin bound oxygen\nDeoxymyoglobin: Myoglobin without oxygen\n\nHigher Oxygen Affinity: Myoglobin higher affinity oxygen hemoglobin, allowing store oxygen muscles\nAffected Allosteric Regulators: Oxygen binding significantly affected pH, carbon dioxide, 2,3-BPG\nOxygen Binding: Iron atom heme binds reversibly oxygen\nOxymyoglobin: Myoglobin bound oxygen\nDeoxymyoglobin: Myoglobin without oxygen\nOxymyoglobin: Myoglobin bound oxygenDeoxymyoglobin: Myoglobin without oxygenHigher Oxygen Affinity: Myoglobin higher affinity oxygen hemoglobin, allowing store oxygen musclesNot Affected Allosteric Regulators: Oxygen binding significantly affected pH, carbon dioxide, 2,3-BPG","code":""},{"path":"properties-2.html","id":"bilirubin","chapter":"Properties","heading":"Bilirubin","text":"Definition: yellow pigment produced breakdown hemeTypes\nUnconjugated Bilirubin (Indirect): Insoluble water, transported blood bound albumin\nConjugated Bilirubin (Direct): Water-soluble, conjugated glucuronic acid liver\nUnconjugated Bilirubin (Indirect): Insoluble water, transported blood bound albuminConjugated Bilirubin (Direct): Water-soluble, conjugated glucuronic acid liverStructure\nTetrapyrrole Ring: linear chain four pyrrole rings\nTetrapyrrole Ring: linear chain four pyrrole ringsPhysical Properties\nColor: Yellow\nSolubility:\nUnconjugated: Insoluble water\nConjugated: Soluble water\n\nLight Sensitivity: Bilirubin degraded light\nColor: YellowSolubility:\nUnconjugated: Insoluble water\nConjugated: Soluble water\nUnconjugated: Insoluble waterConjugated: Soluble waterLight Sensitivity: Bilirubin degraded lightChemical Properties\nFormation Heme: Produced heme oxygenase biliverdin reductase\nConjugation: Conjugated glucuronic acid UDP-glucuronosyltransferase (UGT) liver, making water-soluble\nExcretion: Secreted bile excreted feces\nDiazo Reaction: Reacts diazonium salts form colored product (used laboratory assays)\nPhototherapy: Blue light converts bilirubin soluble isomers can excreted urine (used treating neonatal jaundice)\nFormation Heme: Produced heme oxygenase biliverdin reductaseConjugation: Conjugated glucuronic acid UDP-glucuronosyltransferase (UGT) liver, making water-solubleExcretion: Secreted bile excreted fecesDiazo Reaction: Reacts diazonium salts form colored product (used laboratory assays)Phototherapy: Blue light converts bilirubin soluble isomers can excreted urine (used treating neonatal jaundice)","code":""},{"path":"properties-2.html","id":"urobilinogen","chapter":"Properties","heading":"Urobilinogen","text":"Definition: colorless compound produced intestine bacterial reduction bilirubinStructure\nTetrapyrrole Ring: Similar bilirubin, reduced\nTetrapyrrole Ring: Similar bilirubin, reducedPhysical Properties\nColor: Colorless\nSolubility: Soluble water\nColor: ColorlessSolubility: Soluble waterChemical Properties\nFormation Bilirubin: Produced bacterial reduction bilirubin intestine\nOxidation Urobilin: Urobilinogen can oxidized urobilin, brown pigment\nExcretion:\nurobilinogen excreted feces stercobilin (gives feces brown color)\nsmall amount reabsorbed excreted urine urobilin (gives urine yellow color)\n\nEhrlich’s Reagent: Reacts Ehrlich’s reagent (p-dimethylaminobenzaldehyde) form colored product (used laboratory assays)\nFormation Bilirubin: Produced bacterial reduction bilirubin intestineOxidation Urobilin: Urobilinogen can oxidized urobilin, brown pigmentExcretion:\nurobilinogen excreted feces stercobilin (gives feces brown color)\nsmall amount reabsorbed excreted urine urobilin (gives urine yellow color)\nurobilinogen excreted feces stercobilin (gives feces brown color)small amount reabsorbed excreted urine urobilin (gives urine yellow color)Ehrlich’s Reagent: Reacts Ehrlich’s reagent (p-dimethylaminobenzaldehyde) form colored product (used laboratory assays)","code":""},{"path":"properties-2.html","id":"porphyrins","chapter":"Properties","heading":"Porphyrins","text":"Definition: group cyclic tetrapyrrole compounds intermediates heme synthesisTypes\nUroporphyrin\nCoproporphyrin\nProtoporphyrin\nUroporphyrinCoproporphyrinProtoporphyrinStructure\nCyclic Tetrapyrrole Ring: Four pyrrole rings linked methene bridges\nCyclic Tetrapyrrole Ring: Four pyrrole rings linked methene bridgesPhysical Properties\nColor: Highly colored compounds, exhibiting fluorescence\nSolubility: Varies depending specific porphyrin substituents\nColor: Highly colored compounds, exhibiting fluorescenceSolubility: Varies depending specific porphyrin substituentsChemical Properties\nHeme Precursors: Intermediates synthesis heme\nMetal Binding: Can bind metal ions, iron\nFluorescence: Exhibit fluorescence UV light, allowing detection quantification\nAcid Extraction: Can extracted biological samples using acidic solutions\nPorphyria Markers: Accumulation specific porphyrins urine, blood, feces indicative porphyria\nHeme Precursors: Intermediates synthesis hemeMetal Binding: Can bind metal ions, ironFluorescence: Exhibit fluorescence UV light, allowing detection quantificationAcid Extraction: Can extracted biological samples using acidic solutionsPorphyria Markers: Accumulation specific porphyrins urine, blood, feces indicative porphyria","code":""},{"path":"properties-2.html","id":"key-properties-summarized","chapter":"Properties","heading":"Key Properties Summarized","text":"","code":""},{"path":"properties-2.html","id":"key-terms-18","chapter":"Properties","heading":"Key Terms","text":"Heme: porphyrin ring complex central iron atomHemoglobin: protein red blood cells transports oxygenMyoglobin: protein muscle cells stores oxygenBilirubin: yellow pigment produced breakdown hemeUrobilinogen: colorless compound produced intestine bacterial reduction bilirubinPorphyrins: Cyclic tetrapyrrole compounds intermediates heme synthesisOxyhemoglobin: Hemoglobin bound oxygenDeoxyhemoglobin: Hemoglobin without oxygenUnconjugated Bilirubin: Bilirubin conjugated liverConjugated Bilirubin: Bilirubin conjugated liverPorphyria: genetic disorder caused deficiencies enzymes heme synthesis pathway","code":""},{"path":"procedures-2.html","id":"procedures-2","chapter":"Procedures","heading":"Procedures","text":"Accurate lab testing heme derivatives essential diagnosing managing various conditions. Understanding underlying principles, importance proper technique, potential pitfalls can greatly enhance reliability results","code":""},{"path":"procedures-2.html","id":"test-principles","chapter":"Procedures","heading":"Test Principles","text":"Bilirubin: Diazo reaction Ehrlich’s reagent measures total direct bilirubin. Jendrassik-Grof method minimizes interferencesUrine Bilirubin: Dipstick diazo reagent detects conjugated bilirubinUrine Urobilinogen: Ehrlich’s reagent detects urobilinogen. Quantitative methods offer better accuracyIron Studies: Colorimetric assays measure serum iron, TIBC, transferrin saturation. Immunochemical assays quantify ferritinPorphyrin Analysis: Chromatography (HPLC) separates quantifies porphyrins, detected fluorescence spectrophotometryFecal Occult Blood Test (FOBT): Guaiac-based tests detect heme’s peroxidase activity. Immunochemical tests (FIT) use antibodies human hemoglobin","code":""},{"path":"procedures-2.html","id":"special-precautions-4","chapter":"Procedures","heading":"Special Precautions","text":"Specimen Collection\nBilirubin: Protect light\nUrine Urobilinogen: Use preservative, protect light\nIron Studies: Avoid hemolysis, collect therapy/transfusion\nPorphyrins: Protect light, use appropriate containers/preservatives\nFOBT: Multiple samples, follow dietary/medication restrictions\nBilirubin: Protect lightUrine Urobilinogen: Use preservative, protect lightIron Studies: Avoid hemolysis, collect therapy/transfusionPorphyrins: Protect light, use appropriate containers/preservativesFOBT: Multiple samples, follow dietary/medication restrictionsSpecimen Processing\nTimely processing key\nAppropriate centrifugation\nProper storage (refrigeration freezing)\nTimely processing keyAppropriate centrifugationProper storage (refrigeration freezing)Analytical\nReagent Quality: Use fresh, properly stored reagents\nCalibration: Regular calibration standards\nQuality Control: Run QC samples regularly\nReagent Quality: Use fresh, properly stored reagentsCalibration: Regular calibration standardsQuality Control: Run QC samples regularly","code":""},{"path":"procedures-2.html","id":"interfering-substances-4","chapter":"Procedures","heading":"Interfering Substances","text":"Common Interferences\nLipemia, hemolysis, medications, ascorbic acid, porphyrinogens\nLipemia, hemolysis, medications, ascorbic acid, porphyrinogensMitigation\nUse appropriate techniques clear lipemia\nAvoid hemolysis\naware patient’s medications\nUse appropriate techniques clear lipemiaAvoid hemolysisBe aware patient’s medications","code":""},{"path":"procedures-2.html","id":"troubleshooting-4","chapter":"Procedures","heading":"Troubleshooting","text":"General Steps\nReview patient preparation\nCheck collection processing\nEvaluate reagent quality\nConsider interferences\nReview patient preparationCheck collection processingEvaluate reagent qualityConsider interferencesSpecific Issues\nUnexpected Bilirubin: Light exposure, delayed processing\nUnexpected Iron Studies: Hemolysis, recent iron therapy\nInconsistent Porphyrin Analysis: Extraction/separation issues\nFalse Positive/Negative FOBT: Dietary medication factors\nUnexpected Bilirubin: Light exposure, delayed processingUnexpected Iron Studies: Hemolysis, recent iron therapyInconsistent Porphyrin Analysis: Extraction/separation issuesFalse Positive/Negative FOBT: Dietary medication factors","code":""},{"path":"procedures-2.html","id":"key-reminders","chapter":"Procedures","heading":"Key Reminders","text":"Accuracy: Heme derivative measurements sensitive host preanalytical variablesBest Practice: Following established SOPs essentialClinical Judgement: aware pathological mechanisms influence results","code":""},{"path":"principles-2.html","id":"principles-2","chapter":"Principles","heading":"Principles","text":"Labs play critical role diagnosing monitoring conditions related heme metabolism. Tests include bilirubin, iron studies, porphyrins, moreKey Tests\nBilirubin (Total, Direct, Indirect)\nUrine Bilirubin\nFecal Bilirubin\nIron Studies (Serum Iron, TIBC, Transferrin Saturation, Ferritin)\nPorphyrins (Urine, Blood, Fecal)\nLead\nBilirubin (Total, Direct, Indirect)Urine BilirubinFecal BilirubinIron Studies (Serum Iron, TIBC, Transferrin Saturation, Ferritin)Porphyrins (Urine, Blood, Fecal)Lead","code":""},{"path":"principles-2.html","id":"bilirubin-1","chapter":"Principles","heading":"Bilirubin","text":"Principle: Diazo Reaction basis bilirubin assays. Bilirubin reacts diazonium salt (e.g., diazotized sulfanilic acid) acidic solution form colored azobilirubin pigment, measured spectrophotometricallyTypes Bilirubin Measured\nTotal Bilirubin: Measures conjugated (direct) unconjugated (indirect) bilirubin\nDirect Bilirubin: Measures conjugated bilirubin directly (reacts diazo reagent aqueous solution)\nIndirect Bilirubin: Calculated subtracting direct bilirubin total bilirubin (represents unconjugated bilirubin)\nTotal Bilirubin: Measures conjugated (direct) unconjugated (indirect) bilirubinDirect Bilirubin: Measures conjugated bilirubin directly (reacts diazo reagent aqueous solution)Indirect Bilirubin: Calculated subtracting direct bilirubin total bilirubin (represents unconjugated bilirubin)Reactions\nBilirubin + Diazotized Sulfanilic Acid → Azobilirubin (Colored Product)\nBilirubin + Diazotized Sulfanilic Acid → Azobilirubin (Colored Product)Enhancers/Accelerators: measure total bilirubin, reagent methanol caffeine added solubilize unconjugated bilirubin, allowing react diazo reagentDetection: intensity colored azobilirubin product directly proportional bilirubin concentration sample measured spectrophotometricallyAdvantages: Widely available, relatively inexpensive, well-established methodDisadvantages: Susceptible interferences lipemia, hemolysis, certain medications","code":""},{"path":"principles-2.html","id":"urine-bilirubin","chapter":"Principles","heading":"Urine Bilirubin","text":"Principle: Diazo Reaction used. Bilirubin urine reacts diazonium salt form colored productMethod: Dipstick Ictotest tabletsReactions\nBilirubin + Diazonium Salt → Colored Product\nBilirubin + Diazonium Salt → Colored ProductDetection: color change dipstick tablet compared color chart estimate bilirubin concentration urineAdvantages: Rapid simple screening testDisadvantages: Less sensitive serum bilirubin assays, detects conjugated bilirubin, susceptible false negatives ascorbic acid (vitamin C)","code":""},{"path":"principles-2.html","id":"fecal-bilirubin","chapter":"Principles","heading":"Fecal Bilirubin","text":"Principle: Quantitative measurement fecal bilirubin routinely performed. However, presence absence bilirubin breakdown products (urobilinogen stercobilin) can assessedMethod: Chemical tests detect urobilinogen stercobilinReactions\nUrobilinogen + Ehrlich’s Reagent → Pink-Red Color\nUrobilinogen + Ehrlich’s Reagent → Pink-Red ColorDetection: presence colored product indicates presence urobilinogen stercobilinAdvantages: Can provide information bile flow intestinal functionDisadvantages: quantitative, affected diet medications","code":""},{"path":"principles-2.html","id":"iron-studies","chapter":"Principles","heading":"Iron Studies","text":"Principle: panel tests used evaluate iron metabolism storageTests Included\nSerum Iron: Measures amount iron bound transferrin blood\nTotal Iron-Binding Capacity (TIBC): Measures total amount iron can bound transferrin\nTransferrin Saturation: Calculated (Serum Iron / TIBC) x 100\nFerritin: Measures amount iron stored tissues\nSerum Iron: Measures amount iron bound transferrin bloodTotal Iron-Binding Capacity (TIBC): Measures total amount iron can bound transferrinTransferrin Saturation: Calculated (Serum Iron / TIBC) x 100Ferritin: Measures amount iron stored tissues","code":""},{"path":"principles-2.html","id":"serum-iron","chapter":"Principles","heading":"Serum Iron","text":"Principle: Iron released transferrin acidic buffer reduced Fe2+. Fe2+ reacts chromogen form colored complex, measured spectrophotometricallyReactions\nTransferrin-Fe3+ + Acidic Buffer → Transferrin + Fe3+\nFe3+ + Reducing Agent → Fe2+\nFe2+ + Chromogen → Colored Complex\nTransferrin-Fe3+ + Acidic Buffer → Transferrin + Fe3+Fe3+ + Reducing Agent → Fe2+Fe2+ + Chromogen → Colored ComplexDetection: intensity colored complex directly proportional iron concentration sampleAdvantages: Widely available relatively inexpensiveDisadvantages: Affected diurnal variation recent iron intake","code":""},{"path":"principles-2.html","id":"total-iron-binding-capacity-tibc","chapter":"Principles","heading":"Total Iron-Binding Capacity (TIBC)","text":"Principle: Excess iron added saturate binding sites transferrin. unbound iron removed, total iron measured using similar method serum ironReactions\nTransferrin + Excess Fe3+ → Transferrin-Fe3+ (Saturated)\nRemoval Unbound Fe3+\nTransferrin-Fe3+ + Acidic Buffer → Transferrin + Fe3+\nFe3+ + Reducing Agent → Fe2+\nFe2+ + Chromogen → Colored Complex\nTransferrin + Excess Fe3+ → Transferrin-Fe3+ (Saturated)Removal Unbound Fe3+Transferrin-Fe3+ + Acidic Buffer → Transferrin + Fe3+Fe3+ + Reducing Agent → Fe2+Fe2+ + Chromogen → Colored ComplexDetection: intensity colored complex directly proportional TIBCAdvantages: Provides estimate transferrin concentrationDisadvantages: complex serum iron measurement","code":""},{"path":"principles-2.html","id":"transferrin-saturation","chapter":"Principles","heading":"Transferrin Saturation","text":"Principle: Calculated serum iron TIBC\nTransferrin Saturation = (Serum Iron / TIBC) x 100\nTransferrin Saturation = (Serum Iron / TIBC) x 100Interpretation\nLow Transferrin Saturation: Suggests iron deficiency\nHigh Transferrin Saturation: Suggests iron overload\nLow Transferrin Saturation: Suggests iron deficiencyHigh Transferrin Saturation: Suggests iron overload","code":""},{"path":"principles-2.html","id":"ferritin","chapter":"Principles","heading":"Ferritin","text":"Principle: Immunochemical methods (e.g., ELISA, chemiluminescence) used measure ferritin. Antibodies specific ferritin used capture quantify ferritin blood sampleMethods\nEnzyme-Linked Immunosorbent Assay (ELISA)\nChemiluminescence Immunoassay (CLIA)\nEnzyme-Linked Immunosorbent Assay (ELISA)Chemiluminescence Immunoassay (CLIA)Reactions\nFerritin + Ferritin-Specific Antibody → Antibody-Ferritin Complex\nFerritin + Ferritin-Specific Antibody → Antibody-Ferritin ComplexDetection: amount antibody-ferritin complex formed measured, proportional ferritin concentration sampleAdvantages: Specific sensitiveDisadvantages: Can affected inflammation","code":""},{"path":"principles-2.html","id":"porphyrins-1","chapter":"Principles","heading":"Porphyrins","text":"Principle: Porphyrins extracted urine, blood, feces separated chromatography. quantified spectrophotometry fluorometryMethods\nSpectrophotometry\nFluorometry\nHigh-Performance Liquid Chromatography (HPLC)\nSpectrophotometryFluorometryHigh-Performance Liquid Chromatography (HPLC)Procedure\nExtraction: Porphyrins extracted sample using organic solvents\nSeparation: Porphyrins separated HPLC based chemical properties\nDetection: Porphyrins detected quantified measuring absorbance fluorescence\nExtraction: Porphyrins extracted sample using organic solventsSeparation: Porphyrins separated HPLC based chemical propertiesDetection: Porphyrins detected quantified measuring absorbance fluorescenceAdvantages: Can identify quantify specific porphyrinsDisadvantages: Complex requires specialized equipmentUrine Porphyrins: Reflects porphyrin excretionBlood Porphyrins: Detects porphyrins present bloodFecal Porphyrins: Measures porphyrin excretion feces","code":""},{"path":"principles-2.html","id":"lead","chapter":"Principles","heading":"Lead","text":"Principle: Atomic absorption spectrometry (AAS) inductively coupled plasma mass spectrometry (ICP-MS) used measure lead whole bloodMethods\nAtomic Absorption Spectrometry (AAS)\nInductively Coupled Plasma Mass Spectrometry (ICP-MS)\nAtomic Absorption Spectrometry (AAS)Inductively Coupled Plasma Mass Spectrometry (ICP-MS)Procedure\nSample Preparation: Blood treated release lead\nAnalysis: sample introduced instrument, lead measured based absorption emission light\nSample Preparation: Blood treated release leadAnalysis: sample introduced instrument, lead measured based absorption emission lightAdvantages: Highly sensitive accurateDisadvantages: Requires specialized equipment trained personnel","code":""},{"path":"principles-2.html","id":"key-terms-19","chapter":"Principles","heading":"Key Terms","text":"Diazo Reaction: chemical reaction used measure bilirubinSpectrophotometry: method measure absorbance light solutionChromogen: substance produces colored productELISA (Enzyme-Linked Immunosorbent Assay): immunoassay uses enzyme-labeled antibodiesCLIA (Chemiluminescence Immunoassay): immunoassay uses chemiluminescent labelsHPLC (High-Performance Liquid Chromatography): method separate quantify compoundsAtomic Absorption Spectrometry (AAS): method measure concentration elementsInductively Coupled Plasma Mass Spectrometry (ICP-MS): highly sensitive method measure concentration elementsPorphyrins: Intermediates heme synthesisFerritin: protein stores ironTransferrin: protein transports iron bloodTIBC (Total Iron-Binding Capacity): measure blood’s capacity bind ironHeme: iron-containing porphyrin ring hemoglobin respiratory pigments","code":""},{"path":"special-precautions-5.html","id":"special-precautions-5","chapter":"Special Precautions","heading":"Special Precautions","text":"Accurate measurement heme derivatives relies meticulous technique, starting sample collected continuing way spotting fixing issues come upKey Considerations\nSpecimen Collection\nSpecimen Handling Processing\nAnalytical Considerations\nInterfering Substances\nTroubleshooting\nSpecimen CollectionSpecimen Handling ProcessingAnalytical ConsiderationsInterfering SubstancesTroubleshooting","code":""},{"path":"special-precautions-5.html","id":"specimen-collection-1","chapter":"Special Precautions","heading":"Specimen Collection","text":"Bilirubin\nSpecimen Type: Serum plasma (fasting sample preferred)\nTube Type: SST (serum separator tube) plasma tube heparin EDTA\nSpecial Precautions: Protect sample light, bilirubin light-sensitive. Collect sample contrast dyes administered\nSpecimen Type: Serum plasma (fasting sample preferred)Tube Type: SST (serum separator tube) plasma tube heparin EDTASpecial Precautions: Protect sample light, bilirubin light-sensitive. Collect sample contrast dyes administeredUrine Bilirubin\nSpecimen Type: Fresh, random urine sample\nContainer: Clean, dry container\nSpecial Precautions: Protect light, analyze soon possible\nSpecimen Type: Fresh, random urine sampleContainer: Clean, dry containerSpecial Precautions: Protect light, analyze soon possibleUrine Urobilinogen\nSpecimen Type: Fresh, 2-hour 24-hour urine collection\nCollection: Collect urine container preservative (e.g., sodium carbonate) prevent oxidation urobilinogen urobilin\nSpecial Precautions: Protect light, analyze soon possible\nSpecimen Type: Fresh, 2-hour 24-hour urine collectionCollection: Collect urine container preservative (e.g., sodium carbonate) prevent oxidation urobilinogen urobilinSpecial Precautions: Protect light, analyze soon possibleIron Studies\nSpecimen Type: Serum (fasting sample preferred)\nTube Type: Trace metal-free tube\nSpecial Precautions: Avoid hemolysis, red blood cells contain high concentrations iron. Collect sample iron therapy blood transfusions\nSpecimen Type: Serum (fasting sample preferred)Tube Type: Trace metal-free tubeSpecial Precautions: Avoid hemolysis, red blood cells contain high concentrations iron. Collect sample iron therapy blood transfusionsPorphyrin Analysis\nSpecimen Type: Urine, blood, feces\nCollection: Collect urine dark container preservative (e.g., sodium carbonate acetic acid). Collect blood EDTA tubes. Collect feces clean container\nSpecial Precautions: Protect light, follow specific collection instructions type porphyria\nSpecimen Type: Urine, blood, fecesCollection: Collect urine dark container preservative (e.g., sodium carbonate acetic acid). Collect blood EDTA tubes. Collect feces clean containerSpecial Precautions: Protect light, follow specific collection instructions type porphyriaFecal Occult Blood Test (FOBT)\nSpecimen Type: Stool sample\nCollection: Collect stool samples multiple days (typically three) increase sensitivity\nSpecial Precautions: Follow specific dietary medication restrictions prior collection. Avoid contamination urine toilet paper\nSpecimen Type: Stool sampleCollection: Collect stool samples multiple days (typically three) increase sensitivitySpecial Precautions: Follow specific dietary medication restrictions prior collection. Avoid contamination urine toilet paper","code":""},{"path":"special-precautions-5.html","id":"specimen-handling-and-processing","chapter":"Special Precautions","heading":"Specimen Handling and Processing","text":"Bilirubin\nHandling: Protect sample light times\nProcessing: Centrifuge sample promptly separate serum plasma. Analyze immediately store refrigerated (2-8°C) 24 hours. longer storage, freeze -20°C -70°C\nHandling: Protect sample light timesProcessing: Centrifuge sample promptly separate serum plasma. Analyze immediately store refrigerated (2-8°C) 24 hours. longer storage, freeze -20°C -70°CUrine Bilirubin\nHandling: Protect light\nProcessing: Analyze sample immediately. delay unavoidable, refrigerate 2-8°C 2 hours\nHandling: Protect lightProcessing: Analyze sample immediately. delay unavoidable, refrigerate 2-8°C 2 hoursUrine Urobilinogen\nHandling: Protect light\nProcessing: Analyze sample immediately. delay unavoidable, refrigerate 2-8°C 4 hours\nHandling: Protect lightProcessing: Analyze sample immediately. delay unavoidable, refrigerate 2-8°C 4 hoursIron Studies\nHandling: Avoid hemolysis\nProcessing: Centrifuge sample promptly. Analyze immediately store refrigerated 2-8°C 7 days. longer storage, freeze -20°C -70°C\nHandling: Avoid hemolysisProcessing: Centrifuge sample promptly. Analyze immediately store refrigerated 2-8°C 7 days. longer storage, freeze -20°C -70°CPorphyrin Analysis\nHandling: Protect light\nProcessing: Follow specific extraction purification procedures type sample (urine, blood, feces). Store samples frozen -20°C -70°C analysis\nHandling: Protect lightProcessing: Follow specific extraction purification procedures type sample (urine, blood, feces). Store samples frozen -20°C -70°C analysisFecal Occult Blood Test (FOBT)\nHandling: Follow specific instructions developing test\nProcessing: Develop test within recommended time frame. Store developed tests properly maintain color stability\nHandling: Follow specific instructions developing testProcessing: Develop test within recommended time frame. Store developed tests properly maintain color stability","code":""},{"path":"special-precautions-5.html","id":"analytical-considerations-2","chapter":"Special Precautions","heading":"Analytical Considerations","text":"Reagent Quality\nBilirubin: Use fresh reagents, diazo reagents can degrade time. Store reagents according manufacturer’s instructions\nIron Studies: Use high-quality reagents minimize interferences trace metals\nPorphyrin Analysis: Use high-purity solvents standards chromatography\nFOBT: Ensure guaiac paper expired properly stored\nBilirubin: Use fresh reagents, diazo reagents can degrade time. Store reagents according manufacturer’s instructionsIron Studies: Use high-quality reagents minimize interferences trace metalsPorphyrin Analysis: Use high-purity solvents standards chromatographyFOBT: Ensure guaiac paper expired properly storedCalibration\nBilirubin: Calibrate spectrophotometers regularly using bilirubin standards\nIron Studies: Calibrate instruments using iron standards\nPorphyrin Analysis: Calibrate HPLC instruments using porphyrin standards\nBilirubin: Calibrate spectrophotometers regularly using bilirubin standardsIron Studies: Calibrate instruments using iron standardsPorphyrin Analysis: Calibrate HPLC instruments using porphyrin standardsQuality Control (QC)\nBilirubin: Run quality control samples regular intervals monitor accuracy precision bilirubin assays\nIron Studies: Run quality control samples serum iron, TIBC, transferrin saturation, ferritin assays\nPorphyrin Analysis: Run quality control samples monitor performance chromatographic separations detection\nFOBT: Use positive negative controls ensure test working properly\nBilirubin: Run quality control samples regular intervals monitor accuracy precision bilirubin assaysIron Studies: Run quality control samples serum iron, TIBC, transferrin saturation, ferritin assaysPorphyrin Analysis: Run quality control samples monitor performance chromatographic separations detectionFOBT: Use positive negative controls ensure test working properly","code":""},{"path":"special-precautions-5.html","id":"interfering-substances-5","chapter":"Special Precautions","heading":"Interfering Substances","text":"Bilirubin\nLipemia: Causes turbidity, affecting spectrophotometric readings\nMitigation: Use lipemia clearing techniques (ultracentrifugation, lipid clearing reagents) methods less affected turbidity\n\nHemolysis: Interferes diazo reaction\nMitigation: Avoid hemolysis collection processing\n\nCertain Medications: Can affect bilirubin levels\nMitigation: aware patient’s medication list\n\nLipemia: Causes turbidity, affecting spectrophotometric readings\nMitigation: Use lipemia clearing techniques (ultracentrifugation, lipid clearing reagents) methods less affected turbidity\nMitigation: Use lipemia clearing techniques (ultracentrifugation, lipid clearing reagents) methods less affected turbidityHemolysis: Interferes diazo reaction\nMitigation: Avoid hemolysis collection processing\nMitigation: Avoid hemolysis collection processingCertain Medications: Can affect bilirubin levels\nMitigation: aware patient’s medication list\nMitigation: aware patient’s medication listUrine Bilirubin\nAscorbic Acid (Vitamin C): Can cause false negatives\nMitigation: Avoid high doses ascorbic acid prior testing\n\nCertain Medications: Can cause false positives\nMitigation: aware patient’s medication list\n\nAscorbic Acid (Vitamin C): Can cause false negatives\nMitigation: Avoid high doses ascorbic acid prior testing\nMitigation: Avoid high doses ascorbic acid prior testingCertain Medications: Can cause false positives\nMitigation: aware patient’s medication list\nMitigation: aware patient’s medication listUrine Urobilinogen\nPorphyrinogens, Sulfonamides: Can interfere Ehrlich’s reagent\nMitigation: aware patient’s medication list\n\nPorphyrinogens, Sulfonamides: Can interfere Ehrlich’s reagent\nMitigation: aware patient’s medication list\nMitigation: aware patient’s medication listIron Studies\nHemolysis: Releases iron, falsely elevating serum iron levels\nMitigation: Avoid hemolysis collection processing\n\nRecent Iron Therapy Blood Transfusions: Can falsely elevate serum iron ferritin levels\nMitigation: Collect sample iron therapy blood transfusions\n\nHemolysis: Releases iron, falsely elevating serum iron levels\nMitigation: Avoid hemolysis collection processing\nMitigation: Avoid hemolysis collection processingRecent Iron Therapy Blood Transfusions: Can falsely elevate serum iron ferritin levels\nMitigation: Collect sample iron therapy blood transfusions\nMitigation: Collect sample iron therapy blood transfusionsPorphyrin Analysis\nInterfering Substances: Can affect chromatographic separations detection\nMitigation: Use high-purity solvents reagents\n\nInterfering Substances: Can affect chromatographic separations detection\nMitigation: Use high-purity solvents reagents\nMitigation: Use high-purity solvents reagentsFecal Occult Blood Test (FOBT)\nGuaiac-Based FOBT (gFOBT):\nRed Meat, Certain Fruits Vegetables: Can cause false positives\nMitigation: Restrict red meat, certain fruits vegetables prior testing\n\nVitamin C: Can cause false negatives\nMitigation: Avoid high doses Vitamin C prior testing\n\n\nFecal Immunochemical Test (FIT):\nRarely affected diet, may affected upper GI bleeds\n\nGuaiac-Based FOBT (gFOBT):\nRed Meat, Certain Fruits Vegetables: Can cause false positives\nMitigation: Restrict red meat, certain fruits vegetables prior testing\n\nVitamin C: Can cause false negatives\nMitigation: Avoid high doses Vitamin C prior testing\n\nRed Meat, Certain Fruits Vegetables: Can cause false positives\nMitigation: Restrict red meat, certain fruits vegetables prior testing\nMitigation: Restrict red meat, certain fruits vegetables prior testingVitamin C: Can cause false negatives\nMitigation: Avoid high doses Vitamin C prior testing\nMitigation: Avoid high doses Vitamin C prior testingFecal Immunochemical Test (FIT):\nRarely affected diet, may affected upper GI bleeds\nRarely affected diet, may affected upper GI bleeds","code":""},{"path":"special-precautions-5.html","id":"troubleshooting-5","chapter":"Special Precautions","heading":"Troubleshooting","text":"Unexpected Bilirubin Results\nPre-Analytical:\nExposure light\nDelayed processing\nPatient fasting\n\nAnalytical:\nIncorrect calibration\nReagent deterioration\nInterfering substances\n\nPre-Analytical:\nExposure light\nDelayed processing\nPatient fasting\nExposure lightDelayed processingPatient fastingAnalytical:\nIncorrect calibration\nReagent deterioration\nInterfering substances\nIncorrect calibrationReagent deteriorationInterfering substancesUnexpected Iron Study Results\nPre-Analytical:\nHemolysis\nRecent iron therapy\nImproper collection tube\n\nAnalytical:\nIncorrect calibration\nReagent deterioration\nContamination\n\nPre-Analytical:\nHemolysis\nRecent iron therapy\nImproper collection tube\nHemolysisRecent iron therapyImproper collection tubeAnalytical:\nIncorrect calibration\nReagent deterioration\nContamination\nIncorrect calibrationReagent deteriorationContaminationInconsistent Porphyrin Analysis Results\nCheck extraction purification procedures\nReview chromatographic separations\nEvaluate reagent quality calibration\nCheck extraction purification proceduresReview chromatographic separationsEvaluate reagent quality calibrationFalse Positive Negative FOBT Results\nReview patient preparation\nEvaluate reagent quality developing procedure\nConsider interfering substances pathological conditions\nReview patient preparationEvaluate reagent quality developing procedureConsider interfering substances pathological conditions","code":""},{"path":"special-precautions-5.html","id":"key-terms-20","chapter":"Special Precautions","heading":"Key Terms","text":"Pre-analytical: Processes occur sample analyzedAnalytical: Processes involved analyzing sampleInterfering Substance: substance affects accuracy testLipemia: presence excess lipids bloodHemolysis: breakdown red blood cellsCalibration: Adjusting instrument ensure accurate readingsQuality Control: Samples used monitor accuracy precision testSST: Serum Separator TubeEDTA: Ethylenediaminetetraacetic acid, anticoagulantHPLC: High-Performance Liquid ChromatographyFOBT: Fecal Occult Blood TestFIT: Fecal Immunochemical TestgFOBT: Guaiac-Based Fecal Occult Blood TestTrace metal-free tube: tube designed minimize metal contamination","code":""},{"path":"result-interpretation-2.html","id":"result-interpretation-2","chapter":"Result Interpretation","heading":"Result Interpretation","text":"Interpreting heme derivative test results requires integrating lab values patient’s clinical presentation medical history. Deviations reference intervals can indicate various conditionsKey Tests\nBilirubin (Total, Direct, Indirect)\nUrine Bilirubin\nUrine Urobilinogen\nIron Studies (Serum Iron, TIBC, Transferrin Saturation, Ferritin)\nPorphyrin Analysis (Urine, Blood, Feces)\nBilirubin (Total, Direct, Indirect)Urine BilirubinUrine UrobilinogenIron Studies (Serum Iron, TIBC, Transferrin Saturation, Ferritin)Porphyrin Analysis (Urine, Blood, Feces)","code":""},{"path":"result-interpretation-2.html","id":"bilirubin-2","chapter":"Result Interpretation","heading":"Bilirubin","text":"Total Bilirubin\nReference Interval: 0.3-1.0 mg/dL (5.1-17.1 μmol/L)\nInterpretation\nElevated levels indicate hyperbilirubinemia\n\nReference Interval: 0.3-1.0 mg/dL (5.1-17.1 μmol/L)Interpretation\nElevated levels indicate hyperbilirubinemia\nElevated levels indicate hyperbilirubinemiaDirect (Conjugated) Bilirubin\nReference Interval: 0.0-0.3 mg/dL (0-5.1 μmol/L)\nInterpretation\nElevated levels suggest biliary obstruction liver disease\n\nReference Interval: 0.0-0.3 mg/dL (0-5.1 μmol/L)Interpretation\nElevated levels suggest biliary obstruction liver disease\nElevated levels suggest biliary obstruction liver diseaseIndirect (Unconjugated) Bilirubin\nReference Interval: 0.2-0.8 mg/dL (3.4-13.7 μmol/L)\nInterpretation\nElevated levels suggest increased red blood cell breakdown (hemolysis) impaired liver uptake/conjugation\n\nReference Interval: 0.2-0.8 mg/dL (3.4-13.7 μmol/L)Interpretation\nElevated levels suggest increased red blood cell breakdown (hemolysis) impaired liver uptake/conjugation\nElevated levels suggest increased red blood cell breakdown (hemolysis) impaired liver uptake/conjugationClinical Significance\nElevated total bilirubin increased indirect bilirubin suggests pre-hepatic (hemolytic) jaundice\nElevated total bilirubin increased direct bilirubin suggests hepatic post-hepatic (obstructive) jaundice\nIsolated elevation indirect bilirubin can seen Gilbert’s syndrome\nElevated total bilirubin increased indirect bilirubin suggests pre-hepatic (hemolytic) jaundiceElevated total bilirubin increased direct bilirubin suggests hepatic post-hepatic (obstructive) jaundiceIsolated elevation indirect bilirubin can seen Gilbert’s syndrome","code":""},{"path":"result-interpretation-2.html","id":"urine-bilirubin-1","chapter":"Result Interpretation","heading":"Urine Bilirubin","text":"Reference Interval: NegativeInterpretation\nPositive result indicates conjugated hyperbilirubinemia\nPositive result indicates conjugated hyperbilirubinemiaClinical Significance\nSuggests biliary obstruction liver disease (conjugated bilirubin water-soluble can excreted urine)\nAbsent pre-hepatic jaundice (unconjugated bilirubin water-soluble)\nSuggests biliary obstruction liver disease (conjugated bilirubin water-soluble can excreted urine)Absent pre-hepatic jaundice (unconjugated bilirubin water-soluble)","code":""},{"path":"result-interpretation-2.html","id":"urine-urobilinogen","chapter":"Result Interpretation","heading":"Urine Urobilinogen","text":"Reference Interval: 0.2-1.0 mg/dL (3.4-16.9 μmol/L)Interpretation\nIncreased levels suggest increased red blood cell breakdown liver disease\nDecreased absent levels suggest biliary obstruction\nIncreased levels suggest increased red blood cell breakdown liver diseaseDecreased absent levels suggest biliary obstructionClinical Significance\nElevated hemolytic anemia, hepatitis, early stages biliary obstruction\nDecreased absent complete biliary obstruction (e.g., gallstones, tumors)\nElevated hemolytic anemia, hepatitis, early stages biliary obstructionDecreased absent complete biliary obstruction (e.g., gallstones, tumors)","code":""},{"path":"result-interpretation-2.html","id":"iron-studies-1","chapter":"Result Interpretation","heading":"Iron Studies","text":"Serum Iron\nReference Interval: 60-170 μg/dL (10.7-30.4 μmol/L)\nInterpretation\nDecreased levels suggest iron deficiency\nElevated levels suggest iron overload\n\nReference Interval: 60-170 μg/dL (10.7-30.4 μmol/L)Interpretation\nDecreased levels suggest iron deficiency\nElevated levels suggest iron overload\nDecreased levels suggest iron deficiencyElevated levels suggest iron overloadTotal Iron-Binding Capacity (TIBC)\nReference Interval: 240-450 μg/dL (42.9-80.6 μmol/L)\nInterpretation\nElevated levels suggest iron deficiency\nDecreased levels suggest iron overload chronic inflammation\n\nReference Interval: 240-450 μg/dL (42.9-80.6 μmol/L)Interpretation\nElevated levels suggest iron deficiency\nDecreased levels suggest iron overload chronic inflammation\nElevated levels suggest iron deficiencyDecreased levels suggest iron overload chronic inflammationTransferrin Saturation\nReference Interval: 20-50%\nInterpretation\nDecreased levels suggest iron deficiency\nElevated levels suggest iron overload\n\nReference Interval: 20-50%Interpretation\nDecreased levels suggest iron deficiency\nElevated levels suggest iron overload\nDecreased levels suggest iron deficiencyElevated levels suggest iron overloadFerritin\nReference Interval: 20-200 ng/mL (women), 20-500 ng/mL (men)\nInterpretation\nDecreased levels sensitive indicator iron deficiency\nElevated levels suggest iron overload, inflammation, malignancy\n\nReference Interval: 20-200 ng/mL (women), 20-500 ng/mL (men)Interpretation\nDecreased levels sensitive indicator iron deficiency\nElevated levels suggest iron overload, inflammation, malignancy\nDecreased levels sensitive indicator iron deficiencyElevated levels suggest iron overload, inflammation, malignancyClinical Significance\nIron deficiency anemia: Decreased serum iron, ferritin, transferrin saturation; increased TIBC\nIron overload (Hemochromatosis): Increased serum iron, ferritin, transferrin saturation; decreased TIBC\nAnemia chronic disease: Decreased serum iron TIBC; normal increased ferritin\nIron deficiency anemia: Decreased serum iron, ferritin, transferrin saturation; increased TIBCIron overload (Hemochromatosis): Increased serum iron, ferritin, transferrin saturation; decreased TIBCAnemia chronic disease: Decreased serum iron TIBC; normal increased ferritin","code":""},{"path":"result-interpretation-2.html","id":"porphyrin-analysis","chapter":"Result Interpretation","heading":"Porphyrin Analysis","text":"Interpretation\nElevated levels specific porphyrins porphyrin precursors urine, blood, feces indicate porphyria\nElevated levels specific porphyrins porphyrin precursors urine, blood, feces indicate porphyriaClinical Significance\nDifferent types porphyria associated specific enzyme deficiencies accumulation specific porphyrins\nAccurate identification specific porphyrins essential diagnosis management\nDifferent types porphyria associated specific enzyme deficiencies accumulation specific porphyrinsAccurate identification specific porphyrins essential diagnosis management","code":""},{"path":"result-interpretation-2.html","id":"fecal-occult-blood-test-fobt","chapter":"Result Interpretation","heading":"Fecal Occult Blood Test (FOBT)","text":"Interpretation\nPositive result indicates presence blood stool\nPositive result indicates presence blood stoolClinical Significance\nSuggests gastrointestinal bleeding, may due :\nColorectal cancer\nPolyps\nUlcers\nInflammatory bowel disease\ngastrointestinal conditions\n\nPositive FOBT requires investigation colonoscopy diagnostic procedures\nSuggests gastrointestinal bleeding, may due :\nColorectal cancer\nPolyps\nUlcers\nInflammatory bowel disease\ngastrointestinal conditions\nColorectal cancerPolypsUlcersInflammatory bowel diseaseOther gastrointestinal conditionsPositive FOBT requires investigation colonoscopy diagnostic procedures","code":""},{"path":"result-interpretation-2.html","id":"factors-affecting-interpretation-2","chapter":"Result Interpretation","heading":"Factors Affecting Interpretation","text":"Medications: Certain medications can affect bilirubin iron levels (e.g., rifampin, phenytoin, oral contraceptives, iron supplements)Hemolysis: Can falsely elevate serum iron levels affect bilirubin assaysDiet: Iron-rich foods can affect serum iron levelsLiver Kidney Function: Can affect bilirubin metabolism excretionGenetic Factors: Can influence iron absorption storageAge Gender: Reference intervals may vary age gender","code":""},{"path":"result-interpretation-2.html","id":"key-terms-21","chapter":"Result Interpretation","heading":"Key Terms","text":"Bilirubin: yellow pigment produced breakdown hemeHyperbilirubinemia: Elevated bilirubin levels bloodUrobilinogen: colorless compound produced intestine bacterial reduction bilirubinSerum Iron: measure iron bloodTotal Iron-Binding Capacity (TIBC): measure blood’s capacity bind ironTransferrin Saturation: percentage transferrin bound ironFerritin: protein stores ironPorphyrins: Intermediates heme synthesisFecal Occult Blood Test (FOBT): test detect blood stoolJaundice: Yellowing skin eyes due elevated bilirubinAnemia: condition characterized deficiency red blood cells hemoglobinPorphyria: genetic disorder caused deficiencies enzymes heme synthesis pathwayHemolysis: breakdown red blood cellsPre-hepatic Jaundice: Jaundice due increased red blood cell breakdownHepatic Jaundice: Jaundice due liver dysfunctionPost-hepatic Jaundice: Jaundice due obstruction bile flowGilbert’s Syndrome: common genetic disorder affecting bilirubin metabolism","code":""},{"path":"disease-correlation-2.html","id":"disease-correlation-2","chapter":"Disease Correlation","heading":"Disease Correlation","text":"Accurate heme derivative testing crucial diagnosis, monitoring, management conditions","code":""},{"path":"disease-correlation-2.html","id":"liver-diseases","chapter":"Disease Correlation","heading":"Liver Diseases","text":"Hepatitis (Viral, Alcoholic, Drug-Induced)CirrhosisBiliary Obstruction (Gallstones, Tumors)","code":""},{"path":"disease-correlation-2.html","id":"hepatitis-viral-alcoholic-drug-induced","chapter":"Disease Correlation","heading":"Hepatitis (Viral, Alcoholic, Drug-Induced)","text":"Laboratory Findings\nElevated Total Bilirubin: Typically > 1.0 mg/dL\nElevated Direct (Conjugated) Bilirubin: Increased proportion direct bilirubin\nElevated Liver Enzymes: ALT AST (indicators liver inflammation/damage)\nElevated Total Bilirubin: Typically > 1.0 mg/dLElevated Direct (Conjugated) Bilirubin: Increased proportion direct bilirubinElevated Liver Enzymes: ALT AST (indicators liver inflammation/damage)Disease State Correlation\nLiver inflammation impairs bilirubin conjugation excretion, leading hyperbilirubinemia elevated liver enzymes\nSpecific patterns bilirubin liver enzyme elevation can help differentiate different types hepatitis\nLiver inflammation impairs bilirubin conjugation excretion, leading hyperbilirubinemia elevated liver enzymesSpecific patterns bilirubin liver enzyme elevation can help differentiate different types hepatitis","code":""},{"path":"disease-correlation-2.html","id":"cirrhosis","chapter":"Disease Correlation","heading":"Cirrhosis","text":"Laboratory Findings\nElevated Total Bilirubin: Variable, may normal early stages\nElevated Direct (Conjugated) Bilirubin: Increased proportion direct bilirubin\nElevated Liver Enzymes: Variable, may normal decreased advanced stages\nDecreased Albumin: Indicator impaired liver synthetic function\nProlonged Prothrombin Time (PT): Indicator impaired liver synthetic function\nThrombocytopenia: Low platelet count due portal hypertension splenomegaly\nElevated Total Bilirubin: Variable, may normal early stagesElevated Direct (Conjugated) Bilirubin: Increased proportion direct bilirubinElevated Liver Enzymes: Variable, may normal decreased advanced stagesDecreased Albumin: Indicator impaired liver synthetic functionProlonged Prothrombin Time (PT): Indicator impaired liver synthetic functionThrombocytopenia: Low platelet count due portal hypertension splenomegalyDisease State Correlation\nCirrhosis characterized chronic liver damage scarring, leading impaired bilirubin metabolism, decreased protein synthesis, complications\nElevated bilirubin, decreased albumin, prolonged PT reflect severity liver dysfunction\nCirrhosis characterized chronic liver damage scarring, leading impaired bilirubin metabolism, decreased protein synthesis, complicationsElevated bilirubin, decreased albumin, prolonged PT reflect severity liver dysfunction","code":""},{"path":"disease-correlation-2.html","id":"biliary-obstruction-gallstones-tumors","chapter":"Disease Correlation","heading":"Biliary Obstruction (Gallstones, Tumors)","text":"Laboratory Findings\nElevated Total Bilirubin: Typically > 2.0 mg/dL\nElevated Direct (Conjugated) Bilirubin: Predominantly direct bilirubin\nElevated Alkaline Phosphatase (ALP) Gamma-Glutamyl Transferase (GGT): Indicators biliary obstruction\nElevated Total Bilirubin: Typically > 2.0 mg/dLElevated Direct (Conjugated) Bilirubin: Predominantly direct bilirubinElevated Alkaline Phosphatase (ALP) Gamma-Glutamyl Transferase (GGT): Indicators biliary obstructionDisease State Correlation\nObstruction bile ducts prevents bilirubin excretion, leading conjugated hyperbilirubinemia elevated ALP GGT\nObstruction bile ducts prevents bilirubin excretion, leading conjugated hyperbilirubinemia elevated ALP GGT","code":""},{"path":"disease-correlation-2.html","id":"hemolytic-anemias","chapter":"Disease Correlation","heading":"Hemolytic Anemias","text":"Definition: Anemias caused increased destruction red blood cellsExamples: Hereditary spherocytosis, sickle cell anemia, autoimmune hemolytic anemiaLaboratory Findings\n* Elevated Total Bilirubin: Typically < 5.0 mg/dL\n* Elevated Indirect (Unconjugated) Bilirubin: Predominantly indirect bilirubin\n* Increased Reticulocyte Count: Indicates increased red blood cell production bone marrow\n* Decreased Hemoglobin Hematocrit: Indicators anemia\n* Increased Lactate Dehydrogenase (LDH): Released damaged red blood cells\n* Decreased Haptoglobin: Binds free hemoglobin depleted hemolytic anemiaDisease State Correlation\nIncreased red blood cell breakdown leads elevated indirect bilirubin, increased reticulocyte count, decreased hemoglobin\nIncreased red blood cell breakdown leads elevated indirect bilirubin, increased reticulocyte count, decreased hemoglobin","code":""},{"path":"disease-correlation-2.html","id":"porphyrias-2","chapter":"Disease Correlation","heading":"Porphyrias","text":"Definition: group genetic disorders caused deficiencies enzymes heme synthesis pathwayLaboratory Findings\nElevated levels specific porphyrins porphyrin precursors urine, blood, feces\nSpecific patterns porphyrin elevation depend type porphyria\nElevated levels specific porphyrins porphyrin precursors urine, blood, fecesSpecific patterns porphyrin elevation depend type porphyriaAcute Intermittent Porphyria (AIP): Elevated urine porphobilinogen (PBG) delta-aminolevulinic acid (ALA) acute attacksPorphyria Cutanea Tarda (PCT): Elevated urine uroporphyrinsDisease State Correlation\n* Enzyme deficiencies heme synthesis pathway lead accumulation specific porphyrins porphyrin precursors, causing various symptoms","code":""},{"path":"disease-correlation-2.html","id":"iron-deficiency-anemia-ida","chapter":"Disease Correlation","heading":"Iron Deficiency Anemia (IDA)","text":"Definition: Anemia caused insufficient iron levels, leading impaired heme hemoglobin synthesisLaboratory Findings\n* Decreased Hemoglobin Hematocrit: Indicators anemia\n* Decreased Mean Corpuscular Volume (MCV): Microcytic anemia\n* Decreased Serum Iron: < 60 μg/dL (10.7 μmol/L)\n* Decreased Ferritin: < 20 ng/mL (women), < 20 ng/mL (men)\n* Increased Total Iron-Binding Capacity (TIBC): > 450 μg/dL (80.6 μmol/L)\n* Decreased Transferrin Saturation: < 20%Disease State Correlation\nInadequate iron stores impair heme hemoglobin synthesis, leading microcytic anemia decreased iron levels\nInadequate iron stores impair heme hemoglobin synthesis, leading microcytic anemia decreased iron levels","code":""},{"path":"disease-correlation-2.html","id":"hemochromatosis-1","chapter":"Disease Correlation","heading":"Hemochromatosis","text":"Definition: genetic disorder characterized excessive iron absorption accumulation tissuesLaboratory Findings\n* Elevated Serum Iron: > 170 μg/dL (30.4 μmol/L)\n* Elevated Transferrin Saturation: > 50%\n* Elevated Ferritin: > 200 ng/mL (women), > 500 ng/mL (men)\n* Decreased Total Iron-Binding Capacity (TIBC): < 240 μg/dL (42.9 μmol/L)Disease State Correlation\nExcessive iron absorption leads iron overload, causing tissue damage organ dysfunction\nExcessive iron absorption leads iron overload, causing tissue damage organ dysfunction","code":""},{"path":"disease-correlation-2.html","id":"lead-poisoning-1","chapter":"Disease Correlation","heading":"Lead Poisoning","text":"Definition: Exposure lead, inhibits enzymes heme synthesis pathwayLaboratory Findings\n* Elevated Blood Lead Levels: > 5 μg/dL\n* Elevated Zinc Protoporphyrin (ZPP) Red Blood Cells: Indicates impaired heme synthesis\n* Decreased Hemoglobin: AnemiaDisease State Correlation\nLead inhibits ALA dehydratase ferrochelatase, disrupting heme synthesis causing neurological developmental problems\nLead inhibits ALA dehydratase ferrochelatase, disrupting heme synthesis causing neurological developmental problems","code":""},{"path":"disease-correlation-2.html","id":"anemia-of-chronic-disease-acd","chapter":"Disease Correlation","heading":"Anemia of Chronic Disease (ACD)","text":"Definition: Anemia associated chronic inflammatory conditionsLaboratory Findings\n* Decreased Hemoglobin Hematocrit: Indicators anemia\n* Decreased Serum Iron: < 60 μg/dL (10.7 μmol/L)\n* Decreased Total Iron-Binding Capacity (TIBC): < 240 μg/dL (42.9 μmol/L)\n* Decreased Transferrin Saturation: < 20%\n* Normal Increased Ferritin: > 20 ng/mL (women), > 20 ng/mL (men)Disease State Correlation\nInflammation leads increased hepcidin production, reduces iron absorption release, causing anemia\nInflammation leads increased hepcidin production, reduces iron absorption release, causing anemia","code":""},{"path":"disease-correlation-2.html","id":"summary-table-of-key-findings","chapter":"Disease Correlation","heading":"Summary Table of Key Findings","text":"↑ = Increased, ↓ = Decreased, N = Normal, ↑↑ = Significantly increased, N/↑ = Normal Increased, N/↓ = Normal Decreased","code":""},{"path":"disease-correlation-2.html","id":"key-terms-22","chapter":"Disease Correlation","heading":"Key Terms","text":"Bilirubin: yellow pigment produced breakdown hemeLiver Enzymes: ALT (alanine aminotransferase) AST (aspartate aminotransferase)Hemolytic Anemia: Anemia caused increased destruction red blood cellsPorphyria: genetic disorder caused deficiencies enzymes heme synthesis pathwayIron Deficiency Anemia (IDA): Anemia caused insufficient iron levelsHemochromatosis: genetic disorder characterized excessive iron absorption accumulation tissuesLead Poisoning: Exposure lead, inhibits enzymes heme synthesis pathwayAnemia Chronic Disease (ACD): Anemia associated chronic inflammatory conditionsMCV: Mean Corpuscular Volume, measure red blood cell sizeFerritin: protein stores ironTotal Iron-Binding Capacity (TIBC): measure blood’s capacity bind ironTransferrin Saturation: percentage transferrin bound ironPorphyrins: Intermediates heme synthesis","code":""},{"path":"enzymes.html","id":"enzymes","chapter":"Enzymes","heading":"Enzymes","text":"section outlines role enzymes diagnostics. Accurate measurement enzyme activity interpretation can provide critical insights range diseases","code":""},{"path":"enzymes.html","id":"biochemical-theory-and-physiology-3","chapter":"Enzymes","heading":"Biochemical Theory and Physiology","text":"Enzymes Biological Catalysts: Accelerate biochemical reactionsStructure Function: Active site, cofactors, coenzymesEnzyme Kinetics: Michaelis-Menten Kinetics, Vmax, KmFactors Affecting Enzyme Activity: pH, temperature, inhibitors, activatorsRegulation Enzyme Activity: Allosteric regulation, covalent modificationEnzymes Metabolic Pathways: Key roles glycolysis, Krebs cycle, etcIsoenzymes: Different forms enzyme tissue-specific distribution","code":""},{"path":"enzymes.html","id":"laboratory-test-procedures-3","chapter":"Enzymes","heading":"Laboratory Test Procedures","text":"Types Enzyme Assays\nKinetic Assays (Continuous Monitoring): Measure rate reaction\nFixed-Time Assays (Endpoint Assays): Measure product formed set time\nKinetic Assays (Continuous Monitoring): Measure rate reactionFixed-Time Assays (Endpoint Assays): Measure product formed set timeCommonly Measured Enzymes\nCardiac Markers: Creatine Kinase-MB (CK-MB), Troponin\nLiver Enzymes: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Gamma-Glutamyl Transferase (GGT)\nPancreatic Enzymes: Amylase, Lipase\nMuscle Enzymes: Creatine Kinase (CK)\nOthers: Acid Phosphatase, Angiotensin-Converting Enzyme (ACE)\nCardiac Markers: Creatine Kinase-MB (CK-MB), TroponinLiver Enzymes: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Gamma-Glutamyl Transferase (GGT)Pancreatic Enzymes: Amylase, LipaseMuscle Enzymes: Creatine Kinase (CK)Others: Acid Phosphatase, Angiotensin-Converting Enzyme (ACE)Special Precautions\nProper Specimen Collection\nTimely Specimen Processing Handling\nStrict Adherence QC Procedures\nProper Specimen CollectionTimely Specimen Processing HandlingStrict Adherence QC ProceduresAnalytical Techniques\nSpectrophotometry\nImmunoassay\nEnzyme-Linked Immunosorbent Assay (ELISA)\nSpectrophotometryImmunoassayEnzyme-Linked Immunosorbent Assay (ELISA)","code":""},{"path":"enzymes.html","id":"test-result-interpretation-3","chapter":"Enzymes","heading":"Test Result Interpretation","text":"Establish Reference IntervalsElevated Levels: Indicate tissue damage increased productionIsoenzyme Patterns: Aid identifying source elevated enzymesClinical Correlation: Integrate lab results clinical presentation patient historyFactors Affecting Interpretation: Medications, hemolysis, lipemia","code":""},{"path":"enzymes.html","id":"disease-state-correlation-3","chapter":"Enzymes","heading":"Disease State Correlation","text":"Cardiac Disorders\nMyocardial Infarction: Elevated CK-MB Troponin\nMyocardial Infarction: Elevated CK-MB TroponinLiver Disorders\nHepatitis: Elevated ALT AST\nAlcoholic Liver Disease: Elevated AST GGT\nBiliary Obstruction: Elevated ALP GGT\nHepatitis: Elevated ALT ASTAlcoholic Liver Disease: Elevated AST GGTBiliary Obstruction: Elevated ALP GGTPancreatic Disorders\nPancreatitis: Elevated Amylase Lipase\nPancreatitis: Elevated Amylase LipaseMuscle Disorders\nRhabdomyolysis: Elevated CK\nRhabdomyolysis: Elevated CKOther Disorders\nProstate Cancer: Elevated Acid Phosphatase\nSarcoidosis: Elevated Angiotensin-Converting Enzyme (ACE)\nProstate Cancer: Elevated Acid PhosphataseSarcoidosis: Elevated Angiotensin-Converting Enzyme (ACE)","code":""},{"path":"enzymes.html","id":"putting-it-all-together","chapter":"Enzymes","heading":"Putting it All Together","text":"Enzyme assays can affected number things, accurate collection running importantReview factors can influence tests get accurate complete clinical picture patientConnecting enzyme biochemistry disease states essential accurate diagnosis treatment","code":""},{"path":"biochemicals-3.html","id":"biochemicals-3","chapter":"Biochemicals","heading":"Biochemicals","text":"Enzymes essential biological catalysts, functions central understanding biochemistry disease. comprehensive overview covers biochemical theory, metabolic pathways, normal abnormal states, physical chemical properties","code":""},{"path":"biochemicals-3.html","id":"biochemical-theory-and-pathways","chapter":"Biochemicals","heading":"Biochemical Theory and Pathways","text":"Enzymes Catalysts: Lower activation energy, increase reaction ratesStructure Function: Active site, cofactors, coenzymes, holoenzymesMechanism Action\nSubstrate Binding (Lock--Key vs. Induced Fit)\nTransition State Stabilization\nCatalytic Strategies (Acid-Base, Covalent, Metal Ion)\nSubstrate Binding (Lock--Key vs. Induced Fit)Transition State StabilizationCatalytic Strategies (Acid-Base, Covalent, Metal Ion)Factors Affecting Enzyme Activity\nSubstrate/Enzyme Concentration\nTemperature pH\nInhibitors (Competitive, Noncompetitive, Uncompetitive)\nActivators\nSubstrate/Enzyme ConcentrationTemperature pHInhibitors (Competitive, Noncompetitive, Uncompetitive)ActivatorsEnzyme Regulation\nAllosteric Control\nCovalent Modification\nProteolytic Activation\nGene Expression\nAllosteric ControlCovalent ModificationProteolytic ActivationGene ExpressionEnzymes Metabolic Pathways: Glycolysis, Krebs Cycle, etcKinetics: Michaelis-Menten Kinetics, Lineweaver-Burk Plots","code":""},{"path":"biochemicals-3.html","id":"normal-and-abnormal-states-3","chapter":"Biochemicals","heading":"Normal and Abnormal States","text":"Normal Enzyme Activity\nBalanced enzyme levels activity homeostasis\nCellular compartmentalization efficiency regulation\nBalanced enzyme levels activity homeostasisCellular compartmentalization efficiency regulationAbnormal States\nEnzyme Deficiencies: Genetic mutations, impaired synthesis\nEnzyme Elevations: Tissue damage, disease processes\nIsoenzyme Variations: Altered distribution patterns\nEnzyme Inhibitions: Toxins, drugs, metabolic disorders\nEnzyme Deficiencies: Genetic mutations, impaired synthesisEnzyme Elevations: Tissue damage, disease processesIsoenzyme Variations: Altered distribution patternsEnzyme Inhibitions: Toxins, drugs, metabolic disordersExamples\nPhenylketonuria (PKU): Deficiency phenylalanine hydroxylase\nMyocardial Infarction: Elevated troponin, CK-MB\nHepatitis: Elevated ALT, AST\nPhenylketonuria (PKU): Deficiency phenylalanine hydroxylaseMyocardial Infarction: Elevated troponin, CK-MBHepatitis: Elevated ALT, AST","code":""},{"path":"biochemicals-3.html","id":"physical-and-chemical-properties-4","chapter":"Biochemicals","heading":"Physical and Chemical Properties","text":"General Properties\nProteins unique amino acid sequences\nSoluble aqueous solutions\nHigh substrate specificity\nCatalytic Activity\nSensitivity Environmental Conditions (Temperature, pH)\nProteins unique amino acid sequencesSoluble aqueous solutionsHigh substrate specificityCatalytic ActivitySensitivity Environmental Conditions (Temperature, pH)Specific Enzymes\nLactate Dehydrogenase (LDH): Tetrameric, five isoenzymes\nCreatine Kinase (CK): Dimeric, three isoenzymes (MM, MB, BB)\nAspartate Aminotransferase (AST) Alanine Aminotransferase (ALT): Transaminases different tissue distributions\nGamma-Glutamyl Transferase (GGT): Glycoprotein involved glutathione metabolism\nAmylase: Hydrolyzes starch\nLipase: Hydrolyzes triglycerides\nAlkaline Phosphatase (ALP): Hydrolyzes phosphate esters\nAngiotensin-Converting Enzyme (ACE): Converts angiotensin angiotensin II\nLactate Dehydrogenase (LDH): Tetrameric, five isoenzymesCreatine Kinase (CK): Dimeric, three isoenzymes (MM, MB, BB)Aspartate Aminotransferase (AST) Alanine Aminotransferase (ALT): Transaminases different tissue distributionsGamma-Glutamyl Transferase (GGT): Glycoprotein involved glutathione metabolismAmylase: Hydrolyzes starchLipase: Hydrolyzes triglyceridesAlkaline Phosphatase (ALP): Hydrolyzes phosphate estersAngiotensin-Converting Enzyme (ACE): Converts angiotensin angiotensin II","code":""},{"path":"biochemicals-3.html","id":"interconnections-2","chapter":"Biochemicals","heading":"Interconnections","text":"Enzymes Drive Metabolic Pathways: activity determines flow metabolites overall efficiency pathwaysGenetic Mutations: Genetic mutations can lead enzyme deficiencies metabolic disordersTissue Damage Releases Enzymes: Cell injury results release enzymes bloodstream, providing diagnostic markers specific conditionsRegulation Ensures Homeostasis: Enzyme regulation crucial maintaining metabolic balance","code":""},{"path":"biochemicals-3.html","id":"clinical-significance-2","chapter":"Biochemicals","heading":"Clinical Significance","text":"Diagnostic Markers: Enzyme levels valuable diagnostic markers various diseasesPrognosis: enzyme levels indicate severity organ damage can guide treatment decisionsMonitoring Treatment: Enzyme activity also essential monitoring treatment disorders","code":""},{"path":"metabolic-3.html","id":"metabolic-3","chapter":"Metabolic","heading":"Metabolic","text":"Enzymes catalysts accelerate biochemical reactions within cells. vital metabolic processes, energy production DNA replication","code":""},{"path":"metabolic-3.html","id":"enzymes-1","chapter":"Metabolic","heading":"Enzymes","text":"Definition: Biological catalysts speed chemical reactions living organisms. proteins specific three-dimensional structures enable bind reactants (substrates) facilitate conversion substrates productsImportance: Enzymes essential life allow biochemical reactions occur rate fast enough sustain life. Without enzymes, many reactions occur slowly allKey Concepts\nCatalysis: Enzymes lower activation energy reactions, increasing reaction rate without consumed \nSpecificity: Enzymes highly specific substrates reactions catalyze\nRegulation: Enzyme activity can regulated various factors, including substrate concentration, pH, temperature, inhibitors, activators\nCatalysis: Enzymes lower activation energy reactions, increasing reaction rate without consumed themselvesSpecificity: Enzymes highly specific substrates reactions catalyzeRegulation: Enzyme activity can regulated various factors, including substrate concentration, pH, temperature, inhibitors, activators","code":""},{"path":"metabolic-3.html","id":"structure","chapter":"Metabolic","heading":"Structure","text":"Apoenzyme: protein component enzyme. inactive without cofactorCofactor: non-protein chemical compound bound apoenzyme required biological activity. Cofactors can inorganic ions (e.g., Mg2+, Zn2+) organic molecules (coenzymes)Coenzyme: organic cofactor. Many coenzymes derived vitamins (e.g., NAD+ niacin, FAD riboflavin, coenzyme pantothenic acid)Holoenzyme: catalytically active enzyme complex, consisting apoenzyme cofactor","code":""},{"path":"metabolic-3.html","id":"enzyme-substrate-interaction","chapter":"Metabolic","heading":"Enzyme-Substrate Interaction","text":"Active Site: specific region enzyme substrate binds catalysis occurs. active site three-dimensional pocket cleft formed amino acid residuesBinding\nEnzymes bind substrates non-covalent interactions (e.g., hydrogen bonds, hydrophobic interactions, ionic bonds)\nenzyme-substrate complex (ES complex) formed substrate binds active site\nEnzymes bind substrates non-covalent interactions (e.g., hydrogen bonds, hydrophobic interactions, ionic bonds)enzyme-substrate complex (ES complex) formed substrate binds active siteModels\nLock--Key Model: enzyme’s active site perfectly complementary substrate\nInduced-Fit Model: enzyme’s active site flexible changes shape upon substrate binding achieve better fit\nLock--Key Model: enzyme’s active site perfectly complementary substrateInduced-Fit Model: enzyme’s active site flexible changes shape upon substrate binding achieve better fit","code":""},{"path":"metabolic-3.html","id":"mechanism-of-action","chapter":"Metabolic","heading":"Mechanism of Action","text":"Activation Energy: Enzymes lower activation energy (Ea) reaction, energy required reach transition stateSteps\nSubstrate Binding: enzyme binds substrate form ES complex\nTransition State Formation: enzyme stabilizes transition state, reducing energy facilitating reaction\nProduct Formation: reaction occurs, substrate converted products\nProduct Release: products released enzyme, enzyme returns original state\nSubstrate Binding: enzyme binds substrate form ES complexTransition State Formation: enzyme stabilizes transition state, reducing energy facilitating reactionProduct Formation: reaction occurs, substrate converted productsProduct Release: products released enzyme, enzyme returns original stateCatalytic Strategies\nAcid-Base Catalysis: Enzymes use acidic basic amino acid residues transfer protons stabilize intermediates\nCovalent Catalysis: Enzymes form temporary covalent bond substrate\nMetal Ion Catalysis: Enzymes use metal ions stabilize charged intermediates facilitate redox reactions\nProximity Orientation Effects: Enzymes bring substrates close proximity proper orientation reaction occur\nAcid-Base Catalysis: Enzymes use acidic basic amino acid residues transfer protons stabilize intermediatesCovalent Catalysis: Enzymes form temporary covalent bond substrateMetal Ion Catalysis: Enzymes use metal ions stabilize charged intermediates facilitate redox reactionsProximity Orientation Effects: Enzymes bring substrates close proximity proper orientation reaction occur","code":""},{"path":"metabolic-3.html","id":"factors-affecting-enzyme-activity","chapter":"Metabolic","heading":"Factors Affecting Enzyme Activity","text":"Substrate Concentration\nIncreasing substrate concentration increases reaction rate enzyme saturated (active sites occupied)\nMichaelis-Menten Kinetics: Describes relationship reaction rate substrate concentration\nVmax: maximum reaction rate enzyme saturated substrate\nKm: Michaelis constant, representing substrate concentration reaction rate half Vmax\n\nIncreasing substrate concentration increases reaction rate enzyme saturated (active sites occupied)Michaelis-Menten Kinetics: Describes relationship reaction rate substrate concentration\nVmax: maximum reaction rate enzyme saturated substrate\nKm: Michaelis constant, representing substrate concentration reaction rate half Vmax\nVmax: maximum reaction rate enzyme saturated substrateKm: Michaelis constant, representing substrate concentration reaction rate half VmaxEnzyme Concentration\nIncreasing enzyme concentration increases reaction rate (substrate limiting)\nIncreasing enzyme concentration increases reaction rate (substrate limiting)Temperature\nEnzyme activity increases temperature optimal temperature\noptimal temperature, enzyme denatures activity decreases\nEnzyme activity increases temperature optimal temperatureAbove optimal temperature, enzyme denatures activity decreasespH\nEnzymes optimal pH range activity\nExtreme pH values can denature enzyme abolish activity\nEnzymes optimal pH range activityExtreme pH values can denature enzyme abolish activityInhibitors\nSubstances decrease enzyme activity\nReversible Inhibitors: Bind enzyme non-covalent interactions can removed\nCompetitive Inhibitors: Bind active site compete substrate\nNoncompetitive Inhibitors: Bind site distinct active site reduce enzyme activity\nUncompetitive Inhibitors: Bind ES complex\n\nIrreversible Inhibitors: Form stable covalent bond enzyme, permanently inactivating \nSubstances decrease enzyme activityReversible Inhibitors: Bind enzyme non-covalent interactions can removed\nCompetitive Inhibitors: Bind active site compete substrate\nNoncompetitive Inhibitors: Bind site distinct active site reduce enzyme activity\nUncompetitive Inhibitors: Bind ES complex\nCompetitive Inhibitors: Bind active site compete substrateNoncompetitive Inhibitors: Bind site distinct active site reduce enzyme activityUncompetitive Inhibitors: Bind ES complexIrreversible Inhibitors: Form stable covalent bond enzyme, permanently inactivating itActivators\nSubstances increase enzyme activity\nBind enzyme change conformation, making active\nSubstances increase enzyme activityBind enzyme change conformation, making active","code":""},{"path":"metabolic-3.html","id":"regulation-of-enzyme-activity","chapter":"Metabolic","heading":"Regulation of Enzyme Activity","text":"Allosteric Regulation: Enzymes regulatory sites (allosteric sites) modulators (activators inhibitors) bind, changing enzyme’s conformation activityCovalent Modification: Enzymes can regulated covalent addition removal chemical groups (e.g., phosphorylation, acetylation)Proteolytic Activation: enzymes synthesized inactive precursors (zymogens) activated proteolytic cleavage (e.g., digestive enzymes)Gene Expression: amount enzyme present cell can regulated controlling rate gene transcription translation","code":""},{"path":"metabolic-3.html","id":"enzymes-in-metabolic-pathways","chapter":"Metabolic","heading":"Enzymes in Metabolic Pathways","text":"Role: Enzymes catalyze step metabolic pathways, ensuring reactions occur efficiently coordinated mannerExamples\nGlycolysis: Enzymes hexokinase, phosphofructokinase, pyruvate kinase regulate glucose breakdown\nKrebs Cycle: Enzymes citrate synthase, isocitrate dehydrogenase, alpha-ketoglutarate dehydrogenase regulate Krebs cycle\nFatty Acid Synthesis: Enzymes acetyl-CoA carboxylase fatty acid synthase regulate fatty acid synthesis\nDNA Replication: Enzymes DNA polymerase, helicase, ligase essential DNA replication\nGlycolysis: Enzymes hexokinase, phosphofructokinase, pyruvate kinase regulate glucose breakdownKrebs Cycle: Enzymes citrate synthase, isocitrate dehydrogenase, alpha-ketoglutarate dehydrogenase regulate Krebs cycleFatty Acid Synthesis: Enzymes acetyl-CoA carboxylase fatty acid synthase regulate fatty acid synthesisDNA Replication: Enzymes DNA polymerase, helicase, ligase essential DNA replication","code":""},{"path":"metabolic-3.html","id":"key-terms-23","chapter":"Metabolic","heading":"Key Terms","text":"Enzyme: biological catalyst speeds chemical reactionsSubstrate: reactant enzyme acts onActive Site: specific region enzyme substrate binds catalysis occursCofactor: non-protein chemical compound required enzyme activityCoenzyme: organic cofactorHoloenzyme: catalytically active enzyme complexActivation Energy: energy required reach transition stateVmax: maximum reaction rateKm: Michaelis constant, representing substrate concentration reaction rate half VmaxInhibitor: substance decreases enzyme activityActivator: substance increases enzyme activityAllosteric Regulation: Regulation enzyme activity binding modulators allosteric sitesCovalent Modification: Regulation enzyme activity covalent addition removal chemical groupsZymogen: inactive precursor enzymeMetabolic Pathway: series interconnected biochemical reactions catalyzed enzymesKinase: enzyme transfers phosphate groups molecule (phosphorylates). kinases act hydroxyl groups serine, threonine, tyrosine residues proteinsPhosphatase: enzyme removes phosphate group molecule (dephosphorylates)Decarboxylase: enzyme removes carboxyl group molecule","code":""},{"path":"physiology-3.html","id":"physiology-3","chapter":"Physiology","heading":"Physiology","text":"Enzyme activity crucial maintaining cellular functions, deviations normal levels can indicate range diseases","code":""},{"path":"physiology-3.html","id":"normal-states-2","chapter":"Physiology","heading":"Normal States","text":"Balanced Enzyme Activity: Enzyme levels activity tightly regulated maintain homeostasisCellular Compartmentalization: Enzymes localized specific cellular compartments ensure proper function","code":""},{"path":"physiology-3.html","id":"balanced-enzyme-activity","chapter":"Physiology","heading":"Balanced Enzyme Activity","text":"Appropriate levels enzymes present cells body fluids catalyze biochemical reactions efficientlyEnzyme activity regulated substrate concentration, pH, temperature, inhibitors, activatorsEnzyme synthesis degradation balanced maintain constant enzyme concentrationEnzymes localized specific cellular compartments ensure proper function","code":""},{"path":"physiology-3.html","id":"cellular-compartmentalization","chapter":"Physiology","heading":"Cellular Compartmentalization","text":"Enzymes involved specific metabolic pathways localized specific cellular compartments (e.g., mitochondria, endoplasmic reticulum, cytosol)Compartmentalization ensures reactions occur efficiently coordinated mannerCompartmentalization also prevents enzymes interfering cellular processesExamples:\nEnzymes glycolysis located cytosol\nEnzymes Krebs cycle located mitochondria\nEnzymes fatty acid synthesis located cytosol\nEnzymes electron transport chain located inner mitochondrial membrane\nEnzymes glycolysis located cytosolEnzymes Krebs cycle located mitochondriaEnzymes fatty acid synthesis located cytosolEnzymes electron transport chain located inner mitochondrial membrane","code":""},{"path":"physiology-3.html","id":"abnormal-states-3","chapter":"Physiology","heading":"Abnormal States","text":"Enzyme Deficiencies: Genetic defects leading reduced absent enzyme activityEnzyme Elevations: Increased enzyme levels blood due tissue damage diseaseIsoenzyme Variations: Abnormal distribution isoenzymesEnzyme Inhibitions: Inhibition enzyme activity drugs, toxins, metabolic disorders","code":""},{"path":"physiology-3.html","id":"enzyme-deficiencies","chapter":"Physiology","heading":"Enzyme Deficiencies","text":"Definition: Genetic disorders caused mutations genes encoding enzymes, leading reduced absent enzyme activityPathophysiology: Enzyme deficiencies disrupt metabolic pathways, leading accumulation substrates /deficiency productsLaboratory Findings: Reduced absent enzyme activity affected tissuesSymptoms: Varies depending specific enzyme deficiency metabolic pathway affectedExamples\nPhenylketonuria (PKU): Deficiency phenylalanine hydroxylase (PAH)\nElevated phenylalanine levels blood\nIntellectual disability, seizures\n\nGalactosemia: Deficiency galactose-1-phosphate uridyltransferase (GALT)\nElevated galactose levels blood urine\nLiver damage, cataracts, intellectual disability\n\nTay-Sachs Disease: Deficiency hexosaminidase \nAccumulation gangliosides nerve cells\nNeurological deterioration, seizures, blindness\n\nGaucher Disease: Deficiency glucocerebrosidase\nAccumulation glucocerebrosides macrophages\nSplenomegaly, hepatomegaly, bone pain\n\nLesch-Nyhan Syndrome: Deficiency hypoxanthine-guanine phosphoribosyltransferase (HGPRT)\nElevated uric acid levels blood urine\nNeurological dysfunction, self-mutilation\n\nSevere Combined Immunodeficiency (SCID): Deficiency adenosine deaminase (ADA)\nAccumulation deoxyadenosine lymphocytes\nImpaired immune function, increased susceptibility infections\n\nPhenylketonuria (PKU): Deficiency phenylalanine hydroxylase (PAH)\nElevated phenylalanine levels blood\nIntellectual disability, seizures\nElevated phenylalanine levels bloodIntellectual disability, seizuresGalactosemia: Deficiency galactose-1-phosphate uridyltransferase (GALT)\nElevated galactose levels blood urine\nLiver damage, cataracts, intellectual disability\nElevated galactose levels blood urineLiver damage, cataracts, intellectual disabilityTay-Sachs Disease: Deficiency hexosaminidase \nAccumulation gangliosides nerve cells\nNeurological deterioration, seizures, blindness\nAccumulation gangliosides nerve cellsNeurological deterioration, seizures, blindnessGaucher Disease: Deficiency glucocerebrosidase\nAccumulation glucocerebrosides macrophages\nSplenomegaly, hepatomegaly, bone pain\nAccumulation glucocerebrosides macrophagesSplenomegaly, hepatomegaly, bone painLesch-Nyhan Syndrome: Deficiency hypoxanthine-guanine phosphoribosyltransferase (HGPRT)\nElevated uric acid levels blood urine\nNeurological dysfunction, self-mutilation\nElevated uric acid levels blood urineNeurological dysfunction, self-mutilationSevere Combined Immunodeficiency (SCID): Deficiency adenosine deaminase (ADA)\nAccumulation deoxyadenosine lymphocytes\nImpaired immune function, increased susceptibility infections\nAccumulation deoxyadenosine lymphocytesImpaired immune function, increased susceptibility infections","code":""},{"path":"physiology-3.html","id":"enzyme-elevations","chapter":"Physiology","heading":"Enzyme Elevations","text":"Definition: Increased enzyme levels blood, indicating tissue damage diseasePathophysiology: Tissue damage disease causes release enzymes cells bloodstreamLaboratory Findings: Elevated enzyme levels bloodSymptoms: Varies depending specific enzyme tissue affectedExamples\nMyocardial Infarction (Heart Attack): Elevated troponin, creatine kinase (CK), CK-MB\nChest pain, shortness breath\n\nHepatitis: Elevated alanine aminotransferase (ALT) aspartate aminotransferase (AST)\nFatigue, jaundice, abdominal pain\n\nPancreatitis: Elevated amylase lipase\nAbdominal pain, nausea, vomiting\n\nProstate Cancer: Elevated prostate-specific antigen (PSA)\nUrinary symptoms, bone pain\n\nMuscular Dystrophy: Elevated creatine kinase (CK)\nMuscle weakness, muscle wasting\n\nMyocardial Infarction (Heart Attack): Elevated troponin, creatine kinase (CK), CK-MB\nChest pain, shortness breath\nChest pain, shortness breathHepatitis: Elevated alanine aminotransferase (ALT) aspartate aminotransferase (AST)\nFatigue, jaundice, abdominal pain\nFatigue, jaundice, abdominal painPancreatitis: Elevated amylase lipase\nAbdominal pain, nausea, vomiting\nAbdominal pain, nausea, vomitingProstate Cancer: Elevated prostate-specific antigen (PSA)\nUrinary symptoms, bone pain\nUrinary symptoms, bone painMuscular Dystrophy: Elevated creatine kinase (CK)\nMuscle weakness, muscle wasting\nMuscle weakness, muscle wasting","code":""},{"path":"physiology-3.html","id":"isoenzyme-variations","chapter":"Physiology","heading":"Isoenzyme Variations","text":"Definition: Abnormal distribution isoenzymes, indicating tissue-specific damage diseasePathophysiology: Different tissues express different isoenzymes certain enzymes. Measuring levels isoenzymes can help identify source tissue damageLaboratory Findings: Altered ratios isoenzymesSymptoms: Varies depending specific isoenzyme tissue affectedExamples\nCreatine Kinase (CK) Isoenzymes:\nCK-MM: Found primarily skeletal muscle\nCK-MB: Found primarily heart muscle\nCK-BB: Found primarily brain smooth muscle\nElevated CK-MB suggests myocardial damage\n\nLactate Dehydrogenase (LDH) Isoenzymes:\nLDH-1: Found primarily heart red blood cells\nLDH-2: Found primarily heart red blood cells\nLDH-3: Found primarily lung tissues\nLDH-4: Found primarily liver muscle\nLDH-5: Found primarily liver muscle\nElevated LDH-1 LDH-2 suggest myocardial damage hemolysis\nElevated LDH-5 suggests liver damage muscle damage\n\nAlkaline Phosphatase (ALP) Isoenzymes:\nLiver ALP: Found primarily liver\nBone ALP: Found primarily bone\nIntestinal ALP: Found primarily intestine\nElevated liver ALP suggests liver disease biliary obstruction\nElevated bone ALP suggests bone disease\n\nCreatine Kinase (CK) Isoenzymes:\nCK-MM: Found primarily skeletal muscle\nCK-MB: Found primarily heart muscle\nCK-BB: Found primarily brain smooth muscle\nElevated CK-MB suggests myocardial damage\nCK-MM: Found primarily skeletal muscleCK-MB: Found primarily heart muscleCK-BB: Found primarily brain smooth muscleElevated CK-MB suggests myocardial damageLactate Dehydrogenase (LDH) Isoenzymes:\nLDH-1: Found primarily heart red blood cells\nLDH-2: Found primarily heart red blood cells\nLDH-3: Found primarily lung tissues\nLDH-4: Found primarily liver muscle\nLDH-5: Found primarily liver muscle\nElevated LDH-1 LDH-2 suggest myocardial damage hemolysis\nElevated LDH-5 suggests liver damage muscle damage\nLDH-1: Found primarily heart red blood cellsLDH-2: Found primarily heart red blood cellsLDH-3: Found primarily lung tissuesLDH-4: Found primarily liver muscleLDH-5: Found primarily liver muscleElevated LDH-1 LDH-2 suggest myocardial damage hemolysisElevated LDH-5 suggests liver damage muscle damageAlkaline Phosphatase (ALP) Isoenzymes:\nLiver ALP: Found primarily liver\nBone ALP: Found primarily bone\nIntestinal ALP: Found primarily intestine\nElevated liver ALP suggests liver disease biliary obstruction\nElevated bone ALP suggests bone disease\nLiver ALP: Found primarily liverBone ALP: Found primarily boneIntestinal ALP: Found primarily intestineElevated liver ALP suggests liver disease biliary obstructionElevated bone ALP suggests bone disease","code":""},{"path":"physiology-3.html","id":"enzyme-inhibitions","chapter":"Physiology","heading":"Enzyme Inhibitions","text":"Definition: Inhibition enzyme activity drugs, toxins, metabolic disordersPathophysiology: Inhibitors bind enzymes, preventing catalyzing reactionsLaboratory Findings: Decreased enzyme activitySymptoms: Varies depending specific enzyme metabolic pathway affectedExamples\nCyanide Poisoning: Cyanide inhibits cytochrome oxidase, enzyme electron transport chain\nCellular respiration inhibited, leading rapid death\n\nOrganophosphate Poisoning: Organophosphates inhibit acetylcholinesterase, enzyme breaks acetylcholine\nAcetylcholine accumulates, leading muscle paralysis respiratory failure\n\nMethanol Poisoning: Methanol metabolized formaldehyde formic acid, inhibit cytochrome oxidase\nCellular respiration inhibited, leading metabolic acidosis, blindness, death\n\nWarfarin Therapy: Warfarin inhibits vitamin K epoxide reductase, enzyme required synthesis clotting factors\nBlood clotting inhibited, preventing thrombosis\n\nStatins: Statins inhibit HMG-CoA reductase, enzyme cholesterol synthesis\nCholesterol synthesis reduced, lowering LDL cholesterol levels\n\nCyanide Poisoning: Cyanide inhibits cytochrome oxidase, enzyme electron transport chain\nCellular respiration inhibited, leading rapid death\nCellular respiration inhibited, leading rapid deathOrganophosphate Poisoning: Organophosphates inhibit acetylcholinesterase, enzyme breaks acetylcholine\nAcetylcholine accumulates, leading muscle paralysis respiratory failure\nAcetylcholine accumulates, leading muscle paralysis respiratory failureMethanol Poisoning: Methanol metabolized formaldehyde formic acid, inhibit cytochrome oxidase\nCellular respiration inhibited, leading metabolic acidosis, blindness, death\nCellular respiration inhibited, leading metabolic acidosis, blindness, deathWarfarin Therapy: Warfarin inhibits vitamin K epoxide reductase, enzyme required synthesis clotting factors\nBlood clotting inhibited, preventing thrombosis\nBlood clotting inhibited, preventing thrombosisStatins: Statins inhibit HMG-CoA reductase, enzyme cholesterol synthesis\nCholesterol synthesis reduced, lowering LDL cholesterol levels\nCholesterol synthesis reduced, lowering LDL cholesterol levels","code":""},{"path":"physiology-3.html","id":"key-terms-24","chapter":"Physiology","heading":"Key Terms","text":"Enzyme Deficiency: Genetic disorder reduced absent enzyme activityEnzyme Elevation: Increased enzyme levels bloodIsoenzyme: Different forms enzyme, tissue-specific distributionEnzyme Inhibition: Reduced enzyme activity due inhibitorsPhenylketonuria (PKU): Deficiency phenylalanine hydroxylaseGalactosemia: Deficiency galactose-1-phosphate uridyltransferaseMyocardial Infarction: Heart attackHepatitis: Inflammation liverPancreatitis: Inflammation pancreasProstate Cancer: Cancer prostate glandMuscular Dystrophy: group genetic disorders cause progressive muscle weakness lossIsoenzymes: Different forms enzyme, tissue-specific distribution","code":""},{"path":"properties-3.html","id":"properties-3","chapter":"Properties","heading":"Properties","text":"Understanding physical chemical properties clinically relevant enzymes essential accurate measurement interpretation laboratory","code":""},{"path":"properties-3.html","id":"general-properties","chapter":"Properties","heading":"General Properties","text":"Proteins\nenzymes proteins. , characteristic amino acid compositions, molecular weights, isoelectric points\nenzymes proteins. , characteristic amino acid compositions, molecular weights, isoelectric pointsSolubility\nenzymes soluble aqueous solutions, essential function biological systems\nenzymes soluble aqueous solutions, essential function biological systemsSpecificity\nEnzymes exhibit high specificity substrates reactions catalyze. specificity determined unique three-dimensional structure enzyme’s active site\nEnzymes exhibit high specificity substrates reactions catalyze. specificity determined unique three-dimensional structure enzyme’s active siteCatalytic Activity\nEnzymes act catalysts, accelerating biochemical reactions without consumed process\nEnzymes act catalysts, accelerating biochemical reactions without consumed processSensitivity Conditions\nEnzyme activity sensitive temperature, pH, environmental factors, can affect structure function\nEnzyme activity sensitive temperature, pH, environmental factors, can affect structure function","code":""},{"path":"properties-3.html","id":"ld-or-ldh","chapter":"Properties","heading":"LD or LDH","text":"Definition: Lactate Dehydrogenase (LD LDH) enzyme catalyzes interconversion lactate pyruvate, reduction NAD+ NADH, vice versaStructure\nTetrameric enzyme composed four subunits\nTwo types subunits: M (muscle) H (heart)\nFive isoenzymes: LDH-1 (HHHH), LDH-2 (HHHM), LDH-3 (HHMM), LDH-4 (HMMM), LDH-5 (MMMM)\nTetrameric enzyme composed four subunitsTwo types subunits: M (muscle) H (heart)Five isoenzymes: LDH-1 (HHHH), LDH-2 (HHHM), LDH-3 (HHMM), LDH-4 (HMMM), LDH-5 (MMMM)Physical Properties\nMolecular Weight: Approximately 140,000 Da\nIsoelectric Point (pI): Varies depending isoenzyme\nTissue Distribution:\nLDH-1: Heart, red blood cells\nLDH-2: Heart, red blood cells\nLDH-3: Lung, tissues\nLDH-4: Liver, muscle\nLDH-5: Liver, muscle\n\nMolecular Weight: Approximately 140,000 DaIsoelectric Point (pI): Varies depending isoenzymeTissue Distribution:\nLDH-1: Heart, red blood cells\nLDH-2: Heart, red blood cells\nLDH-3: Lung, tissues\nLDH-4: Liver, muscle\nLDH-5: Liver, muscle\nLDH-1: Heart, red blood cellsLDH-2: Heart, red blood cellsLDH-3: Lung, tissuesLDH-4: Liver, muscleLDH-5: Liver, muscleChemical Properties\nCatalytic Activity: Catalyzes reversible reaction lactate pyruvate\nSubstrate Specificity: Lactate pyruvate primary substrates\nCofactor: NAD+ (nicotinamide adenine dinucleotide)\nSensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 7.4\nInhibition: Inhibited high concentrations pyruvate lactate\n\nCatalytic Activity: Catalyzes reversible reaction lactate pyruvateSubstrate Specificity: Lactate pyruvate primary substratesCofactor: NAD+ (nicotinamide adenine dinucleotide)Sensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 7.4\nInhibition: Inhibited high concentrations pyruvate lactate\nTemperature: Optimal temperature around 37°CpH: Optimal pH around 7.4Inhibition: Inhibited high concentrations pyruvate lactateClinical Significance\nElevated levels indicate tissue damage\nIsoenzyme patterns can help identify source tissue damage\nElevated levels indicate tissue damageIsoenzyme patterns can help identify source tissue damage","code":""},{"path":"properties-3.html","id":"ck","chapter":"Properties","heading":"CK","text":"Definition: Creatine Kinase (CK) enzyme catalyzes reversible transfer phosphate phosphocreatine ADP, forming ATP creatineStructure\nDimeric enzyme composed two subunits\nTwo types subunits: M (muscle) B (brain)\nThree isoenzymes: CK-MM (muscle), CK-MB (heart), CK-BB (brain)\nDimeric enzyme composed two subunitsTwo types subunits: M (muscle) B (brain)Three isoenzymes: CK-MM (muscle), CK-MB (heart), CK-BB (brain)Physical Properties\nMolecular Weight: Approximately 82,000 Da\nIsoelectric Point (pI): Varies depending isoenzyme\nTissue Distribution:\nCK-MM: Skeletal muscle\nCK-MB: Heart muscle\nCK-BB: Brain, smooth muscle\n\nMolecular Weight: Approximately 82,000 DaIsoelectric Point (pI): Varies depending isoenzymeTissue Distribution:\nCK-MM: Skeletal muscle\nCK-MB: Heart muscle\nCK-BB: Brain, smooth muscle\nCK-MM: Skeletal muscleCK-MB: Heart muscleCK-BB: Brain, smooth muscleChemical Properties\nCatalytic Activity: Catalyzes reversible reaction phosphocreatine ADP\nSubstrate Specificity: Phosphocreatine ADP primary substrates\nCofactor: Magnesium ions (Mg2+)\nSensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 9.0\nInhibition: Inhibited high concentrations ATP\n\nCatalytic Activity: Catalyzes reversible reaction phosphocreatine ADPSubstrate Specificity: Phosphocreatine ADP primary substratesCofactor: Magnesium ions (Mg2+)Sensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 9.0\nInhibition: Inhibited high concentrations ATP\nTemperature: Optimal temperature around 37°CpH: Optimal pH around 9.0Inhibition: Inhibited high concentrations ATPClinical Significance\nElevated levels indicate muscle damage\nCK-MB specific marker myocardial damage\nElevated levels indicate muscle damageCK-MB specific marker myocardial damage","code":""},{"path":"properties-3.html","id":"astalt","chapter":"Properties","heading":"AST/ALT","text":"Definition: Aspartate Aminotransferase (AST) Alanine Aminotransferase (ALT) enzymes catalyze transfer amino group amino acid keto acidStructure\nMonomeric enzymes\nAST two isoenzymes: Cytosolic AST (cAST) mitochondrial AST (mAST)\nMonomeric enzymesAST two isoenzymes: Cytosolic AST (cAST) mitochondrial AST (mAST)Physical Properties\nMolecular Weight: Approximately 45,000 Da (AST), 50,000 Da (ALT)\nIsoelectric Point (pI): Varies depending enzyme isoenzyme\nTissue Distribution:\nAST: Liver, heart, muscle, kidney, brain\nALT: Primarily liver\n\nMolecular Weight: Approximately 45,000 Da (AST), 50,000 Da (ALT)Isoelectric Point (pI): Varies depending enzyme isoenzymeTissue Distribution:\nAST: Liver, heart, muscle, kidney, brain\nALT: Primarily liver\nAST: Liver, heart, muscle, kidney, brainALT: Primarily liverChemical Properties\nCatalytic Activity: Catalyze transfer amino group\nAST: Aspartate + α-ketoglutarate ↔︎ Oxaloacetate + Glutamate\nALT: Alanine + α-ketoglutarate ↔︎ Pyruvate + Glutamate\n\nSubstrate Specificity: Aspartate α-ketoglutarate (AST), Alanine α-ketoglutarate (ALT)\nCofactor: Pyridoxal phosphate (vitamin B6)\nSensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 7.4\n\nCatalytic Activity: Catalyze transfer amino group\nAST: Aspartate + α-ketoglutarate ↔︎ Oxaloacetate + Glutamate\nALT: Alanine + α-ketoglutarate ↔︎ Pyruvate + Glutamate\nAST: Aspartate + α-ketoglutarate ↔︎ Oxaloacetate + GlutamateALT: Alanine + α-ketoglutarate ↔︎ Pyruvate + GlutamateSubstrate Specificity: Aspartate α-ketoglutarate (AST), Alanine α-ketoglutarate (ALT)Cofactor: Pyridoxal phosphate (vitamin B6)Sensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 7.4\nTemperature: Optimal temperature around 37°CpH: Optimal pH around 7.4Clinical Significance\nElevated levels indicate liver damage\nALT specific liver damage AST\nAST:ALT ratio can help differentiate different types liver disease\nElevated levels indicate liver damageALT specific liver damage ASTAST:ALT ratio can help differentiate different types liver disease","code":""},{"path":"properties-3.html","id":"ggt","chapter":"Properties","heading":"GGT","text":"Definition: Gamma-Glutamyl Transferase (GGT) enzyme catalyzes transfer gamma-glutamyl groups peptides amino acids peptidesStructure\nGlycoprotein enzyme\nLocated primarily cell membranes liver, kidney, pancreas, intestine\nGlycoprotein enzymeLocated primarily cell membranes liver, kidney, pancreas, intestinePhysical Properties\nMolecular Weight: Approximately 85,000 Da\nIsoelectric Point (pI): Varies depending glycosylation pattern\nTissue Distribution: Liver, kidney, pancreas, intestine\nMolecular Weight: Approximately 85,000 DaIsoelectric Point (pI): Varies depending glycosylation patternTissue Distribution: Liver, kidney, pancreas, intestineChemical Properties\nCatalytic Activity: Catalyzes transfer gamma-glutamyl groups\nSubstrate Specificity: Gamma-glutamyl peptides primary substrates\nSensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 8.0\n\nCatalytic Activity: Catalyzes transfer gamma-glutamyl groupsSubstrate Specificity: Gamma-glutamyl peptides primary substratesSensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 8.0\nTemperature: Optimal temperature around 37°CpH: Optimal pH around 8.0Clinical Significance\nElevated levels indicate liver disease biliary obstruction\nUseful detecting alcohol-induced liver damage\nElevated levels indicate liver disease biliary obstructionUseful detecting alcohol-induced liver damage","code":""},{"path":"properties-3.html","id":"lipase","chapter":"Properties","heading":"Lipase","text":"Definition: enzyme catalyzes hydrolysis triglycerides glycerol fatty acidsStructure\nSerine hydrolase enzyme\nSecreted pancreas\nSerine hydrolase enzymeSecreted pancreasPhysical Properties\nMolecular Weight: Approximately 48,000 Da\nIsoelectric Point (pI): Varies depending glycosylation pattern\nTissue Distribution: Pancreas\nMolecular Weight: Approximately 48,000 DaIsoelectric Point (pI): Varies depending glycosylation patternTissue Distribution: PancreasChemical Properties\nCatalytic Activity: Catalyzes hydrolysis triglycerides\nSubstrate Specificity: Triglycerides primary substrates\nCofactor: Colipase required activity\nSensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 8.0\n\nCatalytic Activity: Catalyzes hydrolysis triglyceridesSubstrate Specificity: Triglycerides primary substratesCofactor: Colipase required activitySensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 8.0\nTemperature: Optimal temperature around 37°CpH: Optimal pH around 8.0Clinical Significance\nElevated levels indicate pancreatic damage (e.g., pancreatitis)\nspecific pancreatic damage amylase\nElevated levels indicate pancreatic damage (e.g., pancreatitis)specific pancreatic damage amylase","code":""},{"path":"properties-3.html","id":"amylase","chapter":"Properties","heading":"Amylase","text":"Definition: enzyme catalyzes hydrolysis starch sugarsStructure\nTwo major isoenzymes: Salivary amylase (S-amylase) pancreatic amylase (P-amylase)\nTwo major isoenzymes: Salivary amylase (S-amylase) pancreatic amylase (P-amylase)Physical Properties\nMolecular Weight: Approximately 54,000 Da\nIsoelectric Point (pI): Varies depending isoenzyme\nTissue Distribution:\nSalivary amylase: Salivary glands\nPancreatic amylase: Pancreas\n\nMolecular Weight: Approximately 54,000 DaIsoelectric Point (pI): Varies depending isoenzymeTissue Distribution:\nSalivary amylase: Salivary glands\nPancreatic amylase: Pancreas\nSalivary amylase: Salivary glandsPancreatic amylase: PancreasChemical Properties\nCatalytic Activity: Catalyzes hydrolysis starch\nSubstrate Specificity: Starch primary substrate\nCofactor: Calcium ions (Ca2+)\nSensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 6.9\n\nCatalytic Activity: Catalyzes hydrolysis starchSubstrate Specificity: Starch primary substrateCofactor: Calcium ions (Ca2+)Sensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 6.9\nTemperature: Optimal temperature around 37°CpH: Optimal pH around 6.9Clinical Significance\nElevated levels indicate pancreatic damage (e.g., pancreatitis) salivary gland disorders\nLess specific pancreatic damage lipase\nElevated levels indicate pancreatic damage (e.g., pancreatitis) salivary gland disordersLess specific pancreatic damage lipase","code":""},{"path":"properties-3.html","id":"alp","chapter":"Properties","heading":"ALP","text":"Definition: Alkaline Phosphatase (ALP) group enzymes catalyze hydrolysis phosphate esters alkaline pHStructure\nTetrameric enzymes\nMultiple isoenzymes, including liver ALP, bone ALP, intestinal ALP, placental ALP\nTetrameric enzymesMultiple isoenzymes, including liver ALP, bone ALP, intestinal ALP, placental ALPPhysical Properties\nMolecular Weight: Approximately 80,000 Da\nIsoelectric Point (pI): Varies depending isoenzyme\nTissue Distribution: Liver, bone, intestine, kidney, placenta\nMolecular Weight: Approximately 80,000 DaIsoelectric Point (pI): Varies depending isoenzymeTissue Distribution: Liver, bone, intestine, kidney, placentaChemical Properties\nCatalytic Activity: Catalyzes hydrolysis phosphate esters\nSubstrate Specificity: Phosphate esters primary substrates\nCofactor: Magnesium ions (Mg2+) Zinc Ions (Zn2+)\nSensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 10.0\nInhibition: Inhibited phosphate inhibitors\n\nCatalytic Activity: Catalyzes hydrolysis phosphate estersSubstrate Specificity: Phosphate esters primary substratesCofactor: Magnesium ions (Mg2+) Zinc Ions (Zn2+)Sensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 10.0\nInhibition: Inhibited phosphate inhibitors\nTemperature: Optimal temperature around 37°CpH: Optimal pH around 10.0Inhibition: Inhibited phosphate inhibitorsClinical Significance\nElevated levels indicate liver disease, biliary obstruction, bone disease\nIsoenzyme analysis can help identify source elevation\nElevated levels indicate liver disease, biliary obstruction, bone diseaseIsoenzyme analysis can help identify source elevation","code":""},{"path":"properties-3.html","id":"ace","chapter":"Properties","heading":"ACE","text":"Definition: ngiotensin-Converting Enzyme (ACE) enzyme catalyzes conversion angiotensin angiotensin IIStructure\nZinc-containing metalloprotease\nTwo isoforms: Somatic ACE testicular ACE\nZinc-containing metalloproteaseTwo isoforms: Somatic ACE testicular ACEPhysical Properties\nMolecular Weight: Approximately 170,000 Da\nIsoelectric Point (pI): Varies depending isoform\nTissue Distribution: Endothelial cells, kidney, lung, brain\nMolecular Weight: Approximately 170,000 DaIsoelectric Point (pI): Varies depending isoformTissue Distribution: Endothelial cells, kidney, lung, brainChemical Properties\nCatalytic Activity: Catalyzes conversion angiotensin angiotensin II\nSubstrate Specificity: Angiotensin primary substrate\nCofactor: Zinc ions (Zn2+)\nSensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 7.5\n\nCatalytic Activity: Catalyzes conversion angiotensin angiotensin IISubstrate Specificity: Angiotensin primary substrateCofactor: Zinc ions (Zn2+)Sensitivity Conditions:\nTemperature: Optimal temperature around 37°C\npH: Optimal pH around 7.5\nTemperature: Optimal temperature around 37°CpH: Optimal pH around 7.5Clinical Significance\nElevated levels suggest sarcoidosis granulomatous diseases\nUsed monitor treatment hypertension ACE inhibitors\nElevated levels suggest sarcoidosis granulomatous diseasesUsed monitor treatment hypertension ACE inhibitors","code":""},{"path":"properties-3.html","id":"key-terms-25","chapter":"Properties","heading":"Key Terms","text":"Enzyme: biological catalystIsoenzyme: Different forms enzymeSubstrate: molecule acted upon enzymeCofactor: non-protein molecule required enzyme activityActive Site: region enzyme substrate bindsCatalysis: acceleration chemical reaction catalystHydrolysis: chemical breakdown compound due reaction waterSpectrophotometry: method measure absorbance light solutionAmylase: enzyme catalyzes breakdown starch sugarsLipase: enzyme catalyzes breakdown fats fatty acids glycerolKinase: enzyme transfers phosphate groups molecule (phosphorylates). kinases act hydroxyl groups serine, threonine, tyrosine residues proteinsPhosphatase: enzyme removes phosphate group molecule (dephosphorylates)Decarboxylase: enzyme removes carboxyl group moleculeAST: Aspartate AminotransferaseALT: Alanine AminotransferaseGGT: Gamma-Glutamyl TransferaseALP: Alkaline PhosphataseLD/LDH: Lactate DehydrogenaseCK: Creatine KinaseACE: Angiotensin-Converting EnzymeSarcoidosis: disease characterized growth tiny collections inflammatory cells (granulomas) part body","code":""},{"path":"procedures-3.html","id":"procedures-3","chapter":"Procedures","heading":"Procedures","text":"Enzymes play crucial role diagnosing monitoring various diseases. Understanding principles enzyme assays, along proper pre-analytical analytical techniques, essential generating accurate reliable results","code":""},{"path":"procedures-3.html","id":"principles-of-enzyme-assays","chapter":"Procedures","heading":"Principles of Enzyme Assays","text":"Kinetic Assays: Measure rate enzyme-catalyzed reactions continuouslyFixed-Time Assays: Measure amount product formed substrate consumed single point timeEnzyme Activity Assays: Measure catalytic activity enzymeEnzyme Concentration Assays: Measure amount enzyme protein present","code":""},{"path":"procedures-3.html","id":"specimen-collection-2","chapter":"Procedures","heading":"Specimen Collection","text":"Patient Preparation\nFasting: enzymes require fasting\nMedications: Certain medications can affect enzyme levels\nRecent Procedures: Defer testing affected\nExercise: Strenuous exercise can elevate levels\nFasting: enzymes require fastingMedications: Certain medications can affect enzyme levelsRecent Procedures: Defer testing affectedExercise: Strenuous exercise can elevate levelsSpecimen Type: Serum common, use plasmaTube Type: Follow lab guidelinesOrder Draw: Follow CLSI standardsTourniquet Time: Keep short avoid hemoconcentrationCollection Technique: Clean venipuncture avoid hemolysis","code":""},{"path":"procedures-3.html","id":"specimen-handling-and-processing-1","chapter":"Procedures","heading":"Specimen Handling and Processing","text":"Timing: Process ASAPCentrifugation: Follow instructionsStorage: Refrigerate freeze, avoid repeated freeze-thaw cyclesHemolysis: Avoid reject hemolyzed samples","code":""},{"path":"procedures-3.html","id":"analytical-considerations-3","chapter":"Procedures","heading":"Analytical Considerations","text":"Reagent Quality: Store reagents according instructions, check expiration datesCalibration: Use appropriate standards, calibrate regularlyQuality Control (QC): Run controls regularly, evaluate results releasing dataInstrumentation: Maintain service instruments per scheduleMethod Validation: Validate new methods","code":""},{"path":"procedures-3.html","id":"interfering-substances-6","chapter":"Procedures","heading":"Interfering Substances","text":"Endogenous: Lipemia, bilirubin, hemoglobin, urea, high protein concentrationsExogenous: Medications, anticoagulants, contaminantsMinimizing Interferences\nUse interference-reducing techniques\nDilute sample (appropriate)\nEmploy blanking background subtraction\nUse interference-reducing techniquesDilute sample (appropriate)Employ blanking background subtraction","code":""},{"path":"procedures-3.html","id":"troubleshooting-6","chapter":"Procedures","heading":"Troubleshooting","text":"High Enzyme Results\nPre-Analytical: Patient factors, collection/processing errors\nAnalytical: Calibration, reagents, interferences, instruments\nPre-Analytical: Patient factors, collection/processing errorsAnalytical: Calibration, reagents, interferences, instrumentsLow Enzyme Results\nPre-Analytical: Enzyme degradation, improper storage\nAnalytical: Calibration, reagents, instrument issues\nPre-Analytical: Enzyme degradation, improper storageAnalytical: Calibration, reagents, instrument issuesInconsistent Results\nCheck patient factors, collection/processing, reagents/calibration, interferences, instruments\nCheck patient factors, collection/processing, reagents/calibration, interferences, instrumentsOut--Control QC: Troubleshoot QC materials, calibration, reagents, instruments","code":""},{"path":"procedures-3.html","id":"key-considerations","chapter":"Procedures","heading":"Key Considerations","text":"Following proper technique yield reliable lab test resultsHigh clinical judgement recommended produce accurate diagnosis","code":""},{"path":"principles-3.html","id":"principles-3","chapter":"Principles","heading":"Principles","text":"Accurate enzyme testing vital diagnosing monitoring wide array diseases. Understanding principles behind tests crucial accurate lab workTypes Enzyme Assays\nKinetic Assays (Continuous Monitoring)\nFixed-Time Assays (Endpoint Assays)\nEnzyme Activity vs. Enzyme Concentration\nKinetic Assays (Continuous Monitoring)Fixed-Time Assays (Endpoint Assays)Enzyme Activity vs. Enzyme Concentration","code":""},{"path":"principles-3.html","id":"kinetic-assays-continuous-monitoring","chapter":"Principles","heading":"Kinetic Assays (Continuous Monitoring)","text":"Principle: kinetic assays, rate enzyme-catalyzed reaction measured continuously time. change absorbance (measurable parameter) monitored reaction proceedsProcess\nInitiation: reaction initiated adding sample containing enzyme solution containing substrate necessary cofactors\nMonitoring: change absorbance (parameter) monitored continuously fixed period (e.g., 1-5 minutes) using spectrophotometer appropriate instrument\nCalculation: rate reaction (ΔA/min) calculated slope absorbance curve. enzyme activity proportional reaction rate\nInitiation: reaction initiated adding sample containing enzyme solution containing substrate necessary cofactorsMonitoring: change absorbance (parameter) monitored continuously fixed period (e.g., 1-5 minutes) using spectrophotometer appropriate instrumentCalculation: rate reaction (ΔA/min) calculated slope absorbance curve. enzyme activity proportional reaction rateReactions\nEnzyme + Substrate → Product(s)\nrate product formation (substrate consumption) measured directly\nEnzyme + Substrate → Product(s)rate product formation (substrate consumption) measured directlyAdvantages\naccurate fixed-time assays, account non-linearity lag phases\nCan detect interferences substrate depletion\naccurate fixed-time assays, account non-linearity lag phasesCan detect interferences substrate depletionDisadvantages\ncomplex instrumentation data analysis\nMay susceptible interferences\ncomplex instrumentation data analysisMay susceptible interferencesExamples\nLactate Dehydrogenase (LDH): Measures rate NADH formation consumption\nCreatine Kinase (CK): Measures rate NADPH formation\nAlanine Aminotransferase (ALT) Aspartate Aminotransferase (AST): Measure rate NADH formation consumption\nGamma-Glutamyl Transferase (GGT): Measures rate p-nitroaniline formation\nLactate Dehydrogenase (LDH): Measures rate NADH formation consumptionCreatine Kinase (CK): Measures rate NADPH formationAlanine Aminotransferase (ALT) Aspartate Aminotransferase (AST): Measure rate NADH formation consumptionGamma-Glutamyl Transferase (GGT): Measures rate p-nitroaniline formation","code":""},{"path":"principles-3.html","id":"fixed-time-assays-endpoint-assays","chapter":"Principles","heading":"Fixed-Time Assays (Endpoint Assays)","text":"Principle: fixed-time assays, reaction allowed proceed fixed period, amount product formed (substrate consumed) measured single endpointProcess\nIncubation: sample containing enzyme incubated substrate necessary cofactors fixed period (e.g., 5 minutes, 10 minutes, 30 minutes)\nStopping Reaction: fixed incubation period, reaction stopped adding reagent denatures enzyme inactivates \nMeasurement: amount product formed (substrate consumed) measured endpoint using spectrophotometer appropriate instrument\nCalculation: enzyme activity proportional amount product formed (substrate consumed) fixed incubation period\nIncubation: sample containing enzyme incubated substrate necessary cofactors fixed period (e.g., 5 minutes, 10 minutes, 30 minutes)Stopping Reaction: fixed incubation period, reaction stopped adding reagent denatures enzyme inactivates itMeasurement: amount product formed (substrate consumed) measured endpoint using spectrophotometer appropriate instrumentCalculation: enzyme activity proportional amount product formed (substrate consumed) fixed incubation periodReactions\nEnzyme + Substrate → Product(s)\namount product formed measured single time point\nEnzyme + Substrate → Product(s)amount product formed measured single time pointAdvantages\nSimpler less expensive kinetic assays\nEasier automate\nSimpler less expensive kinetic assaysEasier automateDisadvantages\nLess accurate kinetic assays, account non-linearity lag phases\nsusceptible interferences\nCan underestimate enzyme activity reaction linear entire incubation period\nLess accurate kinetic assays, account non-linearity lag phasesMore susceptible interferencesCan underestimate enzyme activity reaction linear entire incubation periodExamples\nAmylase: Measures amount reducing sugars formed starch hydrolysis\nLipase: Measures amount fatty acids released triglyceride hydrolysis\nAlkaline Phosphatase (ALP): Measures amount p-nitrophenol formed p-nitrophenyl phosphate\nAmylase: Measures amount reducing sugars formed starch hydrolysisLipase: Measures amount fatty acids released triglyceride hydrolysisAlkaline Phosphatase (ALP): Measures amount p-nitrophenol formed p-nitrophenyl phosphate","code":""},{"path":"principles-3.html","id":"enzyme-activity-vs.-enzyme-concentration","chapter":"Principles","heading":"Enzyme Activity vs. Enzyme Concentration","text":"Enzyme Activity Assays: Measure catalytic activity enzyme (.e., rate catalyzes reaction). assays used assess enzyme function diagnose conditions involving altered enzyme activityEnzyme Concentration Assays: Measure amount enzyme protein present sample, regardless activity. assays used assess enzyme levels diagnose conditions involving altered enzyme expression synthesisMethods Measuring Enzyme Concentration\nImmunoassays: Use antibodies specific enzyme capture quantify enzyme protein. Examples include ELISA, Western blot, immunoturbidimetry\nMass Spectrometry: Used identify quantify enzyme proteins based mass--charge ratio\nImmunoassays: Use antibodies specific enzyme capture quantify enzyme protein. Examples include ELISA, Western blot, immunoturbidimetryMass Spectrometry: Used identify quantify enzyme proteins based mass--charge ratio","code":""},{"path":"principles-3.html","id":"specific-enzyme-assays","chapter":"Principles","heading":"Specific Enzyme Assays","text":"Lactate Dehydrogenase (LDH)\nPrinciple: Measures rate NADH formation consumption lactate converted pyruvate vice versa\nMethod: Kinetic assay\nReactions:\nLactate + NAD+ ↔︎ Pyruvate + NADH + H+\n\nDetection: Increase absorbance 340 nm due NADH formation\nPrinciple: Measures rate NADH formation consumption lactate converted pyruvate vice versaMethod: Kinetic assayReactions:\nLactate + NAD+ ↔︎ Pyruvate + NADH + H+\nLactate + NAD+ ↔︎ Pyruvate + NADH + H+Detection: Increase absorbance 340 nm due NADH formationCreatine Kinase (CK)\nPrinciple: Measures rate ATP formation creatine phosphate ADP, reverse reaction\nMethod: Kinetic assay\nReactions:\nCreatine Phosphate + ADP ↔︎ Creatine + ATP\nATP + Glucose –(Hexokinase)–> Glucose-6-Phosphate + ADP\nGlucose-6-Phosphate + NAD+ –(G6PD)–> 6-Phosphogluconate + NADH + H+\n\nDetection: Increase absorbance 340 nm due NADH formation\nPrinciple: Measures rate ATP formation creatine phosphate ADP, reverse reactionMethod: Kinetic assayReactions:\nCreatine Phosphate + ADP ↔︎ Creatine + ATP\nATP + Glucose –(Hexokinase)–> Glucose-6-Phosphate + ADP\nGlucose-6-Phosphate + NAD+ –(G6PD)–> 6-Phosphogluconate + NADH + H+\nCreatine Phosphate + ADP ↔︎ Creatine + ATPATP + Glucose –(Hexokinase)–> Glucose-6-Phosphate + ADPGlucose-6-Phosphate + NAD+ –(G6PD)–> 6-Phosphogluconate + NADH + H+Detection: Increase absorbance 340 nm due NADH formationAspartate Aminotransferase (AST) Alanine Aminotransferase (ALT)\nPrinciple: Measure rate formation oxaloacetate glutamate (AST) pyruvate glutamate (ALT)\nMethod: Kinetic assay\nReactions:\nAST: Aspartate + α-Ketoglutarate ↔︎ Oxaloacetate + Glutamate\nALT: Alanine + α-Ketoglutarate ↔︎ Pyruvate + Glutamate\nOxaloacetate + NADH + H+ –(Malate Dehydrogenase)–> Malate + NAD+\nPyruvate + NADH + H+ –(Lactate Dehydrogenase)–> Lactate + NAD+\n\nDetection: Decrease absorbance 340 nm due NADH consumption\nPrinciple: Measure rate formation oxaloacetate glutamate (AST) pyruvate glutamate (ALT)Method: Kinetic assayReactions:\nAST: Aspartate + α-Ketoglutarate ↔︎ Oxaloacetate + Glutamate\nALT: Alanine + α-Ketoglutarate ↔︎ Pyruvate + Glutamate\nOxaloacetate + NADH + H+ –(Malate Dehydrogenase)–> Malate + NAD+\nPyruvate + NADH + H+ –(Lactate Dehydrogenase)–> Lactate + NAD+\nAST: Aspartate + α-Ketoglutarate ↔︎ Oxaloacetate + GlutamateALT: Alanine + α-Ketoglutarate ↔︎ Pyruvate + GlutamateOxaloacetate + NADH + H+ –(Malate Dehydrogenase)–> Malate + NAD+Pyruvate + NADH + H+ –(Lactate Dehydrogenase)–> Lactate + NAD+Detection: Decrease absorbance 340 nm due NADH consumptionGamma-Glutamyl Transferase (GGT)\nPrinciple: Measures rate p-nitroaniline formation γ-glutamyl-p-nitroanilide\nMethod: Kinetic assay\nReactions:\nγ-Glutamyl-p-nitroanilide + Amino Acid ↔︎ γ-Glutamyl-Amino Acid + p-Nitroaniline\n\nDetection: Increase absorbance 405 nm due p-nitroaniline formation\nPrinciple: Measures rate p-nitroaniline formation γ-glutamyl-p-nitroanilideMethod: Kinetic assayReactions:\nγ-Glutamyl-p-nitroanilide + Amino Acid ↔︎ γ-Glutamyl-Amino Acid + p-Nitroaniline\nγ-Glutamyl-p-nitroanilide + Amino Acid ↔︎ γ-Glutamyl-Amino Acid + p-NitroanilineDetection: Increase absorbance 405 nm due p-nitroaniline formationAmylase\nPrinciple: Measures hydrolysis starch reducing sugars (e.g., maltose)\nMethod: Fixed-time assay\nReactions:\nStarch + H2O –(Amylase)–> Reducing Sugars\nReducing Sugars + Reagent → Colored Product\n\nDetection: intensity colored product directly proportional amylase activity\nPrinciple: Measures hydrolysis starch reducing sugars (e.g., maltose)Method: Fixed-time assayReactions:\nStarch + H2O –(Amylase)–> Reducing Sugars\nReducing Sugars + Reagent → Colored Product\nStarch + H2O –(Amylase)–> Reducing SugarsReducing Sugars + Reagent → Colored ProductDetection: intensity colored product directly proportional amylase activityLipase\nPrinciple: Measures hydrolysis triglycerides glycerol fatty acids\nMethod: Fixed-time assay\nReactions:\nTriglycerides + H2O –(Lipase)–> Glycerol + Fatty Acids\nGlycerol + ATP –(Glycerol Kinase)–> Glycerol-3-Phosphate + ADP\nGlycerol-3-Phosphate + O2 –(Glycerol-3-Phosphate Oxidase)–> Dihydroxyacetone Phosphate + H2O2\nH2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + H2O\n\nDetection: intensity colored product directly proportional lipase activity\nPrinciple: Measures hydrolysis triglycerides glycerol fatty acidsMethod: Fixed-time assayReactions:\nTriglycerides + H2O –(Lipase)–> Glycerol + Fatty Acids\nGlycerol + ATP –(Glycerol Kinase)–> Glycerol-3-Phosphate + ADP\nGlycerol-3-Phosphate + O2 –(Glycerol-3-Phosphate Oxidase)–> Dihydroxyacetone Phosphate + H2O2\nH2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + H2O\nTriglycerides + H2O –(Lipase)–> Glycerol + Fatty AcidsGlycerol + ATP –(Glycerol Kinase)–> Glycerol-3-Phosphate + ADPGlycerol-3-Phosphate + O2 –(Glycerol-3-Phosphate Oxidase)–> Dihydroxyacetone Phosphate + H2O2H2O2 + Chromogen –(Peroxidase)–> Oxidized Chromogen (Colored) + H2ODetection: intensity colored product directly proportional lipase activityAlkaline Phosphatase (ALP)\nPrinciple: Measures hydrolysis p-nitrophenyl phosphate p-nitrophenol\nMethod: Kinetic assay\nReactions:\np-Nitrophenyl Phosphate + H2O –(Alkaline Phosphatase)–> p-Nitrophenol + Phosphate\n\nDetection: Increase absorbance 405 nm due p-nitrophenol formation\nPrinciple: Measures hydrolysis p-nitrophenyl phosphate p-nitrophenolMethod: Kinetic assayReactions:\np-Nitrophenyl Phosphate + H2O –(Alkaline Phosphatase)–> p-Nitrophenol + Phosphate\np-Nitrophenyl Phosphate + H2O –(Alkaline Phosphatase)–> p-Nitrophenol + PhosphateDetection: Increase absorbance 405 nm due p-nitrophenol formationAngiotensin-Converting Enzyme (ACE)\nPrinciple: Measures conversion angiotensin angiotensin II hydrolysis synthetic substrate\nMethod: Kinetic assay\nReactions:\nAngiotensin –(ACE)–> Angiotensin II\n\nSynthetic Substrate –(ACE)–> Products\n\nDetection: products measured spectrophotometrically fluorometrically\nPrinciple: Measures conversion angiotensin angiotensin II hydrolysis synthetic substrateMethod: Kinetic assayReactions:\nAngiotensin –(ACE)–> Angiotensin II\n\nSynthetic Substrate –(ACE)–> Products\nAngiotensin –(ACE)–> Angiotensin IIOrSynthetic Substrate –(ACE)–> ProductsDetection: products measured spectrophotometrically fluorometrically","code":""},{"path":"principles-3.html","id":"key-terms-26","chapter":"Principles","heading":"Key Terms","text":"Kinetic Assay: assay rate reaction measured continuouslyFixed-Time Assay: assay amount product formed measured single time pointEnzyme Activity: rate enzyme catalyzes reactionSubstrate: molecule acted upon enzymeProduct: molecule produced enzyme-catalyzed reactionCofactor: non-protein molecule required enzyme activitySpectrophotometry: method measure absorbance light solutionChromogen: substance produces colored productELISA (Enzyme-Linked Immunosorbent Assay): immunoassay uses enzyme-labeled antibodiesChemiluminescence Immunoassay (CLIA): immunoassay uses chemiluminescent labelsHPLC (High-Performance Liquid Chromatography): method separate quantify compounds","code":""},{"path":"special-precautions-6.html","id":"special-precautions-6","chapter":"Special Precautions","heading":"Special Precautions","text":"Accurate enzyme testing relies strict attention detail throughout entire process, patient instrument. section outlines key considerations reliable enzyme measurementsSpecimen CollectionSpecimen Handling ProcessingAnalytical ConsiderationsInterfering SubstancesTroubleshooting","code":""},{"path":"special-precautions-6.html","id":"specimen-collection-3","chapter":"Special Precautions","heading":"Specimen Collection","text":"Patient Preparation\nFasting: enzyme tests require fasting (e.g., lipase) minimize effects lipemia. Follow specific guidelines test\nMedications: Certain medications can affect enzyme levels. healthcare provider review patient’s medication list determine medications need temporarily discontinued testing\nRecent Procedures: Recent surgeries, injections, medical procedures can affect enzyme levels. Defer testing patient recovered\nExercise: Strenuous exercise can elevate muscle enzymes (e.g., CK). Avoid strenuous exercise prior blood collection\nFasting: enzyme tests require fasting (e.g., lipase) minimize effects lipemia. Follow specific guidelines testMedications: Certain medications can affect enzyme levels. healthcare provider review patient’s medication list determine medications need temporarily discontinued testingRecent Procedures: Recent surgeries, injections, medical procedures can affect enzyme levels. Defer testing patient recoveredExercise: Strenuous exercise can elevate muscle enzymes (e.g., CK). Avoid strenuous exercise prior blood collectionSpecimen Type\nSerum common specimen type enzyme assays\nPlasma may used enzyme assays, follow laboratory’s guidelines anticoagulant selection\nSerum common specimen type enzyme assaysPlasma may used enzyme assays, follow laboratory’s guidelines anticoagulant selectionTube Type\nSerum separator tubes (SST) red-top tubes commonly used serum collection\nPlasma tubes heparin EDTA may used assays, follow laboratory’s guidelines\nSerum separator tubes (SST) red-top tubes commonly used serum collectionPlasma tubes heparin EDTA may used assays, follow laboratory’s guidelinesOrder Draw\nFollow correct order draw collecting multiple tubes prevent cross-contamination\nFollow correct order draw collecting multiple tubes prevent cross-contaminationTourniquet Time\nMinimize tourniquet time (ideally less 1 minute) prevent hemoconcentration\nMinimize tourniquet time (ideally less 1 minute) prevent hemoconcentrationCollection Technique\nUse clean venipuncture technique minimize hemolysis. Avoid prolonged probing excessive force\nUse clean venipuncture technique minimize hemolysis. Avoid prolonged probing excessive force","code":""},{"path":"special-precautions-6.html","id":"specimen-handling-and-processing-2","chapter":"Special Precautions","heading":"Specimen Handling and Processing","text":"Timing\nProcess specimen soon possible collection prevent enzyme degradation\nAnalyze unstable enzymes (e.g., CK-MB) within short time frame\nProcess specimen soon possible collection prevent enzyme degradationAnalyze unstable enzymes (e.g., CK-MB) within short time frameCentrifugation\nCentrifuge sample according manufacturer’s instructions specific tube type\nProper centrifugation ensures complete separation serum plasma cells\nCentrifuge sample according manufacturer’s instructions specific tube typeProper centrifugation ensures complete separation serum plasma cellsStorage\nanalysis delayed, store specimen refrigerated (2-8°C) short-term storage frozen (-20°C -70°C) longer storage\nAliquot sample smaller portions avoid repeated freeze-thaw cycles, can degrade enzymes\nanalysis delayed, store specimen refrigerated (2-8°C) short-term storage frozen (-20°C -70°C) longer storageAliquot sample smaller portions avoid repeated freeze-thaw cycles, can degrade enzymesHemolysis\nAvoid hemolysis, red blood cells contain high concentrations many enzymes (e.g., LDH, AST), can falsely elevate results\nVisually inspect sample hemolysis reject hemolyzed samples\nAvoid hemolysis, red blood cells contain high concentrations many enzymes (e.g., LDH, AST), can falsely elevate resultsVisually inspect sample hemolysis reject hemolyzed samples","code":""},{"path":"special-precautions-6.html","id":"analytical-considerations-4","chapter":"Special Precautions","heading":"Analytical Considerations","text":"Reagent Quality\nUse high-quality reagents store according manufacturer’s instructions\nCheck expiration dates discard expired reagents\nUse high-quality reagents store according manufacturer’s instructionsCheck expiration dates discard expired reagentsCalibration\nCalibrate instrument regularly using appropriate standards\nUse multiple calibrators ensure linearity entire measurement range\nCalibrate instrument regularly using appropriate standardsUse multiple calibrators ensure linearity entire measurement rangeQuality Control (QC)\nRun quality control samples regular intervals monitor accuracy precision assay\nUse normal abnormal QC levels assess performance across entire range\nEvaluate QC results releasing patient results\nRun quality control samples regular intervals monitor accuracy precision assayUse normal abnormal QC levels assess performance across entire rangeEvaluate QC results releasing patient resultsInstrumentation\nRegularly maintain service instrument according manufacturer’s recommendations\nEnsure instrument functioning properly components good working order\nRegularly maintain service instrument according manufacturer’s recommendationsEnsure instrument functioning properly components good working orderMethod Validation\nValidate new methods implementation ensure accuracy, precision, linearity, performance characteristics\nValidate new methods implementation ensure accuracy, precision, linearity, performance characteristics","code":""},{"path":"special-precautions-6.html","id":"interfering-substances-7","chapter":"Special Precautions","heading":"Interfering Substances","text":"Endogenous\nLipemia: Causes turbidity, affecting spectrophotometric readings\nBilirubin: Absorbs light similar wavelengths, affecting absorbance readings\nHemoglobin: Released hemolyzed red blood cells, interfering enzymatic reactions\nUrea: High concentrations can interfere enzymatic reactions\nHigh Protein Concentrations: Can interfere enzymatic assays affecting reaction kinetics detection system\nLipemia: Causes turbidity, affecting spectrophotometric readingsBilirubin: Absorbs light similar wavelengths, affecting absorbance readingsHemoglobin: Released hemolyzed red blood cells, interfering enzymatic reactionsUrea: High concentrations can interfere enzymatic reactionsHigh Protein Concentrations: Can interfere enzymatic assays affecting reaction kinetics detection systemExogenous\nMedications: Certain drugs can directly affect enzyme levels\nAnticoagulants: anticoagulants can interfere enzymatic reactions\nContaminants: Improperly cleaned glassware containers can introduce contaminants affect enzyme activity\nMedications: Certain drugs can directly affect enzyme levelsAnticoagulants: anticoagulants can interfere enzymatic reactionsContaminants: Improperly cleaned glassware containers can introduce contaminants affect enzyme activityMinimizing Interferences\nUse methods less susceptible interference\nEmploy techniques remove correct interfering substance\nDilute sample reduce concentration interfering substance\nUse appropriate blanking background subtraction techniques\nUse methods less susceptible interferenceEmploy techniques remove correct interfering substanceDilute sample reduce concentration interfering substanceUse appropriate blanking background subtraction techniques","code":""},{"path":"special-precautions-6.html","id":"troubleshooting-7","chapter":"Special Precautions","heading":"Troubleshooting","text":"Unexpectedly High Enzyme Results\nPre-Analytical:\nPatient fasting\nProlonged tourniquet time\nHemolysis\nImproper collection tube\n\nAnalytical:\nIncorrect calibration\nReagent deterioration\nInterfering substances\nInstrument malfunction\n\nPre-Analytical:\nPatient fasting\nProlonged tourniquet time\nHemolysis\nImproper collection tube\nPatient fastingProlonged tourniquet timeHemolysisImproper collection tubeAnalytical:\nIncorrect calibration\nReagent deterioration\nInterfering substances\nInstrument malfunction\nIncorrect calibrationReagent deteriorationInterfering substancesInstrument malfunctionUnexpectedly Low Enzyme Results\nPre-Analytical:\nImproper storage\nEnzyme degradation\n\nAnalytical:\nIncorrect calibration\nReagent deterioration\nInstrument malfunction\n\nPre-Analytical:\nImproper storage\nEnzyme degradation\nImproper storageEnzyme degradationAnalytical:\nIncorrect calibration\nReagent deterioration\nInstrument malfunction\nIncorrect calibrationReagent deteriorationInstrument malfunctionInconsistent Results\nCheck patient preparation\nReview collection processing procedures\nEvaluate reagent quality calibration\nConsider interfering substances\nRepeat test using different method new sample\nCheck patient preparationReview collection processing proceduresEvaluate reagent quality calibrationConsider interfering substancesRepeat test using different method new sampleOut--Control QC Results\nCheck integrity QC materials\nPrepare fresh QC materials\nRe-calibrate instrument\nReview reagent quality\nRepeat QC testing\nproblem persists, contact instrument manufacturer assistance\nCheck integrity QC materialsPrepare fresh QC materialsRe-calibrate instrumentReview reagent qualityRepeat QC testingIf problem persists, contact instrument manufacturer assistance","code":""},{"path":"special-precautions-6.html","id":"examples-3","chapter":"Special Precautions","heading":"Examples","text":"Creatine Kinase (CK)\nInterference adenylate kinase (AK): AK catalyzes conversion ADP ATP, can interfere CK assays\nUse inhibitors AK minimize interference\nInterference adenylate kinase (AK): AK catalyzes conversion ADP ATP, can interfere CK assaysUse inhibitors AK minimize interferenceAlkaline Phosphatase (ALP)\nInhibition phosphate: Phosphate product ALP reaction can inhibit enzyme\nUse optimized substrate concentrations minimize inhibition\nInhibition phosphate: Phosphate product ALP reaction can inhibit enzymeUse optimized substrate concentrations minimize inhibitionAmylase\nInterference chloride ions: Chloride ions required amylase activity, high concentrations can inhibit enzyme\nMaintain appropriate chloride concentrations assay\nInterference chloride ions: Chloride ions required amylase activity, high concentrations can inhibit enzymeMaintain appropriate chloride concentrations assayLipase\nRequirement colipase: Colipase cofactor required lipase activity\nEnsure adequate colipase present assay\nRequirement colipase: Colipase cofactor required lipase activityEnsure adequate colipase present assay","code":""},{"path":"special-precautions-6.html","id":"key-terms-27","chapter":"Special Precautions","heading":"Key Terms","text":"Pre-analytical: Processes occur sample analyzedAnalytical: Processes involved analyzing sampleInterfering Substance: substance affects accuracy testHemolysis: breakdown red blood cellsLipemia: presence excess lipids bloodCalibration: Adjusting instrument ensure accurate readingsQuality Control: Samples used monitor accuracy precision testSST: Serum Separator TubeEDTA: Ethylenediaminetetraacetic acid, anticoagulantSOP: Standard Operating ProcedureAccuracy: close measurement true valuePrecision: reproducible measurement ","code":""},{"path":"result-interpretation-3.html","id":"result-interpretation-3","chapter":"Result Interpretation","heading":"Result Interpretation","text":"Accurate interpretation enzyme test results essential proper diagnosis management various medical conditions. Deviations reference intervals can indicate tissue damage, disease, physiological abnormalitiesKey Considerations\nEnzyme-Specific Information\nClinical Context\nPatient Factors\nLimitations Enzyme Testing\nEnzyme-Specific InformationClinical ContextPatient FactorsLimitations Enzyme Testing","code":""},{"path":"result-interpretation-3.html","id":"key-considerations-1","chapter":"Result Interpretation","heading":"Key Considerations","text":"Enzyme-Specific Information\nKnow normal ranges\nUnderstand tissue distribution\nKnow normal rangesUnderstand tissue distributionClinical Context\n’s patient’s medical history?\nmeds ?\nsymptoms experiencing?\n’s patient’s medical history?meds ?symptoms experiencing?Patient Factors\nAge, gender, ethnicity can affect enzyme levels\nAge, gender, ethnicity can affect enzyme levelsLimitations Enzyme Testing\nEnzyme levels may always correlate directly severity disease\nconditions may cause enzyme levels within normal range, even presence disease\nEnzyme levels may always correlate directly severity diseaseSome conditions may cause enzyme levels within normal range, even presence disease","code":""},{"path":"result-interpretation-3.html","id":"ck-1","chapter":"Result Interpretation","heading":"CK","text":"Reference Interval\nVaries depending age, gender, muscle mass\nTypical range: 20-200 U/L\nVaries depending age, gender, muscle massTypical range: 20-200 U/LInterpretation\nElevated CK levels indicate muscle damage\nMarkedly elevated levels (e.g., > 10 times upper limit normal) suggest severe muscle injury\nElevated CK levels indicate muscle damageMarkedly elevated levels (e.g., > 10 times upper limit normal) suggest severe muscle injuryClinical Significance\nMyocardial Infarction (CK-MB elevation): Suggests heart damage\nSkeletal Muscle Injury (CK-MM elevation): Suggests rhabdomyolysis, trauma, muscular dystrophy\nConditions: Hypothyroidism, strenuous exercise\nMyocardial Infarction (CK-MB elevation): Suggests heart damageSkeletal Muscle Injury (CK-MM elevation): Suggests rhabdomyolysis, trauma, muscular dystrophyOther Conditions: Hypothyroidism, strenuous exercise","code":""},{"path":"result-interpretation-3.html","id":"ck-isoenzymes","chapter":"Result Interpretation","heading":"CK Isoenzymes","text":"CK-MB\nReference Interval: < 3-5% total CK activity\nInterpretation\nElevated CK-MB suggests myocardial damage\nSerial measurements used assess rise fall CK-MB suspected heart attack\n\nClinical Significance\nMyocardial Infarction: Used support diagnosis acute myocardial infarction\n\nIncreased False Positives\nRenal Failure\nStrenuous Exercise\nSkeletal Muscle Trauma\nMyocarditis\n\nReference Interval: < 3-5% total CK activityInterpretation\nElevated CK-MB suggests myocardial damage\nSerial measurements used assess rise fall CK-MB suspected heart attack\nElevated CK-MB suggests myocardial damageSerial measurements used assess rise fall CK-MB suspected heart attackClinical Significance\nMyocardial Infarction: Used support diagnosis acute myocardial infarction\nMyocardial Infarction: Used support diagnosis acute myocardial infarctionIncreased False Positives\nRenal Failure\nStrenuous Exercise\nSkeletal Muscle Trauma\nMyocarditis\nRenal FailureStrenuous ExerciseSkeletal Muscle TraumaMyocarditisCK-MM\nReference Interval: > 95% total CK activity\nInterpretation\nElevated CK-MM suggests skeletal muscle damage\n\nClinical Significance\nRhabdomyolysis: Severe muscle injury leading release muscle contents bloodstream\nMuscular Dystrophy: Genetic disorders causing progressive muscle weakness\nTrauma: Crush injuries, burns, trauma\nStrenuous Exercise: Can cause temporary elevation\n\nReference Interval: > 95% total CK activityInterpretation\nElevated CK-MM suggests skeletal muscle damage\nElevated CK-MM suggests skeletal muscle damageClinical Significance\nRhabdomyolysis: Severe muscle injury leading release muscle contents bloodstream\nMuscular Dystrophy: Genetic disorders causing progressive muscle weakness\nTrauma: Crush injuries, burns, trauma\nStrenuous Exercise: Can cause temporary elevation\nRhabdomyolysis: Severe muscle injury leading release muscle contents bloodstreamMuscular Dystrophy: Genetic disorders causing progressive muscle weaknessTrauma: Crush injuries, burns, traumaStrenuous Exercise: Can cause temporary elevationCK-BB\nReference Interval: Typically low undetectable\nInterpretation\nElevated CK-BB suggests brain damage\n\nClinical Significance\nBrain Injury: Stroke, traumatic brain injury\nConditions: Lung prostate cancer\n\nReference Interval: Typically low undetectableInterpretation\nElevated CK-BB suggests brain damage\nElevated CK-BB suggests brain damageClinical Significance\nBrain Injury: Stroke, traumatic brain injury\nConditions: Lung prostate cancer\nBrain Injury: Stroke, traumatic brain injuryOther Conditions: Lung prostate cancer","code":""},{"path":"result-interpretation-3.html","id":"astalt-1","chapter":"Result Interpretation","heading":"AST/ALT","text":"Reference Interval\nAST: 10-40 U/L\nALT: 7-56 U/L\nAST: 10-40 U/LALT: 7-56 U/LInterpretation\nElevated AST ALT levels indicate liver damage\nMarkedly elevated levels (e.g., > 10 times upper limit normal) suggest acute liver injury\nElevated AST ALT levels indicate liver damageMarkedly elevated levels (e.g., > 10 times upper limit normal) suggest acute liver injuryClinical Significance\nHepatitis: ALT typically higher AST\nAlcoholic Liver Disease: AST typically higher ALT (AST:ALT ratio > 2:1)\nNon-Alcoholic Fatty Liver Disease (NAFLD): Mildly elevated ALT AST\nDrug-Induced Liver Injury: Variable patterns depending drug\nConditions: Heart failure, muscle injury\nHepatitis: ALT typically higher ASTAlcoholic Liver Disease: AST typically higher ALT (AST:ALT ratio > 2:1)Non-Alcoholic Fatty Liver Disease (NAFLD): Mildly elevated ALT ASTDrug-Induced Liver Injury: Variable patterns depending drugOther Conditions: Heart failure, muscle injury","code":""},{"path":"result-interpretation-3.html","id":"astalt-ratio","chapter":"Result Interpretation","heading":"AST:ALT Ratio","text":"AST:ALT Ratio < 1\nSeen cases acute viral hepatitis\nAlso common non-alcoholic fatty liver disease (NAFLD)\nSeen cases acute viral hepatitisAlso common non-alcoholic fatty liver disease (NAFLD)AST:ALT Ratio > 2\nSuggestive alcoholic liver disease\nAlso seen cases cirrhosis\nSuggestive alcoholic liver diseaseAlso seen cases cirrhosisAST:ALT Ratio > 3\nHighly suggestive alcoholic liver disease\nHighly suggestive alcoholic liver disease","code":""},{"path":"result-interpretation-3.html","id":"ggt-1","chapter":"Result Interpretation","heading":"GGT","text":"Reference Interval\nMales: 8-61 U/L\nFemales: 5-36 U/L\nMales: 8-61 U/LFemales: 5-36 U/LInterpretation\nElevated GGT levels indicate liver disease biliary obstruction\nElevated GGT levels indicate liver disease biliary obstructionClinical Significance\nAlcoholic Liver Disease: Sensitive marker chronic alcohol consumption\nBiliary Obstruction: Elevated cholestatic liver diseases\nConditions: Drug-induced liver injury, NAFLD\nAlcoholic Liver Disease: Sensitive marker chronic alcohol consumptionBiliary Obstruction: Elevated cholestatic liver diseasesOther Conditions: Drug-induced liver injury, NAFLD","code":""},{"path":"result-interpretation-3.html","id":"amylase-and-lipase","chapter":"Result Interpretation","heading":"Amylase and Lipase","text":"Reference Interval\nAmylase: 30-110 U/L\nLipase: 0-160 U/L\nAmylase: 30-110 U/LLipase: 0-160 U/LInterpretation\nElevated amylase lipase levels indicate pancreatic damage\nElevated amylase lipase levels indicate pancreatic damageClinical Significance\nAcute Pancreatitis: amylase lipase elevated, lipase specific\nConditions: Biliary disease, salivary gland disorders, renal failure\nAcute Pancreatitis: amylase lipase elevated, lipase specificOther Conditions: Biliary disease, salivary gland disorders, renal failureAmylase: Elevated levels can also indicate salivary gland issuesLipase: specific pancreatic disease, rule macroamylasemia (serum amylase complexed immunoglobulin)","code":""},{"path":"result-interpretation-3.html","id":"alp-1","chapter":"Result Interpretation","heading":"ALP","text":"Reference Interval: 30-120 U/LInterpretation\nElevated ALP levels indicate liver disease, biliary obstruction, bone disease\nElevated ALP levels indicate liver disease, biliary obstruction, bone diseaseClinical Significance\nBiliary Obstruction: Marked elevation ALP\nLiver Disease: Variable elevation depending type liver disease\nBone Disease: Paget’s disease, bone tumors, hyperparathyroidism\nBiliary Obstruction: Marked elevation ALPLiver Disease: Variable elevation depending type liver diseaseBone Disease: Paget’s disease, bone tumors, hyperparathyroidismALP Isoenzymes\n* test can specify ALP increases\nLiver\nBone\nIntestinal\nLiverBoneIntestinal","code":""},{"path":"result-interpretation-3.html","id":"ace-1","chapter":"Result Interpretation","heading":"ACE","text":"Reference Interval: 8-52 U/LInterpretation\nElevated ACE levels suggest sarcoidosis\nElevated ACE levels suggest sarcoidosisClinical Significance\nSarcoidosis: Used support diagnosis monitor disease activity\nConditions: Gaucher’s disease, hyperthyroidism\nSarcoidosis: Used support diagnosis monitor disease activityOther Conditions: Gaucher’s disease, hyperthyroidism","code":""},{"path":"result-interpretation-3.html","id":"factors-affecting-interpretation-3","chapter":"Result Interpretation","heading":"Factors Affecting Interpretation","text":"Hemolysis: Can falsely elevate enzyme levels (e.g., LDH, AST)Lipemia: Can interfere spectrophotometric assaysMedications: Certain drugs can affect enzyme levelsMuscle Mass: Higher muscle mass can lead higher CK levelsPregnancy: ALP levels normally elevated pregnancy","code":""},{"path":"result-interpretation-3.html","id":"key-terms-28","chapter":"Result Interpretation","heading":"Key Terms","text":"Reference Interval: range values considered normal particular testSpecificity: ability test correctly identify individuals without disease conditionSensitivity: ability test correctly identify individuals disease conditionIsoenzymes: Different forms enzyme, tissue-specific distributionALT: Alanine AminotransferaseAST: Aspartate AminotransferaseGGT: Gamma-Glutamyl TransferaseALP: Alkaline PhosphataseCK: Creatine KinaseACE: Angiotensin-Converting EnzymeHepatitis: Inflammation liverCirrhosis: Chronic liver damage leading scarring liver failureMyocardial Infarction: Heart attackPancreatitis: Inflammation pancreasSarcoidosis: disease characterized growth tiny collections inflammatory cells (granulomas) part bodyNAFLD: Non-Alcoholic Fatty Liver Disease","code":""},{"path":"result-interpretation-3.html","id":"clinical-significance-3","chapter":"Result Interpretation","heading":"Clinical Significance","text":"Diagnosis: Enzyme testing helps diagnose various conditions, including liver disease, heart disease, muscle disorders, pancreatic diseasesPrognosis: Enzyme levels can provide information severity disease predict outcomesMonitoring: Enzyme testing used monitor treatment response detect disease recurrence","code":""},{"path":"disease-correlation-3.html","id":"disease-correlation-3","chapter":"Disease Correlation","heading":"Disease Correlation","text":"Enzyme testing cornerstone clinical diagnostics. Connecting enzyme levels specific diseases crucial accurate diagnoses treatmentKey Considerations: Tissue Distribution, Kinetics, Sensitivity/SpecificityKey Considerations: Tissue Distribution, Kinetics, Sensitivity/SpecificityClinical Significance: Aid differential diagnoses disease stagesClinical Significance: Aid differential diagnoses disease stages","code":""},{"path":"disease-correlation-3.html","id":"cardiac-markers","chapter":"Disease Correlation","heading":"Cardiac Markers","text":"Creatine Kinase - MB (CK-MB)\nLaboratory Findings: Elevated serum, peaks within 24 hours\nDisease State Correlation: Myocardial Infarction\nElevated CK-MB confirms myocardial necrosis\n\nClinical Significance: support diagnosis myocardial infarction\nTroponin (T): protein specific indicator myocardial damage CK-MB\nLaboratory Findings: Elevated serum, peaks within 24 hoursDisease State Correlation: Myocardial Infarction\nElevated CK-MB confirms myocardial necrosis\nElevated CK-MB confirms myocardial necrosisClinical Significance: support diagnosis myocardial infarctionTroponin (T): protein specific indicator myocardial damage CK-MB","code":""},{"path":"disease-correlation-3.html","id":"liver-function","chapter":"Disease Correlation","heading":"Liver Function","text":"Alanine Aminotransferase (ALT)\nLaboratory Findings: Elevated serum\nDisease State Correlation: Hepatitis\nClinical Significance: High level can confirm hepatitis present\nLaboratory Findings: Elevated serumDisease State Correlation: HepatitisClinical Significance: High level can confirm hepatitis presentAspartate Aminotransferase (AST)\nLaboratory Findings: Elevated serum\nDisease State Correlation: Liver Damage, Myocardial Infarction, Muscle Injury\nClinical Significance: Used assess liver damage\nLaboratory Findings: Elevated serumDisease State Correlation: Liver Damage, Myocardial Infarction, Muscle InjuryClinical Significance: Used assess liver damageAlkaline Phosphatase (ALP)\nLaboratory Findings: Elevated serum\nDisease State Correlation: Biliary Obstruction, Bone Disease\nClinical Significance: Help determine liver damage vs bile duct restriction\nLaboratory Findings: Elevated serumDisease State Correlation: Biliary Obstruction, Bone DiseaseClinical Significance: Help determine liver damage vs bile duct restrictionGamma-Glutamyl Transferase (GGT)\nLaboratory Findings: Elevated serum\nDisease State Correlation: Alcohol-Induced Liver Disease, Biliary Obstruction\nClinical Significance: Help confirm liver damage bile duct restrictions, moreso alcohol\nLaboratory Findings: Elevated serumDisease State Correlation: Alcohol-Induced Liver Disease, Biliary ObstructionClinical Significance: Help confirm liver damage bile duct restrictions, moreso alcohol","code":""},{"path":"disease-correlation-3.html","id":"pancreatic-function","chapter":"Disease Correlation","heading":"Pancreatic Function","text":"Amylase\nLaboratory Findings: Elevated serum\nDisease State Correlation: Pancreatitis\nClinical Significance: Support diagnosis pancreatitis\nLaboratory Findings: Elevated serumDisease State Correlation: PancreatitisClinical Significance: Support diagnosis pancreatitisLipase\nLaboratory Findings: Elevated serum\nDisease State Correlation: Pancreatitis\nClinical Significance: Help diagnose pancreatitis - specific pancreas\nLaboratory Findings: Elevated serumDisease State Correlation: PancreatitisClinical Significance: Help diagnose pancreatitis - specific pancreas","code":""},{"path":"disease-correlation-3.html","id":"muscle-damage","chapter":"Disease Correlation","heading":"Muscle Damage","text":"Creatine Kinase (CK) - Total\nLaboratory Findings: Elevated serum\nDisease State Correlation: Rhabdomyolysis\nClinical Significance: Confirm muscles damaged\nLaboratory Findings: Elevated serumDisease State Correlation: RhabdomyolysisClinical Significance: Confirm muscles damaged","code":""},{"path":"disease-correlation-3.html","id":"other-enzymes","chapter":"Disease Correlation","heading":"Other Enzymes","text":"Acid Phosphatase\nLaboratory Findings: Elevated serum\nDisease State Correlation: Prostate Cancer\nClinical Significance: check prostate cancer\nLaboratory Findings: Elevated serumDisease State Correlation: Prostate CancerClinical Significance: check prostate cancerAngiotensin-Converting Enzyme (ACE)\nLaboratory Findings: Elevated serum\nDisease State Correlation: Sarcoidosis\nClinical Significance: Help support diagnosis sarcoidosis\nLaboratory Findings: Elevated serumDisease State Correlation: SarcoidosisClinical Significance: Help support diagnosis sarcoidosis","code":""},{"path":"disease-correlation-3.html","id":"key-considerations-2","chapter":"Disease Correlation","heading":"Key Considerations","text":"confirm appropriate tissues damagedTo rule causes elevated enzymesTo test isoenzymes biomarkers may correlate current lab results","code":""},{"path":"disease-correlation-3.html","id":"caveats","chapter":"Disease Correlation","heading":"Caveats","text":"Enzymes can elevated due injury damage cellsEnzyme activity can influenced interfering substancesNormal range can vary","code":""},{"path":"proteins.html","id":"proteins","chapter":"Proteins","heading":"Proteins","text":"section designed help understand role proteins nitrogen-containing compounds health disease. Topics covered biochemical theory, lab testing, result interpretation, disease-specific implications","code":""},{"path":"proteins.html","id":"biochemical-theory-and-physiology-4","chapter":"Proteins","heading":"Biochemical Theory and Physiology","text":"Protein Building Blocks: Made amino acids, proteins perform diverse cellular functionsProtein Synthesis: Transcription translation guided genetic codeProtein Degradation: Breakdown proteins amino acids via lysosomes proteasomesAmino Acid Metabolism: Transamination, deamination, use compoundsNitrogen Balance: Intake vs. excretion, reflecting protein synthesis/breakdownKey Compounds\nProteins\nAmino Acids\nUrea\nUric Acid\nCreatinine\nAmmonia\nProteinsAmino AcidsUreaUric AcidCreatinineAmmonia","code":""},{"path":"proteins.html","id":"laboratory-test-procedures-4","chapter":"Proteins","heading":"Laboratory Test Procedures","text":"Protein Tests\nTotal Protein: Biuret method\nAlbumin: Dye-binding methods (BCG BCP)\nPrealbumin: Immunoassay\nTotal Protein: Biuret methodAlbumin: Dye-binding methods (BCG BCP)Prealbumin: ImmunoassayNitrogen Waste Product Tests\nUrea (BUN): Enzymatic methods\nCreatinine: Jaffe reaction enzymatic assays\nUric Acid: Uricase method\nAmmonia: Enzymatic ISE methods\nUrea (BUN): Enzymatic methodsCreatinine: Jaffe reaction enzymatic assaysUric Acid: Uricase methodAmmonia: Enzymatic ISE methodsSpecialized Protein Tests\nProtein Electrophoresis: Separates proteins charge/size\nImmunofixation Electrophoresis (IFE): Identifies monoclonal proteins\nTumor Markers: Measured immunoassay\nCardiac Markers: Measured immunoassay\nProtein Electrophoresis: Separates proteins charge/sizeImmunofixation Electrophoresis (IFE): Identifies monoclonal proteinsTumor Markers: Measured immunoassayCardiac Markers: Measured immunoassay","code":""},{"path":"proteins.html","id":"test-result-interpretation-4","chapter":"Proteins","heading":"Test Result Interpretation","text":"General Markers\nHigh levels proteins indicate high protein level\nLow levels protein indicate low protein level\nHigh levels proteins indicate high protein levelLow levels protein indicate low protein levelKidney Function Tests\nElevated Urea Creatinine indicate decreased kidney function\nElevated Urea Creatinine indicate decreased kidney functionProtein Electrophoresis: Interpret relative protein band intensity compared others find abnormal distributions, special note monoclonal gammopathy gamma globulin regionMalignancy markers indicate increased cancer riskPatient specific medical history","code":""},{"path":"proteins.html","id":"disease-state-correlation-4","chapter":"Proteins","heading":"Disease State Correlation","text":"Liver Disease: Decreased albumin, increased bilirubin ammoniaKidney Disease: Elevated creatinine urea, proteinuriaMalnutrition: Decreased albumin prealbuminMultiple Myeloma: Monoclonal protein electrophoresisHeart Failure: Elevated BNPCancer: Elevated tumor markers","code":""},{"path":"biochemicals-4.html","id":"biochemicals-4","chapter":"Biochemicals","heading":"Biochemicals","text":"Protein metabolism related compounds crucial life, imbalances can lead many diseases. overview ties together protein biochemistry human health, covering metabolic pathways, disease, molecular properties","code":""},{"path":"biochemicals-4.html","id":"biochemical-theory-and-metabolic-pathways-2","chapter":"Biochemicals","heading":"Biochemical Theory and Metabolic Pathways","text":"Proteins Building Blocks: Essential structure, enzymes, transport, immunityKey Metabolic Pathways\nProtein Synthesis: Amino acids linked make proteins\nProtein Degradation: Proteins broken amino acids\nAmino Acid Metabolism: Amino acids can recycled used molecules\nTransamination: Transfer amino groups\nDeamination: Removal amino groups (produces ammonia)\nUrea Cycle: Conversion toxic ammonia urea excretion\n\nCreatine Metabolism: Production use creatine muscle energy\nProtein Synthesis: Amino acids linked make proteinsProtein Degradation: Proteins broken amino acidsAmino Acid Metabolism: Amino acids can recycled used molecules\nTransamination: Transfer amino groups\nDeamination: Removal amino groups (produces ammonia)\nUrea Cycle: Conversion toxic ammonia urea excretion\nTransamination: Transfer amino groupsDeamination: Removal amino groups (produces ammonia)Urea Cycle: Conversion toxic ammonia urea excretionCreatine Metabolism: Production use creatine muscle energyOther Nitrogen-Containing Molecules: Nucleotides, hormones, neurotransmitters","code":""},{"path":"biochemicals-4.html","id":"normal-and-abnormal-states-4","chapter":"Biochemicals","heading":"Normal and Abnormal States","text":"Normal States\nNitrogen Balance: Intake = excretion\nNormal Protein Turnover: Balanced synthesis breakdown\nAdequate Levels: Normal Amino acid levels\nNitrogen Balance: Intake = excretionNormal Protein Turnover: Balanced synthesis breakdownAdequate Levels: Normal Amino acid levelsAbnormal States\nProtein-Energy Malnutrition (PEM): Marasmus (calorie deficiency) Kwashiorkor (protein deficiency)\nAmino Acid Disorders: Genetic defects (e.g., PKU)\nUrea Cycle Disorders: Elevated ammonia\nHyperammonemia: Elevated ammonia blood\nProteinuria: Excess protein urine\nHypoproteinemia: Low protein blood\nProtein-Energy Malnutrition (PEM): Marasmus (calorie deficiency) Kwashiorkor (protein deficiency)Amino Acid Disorders: Genetic defects (e.g., PKU)Urea Cycle Disorders: Elevated ammoniaHyperammonemia: Elevated ammonia bloodProteinuria: Excess protein urineHypoproteinemia: Low protein blood","code":""},{"path":"biochemicals-4.html","id":"physical-and-chemical-properties-5","chapter":"Biochemicals","heading":"Physical and Chemical Properties","text":"Proteins\nComplex 3D structure (primary, secondary, tertiary, quaternary)\nAmphoteric (can act acid base)\nSubject denaturation\nComplex 3D structure (primary, secondary, tertiary, quaternary)Amphoteric (can act acid base)Subject denaturationAmino Acids\nBuilding blocks proteins\nAmphoteric\nLinked peptide bonds\nBuilding blocks proteinsAmphotericLinked peptide bondsUrea\nEnd product nitrogen metabolism\nWater-soluble\nExcreted urine\nEnd product nitrogen metabolismWater-solubleExcreted urineUric Acid\nEnd product purine metabolism\nSparingly soluble\nCan form crystals (gout)\nEnd product purine metabolismSparingly solubleCan form crystals (gout)Creatinine\nWaste product muscle creatine\nWater-soluble\nExcreted kidneys\nWaste product muscle creatineWater-solubleExcreted kidneysAmmonia\nToxic breakdown product amino acids\nConverted urea liver\nToxic breakdown product amino acidsConverted urea liverTumor Markers (CEA, PSA, AFP, CA 125)\nProteins glycoproteins\nAssociated cancer\nProteins glycoproteinsAssociated cancerCardiac Markers (Troponin, CK-MB, Myoglobin)\nProteins released heart damage\nProteins released heart damage","code":""},{"path":"biochemicals-4.html","id":"key-connections","chapter":"Biochemicals","heading":"Key Connections","text":"Protein structure determines functionGenetic defects lead metabolic disordersProtein turnover reflects tissue healthWaste products indicate organ function","code":""},{"path":"biochemicals-4.html","id":"clinical-significance-4","chapter":"Biochemicals","heading":"Clinical Significance","text":"Diagnostic Tools: Measuring proteins nitrogen compounds helps diagnose many disordersMonitoring Health: Tests can monitor disease progression treatment effectsHolistic View: Integrating biochemistry clinical findings leads better patient care","code":""},{"path":"metabolic-4.html","id":"metabolic-4","chapter":"Metabolic","heading":"Metabolic","text":"Proteins essential cell structure, enzyme catalysis, immune responses. body uses proteins nitrogen-containing compounds building block final product. Understanding protein metabolism crucial understanding numerous physiological processes","code":""},{"path":"metabolic-4.html","id":"proteins-and-other-nitrogen-containing-compounds","chapter":"Metabolic","heading":"Proteins and Other Nitrogen-Containing Compounds","text":"Definition: Proteins large biomolecules consisting one long chains amino acids linked peptide bondsFunction: Proteins perform wide variety functions living organisms, including:\nEnzymes: Catalyze biochemical reactions\nStructural Proteins: Provide support shape cells tissues\nTransport Proteins: Carry molecules across cell membranes bloodstream\nHormones: Act chemical messengers\nAntibodies: Recognize bind foreign substances\nContractile Proteins: Enable muscle contraction\nEnzymes: Catalyze biochemical reactionsStructural Proteins: Provide support shape cells tissuesTransport Proteins: Carry molecules across cell membranes bloodstreamHormones: Act chemical messengersAntibodies: Recognize bind foreign substancesContractile Proteins: Enable muscle contractionOther Nitrogen-Containing Compounds: addition proteins, important nitrogen-containing compounds include amino acids, nucleotides, creatine, porphyrins, neurotransmittersKey Metabolic Pathways\nProtein Synthesis: Production proteins amino acids\nProtein Degradation: Breakdown proteins amino acids\nAmino Acid Metabolism:\nTransamination\nDeamination\nUrea Cycle\nSynthesis Specialized Products\n\nProtein Synthesis: Production proteins amino acidsProtein Degradation: Breakdown proteins amino acidsAmino Acid Metabolism:\nTransamination\nDeamination\nUrea Cycle\nSynthesis Specialized Products\nTransaminationDeaminationUrea CycleSynthesis Specialized Products","code":""},{"path":"metabolic-4.html","id":"protein-synthesis","chapter":"Metabolic","heading":"Protein Synthesis","text":"Purpose: produce proteins amino acids, based genetic codeLocation: Ribosomes cytoplasmProcess\nTranscription: DNA transcribed mRNA nucleus\nTranslation: mRNA translated protein ribosomes cytoplasm\nmRNA binds ribosomes\ntRNA molecules bring specific amino acids ribosome\nAmino acids linked together peptide bonds form polypeptide chain\n\nPost-Translational Modification: polypeptide chain modified form functional protein\nFolding: polypeptide chain folds specific three-dimensional structure\nModification: Chemical groups may added removed (e.g., glycosylation, phosphorylation)\nCleavage: polypeptide chain may cleaved smaller fragments\nQuaternary Structure: Multiple polypeptide chains may assemble form complex protein\n\nTranscription: DNA transcribed mRNA nucleusTranslation: mRNA translated protein ribosomes cytoplasm\nmRNA binds ribosomes\ntRNA molecules bring specific amino acids ribosome\nAmino acids linked together peptide bonds form polypeptide chain\nmRNA binds ribosomestRNA molecules bring specific amino acids ribosomeAmino acids linked together peptide bonds form polypeptide chainPost-Translational Modification: polypeptide chain modified form functional protein\nFolding: polypeptide chain folds specific three-dimensional structure\nModification: Chemical groups may added removed (e.g., glycosylation, phosphorylation)\nCleavage: polypeptide chain may cleaved smaller fragments\nQuaternary Structure: Multiple polypeptide chains may assemble form complex protein\nFolding: polypeptide chain folds specific three-dimensional structureModification: Chemical groups may added removed (e.g., glycosylation, phosphorylation)Cleavage: polypeptide chain may cleaved smaller fragmentsQuaternary Structure: Multiple polypeptide chains may assemble form complex proteinRegulation\nTranscription Factors: Regulate transcription genes\nmRNA Stability: Affects amount protein produced\nRibosome Availability: Affects rate translation\nPost-Translational Modification: Can activate inactivate proteins\nTranscription Factors: Regulate transcription genesmRNA Stability: Affects amount protein producedRibosome Availability: Affects rate translationPost-Translational Modification: Can activate inactivate proteins","code":""},{"path":"metabolic-4.html","id":"protein-degradation","chapter":"Metabolic","heading":"Protein Degradation","text":"Purpose: break proteins amino acidsLocation: Lysosomes proteasomesProcess\nLysosomal Degradation\nProteins taken lysosomes\nLysosomes contain proteases degrade proteins amino acids\n\nUbiquitin-Proteasome Pathway\nProteins tagged ubiquitin\nUbiquitinated proteins degraded proteasomes small peptides\nPeptides degraded amino acids\n\nLysosomal Degradation\nProteins taken lysosomes\nLysosomes contain proteases degrade proteins amino acids\nProteins taken lysosomesLysosomes contain proteases degrade proteins amino acidsUbiquitin-Proteasome Pathway\nProteins tagged ubiquitin\nUbiquitinated proteins degraded proteasomes small peptides\nPeptides degraded amino acids\nProteins tagged ubiquitinUbiquitinated proteins degraded proteasomes small peptidesPeptides degraded amino acidsRegulation\nUbiquitin Ligases: Regulate ubiquitination proteins\nProteasome Activity: Regulated ATP factors\nUbiquitin Ligases: Regulate ubiquitination proteinsProteasome Activity: Regulated ATP factors","code":""},{"path":"metabolic-4.html","id":"amino-acid-metabolism","chapter":"Metabolic","heading":"Amino Acid Metabolism","text":"Purpose: convert amino acids molecules, including energy, glucose, lipids, specialized productsTransamination\nTransfer amino group amino acid keto acid\nCatalyzed aminotransferases (transaminases)\nRequires pyridoxal phosphate (vitamin B6) cofactor\nImportant synthesizing non-essential amino acids\nTransfer amino group amino acid keto acidCatalyzed aminotransferases (transaminases)Requires pyridoxal phosphate (vitamin B6) cofactorImportant synthesizing non-essential amino acidsDeamination\nRemoval amino group amino acid\nProduces ammonia (NH3)\nAmmonia toxic must converted urea excretion\nRemoval amino group amino acidProduces ammonia (NH3)Ammonia toxic must converted urea excretionUrea Cycle\nConversion ammonia urea\nOccurs liver\nInvolves series enzymatic reactions\nUrea excreted urine\nConversion ammonia ureaOccurs liverInvolves series enzymatic reactionsUrea excreted urineSynthesis Specialized Products\nAmino acids used synthesize variety specialized products, including:\nNeurotransmitters (e.g., serotonin, dopamine)\nHormones (e.g., thyroid hormones)\nPurines Pyrimidines (building blocks DNA RNA)\nPorphyrins (e.g., heme)\nCreatine\n\nAmino acids used synthesize variety specialized products, including:\nNeurotransmitters (e.g., serotonin, dopamine)\nHormones (e.g., thyroid hormones)\nPurines Pyrimidines (building blocks DNA RNA)\nPorphyrins (e.g., heme)\nCreatine\nNeurotransmitters (e.g., serotonin, dopamine)Hormones (e.g., thyroid hormones)Purines Pyrimidines (building blocks DNA RNA)Porphyrins (e.g., heme)CreatineRegulation\nHormonal Control: Insulin, glucagon, cortisol regulate amino acid metabolism\nAllosteric Regulation: Enzymes amino acid metabolic pathways regulated allosteric effectors\nSubstrate Availability: availability amino acids affects rate metabolism\nHormonal Control: Insulin, glucagon, cortisol regulate amino acid metabolismAllosteric Regulation: Enzymes amino acid metabolic pathways regulated allosteric effectorsSubstrate Availability: availability amino acids affects rate metabolism","code":""},{"path":"metabolic-4.html","id":"creatine-metabolism","chapter":"Metabolic","heading":"Creatine Metabolism","text":"Purpose: synthesize creatine phosphocreatine, important energy storage muscle cellsProcess\nSynthesis Creatine\nArginine + Glycine → Guanidinoacetate + Ornithine (kidney)\nGuanidinoacetate + SAM → Creatine + SAH (liver)\n\nTransport Muscle\nCreatine transported liver muscle cells\n\nPhosphorylation Creatine\nCreatine + ATP ↔︎ Phosphocreatine + ADP (catalyzed creatine kinase)\n\nUse Phosphocreatine\nPhosphocreatine used regenerate ATP muscle contraction\n\nDegradation Creatine Phosphocreatine\nCreatine phosphocreatine spontaneously converted creatinine\nCreatinine excreted urine\n\nSynthesis Creatine\nArginine + Glycine → Guanidinoacetate + Ornithine (kidney)\nGuanidinoacetate + SAM → Creatine + SAH (liver)\nArginine + Glycine → Guanidinoacetate + Ornithine (kidney)Guanidinoacetate + SAM → Creatine + SAH (liver)Transport Muscle\nCreatine transported liver muscle cells\nCreatine transported liver muscle cellsPhosphorylation Creatine\nCreatine + ATP ↔︎ Phosphocreatine + ADP (catalyzed creatine kinase)\nCreatine + ATP ↔︎ Phosphocreatine + ADP (catalyzed creatine kinase)Use Phosphocreatine\nPhosphocreatine used regenerate ATP muscle contraction\nPhosphocreatine used regenerate ATP muscle contractionDegradation Creatine Phosphocreatine\nCreatine phosphocreatine spontaneously converted creatinine\nCreatinine excreted urine\nCreatine phosphocreatine spontaneously converted creatinineCreatinine excreted urineClinical Significance\nCreatine kinase (CK) used marker muscle damage\nCreatinine used measure kidney function\nCreatine kinase (CK) used marker muscle damageCreatinine used measure kidney function","code":""},{"path":"metabolic-4.html","id":"key-terms-29","chapter":"Metabolic","heading":"Key Terms","text":"Protein Synthesis: production proteins amino acidsProtein Degradation: breakdown proteins amino acidsAmino Acid Metabolism: processing amino acids energy, glucose, lipids, specialized productsTransamination: transfer amino group amino acid keto acidDeamination: removal amino group amino acidUrea Cycle: conversion ammonia ureaCreatine: molecule stores energy muscle cellsPhosphocreatine: phosphorylated form creatine stores energyCreatinine: waste product formed breakdown creatine phosphocreatineRibosome: cellular structure synthesizes proteinstRNA (transfer RNA): RNA molecule brings amino acids ribosomemRNA (messenger RNA): RNA molecule carries genetic code DNA ribosomeTranscription: process copying DNA RNATranslation: process converting mRNA proteinProtease: enzyme breaks proteinsAminotransferase (Transaminase): enzyme catalyzes transfer amino groupSAM (S-Adenosylmethionine): methyl donor biochemical reactionsSAH (S-Adenosylhomocysteine): product SAM-dependent methylation reactionsHormones: Molecules synthesized amino acids act signaling molecule. examples include, thyroxine, epinephrine, dopamineNeurotransmitters: Signaling molecules responsible transmitting messages neurons. Amino acids building blocks neurotransmitters GABA, glutamate, dopamine, serotonin, etcPurines Pyrimidines: nitrogenous compounds essential components genetic material (DNA & RNA)Porphyrins: group heterocyclic organic compounds, often forming ring. porphyrin crucial building block heme-containing molecules include hemoglobin cytochromes","code":""},{"path":"physiology-4.html","id":"physiology-4","chapter":"Physiology","heading":"Physiology","text":"Protein nitrogen balance essential health. Abnormalities protein metabolism can lead variety disorders","code":""},{"path":"physiology-4.html","id":"normal-states-3","chapter":"Physiology","heading":"Normal States","text":"Nitrogen Balance: Intake nitrogen equals excretion nitrogenNormal Protein Synthesis Degradation: Balanced synthesis degradation proteinsNormal Amino Acid Levels: Appropriate levels amino acids blood tissues","code":""},{"path":"physiology-4.html","id":"nitrogen-balance","chapter":"Physiology","heading":"Nitrogen Balance","text":"Nitrogen balance state amount nitrogen consumed (primarily protein) equals amount nitrogen excreted (primarily urea)Positive Nitrogen Balance: Nitrogen intake exceeds nitrogen excretion, indicating net protein synthesis. occurs growth, pregnancy, recovery illnessNegative Nitrogen Balance: Nitrogen excretion exceeds nitrogen intake, indicating net protein breakdown. occurs starvation, severe illness, traumaFactors Affecting Nitrogen Balance\nDietary protein intake\nHormonal status (e.g., growth hormone, insulin, cortisol)\nIllness stress\nPhysical activity\nDietary protein intakeHormonal status (e.g., growth hormone, insulin, cortisol)Illness stressPhysical activity","code":""},{"path":"physiology-4.html","id":"normal-protein-synthesis-and-degradation","chapter":"Physiology","heading":"Normal Protein Synthesis and Degradation","text":"Protein synthesis degradation continuous processes occur cellsProtein synthesis regulated :\nAvailability amino acids\nHormonal signals\nEnergy availability\nGenetic factors\nAvailability amino acidsHormonal signalsEnergy availabilityGenetic factorsProtein degradation regulated :\nLysosomal degradation\nUbiquitin-proteasome pathway\nLysosomal degradationUbiquitin-proteasome pathwayThe balance protein synthesis degradation essential maintaining tissue mass function","code":""},{"path":"physiology-4.html","id":"normal-amino-acid-levels","chapter":"Physiology","heading":"Normal Amino Acid Levels","text":"Amino acids present blood tissues specific concentrationsEssential Amino Acids: Must obtained dietNon-Essential Amino Acids: Can synthesized bodyAmino acid levels regulated :\nDietary intake\nProtein synthesis degradation\nTransamination deamination\nHormonal signals\nRenal function\nDietary intakeProtein synthesis degradationTransamination deaminationHormonal signalsRenal function","code":""},{"path":"physiology-4.html","id":"abnormal-states-4","chapter":"Physiology","heading":"Abnormal States","text":"Protein-Energy Malnutrition (PEM): Insufficient intake protein energyAmino Acid Disorders: Genetic defects amino acid metabolismUrea Cycle Disorders: Genetic defects urea cycleHyperammonemia: Elevated ammonia levels bloodProteinuria: Presence excess protein urineHypoproteinemia: Abnormally low levels protein blood","code":""},{"path":"physiology-4.html","id":"protein-energy-malnutrition-pem","chapter":"Physiology","heading":"Protein-Energy Malnutrition (PEM)","text":"Definition: condition caused insufficient intake protein energy, leading depletion body protein storesTypes\nMarasmus: Severe deficiency calories, leading wasting muscle fat\nKwashiorkor: Adequate calorie intake severe deficiency protein, leading edema ascites\nMarasmus: Severe deficiency calories, leading wasting muscle fatKwashiorkor: Adequate calorie intake severe deficiency protein, leading edema ascitesPathophysiology\nInadequate intake protein energy leads :\nDecreased protein synthesis\nIncreased protein degradation\nDepletion body protein stores\nImpaired immune function\nOrgan dysfunction\n\nInadequate intake protein energy leads :\nDecreased protein synthesis\nIncreased protein degradation\nDepletion body protein stores\nImpaired immune function\nOrgan dysfunction\nDecreased protein synthesisIncreased protein degradationDepletion body protein storesImpaired immune functionOrgan dysfunctionLaboratory Findings\nDecreased serum albumin prealbumin levels\nDecreased transferrin retinol-binding protein levels\nDecreased lymphocyte count\nNegative nitrogen balance\nDecreased serum albumin prealbumin levelsDecreased transferrin retinol-binding protein levelsDecreased lymphocyte countNegative nitrogen balanceSymptoms\nWasting muscle fat\nEdema ascites (Kwashiorkor)\nGrowth retardation (children)\nImpaired immune function\nIncreased susceptibility infections\nWasting muscle fatEdema ascites (Kwashiorkor)Growth retardation (children)Impaired immune functionIncreased susceptibility infections","code":""},{"path":"physiology-4.html","id":"amino-acid-disorders","chapter":"Physiology","heading":"Amino Acid Disorders","text":"Definition: Genetic defects amino acid metabolism, leading accumulation specific amino acids /metabolitesPathophysiology\nEnzyme deficiencies disrupt metabolic pathways, leading :\nAccumulation substrates\nDeficiency products\nToxic effects accumulated metabolites\n\nEnzyme deficiencies disrupt metabolic pathways, leading :\nAccumulation substrates\nDeficiency products\nToxic effects accumulated metabolites\nAccumulation substratesDeficiency productsToxic effects accumulated metabolitesLaboratory Findings\nElevated levels specific amino acids blood urine\nReduced absent enzyme activity affected tissues\nElevated levels specific amino acids blood urineReduced absent enzyme activity affected tissuesSymptoms\nVaries depending specific amino acid disorder metabolic pathway affected\nVaries depending specific amino acid disorder metabolic pathway affectedExamples\nPhenylketonuria (PKU): Deficiency phenylalanine hydroxylase (PAH)\nElevated phenylalanine levels blood\nIntellectual disability, seizures\n\nMaple Syrup Urine Disease (MSUD): Deficiency branched-chain alpha-keto acid dehydrogenase (BCKDH)\nElevated levels branched-chain amino acids (leucine, isoleucine, valine) blood urine\nNeurological dysfunction, feeding difficulties, maple syrup odor urine\n\nHomocystinuria: Deficiency cystathionine beta-synthase (CBS)\nElevated homocysteine levels blood urine\nCardiovascular disease, thromboembolism, intellectual disability\n\nAlkaptonuria: Deficiency homogentisate 1,2-dioxygenase\nAccumulation homogentisic acid tissues urine\nDarkening urine upon exposure air, ochronosis (pigmentation cartilage), arthritis\n\nPhenylketonuria (PKU): Deficiency phenylalanine hydroxylase (PAH)\nElevated phenylalanine levels blood\nIntellectual disability, seizures\nElevated phenylalanine levels bloodIntellectual disability, seizuresMaple Syrup Urine Disease (MSUD): Deficiency branched-chain alpha-keto acid dehydrogenase (BCKDH)\nElevated levels branched-chain amino acids (leucine, isoleucine, valine) blood urine\nNeurological dysfunction, feeding difficulties, maple syrup odor urine\nElevated levels branched-chain amino acids (leucine, isoleucine, valine) blood urineNeurological dysfunction, feeding difficulties, maple syrup odor urineHomocystinuria: Deficiency cystathionine beta-synthase (CBS)\nElevated homocysteine levels blood urine\nCardiovascular disease, thromboembolism, intellectual disability\nElevated homocysteine levels blood urineCardiovascular disease, thromboembolism, intellectual disabilityAlkaptonuria: Deficiency homogentisate 1,2-dioxygenase\nAccumulation homogentisic acid tissues urine\nDarkening urine upon exposure air, ochronosis (pigmentation cartilage), arthritis\nAccumulation homogentisic acid tissues urineDarkening urine upon exposure air, ochronosis (pigmentation cartilage), arthritis","code":""},{"path":"physiology-4.html","id":"urea-cycle-disorders","chapter":"Physiology","heading":"Urea Cycle Disorders","text":"Definition: Genetic defects enzymes urea cycle, leading impaired conversion ammonia ureaPathophysiology\nEnzyme deficiencies disrupt urea cycle, leading :\nAccumulation ammonia blood (hyperammonemia)\nDeficiency urea\n\nEnzyme deficiencies disrupt urea cycle, leading :\nAccumulation ammonia blood (hyperammonemia)\nDeficiency urea\nAccumulation ammonia blood (hyperammonemia)Deficiency ureaLaboratory Findings\nElevated ammonia levels blood\nDecreased blood urea nitrogen (BUN) levels\nElevated ammonia levels bloodDecreased blood urea nitrogen (BUN) levelsSymptoms\nVomiting, irritability, lethargy, seizures, coma\nVomiting, irritability, lethargy, seizures, comaExamples\nOrnithine Transcarbamylase Deficiency (OTC): common urea cycle disorder\nElevated ammonia levels blood\nNeurological symptoms\n\nCarbamoyl Phosphate Synthetase Deficiency (CPS ): Deficiency first enzyme urea cycle\nElevated ammonia levels blood\nNeurological symptoms\n\nOrnithine Transcarbamylase Deficiency (OTC): common urea cycle disorder\nElevated ammonia levels blood\nNeurological symptoms\nElevated ammonia levels bloodNeurological symptomsCarbamoyl Phosphate Synthetase Deficiency (CPS ): Deficiency first enzyme urea cycle\nElevated ammonia levels blood\nNeurological symptoms\nElevated ammonia levels bloodNeurological symptoms","code":""},{"path":"physiology-4.html","id":"hyperammonemia","chapter":"Physiology","heading":"Hyperammonemia","text":"Definition: Elevated ammonia levels bloodCauses\nUrea cycle disorders\nLiver failure\nReye’s syndrome\nCertain medications\nUrea cycle disordersLiver failureReye’s syndromeCertain medicationsPathophysiology\nElevated ammonia levels toxic brain, leading :\nCerebral edema\nSeizures\nComa\nDeath\n\nElevated ammonia levels toxic brain, leading :\nCerebral edema\nSeizures\nComa\nDeath\nCerebral edemaSeizuresComaDeathLaboratory Findings\nElevated ammonia levels blood\nElevated ammonia levels blood","code":""},{"path":"physiology-4.html","id":"proteinuria","chapter":"Physiology","heading":"Proteinuria","text":"Definition: Presence excess protein urineCauses\nKidney disease (e.g., glomerulonephritis, nephrotic syndrome)\nDiabetes\nHypertension\nMultiple myeloma\nKidney disease (e.g., glomerulonephritis, nephrotic syndrome)DiabetesHypertensionMultiple myelomaPathophysiology\nDamage glomeruli tubules kidneys leads increased protein excretion urine\nDamage glomeruli tubules kidneys leads increased protein excretion urineLaboratory Findings\nElevated protein levels urine\nAlbumin common protein detected\nElevated protein levels urineAlbumin common protein detectedSymptoms\nFoamy urine\nEdema\nFatigue\nFoamy urineEdemaFatigue","code":""},{"path":"physiology-4.html","id":"hypoproteinemia","chapter":"Physiology","heading":"Hypoproteinemia","text":"Definition: Abnormally low levels protein bloodCauses\nMalnutrition\nLiver disease (impaired protein synthesis)\nKidney disease (protein loss urine)\nInflammatory bowel disease (impaired protein absorption)\nMalnutritionLiver disease (impaired protein synthesis)Kidney disease (protein loss urine)Inflammatory bowel disease (impaired protein absorption)Pathophysiology\nReduced protein synthesis increased protein loss leads :\nDecreased serum albumin levels\nEdema\nImpaired immune function\nIncreased susceptibility infections\n\nReduced protein synthesis increased protein loss leads :\nDecreased serum albumin levels\nEdema\nImpaired immune function\nIncreased susceptibility infections\nDecreased serum albumin levelsEdemaImpaired immune functionIncreased susceptibility infectionsLaboratory Findings\nDecreased serum albumin total protein levels\nDecreased serum albumin total protein levels","code":""},{"path":"physiology-4.html","id":"key-terms-30","chapter":"Physiology","heading":"Key Terms","text":"Nitrogen Balance: balance nitrogen intake excretionProtein Synthesis: production proteins amino acidsProtein Degradation: breakdown proteins amino acidsEssential Amino Acids: Amino acids must obtained dietNon-Essential Amino Acids: Amino acids can synthesized bodyProtein-Energy Malnutrition (PEM): condition caused insufficient intake protein energyAmino Acid Disorders: Genetic defects amino acid metabolismUrea Cycle Disorders: Genetic defects urea cycleHyperammonemia: Elevated ammonia levels bloodProteinuria: Presence excess protein urineHypoproteinemia: Abnormally low levels protein bloodAlbumin: major protein bloodGlomeruli: Filtering units within kidneyTubules: Portion nephron carrying filtrate glomerulusEdema: Swelling caused excess fluid trapped body’s tissuesAscites: accumulation fluid peritoneal cavity, causing abdominal swellingLymphocytes: type white blood cell part immune systemAnabolism: synthesis complex molecules simpler ones, energy-consuming processCatabolism: breakdown complex molecules simpler ones, releasing energyProteases: enzyme breaks proteins peptidesLysosomal Degradation: Degradation occurs lysosomesUbiquitin-Proteasome Pathway: major pathway protein degradation eukaryotesTransamination: transfer amino group one molecule anotherDeamination: removal amino group moleculeOchronosis: condition characterized abnormal accumulation homogentisic acid connective tissues, leading bluish-black discolorationGlomerulonephritis: Inflammation glomeruli, filtering units kidneysNephrotic Syndrome: kidney disorder characterized proteinuria, hypoalbuminemia, edemaMyeloma: cancer plasma cellsInflammatory Bowel Disease (IBD): group inflammatory conditions colon small intestineMitochondria: Membrane-bound cell organelles (mitochondrion, singular) generate chemical energy needed power cell’s biochemical reactions. Chemical energy produced mitochondria stored small molecule called adenosine triphosphate (ATP)Endoplasmic Reticulum: network membranes inside cell proteins molecules move. Proteins synthesized ribosomes attached endoplasmic reticulumCytosol: part cytoplasm contain organellesEnzyme: substance produced living organism acts catalyst bring specific biochemical reactionReceptors: protein molecule receives responds chemical signalOrganelles: number organized specialized structures within living cell","code":""},{"path":"properties-4.html","id":"properties-4","chapter":"Properties","heading":"Properties","text":"Understanding physical chemical properties proteins nitrogen-containing compounds crucial accurate measurement interpretation clinical laboratoryKey Compounds\nProteins\nAmino Acids\nUrea\nUric Acid\nCreatinine\nAmmonia\nTumor Markers (CEA, PSA, AFP, CA 125)\nCardiac Markers (Troponin, CK-MB, Myoglobin)\nProteinsAmino AcidsUreaUric AcidCreatinineAmmoniaTumor Markers (CEA, PSA, AFP, CA 125)Cardiac Markers (Troponin, CK-MB, Myoglobin)","code":""},{"path":"properties-4.html","id":"proteins-1","chapter":"Properties","heading":"Proteins","text":"Definition: Large molecules composed amino acids linked peptide bonds. essential structure, function, regulation living organismsStructure\nPrimary: linear sequence amino acids\nSecondary: Local folding patterns (alpha-helices, beta-sheets) stabilized hydrogen bonds\nTertiary: overall three-dimensional structure, determined interactions amino acid side chains\nQuaternary: arrangement multiple polypeptide chains multi-subunit protein\nPrimary: linear sequence amino acidsSecondary: Local folding patterns (alpha-helices, beta-sheets) stabilized hydrogen bondsTertiary: overall three-dimensional structure, determined interactions amino acid side chainsQuaternary: arrangement multiple polypeptide chains multi-subunit proteinPhysical Properties\nMolecular Weight: Varies widely depending number type amino acids\nSolubility: Varies depending amino acid composition three-dimensional structure\nAmphoteric Nature: Proteins acidic basic groups can act zwitterions\nOptical Activity: Proteins chiral exhibit optical activity\nColloidal Properties: Proteins form colloidal solutions water\nMolecular Weight: Varies widely depending number type amino acidsSolubility: Varies depending amino acid composition three-dimensional structureAmphoteric Nature: Proteins acidic basic groups can act zwitterionsOptical Activity: Proteins chiral exhibit optical activityColloidal Properties: Proteins form colloidal solutions waterChemical Properties\nPeptide Bond Formation: Amino acids linked peptide bonds\nDenaturation: Proteins can denatured heat, pH changes, organic solvents, detergents, leading loss structure function\nHydrolysis: Proteins can hydrolyzed acids, bases, enzymes, breaking peptide bonds releasing amino acids\nAmphoteric Nature: Proteins can act acids bases due presence ionizable groups\nColor Reactions: Proteins react various reagents produce colored products, used protein quantification assays\nPeptide Bond Formation: Amino acids linked peptide bondsDenaturation: Proteins can denatured heat, pH changes, organic solvents, detergents, leading loss structure functionHydrolysis: Proteins can hydrolyzed acids, bases, enzymes, breaking peptide bonds releasing amino acidsAmphoteric Nature: Proteins can act acids bases due presence ionizable groupsColor Reactions: Proteins react various reagents produce colored products, used protein quantification assays","code":""},{"path":"properties-4.html","id":"amino-acids","chapter":"Properties","heading":"Amino Acids","text":"Definition: Organic molecules containing amino group (-NH2), carboxyl group (-COOH), hydrogen atom (-H), unique side chain (R group) attached central carbon atomStructure\nAlpha Carbon: central carbon atom amino carboxyl groups attached\nAmino Group: basic group (-NH2)\nCarboxyl Group: acidic group (-COOH)\nSide Chain (R Group): unique group determines identity properties amino acid\nAlpha Carbon: central carbon atom amino carboxyl groups attachedAmino Group: basic group (-NH2)Carboxyl Group: acidic group (-COOH)Side Chain (R Group): unique group determines identity properties amino acidPhysical Properties\nSolid Room Temperature: Amino acids crystalline solids room temperature\nSolubility: Soluble water\nAmphoteric Nature: Amino acids acidic basic groups can act zwitterions\nOptical Activity: amino acids except glycine chiral exhibit optical activity\nSolid Room Temperature: Amino acids crystalline solids room temperatureSolubility: Soluble waterAmphoteric Nature: Amino acids acidic basic groups can act zwitterionsOptical Activity: amino acids except glycine chiral exhibit optical activityChemical Properties\nPeptide Bond Formation: Amino acids linked peptide bonds form proteins\nAmphoteric Nature: Amino acids can act acids bases due presence ionizable groups\nReactions Side Chains: side chains amino acids undergo various chemical reactions, contributing protein function modification\nReactions Ninhydrin: Amino acids react ninhydrin form colored product, used amino acid quantification assays\nPeptide Bond Formation: Amino acids linked peptide bonds form proteinsAmphoteric Nature: Amino acids can act acids bases due presence ionizable groupsReactions Side Chains: side chains amino acids undergo various chemical reactions, contributing protein function modificationReactions Ninhydrin: Amino acids react ninhydrin form colored product, used amino acid quantification assays","code":""},{"path":"properties-4.html","id":"urea","chapter":"Properties","heading":"Urea","text":"Definition: nitrogen-containing compound (NH2-CO-NH2) major end product protein metabolism mammals. synthesized liver excreted urineStructure\nMolecular Formula: CH4N2O\nAmide Groups: Two amide groups (-NH2) attached carbonyl group (C=O)\nMolecular Formula: CH4N2OAmide Groups: Two amide groups (-NH2) attached carbonyl group (C=O)Physical Properties\nSolid Room Temperature: Urea crystalline solid room temperature\nSolubility: Highly soluble water alcohol\nOdorless: Pure urea odorless, can decompose form ammonia, pungent odor\nSolid Room Temperature: Urea crystalline solid room temperatureSolubility: Highly soluble water alcoholOdorless: Pure urea odorless, can decompose form ammonia, pungent odorChemical Properties\nNeutral pH: Urea neutral pH solution\nHydrolysis: Urea can hydrolyzed urease, enzyme, produce ammonia carbon dioxide\nBiuret Reaction: Urea reacts biuret reagent form colored product, used urea quantification assays\nDecomposition: Urea decomposes upon heating form ammonia products\nNeutral pH: Urea neutral pH solutionHydrolysis: Urea can hydrolyzed urease, enzyme, produce ammonia carbon dioxideBiuret Reaction: Urea reacts biuret reagent form colored product, used urea quantification assaysDecomposition: Urea decomposes upon heating form ammonia products","code":""},{"path":"properties-4.html","id":"uric-acid","chapter":"Properties","heading":"Uric Acid","text":"Definition: nitrogen-containing compound (C5H4N4O3) major end product purine metabolism humans. excreted urineStructure\nHeterocyclic Compound: Contains fused pyrimidine imidazole rings\nKeto-Enol Tautomerism: Exists keto enol forms\nHeterocyclic Compound: Contains fused pyrimidine imidazole ringsKeto-Enol Tautomerism: Exists keto enol formsPhysical Properties\nSolid Room Temperature: Uric acid crystalline solid room temperature\nSolubility: Sparingly soluble water\npH: Weakly acidic\nSolid Room Temperature: Uric acid crystalline solid room temperatureSolubility: Sparingly soluble waterpH: Weakly acidicChemical Properties\nSalt Formation: Forms salts metals\nOxidation: Can oxidized allantoin uricase\nReduction: Can reduced xanthine\nReaction Phosphotungstic Acid: Reacts phosphotungstic acid form colored product, used uric acid quantification assays\nSalt Formation: Forms salts metalsOxidation: Can oxidized allantoin uricaseReduction: Can reduced xanthineReaction Phosphotungstic Acid: Reacts phosphotungstic acid form colored product, used uric acid quantification assays","code":""},{"path":"properties-4.html","id":"creatinine","chapter":"Properties","heading":"Creatinine","text":"Definition: nitrogen-containing compound (C4H7N3O) waste product muscle metabolism. formed creatine phosphocreatine excreted urineStructure\nCyclic Amide: Contains cyclic amide group\nCyclic Amide: Contains cyclic amide groupPhysical Properties\nSolid Room Temperature: Creatinine crystalline solid room temperature\nSolubility: Soluble water\nSolid Room Temperature: Creatinine crystalline solid room temperatureSolubility: Soluble waterChemical Properties\nTautomerism: Exists different tautomeric forms\nPicrate Reaction (Jaffe Reaction): Reacts picric acid alkaline solution form colored product, used creatinine quantification assays\nEnzymatic Methods: Can measured using enzymatic assays convert creatinine measurable products\nTautomerism: Exists different tautomeric formsPicrate Reaction (Jaffe Reaction): Reacts picric acid alkaline solution form colored product, used creatinine quantification assaysEnzymatic Methods: Can measured using enzymatic assays convert creatinine measurable products","code":""},{"path":"properties-4.html","id":"ammonia","chapter":"Properties","heading":"Ammonia","text":"Definition: nitrogen-containing compound (NH3) product amino acid deamination metabolic processes. toxic must converted urea excretionStructure\nMolecular Formula: NH3\nTrigonal Pyramidal Shape: nitrogen atom lone pair electrons\nMolecular Formula: NH3Trigonal Pyramidal Shape: nitrogen atom lone pair electronsPhysical Properties\nGas Room Temperature: Ammonia colorless gas room temperature\nPungent Odor: characteristic pungent odor\nSolubility: Highly soluble water\nGas Room Temperature: Ammonia colorless gas room temperaturePungent Odor: characteristic pungent odorSolubility: Highly soluble waterChemical Properties\nBasic: Acts base can accept proton (H+) form ammonium ion (NH4+)\nToxicity: Toxic central nervous system\nConversion Urea: Converted urea liver urea cycle\nReaction Nessler’s Reagent: Reacts Nessler’s reagent form colored product, used ammonia quantification assays\nBasic: Acts base can accept proton (H+) form ammonium ion (NH4+)Toxicity: Toxic central nervous systemConversion Urea: Converted urea liver urea cycleReaction Nessler’s Reagent: Reacts Nessler’s reagent form colored product, used ammonia quantification assays","code":""},{"path":"properties-4.html","id":"tumor-markers","chapter":"Properties","heading":"Tumor Markers","text":"Definition: Substances produced cancer cells cells body response cancer certain benign (noncancerous) conditions. often proteins glycoproteinsCEA (Carcinoembryonic Antigen)\nGlycoprotein involved cell adhesion\nElevated colorectal cancer, lung cancer, breast cancer, cancers\nGlycoprotein involved cell adhesionElevated colorectal cancer, lung cancer, breast cancer, cancersPSA (Prostate-Specific Antigen)\nSerine protease produced prostate gland cells\nElevated prostate cancer benign prostatic hyperplasia (BPH)\nSerine protease produced prostate gland cellsElevated prostate cancer benign prostatic hyperplasia (BPH)AFP (Alpha-Fetoprotein)\nGlycoprotein produced fetal liver yolk sac\nElevated hepatocellular carcinoma, germ cell tumors, certain cancers\nGlycoprotein produced fetal liver yolk sacElevated hepatocellular carcinoma, germ cell tumors, certain cancersCA 125 (Cancer Antigen 125)\nGlycoprotein expressed surface ovarian cancer cells\nElevated ovarian cancer certain conditions\nGlycoprotein expressed surface ovarian cancer cellsElevated ovarian cancer certain conditionsPhysical Chemical Properties\nProteins Glycoproteins: Varies depending specific marker\nSolubility: Soluble blood body fluids\nImmunogenicity: Can detected quantified using immunoassays\nProteins Glycoproteins: Varies depending specific markerSolubility: Soluble blood body fluidsImmunogenicity: Can detected quantified using immunoassaysDetection\nTypically measured using immunoassays (e.g., ELISA, chemiluminescence)\nTypically measured using immunoassays (e.g., ELISA, chemiluminescence)","code":""},{"path":"properties-4.html","id":"cardiac-markers-1","chapter":"Properties","heading":"Cardiac Markers","text":"Definition: Substances released blood heart damaged stressed. typically proteinsTroponin\nProteins involved muscle contraction\nTroponin (cTnI) Troponin T (cTnT) cardiac-specific isoforms\nElevated myocardial infarction\nProteins involved muscle contractionTroponin (cTnI) Troponin T (cTnT) cardiac-specific isoformsElevated myocardial infarctionCK-MB (Creatine Kinase-MB)\nIsoenzyme creatine kinase found primarily heart muscle\nElevated myocardial infarction\nIsoenzyme creatine kinase found primarily heart muscleElevated myocardial infarctionMyoglobin\nOxygen-binding protein found muscle tissue\nElevated myocardial infarction muscle injuries\nOxygen-binding protein found muscle tissueElevated myocardial infarction muscle injuriesPhysical Chemical Properties\nProteins: Varies depending specific marker\nSolubility: Soluble blood\nImmunogenicity: Can detected quantified using immunoassays\nProteins: Varies depending specific markerSolubility: Soluble bloodImmunogenicity: Can detected quantified using immunoassaysDetection\nTypically measured using immunoassays (e.g., ELISA, chemiluminescence)\nTypically measured using immunoassays (e.g., ELISA, chemiluminescence)","code":""},{"path":"properties-4.html","id":"key-terms-31","chapter":"Properties","heading":"Key Terms","text":"Protein: large molecule composed amino acids linked peptide bondsAmino Acid: building block proteinsPeptide Bond: covalent bond linking amino acids togetherUrea: major end product protein metabolismUric Acid: major end product purine metabolismCreatinine: waste product muscle metabolismAmmonia: toxic nitrogen-containing compoundTumor Marker: substance produced cancer cells cells response cancerCardiac Marker: substance released blood heart damagedIsoelectric Point: pH molecule net electrical chargeZwitterion: molecule positive negative electrical chargeHeterocyclic Compound: cyclic compound containing atoms least two different elements members ring(s)Tautomerism: ability certain chemical compounds exist mixture two interconvertible isomers","code":""},{"path":"procedures-4.html","id":"procedures-4","chapter":"Procedures","heading":"Procedures","text":"Understanding principles procedures testing proteins nitrogen compounds key clinical diagnosis. Proper technique careful attention detail produce accurate reliable data","code":""},{"path":"procedures-4.html","id":"principles-of-laboratory-tests","chapter":"Procedures","heading":"Principles of Laboratory Tests","text":"Tests measure levels proteins nitrogen-containing compounds bodily fluids, using variety chemical immunochemical techniquesTotal Protein: Biuret reaction (measures peptide bonds)Albumin: Dye-binding methods (Bromcresol Green Bromcresol Purple)Prealbumin: Immunochemical MethodsGlobulins: Calculated (Total Protein - Albumin)Urea (BUN): Enzymatic (urease) direct chemical methodsCreatinine: Jaffe reaction enzymatic methodsUric Acid: Enzymatic (uricase) chemical methodsAmmonia: Enzymatic ion-selective electrode (ISE) methodsCSF Protein: Biuret dye-binding methodsUrine Protein: Turbidimetric dye-binding methodsProtein Electrophoresis: Separates proteins charge/sizeImmunofixation Electrophoresis (IFE): Identifies monoclonal proteinsTumor Markers: ImmunoassaysCardiac Markers: Immunoassays","code":""},{"path":"procedures-4.html","id":"special-precautions-7","chapter":"Procedures","heading":"Special Precautions","text":"Patient preparation handling specimens correctly groundwork reliable resultsPatient Preparation: Fasting, medication review, hydration status, postureSpecimen Collection\nCorrect specimen tube type\nProper order draw\nMinimize tourniquet time\nClean venipuncture technique\nCorrect specimen tube typeProper order drawMinimize tourniquet timeClean venipuncture techniqueSpecimen Handling Processing\nProcess specimens promptly\nProper centrifugation techniques\nAppropriate storage conditions (temperature, light exposure)\nProcess specimens promptlyProper centrifugation techniquesAppropriate storage conditions (temperature, light exposure)Analytical Considerations\nReagent Quality: Check expiration dates storage conditions\nCalibration: Use appropriate standards calibrate regularly\nQuality Control (QC): Run controls regularly, evaluate results\nInstrumentation: Proper instrument maintenance function\nReagent Quality: Check expiration dates storage conditionsCalibration: Use appropriate standards calibrate regularlyQuality Control (QC): Run controls regularly, evaluate resultsInstrumentation: Proper instrument maintenance function","code":""},{"path":"procedures-4.html","id":"troubleshooting-8","chapter":"Procedures","heading":"Troubleshooting","text":"Recognizing causes errors ensure accuracy measurementsHigh Low Results\nPre-Analytical: Patient factors, collection/processing errors\nAnalytical: Reagents, calibration, interferences, instrument malfunction\nPre-Analytical: Patient factors, collection/processing errorsAnalytical: Reagents, calibration, interferences, instrument malfunctionInconsistent Results\nReview patient preparation\nCheck collection, processing, reagents, calibration\nConsider interfering substances\nRepeat test, use different method\nReview patient preparationCheck collection, processing, reagents, calibrationConsider interfering substancesRepeat test, use different methodOut--Control QC\nCheck QC materials, reagents, calibration\nRepeat QC testing\nContact manufacturer problem persists\nCheck QC materials, reagents, calibrationRepeat QC testingContact manufacturer problem persists","code":""},{"path":"procedures-4.html","id":"interfering-substances-8","chapter":"Procedures","heading":"Interfering Substances","text":"Endogenous substances exogenous contaminants can throw lab results. aware potential interferences can minimize errorEndogenous: Lipemia, hemolysis, bilirubin, high protein concentrationsExogenous: Medications, anticoagulants, contaminantsMinimizing Interferences\nUse methods less susceptible interference\nEmploy techniques remove correct interferences\nDilute sample (appropriate)\nUse blanking background subtraction\nUse methods less susceptible interferenceEmploy techniques remove correct interferencesDilute sample (appropriate)Use blanking background subtraction","code":""},{"path":"procedures-4.html","id":"clearances","chapter":"Procedures","heading":"Clearances","text":"Clearance tests measure rate substance removed blood kidneys, reflecting kidney functionCreatinine Clearance\nCollection: 24-hour urine collection, serum sample\nPrinciple: Measures rate creatinine removed blood kidneys\nFormula: C = (U x V) / P\nEstimating GFR: Estimated Glomerular Filtration Rate (eGFR) Equations\nCollection: 24-hour urine collection, serum samplePrinciple: Measures rate creatinine removed blood kidneysFormula: C = (U x V) / PEstimating GFR: Estimated Glomerular Filtration Rate (eGFR) EquationsUrea Clearance\nUrine collected one hour\nUrea concentrations measured determine kidney function\nUrine collected one hourUrea concentrations measured determine kidney function","code":""},{"path":"principles-4.html","id":"principles-4","chapter":"Principles","heading":"Principles","text":"Labs perform many tests assess protein status nitrogen balance. Understanding principles key accurate testingTotal ProteinAlbuminPrealbumin (Transthyretin)GlobulinsUrea (Blood Urea Nitrogen - BUN)CreatinineUric AcidAmmoniaCerebrospinal Fluid (CSF) ProteinUrine ProteinProtein Electrophoresis (Serum Urine)Immunofixation Electrophoresis (IFE)Tumor Markers (PSA, AFP, CEA, CA-125, etc.)","code":""},{"path":"principles-4.html","id":"total-protein","chapter":"Principles","heading":"Total Protein","text":"Principle: Biuret Reaction basis total protein assays. alkaline solution, peptide bonds react copper(II) ions (Cu2+) form colored complex. intensity colored complex directly proportional number peptide bonds, therefore protein concentration, sampleReactions\nPeptide Bonds + Cu2+ (Alkaline Solution) → Colored Complex\nPeptide Bonds + Cu2+ (Alkaline Solution) → Colored ComplexComponents Biuret Reagent\nCopper(II) Sulfate (CuSO4): Provides Cu2+ ions\nSodium Potassium Tartrate: Chelates Cu2+ ions prevent precipitation\nSodium Hydroxide (NaOH): Provides alkaline environment\nPotassium Iodide (KI): Prevents reduction Cu2+\nCopper(II) Sulfate (CuSO4): Provides Cu2+ ionsSodium Potassium Tartrate: Chelates Cu2+ ions prevent precipitationSodium Hydroxide (NaOH): Provides alkaline environmentPotassium Iodide (KI): Prevents reduction Cu2+Detection: intensity colored complex measured spectrophotometrically wavelength 540-560 nmAdvantages: Simple, widely available, relatively inexpensiveDisadvantages: Susceptible interferences lipemia, hemolysis, icterus","code":""},{"path":"principles-4.html","id":"albumin","chapter":"Principles","heading":"Albumin","text":"Principle: Dye-binding methods commonly used. Albumin binds dye (e.g., bromcresol green bromcresol purple) specific pH, causing change dye’s absorbance. change absorbance directly proportional albumin concentrationDyes Used\nBromcresol Green (BCG): pH 4.2, BCG binds albumin, causing color change\nBromcresol Purple (BCP): pH 5.2, BCP binds albumin, causing color change\nBromcresol Green (BCG): pH 4.2, BCG binds albumin, causing color changeBromcresol Purple (BCP): pH 5.2, BCP binds albumin, causing color changeReactions\nAlbumin + Dye → Albumin-Dye Complex (Colored)\nAlbumin + Dye → Albumin-Dye Complex (Colored)Detection: absorbance Albumin-Dye Complex measured spectrophotometricallyAdvantages: Simple, rapid, automatedDisadvantages: Susceptible interferences certain medications elevated bilirubin levels","code":""},{"path":"principles-4.html","id":"prealbumin-transthyretin","chapter":"Principles","heading":"Prealbumin (Transthyretin)","text":"Principle: Immunochemical methods (e.g., nephelometry, turbidimetry) used measure prealbumin. Antibodies specific prealbumin used capture quantify prealbumin blood sampleMethods\nNephelometry\nTurbidimetry\nNephelometryTurbidimetryReactions\nPrealbumin + Prealbumin-Specific Antibody → Antibody-Prealbumin Complex\nPrealbumin + Prealbumin-Specific Antibody → Antibody-Prealbumin ComplexDetection: amount antibody-prealbumin complex formed measured, proportional prealbumin concentrationAdvantages: Specific automatedDisadvantages: Can affected interfering substances requires specialized equipment","code":""},{"path":"principles-4.html","id":"globulins","chapter":"Principles","heading":"Globulins","text":"Principle: Globulins typically measured directly, calculated subtracting albumin total protein\nGlobulins = Total Protein - Albumin\nGlobulins = Total Protein - Albumin","code":""},{"path":"principles-4.html","id":"urea-blood-urea-nitrogen---bun","chapter":"Principles","heading":"Urea (Blood Urea Nitrogen - BUN)","text":"Principle: Several methods available measuring BUN. Two common methods enzymatic method direct chemical methodEnzymatic Method (Urease Method)\nUrease hydrolyzes urea ammonia carbon dioxide. ammonia reacted chromogen produce colored product\nReactions\nUrea + H2O –(Urease)–> 2 NH3 + CO2\nNH3 + Reagent → Colored Product\n\nUrease hydrolyzes urea ammonia carbon dioxide. ammonia reacted chromogen produce colored productReactions\nUrea + H2O –(Urease)–> 2 NH3 + CO2\nNH3 + Reagent → Colored Product\nUrea + H2O –(Urease)–> 2 NH3 + CO2NH3 + Reagent → Colored ProductDirect Chemical Method (Diacetyl Monoxime Method)\nUrea reacts diacetyl monoxime presence acid catalyst form colored product\nReactions\nUrea + Diacetyl Monoxime → Colored Product\n\nUrea reacts diacetyl monoxime presence acid catalyst form colored productReactions\nUrea + Diacetyl Monoxime → Colored Product\nUrea + Diacetyl Monoxime → Colored ProductDetection: intensity colored product measured spectrophotometricallyAdvantages: methods widely available relatively inexpensiveDisadvantages: Susceptible interferences ammonia nitrogen-containing compounds","code":""},{"path":"principles-4.html","id":"creatinine-1","chapter":"Principles","heading":"Creatinine","text":"Principle: Jaffe Reaction commonly used. Creatinine reacts picric acid alkaline solution form colored Janovski complex. rate color formation measured spectrophotometricallyReactions\nCreatinine + Picric Acid (Alkaline Solution) → Janovski Complex (Colored)\nCreatinine + Picric Acid (Alkaline Solution) → Janovski Complex (Colored)Methods\nKinetic Jaffe Method: Measures rate color formation, reducing interferences\nCompensated Jaffe Method: Uses blank correct interferences\nEnzymatic Methods: Use enzymes convert creatinine measurable products\nKinetic Jaffe Method: Measures rate color formation, reducing interferencesCompensated Jaffe Method: Uses blank correct interferencesEnzymatic Methods: Use enzymes convert creatinine measurable productsDetection: intensity colored complex measured spectrophotometricallyAdvantages: Simple widely availableDisadvantages: Susceptible interferences bilirubin, glucose, certain medications","code":""},{"path":"principles-4.html","id":"uric-acid-1","chapter":"Principles","heading":"Uric Acid","text":"Principle: Several methods available measuring uric acid. Two common methods enzymatic method chemical methodEnzymatic Method (Uricase Method)\nUricase oxidizes uric acid allantoin, decrease absorbance 290 nm measured\nReactions\nUric Acid + O2 + H2O –(Uricase)–> Allantoin + H2O2 + CO2\n\nCoupled enzyme reactions can used quantify H2O2 produced\nUricase oxidizes uric acid allantoin, decrease absorbance 290 nm measuredReactions\nUric Acid + O2 + H2O –(Uricase)–> Allantoin + H2O2 + CO2\nUric Acid + O2 + H2O –(Uricase)–> Allantoin + H2O2 + CO2Coupled enzyme reactions can used quantify H2O2 producedChemical Method (Phosphotungstic Acid Method)\nUric acid reduces phosphotungstic acid tungsten blue alkaline solution\nReactions\nUric Acid + Phosphotungstic Acid → Tungsten Blue\n\nUric acid reduces phosphotungstic acid tungsten blue alkaline solutionReactions\nUric Acid + Phosphotungstic Acid → Tungsten Blue\nUric Acid + Phosphotungstic Acid → Tungsten BlueDetection: decrease absorbance 290 nm (enzymatic method) intensity tungsten blue (chemical method) measured spectrophotometricallyAdvantages: enzymatic method specific less susceptible interferencesDisadvantages: chemical method less expensive susceptible interferences","code":""},{"path":"principles-4.html","id":"ammonia-1","chapter":"Principles","heading":"Ammonia","text":"Principle: Ammonia reacts chromogen presence alkali form colored productMethods\nEnzymatic Method: Ammonia reacts α-ketoglutarate NADPH presence glutamate dehydrogenase (GLDH) form glutamate NADP+. decrease absorbance 340 nm measured\nIon-Selective Electrode (ISE) Method: Ammonia measured using ion-selective electrode\nEnzymatic Method: Ammonia reacts α-ketoglutarate NADPH presence glutamate dehydrogenase (GLDH) form glutamate NADP+. decrease absorbance 340 nm measuredIon-Selective Electrode (ISE) Method: Ammonia measured using ion-selective electrodeReactions\nNH4+ + α-Ketoglutarate + NADPH –(GLDH)–> Glutamate + NADP+ + H2O\nNH4+ + α-Ketoglutarate + NADPH –(GLDH)–> Glutamate + NADP+ + H2ODetection: decrease absorbance 340 nm (enzymatic method) measured spectrophotometrically potential difference measured (ISE)Advantages: enzymatic method sensitive specificDisadvantages: Ammonia volatile can easily contaminated","code":""},{"path":"principles-4.html","id":"cerebrospinal-fluid-csf-protein","chapter":"Principles","heading":"Cerebrospinal Fluid (CSF) Protein","text":"Principle: Similar total protein methods, Biuret Reaction dye-binding methods (e.g., Coomassie Brilliant Blue) used measure total protein CSFSpecial Considerations\nCSF protein levels much lower serum protein levels, requiring sensitive methods\nSamples free blood contamination\nCSF protein levels much lower serum protein levels, requiring sensitive methodsSamples free blood contamination","code":""},{"path":"principles-4.html","id":"urine-protein","chapter":"Principles","heading":"Urine Protein","text":"Principle: Several methods available measuring urine protein. Two common methods turbidimetric method dye-binding methodTurbidimetric Method\nProtein precipitated adding reagent (e.g., sulfosalicylic acid, trichloroacetic acid), turbidity solution measured\nReactions\nProtein + Precipitating Reagent → Turbidity\n\nProtein precipitated adding reagent (e.g., sulfosalicylic acid, trichloroacetic acid), turbidity solution measuredReactions\nProtein + Precipitating Reagent → Turbidity\nProtein + Precipitating Reagent → TurbidityDye-Binding Method\nSimilar serum albumin methods, protein binds dye (e.g., Coomassie Brilliant Blue) causing change absorbance\nReactions\nProtein + Dye → Protein-Dye Complex (Colored)\n\nSimilar serum albumin methods, protein binds dye (e.g., Coomassie Brilliant Blue) causing change absorbanceReactions\nProtein + Dye → Protein-Dye Complex (Colored)\nProtein + Dye → Protein-Dye Complex (Colored)Detection: turbidity intensity colored complex measured spectrophotometricallyAdvantages: dye-binding method sensitive less susceptible interferencesDisadvantages: Turbidimetric methods less sensitive","code":""},{"path":"principles-4.html","id":"protein-electrophoresis-serum-and-urine","chapter":"Principles","heading":"Protein Electrophoresis (Serum and Urine)","text":"Principle: Proteins separated based electrical charge sizeProcedure\nSample applied support medium (e.g., agarose gel cellulose acetate)\nelectric field applied, causing proteins migrate different rates\nProteins stained protein-specific dye\nseparated protein bands visualized quantified\nSample applied support medium (e.g., agarose gel cellulose acetate)electric field applied, causing proteins migrate different ratesProteins stained protein-specific dyeThe separated protein bands visualized quantifiedClinical Significance\nHelps identify abnormal protein patterns, :\nMonoclonal Gammopathies (e.g., multiple myeloma)\nNephrotic Syndrome\nLiver Disease\nInflammatory Conditions\n\nHelps identify abnormal protein patterns, :\nMonoclonal Gammopathies (e.g., multiple myeloma)\nNephrotic Syndrome\nLiver Disease\nInflammatory Conditions\nMonoclonal Gammopathies (e.g., multiple myeloma)Nephrotic SyndromeLiver DiseaseInflammatory ConditionsProtein electrophoresis fractions\n* Albumin\n* Alpha-1 Globulins\n* Alpha-2 Globulins\n* Beta Globulins\n* Gamma Globulins","code":""},{"path":"principles-4.html","id":"immunofixation-electrophoresis-ife","chapter":"Principles","heading":"Immunofixation Electrophoresis (IFE)","text":"Principle: Similar protein electrophoresis, electrophoresis, gel overlaid specific antibodies bind specific proteins. antibody-protein complexes visualizedClinical Significance\nUsed identify monoclonal proteins serum urine\nHelps diagnose multiple myeloma plasma cell disorders\nUsed identify monoclonal proteins serum urineHelps diagnose multiple myeloma plasma cell disorders","code":""},{"path":"principles-4.html","id":"tumor-markers-psa-afp-cea-ca-125-etc.","chapter":"Principles","heading":"Tumor Markers (PSA, AFP, CEA, CA-125, etc.)","text":"Principle: Immunoassays (e.g., ELISA, chemiluminescence) used measure tumor markers. Antibodies specific tumor marker used capture quantify tumor marker blood sampleMethods\nELISA\nChemiluminescence Immunoassay (CLIA)\nELISAChemiluminescence Immunoassay (CLIA)Reactions\nTumor Marker + Tumor Marker-Specific Antibody → Antibody-Tumor Marker Complex\nTumor Marker + Tumor Marker-Specific Antibody → Antibody-Tumor Marker ComplexDetection: amount antibody-tumor marker complex formed measured, proportional tumor marker concentrationClinical Significance\nPSA: Prostate-Specific Antigen; prostate cancer\nAFP: Alpha-Fetoprotein; liver cancer, germ cell tumors\nCEA: Carcinoembryonic Antigen; colorectal cancer, lung cancer\nCA-125: Cancer Antigen 125; ovarian cancer\nPSA: Prostate-Specific Antigen; prostate cancerAFP: Alpha-Fetoprotein; liver cancer, germ cell tumorsCEA: Carcinoembryonic Antigen; colorectal cancer, lung cancerCA-125: Cancer Antigen 125; ovarian cancer","code":""},{"path":"principles-4.html","id":"cardiac-markers-troponin-ck-mb-myoglobin","chapter":"Principles","heading":"Cardiac Markers (Troponin, CK-MB, Myoglobin)","text":"Principle: Immunoassays (e.g., ELISA, chemiluminescence) used measure cardiac markers. Antibodies specific cardiac marker used capture quantify cardiac marker blood sampleMethods\nELISA\nChemiluminescence Immunoassay (CLIA)\nELISAChemiluminescence Immunoassay (CLIA)Reactions\nCardiac Marker + Cardiac Marker-Specific Antibody → Antibody-Cardiac Marker Complex\nCardiac Marker + Cardiac Marker-Specific Antibody → Antibody-Cardiac Marker ComplexDetection: amount antibody-cardiac marker complex formed measured, proportional cardiac marker concentrationClinical Significance\nTroponin: Myocardial Infarction\nCK-MB: Myocardial Infarction\nMyoglobin: Myocardial Infarction\nTroponin: Myocardial InfarctionCK-MB: Myocardial InfarctionMyoglobin: Myocardial Infarction","code":""},{"path":"principles-4.html","id":"key-terms-32","chapter":"Principles","heading":"Key Terms","text":"Biuret Reaction: chemical reaction used measure total proteinDye-Binding Method: method measure albumin using dyesTurbidimetry: method measure turbidity solutionNephelometry: method measure amount light scattered angleUrease Method: enzymatic method measure blood urea nitrogen (BUN)Jaffe Reaction: chemical reaction used measure creatinineUricase Method: enzymatic method measure uric acidIon-Selective Electrode (ISE): method measure concentration ionsProtein Electrophoresis: method separate proteins based electrical charge sizeImmunofixation Electrophoresis (IFE): method identify monoclonal proteinsELISA (Enzyme-Linked Immunosorbent Assay): immunoassay uses enzyme-labeled antibodiesChemiluminescence Immunoassay (CLIA): immunoassay uses chemiluminescent labelsTumor Marker: substance produced cancer cells cells response cancerCardiac Marker: substance released blood heart damagedSpectrophotometry: method measure absorbance light solutionAlbumin: major protein bloodGlobulin: group proteins bloodUrea: nitrogen-containing compound major end product protein metabolismUric Acid: nitrogen-containing compound major end product purine metabolismCreatinine: waste product muscle metabolismAmmonia: toxic nitrogen-containing compoundBUN: Blood Urea Nitrogen","code":""},{"path":"special-precautions-8.html","id":"special-precautions-8","chapter":"Special Precautions","heading":"Special Precautions","text":"Accurate testing proteins nitrogen compounds depends careful technique proper handling. section discussSpecimen CollectionSpecimen Handling ProcessingAnalytical ConsiderationsInterfering SubstancesTroubleshooting","code":""},{"path":"special-precautions-8.html","id":"specimen-collection-4","chapter":"Special Precautions","heading":"Specimen Collection","text":"Patient Preparation\nFasting: tests require fasting (e.g., lipid profile, ammonia) minimize interferences. Follow specific guidelines\nMedications: Certain medications can affect protein nitrogen compound levels. healthcare provider review patient’s medication list\nRecent Procedures: Recent surgeries, injections, medical procedures can affect levels substances\nDiet: High-protein diets can affect urea uric acid levels. Standardize dietary intake prior testing\nExercise: Strenuous exercise can affect muscle enzyme levels (e.g., CK) creatinine levels. Avoid strenuous exercise prior blood collection\nFasting: tests require fasting (e.g., lipid profile, ammonia) minimize interferences. Follow specific guidelinesMedications: Certain medications can affect protein nitrogen compound levels. healthcare provider review patient’s medication listRecent Procedures: Recent surgeries, injections, medical procedures can affect levels substancesDiet: High-protein diets can affect urea uric acid levels. Standardize dietary intake prior testingExercise: Strenuous exercise can affect muscle enzyme levels (e.g., CK) creatinine levels. Avoid strenuous exercise prior blood collectionSpecimen Type\nSerum common specimen type protein nitrogen compound assays\nPlasma may used assays, follow laboratory’s guidelines anticoagulant selection\nUrine used protein, creatinine, porphyrin measurements\nCerebrospinal fluid (CSF) used protein measurements neurological disorders\nSerum common specimen type protein nitrogen compound assaysPlasma may used assays, follow laboratory’s guidelines anticoagulant selectionUrine used protein, creatinine, porphyrin measurementsCerebrospinal fluid (CSF) used protein measurements neurological disordersTube Type\nSerum separator tubes (SST) red-top tubes commonly used serum collection\nPlasma tubes heparin EDTA may used assays, follow laboratory’s guidelines\nUrine collected clean, dry container, without preservatives, depending test\nCSF collected sterile tubes\nSerum separator tubes (SST) red-top tubes commonly used serum collectionPlasma tubes heparin EDTA may used assays, follow laboratory’s guidelinesUrine collected clean, dry container, without preservatives, depending testCSF collected sterile tubesOrder Draw\nFollow correct order draw collecting multiple tubes prevent cross-contamination\nFollow correct order draw collecting multiple tubes prevent cross-contaminationTourniquet Time\nMinimize tourniquet time (ideally less 1 minute) prevent hemoconcentration\nMinimize tourniquet time (ideally less 1 minute) prevent hemoconcentrationCollection Technique\nUse clean venipuncture technique minimize hemolysis. Avoid prolonged probing excessive force\nUse clean venipuncture technique minimize hemolysis. Avoid prolonged probing excessive force","code":""},{"path":"special-precautions-8.html","id":"specimen-handling-and-processing-3","chapter":"Special Precautions","heading":"Specimen Handling and Processing","text":"Timing\nProcess specimen soon possible collection prevent degradation changes analyte concentrations\nAnalyze unstable analytes (e.g., ammonia) immediately\nProcess specimen soon possible collection prevent degradation changes analyte concentrationsAnalyze unstable analytes (e.g., ammonia) immediatelyCentrifugation\nCentrifuge sample according manufacturer’s instructions specific tube type\nProper centrifugation ensures complete separation serum plasma cells\nCentrifuge sample according manufacturer’s instructions specific tube typeProper centrifugation ensures complete separation serum plasma cellsStorage\nanalysis delayed, store specimen refrigerated (2-8°C) short-term storage frozen (-20°C -70°C) longer storage\nAliquot sample smaller portions avoid repeated freeze-thaw cycles, can degrade proteins analytes\nanalysis delayed, store specimen refrigerated (2-8°C) short-term storage frozen (-20°C -70°C) longer storageAliquot sample smaller portions avoid repeated freeze-thaw cycles, can degrade proteins analytesHemolysis\nAvoid hemolysis, red blood cells contain high concentrations many enzymes proteins, can falsely elevate results\nVisually inspect sample hemolysis reject hemolyzed samples\nAvoid hemolysis, red blood cells contain high concentrations many enzymes proteins, can falsely elevate resultsVisually inspect sample hemolysis reject hemolyzed samplesLipemia\nLipemia (excess lipids) can interfere spectrophotometric assays\nUse lipemia clearing techniques (ultracentrifugation, lipid clearing reagents) consider methods less affected turbidity\nLipemia (excess lipids) can interfere spectrophotometric assaysUse lipemia clearing techniques (ultracentrifugation, lipid clearing reagents) consider methods less affected turbidityUrine Specimens\nPreservatives may required urine tests prevent bacterial growth analyte degradation\nFollow specific instructions urine collection storage\nPreservatives may required urine tests prevent bacterial growth analyte degradationFollow specific instructions urine collection storage","code":""},{"path":"special-precautions-8.html","id":"analytical-considerations-5","chapter":"Special Precautions","heading":"Analytical Considerations","text":"Reagent Quality\nUse high-quality reagents store according manufacturer’s instructions\nCheck expiration dates discard expired reagents\nUse high-quality reagents store according manufacturer’s instructionsCheck expiration dates discard expired reagentsCalibration\nCalibrate instrument regularly using appropriate standards\nUse multiple calibrators ensure linearity entire measurement range\nCalibrate instrument regularly using appropriate standardsUse multiple calibrators ensure linearity entire measurement rangeQuality Control (QC)\nRun quality control samples regular intervals monitor accuracy precision assay\nUse normal abnormal QC levels assess performance across entire range\nEvaluate QC results releasing patient results\nRun quality control samples regular intervals monitor accuracy precision assayUse normal abnormal QC levels assess performance across entire rangeEvaluate QC results releasing patient resultsInstrumentation\nRegularly maintain service instrument according manufacturer’s recommendations\nEnsure instrument functioning properly components good working order\nRegularly maintain service instrument according manufacturer’s recommendationsEnsure instrument functioning properly components good working orderMethod Validation\nValidate new methods implementation ensure accuracy, precision, linearity, performance characteristics\nValidate new methods implementation ensure accuracy, precision, linearity, performance characteristics","code":""},{"path":"special-precautions-8.html","id":"interfering-substances-9","chapter":"Special Precautions","heading":"Interfering Substances","text":"Endogenous\nLipemia: Causes turbidity, affecting spectrophotometric readings\nBilirubin: Absorbs light similar wavelengths, affecting absorbance readings\nHemoglobin: Released hemolyzed red blood cells, interfering enzymatic reactions\nHigh Protein Concentrations: Can interfere enzymatic assays affecting reaction kinetics detection system\nLipemia: Causes turbidity, affecting spectrophotometric readingsBilirubin: Absorbs light similar wavelengths, affecting absorbance readingsHemoglobin: Released hemolyzed red blood cells, interfering enzymatic reactionsHigh Protein Concentrations: Can interfere enzymatic assays affecting reaction kinetics detection systemExogenous\nMedications: Certain drugs can directly affect protein nitrogen compound levels\nAnticoagulants: anticoagulants can interfere enzymatic reactions\nContaminants: Improperly cleaned glassware containers can introduce contaminants affect assay performance\nMedications: Certain drugs can directly affect protein nitrogen compound levelsAnticoagulants: anticoagulants can interfere enzymatic reactionsContaminants: Improperly cleaned glassware containers can introduce contaminants affect assay performanceMinimizing Interferences\nUse methods less susceptible interference\nEmploy techniques remove correct interfering substance\nDilute sample reduce concentration interfering substance\nUse appropriate blanking background subtraction techniques\nUse methods less susceptible interferenceEmploy techniques remove correct interfering substanceDilute sample reduce concentration interfering substanceUse appropriate blanking background subtraction techniques","code":""},{"path":"special-precautions-8.html","id":"troubleshooting-9","chapter":"Special Precautions","heading":"Troubleshooting","text":"Unexpectedly High Results\nPre-Analytical:\nPatient fasting\nProlonged tourniquet time\nHemolysis\nImproper collection tube\n\nAnalytical:\nIncorrect calibration\nReagent deterioration\nInterfering substances\nInstrument malfunction\n\nPre-Analytical:\nPatient fasting\nProlonged tourniquet time\nHemolysis\nImproper collection tube\nPatient fastingProlonged tourniquet timeHemolysisImproper collection tubeAnalytical:\nIncorrect calibration\nReagent deterioration\nInterfering substances\nInstrument malfunction\nIncorrect calibrationReagent deteriorationInterfering substancesInstrument malfunctionUnexpectedly Low Results\nPre-Analytical:\nImproper storage\nAnalyte degradation\n\nAnalytical:\nIncorrect calibration\nReagent deterioration\nInstrument malfunction\n\nPre-Analytical:\nImproper storage\nAnalyte degradation\nImproper storageAnalyte degradationAnalytical:\nIncorrect calibration\nReagent deterioration\nInstrument malfunction\nIncorrect calibrationReagent deteriorationInstrument malfunctionInconsistent Results\nCheck patient preparation\nReview collection processing procedures\nEvaluate reagent quality calibration\nConsider interfering substances\nRepeat test using different method new sample\nCheck patient preparationReview collection processing proceduresEvaluate reagent quality calibrationConsider interfering substancesRepeat test using different method new sampleOut--Control QC Results\nCheck integrity QC materials\nPrepare fresh QC materials\nRe-calibrate instrument\nReview reagent quality\nRepeat QC testing\nproblem persists, contact instrument manufacturer assistance\nCheck integrity QC materialsPrepare fresh QC materialsRe-calibrate instrumentReview reagent qualityRepeat QC testingIf problem persists, contact instrument manufacturer assistance","code":""},{"path":"special-precautions-8.html","id":"key-terms-33","chapter":"Special Precautions","heading":"Key Terms","text":"Pre-analytical: Processes occur sample analyzedAnalytical: Processes involved analyzing sampleInterfering Substance: substance affects accuracy testHemolysis: breakdown red blood cellsLipemia: presence excess lipids bloodCalibration: Adjusting instrument ensure accurate readingsQuality Control: Samples used monitor accuracy precision testSST: Serum Separator TubeEDTA: Ethylenediaminetetraacetic acid, anticoagulantSOP: Standard Operating ProcedureAccuracy: close measurement true valuePrecision: Reproducibility measurement","code":""},{"path":"clearances-1.html","id":"clearances-1","chapter":"Clearances","heading":"Clearances","text":"Clearance tests assess rate substances removed body, usually kidneys. essential evaluating kidney functionKey Concepts: Glomerular Filtration, Tubular Reabsorption, Tubular SecretionKey Concepts: Glomerular Filtration, Tubular Reabsorption, Tubular SecretionCalculations: Clearance calculated using following formula:\nC = (U x V) / P\nC = Clearance (mL/min)\nU = Urine concentration substance (mg/dL)\nV = Urine flow rate (mL/min)\nP = Plasma concentration substance (mg/dL)\n\nCalculations: Clearance calculated using following formula:C = (U x V) / P\nC = Clearance (mL/min)\nU = Urine concentration substance (mg/dL)\nV = Urine flow rate (mL/min)\nP = Plasma concentration substance (mg/dL)\nC = (U x V) / PC = Clearance (mL/min)U = Urine concentration substance (mg/dL)V = Urine flow rate (mL/min)P = Plasma concentration substance (mg/dL)","code":""},{"path":"clearances-1.html","id":"creatinine-clearance","chapter":"Clearances","heading":"Creatinine Clearance","text":"Principle: Measures rate creatinine removed blood kidneys. Creatinine waste product muscle metabolism freely filtered glomeruli neither reabsorbed significantly secreted tubulesProcedure\n24-Hour Urine Collection: patient collects urine 24-hour period, starting ending time day. total volume urine measured, small aliquot sent laboratory\nBlood Sample Collection: blood sample collected 24-hour urine collection period\nCreatinine Measurement: Creatinine measured urine serum samples using Jaffe reaction enzymatic method\nCalculation: Creatinine clearance calculated using formula:\nC = (U x V) / P\n\n24-Hour Urine Collection: patient collects urine 24-hour period, starting ending time day. total volume urine measured, small aliquot sent laboratoryBlood Sample Collection: blood sample collected 24-hour urine collection periodCreatinine Measurement: Creatinine measured urine serum samples using Jaffe reaction enzymatic methodCalculation: Creatinine clearance calculated using formula:\nC = (U x V) / P\nC = (U x V) / PCorrections: Corrected Body Surface Area (BSA)Reportable Range: 25 - 250 mL/minSources Error\n* Incomplete Urine Collection: major source error. Ensure patient understands importance collecting urine 24-hour period\n* Improper Timing: Starting ending collection wrong time\n* Medications: medications can affect creatinine clearance\n* Muscle Mass: Creatinine production related muscle mass. Individuals high low muscle mass may inaccurate creatinine clearance estimatesAlternate Estimates (eGFR)\nEquations\nCockcroft-Gault Equation: Estimates creatinine clearance based serum creatinine, age, weight, sex. Overestimates GFR obese patients\nMDRD (Modification Diet Renal Disease) Equation: Estimates GFR based serum creatinine, age, sex, ethnicity\nCKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equation: accurate MDRD, particularly higher GFR levels\n\nEquations\nCockcroft-Gault Equation: Estimates creatinine clearance based serum creatinine, age, weight, sex. Overestimates GFR obese patients\nMDRD (Modification Diet Renal Disease) Equation: Estimates GFR based serum creatinine, age, sex, ethnicity\nCKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equation: accurate MDRD, particularly higher GFR levels\nCockcroft-Gault Equation: Estimates creatinine clearance based serum creatinine, age, weight, sex. Overestimates GFR obese patientsMDRD (Modification Diet Renal Disease) Equation: Estimates GFR based serum creatinine, age, sex, ethnicityCKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equation: accurate MDRD, particularly higher GFR levelsClinical Significance\nCreatinine clearance measure glomerular filtration rate (GFR) used assess kidney function\nDecreased creatinine clearance indicates impaired kidney function\nCreatinine clearance used stage chronic kidney disease (CKD) adjust medication dosages\nCreatinine clearance measure glomerular filtration rate (GFR) used assess kidney functionDecreased creatinine clearance indicates impaired kidney functionCreatinine clearance used stage chronic kidney disease (CKD) adjust medication dosagesCKD Stages\n* Stage 1: Kidney damage normal increased GFR (≥ 90 mL/min/1.73 m2)\n* Stage 2: Kidney damage mild decrease GFR (60-89 mL/min/1.73 m2)\n* Stage 3a: Moderate decrease GFR (45-59 mL/min/1.73 m2)\n* Stage 3b: Moderate decrease GFR (30-44 mL/min/1.73 m2)\n* Stage 4: Severe decrease GFR (15-29 mL/min/1.73 m2)\n* Stage 5: Kidney failure (GFR < 15 mL/min/1.73 m2 dialysis)","code":""},{"path":"clearances-1.html","id":"urea-clearance","chapter":"Clearances","heading":"Urea Clearance","text":"Principle: Measures rate urea removed blood kidneys. Urea freely filtered glomeruli partially reabsorbed tubulesProcedure\nTimed Urine Collection: patient collects urine timed period (e.g., 1 hour, 2 hours). total volume urine measured, small aliquot sent laboratory\nBlood Sample Collection: blood sample collected urine collection period\nUrea Measurement: Urea measured urine serum samples using urease method\nCalculation: Urea clearance calculated using formula:\nC = (U x V) / P\n\nTimed Urine Collection: patient collects urine timed period (e.g., 1 hour, 2 hours). total volume urine measured, small aliquot sent laboratoryBlood Sample Collection: blood sample collected urine collection periodUrea Measurement: Urea measured urine serum samples using urease methodCalculation: Urea clearance calculated using formula:\nC = (U x V) / P\nC = (U x V) / PClinical Significance\nUrea clearance measure kidney function can used assess GFR\nUrea clearance less accurate creatinine clearance urea reabsorption varies urine flow rate hydration status\nUrea clearance primarily historical interest commonly used clinical practice\nUrea clearance measure kidney function can used assess GFRUrea clearance less accurate creatinine clearance urea reabsorption varies urine flow rate hydration statusUrea clearance primarily historical interest commonly used clinical practice","code":""},{"path":"clearances-1.html","id":"key-terms-34","chapter":"Clearances","heading":"Key Terms","text":"Clearance: rate substance removed blood kidneysGlomerular Filtration Rate (GFR): rate blood filtered glomeruliTubular Reabsorption: process substances reabsorbed renal tubules back bloodstreamTubular Secretion: process substances secreted bloodstream renal tubulesCreatinine: waste product muscle metabolismUrea: waste product protein metabolism24-Hour Urine Collection: collection urine produced 24-hour periodTimed Urine Collection: collection urine produced specified period timeJaffe Reaction: chemical reaction used measure creatinineUrease Method: enzymatic method used measure ureaEstimated Glomerular Filtration Rate (eGFR): estimate GFR based serum creatinine, age, sex, ethnicityBody Surface Area (BSA): measured calculated surface human bodyCKD Stages: Stages chronic kidney disease based GFR","code":""},{"path":"result-interpretation-4.html","id":"result-interpretation-4","chapter":"Result Interpretation","heading":"Result Interpretation","text":"Interpreting protein nitrogen compound test results key aspect clinical diagnostics. results often reflect status liver, kidneys, nutritional status, presence certain diseases. ’s guideTotal ProteinAlbuminPrealbumin (Transthyretin)GlobulinsAlbumin/Globulin (/G) RatioBlood Urea Nitrogen (BUN)CreatinineBlood Urea Nitrogen/Creatinine RatioUric AcidAmmoniaCerebrospinal Fluid (CSF) ProteinUrine ProteinProtein Electrophoresis (Serum Urine)Immunofixation Electrophoresis (IFE)Tumor Markers (PSA, AFP, CEA, CA-125, etc.)","code":""},{"path":"result-interpretation-4.html","id":"total-protein-1","chapter":"Result Interpretation","heading":"Total Protein","text":"Reference Interval: 6.0-8.3 g/dLInterpretation\nElevated Total Protein (Hyperproteinemia)\nDehydration (hemoconcentration)\nMultiple Myeloma (increased globulins)\nChronic Inflammation\n\nDecreased Total Protein (Hypoproteinemia)\nMalnutrition\nLiver Disease (decreased albumin synthesis)\nKidney Disease (protein loss)\nInflammation (acute phase response)\n\nElevated Total Protein (Hyperproteinemia)\nDehydration (hemoconcentration)\nMultiple Myeloma (increased globulins)\nChronic Inflammation\nDehydration (hemoconcentration)Multiple Myeloma (increased globulins)Chronic InflammationDecreased Total Protein (Hypoproteinemia)\nMalnutrition\nLiver Disease (decreased albumin synthesis)\nKidney Disease (protein loss)\nInflammation (acute phase response)\nMalnutritionLiver Disease (decreased albumin synthesis)Kidney Disease (protein loss)Inflammation (acute phase response)Clinical Significance\nProvides general assessment protein status\nUseful evaluating malnutrition, liver disease, kidney disease, inflammatory conditions\nProvides general assessment protein statusUseful evaluating malnutrition, liver disease, kidney disease, inflammatory conditions","code":""},{"path":"result-interpretation-4.html","id":"albumin-1","chapter":"Result Interpretation","heading":"Albumin","text":"Reference Interval: 3.5-5.0 g/dLInterpretation\nElevated Albumin\nDehydration\n\nDecreased Albumin (Hypoalbuminemia)\nLiver Disease (decreased synthesis)\nKidney Disease (protein loss)\nMalnutrition (decreased protein intake)\nInflammation (acute phase response)\nProtein-Losing Enteropathy (loss protein GI tract)\nEdema Ascites: Due decreased oncotic pressure\n\nElevated Albumin\nDehydration\nDehydrationDecreased Albumin (Hypoalbuminemia)\nLiver Disease (decreased synthesis)\nKidney Disease (protein loss)\nMalnutrition (decreased protein intake)\nInflammation (acute phase response)\nProtein-Losing Enteropathy (loss protein GI tract)\nEdema Ascites: Due decreased oncotic pressure\nLiver Disease (decreased synthesis)Kidney Disease (protein loss)Malnutrition (decreased protein intake)Inflammation (acute phase response)Protein-Losing Enteropathy (loss protein GI tract)Edema Ascites: Due decreased oncotic pressureClinical Significance\nMajor indicator liver function\nMarker nutritional status\nIndicator kidney function protein loss\nMajor indicator liver functionMarker nutritional statusIndicator kidney function protein loss","code":""},{"path":"result-interpretation-4.html","id":"prealbumin-transthyretin-1","chapter":"Result Interpretation","heading":"Prealbumin (Transthyretin)","text":"Reference Interval: 15-36 mg/dLInterpretation\nElevated Prealbumin: commonly seen\nDecreased Prealbumin\nMalnutrition (early indicator)\nLiver Disease\nInflammation (acute phase response)\nTissue Damage Neoplasia: Can falsely increase decrease prealbumin\n\nElevated Prealbumin: commonly seenDecreased Prealbumin\nMalnutrition (early indicator)\nLiver Disease\nInflammation (acute phase response)\nTissue Damage Neoplasia: Can falsely increase decrease prealbumin\nMalnutrition (early indicator)Liver DiseaseInflammation (acute phase response)Tissue Damage Neoplasia: Can falsely increase decrease prealbuminClinical Significance\nsensitive marker nutritional status albumin due shorter half-life\nUseful monitoring nutritional support\nsensitive marker nutritional status albumin due shorter half-lifeUseful monitoring nutritional support","code":""},{"path":"result-interpretation-4.html","id":"globulins-1","chapter":"Result Interpretation","heading":"Globulins","text":"Calculation: Globulins = Total Protein - AlbuminInterpretation\nElevated Globulins\nChronic Infections\nAutoimmune Disorders\nLiver Disease (e.g., cirrhosis)\nMultiple Myeloma (monoclonal gammopathy)\n\nDecreased Globulins\nGenetic Immunodeficiency Disorders\nAcquired Immunodeficiency (e.g., HIV/AIDS)\n\nElevated Globulins\nChronic Infections\nAutoimmune Disorders\nLiver Disease (e.g., cirrhosis)\nMultiple Myeloma (monoclonal gammopathy)\nChronic InfectionsAutoimmune DisordersLiver Disease (e.g., cirrhosis)Multiple Myeloma (monoclonal gammopathy)Decreased Globulins\nGenetic Immunodeficiency Disorders\nAcquired Immunodeficiency (e.g., HIV/AIDS)\nGenetic Immunodeficiency DisordersAcquired Immunodeficiency (e.g., HIV/AIDS)Clinical Significance\nProvide information immune function inflammatory processes\nImportant diagnosing monoclonal gammopathies immunodeficiency disorders\nProvide information immune function inflammatory processesImportant diagnosing monoclonal gammopathies immunodeficiency disorders","code":""},{"path":"result-interpretation-4.html","id":"albuminglobulin-ag-ratio","chapter":"Result Interpretation","heading":"Albumin/Globulin (A/G) Ratio","text":"Calculation: /G Ratio = Albumin / GlobulinsReference Interval: Typically > 1 (1.0-2.0)Interpretation\nDecreased /G Ratio (< 1)\nLiver Disease: Decreased albumin synthesis increased globulin production\nNephrotic Syndrome: Increased albumin loss urine\nMultiple Myeloma: Increased globulin production\n\nDecreased /G Ratio (< 1)\nLiver Disease: Decreased albumin synthesis increased globulin production\nNephrotic Syndrome: Increased albumin loss urine\nMultiple Myeloma: Increased globulin production\nLiver Disease: Decreased albumin synthesis increased globulin productionNephrotic Syndrome: Increased albumin loss urineMultiple Myeloma: Increased globulin productionClinical Significance\nHelpful differentiating causes abnormal protein levels\nHelpful differentiating causes abnormal protein levels","code":""},{"path":"result-interpretation-4.html","id":"blood-urea-nitrogen-bun","chapter":"Result Interpretation","heading":"Blood Urea Nitrogen (BUN)","text":"Reference Interval: 6-20 mg/dLInterpretation\nElevated BUN (Azotemia)\nKidney Disease (decreased urea excretion)\nDehydration (increased urea concentration)\nHigh-Protein Diet (increased urea production)\nGastrointestinal Bleeding (increased protein breakdown)\nHeart Failure (decreased renal perfusion)\n\nDecreased BUN\nLiver Disease (decreased urea synthesis)\nMalnutrition (decreased protein intake)\nOverhydration\n\nElevated BUN (Azotemia)\nKidney Disease (decreased urea excretion)\nDehydration (increased urea concentration)\nHigh-Protein Diet (increased urea production)\nGastrointestinal Bleeding (increased protein breakdown)\nHeart Failure (decreased renal perfusion)\nKidney Disease (decreased urea excretion)Dehydration (increased urea concentration)High-Protein Diet (increased urea production)Gastrointestinal Bleeding (increased protein breakdown)Heart Failure (decreased renal perfusion)Decreased BUN\nLiver Disease (decreased urea synthesis)\nMalnutrition (decreased protein intake)\nOverhydration\nLiver Disease (decreased urea synthesis)Malnutrition (decreased protein intake)OverhydrationClinical Significance\nAssessment kidney function\nEvaluation hydration status\nUseful diagnosing liver disease gastrointestinal bleeding\nAssessment kidney functionEvaluation hydration statusUseful diagnosing liver disease gastrointestinal bleeding","code":""},{"path":"result-interpretation-4.html","id":"creatinine-2","chapter":"Result Interpretation","heading":"Creatinine","text":"Reference Interval: 0.6-1.2 mg/dL (males), 0.5-1.1 mg/dL (females)Interpretation\nElevated Creatinine\nKidney Disease (decreased creatinine excretion)\nDehydration (increased creatinine concentration)\nMuscle Breakdown (increased creatinine production)\nCertain Medications (e.g., NSAIDs, ACE inhibitors)\n\nDecreased Creatinine\nDecreased Muscle Mass\nPregnancy\nMalnutrition\n\nElevated Creatinine\nKidney Disease (decreased creatinine excretion)\nDehydration (increased creatinine concentration)\nMuscle Breakdown (increased creatinine production)\nCertain Medications (e.g., NSAIDs, ACE inhibitors)\nKidney Disease (decreased creatinine excretion)Dehydration (increased creatinine concentration)Muscle Breakdown (increased creatinine production)Certain Medications (e.g., NSAIDs, ACE inhibitors)Decreased Creatinine\nDecreased Muscle Mass\nPregnancy\nMalnutrition\nDecreased Muscle MassPregnancyMalnutritionClinical Significance\nMajor Indicator kidney function\nUseful staging chronic kidney disease\nUsed calculate estimated glomerular filtration rate (eGFR)\nMajor Indicator kidney functionUseful staging chronic kidney diseaseUsed calculate estimated glomerular filtration rate (eGFR)","code":""},{"path":"result-interpretation-4.html","id":"blood-urea-nitrogencreatinine-ratio","chapter":"Result Interpretation","heading":"Blood Urea Nitrogen/Creatinine Ratio","text":"Calculation: BUN/Creatinine Ratio = BUN (mg/dL) / Creatinine (mg/dL)Reference Interval: 10:1 20:1Interpretation\nIncreased BUN/Creatinine Ratio\nPre-Renal Azotemia: Dehydration, heart failure, gastrointestinal bleeding\nPost-Renal Azotemia: Urinary tract obstruction\n\nDecreased BUN/Creatinine Ratio\nLiver Disease\nMalnutrition\nLow-Protein Diet\nAcute Tubular Necrosis: early stages\n\nIncreased BUN/Creatinine Ratio\nPre-Renal Azotemia: Dehydration, heart failure, gastrointestinal bleeding\nPost-Renal Azotemia: Urinary tract obstruction\nPre-Renal Azotemia: Dehydration, heart failure, gastrointestinal bleedingPost-Renal Azotemia: Urinary tract obstructionDecreased BUN/Creatinine Ratio\nLiver Disease\nMalnutrition\nLow-Protein Diet\nAcute Tubular Necrosis: early stages\nLiver DiseaseMalnutritionLow-Protein DietAcute Tubular Necrosis: early stagesClinical Significance\nHelps differentiate causes elevated BUN creatinine\nHelps differentiate causes elevated BUN creatinine","code":""},{"path":"result-interpretation-4.html","id":"uric-acid-2","chapter":"Result Interpretation","heading":"Uric Acid","text":"Reference Interval\nMales: 3.5-7.2 mg/dL\nFemales: 2.6-6.0 mg/dL\nMales: 3.5-7.2 mg/dLFemales: 2.6-6.0 mg/dLInterpretation\nElevated Uric Acid (Hyperuricemia)\nGout\nKidney Disease (decreased uric acid excretion)\nHigh-Purine Diet (increased uric acid production)\nTumor Lysis Syndrome (rapid cell breakdown)\nCertain Medications (e.g., diuretics)\n\nDecreased Uric Acid (Hypouricemia)\nCertain Medications (e.g., allopurinol)\nLiver Disease\nXanthine Oxidase Deficiency\n\nElevated Uric Acid (Hyperuricemia)\nGout\nKidney Disease (decreased uric acid excretion)\nHigh-Purine Diet (increased uric acid production)\nTumor Lysis Syndrome (rapid cell breakdown)\nCertain Medications (e.g., diuretics)\nGoutKidney Disease (decreased uric acid excretion)High-Purine Diet (increased uric acid production)Tumor Lysis Syndrome (rapid cell breakdown)Certain Medications (e.g., diuretics)Decreased Uric Acid (Hypouricemia)\nCertain Medications (e.g., allopurinol)\nLiver Disease\nXanthine Oxidase Deficiency\nCertain Medications (e.g., allopurinol)Liver DiseaseXanthine Oxidase DeficiencyClinical Significance\nDiagnosis management gout\nAssessment kidney function\nMonitoring tumor lysis syndrome\nDiagnosis management goutAssessment kidney functionMonitoring tumor lysis syndrome","code":""},{"path":"result-interpretation-4.html","id":"ammonia-2","chapter":"Result Interpretation","heading":"Ammonia","text":"Reference Interval: 10-80 μg/dLInterpretation\nElevated Ammonia (Hyperammonemia)\nLiver Failure\nUrea Cycle Disorders\nReye’s Syndrome\nHepatic Encephalopathy\n\nDecreased Ammonia: clinically significant\nElevated Ammonia (Hyperammonemia)\nLiver Failure\nUrea Cycle Disorders\nReye’s Syndrome\nHepatic Encephalopathy\nLiver FailureUrea Cycle DisordersReye’s SyndromeHepatic EncephalopathyDecreased Ammonia: clinically significantClinical Significance\nAssessment liver function\nDiagnosis urea cycle disorders\nMonitoring hepatic encephalopathy\nAssessment liver functionDiagnosis urea cycle disordersMonitoring hepatic encephalopathy","code":""},{"path":"result-interpretation-4.html","id":"cerebrospinal-fluid-csf-protein-1","chapter":"Result Interpretation","heading":"Cerebrospinal Fluid (CSF) Protein","text":"Reference Interval: 15-45 mg/dLInterpretation\nElevated CSF Protein\nMeningitis\nEncephalitis\nMultiple Sclerosis\nGuillain-Barré Syndrome\nTumors\n\nElevated CSF Protein\nMeningitis\nEncephalitis\nMultiple Sclerosis\nGuillain-Barré Syndrome\nTumors\nMeningitisEncephalitisMultiple SclerosisGuillain-Barré SyndromeTumorsClinical Significance\nIndicates inflammation damage central nervous system\nIndicates inflammation damage central nervous system","code":""},{"path":"result-interpretation-4.html","id":"urine-protein-1","chapter":"Result Interpretation","heading":"Urine Protein","text":"Reference Interval: < 150 mg/24 hoursInterpretation\nElevated Urine Protein (Proteinuria)\nKidney Disease (e.g., glomerulonephritis, nephrotic syndrome)\nDiabetes\nHypertension\nMultiple Myeloma\n\nElevated Urine Protein (Proteinuria)\nKidney Disease (e.g., glomerulonephritis, nephrotic syndrome)\nDiabetes\nHypertension\nMultiple Myeloma\nKidney Disease (e.g., glomerulonephritis, nephrotic syndrome)DiabetesHypertensionMultiple MyelomaClinical Significance\nIndicates kidney damage dysfunction\nUsed assess severity kidney disease\nIndicates kidney damage dysfunctionUsed assess severity kidney disease","code":""},{"path":"result-interpretation-4.html","id":"protein-electrophoresis-serum-and-urine-1","chapter":"Result Interpretation","heading":"Protein Electrophoresis (Serum and Urine)","text":"Interpretation\nAbnormal patterns protein electrophoresis can indicate various conditions\nMonoclonal Spike: Suggests multiple myeloma monoclonal gammopathy\nDecreased Albumin: Suggests liver disease, kidney disease, malnutrition\nIncreased Alpha-1 Globulins: Suggests acute inflammation\nIncreased Alpha-2 Globulins: Suggests nephrotic syndrome acute inflammation\nIncreased Gamma Globulins: Suggests chronic infections, autoimmune disorders, liver disease\nAbnormal patterns protein electrophoresis can indicate various conditionsMonoclonal Spike: Suggests multiple myeloma monoclonal gammopathyDecreased Albumin: Suggests liver disease, kidney disease, malnutritionIncreased Alpha-1 Globulins: Suggests acute inflammationIncreased Alpha-2 Globulins: Suggests nephrotic syndrome acute inflammationIncreased Gamma Globulins: Suggests chronic infections, autoimmune disorders, liver diseaseClinical Significance\nUseful diagnosing monoclonal gammopathies, liver disease, kidney disease, inflammatory conditions\nUseful diagnosing monoclonal gammopathies, liver disease, kidney disease, inflammatory conditions","code":""},{"path":"result-interpretation-4.html","id":"immunofixation-electrophoresis-ife-1","chapter":"Result Interpretation","heading":"Immunofixation Electrophoresis (IFE)","text":"Interpretation\nIdentifies monoclonal proteins serum urine\nIdentifies monoclonal proteins serum urineClinical Significance\nConfirms presence monoclonal proteins suspected serum protein electrophoresis\nEssential diagnosing multiple myeloma plasma cell disorders\nConfirms presence monoclonal proteins suspected serum protein electrophoresisEssential diagnosing multiple myeloma plasma cell disorders","code":""},{"path":"result-interpretation-4.html","id":"tumor-markers-psa-afp-cea-ca-125-etc.-1","chapter":"Result Interpretation","heading":"Tumor Markers (PSA, AFP, CEA, CA-125, etc.)","text":"Interpretation\nElevated levels suggest presence cancer\nHowever, tumor markers always specific cancer can elevated benign conditions\nElevated levels suggest presence cancerHowever, tumor markers always specific cancer can elevated benign conditionsClinical Significance\nScreening: Limited use screening due low sensitivity specificity\nDiagnosis: Used support diagnosis cancer\nPrognosis: Can provide information prognosis cancer\nMonitoring: Used monitor treatment response detect disease recurrence\nScreening: Limited use screening due low sensitivity specificityDiagnosis: Used support diagnosis cancerPrognosis: Can provide information prognosis cancerMonitoring: Used monitor treatment response detect disease recurrence","code":""},{"path":"result-interpretation-4.html","id":"key-terms-35","chapter":"Result Interpretation","heading":"Key Terms","text":"Hyperproteinemia: Elevated total protein levels bloodHypoproteinemia: Abnormally low levels protein bloodProteinuria: Presence excess protein urineAlbumin: major protein bloodGlobulin: group proteins bloodBUN: Blood Urea Nitrogen, measure urea bloodCreatinine: waste product muscle metabolismUric Acid: waste product purine metabolismAmmonia: toxic nitrogen-containing compoundGlomerulonephritis: Inflammation glomeruli, filtering units kidneysNephrotic Syndrome: kidney disorder characterized proteinuria, hypoalbuminemia, edemaMyeloma: cancer plasma cellsIFE (Immunofixation Electrophoresis): method identify monoclonal proteinsTumor Marker: substance produced cancer cells cells response cancerCardiac Marker: substance released blood heart damaged","code":""},{"path":"disease-correlation-4.html","id":"disease-correlation-4","chapter":"Disease Correlation","heading":"Disease Correlation","text":"Accurate lab testing, ability correlate results patient’s symptoms, greatly assists accurate diagnosis treatment","code":""},{"path":"disease-correlation-4.html","id":"liver-diseases-1","chapter":"Disease Correlation","heading":"Liver Diseases","text":"Cirrhosis\nLaboratory Findings:\nChemistry\nHypoalbuminemia (low albumin): Decreased liver synthesis\nElevated Total Bilirubin: Impaired bilirubin metabolism excretion\nElevated Liver Enzymes (AST, ALT, ALP, GGT): Variable, may normal decreased advanced stages\n\nHematology\nProlonged Prothrombin Time (PT): Decreased synthesis clotting factors\n\n\nDisease State Correlation: Chronic liver damage leads impaired protein synthesis, bilirubin metabolism, clotting factor production\nClinical Significance: Reflects severity liver dysfunction\nLaboratory Findings:\nChemistry\nHypoalbuminemia (low albumin): Decreased liver synthesis\nElevated Total Bilirubin: Impaired bilirubin metabolism excretion\nElevated Liver Enzymes (AST, ALT, ALP, GGT): Variable, may normal decreased advanced stages\n\nHematology\nProlonged Prothrombin Time (PT): Decreased synthesis clotting factors\n\nChemistry\nHypoalbuminemia (low albumin): Decreased liver synthesis\nElevated Total Bilirubin: Impaired bilirubin metabolism excretion\nElevated Liver Enzymes (AST, ALT, ALP, GGT): Variable, may normal decreased advanced stages\nHypoalbuminemia (low albumin): Decreased liver synthesisElevated Total Bilirubin: Impaired bilirubin metabolism excretionElevated Liver Enzymes (AST, ALT, ALP, GGT): Variable, may normal decreased advanced stagesHematology\nProlonged Prothrombin Time (PT): Decreased synthesis clotting factors\nProlonged Prothrombin Time (PT): Decreased synthesis clotting factorsDisease State Correlation: Chronic liver damage leads impaired protein synthesis, bilirubin metabolism, clotting factor productionClinical Significance: Reflects severity liver dysfunctionHepatitis (Viral, Alcoholic, Drug-Induced)\nLaboratory Findings:\nElevated Liver Enzymes (ALT AST): Indicators liver inflammation damage\nElevated Total Bilirubin: Impaired bilirubin metabolism\nElevated Direct (Conjugated) Bilirubin: Indicates cholestasis (impaired bile flow)\n\nDisease State Correlation: Liver inflammation causes cell damage, leading elevated liver enzymes impaired bilirubin metabolism\nClinical Significance: Provides insights extent liver damage\nSpecific causes alcoholic hepatitis show elevated GGT (gamma-glutamyl transferase)\nLaboratory Findings:\nElevated Liver Enzymes (ALT AST): Indicators liver inflammation damage\nElevated Total Bilirubin: Impaired bilirubin metabolism\nElevated Direct (Conjugated) Bilirubin: Indicates cholestasis (impaired bile flow)\nElevated Liver Enzymes (ALT AST): Indicators liver inflammation damageElevated Total Bilirubin: Impaired bilirubin metabolismElevated Direct (Conjugated) Bilirubin: Indicates cholestasis (impaired bile flow)Disease State Correlation: Liver inflammation causes cell damage, leading elevated liver enzymes impaired bilirubin metabolismClinical Significance: Provides insights extent liver damageSpecific causes alcoholic hepatitis show elevated GGT (gamma-glutamyl transferase)Hepatic Encephalopathy\nLaboratory Findings:\nElevated Ammonia: Impaired urea cycle function\n\nDisease State Correlation: Liver failure leads impaired ammonia detoxification, resulting neurological dysfunction\nClinical Significance: Requires quick treatment help prevent permanent brain damage\nLaboratory Findings:\nElevated Ammonia: Impaired urea cycle function\nElevated Ammonia: Impaired urea cycle functionDisease State Correlation: Liver failure leads impaired ammonia detoxification, resulting neurological dysfunctionClinical Significance: Requires quick treatment help prevent permanent brain damage","code":""},{"path":"disease-correlation-4.html","id":"kidney-diseases","chapter":"Disease Correlation","heading":"Kidney Diseases","text":"Nephrotic Syndrome\nLaboratory Findings:\nProteinuria: Excretion > 3.5 g protein per day urine\nHypoalbuminemia: Decreased protein intake\n\nDisease State Correlation: Damage glomeruli leads increased protein loss urine, decreased serum albumin, edema\nClinical Significance: Indicates glomerular damage\nLaboratory Findings:\nProteinuria: Excretion > 3.5 g protein per day urine\nHypoalbuminemia: Decreased protein intake\nProteinuria: Excretion > 3.5 g protein per day urineHypoalbuminemia: Decreased protein intakeDisease State Correlation: Damage glomeruli leads increased protein loss urine, decreased serum albumin, edemaClinical Significance: Indicates glomerular damageChronic Kidney Disease (CKD)\nLaboratory Findings:\nElevated Serum Creatinine Blood Urea Nitrogen (BUN): Decreased renal excretion\nProteinuria: Kidney damage leads increased protein excretion\n\nDisease State Correlation: Gradual loss kidney function leads decreased excretion waste products increased protein excretion\nClinical Significance: Indicates impaired kidney function\nLaboratory Findings:\nElevated Serum Creatinine Blood Urea Nitrogen (BUN): Decreased renal excretion\nProteinuria: Kidney damage leads increased protein excretion\nElevated Serum Creatinine Blood Urea Nitrogen (BUN): Decreased renal excretionProteinuria: Kidney damage leads increased protein excretionDisease State Correlation: Gradual loss kidney function leads decreased excretion waste products increased protein excretionClinical Significance: Indicates impaired kidney function","code":""},{"path":"disease-correlation-4.html","id":"nutritional-disorders","chapter":"Disease Correlation","heading":"Nutritional Disorders","text":"Protein-Energy Malnutrition (PEM)\nLaboratory Findings:\nHypoalbuminemia: Due decreased protein synthesis\nLow Prealbumin (Transthyretin): Indicates recent protein loss\n\nDisease State Correlation: Inadequate intake protein energy leads depletion body protein stores impaired organ function\nClinical Significance: Used measure nutritional deficiency\nLaboratory Findings:\nHypoalbuminemia: Due decreased protein synthesis\nLow Prealbumin (Transthyretin): Indicates recent protein loss\nHypoalbuminemia: Due decreased protein synthesisLow Prealbumin (Transthyretin): Indicates recent protein lossDisease State Correlation: Inadequate intake protein energy leads depletion body protein stores impaired organ functionClinical Significance: Used measure nutritional deficiency","code":""},{"path":"disease-correlation-4.html","id":"cancer","chapter":"Disease Correlation","heading":"Cancer","text":"Multiple Myeloma\nLaboratory Findings:\nMonoclonal Gammopathy: single, abnormally elevated immunoglobulin peak serum protein electrophoresis\nBence Jones Protein: Monoclonal light chains urine\n\nDisease State Correlation: proliferation plasma cells produces large amounts single immunoglobulin light chain, can detected serum urine\nClinical Significance: Helpful diagnosing cancer\nLaboratory Findings:\nMonoclonal Gammopathy: single, abnormally elevated immunoglobulin peak serum protein electrophoresis\nBence Jones Protein: Monoclonal light chains urine\nMonoclonal Gammopathy: single, abnormally elevated immunoglobulin peak serum protein electrophoresisBence Jones Protein: Monoclonal light chains urineDisease State Correlation: proliferation plasma cells produces large amounts single immunoglobulin light chain, can detected serum urineClinical Significance: Helpful diagnosing cancerTumor Markers (Prostate Cancer, Hepatocellular Carcinoma, Ovarian Cancer)\nProstate-Specific Antigen (PSA) - Prostate Cancer\nAlpha-Fetoprotein (AFP) - Hepatocellular Carcinoma, Germ Cell Tumors\nCancer Antigen 125 (CA-125) - Ovarian Cancer\nCarcinoembryonic Antigen (CEA) - Colorectal, Lung Cancer\nLaboratory Findings: Elevated levels specific tumor marker\nDisease State Correlation: Tumor cells produce specific tumor markers can detected blood\nClinical Significance: Monitoring, assessing, helping determine stage cancer\nProstate-Specific Antigen (PSA) - Prostate CancerAlpha-Fetoprotein (AFP) - Hepatocellular Carcinoma, Germ Cell TumorsCancer Antigen 125 (CA-125) - Ovarian CancerCarcinoembryonic Antigen (CEA) - Colorectal, Lung CancerLaboratory Findings: Elevated levels specific tumor markerDisease State Correlation: Tumor cells produce specific tumor markers can detected bloodClinical Significance: Monitoring, assessing, helping determine stage cancer","code":""},{"path":"disease-correlation-4.html","id":"other-conditions-1","chapter":"Disease Correlation","heading":"Other Conditions","text":"Gout\nLaboratory Findings:\nHyperuricemia (Elevated Serum Uric Acid)\n\nDisease State Correlation: Increased uric acid production decreased excretion leads urate crystal deposition joints\nClinical Significance: Confirmation gout possible detection uric acid crystals within synovial fluid joints\nLaboratory Findings:\nHyperuricemia (Elevated Serum Uric Acid)\nHyperuricemia (Elevated Serum Uric Acid)Disease State Correlation: Increased uric acid production decreased excretion leads urate crystal deposition jointsClinical Significance: Confirmation gout possible detection uric acid crystals within synovial fluid joints","code":""},{"path":"disease-correlation-4.html","id":"key-terms-36","chapter":"Disease Correlation","heading":"Key Terms","text":"Hyperproteinemia: Elevated total protein levels bloodHypoalbuminemia: Abnormally low levels albumin bloodProteinuria: Presence excess protein urineHypoalbuminemia: Abnormally low levels albumin bloodAST: Aspartate AminotransferaseALT: Alanine AminotransferaseGGT: Gamma-Glutamyl TransferaseALP: Alkaline PhosphatasePT: Prothrombin TimeCKD: Chronic Kidney DiseasePSA: Prostate-Specific AntigenAFP: Alpha-FetoproteinCEA: Carcinoembryonic AntigenCA-125: Cancer Antigen 125Bence Jones Protein: abnormal protein found urine patients multiple myeloma B cell neoplasms. Bence Jones proteins monoclonal globulin light chains","code":""},{"path":"acid-base.html","id":"acid-base","chapter":"Acid-Base","heading":"Acid-Base","text":"Blood gas analysis critical tool assessing patient’s respiratory metabolic statusUnderlying biochemical principlesProper testing techniquesAccurate interpretation results","code":""},{"path":"acid-base.html","id":"biochemical-theory-and-pathways-1","chapter":"Acid-Base","heading":"Biochemical Theory and Pathways","text":"Fundamentals\nAcids donate \\(H^+\\), bases accept \\(H^+\\)\npH: measure acidity/alkalinity\nBuffers: Resist pH changes\nAcids donate \\(H^+\\), bases accept \\(H^+\\)pH: measure acidity/alkalinityBuffers: Resist pH changesKey Players\nrelationship \\(pH\\), \\(HCO_3^-\\), Pa\\(CO_2\\) bicarbonate buffer system (Henderson-Hasselbalch equation)\n\\(O_2\\) \\(CO_2\\): Transport mechanisms influencers\nAcid-Base Control\nLungs ventilation (fast response)\nKidneys, \\(HCO_3^-\\) regulation (slow response)\nUnderstanding concepts respiratory metabolic balance help understand disease state\n\nrelationship \\(pH\\), \\(HCO_3^-\\), Pa\\(CO_2\\) bicarbonate buffer system (Henderson-Hasselbalch equation)\\(O_2\\) \\(CO_2\\): Transport mechanisms influencersAcid-Base Control\nLungs ventilation (fast response)\nKidneys, \\(HCO_3^-\\) regulation (slow response)\nUnderstanding concepts respiratory metabolic balance help understand disease state\nLungs ventilation (fast response)Kidneys, \\(HCO_3^-\\) regulation (slow response)Understanding concepts respiratory metabolic balance help understand disease stateUnderstanding Arterial Blood Gasses (ABGs) requires understanding underlying physiology\nUnderstanding acid production elimination\nUnderstanding acid-base balance within body\nUnderstanding acid production eliminationUnderstanding acid-base balance within body","code":""},{"path":"acid-base.html","id":"laboratory-test-procedures-5","chapter":"Acid-Base","heading":"Laboratory Test Procedures","text":"Measurements\n\\(pH\\): Potentiometry glass electrode\nPa\\(O_2\\): Amperometry Clark electrode\nPa\\(CO_2\\): Potentiometry Severinghaus electrode\n\\(pH\\): Potentiometry glass electrodePa\\(O_2\\): Amperometry Clark electrodePa\\(CO_2\\): Potentiometry Severinghaus electrodeCalculations\n\\(HCO_3^-\\) calculated using Henderson-Hasselbalch equation\nBase Excess () Anion Gap (AG) also calculated\n\\(HCO_3^-\\) calculated using Henderson-Hasselbalch equationBase Excess () Anion Gap (AG) also calculatedConsiderations\nSample handling: anaerobic prompt processing\nQuality Control: Calibrate instruments correctly\nTroubleshooting interfering substances\nSample handling: anaerobic prompt processingQuality Control: Calibrate instruments correctlyTroubleshooting interfering substances","code":""},{"path":"acid-base.html","id":"test-result-interpretation-5","chapter":"Acid-Base","heading":"Test Result Interpretation","text":"Normal Values Know\npH: 7.35-7.45\nPa\\(CO_2\\): 35-45 mmHg\n\\(HCO_3^-\\): 22-26 mEq/L\nPa\\(O_2\\): 80-100 mmHg\nSa\\(O_2\\): 95-100%\nBase Excess: -2 +2 mEq/L\npH: 7.35-7.45Pa\\(CO_2\\): 35-45 mmHg\\(HCO_3^-\\): 22-26 mEq/LPa\\(O_2\\): 80-100 mmHgSa\\(O_2\\): 95-100%Base Excess: -2 +2 mEq/LSteps interpretation\npH normal, acidemic, alkalemic?\nMatch primary disorder abnormal levels Pa\\(CO_2\\) \\(HCO_3^-\\)\ncompensation? values appropriate\nPa\\(O_2\\)/Sa\\(O_2\\)?\npH normal, acidemic, alkalemic?Match primary disorder abnormal levels Pa\\(CO_2\\) \\(HCO_3^-\\)compensation? values appropriateWhat Pa\\(O_2\\)/Sa\\(O_2\\)?Important Formulas\nHenderson-Hasselbalch Equation\n\\(pH = pKa + \\log \\left( \\frac {[^-]} {[HA]} \\right)\\)\n\\(pH = 6.1 + \\log \\left( {\\frac {[HCO_3^-]} {0.03 \\times pCO_2}} \\right)\\)\n\nAnion Gap Calculation\n[\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]\n\nHenderson-Hasselbalch Equation\n\\(pH = pKa + \\log \\left( \\frac {[^-]} {[HA]} \\right)\\)\n\\(pH = 6.1 + \\log \\left( {\\frac {[HCO_3^-]} {0.03 \\times pCO_2}} \\right)\\)\n\\(pH = pKa + \\log \\left( \\frac {[^-]} {[HA]} \\right)\\)\\(pH = 6.1 + \\log \\left( {\\frac {[HCO_3^-]} {0.03 \\times pCO_2}} \\right)\\)Anion Gap Calculation\n[\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]\n[\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]","code":""},{"path":"acid-base.html","id":"disease-state-correlation-5","chapter":"Acid-Base","heading":"Disease State Correlation","text":"Respiratory Acidosis\npH < 7.35, Pa\\(CO_2\\) > 45\nCauses: COPD, drug overdose\npH < 7.35, Pa\\(CO_2\\) > 45Causes: COPD, drug overdoseRespiratory Alkalosis\npH > 7.45, Pa\\(CO_2\\) < 35\nCauses: Anxiety, hypoxia\npH > 7.45, Pa\\(CO_2\\) < 35Causes: Anxiety, hypoxiaMetabolic Acidosis\npH < 7.35, \\(HCO_3^-\\) < 22\nCauses: DKA, renal failure\npH < 7.35, \\(HCO_3^-\\) < 22Causes: DKA, renal failureMetabolic Alkalosis\npH > 7.45, \\(HCO_3^-\\) > 26\nCauses: Vomiting, diuretic use\npH > 7.45, \\(HCO_3^-\\) > 26Causes: Vomiting, diuretic useAdditional Clinical Considerations\nUse Anion Gap calculation distinguish causes metabolic acidosis\nConsider Hypoxemia\nUse Anion Gap calculation distinguish causes metabolic acidosisConsider Hypoxemia","code":""},{"path":"acid-base.html","id":"in-summary","chapter":"Acid-Base","heading":"In Summary","text":"ABGs require understanding basic chemistry, well understanding clinical implications resultThe Henderson-Hasselbalch equation can used identify potential disturbance values collectedThe kidneys, lungs, chemical buffers work together maintain homeostasis body","code":""},{"path":"metabolic-5.html","id":"metabolic-5","chapter":"Metabolic","heading":"Metabolic","text":"section acid-base determinations (including blood gases) cover topics associated biochemical theory pathways, including:pH relates acidity alkalinityHow Henderson-Hasselbalch equation explains interactionsHow evaluate parameters associated normal abnormal statesHow classify disease states","code":""},{"path":"metabolic-5.html","id":"biochemical-theory","chapter":"Metabolic","heading":"Biochemical Theory","text":"Acids, Bases, pH\nAcids donate \\(H^+\\), bases accept \n\\(pH = -log[H^+]\\), reflecting acidity alkalinity\nAcids donate \\(H^+\\), bases accept \\(pH = -log[H^+]\\), reflecting acidity alkalinityBuffer Systems\nResist pH changes (bicarbonate, hemoglobin, phosphate, protein)\nResist pH changes (bicarbonate, hemoglobin, phosphate, protein)Henderson-Hasselbalch Equation\n\\(pH = pKa + \\log \\left( {\\frac {[HCO_3^-]} {0.03 \\times PaCO_2}} \\right)\\)\nRelates pH, bicarbonate, Pa\\(CO_2\\), crucial acid-base assessment\n\\(pH = pKa + \\log \\left( {\\frac {[HCO_3^-]} {0.03 \\times PaCO_2}} \\right)\\)Relates pH, bicarbonate, Pa\\(CO_2\\), crucial acid-base assessmentpH H+ Ion Concentration\nInverse relationship: Increased [\\(H^+\\)] decreases pH\nInverse relationship: Increased [\\(H^+\\)] decreases pHCO2 O2 Transport\n\\(O_2\\) transport relies hemoglobin, affected pH, \\(CO_2\\), temperature, 2,3-BPG\n\\(CO_2\\) transported dissolved gas, carbaminohemoglobin, bicarbonate\nCarbonic anhydrase catalyzes \\(CO_2\\) bicarbonate, chloride shift maintains balance\n\\(O_2\\) transport relies hemoglobin, affected pH, \\(CO_2\\), temperature, 2,3-BPG\\(CO_2\\) transported dissolved gas, carbaminohemoglobin, bicarbonateCarbonic anhydrase catalyzes \\(CO_2\\) bicarbonate, chloride shift maintains balanceRegulation\nChemical Buffers: Immediate action maintain pH balance binding releasing \\(H^+\\) ions\nLungs (respiratory compensation)\nKidneys (metabolic compensation)\nChemical Buffers: Immediate action maintain pH balance binding releasing \\(H^+\\) ionsLungs (respiratory compensation)Kidneys (metabolic compensation)","code":""},{"path":"metabolic-5.html","id":"metabolic-pathways","chapter":"Metabolic","heading":"Metabolic Pathways","text":"Acid production normal bodily process, requiring regulation chemical buffers, well renal respiratory systemsKidneys filter selectively secrete reabsorb ions maintain balanceLungs adjust breathing patterns response pH imbalances","code":""},{"path":"metabolic-5.html","id":"normal-states-4","chapter":"Metabolic","heading":"Normal States","text":"Blood pH = 7.35-7.45Arterial Blood Gas Values\nPa\\(O_2\\): 80-100 mmHg\nPa\\(CO_2\\): 35-45 mmHg\n\\(HCO_3^-\\): 22-26 mEq/L\nBase Excess: -2 +2 mEq/L\nSa\\(O_2\\): 95-100%\nPa\\(O_2\\): 80-100 mmHgPa\\(CO_2\\): 35-45 mmHg\\(HCO_3^-\\): 22-26 mEq/LBase Excess: -2 +2 mEq/LSa\\(O_2\\): 95-100%Normal acid-base balance requires functional renal, pulmonary, metabolic systems","code":""},{"path":"metabolic-5.html","id":"abnormal-states-5","chapter":"Metabolic","heading":"Abnormal States","text":"Acidosis (pH < 7.35)\nRespiratory: Increased Pa\\(CO_2\\)\nHypoventilation (COPD, drug OD, muscular disorders)\n\nMetabolic: Decreased \\(HCO_3^-\\)\nIncreased acid production (DKA, lactic acidosis, toxins)\nBicarbonate loss (diarrhea, RTA)\nImpaired acid excretion (kidney failure)\n\nRespiratory: Increased Pa\\(CO_2\\)\nHypoventilation (COPD, drug OD, muscular disorders)\nHypoventilation (COPD, drug OD, muscular disorders)Metabolic: Decreased \\(HCO_3^-\\)\nIncreased acid production (DKA, lactic acidosis, toxins)\nBicarbonate loss (diarrhea, RTA)\nImpaired acid excretion (kidney failure)\nIncreased acid production (DKA, lactic acidosis, toxins)Bicarbonate loss (diarrhea, RTA)Impaired acid excretion (kidney failure)Alkalosis (pH > 7.45)\nRespiratory: Decreased Pa\\(CO_2\\)\nHyperventilation (anxiety, pain, hypoxia)\n\nMetabolic: Increased \\(HCO_3^-\\)\nAcid loss (vomiting, suctioning)\nBicarbonate intake retention\n\nRespiratory: Decreased Pa\\(CO_2\\)\nHyperventilation (anxiety, pain, hypoxia)\nHyperventilation (anxiety, pain, hypoxia)Metabolic: Increased \\(HCO_3^-\\)\nAcid loss (vomiting, suctioning)\nBicarbonate intake retention\nAcid loss (vomiting, suctioning)Bicarbonate intake retentionOther Abnormalities\nHypoxemia (Pa\\(O_2\\) < 80 mmHg)\nReduced inspired oxygen, hypoventilation, diffusion impairment, V/Q mismatch\n\nHypercapnia (Pa\\(CO_2\\) > 45 mmHg)\nHypoventilation, increased dead space ventilation, increased \\(CO_2\\) production\n\nHypoxemia (Pa\\(O_2\\) < 80 mmHg)\nReduced inspired oxygen, hypoventilation, diffusion impairment, V/Q mismatch\nReduced inspired oxygen, hypoventilation, diffusion impairment, V/Q mismatchHypercapnia (Pa\\(CO_2\\) > 45 mmHg)\nHypoventilation, increased dead space ventilation, increased \\(CO_2\\) production\nHypoventilation, increased dead space ventilation, increased \\(CO_2\\) production","code":""},{"path":"metabolic-5.html","id":"interconnections-3","chapter":"Metabolic","heading":"Interconnections","text":"Respiratory & Renal Systems Coordinate: Imbalances one system compensated otherpH & Ion Concentrations: pH affects electrolytes enzyme activity","code":""},{"path":"metabolic-5.html","id":"clinical-significance-5","chapter":"Metabolic","heading":"Clinical Significance","text":"Blood gases essential diagnosis treatment acid base metabolic disordersKey remember apply Henderson-Hasselbalch equation, allowing mechanistic approach metabolic disturbances","code":""},{"path":"henderson-hasselbach.html","id":"henderson-hasselbach","chapter":"Henderson-Hasselbach","heading":"Henderson-Hasselbach","text":"Blood gases pH vital homeostasis","code":""},{"path":"henderson-hasselbach.html","id":"acid-base-balance","chapter":"Henderson-Hasselbach","heading":"Acid-Base Balance","text":"Definition Acids Bases\nAcid: substance donates protons (\\(H^+\\))\nBase: substance accepts protons (\\(H^+\\))\nAcid: substance donates protons (\\(H^+\\))Base: substance accepts protons (\\(H^+\\))pH Scale\n\\(pH = -log[H^+] = -log[H_3O^+]\\)\nRanges 0 14, 7 neutral\npH < 7: Acidic\npH > 7: Basic (alkaline)\n\\(pH = -log[H^+] = -log[H_3O^+]\\)Ranges 0 14, 7 neutralpH < 7: AcidicpH > 7: Basic (alkaline)Normal Blood pH: 7.35-7.45Importance Acid-Base Balance\nOptimal enzyme function\nMaintenance cell membrane integrity\nAppropriate protein structure function\nElectrolyte balance\nOptimal enzyme functionMaintenance cell membrane integrityAppropriate protein structure functionElectrolyte balanceAcidemia: Blood pH < 7.35Alkalemia: Blood pH > 7.45Major Buffer Systems Body\nBicarbonate Buffer System: Primary buffer system extracellular fluid\nHemoglobin Buffer System: Buffers pH changes within red blood cells\nPhosphate Buffer System: Important intracellular fluid urine\nProtein Buffer System: Buffers pH changes intracellular extracellular fluid\nBicarbonate Buffer System: Primary buffer system extracellular fluidHemoglobin Buffer System: Buffers pH changes within red blood cellsPhosphate Buffer System: Important intracellular fluid urineProtein Buffer System: Buffers pH changes intracellular extracellular fluid","code":""},{"path":"henderson-hasselbach.html","id":"biochemical-theory-1","chapter":"Henderson-Hasselbach","heading":"Biochemical Theory","text":"Sources Acids Bases\nVolatile Acid: Carbon dioxide (\\(CO_2\\)), produced metabolism, converted carbonic acid (\\(H_2CO_3\\))\n\\(CO_2\\) + \\(H_2O\\) ↔︎ \\(H_2CO_3\\) ↔︎ \\(H^+\\) + \\(HCO_3^-\\)\nlungs regulate \\(CO_2\\) levels ventilation\n\nNonvolatile Acids: Produced metabolism proteins organic compounds\nExamples: Sulfuric acid, phosphoric acid, lactic acid, ketoacids\nkidneys excrete nonvolatile acids\n\nBases: Generated metabolic processes, less significant acid production\nVolatile Acid: Carbon dioxide (\\(CO_2\\)), produced metabolism, converted carbonic acid (\\(H_2CO_3\\))\n\\(CO_2\\) + \\(H_2O\\) ↔︎ \\(H_2CO_3\\) ↔︎ \\(H^+\\) + \\(HCO_3^-\\)\nlungs regulate \\(CO_2\\) levels ventilation\n\\(CO_2\\) + \\(H_2O\\) ↔︎ \\(H_2CO_3\\) ↔︎ \\(H^+\\) + \\(HCO_3^-\\)lungs regulate \\(CO_2\\) levels ventilationNonvolatile Acids: Produced metabolism proteins organic compounds\nExamples: Sulfuric acid, phosphoric acid, lactic acid, ketoacids\nkidneys excrete nonvolatile acids\nExamples: Sulfuric acid, phosphoric acid, lactic acid, ketoacidsThe kidneys excrete nonvolatile acidsBases: Generated metabolic processes, less significant acid production","code":""},{"path":"henderson-hasselbach.html","id":"regulation-of-acid-base-balance","chapter":"Henderson-Hasselbach","heading":"Regulation of Acid-Base Balance","text":"Buffer Systems\nAct immediately resist pH changes\neliminate acids bases body\nAct immediately resist pH changesDo eliminate acids bases bodyRespiratory System\nRegulates \\(CO_2\\) levels ventilation\nResponds rapidly (within minutes) pH changes\nRegulates \\(CO_2\\) levels ventilationResponds rapidly (within minutes) pH changesRenal System\nExcretes nonvolatile acids regenerates bicarbonate (\\(HCO_3^-\\))\nResponds slowly (hours days) pH changes\nExcretes nonvolatile acids regenerates bicarbonate (\\(HCO_3^-\\))Responds slowly (hours days) pH changesCompensation Mechanisms\nRespiratory Compensation: lungs adjust ventilation change \\(CO_2\\) levels response metabolic acid-base disturbances\nRenal Compensation: kidneys adjust \\(HCO_3^-\\) excretion \\(H^+\\) secretion compensate respiratory acid-base disturbances\nRespiratory Compensation: lungs adjust ventilation change \\(CO_2\\) levels response metabolic acid-base disturbancesRenal Compensation: kidneys adjust \\(HCO_3^-\\) excretion \\(H^+\\) secretion compensate respiratory acid-base disturbances","code":""},{"path":"henderson-hasselbach.html","id":"respiratory-control","chapter":"Henderson-Hasselbach","heading":"Respiratory Control","text":"Ventilation\nIncreased Ventilation: Blows \\(CO_2\\), decreases \\(H_2CO_3\\), raises pH\nDecreased Ventilation: Retains \\(CO_2\\), increases \\(H_2CO_3\\), lowers pH\nIncreased Ventilation: Blows \\(CO_2\\), decreases \\(H_2CO_3\\), raises pHDecreased Ventilation: Retains \\(CO_2\\), increases \\(H_2CO_3\\), lowers pHChemoreceptors\nCentral Chemoreceptors: Located medulla oblongata respond changes pH \\(CO_2\\) levels cerebrospinal fluid (CSF)\nPeripheral Chemoreceptors: Located carotid aortic bodies respond changes pH, \\(CO_2\\), \\(O_2\\) levels blood\nCentral Chemoreceptors: Located medulla oblongata respond changes pH \\(CO_2\\) levels cerebrospinal fluid (CSF)Peripheral Chemoreceptors: Located carotid aortic bodies respond changes pH, \\(CO_2\\), \\(O_2\\) levels bloodResponse Acidosis\nIncreased ventilation blow \\(CO_2\\) raise pH\nIncreased ventilation blow \\(CO_2\\) raise pHResponse Alkalosis\nDecreased ventilation retain \\(CO_2\\) lower pH\nDecreased ventilation retain \\(CO_2\\) lower pH","code":""},{"path":"henderson-hasselbach.html","id":"renal-control","chapter":"Henderson-Hasselbach","heading":"Renal Control","text":"Bicarbonate Reabsorption\nbicarbonate (\\(HCO_3^-\\)) reabsorbed proximal tubule\nInvolves enzyme carbonic anhydrase secretion \\(H^+\\) tubular lumen\nbicarbonate (\\(HCO_3^-\\)) reabsorbed proximal tubuleInvolves enzyme carbonic anhydrase secretion \\(H^+\\) tubular lumenAcid Excretion\n\\(H^+\\) secreted tubular lumen\n\\(H^+\\) combines buffers phosphate (\\(HPO_4^{2-}\\)) ammonia (\\(NH_3\\)) form titratable acid (\\(H_2PO_4^-\\)) ammonium (\\(NH_4^+\\))\nAmmonia produced glutamine proximal tubule\n\\(H^+\\) secreted tubular lumen\\(H^+\\) combines buffers phosphate (\\(HPO_4^{2-}\\)) ammonia (\\(NH_3\\)) form titratable acid (\\(H_2PO_4^-\\)) ammonium (\\(NH_4^+\\))Ammonia produced glutamine proximal tubuleResponse Acidosis\nIncreased \\(H^+\\) secretion\nIncreased bicarbonate reabsorption\nIncreased ammonia production\nIncreased \\(H^+\\) secretionIncreased bicarbonate reabsorptionIncreased ammonia productionResponse Alkalosis\nDecreased \\(H^+\\) secretion\nDecreased bicarbonate reabsorption\nDecreased \\(H^+\\) secretionDecreased bicarbonate reabsorption","code":""},{"path":"henderson-hasselbach.html","id":"acid-base-imbalances","chapter":"Henderson-Hasselbach","heading":"Acid-Base Imbalances","text":"Acidosis: condition blood pH normal range (< 7.35)\nRespiratory Acidosis: Caused increased \\(CO_2\\) levels (decreased ventilation)\nMetabolic Acidosis: Caused decreased \\(HCO_3^-\\) levels increased nonvolatile acid production\nRespiratory Acidosis: Caused increased \\(CO_2\\) levels (decreased ventilation)Metabolic Acidosis: Caused decreased \\(HCO_3^-\\) levels increased nonvolatile acid productionAlkalosis: condition blood pH normal range (> 7.45)\nRespiratory Alkalosis: Caused decreased \\(CO_2\\) levels (increased ventilation)\nMetabolic Alkalosis: Caused increased \\(HCO_3^-\\) levels decreased nonvolatile acid levels\nRespiratory Alkalosis: Caused decreased \\(CO_2\\) levels (increased ventilation)Metabolic Alkalosis: Caused increased \\(HCO_3^-\\) levels decreased nonvolatile acid levels","code":""},{"path":"henderson-hasselbach.html","id":"henderson-hasselbalch-equation","chapter":"Henderson-Hasselbach","heading":"Henderson-Hasselbalch Equation","text":"Equation\n\\(pH = pKa + \\log \\left( \\frac {[^-]} {[HA]} \\right)\\)\n\\(pH\\): Measure acidity basicity\n\\(pKa\\): negative log acid dissociation constant (Ka), indicating strength acid\n[\\(^-\\)]: Concentration conjugate base\n[\\(HA\\)]: Concentration weak acid\n\n\\(pH = pKa + \\log \\left( \\frac {[^-]} {[HA]} \\right)\\)\n\\(pH\\): Measure acidity basicity\n\\(pKa\\): negative log acid dissociation constant (Ka), indicating strength acid\n[\\(^-\\)]: Concentration conjugate base\n[\\(HA\\)]: Concentration weak acid\n\\(pH\\): Measure acidity basicity\\(pKa\\): negative log acid dissociation constant (Ka), indicating strength acid[\\(^-\\)]: Concentration conjugate base[\\(HA\\)]: Concentration weak acidApplication Bicarbonate Buffer System\n\\(pH = 6.1 + \\log \\left( {\\frac {[HCO_3^-]} {0.03 \\times PaCO_2}} \\right)\\)\n6.1 = \\(pKa\\) carbonic acid (\\(H_2CO_3\\))\n[\\(HCO_3^-\\)] = Concentration bicarbonate mmol/L\nPa\\(CO_2\\) = Partial pressure carbon dioxide mmHg\n0.03 = Solubility coefficient \\(CO_2\\) blood (converts Pa\\(CO_2\\) [\\(H_2CO_3\\)])\n\n\\(pH = 6.1 + \\log \\left( {\\frac {[HCO_3^-]} {0.03 \\times PaCO_2}} \\right)\\)\n6.1 = \\(pKa\\) carbonic acid (\\(H_2CO_3\\))\n[\\(HCO_3^-\\)] = Concentration bicarbonate mmol/L\nPa\\(CO_2\\) = Partial pressure carbon dioxide mmHg\n0.03 = Solubility coefficient \\(CO_2\\) blood (converts Pa\\(CO_2\\) [\\(H_2CO_3\\)])\n6.1 = \\(pKa\\) carbonic acid (\\(H_2CO_3\\))[\\(HCO_3^-\\)] = Concentration bicarbonate mmol/LPa\\(CO_2\\) = Partial pressure carbon dioxide mmHg0.03 = Solubility coefficient \\(CO_2\\) blood (converts Pa\\(CO_2\\) [\\(H_2CO_3\\)])Clinical Significance\nHenderson-Hasselbalch equation describes relationship pH, bicarbonate, Pa\\(CO_2\\) blood\nused assess acid-base balance determine cause acid-base disturbances\nChanges bicarbonate Pa\\(CO_2\\) affect pH, body uses compensation mechanisms maintain pH within normal range\nHenderson-Hasselbalch equation describes relationship pH, bicarbonate, Pa\\(CO_2\\) bloodIt used assess acid-base balance determine cause acid-base disturbancesChanges bicarbonate Pa\\(CO_2\\) affect pH, body uses compensation mechanisms maintain pH within normal range","code":""},{"path":"henderson-hasselbach.html","id":"key-terms-37","chapter":"Henderson-Hasselbach","heading":"Key Terms","text":"Acid: substance donates protons (\\(H^+\\))Base: substance accepts protons (\\(H^+\\))pH: measure acidity basicity solutionBuffer: solution resists changes pHAcidosis: condition blood pH normal rangeAlkalosis: condition blood pH normal rangeBicarbonate (\\(HCO_3^-\\)): major buffer bloodPartial Pressure Carbon Dioxide (Pa\\(CO_2\\)): measure carbon dioxide level bloodVentilation: process moving air lungsRespiratory Compensation: adjustment ventilation correct metabolic acid-base disturbancesRenal Compensation: adjustment renal excretion acid base correct respiratory acid-base disturbancesAnion Gap: difference measured cations anions serum, used assess metabolic acidosisHenderson-Hasselbalch Equation: equation describes relationship pH, bicarbonate, Pa\\(CO_2\\)Hyperventilation: Increased rate depth breathingHypoventilation: Decreased rate depth breathingBohr Effect: effect pH \\(CO_2\\) oxygen-binding affinity hemoglobinCarbonic Anhydrase: enzyme catalyzes interconversion carbon dioxide bicarbonateNormoventilation: state normal breathing, appropriate balance oxygen carbon dioxideHypoxemia: Deficiency saturation oxygen arterial blood","code":""},{"path":"ph-and-h.html","id":"ph-and-h","chapter":"pH and [H+]","heading":"pH and [H+]","text":"Understanding relationship pH hydrogen ion concentration fundamental understanding acid-base balance","code":""},{"path":"ph-and-h.html","id":"ph-and-hydrogen-ion-concentration-h","chapter":"pH and [H+]","heading":"pH and Hydrogen Ion Concentration [\\(H^+\\)]","text":"Acids Bases\nAcids: Substances donate hydrogen ions (\\(H^+\\)) solution\nBases: Substances accept hydrogen ions (\\(H^+\\)) solution\nAcids: Substances donate hydrogen ions (\\(H^+\\)) solutionBases: Substances accept hydrogen ions (\\(H^+\\)) solutionpH Definition: pH measure acidity alkalinity solution. defined negative base-10 logarithm hydrogen ion concentration:\\[pH = -log [H^+] = -log [H_3O^+]\\]Hydrogen Ion Concentration [\\(H^+\\)]\nhydrogen ion concentration [\\(H^+\\)] refers amount hydrogen ions present solution\n[\\(H^+\\)] typically expressed units moles per liter (mol/L) nanomoles per liter (nmol/L)\nhydrogen ion concentration [\\(H^+\\)] refers amount hydrogen ions present solution[\\(H^+\\)] typically expressed units moles per liter (mol/L) nanomoles per liter (nmol/L)Relationship pH [\\(H^+\\)]\nInverse Relationship: pH [\\(H^+\\)] inversely related. [\\(H^+\\)] increases, pH decreases, [\\(H^+\\)] decreases, pH increases\nAcidic Solutions: high [\\(H^+\\)] low pH (pH < 7)\nBasic Solutions: low [\\(H^+\\)] high pH (pH > 7)\nNeutral Solutions: [\\(H^+\\)] equal [\\(OH^-\\)] pH 7\nInverse Relationship: pH [\\(H^+\\)] inversely related. [\\(H^+\\)] increases, pH decreases, [\\(H^+\\)] decreases, pH increasesAcidic Solutions: high [\\(H^+\\)] low pH (pH < 7)Basic Solutions: low [\\(H^+\\)] high pH (pH > 7)Neutral Solutions: [\\(H^+\\)] equal [\\(OH^-\\)] pH 7The pH Scale\npH scale ranges 0 14\npH 0-7: Acidic\npH 7: Neutral\npH 7-14: Basic (alkaline)\npH scale ranges 0 14pH 0-7: AcidicpH 7: NeutralpH 7-14: Basic (alkaline)Normal Physiological pH\nArterial Blood: 7.35-7.45\nVenous Blood: 7.32-7.42\nCerebrospinal Fluid (CSF): 7.35-7.40\nIntracellular Fluid: Varies depending cell type, typically slightly lower extracellular fluid\nArterial Blood: 7.35-7.45Venous Blood: 7.32-7.42Cerebrospinal Fluid (CSF): 7.35-7.40Intracellular Fluid: Varies depending cell type, typically slightly lower extracellular fluidImportance Maintaining Physiological pH\nEnzyme Activity: enzymes function optimally within narrow pH range\nProtein Structure: pH affects ionization state amino acids, influences protein folding stability\nOxygen Transport: pH affects affinity hemoglobin oxygen\nElectrolyte Balance: pH affects distribution transport electrolytes\nCellular Metabolism: pH influences various metabolic processes\nEnzyme Activity: enzymes function optimally within narrow pH rangeProtein Structure: pH affects ionization state amino acids, influences protein folding stabilityOxygen Transport: pH affects affinity hemoglobin oxygenElectrolyte Balance: pH affects distribution transport electrolytesCellular Metabolism: pH influences various metabolic processesCalculations Involving pH [\\(H^+\\)]\nCalculating pH [\\(H^+\\)]: \\(pH = -log[H^+]\\)\nCalculating [\\(H^+\\)] pH: \\([H^+] = 10^{(-pH)}\\)\nCalculating pH [\\(H^+\\)]: \\(pH = -log[H^+]\\)Calculating [\\(H^+\\)] pH: \\([H^+] = 10^{(-pH)}\\)Henderson-Hasselbalch Equation\nequation relates pH concentrations bicarbonate (\\(HCO_3^-\\)) carbon dioxide (\\(CO_2\\)) blood:\n\\[pH = 6.1 + \\log \\left( \\frac{[HCO_3^-]}{0.03 \\times pCO_2} \\right)\\]\n\\(pH\\): Blood pH\n\\(pKa\\): Dissociation constant (e.g. carbonic acid \\(pKa\\) = 6.1)\n[\\(HCO_3^-\\)]: Bicarbonate concentration (mmol/L)\n0.03 solubility coefficient, converting Pa\\(CO_2\\) dissolved \\(CO_2\\)\nPa\\(CO_2\\): Partial pressure carbon dioxide (mmHg)\n\nequation relates pH concentrations bicarbonate (\\(HCO_3^-\\)) carbon dioxide (\\(CO_2\\)) blood:\n\\[pH = 6.1 + \\log \\left( \\frac{[HCO_3^-]}{0.03 \\times pCO_2} \\right)\\]\n\\(pH\\): Blood pH\n\\(pKa\\): Dissociation constant (e.g. carbonic acid \\(pKa\\) = 6.1)\n[\\(HCO_3^-\\)]: Bicarbonate concentration (mmol/L)\n0.03 solubility coefficient, converting Pa\\(CO_2\\) dissolved \\(CO_2\\)\nPa\\(CO_2\\): Partial pressure carbon dioxide (mmHg)\n\\(pH\\): Blood pH\\(pKa\\): Dissociation constant (e.g. carbonic acid \\(pKa\\) = 6.1)[\\(HCO_3^-\\)]: Bicarbonate concentration (mmol/L)0.03 solubility coefficient, converting Pa\\(CO_2\\) dissolved \\(CO_2\\)Pa\\(CO_2\\): Partial pressure carbon dioxide (mmHg)Clinical Significance\nHenderson-Hasselbalch equation used assess acid-base disturbances\nArterial Blood Gas (ABG) analysis measures pH, Pa\\(CO_2\\), \\(HCO_3^-\\), allowing diagnosis classification acid-base disorders\nHenderson-Hasselbalch equation used assess acid-base disturbancesArterial Blood Gas (ABG) analysis measures pH, Pa\\(CO_2\\), \\(HCO_3^-\\), allowing diagnosis classification acid-base disordersAcid-Base Imbalances\nAcidosis: condition blood pH 7.35\nIncreased [\\(H^+\\)]\n\nAlkalosis: condition blood pH 7.45\nDecreased [\\(H^+\\)]\n\nAcidosis: condition blood pH 7.35\nIncreased [\\(H^+\\)]\nIncreased [\\(H^+\\)]Alkalosis: condition blood pH 7.45\nDecreased [\\(H^+\\)]\nDecreased [\\(H^+\\)]","code":""},{"path":"ph-and-h.html","id":"key-terms-38","chapter":"pH and [H+]","heading":"Key Terms","text":"Acid: substance donates hydrogen ions (\\(H^+\\))Base: substance accepts hydrogen ions (\\(H^+\\))pH: measure acidity alkalinity solutionHydrogen Ion Concentration [\\(H^+\\)]: amount hydrogen ions present solutionAcidosis: condition blood pH 7.35Alkalosis: condition blood pH 7.45Buffer: substance resists changes pHHenderson-Hasselbalch Equation: equation relates pH concentrations bicarbonate carbon dioxidepKa: number characterizes strength acid","code":""},{"path":"co2-o2-transport.html","id":"co2-o2-transport","chapter":"CO2 & O2 Transport","heading":"CO2 & O2 Transport","text":"Oxygen carbon dioxide transport essential processes maintaining life. Oxygen, vital cellular respiration, primarily transported hemoglobin within red blood cells, small fraction dissolved plasma. Hemoglobin’s affinity oxygen influenced factors like pH, \\(CO_2\\), temperature, 2,3-BPG, reflected oxygen dissociation curve.Carbon dioxide, byproduct metabolism, transported three forms: dissolved plasma, bound hemoglobin carbaminohemoglobin, predominantly bicarbonate ions. conversion carbon dioxide bicarbonate catalyzed carbonic anhydrase within red blood cells, chloride shift maintains electrical neutrality process. intricate mechanisms ensure efficient gas exchange, supporting cellular function overall homeostasis","code":""},{"path":"co2-o2-transport.html","id":"oxygen-o_2-transport","chapter":"CO2 & O2 Transport","heading":"Oxygen (\\(O_2\\)) Transport","text":"Partial Pressure Oxygen (\\(PO_2\\))\nDefinition: pressure exerted oxygen mixture gases\nUnits: mmHg kPa\nNormal Range:\nArterial Blood (Pa\\(O_2\\)): 80-100 mmHg\nVenous Blood (Pv\\(O_2\\)): 30-40 mmHg\n\nDefinition: pressure exerted oxygen mixture gasesUnits: mmHg kPaNormal Range:\nArterial Blood (Pa\\(O_2\\)): 80-100 mmHg\nVenous Blood (Pv\\(O_2\\)): 30-40 mmHg\nArterial Blood (Pa\\(O_2\\)): 80-100 mmHgVenous Blood (Pv\\(O_2\\)): 30-40 mmHgOxygen Blood\nDissolved Oxygen: small amount oxygen dissolved directly plasma\nApproximately 1.5-3% total oxygen blood\nDetermines partial pressure oxygen (Pa\\(O_2\\))\n\nHemoglobin-Bound Oxygen: oxygen transported bound hemoglobin (Hb) red blood cells\nhemoglobin molecule can bind four oxygen molecules\nbinding oxygen hemoglobin reversible\n\nDissolved Oxygen: small amount oxygen dissolved directly plasma\nApproximately 1.5-3% total oxygen blood\nDetermines partial pressure oxygen (Pa\\(O_2\\))\nApproximately 1.5-3% total oxygen bloodDetermines partial pressure oxygen (Pa\\(O_2\\))Hemoglobin-Bound Oxygen: oxygen transported bound hemoglobin (Hb) red blood cells\nhemoglobin molecule can bind four oxygen molecules\nbinding oxygen hemoglobin reversible\nhemoglobin molecule can bind four oxygen moleculesThe binding oxygen hemoglobin reversibleHemoglobin Structure\nTetrameric protein consisting four polypeptide chains (globins): two alpha (α) chains two beta (β) chains\nglobin chain associated heme group, contains iron (\\(Fe^{2+}\\)) atom\niron atom binds oxygen reversibly\nTetrameric protein consisting four polypeptide chains (globins): two alpha (α) chains two beta (β) chainsEach globin chain associated heme group, contains iron (\\(Fe^{2+}\\)) atomThe iron atom binds oxygen reversiblyOxygen Binding Hemoglobin\nOxyhemoglobin: Hemoglobin bound oxygen (Hb\\(O_2\\))\nDeoxyhemoglobin: Hemoglobin bound oxygen (Hb)\nCooperative Binding: binding first oxygen molecule hemoglobin increases affinity hemoglobin subsequent oxygen molecules\nSigmoidal Oxygen Dissociation Curve: Reflects cooperative binding oxygen hemoglobin\nOxyhemoglobin: Hemoglobin bound oxygen (Hb\\(O_2\\))Deoxyhemoglobin: Hemoglobin bound oxygen (Hb)Cooperative Binding: binding first oxygen molecule hemoglobin increases affinity hemoglobin subsequent oxygen moleculesSigmoidal Oxygen Dissociation Curve: Reflects cooperative binding oxygen hemoglobinOxygen Dissociation Curve\nDefinition: graph plots percentage hemoglobin saturation (Sa\\(O_2\\)) partial pressure oxygen (Pa\\(O_2\\))\nShape: Sigmoidal (S-shaped)\nP50: partial pressure oxygen hemoglobin 50% saturated\nNormal P50: Approximately 27 mmHg\nShift Right: Decreased affinity hemoglobin oxygen (increased P50)\nCaused increased temperature, increased Pa\\(CO_2\\), decreased pH, increased 2,3-BPG\n\nShift Left: Increased affinity hemoglobin oxygen (decreased P50)\nCaused decreased temperature, decreased Pa\\(CO_2\\), increased pH, decreased 2,3-BPG\n\n\nDefinition: graph plots percentage hemoglobin saturation (Sa\\(O_2\\)) partial pressure oxygen (Pa\\(O_2\\))Shape: Sigmoidal (S-shaped)P50: partial pressure oxygen hemoglobin 50% saturated\nNormal P50: Approximately 27 mmHg\nShift Right: Decreased affinity hemoglobin oxygen (increased P50)\nCaused increased temperature, increased Pa\\(CO_2\\), decreased pH, increased 2,3-BPG\n\nShift Left: Increased affinity hemoglobin oxygen (decreased P50)\nCaused decreased temperature, decreased Pa\\(CO_2\\), increased pH, decreased 2,3-BPG\n\nNormal P50: Approximately 27 mmHgShift Right: Decreased affinity hemoglobin oxygen (increased P50)\nCaused increased temperature, increased Pa\\(CO_2\\), decreased pH, increased 2,3-BPG\nCaused increased temperature, increased Pa\\(CO_2\\), decreased pH, increased 2,3-BPGShift Left: Increased affinity hemoglobin oxygen (decreased P50)\nCaused decreased temperature, decreased Pa\\(CO_2\\), increased pH, decreased 2,3-BPG\nCaused decreased temperature, decreased Pa\\(CO_2\\), increased pH, decreased 2,3-BPGFactors Affecting Oxygen Binding\npH (Bohr Effect):\nDecreased pH (increased acidity) decreases affinity hemoglobin oxygen, shifting curve right\nIncreased pH (decreased acidity) increases affinity hemoglobin oxygen, shifting curve left\n\nCarbon Dioxide (\\(CO_2\\)):\nIncreased Pa\\(CO_2\\) decreases affinity hemoglobin oxygen, shifting curve right\nDecreased Pa\\(CO_2\\) increases affinity hemoglobin oxygen, shifting curve left\n\nTemperature:\nIncreased temperature decreases affinity hemoglobin oxygen, shifting curve right\nDecreased temperature increases affinity hemoglobin oxygen, shifting curve left\n\n2,3-Bisphosphoglycerate (2,3-BPG):\nIncreased 2,3-BPG decreases affinity hemoglobin oxygen, shifting curve right\nDecreased 2,3-BPG increases affinity hemoglobin oxygen, shifting curve left\n2,3-BPG binds deoxyhemoglobin stabilizes conformation, reducing oxygen affinity\n\npH (Bohr Effect):\nDecreased pH (increased acidity) decreases affinity hemoglobin oxygen, shifting curve right\nIncreased pH (decreased acidity) increases affinity hemoglobin oxygen, shifting curve left\nDecreased pH (increased acidity) decreases affinity hemoglobin oxygen, shifting curve rightIncreased pH (decreased acidity) increases affinity hemoglobin oxygen, shifting curve leftCarbon Dioxide (\\(CO_2\\)):\nIncreased Pa\\(CO_2\\) decreases affinity hemoglobin oxygen, shifting curve right\nDecreased Pa\\(CO_2\\) increases affinity hemoglobin oxygen, shifting curve left\nIncreased Pa\\(CO_2\\) decreases affinity hemoglobin oxygen, shifting curve rightDecreased Pa\\(CO_2\\) increases affinity hemoglobin oxygen, shifting curve leftTemperature:\nIncreased temperature decreases affinity hemoglobin oxygen, shifting curve right\nDecreased temperature increases affinity hemoglobin oxygen, shifting curve left\nIncreased temperature decreases affinity hemoglobin oxygen, shifting curve rightDecreased temperature increases affinity hemoglobin oxygen, shifting curve left2,3-Bisphosphoglycerate (2,3-BPG):\nIncreased 2,3-BPG decreases affinity hemoglobin oxygen, shifting curve right\nDecreased 2,3-BPG increases affinity hemoglobin oxygen, shifting curve left\n2,3-BPG binds deoxyhemoglobin stabilizes conformation, reducing oxygen affinity\nIncreased 2,3-BPG decreases affinity hemoglobin oxygen, shifting curve rightDecreased 2,3-BPG increases affinity hemoglobin oxygen, shifting curve left2,3-BPG binds deoxyhemoglobin stabilizes conformation, reducing oxygen affinity","code":""},{"path":"co2-o2-transport.html","id":"carbon-dioxide-co_2-transport","chapter":"CO2 & O2 Transport","heading":"Carbon Dioxide (\\(CO_2\\)) Transport","text":"Partial Pressure Carbon Dioxide (Pa\\(CO_2\\))\nDefinition: pressure exerted carbon dioxide mixture gases\nUnits: mmHg kPa\nNormal Range:\nArterial Blood (Pa\\(CO_2\\)): 35-45 mmHg\nVenous Blood (Pv\\(CO_2\\)): 40-46 mmHg\n\nDefinition: pressure exerted carbon dioxide mixture gasesUnits: mmHg kPaNormal Range:\nArterial Blood (Pa\\(CO_2\\)): 35-45 mmHg\nVenous Blood (Pv\\(CO_2\\)): 40-46 mmHg\nArterial Blood (Pa\\(CO_2\\)): 35-45 mmHgVenous Blood (Pv\\(CO_2\\)): 40-46 mmHgCarbon Dioxide Blood\nDissolved Carbon Dioxide: small amount carbon dioxide dissolved directly plasma\nApproximately 5-10% total carbon dioxide blood\n\nCarbamino Compounds: Carbon dioxide binds amino groups proteins, primarily hemoglobin\nCarbaminohemoglobin (Hb\\(CO_2\\)): Hemoglobin bound carbon dioxide\nApproximately 5-10% total carbon dioxide blood\n\nBicarbonate (\\(HCO_3^-\\)): carbon dioxide transported bicarbonate ions plasma\nApproximately 80-90% total carbon dioxide blood\n\nDissolved Carbon Dioxide: small amount carbon dioxide dissolved directly plasma\nApproximately 5-10% total carbon dioxide blood\nApproximately 5-10% total carbon dioxide bloodCarbamino Compounds: Carbon dioxide binds amino groups proteins, primarily hemoglobin\nCarbaminohemoglobin (Hb\\(CO_2\\)): Hemoglobin bound carbon dioxide\nApproximately 5-10% total carbon dioxide blood\nCarbaminohemoglobin (Hb\\(CO_2\\)): Hemoglobin bound carbon dioxideApproximately 5-10% total carbon dioxide bloodBicarbonate (\\(HCO_3^-\\)): carbon dioxide transported bicarbonate ions plasma\nApproximately 80-90% total carbon dioxide blood\nApproximately 80-90% total carbon dioxide bloodCarbon Dioxide Bicarbonate Conversion\nReaction: \\(CO_2\\) + \\(H_2O\\) ↔︎ \\(H_2CO_3\\) ↔︎ \\(H^+\\) + \\(HCO_3^-\\)\nCatalyzed Carbonic Anhydrase: enzyme present red blood cells greatly accelerates conversion carbon dioxide bicarbonate\nReaction: \\(CO_2\\) + \\(H_2O\\) ↔︎ \\(H_2CO_3\\) ↔︎ \\(H^+\\) + \\(HCO_3^-\\)Catalyzed Carbonic Anhydrase: enzyme present red blood cells greatly accelerates conversion carbon dioxide bicarbonateChloride Shift\nProcess: Bicarbonate ions (\\(HCO_3^-\\)) diffuse red blood cells plasma, chloride ions (\\(Cl^-\\)) move red blood cells maintain electrical neutrality\nReversal: lungs, process reversed: bicarbonate ions move back red blood cells, chloride ions move , carbon dioxide released exhaled\nProcess: Bicarbonate ions (\\(HCO_3^-\\)) diffuse red blood cells plasma, chloride ions (\\(Cl^-\\)) move red blood cells maintain electrical neutralityReversal: lungs, process reversed: bicarbonate ions move back red blood cells, chloride ions move , carbon dioxide released exhaled","code":""},{"path":"co2-o2-transport.html","id":"key-terms-39","chapter":"CO2 & O2 Transport","heading":"Key Terms","text":"Partial Pressure: pressure exerted single gas mixture gasesHemoglobin: protein red blood cells binds transports oxygenOxygen Dissociation Curve: graph plots percentage hemoglobin saturation partial pressure oxygenP50: partial pressure oxygen hemoglobin 50% saturatedBohr Effect: effect pH \\(CO_2\\) oxygen-binding affinity hemoglobin2,3-Bisphosphoglycerate (2,3-BPG): molecule binds deoxyhemoglobin reduces affinity oxygenCarbonic Anhydrase: enzyme catalyzes interconversion carbon dioxide bicarbonateChloride Shift: movement chloride ions red blood cells maintain electrical neutrality carbon dioxide transportOxyhemoglobin: Hemoglobin bound oxygen (Hb\\(O_2\\))Deoxyhemoglobin: Hemoglobin bound oxygen (Hb)Carbaminohemoglobin: Hemoglobin bound carbon dioxide (Hb\\(CO_2\\))Normal Saline: Normal Saline (Saline) mixture sodium chloride (salt) water. used rinsing wounds, nasal passages, contact lenses. Intravenous normal saline can used fluid replacement number conditions, dehydration, hypovolemia, sepsisHypovolemia: medical term decrease blood volume results decreased oxygen delivery bodySepsis: life-threatening condition happens body’s response infection damages tissues organsRed Blood Cell Saturation: Reflects percentage hemoglobin molecules red blood cells bound oxygen. also known oxygen saturation commonly abbreviated Sa\\(O_2\\)Hypoxia: deficiency amount oxygen reaching tissuesHypercapnia: presence abnormally high levels carbon dioxide blood","code":""},{"path":"physiology-5.html","id":"physiology-5","chapter":"Physiology","heading":"Physiology","text":"Maintaining proper balance acids bases body crucial sustaining life. Disruptions balance can lead various life-threatening conditions, including acidosis alkalosis. Understanding causes effects acid-base imbalances crucial proper diagnosis treatment. Effective management acid-base disorders requires addressing underlying cause restoring normal pH, oxygenation, ventilation. Arterial blood gas analysis provides essential information assessing acid-base status guiding therapy","code":""},{"path":"physiology-5.html","id":"normal-states-5","chapter":"Physiology","heading":"Normal States","text":"Normal Blood pH: 7.35-7.45\nMaintaining blood pH within narrow range essential optimal enzyme function, protein structure, cellular metabolism\nMaintaining blood pH within narrow range essential optimal enzyme function, protein structure, cellular metabolismNormal Arterial Blood Gas Values\nPa\\(O_2\\): 80-100 mmHg\nPartial pressure oxygen arterial blood\nIndicates amount oxygen available tissues\n\nPa\\(CO_2\\): 35-45 mmHg\nPartial pressure carbon dioxide arterial blood\nReflects effectiveness ventilation\n\n\\(HCO_3^-\\): 22-26 mEq/L\nBicarbonate concentration arterial blood\nRepresents metabolic component acid-base balance\n\nBase Excess (): -2 +2 mEq/L\nRepresents amount acid base needed restore normal pH\nPositive : Indicates excess base (alkalosis)\nNegative : Indicates excess acid (acidosis)\n\nSa\\(O_2\\): 95-100%\nOxygen saturation\nIndicates percentage hemoglobin saturated oxygen\n\nPa\\(O_2\\): 80-100 mmHg\nPartial pressure oxygen arterial blood\nIndicates amount oxygen available tissues\nPartial pressure oxygen arterial bloodIndicates amount oxygen available tissuesPa\\(CO_2\\): 35-45 mmHg\nPartial pressure carbon dioxide arterial blood\nReflects effectiveness ventilation\nPartial pressure carbon dioxide arterial bloodReflects effectiveness ventilation\\(HCO_3^-\\): 22-26 mEq/L\nBicarbonate concentration arterial blood\nRepresents metabolic component acid-base balance\nBicarbonate concentration arterial bloodRepresents metabolic component acid-base balanceBase Excess (): -2 +2 mEq/L\nRepresents amount acid base needed restore normal pH\nPositive : Indicates excess base (alkalosis)\nNegative : Indicates excess acid (acidosis)\nRepresents amount acid base needed restore normal pHPositive : Indicates excess base (alkalosis)Negative : Indicates excess acid (acidosis)Sa\\(O_2\\): 95-100%\nOxygen saturation\nIndicates percentage hemoglobin saturated oxygen\nOxygen saturationIndicates percentage hemoglobin saturated oxygen","code":""},{"path":"physiology-5.html","id":"abnormal-states-6","chapter":"Physiology","heading":"Abnormal States","text":"Acidosis: condition characterized excess acid body, resulting blood pH 7.35\nRespiratory Acidosis\nMetabolic Acidosis\nRespiratory AcidosisMetabolic AcidosisAlkalosis: condition characterized excess base body, resulting blood pH 7.45\nRespiratory Alkalosis\nMetabolic Alkalosis\nRespiratory AlkalosisMetabolic AlkalosisHypoxemia: condition characterized low oxygen levels bloodHypercapnia: condition characterized elevated carbon dioxide levels bloodMixed Acid-Base Disorders: presence one primary acid-base disorder","code":""},{"path":"physiology-5.html","id":"acid-base-disorders","chapter":"Physiology","heading":"Acid-Base Disorders","text":"","code":""},{"path":"physiology-5.html","id":"respiratory-acidosis","chapter":"Physiology","heading":"Respiratory Acidosis","text":"Definition: condition characterized decrease blood pH due increased carbon dioxide levels (hypercapnia)Causes\nHypoventilation: Impaired breathing due lung disease (e.g., COPD, pneumonia), central nervous system depression (e.g., drug overdose), neuromuscular disorders (e.g., muscular dystrophy)\nIncreased Carbon Dioxide Production: rare cases, can caused increased carbon dioxide production (e.g., malignant hyperthermia)\nHypoventilation: Impaired breathing due lung disease (e.g., COPD, pneumonia), central nervous system depression (e.g., drug overdose), neuromuscular disorders (e.g., muscular dystrophy)Increased Carbon Dioxide Production: rare cases, can caused increased carbon dioxide production (e.g., malignant hyperthermia)Laboratory Findings\npH: < 7.35\nPa\\(CO_2\\): > 45 mmHg\n\\(HCO_3^-\\): Normal acute respiratory acidosis; elevated chronic respiratory acidosis (due renal compensation)\npH: < 7.35Pa\\(CO_2\\): > 45 mmHg\\(HCO_3^-\\): Normal acute respiratory acidosis; elevated chronic respiratory acidosis (due renal compensation)Compensation\nRenal Compensation: Kidneys increase bicarbonate reabsorption acid excretion several days\nRenal Compensation: Kidneys increase bicarbonate reabsorption acid excretion several daysSymptoms\nConfusion, lethargy, headache, shortness breath\nConfusion, lethargy, headache, shortness breath","code":""},{"path":"physiology-5.html","id":"metabolic-acidosis","chapter":"Physiology","heading":"Metabolic Acidosis","text":"Definition: condition characterized decrease blood pH due decreased bicarbonate levels increased acid productionCauses\nIncreased Acid Production:\nDiabetic Ketoacidosis (DKA): Accumulation ketoacids due insulin deficiency\nLactic Acidosis: Accumulation lactic acid due anaerobic metabolism\nStarvation: Breakdown fats proteins leads increased ketoacid production\nToxins: Ingestion methanol, ethylene glycol, salicylates\n\nLoss Bicarbonate:\nDiarrhea: Loss bicarbonate-rich intestinal secretions\nRenal Tubular Acidosis (RTA): Impaired reabsorption bicarbonate kidneys\n\nImpaired Acid Excretion:\nKidney Failure: Reduced ability excrete acids regenerate bicarbonate\n\nIncreased Acid Production:\nDiabetic Ketoacidosis (DKA): Accumulation ketoacids due insulin deficiency\nLactic Acidosis: Accumulation lactic acid due anaerobic metabolism\nStarvation: Breakdown fats proteins leads increased ketoacid production\nToxins: Ingestion methanol, ethylene glycol, salicylates\nDiabetic Ketoacidosis (DKA): Accumulation ketoacids due insulin deficiencyLactic Acidosis: Accumulation lactic acid due anaerobic metabolismStarvation: Breakdown fats proteins leads increased ketoacid productionToxins: Ingestion methanol, ethylene glycol, salicylatesLoss Bicarbonate:\nDiarrhea: Loss bicarbonate-rich intestinal secretions\nRenal Tubular Acidosis (RTA): Impaired reabsorption bicarbonate kidneys\nDiarrhea: Loss bicarbonate-rich intestinal secretionsRenal Tubular Acidosis (RTA): Impaired reabsorption bicarbonate kidneysImpaired Acid Excretion:\nKidney Failure: Reduced ability excrete acids regenerate bicarbonate\nKidney Failure: Reduced ability excrete acids regenerate bicarbonateLaboratory Findings\npH: < 7.35\nPa\\(CO_2\\): Normal decreased (due respiratory compensation)\n\\(HCO_3^-\\): < 22 mEq/L\nBase Excess (): negative -2 mEq/L\npH: < 7.35Pa\\(CO_2\\): Normal decreased (due respiratory compensation)\\(HCO_3^-\\): < 22 mEq/LBase Excess (): negative -2 mEq/LAnion Gap\nDefinition: difference measured cations (Na+, \\(K^+\\)) anions (Cl-, \\(HCO_3^-\\)) serum plasma\nCalculation: Anion Gap = [\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]\nNormal Anion Gap: 8-16 mEq/L (\\(K^+\\)), 10-20 mEq/L (without \\(K^+\\))\nDefinition: difference measured cations (Na+, \\(K^+\\)) anions (Cl-, \\(HCO_3^-\\)) serum plasmaCalculation: Anion Gap = [\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]Normal Anion Gap: 8-16 mEq/L (\\(K^+\\)), 10-20 mEq/L (without \\(K^+\\))High Anion Gap Metabolic Acidosis\nIncreased production organic acids (e.g., ketoacids, lactic acid)\nCommon causes: DKA, lactic acidosis, toxins (methanol, ethylene glycol, salicylates), kidney failure\nIncreased production organic acids (e.g., ketoacids, lactic acid)Common causes: DKA, lactic acidosis, toxins (methanol, ethylene glycol, salicylates), kidney failureNormal Anion Gap (Hyperchloremic) Metabolic Acidosis\nLoss bicarbonate impaired acid excretion\nCommon causes: Diarrhea, renal tubular acidosis (RTA), administration chloride-containing solutions\nLoss bicarbonate impaired acid excretionCommon causes: Diarrhea, renal tubular acidosis (RTA), administration chloride-containing solutionsCompensation\nRespiratory Compensation: Increased ventilation blow \\(CO_2\\) raise pH\nRenal Compensation: Kidneys increase acid excretion bicarbonate reabsorption\nRespiratory Compensation: Increased ventilation blow \\(CO_2\\) raise pHRenal Compensation: Kidneys increase acid excretion bicarbonate reabsorptionSymptoms\nRapid breathing, fatigue, confusion, nausea, vomiting\nRapid breathing, fatigue, confusion, nausea, vomiting","code":""},{"path":"physiology-5.html","id":"respiratory-alkalosis","chapter":"Physiology","heading":"Respiratory Alkalosis","text":"Definition: condition characterized increase blood pH due decreased carbon dioxide levels (hypocapnia)Causes\nHyperventilation: Increased breathing rate due anxiety, pain, hypoxia, certain medical conditions (e.g., pulmonary embolism, asthma)\nMechanical Ventilation: Excessive ventilation mechanical ventilator\nCentral Nervous System Disorders: Conditions stimulate respiratory center brain\nHyperventilation: Increased breathing rate due anxiety, pain, hypoxia, certain medical conditions (e.g., pulmonary embolism, asthma)Mechanical Ventilation: Excessive ventilation mechanical ventilatorCentral Nervous System Disorders: Conditions stimulate respiratory center brainLaboratory Findings\npH: > 7.45\nPa\\(CO_2\\): < 35 mmHg\n\\(HCO_3^-\\): Normal acute respiratory alkalosis; decreased chronic respiratory alkalosis (due renal compensation)\npH: > 7.45Pa\\(CO_2\\): < 35 mmHg\\(HCO_3^-\\): Normal acute respiratory alkalosis; decreased chronic respiratory alkalosis (due renal compensation)Compensation\nRenal Compensation: Kidneys decrease bicarbonate reabsorption acid excretion several days\nRenal Compensation: Kidneys decrease bicarbonate reabsorption acid excretion several daysSymptoms\nLightheadedness, dizziness, tingling, numbness, muscle cramps, rapid breathing\nLightheadedness, dizziness, tingling, numbness, muscle cramps, rapid breathing","code":""},{"path":"physiology-5.html","id":"metabolic-alkalosis","chapter":"Physiology","heading":"Metabolic Alkalosis","text":"Definition: condition characterized increase blood pH due increased bicarbonate levels decreased acid levelsCauses\nLoss Acid:\nVomiting: Loss gastric acid (hydrochloric acid, HCl)\nNasogastric Suctioning: Removal gastric acid\n\nIncreased Bicarbonate:\nExcessive Bicarbonate Intake: Ingestion antacids\nAdministration Bicarbonate: resuscitation treatment acidosis\nContraction Alkalosis: Due volume depletion, leading increased bicarbonate concentration\n\nMineralocorticoid Excess:\nHyperaldosteronism: Increased aldosterone leads increased sodium reabsorption increased hydrogen ion excretion\n\nLoss Acid:\nVomiting: Loss gastric acid (hydrochloric acid, HCl)\nNasogastric Suctioning: Removal gastric acid\nVomiting: Loss gastric acid (hydrochloric acid, HCl)Nasogastric Suctioning: Removal gastric acidIncreased Bicarbonate:\nExcessive Bicarbonate Intake: Ingestion antacids\nAdministration Bicarbonate: resuscitation treatment acidosis\nContraction Alkalosis: Due volume depletion, leading increased bicarbonate concentration\nExcessive Bicarbonate Intake: Ingestion antacidsAdministration Bicarbonate: resuscitation treatment acidosisContraction Alkalosis: Due volume depletion, leading increased bicarbonate concentrationMineralocorticoid Excess:\nHyperaldosteronism: Increased aldosterone leads increased sodium reabsorption increased hydrogen ion excretion\nHyperaldosteronism: Increased aldosterone leads increased sodium reabsorption increased hydrogen ion excretionLaboratory Findings\npH: > 7.45\nPa\\(CO_2\\): Normal increased (due respiratory compensation)\n\\(HCO_3^-\\): > 26 mEq/L\nBase Excess (): positive +2 mEq/L\npH: > 7.45Pa\\(CO_2\\): Normal increased (due respiratory compensation)\\(HCO_3^-\\): > 26 mEq/LBase Excess (): positive +2 mEq/LCompensation\nRespiratory Compensation: Decreased ventilation retain \\(CO_2\\) lower pH\nRenal Compensation: Kidneys decrease bicarbonate reabsorption increase acid excretion\nRespiratory Compensation: Decreased ventilation retain \\(CO_2\\) lower pHRenal Compensation: Kidneys decrease bicarbonate reabsorption increase acid excretionSymptoms\n* Confusion, lightheadedness, muscle cramps, nausea, vomiting","code":""},{"path":"physiology-5.html","id":"other-abnormal-states","chapter":"Physiology","heading":"Other Abnormal States","text":"","code":""},{"path":"physiology-5.html","id":"hypoxemia","chapter":"Physiology","heading":"Hypoxemia","text":"Definition: condition characterized low oxygen levels bloodCauses\nReduced Inspired Oxygen: High altitude, breathing air low oxygen content\nHypoventilation: Decreased breathing rate depth\nDiffusion Impairment: Thickening damage alveolar membrane\nVentilation-Perfusion Mismatch: Imbalance ventilation blood flow lungs\nShunt: Blood bypasses lungs without oxygenated\nReduced Inspired Oxygen: High altitude, breathing air low oxygen contentHypoventilation: Decreased breathing rate depthDiffusion Impairment: Thickening damage alveolar membraneVentilation-Perfusion Mismatch: Imbalance ventilation blood flow lungsShunt: Blood bypasses lungs without oxygenatedLaboratory Findings\nDecreased Pa\\(O_2\\): < 80 mmHg\nDecreased Sa\\(O_2\\): < 95%\nDecreased Pa\\(O_2\\): < 80 mmHgDecreased Sa\\(O_2\\): < 95%Symptoms\n* Shortness breath, rapid breathing, confusion, cyanosis (bluish discoloration skin)","code":""},{"path":"physiology-5.html","id":"hypercapnia","chapter":"Physiology","heading":"Hypercapnia","text":"Definition: condition characterized elevated carbon dioxide levels bloodCauses\nHypoventilation: Decreased breathing rate depth\nIncreased Dead Space Ventilation: Ventilation areas lung perfused blood\nIncreased Carbon Dioxide Production: rare cases, can caused increased carbon dioxide production (e.g., malignant hyperthermia)\nHypoventilation: Decreased breathing rate depthIncreased Dead Space Ventilation: Ventilation areas lung perfused bloodIncreased Carbon Dioxide Production: rare cases, can caused increased carbon dioxide production (e.g., malignant hyperthermia)Laboratory Findings\nIncreased Pa\\(CO_2\\): > 45 mmHg\nIncreased Pa\\(CO_2\\): > 45 mmHgSymptoms\nHeadache, confusion, lethargy, shortness breath\nHeadache, confusion, lethargy, shortness breath","code":""},{"path":"physiology-5.html","id":"mixed-acid-base-disorders","chapter":"Physiology","heading":"Mixed Acid-Base Disorders","text":"Definition: presence one primary acid-base disorder occurring simultaneouslyExamples\nMetabolic Acidosis Respiratory Acidosis: Occurs patients COPD kidney failure\nMetabolic Alkalosis Respiratory Alkalosis: Occurs patients anxiety vomiting\nMetabolic Acidosis Respiratory Acidosis: Occurs patients COPD kidney failureMetabolic Alkalosis Respiratory Alkalosis: Occurs patients anxiety vomitingDiagnosis\nRequires careful analysis arterial blood gas results clinical context\nMay involve calculating expected compensation comparing actual compensation\nRequires careful analysis arterial blood gas results clinical contextMay involve calculating expected compensation comparing actual compensation","code":""},{"path":"physiology-5.html","id":"key-terms-40","chapter":"Physiology","heading":"Key Terms","text":"Acidosis: condition blood pH normal rangeAlkalosis: condition blood pH normal rangeHypoxemia: Low oxygen levels bloodHypercapnia: Elevated carbon dioxide levels bloodArterial Blood Gas (ABG): test measures levels oxygen carbon dioxide arterial bloodPartial Pressure Oxygen (Pa\\(O_2\\)): measure oxygen level arterial bloodPartial Pressure Carbon Dioxide (Pa\\(CO_2\\)): measure carbon dioxide level arterial bloodBicarbonate (\\(HCO_3^-\\)): major buffer bloodBase Excess (): measure amount acid base needed restore normal pHOxygen Saturation (Sa\\(O_2\\)): measure percentage hemoglobin saturated oxygenRespiratory Acidosis: Acidosis caused increased carbon dioxide levelsMetabolic Acidosis: Acidosis caused decreased bicarbonate levels increased acid productionRespiratory Alkalosis: Alkalosis caused decreased carbon dioxide levelsMetabolic Alkalosis: Alkalosis caused increased bicarbonate levels decreased acid levelsAnion Gap: difference measured cations anions serum plasmaHyperventilation: Increased rate depth breathingHypoventilation: Decreased rate depth breathingCOPD: Chronic obstructive pulmonary disease","code":""},{"path":"procedures-5.html","id":"procedures-5","chapter":"Procedures","heading":"Procedures","text":"Reliable blood gas analysis essential assessing patient’s respiratory metabolic health","code":""},{"path":"procedures-5.html","id":"analytical-principles","chapter":"Procedures","heading":"Analytical Principles","text":"Blood gas measurements assess pH, oxygen (Pa\\(O_2\\)), carbon dioxide (Pa\\(CO_2\\)) levels\npH: Potentiometric measurement using pH-sensitive electrode\nPa\\(O_2\\): Amperometric measurement using Clark electrode\nPa\\(CO_2\\): Potentiometric measurement using Severinghaus electrode\npH: Potentiometric measurement using pH-sensitive electrodePa\\(O_2\\): Amperometric measurement using Clark electrodePa\\(CO_2\\): Potentiometric measurement using Severinghaus electrodeBicarbonate (\\(HCO_3^-\\)) calculated, measured directly, using Henderson-Hasselbalch equationSome analyzers measure electrolytes (\\(Na^+\\), \\(K^+\\), \\(Cl^-\\), \\(Ca^{2+}\\)) using ion-selective electrodes","code":""},{"path":"procedures-5.html","id":"special-precautions-9","chapter":"Procedures","heading":"Special Precautions","text":"Patient Preparation\nSteady state: Ensure patient’s condition therapy stabilized\nSupplemental oxygen: Document patient’s oxygen level\nSteady state: Ensure patient’s condition therapy stabilizedSupplemental oxygen: Document patient’s oxygen levelSpecimen Collection\nArterial sample preferred: accurate assessment oxygen acid-base status\nSite selection: Radial artery common due collateral circulation\nTechnique:\nPerform Modified Allen Test\nUse correct needle angle\nPrevent air bubbles\nProper mixing: Promptly mix specimen\n\nSyringe Type: Pre-heparinized syringe\nArterial sample preferred: accurate assessment oxygen acid-base statusSite selection: Radial artery common due collateral circulationTechnique:\nPerform Modified Allen Test\nUse correct needle angle\nPrevent air bubbles\nProper mixing: Promptly mix specimen\nPerform Modified Allen TestUse correct needle anglePrevent air bubblesProper mixing: Promptly mix specimenSyringe Type: Pre-heparinized syringe","code":""},{"path":"procedures-5.html","id":"specimen-handling-and-processing-4","chapter":"Procedures","heading":"Specimen Handling and Processing","text":"Timing: Analyze promptly (within 15-30 minutes) store ice slow metabolismStorage: delay unavoidable, store ice (analyze within 1-2 hours)Air Exposure: Prevent air exposureClotting: Reject clotted samples","code":""},{"path":"procedures-5.html","id":"interfering-substances-10","chapter":"Procedures","heading":"Interfering Substances","text":"Air Contamination\nFalsely elevates Pa\\(O_2\\), decreases Pa\\(CO_2\\)\nFalsely elevates Pa\\(O_2\\), decreases Pa\\(CO_2\\)Excess Heparin\nLowers pH\nLowers pHMetabolic Activity\nDecreases Pa\\(O_2\\), increases Pa\\(CO_2\\)\nDecreases Pa\\(O_2\\), increases Pa\\(CO_2\\)Temperature: Affects gas solubility electrode functionHigh Bilirubin Lipids: Affect electrode measurementsCalibration Errors: Inaccurate results","code":""},{"path":"procedures-5.html","id":"troubleshooting-10","chapter":"Procedures","heading":"Troubleshooting","text":"Unexpected Results\nCheck patient preparation\nReview collection/processing\nEvaluate reagent quality\nConsider interferences\nRepeat test\nCheck patient preparationReview collection/processingEvaluate reagent qualityConsider interferencesRepeat testOut--Control QC\nCheck QC materials\nRecalibrate instrument\nReview reagents\nCheck QC materialsRecalibrate instrumentReview reagentsInconsistent Results\nCheck electrode performance\nPerform instrument maintenance\nCheck electrode performancePerform instrument maintenance","code":""},{"path":"principles-5.html","id":"principles-5","chapter":"Principles","heading":"Principles","text":"Accurate blood gas analysis crucial assessing patient’s respiratory metabolic status. Understanding analytical principles behind measurements key ensuring reliable resultspH MeasurementPartial Pressure Oxygen (Pa\\(O_2\\)) MeasurementPartial Pressure Carbon Dioxide (Pa\\(CO_2\\)) MeasurementBicarbonate (\\(HCO_3^-\\)) MeasurementElectrolyte MeasurementsCalculated Parameters","code":""},{"path":"principles-5.html","id":"ph-measurement","chapter":"Principles","heading":"pH Measurement","text":"Principle: measurement pH blood gas analysis based potentiometry, using pH-sensitive electrodeElectrode: pH electrode consists two half-cells: measuring electrode reference electrode\nMeasuring Electrode: Contains pH-sensitive glass membrane selectively binds hydrogen ions (\\(H^+\\))\nReference Electrode: Provides stable known electrical potential\nMeasuring Electrode: Contains pH-sensitive glass membrane selectively binds hydrogen ions (\\(H^+\\))Reference Electrode: Provides stable known electrical potentialProcess\nblood sample introduced measuring chamber, comes contact pH-sensitive glass membrane\nhydrogen ions sample interact glass membrane, creating potential difference measuring electrode reference electrode\npotential difference measured voltmeter, calibrated display pH value\nblood sample introduced measuring chamber, comes contact pH-sensitive glass membraneThe hydrogen ions sample interact glass membrane, creating potential difference measuring electrode reference electrodeThe potential difference measured voltmeter, calibrated display pH valueReactions\nglass membrane measuring electrode selectively binds \\(H^+\\) ions\npotential difference generated proportional pH sample\nglass membrane measuring electrode selectively binds \\(H^+\\) ionsThe potential difference generated proportional pH sampleDetection: pH displayed instrument readoutAdvantages: Accurate, precise, rapid measurement pHDisadvantages: Requires careful calibration maintenance electrodesTemperature Correction: pH temperature dependent (temperature goes , pH goes ). Blood gas analyzers temperature controlled, may able adjust pH value","code":""},{"path":"principles-5.html","id":"partial-pressure-of-oxygen-pao_2-measurement","chapter":"Principles","heading":"Partial Pressure of Oxygen (Pa\\(O_2\\)) Measurement","text":"Principle: measurement Pa\\(O_2\\) blood gas analysis based amperometry, using Clark electrodeElectrode: Clark electrode consists platinum cathode silver/silver chloride anode immersed electrolyte solution, separated sample oxygen-permeable membraneProcess\nblood sample introduced measuring chamber, oxygen diffuses membrane reduced platinum cathode\nreduction oxygen generates current proportional partial pressure oxygen sample\ncurrent measured ammeter, calibrated display Pa\\(O_2\\) value\nblood sample introduced measuring chamber, oxygen diffuses membrane reduced platinum cathodeThe reduction oxygen generates current proportional partial pressure oxygen sampleThe current measured ammeter, calibrated display Pa\\(O_2\\) valueReactions\nplatinum cathode: \\(O_2 + 2H_2O + 4e^- → 4OH^-\\)\nsilver anode: \\(4Ag + 4Cl^- → 4AgCl + 4e^-\\)\nplatinum cathode: \\(O_2 + 2H_2O + 4e^- → 4OH^-\\)silver anode: \\(4Ag + 4Cl^- → 4AgCl + 4e^-\\)Detection: Pa\\(O_2\\) displayed instrument readoutAdvantages: Accurate, precise, rapid measurement Pa\\(O_2\\)Disadvantages: Requires careful calibration maintenance electrode, can affected protein contaminationTemperature Correction: Pa\\(O_2\\) temperature dependent, blood gas analyzers temperature controlled","code":""},{"path":"principles-5.html","id":"partial-pressure-of-carbon-dioxide-paco_2-measurement","chapter":"Principles","heading":"Partial Pressure of Carbon Dioxide (Pa\\(CO_2\\)) Measurement","text":"Principle: measurement Pa\\(CO_2\\) blood gas analysis based potentiometry, using Severinghaus electrodeElectrode: Severinghaus electrode consists pH-sensitive glass electrode surrounded bicarbonate electrolyte solution, separated sample carbon dioxide-permeable membraneProcess\nblood sample introduced measuring chamber, carbon dioxide diffuses membrane equilibrates bicarbonate solution\nchange pH bicarbonate solution measured pH-sensitive glass electrode, proportional partial pressure carbon dioxide sample\nchange pH measured voltmeter, calibrated display Pa\\(CO_2\\) value\nblood sample introduced measuring chamber, carbon dioxide diffuses membrane equilibrates bicarbonate solutionThe change pH bicarbonate solution measured pH-sensitive glass electrode, proportional partial pressure carbon dioxide sampleThe change pH measured voltmeter, calibrated display Pa\\(CO_2\\) valueReactions\n\\(CO_2\\) diffuses membrane reacts \\(H_2O\\) form \\(H_2CO_3\\)\n\\(H_2CO_3\\) dissociates \\(H^+\\) \\(HCO_3^-\\)\n\\(CO_2 + H_2O ↔ H_2CO_3 ↔ H^+ + HCO_3^-\\)\n\\(CO_2\\) diffuses membrane reacts \\(H_2O\\) form \\(H_2CO_3\\)\\(H_2CO_3\\) dissociates \\(H^+\\) \\(HCO_3^-\\)\\(CO_2 + H_2O ↔ H_2CO_3 ↔ H^+ + HCO_3^-\\)Detection: Pa\\(CO_2\\) displayed instrument readoutAdvantages: Accurate, precise, rapid measurement Pa\\(CO_2\\)Disadvantages: Requires careful calibration maintenance electrode, can affected protein contamination","code":""},{"path":"principles-5.html","id":"bicarbonate-hco3--measurement","chapter":"Principles","heading":"Bicarbonate (HCO3-) Measurement","text":"Principle: Bicarbonate measured directly blood gas analyzers. Instead, calculated using Henderson-Hasselbalch equation, based measured values pH Pa\\(CO_2\\)Henderson-Hasselbalch Equation\n\\(pH = pKa + log \\left( \\frac{[HCO_3^-]}{[H_2CO_3]} \\right)\\)\nSince \\([H_2CO_3]\\) proportional \\(PCO_2\\), equation can written :\n\\(pH = pKa + log \\left( \\frac{[HCO_3^-]}{0.03 \\times PCO_2} \\right)\\)\n:\npKa = 6.1 (dissociation constant carbonic acid)\n0.03 = Solubility coefficient \\(CO_2\\) plasma\n\n\\(pH = pKa + log \\left( \\frac{[HCO_3^-]}{[H_2CO_3]} \\right)\\)Since \\([H_2CO_3]\\) proportional \\(PCO_2\\), equation can written :\\(pH = pKa + log \\left( \\frac{[HCO_3^-]}{0.03 \\times PCO_2} \\right)\\):\npKa = 6.1 (dissociation constant carbonic acid)\n0.03 = Solubility coefficient \\(CO_2\\) plasma\npKa = 6.1 (dissociation constant carbonic acid)0.03 = Solubility coefficient \\(CO_2\\) plasmaCalculation: bicarbonate concentration (\\([HCO_3^-]\\)) calculated measured pH Pa\\(CO_2\\) using rearranged Henderson-Hasselbalch equation:\n\\([HCO_3^-] = 10^{(pH - 6.1)} \\times 0.03 \\times PCO_2\\)\n\\([HCO_3^-] = 10^{(pH - 6.1)} \\times 0.03 \\times PCO_2\\)Advantages: Provides clinically useful estimate bicarbonate concentrationDisadvantages: subject errors pH PCO2 measurements","code":""},{"path":"principles-5.html","id":"electrolyte-measurements","chapter":"Principles","heading":"Electrolyte Measurements","text":"Principle: blood gas analyzers can also measure electrolytes (e.g., sodium, potassium, chloride, calcium) using ion-selective electrodes (ISEs)Ion-Selective Electrodes (ISEs)\nISEs electrochemical sensors respond selectively specific ions\nISE consists membrane selectively permeable ion interest\nelectrode immersed solution containing ion, potential difference develops across membrane\npotential difference proportional activity (concentration) ion sample\nISEs electrochemical sensors respond selectively specific ionsEach ISE consists membrane selectively permeable ion interestWhen electrode immersed solution containing ion, potential difference develops across membraneThe potential difference proportional activity (concentration) ion sampleProcess\nsample introduced measuring chamber, ISE comes contact sample\nion interest diffuses across membrane, creating potential difference\npotential difference measured voltmeter, calibrated display ion concentration\nsample introduced measuring chamber, ISE comes contact sampleThe ion interest diffuses across membrane, creating potential differenceThe potential difference measured voltmeter, calibrated display ion concentrationAdvantages: Rapid accurate measurement electrolyte concentrationsDisadvantages: Requires careful calibration maintenance electrodes, can affected protein contamination interfering substances","code":""},{"path":"principles-5.html","id":"calculated-parameters","chapter":"Principles","heading":"Calculated Parameters","text":"Base Excess ()\nDefinition: amount acid base needed restore normal pH blood sample\nCalculation: Base excess calculated blood gas analyzer using complex equation takes account pH, Pa\\(CO_2\\), hemoglobin concentration\nInterpretation:\nPositive Base Excess: Indicates excess base (alkalosis)\nNegative Base Excess: Indicates deficit base (acidosis)\n\nDefinition: amount acid base needed restore normal pH blood sampleCalculation: Base excess calculated blood gas analyzer using complex equation takes account pH, Pa\\(CO_2\\), hemoglobin concentrationInterpretation:\nPositive Base Excess: Indicates excess base (alkalosis)\nNegative Base Excess: Indicates deficit base (acidosis)\nPositive Base Excess: Indicates excess base (alkalosis)Negative Base Excess: Indicates deficit base (acidosis)Anion Gap (AG)\nDefinition: difference measured cations (\\(Na^+\\), \\(K^+\\)) anions (\\(Cl^-\\), \\(HCO_3^-\\)) serum plasma\nCalculation: Anion Gap = [\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]\nNormal Range: 8-16 mEq/L (\\(K^+\\)), 10-20 mEq/L (without \\(K^+\\))\nClinical Significance: Used assess metabolic acidosis\nDefinition: difference measured cations (\\(Na^+\\), \\(K^+\\)) anions (\\(Cl^-\\), \\(HCO_3^-\\)) serum plasmaCalculation: Anion Gap = [\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]Normal Range: 8-16 mEq/L (\\(K^+\\)), 10-20 mEq/L (without \\(K^+\\))Clinical Significance: Used assess metabolic acidosis","code":""},{"path":"principles-5.html","id":"key-terms-41","chapter":"Principles","heading":"Key Terms","text":"Potentiometry: method measure electrical potential difference two electrodesAmperometry: method measure electrical current flowing electrochemical cellClark Electrode: electrode used measure partial pressure oxygen (Pa\\(O_2\\))Severinghaus Electrode: electrode used measure partial pressure carbon dioxide (Pa\\(CO_2\\))Ion-Selective Electrode (ISE): electrochemical sensor responds selectively specific ionsHenderson-Hasselbalch Equation: equation relates pH concentrations bicarbonate carbon dioxideBase Excess (): measure amount acid base needed restore normal pHAnion Gap (AG): difference measured cations anions serum plasmaTemperature Coefficient: amount change pH substance per degree change temperatureAssayed Quality Control Material: Commercial reference material known values control calibration blood gas instruments","code":""},{"path":"precautions.html","id":"precautions","chapter":"Precautions","heading":"Precautions","text":"Accurate blood gas analysis requires careful technique attention detail ensure reliable results. includes proper handling collection troubleshootingSpecimen CollectionSpecimen Handling ProcessingCalibration Quality ControlInterfering SubstancesTroubleshooting","code":""},{"path":"precautions.html","id":"specimen-collection-5","chapter":"Precautions","heading":"Specimen Collection","text":"Patient Preparation\nSteady State: Ensure patient steady state least 20-30 minutes collection. Avoid recent changes oxygen therapy ventilation settings\nSupplemental Oxygen: Document amount supplemental oxygen patient receiving (e.g., Fi\\(O_2\\), flow rate)\nAnticoagulant Therapy: aware patients anticoagulant therapy, increases risk bleeding\nSteady State: Ensure patient steady state least 20-30 minutes collection. Avoid recent changes oxygen therapy ventilation settingsSupplemental Oxygen: Document amount supplemental oxygen patient receiving (e.g., Fi\\(O_2\\), flow rate)Anticoagulant Therapy: aware patients anticoagulant therapy, increases risk bleedingArterial vs. Venous Samples\nArterial samples preferred acid-base assessment oxygenation status\nVenous samples can used pH carbon dioxide measurements, oxygen levels accurate\nArterial samples preferred acid-base assessment oxygenation statusVenous samples can used pH carbon dioxide measurements, oxygen levels accurateSite Selection\nRadial Artery: common site due accessibility collateral circulation\nBrachial Artery: Larger easier access, higher risk complications\nFemoral Artery: Used emergency situations, highest risk complications\nRadial Artery: common site due accessibility collateral circulationBrachial Artery: Larger easier access, higher risk complicationsFemoral Artery: Used emergency situations, highest risk complicationsTechnique\nModified Allen Test: Perform modified Allen test radial artery puncture assess collateral circulation\nProper Angle: Insert needle 30-45 degree angle radial artery puncture\nAvoid Air Bubbles: Prevent air bubbles entering syringe, can affect gas measurements\nModified Allen Test: Perform modified Allen test radial artery puncture assess collateral circulationProper Angle: Insert needle 30-45 degree angle radial artery punctureAvoid Air Bubbles: Prevent air bubbles entering syringe, can affect gas measurementsSyringe Type\nUse pre-heparinized syringe designed blood gas collection\nAvoid using excessive heparin, can alter pH electrolyte measurements\nusing dry heparin syringe, ensure heparin evenly distributed\nUse pre-heparinized syringe designed blood gas collectionAvoid using excessive heparin, can alter pH electrolyte measurementsIf using dry heparin syringe, ensure heparin evenly distributedMixing\nImmediately collection, gently mix sample rolling syringe ensure adequate anticoagulation\nImmediately collection, gently mix sample rolling syringe ensure adequate anticoagulation","code":""},{"path":"precautions.html","id":"specimen-handling-and-processing-5","chapter":"Precautions","heading":"Specimen Handling and Processing","text":"Timing\nAnalyze sample soon possible collection (ideally within 15-30 minutes) minimize changes pH gas levels due cellular metabolism\nAnalyze sample soon possible collection (ideally within 15-30 minutes) minimize changes pH gas levels due cellular metabolismStorage\nanalysis delayed, store sample ice slow cellular metabolism\nSamples analyzed within 1-2 hours collection, even stored ice\nanalysis delayed, store sample ice slow cellular metabolismSamples analyzed within 1-2 hours collection, even stored iceAir Exposure\nPrevent air exposure, can affect Pa\\(O_2\\) Pa\\(CO_2\\) measurements\nair bubbles present, remove immediately mix sample \nPrevent air exposure, can affect Pa\\(O_2\\) Pa\\(CO_2\\) measurementsIf air bubbles present, remove immediately mix sample againClotting\nInspect sample clots. clots present, reject sample\nInspect sample clots. clots present, reject sampleTransportation\nTransport sample laboratory timely manner, using appropriate temperature control (ice)\nTransport sample laboratory timely manner, using appropriate temperature control (ice)","code":""},{"path":"precautions.html","id":"interfering-substances-11","chapter":"Precautions","heading":"Interfering Substances","text":"Air Contamination\nFalsely elevates Pa\\(O_2\\) decreases Pa\\(CO_2\\)\nPrevent carefully expelling air bubbles syringe\nFalsely elevates Pa\\(O_2\\) decreases Pa\\(CO_2\\)Prevent carefully expelling air bubbles syringeExcess Heparin\nCan lower pH\nUse pre-heparinized syringes minimize amount heparin used\nCan lower pHUse pre-heparinized syringes minimize amount heparin usedMetabolic Activity\nContinued metabolism sample consumes oxygen produces carbon dioxide, leading decreased Pa\\(O_2\\) increased Pa\\(CO_2\\)\nAnalyze samples promptly store ice slow metabolism\nContinued metabolism sample consumes oxygen produces carbon dioxide, leading decreased Pa\\(O_2\\) increased Pa\\(CO_2\\)Analyze samples promptly store ice slow metabolismTemperature\nTemperature affects gas solubility electrode function\nEnsure blood gas analyzer temperature controlled\nTemperature affects gas solubility electrode functionEnsure blood gas analyzer temperature controlledHigh Bilirubin Lipids\nCan interfere electrode measurements\nUse methods less susceptible interference employ techniques remove interfering substance\nCan interfere electrode measurementsUse methods less susceptible interference employ techniques remove interfering substanceCalibration Errors\nImproper calibration can lead inaccurate results\nFollow manufacturer’s calibration procedures use certified reference materials\nImproper calibration can lead inaccurate resultsFollow manufacturer’s calibration procedures use certified reference materials","code":""},{"path":"precautions.html","id":"troubleshooting-11","chapter":"Precautions","heading":"Troubleshooting","text":"Unexpected Results\nCheck patient preparation\nReview collection processing procedures\nEvaluate reagent quality calibration\nConsider interfering substances\nRepeat test using new sample\nCheck patient preparationReview collection processing proceduresEvaluate reagent quality calibrationConsider interfering substancesRepeat test using new sampleOut--Control QC\nCheck integrity QC materials\nPrepare fresh QC materials\nRe-calibrate instrument\nReview reagent quality\nRepeat QC testing\nproblem persists, contact instrument manufacturer assistance\nCheck integrity QC materialsPrepare fresh QC materialsRe-calibrate instrumentReview reagent qualityRepeat QC testingIf problem persists, contact instrument manufacturer assistanceInconsistent Results\nCheck electrode performance, replace needed\nPerform maintenance instructed manufacturer\nVerify proper instrument configuration\nCheck electrode performance, replace neededPerform maintenance instructed manufacturerVerify proper instrument configuration","code":""},{"path":"precautions.html","id":"key-terms-42","chapter":"Precautions","heading":"Key Terms","text":"Pre-analytical: Processes occur sample analyzedAnalytical: Processes involved analyzing samplePost-analytical: Processes occur sample analyzedArterial Blood Gas (ABG): test measures levels oxygen carbon dioxide arterial bloodVenous Blood Gas (VBG): test measures levels oxygen carbon dioxide venous bloodCalibration: Adjusting instrument ensure accurate readingsQuality Control: Samples used monitor accuracy precision testInterfering Substance: substance affects accuracy testModified Allen Test: test assess collateral circulation handCollateral Circulation: Circulation area supplied one artery veinHypoventilation: state reduced amount air enters lungsHyperventilation: state breathing fast deeplyPa\\(O_2\\): Partial pressure oxygen arterial bloodPa\\(CO_2\\): Partial pressure carbon dioxide arterial bloodAnticoagulation: Slows clotting blood","code":""},{"path":"result-interpretation-5.html","id":"result-interpretation-5","chapter":"Result Interpretation","heading":"Result Interpretation","text":"Interpreting blood gas results requires systematic approach assess patient’s acid-base oxygenation statusKey ParametersStep--Step InterpretationAcid-Base DisordersCompensationClinical Scenarios","code":""},{"path":"result-interpretation-5.html","id":"key-parameters","chapter":"Result Interpretation","heading":"Key Parameters","text":"pH: 7.35-7.45\nPrimary indicator acid-base balance\n\\(<\\) 7.35: Acidemia\n\\(>\\) 7.45: Alkalemia\nPrimary indicator acid-base balance\\(<\\) 7.35: Acidemia\\(>\\) 7.45: AlkalemiaPa\\(CO_2\\): 35-45 mmHg\nPartial pressure carbon dioxide arterial blood\nReflects respiratory component acid-base balance\n\\(>\\) 45 mmHg: Respiratory Acidosis\n\\(<\\) 35 mmHg: Respiratory Alkalosis\nPartial pressure carbon dioxide arterial bloodReflects respiratory component acid-base balance\\(>\\) 45 mmHg: Respiratory Acidosis\\(<\\) 35 mmHg: Respiratory Alkalosis\\(HCO_3^-\\): 22-26 mEq/L\nBicarbonate concentration arterial blood\nReflects metabolic component acid-base balance\n\\(<\\) 22 mEq/L: Metabolic Acidosis\n\\(>\\) 26 mEq/L: Metabolic Alkalosis\nBicarbonate concentration arterial bloodReflects metabolic component acid-base balance\\(<\\) 22 mEq/L: Metabolic Acidosis\\(>\\) 26 mEq/L: Metabolic AlkalosisPa\\(O_2\\): 80-100 mmHg\nPartial pressure oxygen arterial blood\nIndicates oxygenation status\n\\(<\\) 80 mmHg: Hypoxemia\nPartial pressure oxygen arterial bloodIndicates oxygenation status\\(<\\) 80 mmHg: HypoxemiaSa\\(O_2\\): 95-100%\nOxygen saturation\nIndicates percentage hemoglobin saturated oxygen\n\\(<\\) 95%: Hypoxemia\nOxygen saturationIndicates percentage hemoglobin saturated oxygen\\(<\\) 95%: HypoxemiaBase Excess (): -2 +2 mEq/L\nRepresents amount acid base needed restore normal pH\n\\(<\\) -2 mEq/L: Metabolic Acidosis\n\\(>\\) +2 mEq/L: Metabolic Alkalosis\nRepresents amount acid base needed restore normal pH\\(<\\) -2 mEq/L: Metabolic Acidosis\\(>\\) +2 mEq/L: Metabolic AlkalosisAnion Gap: 8-16 mEq/L (\\(K^+\\)), 10-20 mEq/L (without \\(K^+\\))\nAnion Gap = [\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]\nUsed assess metabolic acidosis\nAnion Gap = [\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]Used assess metabolic acidosis","code":""},{"path":"result-interpretation-5.html","id":"step-by-step-interpretation","chapter":"Result Interpretation","heading":"Step-by-Step Interpretation","text":"Examine pH:\npH within normal range (7.35-7.45)?\n, acidemic (< 7.35) alkalemic (> 7.45)?\npH within normal range (7.35-7.45)?, acidemic (< 7.35) alkalemic (> 7.45)?Evaluate Respiratory Component (Pa\\(CO_2\\)):\nPa\\(CO_2\\) within normal range (35-45 mmHg)?\n, elevated (> 45 mmHg, indicating respiratory acidosis) decreased (< 35 mmHg, indicating respiratory alkalosis)?\nPa\\(CO_2\\) within normal range (35-45 mmHg)?, elevated (> 45 mmHg, indicating respiratory acidosis) decreased (< 35 mmHg, indicating respiratory alkalosis)?Assess Metabolic Component (\\(HCO_3^-\\)):\n\\(HCO_3^-\\) within normal range (22-26 mEq/L)?\n, decreased (< 22 mEq/L, indicating metabolic acidosis) elevated (> 26 mEq/L, indicating metabolic alkalosis)?\n\\(HCO_3^-\\) within normal range (22-26 mEq/L)?, decreased (< 22 mEq/L, indicating metabolic acidosis) elevated (> 26 mEq/L, indicating metabolic alkalosis)?Determine Primary Disorder:\nMatch pH abnormality corresponding primary disturbance:\nAcidemia + Elevated Pa\\(CO_2\\): Respiratory Acidosis\nAcidemia + Decreased \\(HCO_3^-\\): Metabolic Acidosis\nAlkalemia + Decreased Pa\\(CO_2\\): Respiratory Alkalosis\nAlkalemia + Elevated \\(HCO_3^-\\): Metabolic Alkalosis\n\nMatch pH abnormality corresponding primary disturbance:\nAcidemia + Elevated Pa\\(CO_2\\): Respiratory Acidosis\nAcidemia + Decreased \\(HCO_3^-\\): Metabolic Acidosis\nAlkalemia + Decreased Pa\\(CO_2\\): Respiratory Alkalosis\nAlkalemia + Elevated \\(HCO_3^-\\): Metabolic Alkalosis\nAcidemia + Elevated Pa\\(CO_2\\): Respiratory AcidosisAcidemia + Decreased \\(HCO_3^-\\): Metabolic AcidosisAlkalemia + Decreased Pa\\(CO_2\\): Respiratory AlkalosisAlkalemia + Elevated \\(HCO_3^-\\): Metabolic AlkalosisEvaluate Compensation:\nevidence compensation system?\nRespiratory Compensation: lungs try compensate metabolic disorders adjusting Pa\\(CO_2\\)\nRenal Compensation: kidneys try compensate respiratory disorders adjusting \\(HCO_3^-\\)\nCompensation present non-causative parameter also abnormal\nevidence compensation system?Respiratory Compensation: lungs try compensate metabolic disorders adjusting Pa\\(CO_2\\)Renal Compensation: kidneys try compensate respiratory disorders adjusting \\(HCO_3^-\\)Compensation present non-causative parameter also abnormalAssess Oxygenation:\nPa\\(O_2\\) within normal range (80-100 mmHg)?\nSa\\(O_2\\) within normal range (95-100%)?\n, evidence hypoxemia?\nPa\\(O_2\\) within normal range (80-100 mmHg)?Sa\\(O_2\\) within normal range (95-100%)?, evidence hypoxemia?Calculate Anion Gap (Metabolic Acidosis present):\nAnion Gap = [\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]\nNormal Anion Gap: 8-16 mEq/L (\\(K^+\\)), 10-20 mEq/L (without \\(K^+\\))\nElevated Anion Gap: Suggests presence unmeasured acids (e.g., ketoacids, lactic acid)\nAnion Gap = [\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]Normal Anion Gap: 8-16 mEq/L (\\(K^+\\)), 10-20 mEq/L (without \\(K^+\\))Elevated Anion Gap: Suggests presence unmeasured acids (e.g., ketoacids, lactic acid)Determine Expected Compensation Appropriate:\nprimary disorder determined, calculate “expected” range compensating parameter\nmeasured value doesn’t fall range, may mixed acid-base disorder\nprimary disorder determined, calculate “expected” range compensating parameterIf measured value doesn’t fall range, may mixed acid-base disorder","code":""},{"path":"result-interpretation-5.html","id":"acid-base-disorders-1","chapter":"Result Interpretation","heading":"Acid-Base Disorders","text":"Respiratory Acidosis\nDefinition: Decreased pH Increased Pa\\(CO_2\\)\nCauses: Hypoventilation due COPD, drug overdose, neuromuscular disorders\nCompensation: Increased \\(HCO_3^-\\) (renal compensation)\nDefinition: Decreased pH Increased Pa\\(CO_2\\)Causes: Hypoventilation due COPD, drug overdose, neuromuscular disordersCompensation: Increased \\(HCO_3^-\\) (renal compensation)Respiratory Alkalosis\nDefinition: Increased pH Decreased Pa\\(CO_2\\)\nCauses: Hyperventilation due anxiety, pain, hypoxia\nCompensation: Decreased \\(HCO_3^-\\) (renal compensation)\nDefinition: Increased pH Decreased Pa\\(CO_2\\)Causes: Hyperventilation due anxiety, pain, hypoxiaCompensation: Decreased \\(HCO_3^-\\) (renal compensation)Metabolic Acidosis\nDefinition: Decreased pH Decreased \\(HCO_3^-\\)\nCauses: Increased acid production (DKA, lactic acidosis), bicarbonate loss (diarrhea), impaired acid excretion (renal failure)\nCompensation: Decreased Pa\\(CO_2\\) (respiratory compensation)\nAssess Anion Gap: determine cause metabolic acidosis\nDefinition: Decreased pH Decreased \\(HCO_3^-\\)Causes: Increased acid production (DKA, lactic acidosis), bicarbonate loss (diarrhea), impaired acid excretion (renal failure)Compensation: Decreased Pa\\(CO_2\\) (respiratory compensation)Assess Anion Gap: determine cause metabolic acidosisMetabolic Alkalosis\nDefinition: Increased pH Increased \\(HCO_3^-\\)\nCauses: Loss acid (vomiting), increased bicarbonate intake, mineralocorticoid excess\nCompensation: Increased Pa\\(CO_2\\) (respiratory compensation)\nDefinition: Increased pH Increased \\(HCO_3^-\\)Causes: Loss acid (vomiting), increased bicarbonate intake, mineralocorticoid excessCompensation: Increased Pa\\(CO_2\\) (respiratory compensation)","code":""},{"path":"result-interpretation-5.html","id":"compensation","chapter":"Result Interpretation","heading":"Compensation","text":"Respiratory Compensation Metabolic Acidosis\nExpected Pa\\(CO_2\\) = 1.5 x [\\(HCO_3^-\\)] + 8 ± 2\nExpected Pa\\(CO_2\\) = 1.5 x [\\(HCO_3^-\\)] + 8 ± 2Respiratory Compensation Metabolic Alkalosis\nExpected Pa\\(CO_2\\) = 0.7 x [\\(HCO_3^-\\)] + 20 ± 5\nExpected Pa\\(CO_2\\) = 0.7 x [\\(HCO_3^-\\)] + 20 ± 5Metabolic Compensation Respiratory Acidosis\nAcute: \\(HCO_3^-\\) increases 1 mEq/L every 10 mmHg increase Pa\\(CO_2\\)\nChronic: \\(HCO_3^-\\) increases 3.5 mEq/L every 10 mmHg increase Pa\\(CO_2\\)\nAcute: \\(HCO_3^-\\) increases 1 mEq/L every 10 mmHg increase Pa\\(CO_2\\)Chronic: \\(HCO_3^-\\) increases 3.5 mEq/L every 10 mmHg increase Pa\\(CO_2\\)Metabolic Compensation Respiratory Alkalosis\nAcute: \\(HCO_3^-\\) decreases 2 mEq/L every 10 mmHg decrease Pa\\(CO_2\\)\nChronic: \\(HCO_3^-\\) decreases 5 mEq/L every 10 mmHg decrease Pa\\(CO_2\\)\nAcute: \\(HCO_3^-\\) decreases 2 mEq/L every 10 mmHg decrease Pa\\(CO_2\\)Chronic: \\(HCO_3^-\\) decreases 5 mEq/L every 10 mmHg decrease Pa\\(CO_2\\)","code":""},{"path":"result-interpretation-5.html","id":"clinical-scenarios","chapter":"Result Interpretation","heading":"Clinical Scenarios","text":"Patient COPD Pneumonia: Low pH, high Pa\\(CO_2\\), high \\(HCO_3^-\\). Diagnosis: Partially compensated respiratory acidosisPatient DKA: Low pH, low \\(HCO_3^-\\), low Pa\\(CO_2\\), high anion gap. Diagnosis: Fully compensated metabolic acidosis elevated anion gapPatient Hyperventilation Due Anxiety: High pH, low Pa\\(CO_2\\), low \\(HCO_3^-\\). Diagnosis: Partially compensated respiratory alkalosisPatient Prolonged Vomiting: High pH, high \\(HCO_3^-\\), high Pa\\(CO_2\\). Diagnosis: Fully compensated metabolic alkalosis","code":""},{"path":"result-interpretation-5.html","id":"key-terms-43","chapter":"Result Interpretation","heading":"Key Terms","text":"Acidemia: condition blood pH normal rangeAlkalemia: condition blood pH normal rangeHypoxemia: Low oxygen levels bloodHypercapnia: Elevated carbon dioxide levels bloodAcidosis: condition much acid body fluidsAlkalosis: condition much base body fluidsArterial Blood Gas (ABG): test measures levels oxygen carbon dioxide arterial bloodPartial Pressure Oxygen (Pa\\(O_2\\)): measure oxygen level arterial bloodPartial Pressure Carbon Dioxide (Pa\\(CO_2\\)): measure carbon dioxide level arterial bloodBicarbonate (\\(HCO_3^-\\)): major buffer bloodBase Excess (): measure amount acid base needed restore normal pHOxygen Saturation (Sa\\(O_2\\)): measure percentage hemoglobin saturated oxygenRespiratory Acidosis: Acidosis caused increased carbon dioxide levelsMetabolic Acidosis: Acidosis caused decreased bicarbonate levels increased acid productionRespiratory Alkalosis: Alkalosis caused decreased carbon dioxide levelsMetabolic Alkalosis: Alkalosis caused increased bicarbonate levels decreased acid levelsAnion Gap: difference measured cations anions serum plasmaCompensation: physiological response acid-base disturbance attempts restore normal pHEstimated Glomerular Filtration Rate (eGFR): estimate GFR based serum creatinine, age, sex, ethnicityBody Surface Area (BSA): measured calculated surface human bodyModified Allen Test: test assess collateral circulation hand","code":""},{"path":"disease-correlation-5.html","id":"disease-correlation-5","chapter":"Disease Correlation","heading":"Disease Correlation","text":"Connecting acid-base disturbances specific disease states allows accurate diagnosis targeted treatment. helps assess patient’s condition guide right approach managementRespiratory AcidosisRespiratory AlkalosisMetabolic AcidosisMetabolic Alkalosis","code":""},{"path":"disease-correlation-5.html","id":"respiratory-acidosis-1","chapter":"Disease Correlation","heading":"Respiratory Acidosis","text":"Definition: condition characterized decrease blood pH (< 7.35) due increase arterial carbon dioxide tension (Pa\\(CO_2\\) > 45 mmHg) resulting inadequate alveolar ventilationUnderlying Pathophysiology:\nInadequate alveolar ventilation causes carbon dioxide retention, leading increased carbonic acid (\\(H_2CO_3\\)) concentration blood\nresults increase hydrogen ion (\\(H^+\\)) concentration decrease pH\nInadequate alveolar ventilation causes carbon dioxide retention, leading increased carbonic acid (\\(H_2CO_3\\)) concentration bloodThis results increase hydrogen ion (\\(H^+\\)) concentration decrease pHCommon Causes\nChronic Obstructive Pulmonary Disease (COPD): Emphysema, chronic bronchitis\nCentral Nervous System (CNS) Depression: Drug overdose (e.g., opioids, sedatives), brainstem injury\nNeuromuscular Disorders: Muscular dystrophy, amyotrophic lateral sclerosis (ALS), myasthenia gravis\nSevere Pneumonia Acute Respiratory Distress Syndrome (ARDS): Impaired gas exchange\nChest Wall Abnormalities: Kyphoscoliosis, flail chest\nChronic Obstructive Pulmonary Disease (COPD): Emphysema, chronic bronchitisCentral Nervous System (CNS) Depression: Drug overdose (e.g., opioids, sedatives), brainstem injuryNeuromuscular Disorders: Muscular dystrophy, amyotrophic lateral sclerosis (ALS), myasthenia gravisSevere Pneumonia Acute Respiratory Distress Syndrome (ARDS): Impaired gas exchangeChest Wall Abnormalities: Kyphoscoliosis, flail chestLaboratory Findings\npH: < 7.35\nPa\\(CO_2\\): > 45 mmHg\n\\(HCO_3^-\\): Normal acute respiratory acidosis; elevated chronic respiratory acidosis (due renal compensation)\nPa\\(O_2\\): May decreased, depending underlying cause\npH: < 7.35Pa\\(CO_2\\): > 45 mmHg\\(HCO_3^-\\): Normal acute respiratory acidosis; elevated chronic respiratory acidosis (due renal compensation)Pa\\(O_2\\): May decreased, depending underlying causeSymptoms\nAcute Respiratory Acidosis: Confusion, anxiety, restlessness, dyspnea (shortness breath), cyanosis (bluish discoloration skin), headache, dizziness, cardiac arrhythmias\nChronic Respiratory Acidosis: Often asymptomatic mild symptoms fatigue, lethargy, sleep disturbances\nAcute Respiratory Acidosis: Confusion, anxiety, restlessness, dyspnea (shortness breath), cyanosis (bluish discoloration skin), headache, dizziness, cardiac arrhythmiasChronic Respiratory Acidosis: Often asymptomatic mild symptoms fatigue, lethargy, sleep disturbancesDisease State Correlation\nCOPD: Chronic bronchitis emphysema cause airflow obstruction, leading carbon dioxide retention\nDrug Overdose: Opioids sedatives depress respiratory center brain, resulting hypoventilation\nNeuromuscular Disorders: Muscle weakness impairs ability breathe effectively\nPneumonia ARDS: Inflammation fluid accumulation lungs impair gas exchange\nChest Wall Abnormalities: Restrict lung expansion impair ventilation\nCOPD: Chronic bronchitis emphysema cause airflow obstruction, leading carbon dioxide retentionDrug Overdose: Opioids sedatives depress respiratory center brain, resulting hypoventilationNeuromuscular Disorders: Muscle weakness impairs ability breathe effectivelyPneumonia ARDS: Inflammation fluid accumulation lungs impair gas exchangeChest Wall Abnormalities: Restrict lung expansion impair ventilation","code":""},{"path":"disease-correlation-5.html","id":"respiratory-alkalosis-1","chapter":"Disease Correlation","heading":"Respiratory Alkalosis","text":"Definition: condition characterized increase blood pH (> 7.45) due decreased arterial carbon dioxide tension (Pa\\(CO_2\\) < 35 mmHg) resulting excessive alveolar ventilationUnderlying Pathophysiology\nExcessive alveolar ventilation causes carbon dioxide blown , leading decreased carbonic acid (\\(H_2CO_3\\)) concentration blood\nresults decrease hydrogen ion (\\(H^+\\)) concentration increase pH\nExcessive alveolar ventilation causes carbon dioxide blown , leading decreased carbonic acid (\\(H_2CO_3\\)) concentration bloodThis results decrease hydrogen ion (\\(H^+\\)) concentration increase pHCommon Causes\nHyperventilation Syndrome: Anxiety, panic attacks\nHypoxia: High altitude, severe anemia\nPulmonary Embolism: Stimulation respiratory centers\nCentral Nervous System Disorders: Stroke, meningitis, encephalitis\nMechanical Ventilation: Excessive ventilation mechanical ventilator\nPregnancy: Hormonal stimulation respiratory center\nSalicylate Poisoning: Direct stimulation respiratory center\nHyperventilation Syndrome: Anxiety, panic attacksHypoxia: High altitude, severe anemiaPulmonary Embolism: Stimulation respiratory centersCentral Nervous System Disorders: Stroke, meningitis, encephalitisMechanical Ventilation: Excessive ventilation mechanical ventilatorPregnancy: Hormonal stimulation respiratory centerSalicylate Poisoning: Direct stimulation respiratory centerLaboratory Findings\npH: > 7.45\nPa\\(CO_2\\): < 35 mmHg\n\\(HCO_3^-\\): Normal acute respiratory alkalosis; decreased chronic respiratory alkalosis (due renal compensation)\nPa\\(O_2\\): May normal decreased, depending underlying cause\npH: > 7.45Pa\\(CO_2\\): < 35 mmHg\\(HCO_3^-\\): Normal acute respiratory alkalosis; decreased chronic respiratory alkalosis (due renal compensation)Pa\\(O_2\\): May normal decreased, depending underlying causeSymptoms\nDizziness, lightheadedness, confusion, paresthesias (numbness tingling), muscle cramps, carpopedal spasm (spasm hands feet), chest pain, palpitations\nDizziness, lightheadedness, confusion, paresthesias (numbness tingling), muscle cramps, carpopedal spasm (spasm hands feet), chest pain, palpitationsDisease State Correlation\nHyperventilation Syndrome: Anxiety panic attacks cause rapid breathing, leading excessive carbon dioxide elimination\nHypoxia: Low oxygen levels stimulate respiratory center increase ventilation\nPulmonary Embolism: Blood clot lungs stimulates respiratory centers, leading hyperventilation\nPregnancy: Progesterone hormones stimulate respiratory center\nHyperventilation Syndrome: Anxiety panic attacks cause rapid breathing, leading excessive carbon dioxide eliminationHypoxia: Low oxygen levels stimulate respiratory center increase ventilationPulmonary Embolism: Blood clot lungs stimulates respiratory centers, leading hyperventilationPregnancy: Progesterone hormones stimulate respiratory center","code":""},{"path":"disease-correlation-5.html","id":"metabolic-acidosis-1","chapter":"Disease Correlation","heading":"Metabolic Acidosis","text":"Definition: condition characterized decrease blood pH (< 7.35) due primary decrease serum bicarbonate concentration (\\(HCO_3^-\\) < 22 mEq/L)Underlying Pathophysiology\nLoss bicarbonate: Results decrease buffering capacity drop pH\nExcess production acids: Overwhelms body’s buffering capacity, leading decrease pH\nImpaired excretion acids: Leads accumulation acids blood, lowering pH\nLoss bicarbonate: Results decrease buffering capacity drop pHExcess production acids: Overwhelms body’s buffering capacity, leading decrease pHImpaired excretion acids: Leads accumulation acids blood, lowering pHCommon Causes\nIncreased Acid Production:\nDiabetic Ketoacidosis (DKA): Insulin deficiency leads increased ketone production\nLactic Acidosis: Anaerobic metabolism due shock, sepsis, severe exercise\nStarvation: Breakdown fats proteins leads increased ketoacid production\nToxins: Ingestion methanol, ethylene glycol, salicylates\n\nLoss Bicarbonate:\nDiarrhea: Loss bicarbonate-rich intestinal secretions\nRenal Tubular Acidosis (RTA): Impaired reabsorption bicarbonate kidneys\n\nImpaired Acid Excretion:\nKidney Failure: Reduced ability excrete acids regenerate bicarbonate\n\nIncreased Acid Production:\nDiabetic Ketoacidosis (DKA): Insulin deficiency leads increased ketone production\nLactic Acidosis: Anaerobic metabolism due shock, sepsis, severe exercise\nStarvation: Breakdown fats proteins leads increased ketoacid production\nToxins: Ingestion methanol, ethylene glycol, salicylates\nDiabetic Ketoacidosis (DKA): Insulin deficiency leads increased ketone productionLactic Acidosis: Anaerobic metabolism due shock, sepsis, severe exerciseStarvation: Breakdown fats proteins leads increased ketoacid productionToxins: Ingestion methanol, ethylene glycol, salicylatesLoss Bicarbonate:\nDiarrhea: Loss bicarbonate-rich intestinal secretions\nRenal Tubular Acidosis (RTA): Impaired reabsorption bicarbonate kidneys\nDiarrhea: Loss bicarbonate-rich intestinal secretionsRenal Tubular Acidosis (RTA): Impaired reabsorption bicarbonate kidneysImpaired Acid Excretion:\nKidney Failure: Reduced ability excrete acids regenerate bicarbonate\nKidney Failure: Reduced ability excrete acids regenerate bicarbonateLaboratory Findings\npH: < 7.35\nPa\\(CO_2\\): Normal decreased (due respiratory compensation)\n\\(HCO_3^-\\): < 22 mEq/L\nBase Excess (): negative -2 mEq/L\nAnion Gap: May normal elevated, depending cause\npH: < 7.35Pa\\(CO_2\\): Normal decreased (due respiratory compensation)\\(HCO_3^-\\): < 22 mEq/LBase Excess (): negative -2 mEq/LAnion Gap: May normal elevated, depending causeAnion Gap\nDefinition: difference measured cations (Na+, \\(K^+\\)) anions (Cl-, \\(HCO_3^-\\)) serum plasma\nCalculation: Anion Gap = [\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]\nNormal Anion Gap: 8-16 mEq/L (\\(K^+\\)), 10-20 mEq/L (without \\(K^+\\))\nDefinition: difference measured cations (Na+, \\(K^+\\)) anions (Cl-, \\(HCO_3^-\\)) serum plasmaCalculation: Anion Gap = [\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]Normal Anion Gap: 8-16 mEq/L (\\(K^+\\)), 10-20 mEq/L (without \\(K^+\\))Disease State Correlation\nDiabetic Ketoacidosis (DKA): Insulin deficiency leads increased ketone production, resulting high anion gap metabolic acidosis\nLactic Acidosis: Anaerobic metabolism due shock, sepsis, severe exercise results increased lactic acid production, leading high anion gap metabolic acidosis\nDiarrhea: Loss bicarbonate-rich intestinal secretions results normal anion gap (hyperchloremic) metabolic acidosis\nKidney Failure: Reduced ability excrete acids regenerate bicarbonate results high anion gap metabolic acidosis\nToxins:\nMethanol: Metabolism formic acid\nEthylene Glycol: Metabolism glycolic acid oxalic acid\nSalicylates: Complex effects metabolism respiration\n\nDiabetic Ketoacidosis (DKA): Insulin deficiency leads increased ketone production, resulting high anion gap metabolic acidosisLactic Acidosis: Anaerobic metabolism due shock, sepsis, severe exercise results increased lactic acid production, leading high anion gap metabolic acidosisDiarrhea: Loss bicarbonate-rich intestinal secretions results normal anion gap (hyperchloremic) metabolic acidosisKidney Failure: Reduced ability excrete acids regenerate bicarbonate results high anion gap metabolic acidosisToxins:\nMethanol: Metabolism formic acid\nEthylene Glycol: Metabolism glycolic acid oxalic acid\nSalicylates: Complex effects metabolism respiration\nMethanol: Metabolism formic acidEthylene Glycol: Metabolism glycolic acid oxalic acidSalicylates: Complex effects metabolism respirationCompensation\nRespiratory Compensation: Increased ventilation blow carbon dioxide raise pH\nRenal Compensation: Increased excretion acid increased reabsorption bicarbonate several days\nRespiratory Compensation: Increased ventilation blow carbon dioxide raise pHRenal Compensation: Increased excretion acid increased reabsorption bicarbonate several daysSymptoms\nRapid breathing, fatigue, confusion, nausea, vomiting\nRapid breathing, fatigue, confusion, nausea, vomiting","code":""},{"path":"disease-correlation-5.html","id":"metabolic-alkalosis-1","chapter":"Disease Correlation","heading":"Metabolic Alkalosis","text":"Definition: condition characterized increase blood pH (> 7.45) due primary increase serum bicarbonate concentration (\\(HCO_3^-\\) > 26 mEq/L)Underlying Pathophysiology\nExcess alkali administration: Overwhelms body’s acid-base regulatory mechanisms\nExcess loss acid: Depletes body’s acid stores, leading relative excess bicarbonate\nContraction alkalosis: Volume contraction stimulates bicarbonate reabsorption kidneys\nExcess alkali administration: Overwhelms body’s acid-base regulatory mechanismsExcess loss acid: Depletes body’s acid stores, leading relative excess bicarbonateContraction alkalosis: Volume contraction stimulates bicarbonate reabsorption kidneysCommon Causes\nLoss Acid:\nVomiting: Loss gastric acid (hydrochloric acid, \\(HCl\\))\nNasogastric Suctioning: Removal gastric acid\n\nExcess Bicarbonate Administration:\nAdministration Bicarbonate: resuscitation treatment acidosis\nExcessive Antacid Use: Ingestion large amounts antacids containing bicarbonate\n\nContraction Alkalosis:\nDiuretic Therapy: Volume depletion stimulates bicarbonate reabsorption kidneys\n\nMineralocorticoid Excess:\nHyperaldosteronism: Increased aldosterone leads increased sodium reabsorption increased hydrogen ion excretion\n\nLoss Acid:\nVomiting: Loss gastric acid (hydrochloric acid, \\(HCl\\))\nNasogastric Suctioning: Removal gastric acid\nVomiting: Loss gastric acid (hydrochloric acid, \\(HCl\\))Nasogastric Suctioning: Removal gastric acidExcess Bicarbonate Administration:\nAdministration Bicarbonate: resuscitation treatment acidosis\nExcessive Antacid Use: Ingestion large amounts antacids containing bicarbonate\nAdministration Bicarbonate: resuscitation treatment acidosisExcessive Antacid Use: Ingestion large amounts antacids containing bicarbonateContraction Alkalosis:\nDiuretic Therapy: Volume depletion stimulates bicarbonate reabsorption kidneys\nDiuretic Therapy: Volume depletion stimulates bicarbonate reabsorption kidneysMineralocorticoid Excess:\nHyperaldosteronism: Increased aldosterone leads increased sodium reabsorption increased hydrogen ion excretion\nHyperaldosteronism: Increased aldosterone leads increased sodium reabsorption increased hydrogen ion excretionLaboratory Findings\npH: > 7.45\nPa\\(CO_2\\): Normal increased (due respiratory compensation)\n\\(HCO_3^-\\): > 26 mEq/L\nBase Excess (): positive +2 mEq/L\npH: > 7.45Pa\\(CO_2\\): Normal increased (due respiratory compensation)\\(HCO_3^-\\): > 26 mEq/LBase Excess (): positive +2 mEq/LDisease State Correlation\nVomiting: Loss gastric acid leads metabolic alkalosis\nDiuretic Therapy: Volume depletion increased aldosterone levels stimulate bicarbonate reabsorption\nHyperaldosteronism: Increased aldosterone levels promote hydrogen ion excretion bicarbonate reabsorption\nVomiting: Loss gastric acid leads metabolic alkalosisDiuretic Therapy: Volume depletion increased aldosterone levels stimulate bicarbonate reabsorptionHyperaldosteronism: Increased aldosterone levels promote hydrogen ion excretion bicarbonate reabsorptionCompensation\nRespiratory Compensation: Decreased ventilation retain carbon dioxide lower pH\nRenal Compensation: Increased excretion bicarbonate decreased excretion acid several days\nRespiratory Compensation: Decreased ventilation retain carbon dioxide lower pHRenal Compensation: Increased excretion bicarbonate decreased excretion acid several daysSymptoms\nConfusion, lightheadedness, muscle cramps, nausea, vomiting\nConfusion, lightheadedness, muscle cramps, nausea, vomiting","code":""},{"path":"disease-correlation-5.html","id":"key-terms-44","chapter":"Disease Correlation","heading":"Key Terms","text":"Acidosis: condition blood pH normal rangeAlkalosis: condition blood pH normal rangeHypercapnia: presence abnormally high levels carbon dioxide bloodHypocapnia: presence abnormally low levels carbon dioxide bloodHypoxemia: condition blood oxygen level lower normalArterial Blood Gas (ABG): test measures levels oxygen carbon dioxide arterial bloodPartial Pressure Oxygen (Pa\\(O_2\\)): measure oxygen level arterial bloodPartial Pressure Carbon Dioxide (Pa\\(CO_2\\)): measure carbon dioxide level arterial bloodBicarbonate (\\(HCO_3^-\\)): major buffer bloodBase Excess (): measure amount acid base needed restore normal pHOxygen Saturation (Sa\\(O_2\\)): measure percentage hemoglobin saturated oxygenRespiratory Acidosis: Acidosis caused increased carbon dioxide levelsMetabolic Acidosis: Acidosis caused decreased bicarbonate levels increased acid productionRespiratory Alkalosis: Alkalosis caused decreased carbon dioxide levelsMetabolic Alkalosis: Alkalosis caused increased bicarbonate levels decreased acid levelsAnion Gap: difference measured cations anions serum plasmaCompensation: physiological response acid-base disturbance attempts restore normal pHEstimated Glomerular Filtration Rate (eGFR): estimate GFR based serum creatinine, age, sex, ethnicityBody Surface Area (BSA): measured calculated surface human bodyModified Allen Test: test assess collateral circulation handCOPD: Chronic Obstructive Pulmonary DiseaseCNS: Central Nervous SystemARDS: Acute Respiratory Distress SyndromeDKA: Diabetic KetoacidosisRTA: Renal Tubular AcidosisHypoventilation: state reduced amount air enters lungsHyperventilation: state breathing fast deeplyParesthesias: abnormal sensation, typically tingling pricking (“pins needles”), caused chiefly pressure damage peripheral nervesCarpopedal Spasm: Cramps hands feetLactate: organic acid, C3H6O3, present blood, muscle, tissues, formed end product anaerobic glucose metabolism; produced increased amounts strenuous muscular exercise anoxiaKetones: Chemicals liver makes ’s enough insulin blood body breaks fat energyGlomeruli: Filtering units within kidneyProteinuria: presence excess protein urineMetabolic Disorder: Occurs abnormal chemical reactions body disrupt metabolismAlveolar: Relating alveoli lungsAlkaline Phosphatase (ALP): hydrolase enzyme responsible removing phosphate groups many different types molecules, including nucleotides, proteins, phosphatesIn Vitro: Taking place test tube, culture dish, elsewhere outside living organismIn Vivo: Occurring within living organismHomeostasis: process organisms maintain relatively stable internal environmentPulmonary Embolism: blood clot occurs lungsTransfusion: process transferring blood blood products one person anotherLethargy: state tiredness, weariness, fatigue, lack energyIschemia: inadequate blood supply organ part bodyHypoxia: inadequate oxygen supply cells tissues body","code":""},{"path":"electrolytes.html","id":"electrolytes","chapter":"Electrolytes","heading":"Electrolytes","text":"section cover:Electrolytes’ roles bodyHow measure interpret electrolyte levelsHow connect laboratory results clinical diagnosis","code":""},{"path":"electrolytes.html","id":"biochemical-theory-and-pathways-2","chapter":"Electrolytes","heading":"Biochemical Theory and Pathways","text":"Electrolytes: Ions solution, crucial fluid balance, nerve/muscle functionKey Electrolytes\n\\(Na^+\\), \\(K^+\\), \\(Cl^-\\), \\(HCO_3^-\\), \\(Ca^{2+}\\), \\(Mg^{2+}\\), \\(P\\), \\(Fe\\)\n\\(Na^+\\), \\(K^+\\), \\(Cl^-\\), \\(HCO_3^-\\), \\(Ca^{2+}\\), \\(Mg^{2+}\\), \\(P\\), \\(Fe\\)Regulation\nHormones: Aldosterone, ADH, PTH, Vitamin D\nOrgans: Kidneys, parathyroid glands\nHormones: Aldosterone, ADH, PTH, Vitamin DOrgans: Kidneys, parathyroid glandsTransport Mechanisms\nIon channels, pumps, binding proteins\nIon channels, pumps, binding proteins","code":""},{"path":"electrolytes.html","id":"laboratory-test-procedures-6","chapter":"Electrolytes","heading":"Laboratory Test Procedures","text":"Common Methods\nIon Selective Electrodes (ISE)\nSpectrophotometry\nBlood Gas Analysis\nIon Selective Electrodes (ISE)SpectrophotometryBlood Gas AnalysisKey Analytes Measured\nElectrolyte concentrations serum, plasma, whole blood\nTotal Iron-Binding Capacity (TIBC)\nElectrolyte concentrations serum, plasma, whole bloodTotal Iron-Binding Capacity (TIBC)Important Considerations:\nProper specimen collection handling\nReagent calibration controls\nProper specimen collection handlingReagent calibration controls","code":""},{"path":"electrolytes.html","id":"calculations","chapter":"Electrolytes","heading":"Calculations","text":"Osmolality\nFormula: \\(2[Na^+] + \\left( \\frac {[Glucose (mg/dL)]} {18} \\right) + \\left( \\frac {[BUN (mg/dL)]} {2.8} \\right)\\)\nAssesses hydration, presence toxins\nFormula: \\(2[Na^+] + \\left( \\frac {[Glucose (mg/dL)]} {18} \\right) + \\left( \\frac {[BUN (mg/dL)]} {2.8} \\right)\\)Assesses hydration, presence toxinsAnion Gap\nFormula: (\\(Na^+\\) + \\(K^+\\)) - (\\(Cl^-\\) + \\(HCO_3^-\\))\nIdentifies causes metabolic acidosis\nFormula: (\\(Na^+\\) + \\(K^+\\)) - (\\(Cl^-\\) + \\(HCO_3^-\\))Identifies causes metabolic acidosis","code":""},{"path":"electrolytes.html","id":"test-result-interpretation-6","chapter":"Electrolytes","heading":"Test Result Interpretation","text":"Relate patient’s specific informationConsider reference rangesLook patterns trendsWhat conditions indicated ruled patterns?","code":""},{"path":"electrolytes.html","id":"disease-state-correlation-6","chapter":"Electrolytes","heading":"Disease State Correlation","text":"Key Diseases\nHyponatremia, hypernatremia\nHypokalemia, hyperkalemia\nHypocalcemia, hypercalcemia\nHypomagnesemia, hypermagnesemia\nHypophosphatemia, hyperphosphatemia\nIron Deficiency Anemia, hemochromatosis\nList may also include cardiac, renal, neurological, etc\nHyponatremia, hypernatremiaHypokalemia, hyperkalemiaHypocalcemia, hypercalcemiaHypomagnesemia, hypermagnesemiaHypophosphatemia, hyperphosphatemiaIron Deficiency Anemia, hemochromatosisList may also include cardiac, renal, neurological, etc","code":""},{"path":"metabolic-6.html","id":"metabolic-6","chapter":"Metabolic","heading":"Metabolic","text":"Electrolytes trace elements crucial life, abnormal levels can indicate underlying disease. section provides summary major electrolyte metabolic function properties","code":""},{"path":"metabolic-6.html","id":"biochemical-theory-and-pathways-3","chapter":"Metabolic","heading":"Biochemical Theory and Pathways","text":"Electrolytes: Crucial fluid balance, nerve/muscle functionTrace Elements: Essential enzymes, hormones, immunityKey Electrolytes: Sodium, potassium, chloride, bicarbonateOther Important ions: Calcium, magnesium, phosphorus, iron, Trace elementsRegulation\nHormones: Aldosterone, ADH, PTH, Vitamin D, FGF23\nOrgans: Kidneys, lungs, parathyroid glands\nHormones: Aldosterone, ADH, PTH, Vitamin D, FGF23Organs: Kidneys, lungs, parathyroid glandsTransport Mechanisms\nIon channels\nPumps (e.g., \\(Na^+\\)/\\(K^+\\) ATPase)\nBinding proteins (e.g., transferrin)\nIon channelsPumps (e.g., \\(Na^+\\)/\\(K^+\\) ATPase)Binding proteins (e.g., transferrin)","code":""},{"path":"metabolic-6.html","id":"normal-states-6","chapter":"Metabolic","heading":"Normal States","text":"Normal Electrolyte Concentrations\n\\(Na^+\\): 136-145 mmol/L\n\\(K^+\\): 3.5-5.1 mmol/L\n\\(Cl^-\\): 98-107 mmol/L\n\\(HCO_3^-\\): 23-29 mmol/L\n\\(Ca^{2+}\\): 8.6-10.2 mg/dL\n\\(Mg^{2+}\\): 1.7-2.2 mg/dL\n\\(P\\): 2.5-4.5 mg/dL\n\\(Fe\\): 60-170 μg/dL\nTIBC: 240-450 μg/dL\n\\(Na^+\\): 136-145 mmol/L\\(K^+\\): 3.5-5.1 mmol/L\\(Cl^-\\): 98-107 mmol/L\\(HCO_3^-\\): 23-29 mmol/L\\(Ca^{2+}\\): 8.6-10.2 mg/dL\\(Mg^{2+}\\): 1.7-2.2 mg/dL\\(P\\): 2.5-4.5 mg/dL\\(Fe\\): 60-170 μg/dLTIBC: 240-450 μg/dLBalanced Distribution: ICF ECFFunctional Regulation: hormones kidneys","code":""},{"path":"metabolic-6.html","id":"abnormal-states-7","chapter":"Metabolic","heading":"Abnormal States","text":"Sodium Imbalances: Hyponatremia, hypernatremiaPotassium Imbalances: Hypokalemia, hyperkalemiaChloride Imbalances: Hypochloremia, hyperchloremiaCalcium Imbalances: Hypocalcemia, hypercalcemiaMagnesium Imbalances: Hypomagnesemia, hypermagnesemiaPhosphate Imbalances: Hypophosphatemia, hyperphosphatemiaIron Imbalances: Iron deficiency anemia, hemochromatosis","code":""},{"path":"metabolic-6.html","id":"functions-and-imbalances","chapter":"Metabolic","heading":"Functions and Imbalances","text":"Sodium (\\(Na^+\\))\nFunction: Fluid balance, nerve/muscle function\nHyponatremia: Fluid overload, sodium loss\nHypernatremia: Dehydration, sodium gain\nFunction: Fluid balance, nerve/muscle functionHyponatremia: Fluid overload, sodium lossHypernatremia: Dehydration, sodium gainPotassium (\\(K^+\\))\nFunction: Membrane potential, nerve/muscle function\nHypokalemia: Loss (diuretics), cellular shift\nHyperkalemia: Renal failure, cellular release\nFunction: Membrane potential, nerve/muscle functionHypokalemia: Loss (diuretics), cellular shiftHyperkalemia: Renal failure, cellular releaseChloride (\\(Cl^-\\))\nFunction: Fluid balance, nerve transmission\nHypochloremia: Loss (vomiting), increased bicarbonate\nHyperchloremia: Excess infusion, dehydration\nFunction: Fluid balance, nerve transmissionHypochloremia: Loss (vomiting), increased bicarbonateHyperchloremia: Excess infusion, dehydrationCalcium (\\(Ca^{2+}\\))\nFunction: Bone structure, muscle contraction, clotting\nHypocalcemia: Hypoparathyroidism, vitamin D deficiency\nHypercalcemia: Hyperparathyroidism, malignancy\nFunction: Bone structure, muscle contraction, clottingHypocalcemia: Hypoparathyroidism, vitamin D deficiencyHypercalcemia: Hyperparathyroidism, malignancyMagnesium (\\(Mg^{2+}\\))\nFunction: Enzyme activity, muscle function\nHypomagnesemia: Poor intake, impaired absorption\nHypermagnesemia: Renal failure, excess intake\nFunction: Enzyme activity, muscle functionHypomagnesemia: Poor intake, impaired absorptionHypermagnesemia: Renal failure, excess intakePhosphorus (\\(P\\))\nFunction: Bone structure, energy production\nHypophosphatemia: Poor intake, cellular shift\nHyperphosphatemia: Renal failure, hypoparathyroidism\nFunction: Bone structure, energy productionHypophosphatemia: Poor intake, cellular shiftHyperphosphatemia: Renal failure, hypoparathyroidismIron (\\(Fe\\))\nFunction: Oxygen transport (hemoglobin)\nIron Deficiency: Anemia\nIron overload: Hemochromatosis\nFunction: Oxygen transport (hemoglobin)Iron Deficiency: AnemiaIron overload: HemochromatosisTrace Elements\nFunction: Varies element (e.g., enzyme cofactors, hormone synthesis)\nImbalances: Deficiency toxicity\nFunction: Varies element (e.g., enzyme cofactors, hormone synthesis)Imbalances: Deficiency toxicity","code":""},{"path":"metabolic-6.html","id":"underlying-pathologies","chapter":"Metabolic","heading":"Underlying Pathologies","text":"Kidney Disease: Affects electrolyte regulationHormonal Disorders: Affect electrolyte levelsNutritional Deficiencies: Impair electrolyte trace element intakeGenetic Disorders: Affect electrolyte metabolismToxic Exposures: Affect trace elements","code":""},{"path":"metabolic-6.html","id":"key-considerations-3","chapter":"Metabolic","heading":"Key Considerations","text":"Recognizing abnormal electrolyte levels crucial diagnosisImbalances can lead life-threatening complicationsCorrection electrolyte abnormalities requires addressing underlying causeTrace element analysis important specialized disorders","code":""},{"path":"na-k-cl-co2-hco3-.html","id":"na-k-cl-co2-hco3-","chapter":"Na, K, Cl, CO2, HCO3-","heading":"Na, K, Cl, CO2, HCO3-","text":"Electrolytes vital maintaining fluid balance, nerve muscle function, overall homeostasis","code":""},{"path":"na-k-cl-co2-hco3-.html","id":"electrolytes-1","chapter":"Na, K, Cl, CO2, HCO3-","heading":"Electrolytes","text":"Definition: Ions (charged particles) conduct electrical impulses solution. body, electrolytes essential maintaining fluid balance, nerve muscle function, various physiological processesMajor Electrolytes Body\nSodium (\\(Na^+\\))\nPotassium (\\(K^+\\))\nChloride (\\(Cl^-\\))\nBicarbonate (\\(HCO_3^-\\))\nOften measured total \\(CO_2\\)\n\nSodium (\\(Na^+\\))Potassium (\\(K^+\\))Chloride (\\(Cl^-\\))Bicarbonate (\\(HCO_3^-\\))\nOften measured total \\(CO_2\\)\nOften measured total \\(CO_2\\)Location\nIntracellular Fluid (ICF): Fluid within cells\nExtracellular Fluid (ECF): Fluid outside cells\nPlasma: Liquid component blood\nInterstitial Fluid: Fluid surrounding cells\n\nIntracellular Fluid (ICF): Fluid within cellsExtracellular Fluid (ECF): Fluid outside cells\nPlasma: Liquid component blood\nInterstitial Fluid: Fluid surrounding cells\nPlasma: Liquid component bloodInterstitial Fluid: Fluid surrounding cellsNormal Ranges\nSodium (\\(Na^+\\)): 136-145 mmol/L (convential SI units)\nPotassium (\\(K^+\\)): 3.5-5.1 mmol/L (convential SI units)\nChloride (\\(Cl^-\\)): 98-107 mmol/L (convential SI units)\nTotal \\(CO_2\\): 22-33 mEq/L (convential SI units)\nBicarbonate (\\(HCO_3^-\\)): 23-29 mmol/L (convential SI units)\nCalculated blood gases\n\nSodium (\\(Na^+\\)): 136-145 mmol/L (convential SI units)Potassium (\\(K^+\\)): 3.5-5.1 mmol/L (convential SI units)Chloride (\\(Cl^-\\)): 98-107 mmol/L (convential SI units)Total \\(CO_2\\): 22-33 mEq/L (convential SI units)Bicarbonate (\\(HCO_3^-\\)): 23-29 mmol/L (convential SI units)\nCalculated blood gases\nCalculated blood gasesFunctions\nMaintaining Osmotic Pressure: Regulating fluid balance ICF ECF\nNerve Muscle Function: Generating transmitting electrical signals\npH Balance: Buffering acids bases\nEnzyme Function: Activating inhibiting enzymes\nTransport: Facilitating transport molecules across cell membranes\nMaintaining Osmotic Pressure: Regulating fluid balance ICF ECFNerve Muscle Function: Generating transmitting electrical signalspH Balance: Buffering acids basesEnzyme Function: Activating inhibiting enzymesTransport: Facilitating transport molecules across cell membranes","code":""},{"path":"na-k-cl-co2-hco3-.html","id":"biochemical-theory-and-pathways-4","chapter":"Na, K, Cl, CO2, HCO3-","heading":"Biochemical Theory and Pathways","text":"","code":""},{"path":"na-k-cl-co2-hco3-.html","id":"sodium-na","chapter":"Na, K, Cl, CO2, HCO3-","heading":"Sodium (\\(Na^+\\))","text":"Location: Primary cation extracellular fluid (ECF)Regulation\nKidneys: Regulate sodium reabsorption excretion\nAldosterone: hormone increases sodium reabsorption kidneys\nAntidiuretic Hormone (ADH): Regulates water reabsorption kidneys, affecting sodium concentration\nNatriuretic Peptides (ANP, BNP): Promote sodium excretion kidneys\nKidneys: Regulate sodium reabsorption excretionAldosterone: hormone increases sodium reabsorption kidneysAntidiuretic Hormone (ADH): Regulates water reabsorption kidneys, affecting sodium concentrationNatriuretic Peptides (ANP, BNP): Promote sodium excretion kidneysTransport\nSodium-Potassium Pump (\\(Na^+\\)/\\(K^+\\) ATPase): Actively transports sodium cells potassium cells, maintaining electrochemical gradients\nSodium-Potassium Pump (\\(Na^+\\)/\\(K^+\\) ATPase): Actively transports sodium cells potassium cells, maintaining electrochemical gradientsFunctions\nMaintaining ECF Volume: Sodium associated anions (e.g., chloride) major determinants ECF volume\nNerve Muscle Function: Sodium influx essential generating action potentials nerve muscle cells\nAcid-Base Balance: Sodium exchanged hydrogen ions kidneys, affecting pH balance\nMaintaining ECF Volume: Sodium associated anions (e.g., chloride) major determinants ECF volumeNerve Muscle Function: Sodium influx essential generating action potentials nerve muscle cellsAcid-Base Balance: Sodium exchanged hydrogen ions kidneys, affecting pH balancePathophysiology Abnormal Levels\nHyponatremia: Low sodium levels due excess water retention sodium loss\nHypernatremia: High sodium levels due water deficit sodium excess\nHyponatremia: Low sodium levels due excess water retention sodium lossHypernatremia: High sodium levels due water deficit sodium excess","code":""},{"path":"na-k-cl-co2-hco3-.html","id":"potassium-k","chapter":"Na, K, Cl, CO2, HCO3-","heading":"Potassium (\\(K^+\\))","text":"Location: Primary cation intracellular fluid (ICF)Regulation\nKidneys: Regulate potassium excretion\nAldosterone: Increases potassium excretion kidneys\nInsulin: Promotes potassium uptake cells\nEpinephrine: Promotes potassium uptake cells (β2-adrenergic effect)\nKidneys: Regulate potassium excretionAldosterone: Increases potassium excretion kidneysInsulin: Promotes potassium uptake cellsEpinephrine: Promotes potassium uptake cells (β2-adrenergic effect)Transport\nSodium-Potassium Pump (\\(Na^+\\)/\\(K^+\\) ATPase): Actively transports potassium cells sodium cells\nSodium-Potassium Pump (\\(Na^+\\)/\\(K^+\\) ATPase): Actively transports potassium cells sodium cellsFunctions\nMaintaining Cell Membrane Potential: Potassium efflux essential maintaining resting membrane potential cells\nNerve Muscle Function: Potassium critical generating action potentials nerve muscle cells\nCardiac Function: Potassium affects rhythm contractility heart\npH Balance: Potassium exchanged hydrogen ions cells, affecting pH balance\nMaintaining Cell Membrane Potential: Potassium efflux essential maintaining resting membrane potential cellsNerve Muscle Function: Potassium critical generating action potentials nerve muscle cellsCardiac Function: Potassium affects rhythm contractility heartpH Balance: Potassium exchanged hydrogen ions cells, affecting pH balancePathophysiology Abnormal Levels\nHypokalemia: Low potassium levels due potassium loss cellular shift\nHyperkalemia: High potassium levels due potassium release cells impaired excretion\nHypokalemia: Low potassium levels due potassium loss cellular shiftHyperkalemia: High potassium levels due potassium release cells impaired excretion","code":""},{"path":"na-k-cl-co2-hco3-.html","id":"chloride-cl-","chapter":"Na, K, Cl, CO2, HCO3-","heading":"Chloride (\\(Cl^-\\))","text":"Location: Primary anion extracellular fluid (ECF)Regulation\nKidneys: Regulate chloride reabsorption excretion\nAldosterone: Indirectly affects chloride reabsorption regulating sodium reabsorption\nKidneys: Regulate chloride reabsorption excretionAldosterone: Indirectly affects chloride reabsorption regulating sodium reabsorptionTransport\nChloride Channels: Facilitate chloride movement across cell membranes\nChloride-Bicarbonate Exchanger: Exchanges chloride bicarbonate red blood cells (chloride shift)\nChloride Channels: Facilitate chloride movement across cell membranesChloride-Bicarbonate Exchanger: Exchanges chloride bicarbonate red blood cells (chloride shift)Functions\nMaintaining ECF Volume Osmotic Pressure: Chloride major determinant ECF volume osmotic pressure\nNerve Muscle Function: Chloride involved generating inhibitory postsynaptic potentials neurons\nAcid-Base Balance: Chloride exchanged bicarbonate red blood cells, affecting pH balance\nMaintaining ECF Volume Osmotic Pressure: Chloride major determinant ECF volume osmotic pressureNerve Muscle Function: Chloride involved generating inhibitory postsynaptic potentials neuronsAcid-Base Balance: Chloride exchanged bicarbonate red blood cells, affecting pH balancePathophysiology Abnormal Levels\nHypochloremia: Low chloride levels due chloride loss excess water retention\nHyperchloremia: High chloride levels due chloride excess water deficit\nHypochloremia: Low chloride levels due chloride loss excess water retentionHyperchloremia: High chloride levels due chloride excess water deficit","code":""},{"path":"na-k-cl-co2-hco3-.html","id":"carbon-dioxide-co_2-and-bicarbonate-hco_3-","chapter":"Na, K, Cl, CO2, HCO3-","heading":"Carbon Dioxide (\\(CO_2\\)) and Bicarbonate (\\(HCO_3^-\\))","text":"Location: Primarily extracellular fluid (ECF)Regulation\nLungs: Regulate carbon dioxide excretion ventilation\nKidneys: Regulate bicarbonate reabsorption excretion\nLungs: Regulate carbon dioxide excretion ventilationKidneys: Regulate bicarbonate reabsorption excretionBicarbonate Transport\nCarbonic Anhydrase: Catalyzes interconversion carbon dioxide bicarbonate\nChloride-Bicarbonate Exchanger: Exchanges chloride bicarbonate red blood cells (chloride shift)\nCarbonic Anhydrase: Catalyzes interconversion carbon dioxide bicarbonateChloride-Bicarbonate Exchanger: Exchanges chloride bicarbonate red blood cells (chloride shift)Functions\npH Balance: Bicarbonate major buffer blood, helping maintain pH within normal range\nCarbon Dioxide Transport: Carbon dioxide transported blood bicarbonate ions\npH Balance: Bicarbonate major buffer blood, helping maintain pH within normal rangeCarbon Dioxide Transport: Carbon dioxide transported blood bicarbonate ionsPathophysiology Abnormal Levels\nMetabolic Acidosis: Low bicarbonate levels due increased acid production bicarbonate loss\nMetabolic Alkalosis: High bicarbonate levels due acid loss bicarbonate excess\nMetabolic Acidosis: Low bicarbonate levels due increased acid production bicarbonate lossMetabolic Alkalosis: High bicarbonate levels due acid loss bicarbonate excessTotal \\(CO_2\\) Measurement\nMeasures forms carbon dioxide blood, including:\nDissolved \\(CO_2\\)\nBicarbonate (\\(HCO_3^-\\))\nCarbamino Compounds\n\nTotal \\(CO_2\\) often used surrogate marker bicarbonate routine chemistry panels\nMeasures forms carbon dioxide blood, including:\nDissolved \\(CO_2\\)\nBicarbonate (\\(HCO_3^-\\))\nCarbamino Compounds\nDissolved \\(CO_2\\)Bicarbonate (\\(HCO_3^-\\))Carbamino CompoundsTotal \\(CO_2\\) often used surrogate marker bicarbonate routine chemistry panelsBicarbonate Calculation\nBicarbonate can also directly calculated pH PCO2 using Henderson-Hasselbalch equation\nBicarbonate can also directly calculated pH PCO2 using Henderson-Hasselbalch equation","code":""},{"path":"na-k-cl-co2-hco3-.html","id":"key-terms-45","chapter":"Na, K, Cl, CO2, HCO3-","heading":"Key Terms","text":"Electrolyte: ion conducts electrical impulses solutionCation: positively charged ion (e.g., \\(Na^+\\), \\(K^+\\))Anion: negatively charged ion (e.g., \\(Cl^-\\), \\(HCO_3^-\\))Intracellular Fluid (ICF): Fluid within cellsExtracellular Fluid (ECF): Fluid outside cellsPlasma: Liquid component bloodInterstitial Fluid: Fluid surrounding cellsOsmotic Pressure: pressure required prevent flow water across semipermeable membraneAction Potential: rapid change electrical potential across cell membraneElectrochemical Gradient: combined effect electrical chemical forces determine movement ions across cell membraneSodium-Potassium Pump (\\(Na^+\\)/\\(K^+\\) ATPase): enzyme actively transports sodium cells potassium cellsAldosterone: hormone increases sodium reabsorption potassium excretion kidneysAntidiuretic Hormone (ADH): hormone regulates water reabsorption kidneysNatriuretic Peptides (ANP, BNP): Hormones promote sodium excretion kidneysCarbonic Anhydrase: enzyme catalyzes interconversion carbon dioxide bicarbonateChloride Shift: movement chloride ions red blood cells maintain electrical neutrality carbon dioxide transportHypokalemia: condition little potassium bloodHyperkalemia: condition much potassium bloodHypochloremia: condition little chloride bloodHyperchloremia: condition much chloride bloodHyponatremia: condition little sodium bloodHypernatremia: condition much sodium bloodHypovolemia: medical term decrease blood volume results decreased oxygen delivery bodySepsis: life-threatening condition happens body’s response infection damages tissues organs","code":""},{"path":"ca-mg-p-fe-tibc.html","id":"ca-mg-p-fe-tibc","chapter":"Ca, Mg, P, Fe, TIBC","heading":"Ca, Mg, P, Fe, TIBC","text":"Beyond major electrolytes (\\(Na\\), \\(K\\), \\(Cl\\), bicarbonate), calcium, magnesium, phosphorus, iron vital numerous physiological processes. crucial nerve muscle function, bone health, enzyme activity, oxygen transport","code":""},{"path":"ca-mg-p-fe-tibc.html","id":"electrolytes-2","chapter":"Ca, Mg, P, Fe, TIBC","heading":"Electrolytes","text":"Definition: Ions (charged particles) conduct electrical impulses solution. electrolytes essential various physiological processesKey Electrolytes\nCalcium (\\(Ca^{2+}\\))\nMagnesium (\\(Mg^{2+}\\))\nPhosphorus (\\(P\\))\nIron (\\(Fe\\))\nCalcium (\\(Ca^{2+}\\))Magnesium (\\(Mg^{2+}\\))Phosphorus (\\(P\\))Iron (\\(Fe\\))Normal Ranges:\nCalcium (\\(Ca^{2+}\\)): 8.6-10.2 mg/dL 2.2-2.6 mmol/L (SI units)\nMagnesium (\\(Mg^{2+}\\)): 1.7-2.2 mg/dL 0.70-0.90 mmol/L (SI units)\nPhosphorus (\\(P\\)): 2.5-4.5 mg/dL 0.81-1.45 mmol/L (SI units)\nIron (\\(Fe\\)): 60-170 μg/dL 10.7-30.4 μmol/L (SI units)\nTotal Iron-Binding Capacity (TIBC): 240-450 μg/dL 42.9-80.6 μmol/L (SI units)\nCalcium (\\(Ca^{2+}\\)): 8.6-10.2 mg/dL 2.2-2.6 mmol/L (SI units)Magnesium (\\(Mg^{2+}\\)): 1.7-2.2 mg/dL 0.70-0.90 mmol/L (SI units)Phosphorus (\\(P\\)): 2.5-4.5 mg/dL 0.81-1.45 mmol/L (SI units)Iron (\\(Fe\\)): 60-170 μg/dL 10.7-30.4 μmol/L (SI units)Total Iron-Binding Capacity (TIBC): 240-450 μg/dL 42.9-80.6 μmol/L (SI units)","code":""},{"path":"ca-mg-p-fe-tibc.html","id":"calcium-ca2","chapter":"Ca, Mg, P, Fe, TIBC","heading":"Calcium (\\(Ca^{2+}\\))","text":"Distribution\nBone: Approximately 99% calcium stored bone hydroxyapatite\nBlood: Approximately 1% calcium blood\nIonized (Free) Calcium: physiologically active form (45%)\nProtein-Bound Calcium: Bound albumin (40%)\nComplexed Calcium: Complexed anions (e.g., phosphate, citrate) (15%)\n\nBone: Approximately 99% calcium stored bone hydroxyapatiteBlood: Approximately 1% calcium blood\nIonized (Free) Calcium: physiologically active form (45%)\nProtein-Bound Calcium: Bound albumin (40%)\nComplexed Calcium: Complexed anions (e.g., phosphate, citrate) (15%)\nIonized (Free) Calcium: physiologically active form (45%)Protein-Bound Calcium: Bound albumin (40%)Complexed Calcium: Complexed anions (e.g., phosphate, citrate) (15%)Regulation\nParathyroid Hormone (PTH): Increases blood calcium levels stimulating bone resorption, increasing kidney reabsorption, increasing vitamin D activation\nVitamin D: Increases blood calcium levels promoting calcium absorption intestine\nCalcitonin: Decreases blood calcium levels inhibiting bone resorption\nParathyroid Hormone (PTH): Increases blood calcium levels stimulating bone resorption, increasing kidney reabsorption, increasing vitamin D activationVitamin D: Increases blood calcium levels promoting calcium absorption intestineCalcitonin: Decreases blood calcium levels inhibiting bone resorptionFunctions\nBone Structure: Essential bone formation maintenance\nMuscle Contraction: Triggers muscle contraction\nNerve Function: Involved nerve impulse transmission\nBlood Clotting: Required coagulation cascade\nEnzyme Activity: Acts cofactor certain enzymes\nCell Signaling: Involved various cell signaling pathways\nBone Structure: Essential bone formation maintenanceMuscle Contraction: Triggers muscle contractionNerve Function: Involved nerve impulse transmissionBlood Clotting: Required coagulation cascadeEnzyme Activity: Acts cofactor certain enzymesCell Signaling: Involved various cell signaling pathwaysPathophysiology Abnormal Levels\nHypercalcemia: High calcium levels due hyperparathyroidism, malignancy, vitamin D excess\nHypocalcemia: Low calcium levels due hypoparathyroidism, vitamin D deficiency, kidney disease\nHypercalcemia: High calcium levels due hyperparathyroidism, malignancy, vitamin D excessHypocalcemia: Low calcium levels due hypoparathyroidism, vitamin D deficiency, kidney disease","code":""},{"path":"ca-mg-p-fe-tibc.html","id":"magnesium-mg2","chapter":"Ca, Mg, P, Fe, TIBC","heading":"Magnesium (\\(Mg^{2+}\\))","text":"Distribution\nBone: Approximately 60% magnesium stored bone\nIntracellular Fluid (ICF): Approximately 39% ICF\nBlood: Approximately 1% blood\nIonized (Free) Magnesium: physiologically active form\nProtein-Bound Magnesium: Bound albumin\nComplexed Magnesium: Complexed anions\n\nBone: Approximately 60% magnesium stored boneIntracellular Fluid (ICF): Approximately 39% ICFBlood: Approximately 1% blood\nIonized (Free) Magnesium: physiologically active form\nProtein-Bound Magnesium: Bound albumin\nComplexed Magnesium: Complexed anions\nIonized (Free) Magnesium: physiologically active formProtein-Bound Magnesium: Bound albuminComplexed Magnesium: Complexed anionsRegulation\nKidneys: Regulate magnesium reabsorption excretion\nParathyroid Hormone (PTH): Influences magnesium reabsorption kidneys\nKidneys: Regulate magnesium reabsorption excretionParathyroid Hormone (PTH): Influences magnesium reabsorption kidneysFunctions\nEnzyme Activity: Acts cofactor many enzymes, including involved ATP production\nMuscle Nerve Function: Important nerve impulse transmission muscle contraction\nBone Health: Contributes bone structure strength\nDNA Protein Synthesis: Required DNA protein synthesis\nEnzyme Activity: Acts cofactor many enzymes, including involved ATP productionMuscle Nerve Function: Important nerve impulse transmission muscle contractionBone Health: Contributes bone structure strengthDNA Protein Synthesis: Required DNA protein synthesisPathophysiology Abnormal Levels\nHypermagnesemia: High magnesium levels due kidney disease excessive magnesium intake\nHypomagnesemia: Low magnesium levels due poor dietary intake, impaired absorption, increased excretion\nHypermagnesemia: High magnesium levels due kidney disease excessive magnesium intakeHypomagnesemia: Low magnesium levels due poor dietary intake, impaired absorption, increased excretion","code":""},{"path":"ca-mg-p-fe-tibc.html","id":"phosphorus-p","chapter":"Ca, Mg, P, Fe, TIBC","heading":"Phosphorus (\\(P\\))","text":"Distribution\nBone: Approximately 85% phosphorus stored bone hydroxyapatite\nIntracellular Fluid (ICF): remainder located within cells\nBlood: small amount blood inorganic phosphate\nBone: Approximately 85% phosphorus stored bone hydroxyapatiteIntracellular Fluid (ICF): remainder located within cellsBlood: small amount blood inorganic phosphateRegulation\nParathyroid Hormone (PTH): Decreases blood phosphate levels increasing kidney excretion increasing bone turnover\nVitamin D: Increases blood phosphate levels promoting intestinal absorption bone resorption\nFibroblast Growth Factor 23 (FGF23): Decreases blood phosphate levels increasing kidney excretion decreasing intestinal absorption\nParathyroid Hormone (PTH): Decreases blood phosphate levels increasing kidney excretion increasing bone turnoverVitamin D: Increases blood phosphate levels promoting intestinal absorption bone resorptionFibroblast Growth Factor 23 (FGF23): Decreases blood phosphate levels increasing kidney excretion decreasing intestinal absorptionFunctions\nBone Structure: Essential bone formation maintenance\nEnergy Production: Involved ATP production\nDNA RNA Synthesis: Required DNA RNA synthesis\nCell Membrane Structure: Component phospholipids\npH Balance: Acts buffer blood\nBone Structure: Essential bone formation maintenanceEnergy Production: Involved ATP productionDNA RNA Synthesis: Required DNA RNA synthesisCell Membrane Structure: Component phospholipidspH Balance: Acts buffer bloodPathophysiology Abnormal Levels\nHyperphosphatemia: High phosphate levels due kidney disease, hypoparathyroidism, excessive phosphate intake\nHypophosphatemia: Low phosphate levels due poor dietary intake, impaired absorption, increased excretion\nHyperphosphatemia: High phosphate levels due kidney disease, hypoparathyroidism, excessive phosphate intakeHypophosphatemia: Low phosphate levels due poor dietary intake, impaired absorption, increased excretion","code":""},{"path":"ca-mg-p-fe-tibc.html","id":"iron-fe","chapter":"Ca, Mg, P, Fe, TIBC","heading":"Iron (\\(Fe\\))","text":"Distribution\nHemoglobin: Approximately 70% iron hemoglobin\nFerritin: Approximately 25% iron stored ferritin liver, spleen, bone marrow\nTransferrin: small amount iron transported blood bound transferrin\nHemoglobin: Approximately 70% iron hemoglobinFerritin: Approximately 25% iron stored ferritin liver, spleen, bone marrowTransferrin: small amount iron transported blood bound transferrinRegulation\nAbsorption: Iron absorption small intestine regulated hepcidin\nStorage: Iron stored cells ferritin hemosiderin\nTransport: Iron transported blood bound transferrin\nAbsorption: Iron absorption small intestine regulated hepcidinStorage: Iron stored cells ferritin hemosiderinTransport: Iron transported blood bound transferrinFunctions\nOxygen Transport: Component hemoglobin myoglobin, transport oxygen blood muscles\nEnzyme Activity: Acts cofactor many enzymes, including involved energy production DNA synthesis\nOxygen Transport: Component hemoglobin myoglobin, transport oxygen blood musclesEnzyme Activity: Acts cofactor many enzymes, including involved energy production DNA synthesisPathophysiology Abnormal Levels\nIron Deficiency Anemia: Low iron levels due poor dietary intake, impaired absorption, blood loss\nHemochromatosis: Excessive iron absorption accumulation tissues\nIron Deficiency Anemia: Low iron levels due poor dietary intake, impaired absorption, blood lossHemochromatosis: Excessive iron absorption accumulation tissues","code":""},{"path":"ca-mg-p-fe-tibc.html","id":"total-iron-binding-capacity-tibc-1","chapter":"Ca, Mg, P, Fe, TIBC","heading":"Total Iron-Binding Capacity (TIBC)","text":"Definition: measure blood’s capacity bind iron transferrinInterpretation\nElevated TIBC: Suggests iron deficiency\nDecreased TIBC: Suggests iron overload chronic inflammation\nElevated TIBC: Suggests iron deficiencyDecreased TIBC: Suggests iron overload chronic inflammationCalculation\nIndirectly used calculate transferrin saturation\nTransferrin Saturation (%) = (Serum Iron / TIBC) x 100\n\nIndirectly used calculate transferrin saturation\nTransferrin Saturation (%) = (Serum Iron / TIBC) x 100\nTransferrin Saturation (%) = (Serum Iron / TIBC) x 100","code":""},{"path":"ca-mg-p-fe-tibc.html","id":"key-terms-46","chapter":"Ca, Mg, P, Fe, TIBC","heading":"Key Terms","text":"Electrolyte: ion conducts electrical impulses solutionCation: positively charged ion (e.g., \\(Ca^{2+}\\), \\(Mg^{2+}\\), \\(K^+\\), \\(Na^+\\))Anion: negatively charged ion (e.g., \\(Cl^-\\), \\(HCO_3^-\\), \\(PO_4^{3-}\\))Parathyroid Hormone (PTH): hormone increases blood calcium levelsVitamin D: hormone increases blood calcium phosphate levelsCalcitonin: hormone decreases blood calcium levelsFibroblast Growth Factor 23 (FGF23): hormone decreases blood phosphate levelsHydroxyapatite: mineral component boneHemoglobin: protein red blood cells transports oxygenMyoglobin: protein muscle cells stores oxygenFerritin: protein stores ironTransferrin: protein transports iron bloodTotal Iron-Binding Capacity (TIBC): measure blood’s capacity bind ironTransferrin Saturation: percentage transferrin bound ironHepcidin: hormone regulates iron absorption releaseHypercalcemia: Abnormally high calcium bloodHypocalcemia: Abnormally low calcium bloodHypermagnesemia: Abnormally high magnesium bloodHypomagnesemia: Abnormally low magnesium bloodHyperphosphatemia: Abnormally high phosphorus bloodHypophosphatemia: Abnormally low phosphorus bloodHypoferremia: Abnormally low iron bloodHemochromatosis: genetic disorder iron overloadHypoxia: inadequate oxygen supply cells tissues bodyMuscle Contraction: shortening muscle cellsNerve Function: function neurons role nerve impluse transmittionBlood Clotting: coagulation blood","code":""},{"path":"trace-elements.html","id":"trace-elements","chapter":"Trace Elements","heading":"Trace Elements","text":"addition major electrolytes, trace elements critical variety biochemical processes body. elements, though required minute amounts, play essential roles enzyme function, hormone synthesis, immune response, overall health","code":""},{"path":"trace-elements.html","id":"trace-elements-1","chapter":"Trace Elements","heading":"Trace Elements","text":"Definition: Trace elements minerals required living organisms small (trace) amounts ensure normal growth, development, physiological functionImportance\nEnzyme Cofactors: Many trace elements essential components enzymes, acting cofactors facilitate biochemical reactions\nHormone Synthesis: trace elements required synthesis hormones, regulate various bodily functions\nImmune Function: Trace elements play role immune cell development function\nAntioxidant Defense: trace elements components antioxidant enzymes, protecting cells oxidative damage\nEnzyme Cofactors: Many trace elements essential components enzymes, acting cofactors facilitate biochemical reactionsHormone Synthesis: trace elements required synthesis hormones, regulate various bodily functionsImmune Function: Trace elements play role immune cell development functionAntioxidant Defense: trace elements components antioxidant enzymes, protecting cells oxidative damageCategories\nEssential Trace Elements: Required normal physiological function\nNon-Essential Trace Elements: known biological function toxic certain levels\nEssential Trace Elements: Required normal physiological functionNon-Essential Trace Elements: known biological function toxic certain levelsFactors Affecting Trace Element Levels\nDietary Intake\nAbsorption\nTransport\nStorage\nExcretion\nDietary IntakeAbsorptionTransportStorageExcretion","code":""},{"path":"trace-elements.html","id":"iron-fe-1","chapter":"Trace Elements","heading":"Iron (\\(Fe\\))","text":"Normal Range: 60-170 μg/dL (10.7-30.4 μmol/L)Functions:\nOxygen transport (hemoglobin myoglobin)\nEnzyme cofactor (cytochromes, peroxidases)\nImmune function\nOxygen transport (hemoglobin myoglobin)Enzyme cofactor (cytochromes, peroxidases)Immune functionDeficiency: Iron deficiency anemia (fatigue, weakness)Excess: Hemochromatosis (tissue damage)\n## Zinc (\\(Zn\\)) {-}Normal Range: 70-120 μg/dL (10.7-18.4 μmol/L)Functions:\nEnzyme cofactor (DNA polymerase, carbonic anhydrase)\nImmune function\nWound healing\nGrowth development\nEnzyme cofactor (DNA polymerase, carbonic anhydrase)Immune functionWound healingGrowth developmentDeficiency: Impaired immune function, growth retardation, skin lesions, taste smell abnormalitiesExcess: Copper deficiency, impaired immune function\n## Copper (\\(Cu\\)) {-}Normal Range: 70-140 μg/dL (11.0-22.0 μmol/L)Functions:\nEnzyme cofactor (ceruloplasmin, superoxide dismutase)\nIron metabolism\nAntioxidant defense\nEnzyme cofactor (ceruloplasmin, superoxide dismutase)Iron metabolismAntioxidant defenseDeficiency: Anemia, neutropenia, neurological abnormalitiesExcess: Wilson’s disease (liver neurological damage)\n## Selenium (\\(Se\\)) {-}Normal Range: 50-120 μg/L (0.63-1.52 μmol/L)Functions:\nEnzyme cofactor (glutathione peroxidase)\nAntioxidant defense\nThyroid hormone metabolism\nImmune function\nEnzyme cofactor (glutathione peroxidase)Antioxidant defenseThyroid hormone metabolismImmune functionDeficiency: Keshan disease (cardiomyopathy), Kashin-Beck disease (osteoarthritis)Excess: Selenosis (hair loss, nail changes, neurological abnormalities)\n## Iodine (\\(\\)) {-}Normal Range: Varies depending method populationFunctions:\nThyroid hormone synthesis (thyroxine, triiodothyronine)\nThyroid hormone synthesis (thyroxine, triiodothyronine)Deficiency: Hypothyroidism, goiter, developmental abnormalitiesExcess: Hyperthyroidism, thyroiditis\n## Manganese (\\(Mn\\)) {-}Normal Range: 4-15 μg/L (0.07-0.27 μmol/L)Functions:\nEnzyme cofactor (superoxide dismutase, pyruvate carboxylase)\nBone development\nCarbohydrate lipid metabolism\nEnzyme cofactor (superoxide dismutase, pyruvate carboxylase)Bone developmentCarbohydrate lipid metabolismDeficiency: Rare, may cause impaired growth bone developmentExcess: Manganism (neurological abnormalities)\n## Chromium (\\(Cr\\)) {-}Normal Range: 0.5-10 μg/L (0.01-0.19 μmol/L)Functions:\nEnhances insulin action\nGlucose metabolism\nLipid metabolism\nEnhances insulin actionGlucose metabolismLipid metabolismDeficiency: Impaired glucose tolerance, insulin resistanceExcess: Rare, may cause kidney liver damage\n## Molybdenum (\\(Mo\\)) {-}Normal Range: 0.4-1.0 μg/L (0.004-0.01 μmol/L)Functions:\nEnzyme cofactor (sulfite oxidase, xanthine oxidase)\nSulfur amino acid metabolism\nPurine metabolism\nEnzyme cofactor (sulfite oxidase, xanthine oxidase)Sulfur amino acid metabolismPurine metabolismDeficiency: Rare, may cause neurological abnormalitiesExcess: Rare, may cause gout-like symptoms\n## Fluoride (\\(F\\)) {-}Normal Range: Varies depending water fluoridation levelsFunctions:\nBone tooth mineralization\nBone tooth mineralizationDeficiency: Increased risk dental cariesExcess: Fluorosis (dental skeletal abnormalities)","code":""},{"path":"trace-elements.html","id":"key-terms-47","chapter":"Trace Elements","heading":"Key Terms","text":"Trace Element: mineral required living organisms small amountsEssential Trace Element: trace element required normal physiological functionCofactor: non-protein chemical compound bound enzyme required biological activityEnzyme: substance produced living organism acts catalyst bring specific biochemical reactionHormone: regulatory substance produced organism transported tissue fluids blood sap stimulate specific cells tissues actionAntioxidant: substance inhibits oxidation, especially one used counteract deterioration stored food products remove potentially damaging oxidizing agents living organismHemoglobin: protein red blood cells binds transports oxygenMyoglobin: protein muscle cells stores oxygenCeruloplasmin: copper-containing protein blood plays role iron metabolismSuperoxide Dismutase (SOD): enzyme catalyzes dismutation superoxide oxygen hydrogen peroxideGlutathione Peroxidase: enzyme catalyzes reduction hydrogen peroxide organic hydroperoxidesThyroid Hormone: hormones produced released thyroid gland, including thyroxine (T4) triiodothyronine (T3)Neutropenia: condition characterized abnormally low levels neutrophils bloodHypothyroidism: deficiency thyroid activityHyperthyroidism: Excessive activity thyroid glandKeshan Disease: congestive cardiomyopathy caused deficiency seleniumKashin-Beck Disease: chronic endemic osteoarthropathy caused deficiency seleniumFluorosis: condition caused excessive fluoride intake, characterized dental skeletal abnormalitiesManganism: Neurological abnormalities caused excessive manganese exposureEnzyme: substance produced living organism acts catalyst bring specific biochemical reaction","code":""},{"path":"physiology-6.html","id":"physiology-6","chapter":"Physiology","heading":"Physiology","text":"Electrolyte balance critical maintaining cellular function, fluid balance, overall health. Deviations normal electrolyte levels can indicate various underlying conditions","code":""},{"path":"physiology-6.html","id":"normal-states-7","chapter":"Physiology","heading":"Normal States","text":"Normal Electrolyte Concentrations\nElectrolyte concentrations maintained within narrow physiological ranges\nSodium (\\(Na^+\\)): 136-145 mmol/L (conventional SI units)\nPotassium (\\(K^+\\)): 3.5-5.1 mmol/L (conventional SI units)\nChloride (\\(Cl^-\\)): 98-107 mmol/L (conventional SI units)\nBicarbonate (\\(HCO_3^-\\)): 23-29 mmol/L (conventional SI units)\nCalcium (\\(Ca^{2+}\\)): 8.6-10.2 mg/dL 2.2-2.6 mmol/L (SI units)\nMagnesium (\\(Mg^{2+}\\)): 1.7-2.2 mg/dL 0.70-0.90 mmol/L (SI units)\nPhosphorus (\\(P\\)): 2.5-4.5 mg/dL 0.81-1.45 mmol/L (SI units)\nElectrolyte concentrations maintained within narrow physiological rangesSodium (\\(Na^+\\)): 136-145 mmol/L (conventional SI units)Potassium (\\(K^+\\)): 3.5-5.1 mmol/L (conventional SI units)Chloride (\\(Cl^-\\)): 98-107 mmol/L (conventional SI units)Bicarbonate (\\(HCO_3^-\\)): 23-29 mmol/L (conventional SI units)Calcium (\\(Ca^{2+}\\)): 8.6-10.2 mg/dL 2.2-2.6 mmol/L (SI units)Magnesium (\\(Mg^{2+}\\)): 1.7-2.2 mg/dL 0.70-0.90 mmol/L (SI units)Phosphorus (\\(P\\)): 2.5-4.5 mg/dL 0.81-1.45 mmol/L (SI units)Electrolyte Distribution\nAppropriate distribution electrolytes intracellular fluid (ICF) extracellular fluid (ECF)\nSodium: Predominantly extracellular\nPotassium: Predominantly intracellular\nAppropriate distribution electrolytes intracellular fluid (ICF) extracellular fluid (ECF)Sodium: Predominantly extracellularPotassium: Predominantly intracellularHormonal Regulation\nAldosterone: Regulates sodium potassium balance\nAntidiuretic Hormone (ADH): Regulates water balance, affecting sodium concentration\nParathyroid Hormone (PTH): Regulates calcium phosphate balance\nVitamin D: Regulates calcium absorption bone metabolism\nAldosterone: Regulates sodium potassium balanceAntidiuretic Hormone (ADH): Regulates water balance, affecting sodium concentrationParathyroid Hormone (PTH): Regulates calcium phosphate balanceVitamin D: Regulates calcium absorption bone metabolismKidney Function\nNormal kidney function essential maintaining electrolyte balance reabsorption excretion\nNormal kidney function essential maintaining electrolyte balance reabsorption excretion","code":""},{"path":"physiology-6.html","id":"abnormal-states-8","chapter":"Physiology","heading":"Abnormal States","text":"Sodium Imbalances\n* Hyponatremia\n* HypernatremiaPotassium Imbalances\n* Hypokalemia\n* HyperkalemiaChloride Imbalances\n* Hypochloremia\n* HyperchloremiaCalcium Imbalances\n* Hypocalcemia\n* HypercalcemiaMagnesium Imbalances\n* Hypomagnesemia\n* HypermagnesemiaPhosphate Imbalances\n* Hypophosphatemia\n* Hyperphosphatemia","code":""},{"path":"physiology-6.html","id":"sodium-imbalances","chapter":"Physiology","heading":"Sodium Imbalances","text":"Hyponatremia\nDefinition: Serum sodium concentration < 136 mmol/L\nCauses\nHypovolemic Hyponatremia: Sodium loss greater water loss (e.g., vomiting, diarrhea, diuretics)\nEuvolemic Hyponatremia: Normal sodium levels, increased water retention (e.g., SIADH, hypothyroidism)\nHypervolemic Hyponatremia: Increased sodium water retention, water excess greater (e.g., heart failure, cirrhosis)\n\nSymptoms: Nausea, headache, confusion, muscle cramps, seizures, coma\nDefinition: Serum sodium concentration < 136 mmol/LCauses\nHypovolemic Hyponatremia: Sodium loss greater water loss (e.g., vomiting, diarrhea, diuretics)\nEuvolemic Hyponatremia: Normal sodium levels, increased water retention (e.g., SIADH, hypothyroidism)\nHypervolemic Hyponatremia: Increased sodium water retention, water excess greater (e.g., heart failure, cirrhosis)\nHypovolemic Hyponatremia: Sodium loss greater water loss (e.g., vomiting, diarrhea, diuretics)Euvolemic Hyponatremia: Normal sodium levels, increased water retention (e.g., SIADH, hypothyroidism)Hypervolemic Hyponatremia: Increased sodium water retention, water excess greater (e.g., heart failure, cirrhosis)Symptoms: Nausea, headache, confusion, muscle cramps, seizures, comaHypernatremia\nDefinition: Serum sodium concentration > 145 mmol/L\nCauses\nHypovolemic Hypernatremia: Water loss greater sodium loss (e.g., sweating, diarrhea)\nEuvolemic Hypernatremia: Water loss normal sodium levels (e.g., diabetes insipidus)\nHypervolemic Hypernatremia: Sodium gain greater water gain (e.g., hypertonic saline administration)\n\nSymptoms: Thirst, confusion, muscle twitching, seizures, coma\nDefinition: Serum sodium concentration > 145 mmol/LCauses\nHypovolemic Hypernatremia: Water loss greater sodium loss (e.g., sweating, diarrhea)\nEuvolemic Hypernatremia: Water loss normal sodium levels (e.g., diabetes insipidus)\nHypervolemic Hypernatremia: Sodium gain greater water gain (e.g., hypertonic saline administration)\nHypovolemic Hypernatremia: Water loss greater sodium loss (e.g., sweating, diarrhea)Euvolemic Hypernatremia: Water loss normal sodium levels (e.g., diabetes insipidus)Hypervolemic Hypernatremia: Sodium gain greater water gain (e.g., hypertonic saline administration)Symptoms: Thirst, confusion, muscle twitching, seizures, coma","code":""},{"path":"physiology-6.html","id":"potassium-imbalances","chapter":"Physiology","heading":"Potassium Imbalances","text":"Hypokalemia\nDefinition: Serum potassium concentration < 3.5 mmol/L\nCauses\nDecreased Intake: Poor dietary intake\nIncreased Loss: Vomiting, diarrhea, diuretics, hyperaldosteronism\nCellular Shift: Insulin, alkalosis, beta-adrenergic agonists\n\nSymptoms: Muscle weakness, fatigue, cardiac arrhythmias, constipation\nDefinition: Serum potassium concentration < 3.5 mmol/LCauses\nDecreased Intake: Poor dietary intake\nIncreased Loss: Vomiting, diarrhea, diuretics, hyperaldosteronism\nCellular Shift: Insulin, alkalosis, beta-adrenergic agonists\nDecreased Intake: Poor dietary intakeIncreased Loss: Vomiting, diarrhea, diuretics, hyperaldosteronismCellular Shift: Insulin, alkalosis, beta-adrenergic agonistsSymptoms: Muscle weakness, fatigue, cardiac arrhythmias, constipationHyperkalemia\nDefinition: Serum potassium concentration > 5.1 mmol/L\nCauses\nDecreased Excretion: Kidney failure, hypoaldosteronism, potassium-sparing diuretics\nCellular Release: Tissue damage, hemolysis, acidosis, insulin deficiency\nIncreased Intake: Excessive potassium supplementation\n\nSymptoms: Muscle weakness, cardiac arrhythmias, paralysis, cardiac arrest\nDefinition: Serum potassium concentration > 5.1 mmol/LCauses\nDecreased Excretion: Kidney failure, hypoaldosteronism, potassium-sparing diuretics\nCellular Release: Tissue damage, hemolysis, acidosis, insulin deficiency\nIncreased Intake: Excessive potassium supplementation\nDecreased Excretion: Kidney failure, hypoaldosteronism, potassium-sparing diureticsCellular Release: Tissue damage, hemolysis, acidosis, insulin deficiencyIncreased Intake: Excessive potassium supplementationSymptoms: Muscle weakness, cardiac arrhythmias, paralysis, cardiac arrest","code":""},{"path":"physiology-6.html","id":"chloride-imbalances","chapter":"Physiology","heading":"Chloride Imbalances","text":"Hypochloremia\nDefinition: Serum chloride concentration < 98 mmol/L\nCauses\nLoss Chloride: Vomiting, nasogastric suctioning, diuretics\nIncreased Bicarbonate: Metabolic alkalosis\nWater Retention: Heart failure, SIADH\n\nSymptoms: Muscle weakness, confusion, metabolic alkalosis\nDefinition: Serum chloride concentration < 98 mmol/LCauses\nLoss Chloride: Vomiting, nasogastric suctioning, diuretics\nIncreased Bicarbonate: Metabolic alkalosis\nWater Retention: Heart failure, SIADH\nLoss Chloride: Vomiting, nasogastric suctioning, diureticsIncreased Bicarbonate: Metabolic alkalosisWater Retention: Heart failure, SIADHSymptoms: Muscle weakness, confusion, metabolic alkalosisHyperchloremia\nDefinition: Serum chloride concentration > 107 mmol/L\nCauses\nChloride Excess: Excessive saline infusion\nLoss Bicarbonate: Diarrhea, renal tubular acidosis\nDehydration: Water deficit\n\nSymptoms: Lethargy, weakness, metabolic acidosis\nDefinition: Serum chloride concentration > 107 mmol/LCauses\nChloride Excess: Excessive saline infusion\nLoss Bicarbonate: Diarrhea, renal tubular acidosis\nDehydration: Water deficit\nChloride Excess: Excessive saline infusionLoss Bicarbonate: Diarrhea, renal tubular acidosisDehydration: Water deficitSymptoms: Lethargy, weakness, metabolic acidosis","code":""},{"path":"physiology-6.html","id":"calcium-imbalances","chapter":"Physiology","heading":"Calcium Imbalances","text":"Hypocalcemia\nDefinition: Serum calcium concentration < 8.6 mg/dL ionized calcium < 4.6 mg/dL\nCauses\nHypoparathyroidism: Decreased PTH production\nVitamin D Deficiency: Impaired calcium absorption\nKidney Disease: Decreased calcium reabsorption, increased phosphate\nHypomagnesemia: Impairs PTH secretion\n\nSymptoms: Muscle cramps, tetany, paresthesias, seizures, cardiac arrhythmias\nDefinition: Serum calcium concentration < 8.6 mg/dL ionized calcium < 4.6 mg/dLCauses\nHypoparathyroidism: Decreased PTH production\nVitamin D Deficiency: Impaired calcium absorption\nKidney Disease: Decreased calcium reabsorption, increased phosphate\nHypomagnesemia: Impairs PTH secretion\nHypoparathyroidism: Decreased PTH productionVitamin D Deficiency: Impaired calcium absorptionKidney Disease: Decreased calcium reabsorption, increased phosphateHypomagnesemia: Impairs PTH secretionSymptoms: Muscle cramps, tetany, paresthesias, seizures, cardiac arrhythmiasHypercalcemia\nDefinition: Serum calcium concentration > 10.2 mg/dL ionized calcium > 5.6 mg/dL\nCauses\nHyperparathyroidism: Increased PTH production\nMalignancy: Bone metastasis, ectopic PTH production\nVitamin D Excess: Increased calcium absorption\nThiazide Diuretics: Increase calcium reabsorption\n\nSymptoms: Fatigue, weakness, constipation, kidney stones, bone pain, altered mental status\nDefinition: Serum calcium concentration > 10.2 mg/dL ionized calcium > 5.6 mg/dLCauses\nHyperparathyroidism: Increased PTH production\nMalignancy: Bone metastasis, ectopic PTH production\nVitamin D Excess: Increased calcium absorption\nThiazide Diuretics: Increase calcium reabsorption\nHyperparathyroidism: Increased PTH productionMalignancy: Bone metastasis, ectopic PTH productionVitamin D Excess: Increased calcium absorptionThiazide Diuretics: Increase calcium reabsorptionSymptoms: Fatigue, weakness, constipation, kidney stones, bone pain, altered mental status","code":""},{"path":"physiology-6.html","id":"magnesium-imbalances","chapter":"Physiology","heading":"Magnesium Imbalances","text":"Hypomagnesemia\nDefinition: Serum magnesium concentration < 1.7 mg/dL\nCauses\nPoor Dietary Intake: Malnutrition, alcoholism\nImpaired Absorption: Malabsorption syndromes\nIncreased Excretion: Diuretics, hyperaldosteronism\n\nSymptoms: Muscle weakness, tremors, seizures, cardiac arrhythmias\nDefinition: Serum magnesium concentration < 1.7 mg/dLCauses\nPoor Dietary Intake: Malnutrition, alcoholism\nImpaired Absorption: Malabsorption syndromes\nIncreased Excretion: Diuretics, hyperaldosteronism\nPoor Dietary Intake: Malnutrition, alcoholismImpaired Absorption: Malabsorption syndromesIncreased Excretion: Diuretics, hyperaldosteronismSymptoms: Muscle weakness, tremors, seizures, cardiac arrhythmiasHypermagnesemia\nDefinition: Serum magnesium concentration > 2.2 mg/dL\nCauses\nKidney Failure: Decreased magnesium excretion\nExcessive Magnesium Intake: Antacids, laxatives\n\nSymptoms: Muscle weakness, lethargy, respiratory depression, cardiac arrest\nDefinition: Serum magnesium concentration > 2.2 mg/dLCauses\nKidney Failure: Decreased magnesium excretion\nExcessive Magnesium Intake: Antacids, laxatives\nKidney Failure: Decreased magnesium excretionExcessive Magnesium Intake: Antacids, laxativesSymptoms: Muscle weakness, lethargy, respiratory depression, cardiac arrest","code":""},{"path":"physiology-6.html","id":"phosphate-imbalances","chapter":"Physiology","heading":"Phosphate Imbalances","text":"Hypophosphatemia\nDefinition: Serum phosphate concentration < 2.5 mg/dL\nCauses\nDecreased Intake: Malnutrition, alcoholism\nCellular Shift: Insulin, alkalosis\nIncreased Excretion: Hyperparathyroidism, diuretics\n\nSymptoms: Muscle weakness, bone pain, seizures, respiratory failure\nDefinition: Serum phosphate concentration < 2.5 mg/dLCauses\nDecreased Intake: Malnutrition, alcoholism\nCellular Shift: Insulin, alkalosis\nIncreased Excretion: Hyperparathyroidism, diuretics\nDecreased Intake: Malnutrition, alcoholismCellular Shift: Insulin, alkalosisIncreased Excretion: Hyperparathyroidism, diureticsSymptoms: Muscle weakness, bone pain, seizures, respiratory failureHyperphosphatemia\nDefinition: Serum phosphate concentration > 4.5 mg/dL\nCauses\nKidney Failure: Decreased phosphate excretion\nHypoparathyroidism: Decreased PTH production\nCellular Release: Tissue damage, hemolysis\n\nSymptoms: Muscle cramps, tetany, cardiac arrhythmias\nDefinition: Serum phosphate concentration > 4.5 mg/dLCauses\nKidney Failure: Decreased phosphate excretion\nHypoparathyroidism: Decreased PTH production\nCellular Release: Tissue damage, hemolysis\nKidney Failure: Decreased phosphate excretionHypoparathyroidism: Decreased PTH productionCellular Release: Tissue damage, hemolysisSymptoms: Muscle cramps, tetany, cardiac arrhythmias","code":""},{"path":"physiology-6.html","id":"trace-elements-2","chapter":"Physiology","heading":"Trace Elements","text":"Iron (Fe)\nIron Deficiency Anemia: Fatigue, weakness, pallor, low hemoglobin, low serum iron, low ferritin, high TIBC\nHemochromatosis: Fatigue, joint pain, abdominal pain, elevated serum iron, elevated ferritin, elevated transferrin saturation\nIron Deficiency Anemia: Fatigue, weakness, pallor, low hemoglobin, low serum iron, low ferritin, high TIBCHemochromatosis: Fatigue, joint pain, abdominal pain, elevated serum iron, elevated ferritin, elevated transferrin saturationZinc (Zn)\nAcrodermatitis Enteropathica: genetic disorder affects zinc absorption, leading skin lesions, diarrhea, growth retardation\nAcrodermatitis Enteropathica: genetic disorder affects zinc absorption, leading skin lesions, diarrhea, growth retardationCopper (Cu)\nWilson’s Disease: genetic disorder causes copper accumulate liver, brain, organs, leading liver disease neurological symptoms\nWilson’s Disease: genetic disorder causes copper accumulate liver, brain, organs, leading liver disease neurological symptomsSelenium (Se)\nKeshan Disease: congestive cardiomyopathy caused deficiency selenium\nKeshan Disease: congestive cardiomyopathy caused deficiency seleniumIodine ()\nIodine Deficiency: Can result goiter, hypothyroidism, cretinism (children)\nIodine Deficiency: Can result goiter, hypothyroidism, cretinism (children)","code":""},{"path":"physiology-6.html","id":"key-terms-48","chapter":"Physiology","heading":"Key Terms","text":"Electrolyte: ion conducts electrical impulses solutionCation: positively charged ionAnion: negatively charged ionIntracellular Fluid (ICF): Fluid within cellsExtracellular Fluid (ECF): Fluid outside cellsAldosterone: hormone increases sodium reabsorption potassium excretion kidneysAntidiuretic Hormone (ADH): hormone regulates water reabsorption kidneysParathyroid Hormone (PTH): hormone increases blood calcium levelsVitamin D: hormone increases blood calcium phosphate levelsHemochromatosis: genetic disorder iron overloadHemolysis: breakdown red blood cellsDehydration: condition caused excessive loss water bodyAscites: accumulation fluid peritoneal cavity, causing abdominal swellingEdema: Swelling caused excess fluid trapped body’s tissuesHypovolemia: medical term decrease blood volume results decreased oxygen delivery bodyHypoxia: deficiency amount oxygen reaching tissuesHypercapnia: presence abnormally high levels carbon dioxide bloodHypoventilation: state reduced amount air enters lungsHyperventilation: state breathing fast deeplyParesthesias: abnormal sensation, typically tingling pricking (“pins needles”), caused chiefly pressure damage peripheral nervesCarpopedal Spasm: Cramps hands feetAcromegaly: disorder results excess growth hormone (GH) growth plates closedAcrodermatitis Enteropathica: genetic disorder affects zinc absorption, leading skin lesions, diarrhea, growth retardationWilson’s Disease: genetic disorder causes copper accumulate liver, brain, organs, leading liver disease neurological symptomsKeshan Disease: congestive cardiomyopathy caused deficiency seleniumCretinism: Hypothyroidism infants children called cretinismGoiter: abnormal enlargement thyroid glandHormone: regulatory substance produced organism transported tissue fluids blood sap stimulate specific cells tissues actionAtherosclerosis: disease arteries characterized deposition plaques fatty material inner wallsIn Vitro: Taking place test tube, culture dish, elsewhere outside living organismIn Vivo: Occurring within living organismHomeostasis: process organisms maintain relatively stable internal environmentNeuropathy: Weakness, numbness, pain nerve damage, usually hands feet","code":""},{"path":"procedures-6.html","id":"procedures-6","chapter":"Procedures","heading":"Procedures","text":"Reliable lab testing electrolytes crucial accurate clinical diagnosis management","code":""},{"path":"procedures-6.html","id":"analytical-principles-1","chapter":"Procedures","heading":"Analytical Principles","text":"Tests measure electrolyte concentrations serum, plasma, whole blood using various methods:\nIon Selective Electrodes (ISEs): Measure activity ions\nDirect ISE: Uses undiluted sample\nIndirect ISE: Requires sample dilution\n\nSpectrophotometry: Measures light absorbance\nIon Selective Electrodes (ISEs): Measure activity ions\nDirect ISE: Uses undiluted sample\nIndirect ISE: Requires sample dilution\nDirect ISE: Uses undiluted sampleIndirect ISE: Requires sample dilutionSpectrophotometry: Measures light absorbanceKey Electrolytes\nSodium, Potassium, Chloride, Total Carbon Dioxide\nCalcium, Magnesium, Phosphorus, Iron, TIBC\nSodium, Potassium, Chloride, Total Carbon DioxideCalcium, Magnesium, Phosphorus, Iron, TIBC","code":""},{"path":"procedures-6.html","id":"special-precautions-10","chapter":"Procedures","heading":"Special Precautions","text":"Patient Preparation\nFasting: certain analytes\nMedications: Review medication list\nHydration Status: Essential note\nFasting: certain analytesMedications: Review medication listHydration Status: Essential noteSpecimen Collection\nCorrect specimen type (serum, plasma, whole blood)\nCorrect tube type\nAdhere recommended order draw multiple tubes\nMinimize tourniquet time\nAvoid hemolysis\nCorrect specimen type (serum, plasma, whole blood)Correct tube typeAdhere recommended order draw multiple tubesMinimize tourniquet timeAvoid hemolysisSpecimen Handling Processing\nProcess promptly\nUse correct centrifuge settings\nAdhere strict storage temperatures\nProcess promptlyUse correct centrifuge settingsAdhere strict storage temperaturesAnalytical Considerations\nAssure reagent quality\nCalibrate instruments correctly\nRun Quality Control regularly\nAssure reagent qualityCalibrate instruments correctlyRun Quality Control regularly","code":""},{"path":"procedures-6.html","id":"troubleshooting-12","chapter":"Procedures","heading":"Troubleshooting","text":"Unexpected Results\nCheck pre-analytical issues\nCheck analytical steps\nConsider interfering substances\nEvaluate QC data\nRepeat testing necessary\nCheck pre-analytical issuesCheck analytical stepsConsider interfering substancesEvaluate QC dataRepeat testing necessaryOut--Control Quality Control\nCheck integrity QC materials\nPrepare fresh QC materials\nRecalibrate instrument\nReview reagent quality\nCheck integrity QC materialsPrepare fresh QC materialsRecalibrate instrumentReview reagent quality","code":""},{"path":"procedures-6.html","id":"interfering-substances-12","chapter":"Procedures","heading":"Interfering Substances","text":"Endogenous\nLipemia (turbidity)\nBilirubin (absorbance)\nHemoglobin (releases ions)\nUrea (alters enzyme activity)\nLipemia (turbidity)Bilirubin (absorbance)Hemoglobin (releases ions)Urea (alters enzyme activity)Exogenous\nMedications\nContamination\nMedicationsContamination","code":""},{"path":"procedures-6.html","id":"key-takeaways","chapter":"Procedures","heading":"Key Takeaways","text":"Proper lab procedures essential accurate electrolyte resultsKnow underlying analytical techniquesUnderstand factors affect electrolyte measurementsHigh clinical judgment recommended approaching electrolytic results","code":""},{"path":"principles-6.html","id":"principles-6","chapter":"Principles","heading":"Principles","text":"Accurate electrolyte testing essential diagnosing managing wide range medical conditions","code":""},{"path":"principles-6.html","id":"analytical-principles-2","chapter":"Principles","heading":"Analytical Principles","text":"General Considerations\nDirect vs. Indirect Methods: Direct ISEs measure activity undiluted samples, reducing interferences proteins lipids. Indirect ISEs require sample dilution\nInterferences: aware common interfering substances take appropriate steps minimize impact\nDirect vs. Indirect Methods: Direct ISEs measure activity undiluted samples, reducing interferences proteins lipids. Indirect ISEs require sample dilutionInterferences: aware common interfering substances take appropriate steps minimize impactInstrumentation\nAutomated Chemistry Analyzers: electrolyte measurements performed automated chemistry analyzers using ISEs spectrophotometric methods\nBlood Gas Analyzers: Measure electrolytes whole blood using ISEs\nAutomated Chemistry Analyzers: electrolyte measurements performed automated chemistry analyzers using ISEs spectrophotometric methodsBlood Gas Analyzers: Measure electrolytes whole blood using ISEs","code":""},{"path":"principles-6.html","id":"sodium-and-potassium","chapter":"Principles","heading":"Sodium and Potassium","text":"Principle: Ion-Selective Electrodes (ISEs) common method measuring sodium potassium\nDirect ISEs: Measure activity ion undiluted samples\nIndirect ISEs: Measure activity ion dilution\nDirect ISEs: Measure activity ion undiluted samplesIndirect ISEs: Measure activity ion dilutionElectrodes\nSodium Electrode: Contains glass membrane selectively permeable sodium ions (\\(Na^+\\))\nPotassium Electrode: Contains valinomycin membrane selectively permeable potassium ions (\\(K^+\\))\nSodium Electrode: Contains glass membrane selectively permeable sodium ions (\\(Na^+\\))Potassium Electrode: Contains valinomycin membrane selectively permeable potassium ions (\\(K^+\\))Process\nsample (serum, plasma, whole blood) introduced measuring chamber, comes contact ISE\nions interest (sodium potassium) diffuse across membrane, creating potential difference\npotential difference measured high-impedance voltmeter proportional ion concentration\nsample (serum, plasma, whole blood) introduced measuring chamber, comes contact ISEThe ions interest (sodium potassium) diffuse across membrane, creating potential differenceThe potential difference measured high-impedance voltmeter proportional ion concentrationReactions\nion-selective membrane selectively binds ion interest, creating potential difference\nion-selective membrane selectively binds ion interest, creating potential differenceDetection: ion concentration displayed instrument readoutAdvantages: Rapid, accurate, precise measurementsDisadvantages: Susceptible interferences protein contamination (methods) improper calibration","code":""},{"path":"principles-6.html","id":"chloride","chapter":"Principles","heading":"Chloride","text":"Principle: Ion-Selective Electrodes (ISEs) commonly usedElectrode: chloride electrode contains membrane selectively permeable chloride ions (\\(Cl^-\\))Process\nsample introduced measuring chamber, comes contact ISE\nChloride ions diffuse across membrane, creating potential difference\npotential difference measured high-impedance voltmeter proportional chloride concentration\nsample introduced measuring chamber, comes contact ISEChloride ions diffuse across membrane, creating potential differenceThe potential difference measured high-impedance voltmeter proportional chloride concentrationReactions\n* ion-selective membrane selectively binds chloride ions, creating potential differenceDetection: chloride concentration displayed instrument readoutAdvantages: Rapid, accurate, precise measurementsDisadvantages: Susceptible interferences certain medications improper calibrationAmperometric-Chloridometric Titration\nSilver (\\(Ag\\)) ions liberated known rate\n\\(Cl\\) ions react silver\n\\(Cl^- + Ag^+ → AgCl (Solid)\\)\n\n\\(Cl\\) ions consumed, excess Silver can detected amperometry\nSilver (\\(Ag\\)) ions liberated known rateThe \\(Cl\\) ions react silver\n\\(Cl^- + Ag^+ → AgCl (Solid)\\)\n\\(Cl^- + Ag^+ → AgCl (Solid)\\)\\(Cl\\) ions consumed, excess Silver can detected amperometry","code":""},{"path":"principles-6.html","id":"total-carbon-dioxide-co_2","chapter":"Principles","heading":"Total Carbon Dioxide (\\(CO_2\\))","text":"Principle: Enzymatic methods indirect ISEs used measure total carbon dioxide. Total \\(CO_2\\) includes bicarbonate (\\(HCO_3^-\\)), carbonic acid (\\(H_2CO_3\\)), dissolved carbon dioxide (\\(CO_2\\))Enzymatic Method\nAcidification Sample: \\(CO_2\\) converted \\(H_2CO_3\\)\n\\(CO_2 + H_2O ↔ H_2CO_3\\)\n\nConversion Bicarbonate: converted bicarbonate\n\\(H_2CO_3 ↔ H^+ + HCO_3^-\\)\n\nReaction PEP Carboxylase: Bicarbonate react phosphoenolpyruvate (\\(PEP\\)) produce oxaloacetate, converts malate \\(NADH\\)\n\\(HCO_3^- + PEP → Oxaloacetate\\)\n\\(Oxaloacetate + NADH → Malate + NAD^+\\)\n\n\\(NADH\\) becomes \\(NAD^+\\), change measured spectrophotometrically\nAcidification Sample: \\(CO_2\\) converted \\(H_2CO_3\\)\n\\(CO_2 + H_2O ↔ H_2CO_3\\)\n\\(CO_2 + H_2O ↔ H_2CO_3\\)Conversion Bicarbonate: converted bicarbonate\n\\(H_2CO_3 ↔ H^+ + HCO_3^-\\)\n\\(H_2CO_3 ↔ H^+ + HCO_3^-\\)Reaction PEP Carboxylase: Bicarbonate react phosphoenolpyruvate (\\(PEP\\)) produce oxaloacetate, converts malate \\(NADH\\)\n\\(HCO_3^- + PEP → Oxaloacetate\\)\n\\(Oxaloacetate + NADH → Malate + NAD^+\\)\n\\(HCO_3^- + PEP → Oxaloacetate\\)\\(Oxaloacetate + NADH → Malate + NAD^+\\)\\(NADH\\) becomes \\(NAD^+\\), change measured spectrophotometricallyIndirect ISE Method\n\\(CO_2\\) diffuses across membrane bicarbonate buffer solution\nchange pH measured pH-sensitive electrode, proportional \\(CO_2\\) concentration\n\\(CO_2\\) diffuses across membrane bicarbonate buffer solutionThe change pH measured pH-sensitive electrode, proportional \\(CO_2\\) concentrationDetection: change absorbance (enzymatic method) change pH (ISE method) measuredAdvantages: Rapid automatedDisadvantages: Susceptible interferences volatile acids bases, improper calibration","code":""},{"path":"principles-6.html","id":"bicarbonate-hco_3-","chapter":"Principles","heading":"Bicarbonate (\\(HCO_3^-\\))","text":"Principle: Bicarbonate directly measured typically calculated pH Pa\\(CO_2\\) using Henderson-Hasselbalch equationCalculation\nHenderson-Hasselbalch equation relates pH concentrations bicarbonate (\\(HCO_3^-\\)) carbon dioxide (\\(CO_2\\)):\n\\(pH = pKa + log \\left( \\frac{[HCO_3^-]}{[CO_2]} \\right)\\)\nSince [\\(CO_2\\)] proportional Pa\\(CO_2\\), equation can written :\n\\(pH = pKa + log \\left( \\frac{[HCO_3^-]}{0.03 \\times PaCO_2} \\right)\\)\n\\([HCO_3^-] = 10^{(pH - pKa)} \\times 0.03 \\times PaCO_2\\)\npKa = 6.1 (dissociation constant carbonic acid)\n03 = Solubility coefficient \\(CO_2\\) plasma\n\n\nHenderson-Hasselbalch equation relates pH concentrations bicarbonate (\\(HCO_3^-\\)) carbon dioxide (\\(CO_2\\)):\\(pH = pKa + log \\left( \\frac{[HCO_3^-]}{[CO_2]} \\right)\\)Since [\\(CO_2\\)] proportional Pa\\(CO_2\\), equation can written :\\(pH = pKa + log \\left( \\frac{[HCO_3^-]}{0.03 \\times PaCO_2} \\right)\\)\\([HCO_3^-] = 10^{(pH - pKa)} \\times 0.03 \\times PaCO_2\\)\npKa = 6.1 (dissociation constant carbonic acid)\n03 = Solubility coefficient \\(CO_2\\) plasma\n\npKa = 6.1 (dissociation constant carbonic acid)03 = Solubility coefficient \\(CO_2\\) plasma\n03 = Solubility coefficient \\(CO_2\\) plasmaAdvantages: Provides clinically useful estimate bicarbonate concentrationDisadvantages: subject errors pH P\\(CO_2\\) measurementsDirect Measurement Methods\nISE: Measured method using bicarbonate-selective membrane\nSimilar chloride methods, using bicarbonate selective electrode\n\nISE: Measured method using bicarbonate-selective membrane\nSimilar chloride methods, using bicarbonate selective electrode\nSimilar chloride methods, using bicarbonate selective electrode","code":""},{"path":"principles-6.html","id":"calcium-ca2-1","chapter":"Principles","heading":"Calcium (\\(Ca^{2+}\\))","text":"Principle: Several methods available, including spectrophotometry ion-selective electrodes (ISEs)Spectrophotometric Methods\nComplexation Dye: Dyes Arsenazo III o-cresolphthalein complexone (\\(OCPC\\)) bind calcium ions, forming colored complex measured spectrophotometrically\nComplexation Dye: Dyes Arsenazo III o-cresolphthalein complexone (\\(OCPC\\)) bind calcium ions, forming colored complex measured spectrophotometricallyIon-Selective Electrode (ISE) Methods\nmembrane selectively permeable calcium ions produces potential difference related calcium concentration\nMeasures ionized calcium\nmembrane selectively permeable calcium ions produces potential difference related calcium concentrationMeasures ionized calciumReactions\nSpectrophotometric Methods: \\(Ca^{2+} + Dye → Dye-Ca^{2+}\\) Complex (Colored)\nSpectrophotometric Methods: \\(Ca^{2+} + Dye → Dye-Ca^{2+}\\) Complex (Colored)Detection: absorbance colored complex (spectrophotometric methods) potential difference (ISE methods) measuredAdvantages: methods widely available automatedDisadvantages: Spectrophotometric methods susceptible interferences hemolysis lipemia; ISE methods require careful calibration maintenance","code":""},{"path":"principles-6.html","id":"magnesium-mg2-1","chapter":"Principles","heading":"Magnesium (\\(Mg^{2+}\\))","text":"Principle: Several methods available, including spectrophotometry ion-selective electrodes (ISEs)Spectrophotometric Methods\nDye-Binding Methods: Magnesium reacts dye calmagite methylthymol blue form colored complex\nDye-Binding Methods: Magnesium reacts dye calmagite methylthymol blue form colored complexIon-Selective Electrode (ISE) Methods\nUsed measure ionized magnesium\nUsed measure ionized magnesiumReactions\nSpectrophotometric Methods: \\(Mg^{2+} + Dye → Dye-Mg^{2+}\\) Complex (Colored)\nSpectrophotometric Methods: \\(Mg^{2+} + Dye → Dye-Mg^{2+}\\) Complex (Colored)Detection: absorbance colored complex (spectrophotometric methods) potential difference (ISE methods) measuredAdvantages: methods widely available automatedDisadvantages: Spectrophotometric methods susceptible interferences calcium ions; ISE methods require careful calibration maintenance","code":""},{"path":"principles-6.html","id":"phosphorus-p-1","chapter":"Principles","heading":"Phosphorus (\\(P\\))","text":"Principle: Phosphorus (phosphate) reacts ammonium molybdate form phosphomolybdate complex, reduced molybdenum blueReactions\n* \\(P + Ammonium Molybdate → Phosphomolybdate Complex\\)\n* \\(Phosphomolybdate Complex + Reducing Agent → Molybdenum Blue\\)Detection: intensity molybdenum blue color measured spectrophotometricallyAdvantages: Relatively simple widely availableDisadvantages: Susceptible interferences hemolysis, lipemia, bilirubin","code":""},{"path":"principles-6.html","id":"iron-fe-2","chapter":"Principles","heading":"Iron (\\(Fe\\))","text":"Principle: Iron released transferrin acidic buffer reduced \\(Fe^{2+}\\). \\(Fe^{2+}\\) reacts chromogen form colored complex, measured spectrophotometricallyReactions\n\\(Transferrin-Fe^{3+} + Acidic Buffer → Transferrin + Fe^{3+}\\)\n\\(Fe^{3+} + Reducing Agent → Fe^{2+}\\)\n\\(Fe^{2+} + Chromogen → Colored Complex\\)\n\\(Transferrin-Fe^{3+} + Acidic Buffer → Transferrin + Fe^{3+}\\)\\(Fe^{3+} + Reducing Agent → Fe^{2+}\\)\\(Fe^{2+} + Chromogen → Colored Complex\\)Detection: intensity colored complex directly proportional iron concentration sampleAdvantages: Widely available relatively inexpensiveDisadvantages: Affected diurnal variation recent iron intake","code":""},{"path":"principles-6.html","id":"total-iron-binding-capacity-tibc-2","chapter":"Principles","heading":"Total Iron-Binding Capacity (TIBC)","text":"Principle: Excess iron added saturate binding sites transferrin. unbound iron removed, total iron measured using similar method serum ironReactions\n\\(Transferrin + Excess Fe^{3+} → Transferrin-Fe^{3+}\\) (Saturated)\nRemoval Unbound \\(Fe^{3+}\\)\n\\(Transferrin-Fe^{3+} + Acidic Buffer → Transferrin + Fe^{3+}\\)\n\\(Fe^{3+} + Reducing Agent → Fe^{2+}\\)\n\\(Fe^{2+} + Chromogen → Colored Complex\\)\n\\(Transferrin + Excess Fe^{3+} → Transferrin-Fe^{3+}\\) (Saturated)Removal Unbound \\(Fe^{3+}\\)\\(Transferrin-Fe^{3+} + Acidic Buffer → Transferrin + Fe^{3+}\\)\\(Fe^{3+} + Reducing Agent → Fe^{2+}\\)\\(Fe^{2+} + Chromogen → Colored Complex\\)Detection: intensity colored complex directly proportional TIBCAdvantages: Provides estimate transferrin concentrationDisadvantages: complex serum iron measurement","code":""},{"path":"principles-6.html","id":"key-terms-49","chapter":"Principles","heading":"Key Terms","text":"Ion-Selective Electrode (ISE): electrochemical sensor responds selectively specific ionsPotentiometry: method measure electrical potential difference two electrodesAmperometry: method measure electrical current flowing electrochemical cellSpectrophotometry: method measure absorbance light solutionChromogen: substance produces colored productEnzymatic Method: laboratory method uses enzymes catalyze reactionISE (Ion-selective electrode): Measures concentration specific ions membraneISE direct: Uses undiluted sampleISE indirect: Requires sample dilutionCoefficient Variation: Measure precision","code":""},{"path":"precautions-1.html","id":"precautions-1","chapter":"Precautions","heading":"Precautions","text":"Reliable electrolyte measurements depend careful techniquePre-analytical factorsAnalytical factorsPotential interferences","code":""},{"path":"precautions-1.html","id":"specimen-collection-6","chapter":"Precautions","heading":"Specimen Collection","text":"Patient Preparation\nFasting: electrolyte tests require fasting minimize interferences lipemia\nMedications: Certain drugs can affect electrolyte levels. Review patient’s medication list\nHydration Status: Assess hydration, dehydration overhydration can affect electrolyte concentrations\nFasting: electrolyte tests require fasting minimize interferences lipemiaMedications: Certain drugs can affect electrolyte levels. Review patient’s medication listHydration Status: Assess hydration, dehydration overhydration can affect electrolyte concentrationsSpecimen Type\nSerum common specimen type electrolyte measurements\nPlasma may used electrolyte assays, follow laboratory’s guidelines anticoagulant selection\nWhole blood used point--care testing (POCT) devices\nSerum common specimen type electrolyte measurementsPlasma may used electrolyte assays, follow laboratory’s guidelines anticoagulant selectionWhole blood used point--care testing (POCT) devicesTube Type\nSerum separator tubes (SST) red-top tubes commonly used serum collection\nPlasma tubes lithium heparin often used plasma collection\nSerum separator tubes (SST) red-top tubes commonly used serum collectionPlasma tubes lithium heparin often used plasma collectionOrder Draw\nFollow correct order draw collecting multiple tubes prevent cross-contamination\nFollow correct order draw collecting multiple tubes prevent cross-contaminationTourniquet Time\nMinimize tourniquet time (ideally less 1 minute) prevent hemoconcentration\nMinimize tourniquet time (ideally less 1 minute) prevent hemoconcentrationCollection Technique\nUse clean venipuncture technique minimize hemolysis. Avoid prolonged probing excessive force\nAvoid drawing blood arm intravenous (IV) line, possible\nUse clean venipuncture technique minimize hemolysis. Avoid prolonged probing excessive forceAvoid drawing blood arm intravenous (IV) line, possible","code":""},{"path":"precautions-1.html","id":"specimen-handling-and-processing-6","chapter":"Precautions","heading":"Specimen Handling and Processing","text":"Timing\nProcess specimen soon possible collection prevent changes electrolyte concentrations due cellular metabolism\nAnalyze potassium levels promptly, potassium can released cells storage, leading falsely elevated results\nProcess specimen soon possible collection prevent changes electrolyte concentrations due cellular metabolismAnalyze potassium levels promptly, potassium can released cells storage, leading falsely elevated resultsCentrifugation\nCentrifuge sample according manufacturer’s instructions specific tube type\nProper centrifugation ensures complete separation serum plasma cells\nCentrifuge sample according manufacturer’s instructions specific tube typeProper centrifugation ensures complete separation serum plasma cellsStorage\nanalysis delayed, store specimen refrigerated (2-8°C) short-term storage frozen (-20°C -70°C) longer storage\nAliquot sample smaller portions avoid repeated freeze-thaw cycles, can affect electrolyte concentrations\nanalysis delayed, store specimen refrigerated (2-8°C) short-term storage frozen (-20°C -70°C) longer storageAliquot sample smaller portions avoid repeated freeze-thaw cycles, can affect electrolyte concentrationsHemolysis\nAvoid hemolysis, red blood cells contain high concentrations potassium phosphate, can falsely elevate results\nVisually inspect sample hemolysis reject hemolyzed samples\nAvoid hemolysis, red blood cells contain high concentrations potassium phosphate, can falsely elevate resultsVisually inspect sample hemolysis reject hemolyzed samplesLipemia\nLipemia (excess lipids) can interfere spectrophotometric assays\nUse lipemia clearing techniques (ultracentrifugation, lipid clearing reagents) consider methods less affected turbidity\nLipemia (excess lipids) can interfere spectrophotometric assaysUse lipemia clearing techniques (ultracentrifugation, lipid clearing reagents) consider methods less affected turbidityPrecipitation\naware precipitation calcium magnesium, may lead false results\naware precipitation calcium magnesium, may lead false results","code":""},{"path":"precautions-1.html","id":"analytical-considerations-6","chapter":"Precautions","heading":"Analytical Considerations","text":"Reagent Quality\nUse high-quality reagents store according manufacturer’s instructions\nCheck expiration dates discard expired reagents\nUse high-quality reagents store according manufacturer’s instructionsCheck expiration dates discard expired reagentsCalibration\nCalibrate instrument regularly using appropriate standards\nUse multiple calibrators ensure linearity entire measurement range\nCalibrate instrument regularly using appropriate standardsUse multiple calibrators ensure linearity entire measurement rangeQuality Control (QC)\nRun quality control samples regular intervals monitor accuracy precision assay\nUse normal abnormal QC levels assess performance across entire range\nEvaluate QC results releasing patient results\nRun quality control samples regular intervals monitor accuracy precision assayUse normal abnormal QC levels assess performance across entire rangeEvaluate QC results releasing patient resultsInstrumentation\nRegularly maintain service instrument according manufacturer’s recommendations\nEnsure instrument functioning properly components good working order\nRegularly maintain service instrument according manufacturer’s recommendationsEnsure instrument functioning properly components good working orderMethod Validation\nValidate new methods implementation ensure accuracy, precision, linearity, performance characteristics\nReference ranges may vary depending age patient\nValidate new methods implementation ensure accuracy, precision, linearity, performance characteristicsReference ranges may vary depending age patient","code":""},{"path":"precautions-1.html","id":"interfering-substances-13","chapter":"Precautions","heading":"Interfering Substances","text":"Endogenous\nLipemia: Causes turbidity, affecting spectrophotometric readings\nBilirubin: Absorbs light similar wavelengths, affecting absorbance readings\nHemoglobin: Released hemolyzed red blood cells, interfering enzymatic reactions\nHigh Protein Concentrations: Can interfere enzymatic assays affecting reaction kinetics detection system\nLipemia: Causes turbidity, affecting spectrophotometric readingsBilirubin: Absorbs light similar wavelengths, affecting absorbance readingsHemoglobin: Released hemolyzed red blood cells, interfering enzymatic reactionsHigh Protein Concentrations: Can interfere enzymatic assays affecting reaction kinetics detection systemExogenous\nMedications: Certain drugs can directly affect electrolyte levels\nAnticoagulants: anticoagulants can interfere enzymatic reactions\nContaminants: Improperly cleaned glassware containers can introduce contaminants affect assay performance\nMedications: Certain drugs can directly affect electrolyte levelsAnticoagulants: anticoagulants can interfere enzymatic reactionsContaminants: Improperly cleaned glassware containers can introduce contaminants affect assay performancePseudohyponatremia\nOccurs marked hyperlipidemia hyperproteinemia\nSodium concentration appears lower due volume displacement\nDirect ISE methods less susceptible interference\nOccurs marked hyperlipidemia hyperproteinemiaSodium concentration appears lower due volume displacementDirect ISE methods less susceptible interferenceChloride ISE Interference\nBromide can interfere chloride ISE methods\nSweat Contamination: High chloride content\nBromide can interfere chloride ISE methodsSweat Contamination: High chloride content","code":""},{"path":"precautions-1.html","id":"troubleshooting-13","chapter":"Precautions","heading":"Troubleshooting","text":"Unexpectedly High Results\nPre-Analytical:\nPatient fasting\nProlonged tourniquet time\nHemolysis\nImproper collection tube\n\nAnalytical:\nIncorrect calibration\nReagent deterioration\nInterfering substances\nInstrument malfunction\n\nPre-Analytical:\nPatient fasting\nProlonged tourniquet time\nHemolysis\nImproper collection tube\nPatient fastingProlonged tourniquet timeHemolysisImproper collection tubeAnalytical:\nIncorrect calibration\nReagent deterioration\nInterfering substances\nInstrument malfunction\nIncorrect calibrationReagent deteriorationInterfering substancesInstrument malfunctionUnexpectedly Low Results\nPre-Analytical:\nImproper storage\nAnalyte degradation\n\nAnalytical:\nIncorrect calibration\nReagent deterioration\nInstrument malfunction\n\nPre-Analytical:\nImproper storage\nAnalyte degradation\nImproper storageAnalyte degradationAnalytical:\nIncorrect calibration\nReagent deterioration\nInstrument malfunction\nIncorrect calibrationReagent deteriorationInstrument malfunctionInconsistent Results\nCheck patient preparation\nReview collection processing procedures\nEvaluate reagent quality calibration\nConsider interfering substances\nRepeat test using different method new sample\nCheck patient preparationReview collection processing proceduresEvaluate reagent quality calibrationConsider interfering substancesRepeat test using different method new sampleOut--Control QC\nCheck integrity QC materials\nPrepare fresh QC materials\nRe-calibrate instrument\nReview reagent quality\nRepeat QC testing\nproblem persists, contact instrument manufacturer assistance\nCheck integrity QC materialsPrepare fresh QC materialsRe-calibrate instrumentReview reagent qualityRepeat QC testingIf problem persists, contact instrument manufacturer assistanceLipemia: Can cause electrolyte imbalance false interference. Correct either using direct ISEs clearing lipemiaIcterus: Can cause interference, ensure testing reagents correct appropriate testing interferencesHemolysis: Can release electrolytic components within cell, skewing results precautions taken","code":""},{"path":"precautions-1.html","id":"key-terms-50","chapter":"Precautions","heading":"Key Terms","text":"Pre-analytical: Processes occur sample analyzedAnalytical: Processes involved analyzing sampleInterfering Substance: substance affects accuracy testHemolysis: breakdown red blood cellsLipemia: presence excess lipids bloodCalibration: Adjusting instrument ensure accurate readingsQuality Control: Samples used monitor accuracy precision testSST: Serum Separator TubeEDTA: Ethylenediaminetetraacetic acid, anticoagulantSOP: Standard Operating ProcedureAccuracy: close measurement true valuePrecision: Reproducibility measurementISE: Ion-Selective ElectrodePOCT: Point Care Testing","code":""},{"path":"calculations-1.html","id":"calculations-1","chapter":"Calculations","heading":"Calculations","text":"formulas vital assessing fluid electrolyte balance, well identifying underlying metabolic disturbances","code":""},{"path":"calculations-1.html","id":"osmolality","chapter":"Calculations","heading":"Osmolality","text":"Definition: measure concentration solute particles solution. reflects number dissolved particles per kilogram solvent (water)Units: milliosmoles per kilogram (mOsm/kg) millimoles per kilogram (mmol/kg)Measured Osmolality: Determined using osmometer, measures colligative properties solution (e.g., freezing point depression vapor pressure depression)Calculated Osmolality: Estimated concentrations major solutes plasmaOsmolal Gap: difference measured osmolality calculated osmolality. elevated osmolal gap suggests presence unmeasured osmotically active substances plasma","code":""},{"path":"calculations-1.html","id":"calculation-of-osmolality","chapter":"Calculations","heading":"Calculation of Osmolality","text":"Formula\n\\(Osmolality (mOsm/kg) = 2[Na^+] + \\left( \\frac {[Glucose (mg/dL)]} {18} \\right) + \\left( \\frac {[BUN (mg/dL)]} {2.8} \\right)\\)\n:\n[\\(Na^+\\)] = Sodium concentration mmol/L\n[\\(Glucose\\)] = Glucose concentration mg/dL\n[\\(BUN\\)] = Blood urea nitrogen concentration mg/dL\n18 = Conversion factor glucose (mg/dL mmol/L)\n2.8 = Conversion factor BUN (mg/dL mmol/L)\n\n\\(Osmolality (mOsm/kg) = 2[Na^+] + \\left( \\frac {[Glucose (mg/dL)]} {18} \\right) + \\left( \\frac {[BUN (mg/dL)]} {2.8} \\right)\\):\n[\\(Na^+\\)] = Sodium concentration mmol/L\n[\\(Glucose\\)] = Glucose concentration mg/dL\n[\\(BUN\\)] = Blood urea nitrogen concentration mg/dL\n18 = Conversion factor glucose (mg/dL mmol/L)\n2.8 = Conversion factor BUN (mg/dL mmol/L)\n[\\(Na^+\\)] = Sodium concentration mmol/L[\\(Glucose\\)] = Glucose concentration mg/dL[\\(BUN\\)] = Blood urea nitrogen concentration mg/dL18 = Conversion factor glucose (mg/dL mmol/L)2.8 = Conversion factor BUN (mg/dL mmol/L)SI Units\n\\(Osmolality (mmol/kg) = 2[Na^+] + [Glucose] + [Urea]\\)\n:\n[\\(Na^+\\)] = Sodium concentration mmol/L\n[\\(Glucose\\)] = Glucose concentration mmol/L\n[\\(Urea\\)] = Urea concentration mmol/L\n\n\\(Osmolality (mmol/kg) = 2[Na^+] + [Glucose] + [Urea]\\):\n[\\(Na^+\\)] = Sodium concentration mmol/L\n[\\(Glucose\\)] = Glucose concentration mmol/L\n[\\(Urea\\)] = Urea concentration mmol/L\n[\\(Na^+\\)] = Sodium concentration mmol/L[\\(Glucose\\)] = Glucose concentration mmol/L[\\(Urea\\)] = Urea concentration mmol/LNormal Range\n275-295 mOsm/kg\ncontributions measured serum osmolality comes sodium, chloride, potassium, urea, glucose\n275-295 mOsm/kgMost contributions measured serum osmolality comes sodium, chloride, potassium, urea, glucose","code":""},{"path":"calculations-1.html","id":"clinical-significance-of-osmolality","chapter":"Calculations","heading":"Clinical Significance of Osmolality","text":"Assessment Hydration Status: Osmolality reflects balance water solutes bloodEvaluation Kidney Function: Osmolality can used assess kidney’s ability concentrate dilute urineDiagnosis Electrolyte Imbalances: Changes osmolality can indicate electrolyte disordersDetection Toxic Substances: elevated osmolal gap can suggest presence unmeasured osmotically active substances (e.g., ethanol, methanol, ethylene glycol)","code":""},{"path":"calculations-1.html","id":"increased-osmolality","chapter":"Calculations","heading":"Increased Osmolality","text":"Causes\nDehydration: Water deficit leads increased solute concentration\nHypernatremia: Elevated sodium levels\nHyperglycemia: Elevated glucose levels (e.g., diabetes)\nUremia: Elevated BUN levels (e.g., kidney failure)\nToxic Ingestions: Presence unmeasured osmotically active substances (e.g., ethanol, methanol, ethylene glycol)\nDehydration: Water deficit leads increased solute concentrationHypernatremia: Elevated sodium levelsHyperglycemia: Elevated glucose levels (e.g., diabetes)Uremia: Elevated BUN levels (e.g., kidney failure)Toxic Ingestions: Presence unmeasured osmotically active substances (e.g., ethanol, methanol, ethylene glycol)Symptoms\nThirst, confusion, lethargy, seizures, coma\nThirst, confusion, lethargy, seizures, coma","code":""},{"path":"calculations-1.html","id":"decreased-osmolality","chapter":"Calculations","heading":"Decreased Osmolality","text":"Causes\nOverhydration: Water excess leads decreased solute concentration\nHyponatremia: Low sodium levels\nSIADH (Syndrome Inappropriate Antidiuretic Hormone Secretion): Excessive ADH leads water retention\nAdrenal Insufficiency: Impaired cortisol production affects water electrolyte balance\nOverhydration: Water excess leads decreased solute concentrationHyponatremia: Low sodium levelsSIADH (Syndrome Inappropriate Antidiuretic Hormone Secretion): Excessive ADH leads water retentionAdrenal Insufficiency: Impaired cortisol production affects water electrolyte balanceSymptoms\nNausea, headache, confusion, muscle cramps, seizures, coma\nNausea, headache, confusion, muscle cramps, seizures, coma","code":""},{"path":"calculations-1.html","id":"increased-osmolal-gap","chapter":"Calculations","heading":"Increased Osmolal Gap","text":"Causes\nPresence unmeasured osmotically active substances:\nEthanol\nMethanol\nEthylene Glycol\nIsopropanol\nPropylene Glycol\nAcetone\n\nLess Common Causes:\nMannitol\nGlycerol\nSevere Hyperlipidemia Hyperproteinemia\nLactic Acidosis\n\nPresence unmeasured osmotically active substances:\nEthanol\nMethanol\nEthylene Glycol\nIsopropanol\nPropylene Glycol\nAcetone\nEthanolMethanolEthylene GlycolIsopropanolPropylene GlycolAcetoneLess Common Causes:\nMannitol\nGlycerol\nSevere Hyperlipidemia Hyperproteinemia\nLactic Acidosis\nMannitolGlycerolSevere Hyperlipidemia HyperproteinemiaLactic Acidosis","code":""},{"path":"calculations-1.html","id":"anion-gap","chapter":"Calculations","heading":"Anion Gap","text":"Definition: difference measured cations (positively charged ions) anions (negatively charged ions) serum plasma. used assess acid-base balance, particularly cases metabolic acidosisPurpose: anion gap helps identify cause metabolic acidosis distinguishing conditions increase unmeasured anions result loss bicarbonateMeasured Ions\nCations: Sodium (\\(Na^+\\)) Potassium (\\(K^+\\))\nAnions: Chloride (\\(Cl^-\\)) Bicarbonate (\\(HCO_3^-\\))\nCations: Sodium (\\(Na^+\\)) Potassium (\\(K^+\\))Anions: Chloride (\\(Cl^-\\)) Bicarbonate (\\(HCO_3^-\\))","code":""},{"path":"calculations-1.html","id":"calculation-of-anion-gap","chapter":"Calculations","heading":"Calculation of Anion Gap","text":"Formula\nAnion Gap = (\\(Na^+\\) + \\(K^+\\)) - (\\(Cl^-\\) + \\(HCO_3^-\\))\nAnion Gap = \\(Na^+\\) - (\\(Cl^-\\) + \\(HCO_3^-\\)) (potassium measured)\nAnion Gap = (\\(Na^+\\) + \\(K^+\\)) - (\\(Cl^-\\) + \\(HCO_3^-\\))Anion Gap = \\(Na^+\\) - (\\(Cl^-\\) + \\(HCO_3^-\\)) (potassium measured)Normal Range\nPotassium: 8-16 mEq/L mmol/L\nWithout Potassium: 10-20 mEq/L mmol/L\nPotassium: 8-16 mEq/L mmol/LWithout Potassium: 10-20 mEq/L mmol/L","code":""},{"path":"calculations-1.html","id":"clinical-significance-of-anion-gap","chapter":"Calculations","heading":"Clinical Significance of Anion Gap","text":"Normal Anion Gap Metabolic Acidosis (NAGMA)\nAlso known hyperchloremic metabolic acidosis\ndecrease bicarbonate compensated increase chloride, maintaining normal anion gap\nCauses:\nGastrointestinal Bicarbonate Loss: Diarrhea, ileostomy\nRenal Tubular Acidosis (RTA): Impaired reabsorption bicarbonate impaired excretion acid kidneys\nAdministration Chloride-Containing Solutions: Saline infusion\nCertain Medications: Acetazolamide, cholestyramine\n\nAlso known hyperchloremic metabolic acidosisThe decrease bicarbonate compensated increase chloride, maintaining normal anion gapCauses:\nGastrointestinal Bicarbonate Loss: Diarrhea, ileostomy\nRenal Tubular Acidosis (RTA): Impaired reabsorption bicarbonate impaired excretion acid kidneys\nAdministration Chloride-Containing Solutions: Saline infusion\nCertain Medications: Acetazolamide, cholestyramine\nGastrointestinal Bicarbonate Loss: Diarrhea, ileostomyRenal Tubular Acidosis (RTA): Impaired reabsorption bicarbonate impaired excretion acid kidneysAdministration Chloride-Containing Solutions: Saline infusionCertain Medications: Acetazolamide, cholestyramineElevated Anion Gap Metabolic Acidosis (HAGMA)\ndecrease bicarbonate accompanied increase unmeasured anions, resulting elevated anion gap\nCauses:\nKetoacidosis: Diabetic ketoacidosis (DKA), alcoholic ketoacidosis, starvation ketoacidosis\nLactic Acidosis: Anaerobic metabolism due shock, sepsis, severe exercise\nRenal Failure: Accumulation sulfates, phosphates, organic acids\nToxic Ingestions:\nMethanol: Metabolized formic acid\nEthylene Glycol: Metabolized glycolic acid oxalic acid\nSalicylates: Disrupts cellular metabolism\n\n\nMnemonic High Anion Gap Acidosis: “MUDPILES”\nM: Methanol\nU: Uremia (Renal Failure)\nD: Diabetic Ketoacidosis\nP: Propylene Glycol\n: Iron, Isoniazid\nL: Lactic Acidosis\nE: Ethylene Glycol\nS: Salicylates\n\ndecrease bicarbonate accompanied increase unmeasured anions, resulting elevated anion gapCauses:\nKetoacidosis: Diabetic ketoacidosis (DKA), alcoholic ketoacidosis, starvation ketoacidosis\nLactic Acidosis: Anaerobic metabolism due shock, sepsis, severe exercise\nRenal Failure: Accumulation sulfates, phosphates, organic acids\nToxic Ingestions:\nMethanol: Metabolized formic acid\nEthylene Glycol: Metabolized glycolic acid oxalic acid\nSalicylates: Disrupts cellular metabolism\n\nKetoacidosis: Diabetic ketoacidosis (DKA), alcoholic ketoacidosis, starvation ketoacidosisLactic Acidosis: Anaerobic metabolism due shock, sepsis, severe exerciseRenal Failure: Accumulation sulfates, phosphates, organic acidsToxic Ingestions:\nMethanol: Metabolized formic acid\nEthylene Glycol: Metabolized glycolic acid oxalic acid\nSalicylates: Disrupts cellular metabolism\nMethanol: Metabolized formic acidEthylene Glycol: Metabolized glycolic acid oxalic acidSalicylates: Disrupts cellular metabolismMnemonic High Anion Gap Acidosis: “MUDPILES”\nM: Methanol\nU: Uremia (Renal Failure)\nD: Diabetic Ketoacidosis\nP: Propylene Glycol\n: Iron, Isoniazid\nL: Lactic Acidosis\nE: Ethylene Glycol\nS: Salicylates\nM: MethanolU: Uremia (Renal Failure)D: Diabetic KetoacidosisP: Propylene GlycolI: Iron, IsoniazidL: Lactic AcidosisE: Ethylene GlycolS: SalicylatesDecreased Anion Gap\nRare typically less clinically significant\nCauses:\nHypoalbuminemia: Albumin major unmeasured anion, decreased albumin levels can lower anion gap\nMultiple Myeloma: Increased levels cationic immunoglobulins\nBromide Intoxication: Bromide measured chloride, leading artificially elevated chloride level decreased anion gap\nLithium Toxicity: Causes \\(Cl^-\\) retention\n\nRare typically less clinically significantCauses:\nHypoalbuminemia: Albumin major unmeasured anion, decreased albumin levels can lower anion gap\nMultiple Myeloma: Increased levels cationic immunoglobulins\nBromide Intoxication: Bromide measured chloride, leading artificially elevated chloride level decreased anion gap\nLithium Toxicity: Causes \\(Cl^-\\) retention\nHypoalbuminemia: Albumin major unmeasured anion, decreased albumin levels can lower anion gapMultiple Myeloma: Increased levels cationic immunoglobulinsBromide Intoxication: Bromide measured chloride, leading artificially elevated chloride level decreased anion gapLithium Toxicity: Causes \\(Cl^-\\) retention","code":""},{"path":"calculations-1.html","id":"key-terms-51","chapter":"Calculations","heading":"Key Terms","text":"Osmolality: Concentration solute particles solutionOsmolal Gap: Difference measured calculated osmolalityAnion Gap: Difference measured cations anions serumMeasured Cations: Sodium PotassiumMeasured Anions: Chloride BicarbonateHypoalbuminemia: Abnormally low levels protein bloodMultiple Myeloma: cancer plasma cellsBromide Intoxication: condition person ingested toxic amount bromideNormal Saline: Normal Saline (Saline) mixture sodium chloride (salt) water. used rinsing wounds, nasal passages, contact lenses. Intravenous normal saline can used fluid replacement number conditions, dehydration, hypovolemia, sepsisIschemia: inadequate blood supply organ part bodyHypoxia: inadequate oxygen supply cells tissues bodyHypercapnia: presence abnormally high levels carbon dioxide bloodHypoventilation: state reduced amount air enters lungsHyperventilation: state breathing fast deeplyParesthesias: abnormal sensation, typically tingling pricking (“pins needles”), caused chiefly pressure damage peripheral nervesCarpopedal Spasm: Cramps hands feetEnzyme: substance produced living organism acts catalyst bring specific biochemical reactionIn Vitro: Taking place test tube, culture dish, elsewhere outside living organismIn Vivo: Occurring within living organismHomeostasis: process organisms maintain relatively stable internal environmentElectrolyte: ion conducts electrical impulses solution","code":""},{"path":"result-interpretation-6.html","id":"result-interpretation-6","chapter":"Result Interpretation","heading":"Result Interpretation","text":"Accurate interpretation crucial proper diagnosis managementKey Electrolytes\nSodium, Potassium, Chloride, Bicarbonate (Total \\(CO_2\\)), Calcium, Magnesium, Phosphorus\nSodium, Potassium, Chloride, Bicarbonate (Total \\(CO_2\\)), Calcium, Magnesium, PhosphorusCalculations\nOsmolality Anion Gap\nOsmolality Anion Gap","code":""},{"path":"result-interpretation-6.html","id":"key-electrolytes","chapter":"Result Interpretation","heading":"Key Electrolytes","text":"General Considerations\nReference Intervals: Always use reference intervals established laboratory performing tests\nClinical Context: Interpret electrolyte results context patient’s clinical history, physical examination, laboratory findings\nTrends: Serial measurements valuable single measurements assessing electrolyte balance\nReference Intervals: Always use reference intervals established laboratory performing testsClinical Context: Interpret electrolyte results context patient’s clinical history, physical examination, laboratory findingsTrends: Serial measurements valuable single measurements assessing electrolyte balanceCorrected Values: electrolytes (e.g., calcium), may necessary correct measured value based albumin levels","code":""},{"path":"result-interpretation-6.html","id":"sodium-na-1","chapter":"Result Interpretation","heading":"Sodium (\\(Na^+\\))","text":"Reference Interval: 136-145 mmol/LInterpretation\nHyponatremia (Serum \\(Na^+\\) < 136 mmol/L): Indicates excess water relative sodium\nHypovolemic Hyponatremia: Sodium water loss, greater sodium loss\nEuvolemic Hyponatremia: Normal sodium levels, increased water retention\nHypervolemic Hyponatremia: Increased sodium water retention, water excess greater\n\nHypernatremia (Serum \\(Na^+\\) > 145 mmol/L): Indicates water deficit relative sodium\nHypovolemic Hypernatremia: Water loss greater sodium loss\nEuvolemic Hypernatremia: Water loss normal sodium levels\nHypervolemic Hypernatremia: Sodium gain greater water gain\n\nHyponatremia (Serum \\(Na^+\\) < 136 mmol/L): Indicates excess water relative sodium\nHypovolemic Hyponatremia: Sodium water loss, greater sodium loss\nEuvolemic Hyponatremia: Normal sodium levels, increased water retention\nHypervolemic Hyponatremia: Increased sodium water retention, water excess greater\nHypovolemic Hyponatremia: Sodium water loss, greater sodium lossEuvolemic Hyponatremia: Normal sodium levels, increased water retentionHypervolemic Hyponatremia: Increased sodium water retention, water excess greaterHypernatremia (Serum \\(Na^+\\) > 145 mmol/L): Indicates water deficit relative sodium\nHypovolemic Hypernatremia: Water loss greater sodium loss\nEuvolemic Hypernatremia: Water loss normal sodium levels\nHypervolemic Hypernatremia: Sodium gain greater water gain\nHypovolemic Hypernatremia: Water loss greater sodium lossEuvolemic Hypernatremia: Water loss normal sodium levelsHypervolemic Hypernatremia: Sodium gain greater water gainClinical Significance\nAssessment fluid balance hydration status\nEvaluation hormonal disorders (e.g., SIADH, diabetes insipidus)\nDiagnosis management kidney heart failure\nAssessment fluid balance hydration statusEvaluation hormonal disorders (e.g., SIADH, diabetes insipidus)Diagnosis management kidney heart failure","code":""},{"path":"result-interpretation-6.html","id":"potassium-k-1","chapter":"Result Interpretation","heading":"Potassium (\\(K^+\\))","text":"Reference Interval: 3.5-5.1 mmol/LInterpretation\nHypokalemia (Serum \\(K^+\\) < 3.5 mmol/L): Indicates potassium depletion cellular shift\nDecreased Intake: Poor dietary intake\nIncreased Loss: Vomiting, diarrhea, diuretics\nCellular Shift: Insulin, alkalosis\n\nHyperkalemia (Serum \\(K^+\\) > 5.1 mmol/L): Indicates impaired potassium excretion cellular release\nDecreased Excretion: Kidney failure, hypoaldosteronism\nCellular Release: Tissue damage, acidosis\nIncreased Intake: Potassium supplements\n\nHypokalemia (Serum \\(K^+\\) < 3.5 mmol/L): Indicates potassium depletion cellular shift\nDecreased Intake: Poor dietary intake\nIncreased Loss: Vomiting, diarrhea, diuretics\nCellular Shift: Insulin, alkalosis\nDecreased Intake: Poor dietary intakeIncreased Loss: Vomiting, diarrhea, diureticsCellular Shift: Insulin, alkalosisHyperkalemia (Serum \\(K^+\\) > 5.1 mmol/L): Indicates impaired potassium excretion cellular release\nDecreased Excretion: Kidney failure, hypoaldosteronism\nCellular Release: Tissue damage, acidosis\nIncreased Intake: Potassium supplements\nDecreased Excretion: Kidney failure, hypoaldosteronismCellular Release: Tissue damage, acidosisIncreased Intake: Potassium supplementsClinical Significance\nAssessment kidney function\nEvaluation acid-base balance\nDiagnosis management cardiac arrhythmias\nAssessment kidney functionEvaluation acid-base balanceDiagnosis management cardiac arrhythmias","code":""},{"path":"result-interpretation-6.html","id":"chloride-cl--1","chapter":"Result Interpretation","heading":"Chloride (\\(Cl^-\\))","text":"Reference Interval: 98-107 mmol/LInterpretation\nHypochloremia (Serum \\(Cl^-\\) < 98 mmol/L): Indicates chloride depletion increased bicarbonate levels\nLoss Chloride: Vomiting, nasogastric suctioning\nIncreased Bicarbonate: Metabolic alkalosis\n\nHyperchloremia (Serum \\(Cl^-\\) > 107 mmol/L): Indicates chloride excess decreased bicarbonate levels\nChloride Excess: Excessive saline infusion\nDecreased Bicarbonate: Diarrhea, renal tubular acidosis\n\nHypochloremia (Serum \\(Cl^-\\) < 98 mmol/L): Indicates chloride depletion increased bicarbonate levels\nLoss Chloride: Vomiting, nasogastric suctioning\nIncreased Bicarbonate: Metabolic alkalosis\nLoss Chloride: Vomiting, nasogastric suctioningIncreased Bicarbonate: Metabolic alkalosisHyperchloremia (Serum \\(Cl^-\\) > 107 mmol/L): Indicates chloride excess decreased bicarbonate levels\nChloride Excess: Excessive saline infusion\nDecreased Bicarbonate: Diarrhea, renal tubular acidosis\nChloride Excess: Excessive saline infusionDecreased Bicarbonate: Diarrhea, renal tubular acidosisClinical Significance\nAssessment acid-base balance\nEvaluation hydration status kidney function\nAssessment acid-base balanceEvaluation hydration status kidney function","code":""},{"path":"result-interpretation-6.html","id":"total-carbon-dioxide-co_2-1","chapter":"Result Interpretation","heading":"Total Carbon Dioxide (\\(CO_2\\))","text":"Reference Interval: 22-33 mEq/LInterpretation\nDecreased Total \\(CO_2\\): Suggests metabolic acidosis\nIncreased Total \\(CO_2\\): Suggests metabolic alkalosis\nDecreased Total \\(CO_2\\): Suggests metabolic acidosisIncreased Total \\(CO_2\\): Suggests metabolic alkalosisClinical Significance\nScreening test acid-base disturbances\nOften used surrogate marker bicarbonate\nScreening test acid-base disturbancesOften used surrogate marker bicarbonate","code":""},{"path":"result-interpretation-6.html","id":"calcium-ca2-2","chapter":"Result Interpretation","heading":"Calcium (\\(Ca^{2+}\\))","text":"Reference Interval: 8.6-10.2 mg/dL (Total Calcium) 4.6-5.6 mg/dL (Ionized Calcium)Interpretation\nHypocalcemia (Serum \\(Ca^{2+}\\) < 8.6 mg/dL): Indicates decreased calcium levels due decreased PTH vitamin D\nHypoparathyroidism: Decreased PTH production\nVitamin D Deficiency: Impaired calcium absorption\nKidney Disease: Decreased calcium reabsorption\n\nHypercalcemia (Serum \\(Ca^{2+}\\) > 10.2 mg/dL): Indicates increased calcium levels due increased PTH, vitamin D, malignancy\nHyperparathyroidism: Increased PTH production\nMalignancy: Bone metastasis, ectopic PTH production\nVitamin D Excess: Increased calcium absorption\n\nHypocalcemia (Serum \\(Ca^{2+}\\) < 8.6 mg/dL): Indicates decreased calcium levels due decreased PTH vitamin D\nHypoparathyroidism: Decreased PTH production\nVitamin D Deficiency: Impaired calcium absorption\nKidney Disease: Decreased calcium reabsorption\nHypoparathyroidism: Decreased PTH productionVitamin D Deficiency: Impaired calcium absorptionKidney Disease: Decreased calcium reabsorptionHypercalcemia (Serum \\(Ca^{2+}\\) > 10.2 mg/dL): Indicates increased calcium levels due increased PTH, vitamin D, malignancy\nHyperparathyroidism: Increased PTH production\nMalignancy: Bone metastasis, ectopic PTH production\nVitamin D Excess: Increased calcium absorption\nHyperparathyroidism: Increased PTH productionMalignancy: Bone metastasis, ectopic PTH productionVitamin D Excess: Increased calcium absorptionClinical Significance\nAssessment bone metabolism\nEvaluation parathyroid kidney function\nMonitoring malignancy\nAssessment bone metabolismEvaluation parathyroid kidney functionMonitoring malignancy","code":""},{"path":"result-interpretation-6.html","id":"magnesium-mg2-2","chapter":"Result Interpretation","heading":"Magnesium (\\(Mg^{2+}\\))","text":"Reference Interval: 1.7-2.2 mg/dLInterpretation\nHypomagnesemia (Serum \\(Mg^{2+}\\) < 1.7 mg/dL): Indicates magnesium depletion\nPoor Dietary Intake: Malnutrition, alcoholism\nImpaired Absorption: Malabsorption syndromes\nIncreased Excretion: Diuretics, hyperaldosteronism\n\nHypermagnesemia (Serum \\(Mg^{2+}\\) > 2.2 mg/dL): Indicates impaired magnesium excretion\nKidney Failure: Decreased magnesium excretion\nExcessive Magnesium Intake: Antacids, laxatives\n\nHypomagnesemia (Serum \\(Mg^{2+}\\) < 1.7 mg/dL): Indicates magnesium depletion\nPoor Dietary Intake: Malnutrition, alcoholism\nImpaired Absorption: Malabsorption syndromes\nIncreased Excretion: Diuretics, hyperaldosteronism\nPoor Dietary Intake: Malnutrition, alcoholismImpaired Absorption: Malabsorption syndromesIncreased Excretion: Diuretics, hyperaldosteronismHypermagnesemia (Serum \\(Mg^{2+}\\) > 2.2 mg/dL): Indicates impaired magnesium excretion\nKidney Failure: Decreased magnesium excretion\nExcessive Magnesium Intake: Antacids, laxatives\nKidney Failure: Decreased magnesium excretionExcessive Magnesium Intake: Antacids, laxativesClinical Significance\nAssessment kidney function\nEvaluation cardiac arrhythmias neuromuscular disorders\nAssessment kidney functionEvaluation cardiac arrhythmias neuromuscular disorders","code":""},{"path":"result-interpretation-6.html","id":"phosphorus-p-2","chapter":"Result Interpretation","heading":"Phosphorus (\\(P\\))","text":"Reference Interval: 2.5-4.5 mg/dLInterpretation\nHypophosphatemia (Serum \\(P\\) < 2.5 mg/dL): Indicates phosphate depletion\nDecreased Intake: Malnutrition, alcoholism\nCellular Shift: Insulin, alkalosis\nIncreased Excretion: Hyperparathyroidism, diuretics\n\nHyperphosphatemia (Serum \\(P\\) > 4.5 mg/dL): Indicates impaired phosphate excretion\nKidney Failure: Decreased phosphate excretion\nHypoparathyroidism: Decreased PTH production\nCellular Release: Tissue damage, hemolysis\n\nHypophosphatemia (Serum \\(P\\) < 2.5 mg/dL): Indicates phosphate depletion\nDecreased Intake: Malnutrition, alcoholism\nCellular Shift: Insulin, alkalosis\nIncreased Excretion: Hyperparathyroidism, diuretics\nDecreased Intake: Malnutrition, alcoholismCellular Shift: Insulin, alkalosisIncreased Excretion: Hyperparathyroidism, diureticsHyperphosphatemia (Serum \\(P\\) > 4.5 mg/dL): Indicates impaired phosphate excretion\nKidney Failure: Decreased phosphate excretion\nHypoparathyroidism: Decreased PTH production\nCellular Release: Tissue damage, hemolysis\nKidney Failure: Decreased phosphate excretionHypoparathyroidism: Decreased PTH productionCellular Release: Tissue damage, hemolysisClinical Significance\nAssessment kidney function\nEvaluation parathyroid bone metabolism\nMonitoring tumor lysis syndrome\nAssessment kidney functionEvaluation parathyroid bone metabolismMonitoring tumor lysis syndrome","code":""},{"path":"result-interpretation-6.html","id":"calculations-2","chapter":"Result Interpretation","heading":"Calculations","text":"Osmolality Anion Gap calculated parameters provide additional information electrolyte balance acid-base status","code":""},{"path":"result-interpretation-6.html","id":"osmolality-1","chapter":"Result Interpretation","heading":"Osmolality","text":"Calculations:\nConventional: \\(Osmolality (mOsm/kg) = 2[Na^+] + \\left( \\frac {[Glucose (mg/dL)]} {18} \\right) + \\left( \\frac {[BUN (mg/dL)]} {2.8} \\right)\\)\nSI: \\(Osmolality (mmol/kg) = 2[Na^+] + [Glucose] + [Urea]\\)\nConventional: \\(Osmolality (mOsm/kg) = 2[Na^+] + \\left( \\frac {[Glucose (mg/dL)]} {18} \\right) + \\left( \\frac {[BUN (mg/dL)]} {2.8} \\right)\\)SI: \\(Osmolality (mmol/kg) = 2[Na^+] + [Glucose] + [Urea]\\)Reference Interval: 275-295 mOsm/kgInterpretation\nIncreased Osmolality: Dehydration, hypernatremia, hyperglycemia, uremia\nDecreased Osmolality: Overhydration, hyponatremia, SIADH\nIncreased Osmolality: Dehydration, hypernatremia, hyperglycemia, uremiaDecreased Osmolality: Overhydration, hyponatremia, SIADHClinical Significance\nAssessment hydration status\nEvaluation kidney function\nDetection toxic substances (osmolal gap)\nAssessment hydration statusEvaluation kidney functionDetection toxic substances (osmolal gap)","code":""},{"path":"result-interpretation-6.html","id":"anion-gap-1","chapter":"Result Interpretation","heading":"Anion Gap","text":"Calculation: Anion Gap = [\\(Na^+\\)] + [\\(K^+\\)] - [\\(Cl^-\\)] - [\\(HCO_3^-\\)]Reference Interval: 8-16 mEq/L (\\(K^+\\)), 10-20 mEq/L (without \\(K^+\\))Interpretation\nElevated Anion Gap (Anion Gap Metabolic Acidosis)\nIncreased Production Organic Acids: Ketoacidosis, lactic acidosis\nRenal Failure: Accumulation sulfates phosphates\nToxic Ingestions: Methanol, ethylene glycol, salicylates\n\nNormal Anion Gap (Hyperchloremic Metabolic Acidosis)\nLoss Bicarbonate: Diarrhea, renal tubular acidosis (RTA)\nAdministration Chloride-Containing Solutions: Saline infusion\n\nElevated Anion Gap (Anion Gap Metabolic Acidosis)\nIncreased Production Organic Acids: Ketoacidosis, lactic acidosis\nRenal Failure: Accumulation sulfates phosphates\nToxic Ingestions: Methanol, ethylene glycol, salicylates\nIncreased Production Organic Acids: Ketoacidosis, lactic acidosisRenal Failure: Accumulation sulfates phosphatesToxic Ingestions: Methanol, ethylene glycol, salicylatesNormal Anion Gap (Hyperchloremic Metabolic Acidosis)\nLoss Bicarbonate: Diarrhea, renal tubular acidosis (RTA)\nAdministration Chloride-Containing Solutions: Saline infusion\nLoss Bicarbonate: Diarrhea, renal tubular acidosis (RTA)Administration Chloride-Containing Solutions: Saline infusionClinical Significance\nDifferential diagnosis metabolic acidosis\nIdentification specific causes metabolic acidosis\nDifferential diagnosis metabolic acidosisIdentification specific causes metabolic acidosis","code":""},{"path":"result-interpretation-6.html","id":"key-terms-52","chapter":"Result Interpretation","heading":"Key Terms","text":"Hyponatremia: condition blood contains little sodiumHypernatremia: condition blood contains much sodiumHypokalemia: condition blood contains little potassiumHyperkalemia: condition blood contains much potassiumHypochloremia: condition blood contains little chlorideHyperchloremia: condition blood contains much chlorideHypocalcemia: condition blood contains little calciumHypercalcemia: condition blood contains much calciumHypomagnesemia: condition blood contains little magnesiumHypermagnesemia: condition blood contains much magnesiumHypophosphatemia: condition blood contains little phosphorusHyperphosphatemia: condition blood contains much phosphorusGlomeruli: Filtering units within kidneyIn Vitro: Taking place test tube, culture dish, elsewhere outside living organismIn Vivo: Occurring within living organismHyponatremia: condition blood contains little sodiumHypovolemia: medical term decrease blood volume results decreased oxygen delivery bodySepsis: life-threatening condition happens body’s response infection damages tissues organsPulmonary Embolism: blood clot occurs lungsHepatitis: Inflammation liverMetabolic Disorder: Occurs abnormal chemical reactions body disrupt metabolismAlveolar: Relating alveoli lungsBohr Effect: effect pH CO2 oxygen-binding affinity hemoglobinBilirubin: yellow compound occurs normal catabolic pathway breaks heme vertebratesCations: positively charged ion (e.g., \\(Ca^{2+}\\), \\(Mg^{2+}\\), \\(K^+\\), \\(Na^+\\))Anions: negatively charged ion (e.g., \\(Cl^-\\), \\(HCO_3^-\\), \\(PO_4^{3-}\\))Electrolyte: ion conducts electrical impulses solution","code":""},{"path":"disease-correlation-6.html","id":"disease-correlation-6","chapter":"Disease Correlation","heading":"Disease Correlation","text":"Electrolyte imbalances commonly encountered clinical practice can indicative wide range underlying disease states. Accurate assessment electrolyte levels, along consideration patient’s clinical presentation medical history, crucial proper diagnosis managementSodium ImbalancesPotassium ImbalancesChloride ImbalancesCalcium ImbalancesMagnesium ImbalancesPhosphorus Imbalances","code":""},{"path":"disease-correlation-6.html","id":"sodium-imbalances-1","chapter":"Disease Correlation","heading":"Sodium Imbalances","text":"Hyponatremia: Serum Sodium < 136 mmol/L\nHypovolemic Hyponatremia: total body water (TBW) total body sodium (TBNa) decreased, TBNa decreased greater extent TBW\nCauses: Diuretic use (thiazides), vomiting, diarrhea, third spacing\n\nEuvolemic Hyponatremia: TBW increased, TBNa remains normal\nCauses: Syndrome Inappropriate Antidiuretic Hormone Secretion (SIADH), hypothyroidism, glucocorticoid deficiency, psychogenic polydipsia\n\nHypervolemic Hyponatremia: TBW TBNa increased, TBW increased greater extent TBNa\nCauses: Heart failure, cirrhosis, nephrotic syndrome\n\nHypovolemic Hyponatremia: total body water (TBW) total body sodium (TBNa) decreased, TBNa decreased greater extent TBW\nCauses: Diuretic use (thiazides), vomiting, diarrhea, third spacing\nCauses: Diuretic use (thiazides), vomiting, diarrhea, third spacingEuvolemic Hyponatremia: TBW increased, TBNa remains normal\nCauses: Syndrome Inappropriate Antidiuretic Hormone Secretion (SIADH), hypothyroidism, glucocorticoid deficiency, psychogenic polydipsia\nCauses: Syndrome Inappropriate Antidiuretic Hormone Secretion (SIADH), hypothyroidism, glucocorticoid deficiency, psychogenic polydipsiaHypervolemic Hyponatremia: TBW TBNa increased, TBW increased greater extent TBNa\nCauses: Heart failure, cirrhosis, nephrotic syndrome\nCauses: Heart failure, cirrhosis, nephrotic syndromeDisease State Correlation\nCongestive Heart Failure (CHF): Reduced cardiac output leads activation renin-angiotensin-aldosterone system (RAAS) increased water retention, resulting hypervolemic hyponatremia\nSyndrome Inappropriate Antidiuretic Hormone Secretion (SIADH): Excessive ADH secretion leads increased water reabsorption kidneys, resulting euvolemic hyponatremia\nChronic Kidney Disease (CKD): Impaired sodium water excretion kidneys can lead hypervolemic hyponatremia\nDiarrhea: Loss sodium-rich intestinal secretions can lead hypovolemic hyponatremia\nCongestive Heart Failure (CHF): Reduced cardiac output leads activation renin-angiotensin-aldosterone system (RAAS) increased water retention, resulting hypervolemic hyponatremiaSyndrome Inappropriate Antidiuretic Hormone Secretion (SIADH): Excessive ADH secretion leads increased water reabsorption kidneys, resulting euvolemic hyponatremiaChronic Kidney Disease (CKD): Impaired sodium water excretion kidneys can lead hypervolemic hyponatremiaDiarrhea: Loss sodium-rich intestinal secretions can lead hypovolemic hyponatremiaHypernatremia: Serum Sodium > 145 mmol/L\nHypovolemic Hypernatremia: TBW TBNa decreased, TBW decreased greater extent TBNa\nCauses: Diuretics, diarrhea, vomiting, sweating\n\nEuvolemic Hypernatremia: TBW decreased, TBNa remains normal\nCauses: Diabetes Insipidus (DI), decreased water intake\n\nHypervolemic Hypernatremia: TBW TBNa increased, TBNa increased greater extent TBW\nCauses: Sodium bicarbonate administration, hypertonic saline infusion\n\nHypovolemic Hypernatremia: TBW TBNa decreased, TBW decreased greater extent TBNa\nCauses: Diuretics, diarrhea, vomiting, sweating\nCauses: Diuretics, diarrhea, vomiting, sweatingEuvolemic Hypernatremia: TBW decreased, TBNa remains normal\nCauses: Diabetes Insipidus (DI), decreased water intake\nCauses: Diabetes Insipidus (DI), decreased water intakeHypervolemic Hypernatremia: TBW TBNa increased, TBNa increased greater extent TBW\nCauses: Sodium bicarbonate administration, hypertonic saline infusion\nCauses: Sodium bicarbonate administration, hypertonic saline infusionDisease State Correlation\nDiabetes Insipidus (DI): Deficiency ADH (central DI) resistance ADH (nephrogenic DI) leads excessive water loss hypernatremia\nDehydration: Insufficient water intake excessive water loss leads hypernatremia\nHypertonic Saline Infusion: Administration hypertonic saline can lead hypervolemic hypernatremia\nCushing’s Syndrome: Excessive cortisol levels can lead increase sodium levels decrease potassium levels\nDiabetes Insipidus (DI): Deficiency ADH (central DI) resistance ADH (nephrogenic DI) leads excessive water loss hypernatremiaDehydration: Insufficient water intake excessive water loss leads hypernatremiaHypertonic Saline Infusion: Administration hypertonic saline can lead hypervolemic hypernatremiaCushing’s Syndrome: Excessive cortisol levels can lead increase sodium levels decrease potassium levels","code":""},{"path":"disease-correlation-6.html","id":"potassium-imbalances-1","chapter":"Disease Correlation","heading":"Potassium Imbalances","text":"Hypokalemia: Serum Potassium < 3.5 mmol/L\nDecreased Intake: Poor dietary intake, starvation\nIncreased Loss: Diuretics (loop thiazide), vomiting, diarrhea\nCellular Shift: Insulin administration, alkalosis, beta-adrenergic agonists\nDecreased Intake: Poor dietary intake, starvationIncreased Loss: Diuretics (loop thiazide), vomiting, diarrheaCellular Shift: Insulin administration, alkalosis, beta-adrenergic agonistsDisease State Correlation\nDiuretic Use: Loop thiazide diuretics increase potassium excretion kidneys, leading hypokalemia\nGastrointestinal Losses: Vomiting diarrhea lead potassium loss hypokalemia\nInsulin Administration: Insulin promotes potassium uptake cells, leading hypokalemia\nMetabolic Alkalosis: Alkalosis promotes cellular uptake potassium, leading hypokalemia\nDiuretic Use: Loop thiazide diuretics increase potassium excretion kidneys, leading hypokalemiaGastrointestinal Losses: Vomiting diarrhea lead potassium loss hypokalemiaInsulin Administration: Insulin promotes potassium uptake cells, leading hypokalemiaMetabolic Alkalosis: Alkalosis promotes cellular uptake potassium, leading hypokalemiaHyperkalemia: Serum Potassium > 5.1 mmol/L\nDecreased Excretion: Kidney failure, hypoaldosteronism, potassium-sparing diuretics\nCellular Release: Tissue damage, hemolysis, acidosis, insulin deficiency\nIncreased Intake: Excessive potassium supplementation\nDecreased Excretion: Kidney failure, hypoaldosteronism, potassium-sparing diureticsCellular Release: Tissue damage, hemolysis, acidosis, insulin deficiencyIncreased Intake: Excessive potassium supplementationDisease State Correlation\nKidney Failure: Impaired potassium excretion leads hyperkalemia\nHypoaldosteronism: Deficiency aldosterone leads decreased potassium excretion hyperkalemia\nPotassium-Sparing Diuretics: diuretics block sodium reabsorption kidneys, leading increased potassium retention hyperkalemia\nAcidosis: Acidosis promotes cellular release potassium, leading hyperkalemia\nRhabdomyolysis: breakdown muscle tissue releases potassium bloodstream, leading hyperkalemia\nKidney Failure: Impaired potassium excretion leads hyperkalemiaHypoaldosteronism: Deficiency aldosterone leads decreased potassium excretion hyperkalemiaPotassium-Sparing Diuretics: diuretics block sodium reabsorption kidneys, leading increased potassium retention hyperkalemiaAcidosis: Acidosis promotes cellular release potassium, leading hyperkalemiaRhabdomyolysis: breakdown muscle tissue releases potassium bloodstream, leading hyperkalemia","code":""},{"path":"disease-correlation-6.html","id":"chloride-imbalances-1","chapter":"Disease Correlation","heading":"Chloride Imbalances","text":"Hypochloremia: Serum Chloride < 98 mmol/L\nIncreased Loss: Vomiting, nasogastric suctioning, diuretics\nIncreased Bicarbonate: Metabolic alkalosis\nWater Retention: SIADH, heart failure\nIncreased Loss: Vomiting, nasogastric suctioning, diureticsIncreased Bicarbonate: Metabolic alkalosisWater Retention: SIADH, heart failureDisease State Correlation\nVomiting: Loss hydrochloric acid (HCl) gastric secretions leads hypochloremia metabolic alkalosis\nDiuretics: Thiazide diuretics increase chloride excretion kidneys, leading hypochloremia\nSIADH: Excessive water retention dilutes chloride concentration blood, leading hypochloremia\nVomiting: Loss hydrochloric acid (HCl) gastric secretions leads hypochloremia metabolic alkalosisDiuretics: Thiazide diuretics increase chloride excretion kidneys, leading hypochloremiaSIADH: Excessive water retention dilutes chloride concentration blood, leading hypochloremiaHyperchloremia: Serum Chloride > 107 mmol/L\nChloride Excess: Excessive saline infusion\nBicarbonate Loss: Diarrhea, renal tubular acidosis\nDehydration: Water deficit\nChloride Excess: Excessive saline infusionBicarbonate Loss: Diarrhea, renal tubular acidosisDehydration: Water deficitDisease State Correlation\nExcessive Saline Infusion: Administration large volumes saline can lead hyperchloremia\nDiarrhea: Loss bicarbonate-rich intestinal secretions leads hyperchloremic metabolic acidosis\nRenal Tubular Acidosis (RTA): Impaired bicarbonate reabsorption kidneys leads hyperchloremic metabolic acidosis\nDehydration: Loss water leads increased chloride concentration hyperchloremia\nExcessive Saline Infusion: Administration large volumes saline can lead hyperchloremiaDiarrhea: Loss bicarbonate-rich intestinal secretions leads hyperchloremic metabolic acidosisRenal Tubular Acidosis (RTA): Impaired bicarbonate reabsorption kidneys leads hyperchloremic metabolic acidosisDehydration: Loss water leads increased chloride concentration hyperchloremia","code":""},{"path":"disease-correlation-6.html","id":"calcium-imbalances-1","chapter":"Disease Correlation","heading":"Calcium Imbalances","text":"Hypocalcemia: Serum Calcium < 8.6 mg/dL\nDecreased Intake: Poor dietary intake\nVitamin D Deficiency: Leads decreased calcium absorption\nHypoparathyroidism: Decreased parathyroid hormone\nDecreased Intake: Poor dietary intakeVitamin D Deficiency: Leads decreased calcium absorptionHypoparathyroidism: Decreased parathyroid hormoneDisease State Correlation\nHypoparathyroidism: Decreased PTH production leads decreased bone resorption decreased calcium reabsorption kidneys\nVitamin D Deficiency: Impaired calcium absorption intestine leads hypocalcemia\nChronic Kidney Disease (CKD): Decreased kidney function leads decreased vitamin D activation, increased phosphate levels, hypocalcemia\nHypoparathyroidism: Decreased PTH production leads decreased bone resorption decreased calcium reabsorption kidneysVitamin D Deficiency: Impaired calcium absorption intestine leads hypocalcemiaChronic Kidney Disease (CKD): Decreased kidney function leads decreased vitamin D activation, increased phosphate levels, hypocalcemiaHypercalcemia: Serum Calcium > 10.2 mg/dL\nMalignancy: Leads increased bone resorption due release chemicals affect serum albumin\nHyperparathyroidism: Increased calcium absorption calcium release bones\nMalignancy: Leads increased bone resorption due release chemicals affect serum albuminHyperparathyroidism: Increased calcium absorption calcium release bones","code":""},{"path":"disease-correlation-6.html","id":"magnesium-imbalances-1","chapter":"Disease Correlation","heading":"Magnesium Imbalances","text":"Hypomagnesemia: Serum Magnesium < 1.7 mg/dL\nDecreased Intake: Poor dietary intake\nLosses Kidneys: Magnesium depleted\nRenal Loss: Alcohol diabetes can affect magnesium balances\nDecreased Intake: Poor dietary intakeLosses Kidneys: Magnesium depletedRenal Loss: Alcohol diabetes can affect magnesium balancesDisease State Correlation\nAlcoholism: Poor dietary intake, impaired magnesium absorption, increased urinary magnesium excretion\nDiabetes Mellitus: Increased urinary magnesium excretion due osmotic diuresis\nDiarrhea: Large amounts magnesium may lost\nAlcoholism: Poor dietary intake, impaired magnesium absorption, increased urinary magnesium excretionDiabetes Mellitus: Increased urinary magnesium excretion due osmotic diuresisDiarrhea: Large amounts magnesium may lostHypermagnesemia: Serum Magnesium > 2.2 mg/dL\nIncreased intake: conjunction kidney function\nDecreased Kidney Output: Inability magnesium release\nIncreased intake: conjunction kidney functionDecreased Kidney Output: Inability magnesium release","code":""},{"path":"disease-correlation-6.html","id":"phosphorus-imbalances","chapter":"Disease Correlation","heading":"Phosphorus Imbalances","text":"Hypophosphatemia: Serum Phosphorus < 2.5 mg/dL\nDecreased Intake: Poor dietary intake\nShift phosphate intracellular space\nKidney Issues: Excessive losses phosphorus can occur due impaired kidney reabsoption\nDecreased Intake: Poor dietary intakeShift phosphate intracellular spaceKidney Issues: Excessive losses phosphorus can occur due impaired kidney reabsoptionDisease State Correlation\nRefeeding Syndrome: Carbohydrate reintroduction malnourished patients can lead rapid shift phosphorus cells, resulting hypophosphatemia\nAlcohol Use Disorder: Inadequate dietary intake\nHyperparathyroidism: Increased urinary phosphate excretion\nUse Phosphate-Binding Antacids: Reduces intestinal phosphate absorption\nRefeeding Syndrome: Carbohydrate reintroduction malnourished patients can lead rapid shift phosphorus cells, resulting hypophosphatemiaAlcohol Use Disorder: Inadequate dietary intakeHyperparathyroidism: Increased urinary phosphate excretionUse Phosphate-Binding Antacids: Reduces intestinal phosphate absorptionHyperphosphatemia: Serum Phosphorus > 4.5 mg/dL\nDecreased excretion via kidneys\nShift Phosphate extracellular space\nIncreased Phosphorus Intake: Can occur increased phosphorus absorption\nDecreased excretion via kidneysShift Phosphate extracellular spaceIncreased Phosphorus Intake: Can occur increased phosphorus absorptionDisease State Correlation\nKidney Failure: Decreased phosphate excretion leads hyperphosphatemia\nHypoparathyroidism: Decreased parathyroid hormone leads decreased phosphate excretion\nTumor Lysis Syndrome: Rapid cell breakdown releases phosphate bloodstream\nKidney Failure: Decreased phosphate excretion leads hyperphosphatemiaHypoparathyroidism: Decreased parathyroid hormone leads decreased phosphate excretionTumor Lysis Syndrome: Rapid cell breakdown releases phosphate bloodstream","code":""},{"path":"disease-correlation-6.html","id":"trace-elements-3","chapter":"Disease Correlation","heading":"Trace Elements","text":"Iron (Fe)\nIron Deficiency Anemia: Microcytic, hypochromic anemia, fatigue, weakness, pallor, low serum iron, low ferritin, high TIBC\nPoor dietary intake, impaired absorption, chronic blood loss\n\nHemochromatosis: Fatigue, joint pain, abdominal pain, elevated serum iron, elevated ferritin, elevated transferrin saturation\nGenetic disorder leading excessive iron absorption\n\nIron Deficiency Anemia: Microcytic, hypochromic anemia, fatigue, weakness, pallor, low serum iron, low ferritin, high TIBC\nPoor dietary intake, impaired absorption, chronic blood loss\nPoor dietary intake, impaired absorption, chronic blood lossHemochromatosis: Fatigue, joint pain, abdominal pain, elevated serum iron, elevated ferritin, elevated transferrin saturation\nGenetic disorder leading excessive iron absorption\nGenetic disorder leading excessive iron absorptionCopper (Cu)\nWilson’s Disease: Liver disease, neurological symptoms, Kayser-Fleischer rings eyes, low serum ceruloplasmin, elevated urine copper\nGenetic disorder leading copper accumulation liver, brain, organs\n\nWilson’s Disease: Liver disease, neurological symptoms, Kayser-Fleischer rings eyes, low serum ceruloplasmin, elevated urine copper\nGenetic disorder leading copper accumulation liver, brain, organs\nGenetic disorder leading copper accumulation liver, brain, organsIodine ()\nIodine Deficiency: Goiter, hypothyroidism, developmental abnormalities\nInadequate dietary iodine intake\n\nIodine Deficiency: Goiter, hypothyroidism, developmental abnormalities\nInadequate dietary iodine intake\nInadequate dietary iodine intake","code":""},{"path":"disease-correlation-6.html","id":"summary-table-of-key-findings-1","chapter":"Disease Correlation","heading":"Summary Table of Key Findings","text":"↑ = Increased, ↓ = Decreased, N = Normal","code":""},{"path":"disease-correlation-6.html","id":"key-terms-53","chapter":"Disease Correlation","heading":"Key Terms","text":"Electrolyte: substance produces electrically conducting solution dissolved polar solvent, waterIon: atom molecule net electric charge due loss gain electronsCation: positively charged ionAnion: negatively charged ionmmol/L: concentration unit, expressing amount substance solutionmg/dL: concentration unit, expressing amount substance solutionμg/dL: concentration unit, expressing amount substance solutionμmol/L: concentration unit, expressing amount substance solutionmg/L: concentration unit, expressing amount substance solutionNephrogenic Diabetes Insipidus: disease kidneys unable concentrate urineHeart Failure: chronic progressive condition heart muscle unable pump enough blood meet body’s needs blood oxygenHypoparathyroidism: disease parathyroid glands neck produce enough parathyroid hormone (PTH)Hormone: regulatory substance produced organism transported tissue fluids blood sap stimulate specific cells tissues actionAcrodermatitis Enteropathica: genetic disorder affects zinc absorption, leading skin lesions, diarrhea, growth retardationWilson’s Disease: genetic disorder causes copper accumulate liver, brain, organs, leading liver disease neurological symptomsSIADH: Syndrome Inappropriate Antidiuretic Hormone Secretion, condition body retains much waterIn Vitro: Taking place test tube, culture dish, elsewhere outside living organismIn Vivo: Occurring within living organismHomeostasis: process organisms maintain relatively stable internal environmentHypovolemia: medical term decrease blood volume results decreased oxygen delivery bodyTransfusion: process transferring blood blood products one person anotherLethargy: state tiredness, weariness, fatigue, lack energyIschemia: inadequate blood supply organ part bodyHypoxia: inadequate oxygen supply cells tissues bodyHypercapnia: presence abnormally high levels carbon dioxide bloodHypoventilation: state reduced amount air enters lungsHyperventilation: state breathing fast deeplyParesthesias: abnormal sensation, typically tingling pricking (“pins needles”), caused chiefly pressure damage peripheral nervesCarpopedal Spasm: Cramps hands feetHemodialysis: way remove waste products blood kidneys can longer function properlyAnabolic: Pertaining promoting synthesis complex molecules simpler ones","code":""},{"path":"endocrinology.html","id":"endocrinology","chapter":"Endocrinology","heading":"Endocrinology","text":"section covers biochemical basis, testing methods, interpretation results, associations different disease states associated endocrinology","code":""},{"path":"endocrinology.html","id":"biochemical-theory-and-pathways-5","chapter":"Endocrinology","heading":"Biochemical Theory and Pathways","text":"Hormones Messengers\nHormones chemical messengers regulate various physiological processes, including metabolism, growth, reproduction, stress response\nHormones chemical messengers regulate various physiological processes, including metabolism, growth, reproduction, stress responseHormone Synthesis, Secretion, Transport\nHormones synthesized endocrine glands secreted bloodstream response specific stimuli\ntransported either freely bound carrier proteins\nHormones synthesized endocrine glands secreted bloodstream response specific stimuliThey transported either freely bound carrier proteinsMechanisms Action\nHormones bind specific receptors target cells, initiating intracellular signaling cascades alter gene expression cellular function\nReceptors can located cell surface (peptide hormones catecholamines) within cell (steroid hormones thyroid hormones)\nHormones bind specific receptors target cells, initiating intracellular signaling cascades alter gene expression cellular functionReceptors can located cell surface (peptide hormones catecholamines) within cell (steroid hormones thyroid hormones)Key Hormones Functions\nPituitary Hormones: Growth hormone (GH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH)\nThyroid Hormones: Thyroxine (T4), triiodothyronine (T3)\nAdrenal Hormones: Cortisol, aldosterone, epinephrine, norepinephrine\nPancreatic Hormones: Insulin, glucagon\nParathyroid Hormone (PTH)\nGonadal Hormones: Testosterone, estradiol, progesterone\nPituitary Hormones: Growth hormone (GH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH)Thyroid Hormones: Thyroxine (T4), triiodothyronine (T3)Adrenal Hormones: Cortisol, aldosterone, epinephrine, norepinephrinePancreatic Hormones: Insulin, glucagonParathyroid Hormone (PTH)Gonadal Hormones: Testosterone, estradiol, progesteroneFeedback Mechanisms\nHormone levels tightly regulated negative feedback loops maintain homeostasis\nHormone levels tightly regulated negative feedback loops maintain homeostasis","code":""},{"path":"endocrinology.html","id":"laboratory-test-procedures-7","chapter":"Endocrinology","heading":"Laboratory Test Procedures","text":"Principles Hormone Measurement\nImmunoassays: Based antibody-antigen interactions (e.g., ELISA, CLIA, RIA)\nFluorescence Assays: Measure intensity emitted light fluorescently labeled hormones\nLiquid Chromatography-Mass Spectrometry (LC-MS): Separates quantifies hormones based mass--charge ratio\nImmunoassays: Based antibody-antigen interactions (e.g., ELISA, CLIA, RIA)Fluorescence Assays: Measure intensity emitted light fluorescently labeled hormonesLiquid Chromatography-Mass Spectrometry (LC-MS): Separates quantifies hormones based mass--charge ratioSpecimen Collection Handling\nFollow specific guidelines patient preparation, collection tubes, order draw, specimen processing ensure accurate results\nFollow specific guidelines patient preparation, collection tubes, order draw, specimen processing ensure accurate resultsStimulation/Suppression Tests\nUsed assess functional reserve endocrine glands diagnose hormone excess deficiency\nInvolve administration stimulatory suppressive agents serial hormone measurements\nUsed assess functional reserve endocrine glands diagnose hormone excess deficiencyInvolve administration stimulatory suppressive agents serial hormone measurementsCommon Tests\nPituitary: GH, ACTH, TSH, prolactin, LH, FSH\nThyroid: Free T4, Free T3, TSH, thyroid antibodies\nAdrenal: Cortisol, aldosterone, catecholamines\nParathyroid: PTH, calcium, vitamin D\nGonadal: Testosterone, estradiol, progesterone\n: Insulin, C-peptide, human chorionic gonadotropin (hCG)\nPituitary: GH, ACTH, TSH, prolactin, LH, FSHThyroid: Free T4, Free T3, TSH, thyroid antibodiesAdrenal: Cortisol, aldosterone, catecholaminesParathyroid: PTH, calcium, vitamin DGonadal: Testosterone, estradiol, progesteroneOther: Insulin, C-peptide, human chorionic gonadotropin (hCG)","code":""},{"path":"endocrinology.html","id":"test-result-interpretation-7","chapter":"Endocrinology","heading":"Test Result Interpretation","text":"Reference Intervals\nUse appropriate reference intervals specific assay patient population\nUse appropriate reference intervals specific assay patient populationClinical Context\nInterpret test results context patient’s clinical history, physical examination findings, laboratory data\nInterpret test results context patient’s clinical history, physical examination findings, laboratory dataMultiple Tests\nAssess pattern hormone levels rather relying single value; dynamic tests may needed\nAssess pattern hormone levels rather relying single value; dynamic tests may neededInterfering Substances\naware potential interfering substances can affect hormone measurements\naware potential interfering substances can affect hormone measurementsAssay Limitations\nUnderstand limitations specific assay used, including sensitivity, specificity, potential cross-reactivity\nUnderstand limitations specific assay used, including sensitivity, specificity, potential cross-reactivityCommon Findings\nElevated suppressed hormone levels\nAbnormal responses stimulation/suppression tests\nPresence hormone-specific antibodies\nElevated suppressed hormone levelsAbnormal responses stimulation/suppression testsPresence hormone-specific antibodies","code":""},{"path":"endocrinology.html","id":"disease-state-correlation-7","chapter":"Endocrinology","heading":"Disease State Correlation","text":"Pituitary Disorders\nAcromegaly/Gigantism: Elevated GH IGF-1\nCushing’s Disease: Elevated cortisol ACTH\nHypopituitarism: Deficiencies one pituitary hormones\nAcromegaly/Gigantism: Elevated GH IGF-1Cushing’s Disease: Elevated cortisol ACTHHypopituitarism: Deficiencies one pituitary hormonesThyroid Disorders\nHyperthyroidism: Suppressed TSH elevated free T4 /free T3\nHypothyroidism: Elevated TSH low free T4\nHyperthyroidism: Suppressed TSH elevated free T4 /free T3Hypothyroidism: Elevated TSH low free T4Adrenal Disorders\nCushing’s Syndrome: Elevated cortisol levels\nAddison’s Disease (Primary Adrenal Insufficiency): Low cortisol elevated ACTH\nPheochromocytoma: Elevated catecholamines metanephrines\nCushing’s Syndrome: Elevated cortisol levelsAddison’s Disease (Primary Adrenal Insufficiency): Low cortisol elevated ACTHPheochromocytoma: Elevated catecholamines metanephrinesParathyroid Disorders\nHyperparathyroidism: Elevated calcium PTH\nHypoparathyroidism: Low calcium PTH\nHyperparathyroidism: Elevated calcium PTHHypoparathyroidism: Low calcium PTHGonadal Disorders\nHypogonadism Males: Low testosterone elevated LH/FSH (primary) low LH/FSH (secondary)\nPolycystic Ovary Syndrome (PCOS): Elevated testosterone, LH/FSH ratio, insulin resistance\nHypogonadism Males: Low testosterone elevated LH/FSH (primary) low LH/FSH (secondary)Polycystic Ovary Syndrome (PCOS): Elevated testosterone, LH/FSH ratio, insulin resistanceOther Hormones\nDiabetes Mellitus: Elevated glucose HbA1c, variable insulin C-peptide\nPregnancy: Elevated human chorionic gonadotropin (hCG)\nDiabetes Mellitus: Elevated glucose HbA1c, variable insulin C-peptidePregnancy: Elevated human chorionic gonadotropin (hCG)","code":""},{"path":"biochemicals-5.html","id":"biochemicals-5","chapter":"Biochemicals","heading":"Biochemicals","text":"overview summarizes key aspects endocrinology related biochemical theory pathways, providing foundation understanding hormone function associated disorders","code":""},{"path":"biochemicals-5.html","id":"biochemical-theory-and-metabolic-pathways-3","chapter":"Biochemicals","heading":"Biochemical Theory and Metabolic Pathways","text":"Hormones Regulators: Hormones chemical messengers regulate metabolic pathways maintain homeostasis. influence energy production, storage, utilizationKey Hormones\nInsulin: Lowers blood glucose promoting glucose uptake, glycogenesis, glycolysis, lipogenesis. Inhibits gluconeogenesis lipolysis\nGlucagon: Raises blood glucose stimulating glycogenolysis gluconeogenesis. Promotes lipolysis ketogenesis\nEpinephrine: Raises blood glucose stimulating glycogenolysis gluconeogenesis. Promotes lipolysis inhibits insulin secretion\nCortisol: Raises blood glucose stimulating gluconeogenesis protein catabolism. Promotes lipolysis induces insulin resistance\nGrowth Hormone: Promotes protein synthesis lipolysis. Induces insulin resistance stimulates gluconeogenesis\nThyroid Hormones: Increase basal metabolic rate, enhance glucose absorption, affect carbohydrate, lipid, protein metabolism\nInsulin: Lowers blood glucose promoting glucose uptake, glycogenesis, glycolysis, lipogenesis. Inhibits gluconeogenesis lipolysisGlucagon: Raises blood glucose stimulating glycogenolysis gluconeogenesis. Promotes lipolysis ketogenesisEpinephrine: Raises blood glucose stimulating glycogenolysis gluconeogenesis. Promotes lipolysis inhibits insulin secretionCortisol: Raises blood glucose stimulating gluconeogenesis protein catabolism. Promotes lipolysis induces insulin resistanceGrowth Hormone: Promotes protein synthesis lipolysis. Induces insulin resistance stimulates gluconeogenesisThyroid Hormones: Increase basal metabolic rate, enhance glucose absorption, affect carbohydrate, lipid, protein metabolismHormonal Interactions: Hormones often work opposition maintain metabolic homeostasis. effects coordinated complex feedback mechanisms","code":""},{"path":"biochemicals-5.html","id":"ormal-and-abnormal-states","chapter":"Biochemicals","heading":"ormal and Abnormal States","text":"Normal Endocrine Function\nSynthesis Secretion: Hormones synthesized secreted endocrine glands, regulated feedback mechanisms, neural signals, hormonal signals\nTransport: Hormones transported bloodstream, either bound carrier proteins freely\nAction: Hormones bind specific receptors target cells, initiating intracellular signaling cascades\nMetabolism Excretion: Hormones metabolized liver kidneys excreted urine bile\nSynthesis Secretion: Hormones synthesized secreted endocrine glands, regulated feedback mechanisms, neural signals, hormonal signalsTransport: Hormones transported bloodstream, either bound carrier proteins freelyAction: Hormones bind specific receptors target cells, initiating intracellular signaling cascadesMetabolism Excretion: Hormones metabolized liver kidneys excreted urine bileAbnormal Endocrine Function\nHormone Excess: Can caused tumors, autoimmune disorders, ectopic hormone production, leading exaggerated physiological responses\nHormone Deficiency: Can caused autoimmune destruction, surgical removal, genetic defects, leading impaired physiological responses\nReceptor Abnormalities: Receptor resistance mutations can disrupt hormone signaling\nHormone Excess: Can caused tumors, autoimmune disorders, ectopic hormone production, leading exaggerated physiological responsesHormone Deficiency: Can caused autoimmune destruction, surgical removal, genetic defects, leading impaired physiological responsesReceptor Abnormalities: Receptor resistance mutations can disrupt hormone signalingSpecific Endocrine Disorders\nPituitary Disorders: Acromegaly, Cushing’s disease, hyperprolactinemia, growth hormone deficiency, adrenal insufficiency, hypothyroidism, hypogonadism\nThyroid Disorders: Hyperthyroidism (Graves’ disease), hypothyroidism (Hashimoto’s thyroiditis)\nAdrenal Disorders: Cushing’s syndrome, Addison’s disease, hyperaldosteronism, pheochromocytoma\nPancreatic Disorders: Diabetes mellitus (Type 1 & 2), insulinoma\nParathyroid Disorders: Hyperparathyroidism, hypoparathyroidism\nGonadal Disorders: Hypogonadism, polycystic ovary syndrome (PCOS)\nPituitary Disorders: Acromegaly, Cushing’s disease, hyperprolactinemia, growth hormone deficiency, adrenal insufficiency, hypothyroidism, hypogonadismThyroid Disorders: Hyperthyroidism (Graves’ disease), hypothyroidism (Hashimoto’s thyroiditis)Adrenal Disorders: Cushing’s syndrome, Addison’s disease, hyperaldosteronism, pheochromocytomaPancreatic Disorders: Diabetes mellitus (Type 1 & 2), insulinomaParathyroid Disorders: Hyperparathyroidism, hypoparathyroidismGonadal Disorders: Hypogonadism, polycystic ovary syndrome (PCOS)","code":""},{"path":"biochemicals-5.html","id":"mechanism-of-action-1","chapter":"Biochemicals","heading":"Mechanism of Action","text":"Hormone Receptors\nCell Surface Receptors: Bind peptide hormones catecholamines, activating G protein-coupled receptors (GPCRs), receptor tyrosine kinases (RTKs), cytokine receptors\nIntracellular Receptors: Bind steroid hormones thyroid hormones, regulating gene transcription nuclear receptors\nCell Surface Receptors: Bind peptide hormones catecholamines, activating G protein-coupled receptors (GPCRs), receptor tyrosine kinases (RTKs), cytokine receptorsIntracellular Receptors: Bind steroid hormones thyroid hormones, regulating gene transcription nuclear receptorsSignaling Pathways\nGPCRs: Activate G proteins, leading changes cAMP, IP3, DAG levels\nRTKs: Undergo autophosphorylation activate downstream signaling pathways, MAPK/ERK PI3K/Akt\nNuclear Receptors: Bind DNA response elements recruit coactivators corepressors regulate gene transcription\nGPCRs: Activate G proteins, leading changes cAMP, IP3, DAG levelsRTKs: Undergo autophosphorylation activate downstream signaling pathways, MAPK/ERK PI3K/AktNuclear Receptors: Bind DNA response elements recruit coactivators corepressors regulate gene transcriptionCellular Response\nHormone signaling leads changes enzyme activity, gene expression, cellular function\nHormone signaling leads changes enzyme activity, gene expression, cellular functionDrug Development\nUnderstanding hormone receptor signaling pathways crucial developing drugs target specific hormone-related disorders\nAgonists activate hormone receptors, antagonists block hormone receptors\nUnderstanding hormone receptor signaling pathways crucial developing drugs target specific hormone-related disordersAgonists activate hormone receptors, antagonists block hormone receptors","code":""},{"path":"biochemicals-5.html","id":"physical-and-chemical-properties-6","chapter":"Biochemicals","heading":"Physical and Chemical Properties","text":"Steroid Hormones\nDerived cholesterol, lipid-soluble, transported carrier proteins, bind intracellular receptors\nExamples: Cortisol, estradiol, testosterone\nDerived cholesterol, lipid-soluble, transported carrier proteins, bind intracellular receptorsExamples: Cortisol, estradiol, testosteronePeptide Hormones\nComposed amino acid chains, water-soluble, transported freely carrier proteins, bind cell surface receptors\nExamples: Insulin, glucagon, growth hormone\nComposed amino acid chains, water-soluble, transported freely carrier proteins, bind cell surface receptorsExamples: Insulin, glucagon, growth hormoneThyroid Hormones\nDerived tyrosine iodine, lipid-soluble, transported thyroxine-binding globulin (TBG), bind intracellular receptors\nExamples: T3, T4\nDerived tyrosine iodine, lipid-soluble, transported thyroxine-binding globulin (TBG), bind intracellular receptorsExamples: T3, T4Catecholamines\nDerived tyrosine, water-soluble, transported freely carrier proteins, bind cell surface receptors\nExamples: Epinephrine, norepinephrine, dopamine\nDerived tyrosine, water-soluble, transported freely carrier proteins, bind cell surface receptorsExamples: Epinephrine, norepinephrine, dopamineImpact Hormone Function\nphysical chemical properties hormones influence synthesis, transport, receptor binding, mechanism action\naffect design assays measure levels development hormone replacement therapies\nphysical chemical properties hormones influence synthesis, transport, receptor binding, mechanism actionThey affect design assays measure levels development hormone replacement therapies","code":""},{"path":"metabolic-7.html","id":"metabolic-7","chapter":"Metabolic","heading":"Metabolic","text":"Hormones act key regulators numerous metabolic pathways body. Understanding hormones influence pathways crucial understanding endocrine disorders","code":""},{"path":"metabolic-7.html","id":"hormonal-regulation-of-metabolism","chapter":"Metabolic","heading":"Hormonal Regulation of Metabolism","text":"Hormones: Chemical messengers produced endocrine glands travel bloodstream target cells, elicit specific physiological effectsMetabolic Pathways: Biochemical reactions occur cells tissues regulate energy production, storage, utilizationKey Hormones Metabolic Effects\nInsulin\nGlucagon\nEpinephrine (Adrenaline)\nCortisol\nGrowth Hormone\nThyroid Hormones (T3 T4)\nInsulinGlucagonEpinephrine (Adrenaline)CortisolGrowth HormoneThyroid Hormones (T3 T4)General Principles Hormonal Regulation\nHormones exert effects binding specific receptors target cells\nHormone-receptor binding triggers intracellular signaling cascades alter enzyme activity gene expression\nHormonal regulation can rapid (e.g., changes enzyme activity) slow (e.g., changes gene expression)\nHormones often work opposition maintain metabolic homeostasis\nHormones exert effects binding specific receptors target cellsHormone-receptor binding triggers intracellular signaling cascades alter enzyme activity gene expressionHormonal regulation can rapid (e.g., changes enzyme activity) slow (e.g., changes gene expression)Hormones often work opposition maintain metabolic homeostasis","code":""},{"path":"metabolic-7.html","id":"insulin","chapter":"Metabolic","heading":"Insulin","text":"Source: Pancreatic beta cellsStimulus Release: High blood glucose levelsTarget Tissues: Liver, muscle, adipose tissueMetabolic Effects\nGlucose Uptake\nIncreases glucose uptake muscle adipose tissue promoting translocation GLUT4 glucose transporters cell membrane\nFacilitates glucose entry cells, lowering blood glucose levels\n\nGlycogenesis\nStimulates glycogen synthesis (glycogenesis) liver muscle\nPromotes conversion glucose glycogen storage\n\nGlycolysis\nEnhances glycolysis liver muscle\nIncreases breakdown glucose pyruvate ATP\n\nGluconeogenesis\nInhibits gluconeogenesis liver\nReduces production glucose non-carbohydrate precursors\n\nLipogenesis\nStimulates fatty acid synthesis (lipogenesis) liver adipose tissue\nPromotes conversion excess glucose triglycerides storage\n\nLipolysis\nInhibits lipolysis adipose tissue\nReduces breakdown triglycerides fatty acids glycerol\n\nProtein Synthesis\nStimulates protein synthesis muscle tissues\nPromotes uptake amino acids formation new proteins\n\nProtein Degradation\nInhibits protein degradation\nReduces breakdown proteins amino acids\n\nGlucose Uptake\nIncreases glucose uptake muscle adipose tissue promoting translocation GLUT4 glucose transporters cell membrane\nFacilitates glucose entry cells, lowering blood glucose levels\nIncreases glucose uptake muscle adipose tissue promoting translocation GLUT4 glucose transporters cell membraneFacilitates glucose entry cells, lowering blood glucose levelsGlycogenesis\nStimulates glycogen synthesis (glycogenesis) liver muscle\nPromotes conversion glucose glycogen storage\nStimulates glycogen synthesis (glycogenesis) liver musclePromotes conversion glucose glycogen storageGlycolysis\nEnhances glycolysis liver muscle\nIncreases breakdown glucose pyruvate ATP\nEnhances glycolysis liver muscleIncreases breakdown glucose pyruvate ATPGluconeogenesis\nInhibits gluconeogenesis liver\nReduces production glucose non-carbohydrate precursors\nInhibits gluconeogenesis liverReduces production glucose non-carbohydrate precursorsLipogenesis\nStimulates fatty acid synthesis (lipogenesis) liver adipose tissue\nPromotes conversion excess glucose triglycerides storage\nStimulates fatty acid synthesis (lipogenesis) liver adipose tissuePromotes conversion excess glucose triglycerides storageLipolysis\nInhibits lipolysis adipose tissue\nReduces breakdown triglycerides fatty acids glycerol\nInhibits lipolysis adipose tissueReduces breakdown triglycerides fatty acids glycerolProtein Synthesis\nStimulates protein synthesis muscle tissues\nPromotes uptake amino acids formation new proteins\nStimulates protein synthesis muscle tissuesPromotes uptake amino acids formation new proteinsProtein Degradation\nInhibits protein degradation\nReduces breakdown proteins amino acids\nInhibits protein degradationReduces breakdown proteins amino acidsOverall Effect: Lowers blood glucose levels promotes energy storage","code":""},{"path":"metabolic-7.html","id":"glucagon","chapter":"Metabolic","heading":"Glucagon","text":"Source: Pancreatic alpha cellsStimulus Release: Low blood glucose levelsTarget Tissue: LiverMetabolic Effects\nGlycogenolysis\nStimulates glycogen breakdown (glycogenolysis) liver\nPromotes release glucose glycogen stores\n\nGluconeogenesis\nEnhances gluconeogenesis liver\nIncreases production glucose non-carbohydrate precursors\n\nLipolysis\nStimulates lipolysis adipose tissue (lesser extent epinephrine)\nPromotes release fatty acids glycerol\n\nKetogenesis\nStimulates ketogenesis liver\nPromotes production ketone bodies fatty acids\n\nGlycolysis\nInhibits Glycolysis liver\n\nGlycogenesis\nInhibits Glycogenesis liver\n\nGlycogenolysis\nStimulates glycogen breakdown (glycogenolysis) liver\nPromotes release glucose glycogen stores\nStimulates glycogen breakdown (glycogenolysis) liverPromotes release glucose glycogen storesGluconeogenesis\nEnhances gluconeogenesis liver\nIncreases production glucose non-carbohydrate precursors\nEnhances gluconeogenesis liverIncreases production glucose non-carbohydrate precursorsLipolysis\nStimulates lipolysis adipose tissue (lesser extent epinephrine)\nPromotes release fatty acids glycerol\nStimulates lipolysis adipose tissue (lesser extent epinephrine)Promotes release fatty acids glycerolKetogenesis\nStimulates ketogenesis liver\nPromotes production ketone bodies fatty acids\nStimulates ketogenesis liverPromotes production ketone bodies fatty acidsGlycolysis\nInhibits Glycolysis liver\nInhibits Glycolysis liverGlycogenesis\nInhibits Glycogenesis liver\nInhibits Glycogenesis liverOverall Effect: Raises blood glucose levels provides alternative energy sources (fatty acids ketone bodies)","code":""},{"path":"metabolic-7.html","id":"epinephrine-adrenaline","chapter":"Metabolic","heading":"Epinephrine (Adrenaline)","text":"Source: Adrenal medullaStimulus Release: Stress, exercise, low blood glucose levelsTarget Tissues: Liver, muscle, adipose tissueMetabolic Effects\nGlycogenolysis\nStimulates glycogen breakdown liver muscle\nProvides glucose energy stress exercise\n\nGluconeogenesis\nEnhances gluconeogenesis liver\nIncreases glucose production\n\nLipolysis\nStimulates lipolysis adipose tissue\nPromotes release fatty acids energy\n\nInsulin Secretion\nInhibits insulin secretion\nReduces glucose uptake cells\n\nGlycogenolysis\nStimulates glycogen breakdown liver muscle\nProvides glucose energy stress exercise\nStimulates glycogen breakdown liver muscleProvides glucose energy stress exerciseGluconeogenesis\nEnhances gluconeogenesis liver\nIncreases glucose production\nEnhances gluconeogenesis liverIncreases glucose productionLipolysis\nStimulates lipolysis adipose tissue\nPromotes release fatty acids energy\nStimulates lipolysis adipose tissuePromotes release fatty acids energyInsulin Secretion\nInhibits insulin secretion\nReduces glucose uptake cells\nInhibits insulin secretionReduces glucose uptake cellsOverall Effect: Raises blood glucose levels mobilizes energy stores","code":""},{"path":"metabolic-7.html","id":"cortisol","chapter":"Metabolic","heading":"Cortisol","text":"Source: Adrenal cortexStimulus Release: Stress, low blood glucose levelsTarget Tissues: Liver, muscle, adipose tissueMetabolic Effects\nGluconeogenesis\nStimulates gluconeogenesis liver\nIncreases glucose production amino acids glycerol\n\nProtein Catabolism\nPromotes protein breakdown muscle\nReleases amino acids gluconeogenesis\n\nLipolysis\nStimulates lipolysis adipose tissue\nReleases fatty acids energy\n\nInsulin Resistance\nInduces insulin resistance peripheral tissues\nReduces glucose uptake cells\n\nGluconeogenesis\nStimulates gluconeogenesis liver\nIncreases glucose production amino acids glycerol\nStimulates gluconeogenesis liverIncreases glucose production amino acids glycerolProtein Catabolism\nPromotes protein breakdown muscle\nReleases amino acids gluconeogenesis\nPromotes protein breakdown muscleReleases amino acids gluconeogenesisLipolysis\nStimulates lipolysis adipose tissue\nReleases fatty acids energy\nStimulates lipolysis adipose tissueReleases fatty acids energyInsulin Resistance\nInduces insulin resistance peripheral tissues\nReduces glucose uptake cells\nInduces insulin resistance peripheral tissuesReduces glucose uptake cellsOverall Effect: Raises blood glucose levels provides energy stress, prolonged elevation can lead metabolic dysfunction","code":""},{"path":"metabolic-7.html","id":"growth-hormone","chapter":"Metabolic","heading":"Growth Hormone","text":"Source: Anterior pituitary glandStimulus Release: Growth, exercise, low blood glucose levelsTarget Tissues: Liver, muscle, adipose tissueMetabolic Effects\nProtein Synthesis\nStimulates protein synthesis muscle tissues\nPromotes growth development\n\nLipolysis\nStimulates lipolysis adipose tissue\nReleases fatty acids energy\n\nInsulin Resistance\nInduces insulin resistance peripheral tissues\nReduces glucose uptake cells\n\nGluconeogenesis\nStimulates Gluconeogenesis liver\n\nProtein Synthesis\nStimulates protein synthesis muscle tissues\nPromotes growth development\nStimulates protein synthesis muscle tissuesPromotes growth developmentLipolysis\nStimulates lipolysis adipose tissue\nReleases fatty acids energy\nStimulates lipolysis adipose tissueReleases fatty acids energyInsulin Resistance\nInduces insulin resistance peripheral tissues\nReduces glucose uptake cells\nInduces insulin resistance peripheral tissuesReduces glucose uptake cellsGluconeogenesis\nStimulates Gluconeogenesis liver\nStimulates Gluconeogenesis liverOverall Effect: Promotes growth, protein synthesis, energy mobilization, can also impair glucose metabolism","code":""},{"path":"metabolic-7.html","id":"thyroid-hormones-t3-and-t4","chapter":"Metabolic","heading":"Thyroid Hormones (T3 and T4)","text":"Source: Thyroid glandStimulus Release: Thyroid-stimulating hormone (TSH) pituitary glandTarget Tissues: tissues bodyMetabolic Effects\nBasal Metabolic Rate (BMR)\nIncreases BMR\nElevates energy expenditure oxygen consumption\n\nCarbohydrate Metabolism\nEnhances glucose absorption intestine\nIncreases glycolysis gluconeogenesis\n\nLipid Metabolism\nStimulates lipolysis\nReduces cholesterol levels\n\nProtein Metabolism\nPromotes protein synthesis degradation\n\nBasal Metabolic Rate (BMR)\nIncreases BMR\nElevates energy expenditure oxygen consumption\nIncreases BMRElevates energy expenditure oxygen consumptionCarbohydrate Metabolism\nEnhances glucose absorption intestine\nIncreases glycolysis gluconeogenesis\nEnhances glucose absorption intestineIncreases glycolysis gluconeogenesisLipid Metabolism\nStimulates lipolysis\nReduces cholesterol levels\nStimulates lipolysisReduces cholesterol levelsProtein Metabolism\nPromotes protein synthesis degradation\nPromotes protein synthesis degradationOverall Effect: Increases metabolic rate, enhances energy utilization, affects carbohydrate, lipid, protein metabolism","code":""},{"path":"metabolic-7.html","id":"summary-table-of-hormonal-effects-on-metabolic-pathways","chapter":"Metabolic","heading":"Summary Table of Hormonal Effects on Metabolic Pathways","text":"","code":""},{"path":"metabolic-7.html","id":"clinical-significance-6","chapter":"Metabolic","heading":"Clinical Significance","text":"Diabetes Mellitus: Imbalance insulin glucagon leads hyperglycemia metabolic dysfunctionCushing’s Syndrome: Excess cortisol causes hyperglycemia, muscle wasting, lipolysisAcromegaly: Excess growth hormone causes insulin resistance glucose intoleranceHyperthyroidism: Excess thyroid hormones cause increased metabolic rate, weight loss, glucose intoleranceHypothyroidism: Deficiency thyroid hormones causes decreased metabolic rate, weight gain, glucose intolerance","code":""},{"path":"metabolic-7.html","id":"key-terms-54","chapter":"Metabolic","heading":"Key Terms","text":"Hormone: chemical messenger produced endocrine glandsReceptor: protein target cell binds hormoneSignal Transduction: process hormone-receptor interaction triggers intracellular eventsGlycogenesis: synthesis glycogen glucoseGlycogenolysis: breakdown glycogen glucoseGluconeogenesis: synthesis glucose non-carbohydrate precursorsGlycolysis: breakdown glucose pyruvateLipogenesis: synthesis fatty acidsLipolysis: breakdown triglycerides fatty acids glycerolProtein Synthesis: formation new proteinsProtein Degradation: breakdown proteins","code":""},{"path":"physiology-7.html","id":"physiology-7","chapter":"Physiology","heading":"Physiology","text":"Endocrine disorders abnormal states arise either hormone excess deficiency. Understanding constitutes normal hormonal balance crucial identifying interpreting abnormal states","code":""},{"path":"physiology-7.html","id":"normal-endocrine-function","chapter":"Physiology","heading":"Normal Endocrine Function","text":"Hormone Synthesis Secretion\nSynthesis: Hormones synthesized endocrine glands various biochemical pathways, often involving enzymatic reactions precursor molecules\nSecretion: Hormone secretion regulated feedback mechanisms, neural signals, hormonal signals maintain homeostasis\nSynthesis: Hormones synthesized endocrine glands various biochemical pathways, often involving enzymatic reactions precursor moleculesSecretion: Hormone secretion regulated feedback mechanisms, neural signals, hormonal signals maintain homeostasisHormone Transport\nProtein Binding: Many hormones transported bloodstream bound carrier proteins, protect degradation prolong half-life\nFree Hormone: free (unbound) hormone biologically active can interact target tissues\nProtein Binding: Many hormones transported bloodstream bound carrier proteins, protect degradation prolong half-lifeFree Hormone: free (unbound) hormone biologically active can interact target tissuesHormone Action\nReceptor Binding: Hormones bind specific receptors target cells, initiating intracellular signaling cascades\nSignal Transduction: cascades alter cellular function, gene expression, protein synthesis produce physiological effects\nReceptor Binding: Hormones bind specific receptors target cells, initiating intracellular signaling cascadesSignal Transduction: cascades alter cellular function, gene expression, protein synthesis produce physiological effectsHormone Metabolism Excretion\nMetabolism: Hormones metabolized liver, kidneys, tissues inactive forms\nExcretion: Metabolites excreted urine bile\nMetabolism: Hormones metabolized liver, kidneys, tissues inactive formsExcretion: Metabolites excreted urine bileFeedback Mechanisms\nNegative Feedback: Hormone levels tightly regulated negative feedback loops, hormone’s effects inhibit secretion\nPositive Feedback: cases, hormones can stimulate secretion, leading surge hormone levels (e.g., ovulation)\nNegative Feedback: Hormone levels tightly regulated negative feedback loops, hormone’s effects inhibit secretionPositive Feedback: cases, hormones can stimulate secretion, leading surge hormone levels (e.g., ovulation)","code":""},{"path":"physiology-7.html","id":"abnormal-endocrine-function","chapter":"Physiology","heading":"Abnormal Endocrine Function","text":"Hormone Excess\nCauses: Tumors, autoimmune disorders, ectopic hormone production\nEffects: Exaggerated physiological responses, metabolic imbalances, organ damage\nCauses: Tumors, autoimmune disorders, ectopic hormone productionEffects: Exaggerated physiological responses, metabolic imbalances, organ damageHormone Deficiency\nCauses: Autoimmune destruction, surgical removal, genetic defects, infections\nEffects: Impaired physiological responses, metabolic abnormalities, developmental issues\nCauses: Autoimmune destruction, surgical removal, genetic defects, infectionsEffects: Impaired physiological responses, metabolic abnormalities, developmental issuesReceptor Abnormalities\nReceptor Resistance: Target tissues fail respond normally hormones due receptor defects post-receptor signaling abnormalities\nReceptor Mutations: Genetic mutations can alter receptor structure function, leading hormone resistance constitutive activation\nReceptor Resistance: Target tissues fail respond normally hormones due receptor defects post-receptor signaling abnormalitiesReceptor Mutations: Genetic mutations can alter receptor structure function, leading hormone resistance constitutive activationEctopic Hormone Production\nNon-Endocrine Tumors: tumors can produce hormones normally secreted tissue, leading hormonal imbalances\nParaneoplastic Syndromes: syndromes can cause wide range endocrine metabolic abnormalities\nNon-Endocrine Tumors: tumors can produce hormones normally secreted tissue, leading hormonal imbalancesParaneoplastic Syndromes: syndromes can cause wide range endocrine metabolic abnormalities","code":""},{"path":"physiology-7.html","id":"specific-endocrine-disorders","chapter":"Physiology","heading":"Specific Endocrine Disorders","text":"","code":""},{"path":"physiology-7.html","id":"pituitary-disorders","chapter":"Physiology","heading":"0.0.1 Pituitary Disorders","text":"Hyperpituitarism (Hormone Excess)\nAcromegaly: Excess growth hormone (GH) leads enlarged hands, feet, facial features\nCushing’s Disease: Excess adrenocorticotropic hormone (ACTH) leads excess cortisol production, causing weight gain, hypertension, muscle weakness\nHyperprolactinemia: Excess prolactin leads galactorrhea (milk production) amenorrhea (absence menstruation) women, hypogonadism men\nAcromegaly: Excess growth hormone (GH) leads enlarged hands, feet, facial featuresCushing’s Disease: Excess adrenocorticotropic hormone (ACTH) leads excess cortisol production, causing weight gain, hypertension, muscle weaknessHyperprolactinemia: Excess prolactin leads galactorrhea (milk production) amenorrhea (absence menstruation) women, hypogonadism menHypopituitarism (Hormone Deficiency)\nGrowth Hormone Deficiency: Leads growth retardation children metabolic abnormalities adults\nAdrenal Insufficiency: Deficiency ACTH leads decreased cortisol production, causing fatigue, weight loss, hypotension\nHypothyroidism: Deficiency thyroid-stimulating hormone (TSH) leads decreased thyroid hormone production, causing fatigue, weight gain, cold intolerance\nHypogonadism: Deficiency luteinizing hormone (LH) follicle-stimulating hormone (FSH) leads decreased sex hormone production, causing infertility sexual dysfunction\nGrowth Hormone Deficiency: Leads growth retardation children metabolic abnormalities adultsAdrenal Insufficiency: Deficiency ACTH leads decreased cortisol production, causing fatigue, weight loss, hypotensionHypothyroidism: Deficiency thyroid-stimulating hormone (TSH) leads decreased thyroid hormone production, causing fatigue, weight gain, cold intoleranceHypogonadism: Deficiency luteinizing hormone (LH) follicle-stimulating hormone (FSH) leads decreased sex hormone production, causing infertility sexual dysfunction","code":""},{"path":"physiology-7.html","id":"thyroid-disorders","chapter":"Physiology","heading":"0.0.2 Thyroid Disorders","text":"Hyperthyroidism (Hormone Excess)\nGraves’ Disease: Autoimmune disorder stimulates thyroid gland, leading excess thyroid hormone production\nToxic Nodular Goiter: Overactive thyroid nodules produce excess thyroid hormone\nSymptoms: Weight loss, anxiety, heat intolerance, palpitations, exophthalmos (bulging eyes)\nGraves’ Disease: Autoimmune disorder stimulates thyroid gland, leading excess thyroid hormone productionToxic Nodular Goiter: Overactive thyroid nodules produce excess thyroid hormoneSymptoms: Weight loss, anxiety, heat intolerance, palpitations, exophthalmos (bulging eyes)Hypothyroidism (Hormone Deficiency)\nHashimoto’s Thyroiditis: Autoimmune destruction thyroid gland, leading decreased thyroid hormone production\nIodine Deficiency: Inadequate iodine intake impairs thyroid hormone synthesis\nSymptoms: Fatigue, weight gain, cold intolerance, constipation, dry skin\nHashimoto’s Thyroiditis: Autoimmune destruction thyroid gland, leading decreased thyroid hormone productionIodine Deficiency: Inadequate iodine intake impairs thyroid hormone synthesisSymptoms: Fatigue, weight gain, cold intolerance, constipation, dry skin","code":""},{"path":"physiology-7.html","id":"adrenal-disorders","chapter":"Physiology","heading":"0.0.3 Adrenal Disorders","text":"Hypercortisolism (Cushing’s Syndrome) (Hormone Excess)\nCushing’s Disease: Pituitary tumor overproduces ACTH, leading excess cortisol production\nAdrenal Tumors: Tumors adrenal gland produce excess cortisol\nExogenous Steroids: Prolonged use corticosteroids\nSymptoms: Weight gain, moon face, buffalo hump, hypertension, muscle weakness, skin changes\nCushing’s Disease: Pituitary tumor overproduces ACTH, leading excess cortisol productionAdrenal Tumors: Tumors adrenal gland produce excess cortisolExogenous Steroids: Prolonged use corticosteroidsSymptoms: Weight gain, moon face, buffalo hump, hypertension, muscle weakness, skin changesAdrenal Insufficiency (Hormone Deficiency)\nAddison’s Disease: Autoimmune destruction adrenal glands, leading decreased cortisol aldosterone production\nSecondary Adrenal Insufficiency: Pituitary hypothalamic disorders decrease ACTH production\nSymptoms: Fatigue, weight loss, hypotension, hyperpigmentation (Addison’s disease), electrolyte imbalances\nAddison’s Disease: Autoimmune destruction adrenal glands, leading decreased cortisol aldosterone productionSecondary Adrenal Insufficiency: Pituitary hypothalamic disorders decrease ACTH productionSymptoms: Fatigue, weight loss, hypotension, hyperpigmentation (Addison’s disease), electrolyte imbalancesHyperaldosteronism (Hormone Excess)\nPrimary Hyperaldosteronism (Conn’s Syndrome): Adrenal tumor produces excess aldosterone\nSecondary Hyperaldosteronism: Increased renin production due kidney disease conditions\nSymptoms: Hypertension, hypokalemia, muscle weakness\nPrimary Hyperaldosteronism (Conn’s Syndrome): Adrenal tumor produces excess aldosteroneSecondary Hyperaldosteronism: Increased renin production due kidney disease conditionsSymptoms: Hypertension, hypokalemia, muscle weaknessPheochromocytoma (Hormone Excess)\nTumor adrenal medulla produces excess catecholamines (epinephrine norepinephrine)\nSymptoms: Hypertension, palpitations, sweating, anxiety, headaches\nTumor adrenal medulla produces excess catecholamines (epinephrine norepinephrine)Symptoms: Hypertension, palpitations, sweating, anxiety, headaches","code":""},{"path":"physiology-7.html","id":"pancreatic-endocrine-disorders","chapter":"Physiology","heading":"0.0.4 Pancreatic Endocrine Disorders","text":"Diabetes Mellitus (Hormone Deficiency/Resistance)\nType 1 Diabetes: Autoimmune destruction pancreatic beta cells, leading absolute insulin deficiency\nType 2 Diabetes: Insulin resistance progressive beta-cell dysfunction\nSymptoms: Polyuria, polydipsia, polyphagia, weight loss, hyperglycemia\nType 1 Diabetes: Autoimmune destruction pancreatic beta cells, leading absolute insulin deficiencyType 2 Diabetes: Insulin resistance progressive beta-cell dysfunctionSymptoms: Polyuria, polydipsia, polyphagia, weight loss, hyperglycemiaInsulinoma (Hormone Excess)\nTumor pancreatic beta cells produces excess insulin, leading hypoglycemia\nSymptoms: Hypoglycemia, sweating, palpitations, anxiety, confusion\nTumor pancreatic beta cells produces excess insulin, leading hypoglycemiaSymptoms: Hypoglycemia, sweating, palpitations, anxiety, confusion","code":""},{"path":"physiology-7.html","id":"parathyroid-disorders","chapter":"Physiology","heading":"0.0.5 Parathyroid Disorders","text":"Hyperparathyroidism (Hormone Excess)\nPrimary Hyperparathyroidism: Parathyroid adenoma hyperplasia produces excess parathyroid hormone (PTH), leading hypercalcemia\nSecondary Hyperparathyroidism: Increased PTH production due chronic kidney disease vitamin D deficiency\nSymptoms: Hypercalcemia, kidney stones, bone pain, muscle weakness\nPrimary Hyperparathyroidism: Parathyroid adenoma hyperplasia produces excess parathyroid hormone (PTH), leading hypercalcemiaSecondary Hyperparathyroidism: Increased PTH production due chronic kidney disease vitamin D deficiencySymptoms: Hypercalcemia, kidney stones, bone pain, muscle weaknessHypoparathyroidism (Hormone Deficiency)\nSurgical removal autoimmune destruction parathyroid glands, leading hypocalcemia\nSymptoms: Hypocalcemia, muscle cramps, tetany, seizures\nSurgical removal autoimmune destruction parathyroid glands, leading hypocalcemiaSymptoms: Hypocalcemia, muscle cramps, tetany, seizures","code":""},{"path":"physiology-7.html","id":"gonadal-disorders","chapter":"Physiology","heading":"0.0.6 Gonadal Disorders","text":"Hypogonadism (Hormone Deficiency)\nPrimary Hypogonadism: Gonadal failure due genetic disorders, autoimmune destruction, radiation exposure\nSecondary Hypogonadism: Pituitary hypothalamic disorders decrease LH FSH production\nSymptoms: Infertility, sexual dysfunction, decreased muscle mass, osteoporosis\nPrimary Hypogonadism: Gonadal failure due genetic disorders, autoimmune destruction, radiation exposureSecondary Hypogonadism: Pituitary hypothalamic disorders decrease LH FSH productionSymptoms: Infertility, sexual dysfunction, decreased muscle mass, osteoporosisPolycystic Ovary Syndrome (PCOS)\nHormonal disorder characterized hyperandrogenism, irregular menstruation, polycystic ovaries\nSymptoms: Hirsutism (excess hair growth), acne, infertility, metabolic syndrome\nHormonal disorder characterized hyperandrogenism, irregular menstruation, polycystic ovariesSymptoms: Hirsutism (excess hair growth), acne, infertility, metabolic syndrome","code":""},{"path":"physiology-7.html","id":"summary-table-of-normal-and-abnormal-states","chapter":"Physiology","heading":"Summary Table of Normal and Abnormal States","text":"","code":""},{"path":"physiology-7.html","id":"key-terms-55","chapter":"Physiology","heading":"Key Terms","text":"Homeostasis: maintenance stable internal conditionsNegative Feedback: regulatory mechanism output inhibits productionPositive Feedback: regulatory mechanism output stimulates productionHormone Receptor: protein target cell binds hormoneSignal Transduction: process hormone-receptor interaction triggers intracellular eventsHypersecretion: Excessive hormone productionHyposecretion: Insufficient hormone productionHormone Resistance: condition target tissues fail respond normally hormoneEctopic Hormone Production: Hormone production non-endocrine tissuesAutoimmune Disorder: condition immune system attacks body’s tissuesTumor: abnormal mass tissueHyperplasia: increase number cells tissue organAtrophy: decrease size tissue organMetabolic Syndrome: cluster conditions increase risk heart disease, stroke, diabetesPolycystic Ovary Syndrome (PCOS): hormonal disorder characterized hyperandrogenism, irregular menstruation, polycystic ovariesHypertension: High blood pressureHypotension: Low blood pressureHypercalcemia: Elevated blood calcium levelsHypocalcemia: Reduced blood calcium levelsHyperkalemia: Elevated blood potassium levelsHypokalemia: Reduced blood potassium levelsHirsutism: Excess hair growth womenVirilization: Development male characteristics womenGynecomastia: Enlargement breast tissue menGalactorrhea: Spontaneous milk productionAmenorrhea: Absence menstruationInfertility: Inability conceiveOsteoporosis: Reduced bone density, increasing risk fracturesLethargy: state fatigue drowsinessGoiter: Enlargement thyroid glandExophthalmos: Bulging eyes, typically associated hyperthyroidism","code":""},{"path":"action-mechanism.html","id":"action-mechanism","chapter":"Action Mechanism","heading":"Action Mechanism","text":"Understanding hormones work cellular level key understanding endocrinology. Hormones initiate effects binding receptors, triggering cascade intracellular events","code":""},{"path":"action-mechanism.html","id":"hormone-receptors","chapter":"Action Mechanism","heading":"Hormone Receptors","text":"Definition: Proteins located either cell surface within cell bind specific hormones, initiating cellular responseTypes Receptors\nCell Surface Receptors: Typically bind peptide hormones catecholamines\nG Protein-Coupled Receptors (GPCRs): Activate intracellular signaling pathways G proteins\nReceptor Tyrosine Kinases (RTKs): Initiate phosphorylation cascades, leading altered gene expression cellular function\nCytokine Receptors: Activate intracellular signaling pathways Janus kinases (JAKs) signal transducers activators transcription (STATs)\n\nIntracellular Receptors: Located cytoplasm nucleus, typically bind steroid hormones thyroid hormones\nNuclear Receptors: Regulate gene transcription binding DNA response elements\n\nCell Surface Receptors: Typically bind peptide hormones catecholamines\nG Protein-Coupled Receptors (GPCRs): Activate intracellular signaling pathways G proteins\nReceptor Tyrosine Kinases (RTKs): Initiate phosphorylation cascades, leading altered gene expression cellular function\nCytokine Receptors: Activate intracellular signaling pathways Janus kinases (JAKs) signal transducers activators transcription (STATs)\nG Protein-Coupled Receptors (GPCRs): Activate intracellular signaling pathways G proteinsReceptor Tyrosine Kinases (RTKs): Initiate phosphorylation cascades, leading altered gene expression cellular functionCytokine Receptors: Activate intracellular signaling pathways Janus kinases (JAKs) signal transducers activators transcription (STATs)Intracellular Receptors: Located cytoplasm nucleus, typically bind steroid hormones thyroid hormones\nNuclear Receptors: Regulate gene transcription binding DNA response elements\nNuclear Receptors: Regulate gene transcription binding DNA response elements","code":""},{"path":"action-mechanism.html","id":"mechanisms-of-hormone-action","chapter":"Action Mechanism","heading":"Mechanisms of Hormone Action","text":"Peptide Hormones Catecholamines\nBinding Cell Surface Receptors:\nHormone binds specific receptor cell membrane\nReceptor undergoes conformational change, activating intracellular signaling pathways\n\nActivation G Proteins:\nGPCRs activate G proteins (Gs, Gi, Gq)\nGs stimulates adenylyl cyclase, increasing cAMP levels\nGi inhibits adenylyl cyclase, decreasing cAMP levels\nGq activates phospholipase C, increasing IP3 DAG levels\n\nActivation Second Messengers:\ncAMP activates protein kinase (PKA), phosphorylates target proteins, altering activity\nIP3 releases calcium endoplasmic reticulum, activating protein kinase C (PKC) calcium-dependent signaling pathways\nDAG activates PKC, phosphorylates target proteins\n\nActivation Receptor Tyrosine Kinases (RTKs):\nHormone binding causes receptor dimerization autophosphorylation\nPhosphorylated tyrosine residues recruit intracellular signaling proteins, SH2 domain-containing proteins\nActivation downstream signaling pathways, including MAPK/ERK pathway PI3K/Akt pathway\n\nSignal Amplification:\ninitial hormone-receptor interaction amplified signaling cascades, leading large cellular response\n\nCellular Response:\nChanges enzyme activity, gene expression, cellular function\n\nBinding Cell Surface Receptors:\nHormone binds specific receptor cell membrane\nReceptor undergoes conformational change, activating intracellular signaling pathways\nHormone binds specific receptor cell membraneReceptor undergoes conformational change, activating intracellular signaling pathwaysActivation G Proteins:\nGPCRs activate G proteins (Gs, Gi, Gq)\nGs stimulates adenylyl cyclase, increasing cAMP levels\nGi inhibits adenylyl cyclase, decreasing cAMP levels\nGq activates phospholipase C, increasing IP3 DAG levels\nGPCRs activate G proteins (Gs, Gi, Gq)Gs stimulates adenylyl cyclase, increasing cAMP levelsGi inhibits adenylyl cyclase, decreasing cAMP levelsGq activates phospholipase C, increasing IP3 DAG levelsActivation Second Messengers:\ncAMP activates protein kinase (PKA), phosphorylates target proteins, altering activity\nIP3 releases calcium endoplasmic reticulum, activating protein kinase C (PKC) calcium-dependent signaling pathways\nDAG activates PKC, phosphorylates target proteins\ncAMP activates protein kinase (PKA), phosphorylates target proteins, altering activityIP3 releases calcium endoplasmic reticulum, activating protein kinase C (PKC) calcium-dependent signaling pathwaysDAG activates PKC, phosphorylates target proteinsActivation Receptor Tyrosine Kinases (RTKs):\nHormone binding causes receptor dimerization autophosphorylation\nPhosphorylated tyrosine residues recruit intracellular signaling proteins, SH2 domain-containing proteins\nActivation downstream signaling pathways, including MAPK/ERK pathway PI3K/Akt pathway\nHormone binding causes receptor dimerization autophosphorylationPhosphorylated tyrosine residues recruit intracellular signaling proteins, SH2 domain-containing proteinsActivation downstream signaling pathways, including MAPK/ERK pathway PI3K/Akt pathwaySignal Amplification:\ninitial hormone-receptor interaction amplified signaling cascades, leading large cellular response\ninitial hormone-receptor interaction amplified signaling cascades, leading large cellular responseCellular Response:\nChanges enzyme activity, gene expression, cellular function\nChanges enzyme activity, gene expression, cellular functionSteroid Hormones Thyroid Hormones\nEntry Cell:\nHormone diffuses across cell membrane enters cytoplasm\n\nBinding Intracellular Receptors:\nHormone binds specific receptor cytoplasm nucleus\nReceptor undergoes conformational change, forming hormone-receptor complex\n\nTranslocation Nucleus (receptor cytoplasmic):\nHormone-receptor complex translocates nucleus\n\nBinding DNA:\nHormone-receptor complex binds specific DNA response elements (HREs) promoter region target genes\n\nRegulation Gene Transcription:\nhormone-receptor complex recruits coactivator corepressor proteins, altering gene transcription\nIncreased transcription leads increased mRNA synthesis protein production\nDecreased transcription leads decreased mRNA synthesis protein production\n\nCellular Response:\nChanges protein synthesis cellular function\n\nEntry Cell:\nHormone diffuses across cell membrane enters cytoplasm\nHormone diffuses across cell membrane enters cytoplasmBinding Intracellular Receptors:\nHormone binds specific receptor cytoplasm nucleus\nReceptor undergoes conformational change, forming hormone-receptor complex\nHormone binds specific receptor cytoplasm nucleusReceptor undergoes conformational change, forming hormone-receptor complexTranslocation Nucleus (receptor cytoplasmic):\nHormone-receptor complex translocates nucleus\nHormone-receptor complex translocates nucleusBinding DNA:\nHormone-receptor complex binds specific DNA response elements (HREs) promoter region target genes\nHormone-receptor complex binds specific DNA response elements (HREs) promoter region target genesRegulation Gene Transcription:\nhormone-receptor complex recruits coactivator corepressor proteins, altering gene transcription\nIncreased transcription leads increased mRNA synthesis protein production\nDecreased transcription leads decreased mRNA synthesis protein production\nhormone-receptor complex recruits coactivator corepressor proteins, altering gene transcriptionIncreased transcription leads increased mRNA synthesis protein productionDecreased transcription leads decreased mRNA synthesis protein productionCellular Response:\nChanges protein synthesis cellular function\nChanges protein synthesis cellular function","code":""},{"path":"action-mechanism.html","id":"detailed-mechanisms","chapter":"Action Mechanism","heading":"Detailed Mechanisms","text":"G Protein-Coupled Receptors (GPCRs)\nStructure:\nGPCRs transmembrane proteins seven transmembrane domains\nextracellular domain binds hormone, intracellular domain interacts G proteins\n\nActivation:\nHormone binding causes conformational change receptor, activating associated G protein\nG proteins consist three subunits: alpha, beta, gamma\nalpha subunit binds GTP intrinsic GTPase activity\nActivation G protein causes alpha subunit dissociate activate inhibit downstream effectors\n\nDownstream Effectors:\nAdenylyl cyclase: Stimulated Gs, inhibited Gi\nAdenylyl cyclase catalyzes conversion ATP cAMP\ncAMP activates protein kinase (PKA)\n\nPhospholipase C: Activated Gq\nPhospholipase C catalyzes hydrolysis PIP2 IP3 DAG\nIP3 releases calcium endoplasmic reticulum\nDAG activates protein kinase C (PKC)\n\n\nTermination Signal:\nintrinsic GTPase activity G protein alpha subunit hydrolyzes GTP GDP, inactivating G protein\nPhosphodiesterases degrade cAMP, reducing PKA activity\nCalcium pumps remove calcium cytoplasm, reducing PKC activity\n\nStructure:\nGPCRs transmembrane proteins seven transmembrane domains\nextracellular domain binds hormone, intracellular domain interacts G proteins\nGPCRs transmembrane proteins seven transmembrane domainsThe extracellular domain binds hormone, intracellular domain interacts G proteinsActivation:\nHormone binding causes conformational change receptor, activating associated G protein\nG proteins consist three subunits: alpha, beta, gamma\nalpha subunit binds GTP intrinsic GTPase activity\nActivation G protein causes alpha subunit dissociate activate inhibit downstream effectors\nHormone binding causes conformational change receptor, activating associated G proteinG proteins consist three subunits: alpha, beta, gammaThe alpha subunit binds GTP intrinsic GTPase activityActivation G protein causes alpha subunit dissociate activate inhibit downstream effectorsDownstream Effectors:\nAdenylyl cyclase: Stimulated Gs, inhibited Gi\nAdenylyl cyclase catalyzes conversion ATP cAMP\ncAMP activates protein kinase (PKA)\n\nPhospholipase C: Activated Gq\nPhospholipase C catalyzes hydrolysis PIP2 IP3 DAG\nIP3 releases calcium endoplasmic reticulum\nDAG activates protein kinase C (PKC)\n\nAdenylyl cyclase: Stimulated Gs, inhibited Gi\nAdenylyl cyclase catalyzes conversion ATP cAMP\ncAMP activates protein kinase (PKA)\nAdenylyl cyclase catalyzes conversion ATP cAMPcAMP activates protein kinase (PKA)Phospholipase C: Activated Gq\nPhospholipase C catalyzes hydrolysis PIP2 IP3 DAG\nIP3 releases calcium endoplasmic reticulum\nDAG activates protein kinase C (PKC)\nPhospholipase C catalyzes hydrolysis PIP2 IP3 DAGIP3 releases calcium endoplasmic reticulumDAG activates protein kinase C (PKC)Termination Signal:\nintrinsic GTPase activity G protein alpha subunit hydrolyzes GTP GDP, inactivating G protein\nPhosphodiesterases degrade cAMP, reducing PKA activity\nCalcium pumps remove calcium cytoplasm, reducing PKC activity\nintrinsic GTPase activity G protein alpha subunit hydrolyzes GTP GDP, inactivating G proteinPhosphodiesterases degrade cAMP, reducing PKA activityCalcium pumps remove calcium cytoplasm, reducing PKC activityReceptor Tyrosine Kinases (RTKs)\nStructure:\nRTKs transmembrane proteins extracellular domain binds hormone intracellular domain tyrosine kinase activity\n\nActivation:\nHormone binding causes receptor dimerization autophosphorylation tyrosine residues intracellular domain\nPhosphorylated tyrosine residues serve docking sites intracellular signaling proteins SH2 domains\n\nDownstream Signaling Pathways:\nMAPK/ERK Pathway:\nActivated growth factors, epidermal growth factor (EGF)\nInvolves cascade protein kinases: Ras -> Raf -> MEK -> ERK\nERK phosphorylates transcription factors, altering gene expression\n\nPI3K/Akt Pathway:\nActivated insulin growth factors\nInvolves phosphatidylinositol 3-kinase (PI3K) Akt\nAkt promotes cell survival, growth, metabolism\n\n\nTermination Signal:\nProtein phosphatases remove phosphate groups tyrosine residues, inactivating receptor\nGTPase-activating proteins (GAPs) inactivate Ras promoting GTP hydrolysis\n\nStructure:\nRTKs transmembrane proteins extracellular domain binds hormone intracellular domain tyrosine kinase activity\nRTKs transmembrane proteins extracellular domain binds hormone intracellular domain tyrosine kinase activityActivation:\nHormone binding causes receptor dimerization autophosphorylation tyrosine residues intracellular domain\nPhosphorylated tyrosine residues serve docking sites intracellular signaling proteins SH2 domains\nHormone binding causes receptor dimerization autophosphorylation tyrosine residues intracellular domainPhosphorylated tyrosine residues serve docking sites intracellular signaling proteins SH2 domainsDownstream Signaling Pathways:\nMAPK/ERK Pathway:\nActivated growth factors, epidermal growth factor (EGF)\nInvolves cascade protein kinases: Ras -> Raf -> MEK -> ERK\nERK phosphorylates transcription factors, altering gene expression\n\nPI3K/Akt Pathway:\nActivated insulin growth factors\nInvolves phosphatidylinositol 3-kinase (PI3K) Akt\nAkt promotes cell survival, growth, metabolism\n\nMAPK/ERK Pathway:\nActivated growth factors, epidermal growth factor (EGF)\nInvolves cascade protein kinases: Ras -> Raf -> MEK -> ERK\nERK phosphorylates transcription factors, altering gene expression\nActivated growth factors, epidermal growth factor (EGF)Involves cascade protein kinases: Ras -> Raf -> MEK -> ERKERK phosphorylates transcription factors, altering gene expressionPI3K/Akt Pathway:\nActivated insulin growth factors\nInvolves phosphatidylinositol 3-kinase (PI3K) Akt\nAkt promotes cell survival, growth, metabolism\nActivated insulin growth factorsInvolves phosphatidylinositol 3-kinase (PI3K) AktAkt promotes cell survival, growth, metabolismTermination Signal:\nProtein phosphatases remove phosphate groups tyrosine residues, inactivating receptor\nGTPase-activating proteins (GAPs) inactivate Ras promoting GTP hydrolysis\nProtein phosphatases remove phosphate groups tyrosine residues, inactivating receptorGTPase-activating proteins (GAPs) inactivate Ras promoting GTP hydrolysisNuclear Receptors\nStructure:\nNuclear receptors intracellular proteins DNA-binding domain ligand-binding domain\nDNA-binding domain contains zinc finger motifs recognize specific DNA sequences (response elements)\n\nActivation:\nHormone enters cell binds receptor, causing conformational change\nhormone-receptor complex translocates nucleus (receptor cytoplasmic)\n\nRegulation Gene Transcription:\nhormone-receptor complex binds specific DNA response elements (HREs) promoter region target genes\nRecruitment Coactivators:\nCoactivators proteins enhance gene transcription\ninclude histone acetyltransferases (HATs), modify chromatin structure make DNA accessible\n\nRecruitment Corepressors:\nCorepressors proteins inhibit gene transcription\ninclude histone deacetylases (HDACs), modify chromatin structure make DNA less accessible\n\n\nTermination Signal:\nHormone dissociates receptor, inactivating complex\nProtein phosphatases remove phosphate groups transcription factors\n\nStructure:\nNuclear receptors intracellular proteins DNA-binding domain ligand-binding domain\nDNA-binding domain contains zinc finger motifs recognize specific DNA sequences (response elements)\nNuclear receptors intracellular proteins DNA-binding domain ligand-binding domainThe DNA-binding domain contains zinc finger motifs recognize specific DNA sequences (response elements)Activation:\nHormone enters cell binds receptor, causing conformational change\nhormone-receptor complex translocates nucleus (receptor cytoplasmic)\nHormone enters cell binds receptor, causing conformational changeThe hormone-receptor complex translocates nucleus (receptor cytoplasmic)Regulation Gene Transcription:\nhormone-receptor complex binds specific DNA response elements (HREs) promoter region target genes\nRecruitment Coactivators:\nCoactivators proteins enhance gene transcription\ninclude histone acetyltransferases (HATs), modify chromatin structure make DNA accessible\n\nRecruitment Corepressors:\nCorepressors proteins inhibit gene transcription\ninclude histone deacetylases (HDACs), modify chromatin structure make DNA less accessible\n\nhormone-receptor complex binds specific DNA response elements (HREs) promoter region target genesRecruitment Coactivators:\nCoactivators proteins enhance gene transcription\ninclude histone acetyltransferases (HATs), modify chromatin structure make DNA accessible\nCoactivators proteins enhance gene transcriptionThey include histone acetyltransferases (HATs), modify chromatin structure make DNA accessibleRecruitment Corepressors:\nCorepressors proteins inhibit gene transcription\ninclude histone deacetylases (HDACs), modify chromatin structure make DNA less accessible\nCorepressors proteins inhibit gene transcriptionThey include histone deacetylases (HDACs), modify chromatin structure make DNA less accessibleTermination Signal:\nHormone dissociates receptor, inactivating complex\nProtein phosphatases remove phosphate groups transcription factors\nHormone dissociates receptor, inactivating complexProtein phosphatases remove phosphate groups transcription factors","code":""},{"path":"action-mechanism.html","id":"examples-of-hormones-and-their-mechanisms-of-action","chapter":"Action Mechanism","heading":"Examples of Hormones and Their Mechanisms of Action","text":"Insulin: Binds receptor tyrosine kinase, activating PI3K/Akt pathway promoting glucose uptakeGlucagon: Binds G protein-coupled receptor, activating adenylyl cyclase increasing cAMP levelsEpinephrine: Binds adrenergic receptors (GPCRs), activating adenylyl cyclase phospholipase CCortisol: Binds intracellular glucocorticoid receptor, regulating gene transcriptionThyroid Hormone: Binds intracellular thyroid hormone receptor, regulating gene transcription","code":""},{"path":"action-mechanism.html","id":"clinical-significance-7","chapter":"Action Mechanism","heading":"Clinical Significance","text":"Drug Development: Understanding hormone receptor signaling pathways crucial developing drugs target specific hormone-related disorders\nAgonists: Drugs activate hormone receptors\nAntagonists: Drugs block hormone receptors\nAgonists: Drugs activate hormone receptorsAntagonists: Drugs block hormone receptorsHormone Resistance: Mutations hormone receptors can lead hormone resistance, target tissues fail respond normally hormonesCancer: Aberrant hormone signaling can contribute cancer development progressionAutoimmune Disorders: autoimmune disorders, antibodies target hormone receptors, leading either overstimulation blockade hormone signaling","code":""},{"path":"action-mechanism.html","id":"key-terms-56","chapter":"Action Mechanism","heading":"Key Terms","text":"Hormone Receptor: protein binds specific hormoneCell Surface Receptor: receptor located cell membraneIntracellular Receptor: receptor located within cellG Protein-Coupled Receptor (GPCR): receptor activates intracellular signaling pathways G proteinsReceptor Tyrosine Kinase (RTK): receptor initiates phosphorylation cascadesSecond Messenger: intracellular signaling molecule, cAMP, IP3, DAGProtein Kinase: enzyme phosphorylates proteinsTranscription Factor: protein regulates gene transcriptionDNA Response Element (HRE): specific DNA sequence binds hormone-receptor complexesAgonist: drug activates hormone receptorAntagonist: drug blocks hormone receptorHormone Resistance: condition target tissues fail respond normally hormone due receptor defects post-receptor signaling abnormalitiesAutophosphorylation: phosphorylation protein itselfDimerization: formation complex two identical proteins","code":""},{"path":"properties-5.html","id":"properties-5","chapter":"Properties","heading":"Properties","text":"physical chemical properties hormones influence synthesis, transport, receptor binding, mechanism action","code":""},{"path":"properties-5.html","id":"steroid-hormones","chapter":"Properties","heading":"Steroid Hormones","text":"Examples: Cortisol, aldosterone, testosterone, estradiol (estrogen), progesterone, hCGSource: Adrenal cortex, gonads, placentaBiochemical Theory Pathway\nSynthesis: Steroid hormones synthesized cholesterol series enzymatic reactions\nKey Enzymes: Cytochrome P450 enzymes (CYP enzymes) involved many steps steroid hormone synthesis\nSynthesis Pathway\nCholesterol converted pregnenolone CYP11A1 (cholesterol side-chain cleavage enzyme)\nPregnenolone converted various steroid hormones different pathways different tissues\nCortisol: Synthesized adrenal cortex\nAldosterone: Synthesized adrenal cortex\nTestosterone: Synthesized testes\nEstradiol: Synthesized ovaries\nProgesterone: Synthesized ovaries placenta\n\nSynthesis: Steroid hormones synthesized cholesterol series enzymatic reactionsKey Enzymes: Cytochrome P450 enzymes (CYP enzymes) involved many steps steroid hormone synthesisSynthesis Pathway\nCholesterol converted pregnenolone CYP11A1 (cholesterol side-chain cleavage enzyme)\nPregnenolone converted various steroid hormones different pathways different tissues\nCortisol: Synthesized adrenal cortex\nAldosterone: Synthesized adrenal cortex\nTestosterone: Synthesized testes\nEstradiol: Synthesized ovaries\nProgesterone: Synthesized ovaries placenta\nCholesterol converted pregnenolone CYP11A1 (cholesterol side-chain cleavage enzyme)Pregnenolone converted various steroid hormones different pathways different tissuesCortisol: Synthesized adrenal cortexAldosterone: Synthesized adrenal cortexTestosterone: Synthesized testesEstradiol: Synthesized ovariesProgesterone: Synthesized ovaries placentaPhysical Properties\nStructure: Characterized four-ring structure (steroid nucleus)\nSolubility: Lipid-soluble\nHydrophobic poorly soluble water\nTransported bloodstream bound carrier proteins\n\nMolecular Weight: Relatively low (250-400 Da)\nStructure: Characterized four-ring structure (steroid nucleus)Solubility: Lipid-soluble\nHydrophobic poorly soluble water\nTransported bloodstream bound carrier proteins\nHydrophobic poorly soluble waterTransported bloodstream bound carrier proteinsMolecular Weight: Relatively low (250-400 Da)Chemical Properties\nStability: Relatively stable due ring structure\nReactivity: Undergo enzymatic modifications (e.g., hydroxylation, oxidation, reduction)\nmodifications can alter biological activity\n\nPolarity: Nonpolar\nCan diffuse across cell membranes\n\nBinding Affinity: Bind high affinity intracellular receptors\nStability: Relatively stable due ring structureReactivity: Undergo enzymatic modifications (e.g., hydroxylation, oxidation, reduction)\nmodifications can alter biological activity\nmodifications can alter biological activityPolarity: Nonpolar\nCan diffuse across cell membranes\nCan diffuse across cell membranesBinding Affinity: Bind high affinity intracellular receptors","code":""},{"path":"properties-5.html","id":"peptide-hormones","chapter":"Properties","heading":"Peptide Hormones","text":"Examples: Insulin, glucagon, growth hormone, prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), parathyroid hormone (PTH), human chorionic gonadotropin (hCG)Source: Pituitary gland, pancreas, parathyroid gland, placentaBiochemical Theory Pathway\nSynthesis: Peptide hormones synthesized preprohormones, processed prohormones active hormones\nTranslation: Synthesized ribosomes endoplasmic reticulum\nProcessing: Undergo post-translational modifications (e.g., glycosylation, cleavage)\nCleavage signal peptides prohormone sequences\n\nStorage: Stored secretory granules\nSecretion: Released exocytosis response appropriate stimuli\nSynthesis: Peptide hormones synthesized preprohormones, processed prohormones active hormonesTranslation: Synthesized ribosomes endoplasmic reticulumProcessing: Undergo post-translational modifications (e.g., glycosylation, cleavage)\nCleavage signal peptides prohormone sequences\nCleavage signal peptides prohormone sequencesStorage: Stored secretory granulesSecretion: Released exocytosis response appropriate stimuliPhysical Properties\nStructure: Consist amino acid chains\nCan small peptides (e.g., TRH) large proteins (e.g., GH)\n\nSolubility: Water-soluble\nHydrophilic readily soluble water\nTransported bloodstream freely bound carrier proteins\n\nMolecular Weight: Variable, ranging hundreds tens thousands Daltons\nStructure: Consist amino acid chains\nCan small peptides (e.g., TRH) large proteins (e.g., GH)\nCan small peptides (e.g., TRH) large proteins (e.g., GH)Solubility: Water-soluble\nHydrophilic readily soluble water\nTransported bloodstream freely bound carrier proteins\nHydrophilic readily soluble waterTransported bloodstream freely bound carrier proteinsMolecular Weight: Variable, ranging hundreds tens thousands DaltonsChemical Properties\nStability: Less stable steroid hormones\nSusceptible degradation peptidases\n\nReactivity: Undergo glycosylation post-translational modifications\nmodifications can affect biological activity stability\n\nPolarity: Polar\neasily diffuse across cell membranes\n\nBinding Affinity: Bind high affinity cell surface receptors\nStability: Less stable steroid hormones\nSusceptible degradation peptidases\nSusceptible degradation peptidasesReactivity: Undergo glycosylation post-translational modifications\nmodifications can affect biological activity stability\nmodifications can affect biological activity stabilityPolarity: Polar\neasily diffuse across cell membranes\neasily diffuse across cell membranesBinding Affinity: Bind high affinity cell surface receptors","code":""},{"path":"properties-5.html","id":"thyroid-hormones","chapter":"Properties","heading":"Thyroid Hormones","text":"Examples: Thyroxine (T4), triiodothyronine (T3)Source: Thyroid glandBiochemical Theory Pathway\nSynthesis: Thyroid hormones synthesized tyrosine iodine thyroid gland\nIodide Uptake: Iodide actively transported thyroid follicular cells\nThyroglobulin Synthesis: Thyroglobulin synthesized thyroid follicular cells\nIodination: Iodide oxidized attached tyrosine residues thyroglobulin\nMonoiodotyrosine (MIT) diiodotyrosine (DIT) formed\n\nCoupling: MIT DIT molecules coupled form T3 T4\nDIT + DIT = T4 (thyroxine)\nMIT + DIT = T3 (triiodothyronine)\n\nStorage: T3 T4 stored thyroglobulin within thyroid follicles\nRelease: T3 T4 released thyroglobulin proteolysis secreted bloodstream\nConversion: T4 converted T3 peripheral tissues deiodinases\nSynthesis: Thyroid hormones synthesized tyrosine iodine thyroid glandIodide Uptake: Iodide actively transported thyroid follicular cellsThyroglobulin Synthesis: Thyroglobulin synthesized thyroid follicular cellsIodination: Iodide oxidized attached tyrosine residues thyroglobulin\nMonoiodotyrosine (MIT) diiodotyrosine (DIT) formed\nMonoiodotyrosine (MIT) diiodotyrosine (DIT) formedCoupling: MIT DIT molecules coupled form T3 T4\nDIT + DIT = T4 (thyroxine)\nMIT + DIT = T3 (triiodothyronine)\nDIT + DIT = T4 (thyroxine)MIT + DIT = T3 (triiodothyronine)Storage: T3 T4 stored thyroglobulin within thyroid folliclesRelease: T3 T4 released thyroglobulin proteolysis secreted bloodstreamConversion: T4 converted T3 peripheral tissues deiodinasesPhysical Properties\nStructure: Modified amino acids\nContain iodine atoms\n\nSolubility: Lipid-soluble\nTransported bloodstream bound thyroxine-binding globulin (TBG) carrier proteins\n\nMolecular Weight: ~650 Da\nStructure: Modified amino acids\nContain iodine atoms\nContain iodine atomsSolubility: Lipid-soluble\nTransported bloodstream bound thyroxine-binding globulin (TBG) carrier proteins\nTransported bloodstream bound thyroxine-binding globulin (TBG) carrier proteinsMolecular Weight: ~650 DaChemical Properties\nStability: Relatively stable\nReactivity: Can deiodinated peripheral tissues\nT4 converted T3 (active) reverse T3 (inactive)\n\nPolarity: Amphipathic\nCan cross cell membranes bind intracellular receptors\n\nBinding Affinity: Bind high affinity intracellular receptors\nStability: Relatively stableReactivity: Can deiodinated peripheral tissues\nT4 converted T3 (active) reverse T3 (inactive)\nT4 converted T3 (active) reverse T3 (inactive)Polarity: Amphipathic\nCan cross cell membranes bind intracellular receptors\nCan cross cell membranes bind intracellular receptorsBinding Affinity: Bind high affinity intracellular receptors","code":""},{"path":"properties-5.html","id":"catecholamines","chapter":"Properties","heading":"Catecholamines","text":"Examples: Epinephrine (adrenaline), norepinephrine (noradrenaline), dopamineSource: Adrenal medulla, sympathetic nervous systemBiochemical Theory Pathway\nSynthesis: Catecholamines synthesized tyrosine adrenal medulla sympathetic neurons\nTyrosine Hydroxylation: Tyrosine converted L-DOPA tyrosine hydroxylase\nDOPA Decarboxylation: L-DOPA converted dopamine DOPA decarboxylase\nDopamine Hydroxylation: Dopamine converted norepinephrine dopamine beta-hydroxylase\nNorepinephrine Methylation: Norepinephrine converted epinephrine phenylethanolamine N-methyltransferase (PNMT)\nStorage: Catecholamines stored vesicles\nRelease: Released exocytosis response neural stimuli\nMetabolism: Metabolized monoamine oxidase (MAO) catechol-O-methyltransferase (COMT)\nSynthesis: Catecholamines synthesized tyrosine adrenal medulla sympathetic neuronsTyrosine Hydroxylation: Tyrosine converted L-DOPA tyrosine hydroxylaseDOPA Decarboxylation: L-DOPA converted dopamine DOPA decarboxylaseDopamine Hydroxylation: Dopamine converted norepinephrine dopamine beta-hydroxylaseNorepinephrine Methylation: Norepinephrine converted epinephrine phenylethanolamine N-methyltransferase (PNMT)Storage: Catecholamines stored vesiclesRelease: Released exocytosis response neural stimuliMetabolism: Metabolized monoamine oxidase (MAO) catechol-O-methyltransferase (COMT)Physical Properties\nStructure: Derived amino acid tyrosine\nContain catechol ring amine group\n\nSolubility: Water-soluble\nHydrophilic readily soluble water\nTransported bloodstream freely bound carrier proteins\n\nMolecular Weight: Relatively low (150-200 Da)\nStructure: Derived amino acid tyrosine\nContain catechol ring amine group\nContain catechol ring amine groupSolubility: Water-soluble\nHydrophilic readily soluble water\nTransported bloodstream freely bound carrier proteins\nHydrophilic readily soluble waterTransported bloodstream freely bound carrier proteinsMolecular Weight: Relatively low (150-200 Da)Chemical Properties\nStability: Relatively unstable\nSusceptible oxidation degradation\n\nReactivity: Undergo methylation oxidation\nMetabolized MAO COMT\n\nPolarity: Polar\neasily diffuse across cell membranes\n\nBinding Affinity: Bind high affinity cell surface receptors (adrenergic receptors)\nStability: Relatively unstable\nSusceptible oxidation degradation\nSusceptible oxidation degradationReactivity: Undergo methylation oxidation\nMetabolized MAO COMT\nMetabolized MAO COMTPolarity: Polar\neasily diffuse across cell membranes\neasily diffuse across cell membranesBinding Affinity: Bind high affinity cell surface receptors (adrenergic receptors)","code":""},{"path":"properties-5.html","id":"summary-table-of-physical-and-chemical-properties","chapter":"Properties","heading":"Summary Table of Physical and Chemical Properties","text":"","code":""},{"path":"properties-5.html","id":"clinical-significance-8","chapter":"Properties","heading":"Clinical Significance","text":"Drug Development: Understanding physical chemical properties hormones crucial developing drugs mimic block actionsAssay Development: properties hormones influence design assays measure levelsHormone Replacement Therapy: Hormone replacement therapy involves administering hormones specific physical chemical properties treat hormone deficiencies","code":""},{"path":"properties-5.html","id":"key-terms-57","chapter":"Properties","heading":"Key Terms","text":"Steroid Hormone: hormone derived cholesterolPeptide Hormone: hormone composed amino acidsThyroid Hormone: hormone derived tyrosine iodineCatecholamine: hormone derived tyrosine, including epinephrine, norepinephrine, dopamineHydrophobic: Water-repellingHydrophilic: Water-attractingPolarity: distribution electrical charge moleculeCarrier Protein: protein binds transports hormones bloodstreamReceptor: protein binds specific hormone, initiating cellular responseIntracellular Receptor: receptor located within cellCell Surface Receptor: receptor located cell membraneHalf-Life: time takes half substance eliminated body","code":""},{"path":"procedures-7.html","id":"procedures-7","chapter":"Procedures","heading":"Procedures","text":"section covers general endocrinology testing principles, precautions, specimen handling, troubleshooting, interfering substances, stimulation/suppression testing","code":""},{"path":"procedures-7.html","id":"general-principles-of-endocrine-testing","chapter":"Procedures","heading":"General Principles of Endocrine Testing","text":"Purpose: measure hormone levels assess endocrine gland function diagnosis management endocrine disordersTypes Assays\nImmunoassays: Based antibody-antigen interactions (e.g., ELISA, CLIA, RIA)\nFluorescence Assays: Measure intensity emitted light fluorescently labeled hormones\nLiquid Chromatography-Mass Spectrometry (LC-MS): Separates quantifies hormones based mass--charge ratio\nImmunoassays: Based antibody-antigen interactions (e.g., ELISA, CLIA, RIA)Fluorescence Assays: Measure intensity emitted light fluorescently labeled hormonesLiquid Chromatography-Mass Spectrometry (LC-MS): Separates quantifies hormones based mass--charge ratio","code":""},{"path":"procedures-7.html","id":"general-precautions","chapter":"Procedures","heading":"General Precautions","text":"Patient Preparation\nFasting: Required tests minimize effect food intake hormone levels\nMedications: drugs can interfere hormone tests; physician advise whether withhold medications\nTiming: Specimen collection timed appropriately due diurnal variations pulsatile secretion hormones\nStress: Minimize patient stress specimen collection, stress can affect hormone levels\nMenstrual Cycle: women, phase menstrual cycle can affect sex hormone levels; specimens collected specified phase\nFasting: Required tests minimize effect food intake hormone levelsMedications: drugs can interfere hormone tests; physician advise whether withhold medicationsTiming: Specimen collection timed appropriately due diurnal variations pulsatile secretion hormonesStress: Minimize patient stress specimen collection, stress can affect hormone levelsMenstrual Cycle: women, phase menstrual cycle can affect sex hormone levels; specimens collected specified phaseSpecimen Collection\nUse appropriate collection tubes hormone test\nFollow correct order draw collecting multiple tubes prevent cross-contamination\nUse proper venipuncture technique minimize hemolysis contamination\nLabel specimens immediately accurately prevent misidentification\nCollect correct volume blood ensure adequate sample testing\nUse appropriate collection tubes hormone testFollow correct order draw collecting multiple tubes prevent cross-contaminationUse proper venipuncture technique minimize hemolysis contaminationLabel specimens immediately accurately prevent misidentificationCollect correct volume blood ensure adequate sample testingSpecimen Processing\nCentrifuge specimens promptly collection separate serum plasma cells\nSeparate serum plasma cells within specified time frame prevent hormone degradation\nAliquot specimens appropriate containers prevent contamination allow multiple tests\nStore specimens appropriate temperature preserve hormone stability\nThaw specimens properly testing prevent degradation hormones\nCentrifuge specimens promptly collection separate serum plasma cellsSeparate serum plasma cells within specified time frame prevent hormone degradationAliquot specimens appropriate containers prevent contamination allow multiple testsStore specimens appropriate temperature preserve hormone stabilityThaw specimens properly testing prevent degradation hormones","code":""},{"path":"procedures-7.html","id":"troubleshooting-14","chapter":"Procedures","heading":"Troubleshooting","text":"High Hormone Results\nPre-analytical: Patient fasting, specimen collected wrong time, medication interference, stress collection, improper collection tube, delayed processing, contamination specimen\nAnalytical: Incorrect calibration, reagent deterioration, interfering substances, cross-reactivity, non-specific binding\nPre-analytical: Patient fasting, specimen collected wrong time, medication interference, stress collection, improper collection tube, delayed processing, contamination specimenAnalytical: Incorrect calibration, reagent deterioration, interfering substances, cross-reactivity, non-specific bindingLow Hormone Results\nPre-analytical: Improper collection tube, delayed processing, improper storage, medication interference\nAnalytical: Incorrect calibration, reagent deterioration, interfering substances, assay drift\nPre-analytical: Improper collection tube, delayed processing, improper storage, medication interferenceAnalytical: Incorrect calibration, reagent deterioration, interfering substances, assay driftInconsistent Results\nPre-analytical: Patient variability, specimen handling errors\nAnalytical: Assay variability, interfering substances, cross-reactivity\nPost-analytical: Transcription errors, reporting errors\nPre-analytical: Patient variability, specimen handling errorsAnalytical: Assay variability, interfering substances, cross-reactivityPost-analytical: Transcription errors, reporting errorsQuality Control Failures\nPre-analytical: QC material improperly stored, QC material expired\nAnalytical: Incorrect calibration, reagent deterioration, instrument malfunction\nAction: Investigate cause failure take corrective action\nPre-analytical: QC material improperly stored, QC material expiredAnalytical: Incorrect calibration, reagent deterioration, instrument malfunctionAction: Investigate cause failure take corrective action","code":""},{"path":"procedures-7.html","id":"interfering-substances-14","chapter":"Procedures","heading":"Interfering Substances","text":"Heterophile Antibodies: Bind assay antibodies, causing falsely high low results; use blocking reagents mitigateBiotin: High levels can interfere biotin-streptavidin assays; ask patients discontinue biotin supplementsHemolysis: Releases intracellular components can interfere hormone assays; avoid hemolysis collection processingLipemia: Turbidity high lipid concentrations can interfere spectrophotometric assays; use lipemia clearing techniquesBilirubin: High bilirubin levels can interfere spectrophotometric assays; use methods less susceptible bilirubin interferenceDrugs: Certain drugs can directly affect hormone levels interfere hormone assays; aware patient’s medication listCross-Reactivity: Assay antibodies may cross-react structurally similar compounds; use highly specific antibodiesNon-Specific Binding: Non-specific binding assay components solid phase can lead inaccurate results; use blocking reagents","code":""},{"path":"procedures-7.html","id":"stimulationsuppression-tests","chapter":"Procedures","heading":"Stimulation/Suppression Tests","text":"Purpose: evaluate functional reserve endocrine gland assess autonomy hormone productionGeneral Procedure\nBaseline sample collection\nAdministration stimulatory suppressive agent\nSerial sample collection\nInterpretation hormone response\nBaseline sample collectionAdministration stimulatory suppressive agentSerial sample collectionInterpretation hormone responseCommon Stimulation Tests\nACTH Stimulation Test (Cosyntropin Test): Assesses adrenal gland function\nInsulin Tolerance Test (ITT): Assesses growth hormone ACTH reserve; requires close medical supervision due risk severe hypoglycemia\nTRH Stimulation Test: Assesses pituitary TSH reserve\nACTH Stimulation Test (Cosyntropin Test): Assesses adrenal gland functionInsulin Tolerance Test (ITT): Assesses growth hormone ACTH reserve; requires close medical supervision due risk severe hypoglycemiaTRH Stimulation Test: Assesses pituitary TSH reserveCommon Suppression Tests\nDexamethasone Suppression Test (DST): Diagnoses Cushing’s syndrome differentiates causes\nOral Glucose Suppression Test: Diagnoses acromegaly\nDexamethasone Suppression Test (DST): Diagnoses Cushing’s syndrome differentiates causesOral Glucose Suppression Test: Diagnoses acromegalyGeneral Precautions\nPatient Selection: Ensure patient appropriate candidate contraindications\nMedication Review: Review patient’s medication list\nInformed Consent: Obtain informed consent patient\nAdverse Reactions: prepared manage potential adverse reactions\nStandardized Procedures: Follow standardized procedures test administration, sample collection, hormone measurement\nQuality Control: Implement rigorous quality control procedures\nReference Ranges: Use appropriate reference ranges\nClinical Correlation: Interpret test results context patient’s clinical presentation\nPatient Selection: Ensure patient appropriate candidate contraindicationsMedication Review: Review patient’s medication listInformed Consent: Obtain informed consent patientAdverse Reactions: prepared manage potential adverse reactionsStandardized Procedures: Follow standardized procedures test administration, sample collection, hormone measurementQuality Control: Implement rigorous quality control proceduresReference Ranges: Use appropriate reference rangesClinical Correlation: Interpret test results context patient’s clinical presentation","code":""},{"path":"procedures-7.html","id":"key-terms-58","chapter":"Procedures","heading":"Key Terms","text":"Pre-Analytical: Processes occur sample analyzedAnalytical: Processes involved analyzing samplePost-Analytical: Processes occur sample analyzedInterfering Substance: substance affects accuracy testHeterophile Antibodies: Antibodies bind multiple antigensCross-Reactivity: ability antibody bind multiple antigensStimulation Test: test used assess hormone deficiency stimulating hormone releaseSuppression Test: test used assess hormone excess suppressing hormone productionDynamic Testing: Assessing endocrine function measuring response challengeBaseline Sample: blood sample collected prior administration stimulatory suppressive agentReference Range: range values found healthy individuals","code":""},{"path":"principles-7.html","id":"principles-7","chapter":"Principles","heading":"Principles","text":"Understanding analytical principles behind endocrinology laboratory tests critical ensuring accurate reliable results. Fluorescence immunoassay techniques commonly used","code":""},{"path":"principles-7.html","id":"fluorescence-assays","chapter":"Principles","heading":"Fluorescence Assays","text":"Principle\nFluorescence: phenomenon molecule (fluorophore) absorbs light specific wavelength (excitation wavelength) emits light longer wavelength (emission wavelength)\nintensity emitted light directly proportional concentration fluorophore\nFluorescence assays highly sensitive specific, making useful measuring low concentrations hormones\nFluorescence: phenomenon molecule (fluorophore) absorbs light specific wavelength (excitation wavelength) emits light longer wavelength (emission wavelength)intensity emitted light directly proportional concentration fluorophoreFluorescence assays highly sensitive specific, making useful measuring low concentrations hormonesComponents\nLight Source: Provides excitation light (e.g., xenon lamp, laser)\nExcitation Filter: Selects excitation wavelength\nSample: Contains hormone measured, labeled fluorophore\nEmission Filter: Selects emission wavelength\nDetector: Measures intensity emitted light (e.g., photomultiplier tube, photodiode)\nLight Source: Provides excitation light (e.g., xenon lamp, laser)Excitation Filter: Selects excitation wavelengthSample: Contains hormone measured, labeled fluorophoreEmission Filter: Selects emission wavelengthDetector: Measures intensity emitted light (e.g., photomultiplier tube, photodiode)Types Fluorescence Assays\nDirect Fluorescence Assay\nhormone labeled fluorophore\nintensity emitted light measured directly\n\nIndirect Fluorescence Assay\nsecondary reagent labeled fluorophore binds hormone\nintensity emitted light measured indirectly\n\nFluorescence Polarization Immunoassay (FPIA)\nBased change polarization emitted light\nSmall fluorescently labeled hormone molecules emit light rapid depolarization\nlabeled hormone binds antibodies, resulting complex rotates slowly, emitting light increased polarization\ndegree polarization inversely proportional concentration hormone\n\nTime-Resolved Fluorescence Immunoassay (TR-FIA)\nUses lanthanide chelates fluorophores\nLanthanide chelates long emission lifetimes, allowing time-resolved measurements\nBackground fluorescence minimized measuring emission delay period\nTR-FIA highly sensitive specific\n\nDirect Fluorescence Assay\nhormone labeled fluorophore\nintensity emitted light measured directly\nhormone labeled fluorophoreThe intensity emitted light measured directlyIndirect Fluorescence Assay\nsecondary reagent labeled fluorophore binds hormone\nintensity emitted light measured indirectly\nsecondary reagent labeled fluorophore binds hormoneThe intensity emitted light measured indirectlyFluorescence Polarization Immunoassay (FPIA)\nBased change polarization emitted light\nSmall fluorescently labeled hormone molecules emit light rapid depolarization\nlabeled hormone binds antibodies, resulting complex rotates slowly, emitting light increased polarization\ndegree polarization inversely proportional concentration hormone\nBased change polarization emitted lightSmall fluorescently labeled hormone molecules emit light rapid depolarizationWhen labeled hormone binds antibodies, resulting complex rotates slowly, emitting light increased polarizationThe degree polarization inversely proportional concentration hormoneTime-Resolved Fluorescence Immunoassay (TR-FIA)\nUses lanthanide chelates fluorophores\nLanthanide chelates long emission lifetimes, allowing time-resolved measurements\nBackground fluorescence minimized measuring emission delay period\nTR-FIA highly sensitive specific\nUses lanthanide chelates fluorophoresLanthanide chelates long emission lifetimes, allowing time-resolved measurementsBackground fluorescence minimized measuring emission delay periodTR-FIA highly sensitive specificApplications Endocrinology\nThyroid Hormones: Measurement T3 T4\nSteroid Hormones: Measurement cortisol, estradiol, testosterone\nPeptide Hormones: Measurement insulin growth hormone\nThyroid Hormones: Measurement T3 T4Steroid Hormones: Measurement cortisol, estradiol, testosteronePeptide Hormones: Measurement insulin growth hormoneAdvantages\nHigh sensitivity\nHigh specificity\nRelatively simple instrumentation\nWide range applications\nHigh sensitivityHigh specificityRelatively simple instrumentationWide range applicationsDisadvantages\nSusceptible interference fluorescent compounds sample (autofluorescence)\nPhotobleaching fluorophore\nQuenching fluorescence molecules\nSusceptible interference fluorescent compounds sample (autofluorescence)Photobleaching fluorophoreQuenching fluorescence molecules","code":""},{"path":"principles-7.html","id":"immunoassays","chapter":"Principles","heading":"Immunoassays","text":"Principle\nImmunoassays: based specific binding antibodies antigens (haptens)\nhormone measured acts antigen\namount hormone determined measuring amount antibody-antigen complex formed\n\nImmunoassays: based specific binding antibodies antigens (haptens)\nhormone measured acts antigen\namount hormone determined measuring amount antibody-antigen complex formed\nhormone measured acts antigenThe amount hormone determined measuring amount antibody-antigen complex formedComponents\nAntibody: protein produced immune system binds specific antigen\nAntigen: hormone measured\nLabel: molecule attached antibody antigen allow detection\nDetection System: Measures amount label bound antibody-antigen complex\nAntibody: protein produced immune system binds specific antigenAntigen: hormone measuredLabel: molecule attached antibody antigen allow detectionDetection System: Measures amount label bound antibody-antigen complexTypes Immunoassays\nCompetitive Immunoassay\nUnlabeled hormone sample competes labeled hormone binding limited number antibodies\namount labeled hormone bound antibody inversely proportional concentration unlabeled hormone sample\nApplications: Measurement small hormones, steroid hormones thyroid hormones\n\nNon-Competitive Immunoassay (Sandwich Immunoassay)\nTwo antibodies used: capture antibody detection antibody\ncapture antibody binds hormone sample\ndetection antibody, labeled, binds different epitope hormone\namount labeled antibody bound hormone directly proportional concentration hormone sample\nApplications: Measurement large hormones, peptide hormones protein hormones\n\nEnzyme-Linked Immunosorbent Assay (ELISA)\ntype immunoassay uses enzyme label\nenzyme converts substrate detectable product, colored compound\nApplications: Measurement wide range hormones\n\nChemiluminescent Immunoassay (CLIA)\ntype immunoassay uses chemiluminescent compound label\nchemiluminescent compound emits light undergoes chemical reaction\namount light emitted proportional concentration hormone\nApplications: Measurement hormones requiring high sensitivity\n\nRadioimmunoassay (RIA)\ntype immunoassay uses radioactive isotope label\namount radioactivity measured determine concentration hormone\nApplications: Historically used many hormones, now less common due safety concerns regulatory requirements\n\nCompetitive Immunoassay\nUnlabeled hormone sample competes labeled hormone binding limited number antibodies\namount labeled hormone bound antibody inversely proportional concentration unlabeled hormone sample\nApplications: Measurement small hormones, steroid hormones thyroid hormones\nUnlabeled hormone sample competes labeled hormone binding limited number antibodiesThe amount labeled hormone bound antibody inversely proportional concentration unlabeled hormone sampleApplications: Measurement small hormones, steroid hormones thyroid hormonesNon-Competitive Immunoassay (Sandwich Immunoassay)\nTwo antibodies used: capture antibody detection antibody\ncapture antibody binds hormone sample\ndetection antibody, labeled, binds different epitope hormone\namount labeled antibody bound hormone directly proportional concentration hormone sample\nApplications: Measurement large hormones, peptide hormones protein hormones\nTwo antibodies used: capture antibody detection antibodyThe capture antibody binds hormone sampleThe detection antibody, labeled, binds different epitope hormoneThe amount labeled antibody bound hormone directly proportional concentration hormone sampleApplications: Measurement large hormones, peptide hormones protein hormonesEnzyme-Linked Immunosorbent Assay (ELISA)\ntype immunoassay uses enzyme label\nenzyme converts substrate detectable product, colored compound\nApplications: Measurement wide range hormones\ntype immunoassay uses enzyme labelThe enzyme converts substrate detectable product, colored compoundApplications: Measurement wide range hormonesChemiluminescent Immunoassay (CLIA)\ntype immunoassay uses chemiluminescent compound label\nchemiluminescent compound emits light undergoes chemical reaction\namount light emitted proportional concentration hormone\nApplications: Measurement hormones requiring high sensitivity\ntype immunoassay uses chemiluminescent compound labelThe chemiluminescent compound emits light undergoes chemical reactionThe amount light emitted proportional concentration hormoneApplications: Measurement hormones requiring high sensitivityRadioimmunoassay (RIA)\ntype immunoassay uses radioactive isotope label\namount radioactivity measured determine concentration hormone\nApplications: Historically used many hormones, now less common due safety concerns regulatory requirements\ntype immunoassay uses radioactive isotope labelThe amount radioactivity measured determine concentration hormoneApplications: Historically used many hormones, now less common due safety concerns regulatory requirementsApplications Endocrinology\nThyroid Hormones: Measurement T3, T4, TSH\nSteroid Hormones: Measurement cortisol, estradiol, testosterone, progesterone\nPeptide Hormones: Measurement insulin, growth hormone, prolactin, FSH, LH, ACTH, PTH, hCG\nThyroid Hormones: Measurement T3, T4, TSHSteroid Hormones: Measurement cortisol, estradiol, testosterone, progesteronePeptide Hormones: Measurement insulin, growth hormone, prolactin, FSH, LH, ACTH, PTH, hCGAdvantages\nHigh sensitivity\nHigh specificity\nWide range applications\nHigh sensitivityHigh specificityWide range applicationsDisadvantages\nSusceptible interference heterophile antibodies factors\nCross-reactivity structurally similar compounds\nRequirement specific antibodies\nSusceptible interference heterophile antibodies factorsCross-reactivity structurally similar compoundsRequirement specific antibodies","code":""},{"path":"principles-7.html","id":"comparison-of-fluorescence-and-immunoassay-techniques","chapter":"Principles","heading":"Comparison of Fluorescence and Immunoassay Techniques","text":"","code":""},{"path":"principles-7.html","id":"key-terms-59","chapter":"Principles","heading":"Key Terms","text":"Fluorescence: Emission light molecule absorbing light specific wavelengthFluorophore: molecule emits fluorescenceImmunoassay: assay based specific binding antibodies antigensAntibody: protein produced immune system binds specific antigenAntigen: molecule binds antibodyCompetitive Immunoassay: immunoassay unlabeled antigen competes labeled antigen antibody bindingNon-Competitive Immunoassay: immunoassay labeled antibody binds antigenEnzyme-Linked Immunosorbent Assay (ELISA): immunoassay uses enzyme labelChemiluminescent Immunoassay (CLIA): immunoassay uses chemiluminescent compound labelRadioimmunoassay (RIA): immunoassay uses radioactive isotope labelHeterophile Antibodies: Antibodies bind multiple antigensCross-Reactivity: ability antibody bind multiple antigensEpitope: specific region antigen recognized antibodyHomogeneous Assay: immunoassay separation bound unbound reactants requiredHeterogeneous Assay: immunoassay separation bound unbound reactants requiredPolarization: alignment electric field vector light wavesQuenching: process decreases fluorescence intensity fluorophorePhotobleaching: destruction fluorophore lightLanthanide: rare earth element exhibits long-lived fluorescence","code":""},{"path":"precautions-2.html","id":"precautions-2","chapter":"Precautions","heading":"Precautions","text":"","code":""},{"path":"precautions-2.html","id":"special-precautions-11","chapter":"Precautions","heading":"Special Precautions","text":"Patient Preparation\nFasting: hormone tests require patients fast specified period (e.g., 8-12 hours) specimen collection\nRationale: Fasting minimizes effects food intake hormone levels\nExamples: Insulin, glucose, lipid profiles\n\nMedications: Certain medications can interfere hormone tests\nRationale: Medications can affect hormone synthesis, secretion, metabolism, receptor binding\nExamples\nOral contraceptives: Affect sex hormone levels\nCorticosteroids: Affect cortisol levels\nThyroid medications: Affect thyroid hormone levels\n\nAction: physician advise patient whether withhold medications prior testing\n\nTiming: timing specimen collection crucial hormone tests due diurnal variations pulsatile secretion\nRationale: Hormone levels can fluctuate throughout day\nExamples\nCortisol: Highest morning, lowest night\nACTH: Highest morning, lowest night\nGrowth hormone: Secreted pulses\n\nAction: Collect specimens specified time ensure accurate results\n\nStress: Stress can affect hormone levels\nRationale: Stress increases release cortisol, catecholamines, hormones\nAction: Minimize patient stress specimen collection\n\nMenstrual Cycle: women, phase menstrual cycle can affect sex hormone levels\nRationale: Estrogen progesterone levels vary throughout menstrual cycle\nAction: Collect specimens specified phase menstrual cycle\n\nFasting: hormone tests require patients fast specified period (e.g., 8-12 hours) specimen collection\nRationale: Fasting minimizes effects food intake hormone levels\nExamples: Insulin, glucose, lipid profiles\nRationale: Fasting minimizes effects food intake hormone levelsExamples: Insulin, glucose, lipid profilesMedications: Certain medications can interfere hormone tests\nRationale: Medications can affect hormone synthesis, secretion, metabolism, receptor binding\nExamples\nOral contraceptives: Affect sex hormone levels\nCorticosteroids: Affect cortisol levels\nThyroid medications: Affect thyroid hormone levels\n\nAction: physician advise patient whether withhold medications prior testing\nRationale: Medications can affect hormone synthesis, secretion, metabolism, receptor bindingExamples\nOral contraceptives: Affect sex hormone levels\nCorticosteroids: Affect cortisol levels\nThyroid medications: Affect thyroid hormone levels\nOral contraceptives: Affect sex hormone levelsCorticosteroids: Affect cortisol levelsThyroid medications: Affect thyroid hormone levelsAction: physician advise patient whether withhold medications prior testingTiming: timing specimen collection crucial hormone tests due diurnal variations pulsatile secretion\nRationale: Hormone levels can fluctuate throughout day\nExamples\nCortisol: Highest morning, lowest night\nACTH: Highest morning, lowest night\nGrowth hormone: Secreted pulses\n\nAction: Collect specimens specified time ensure accurate results\nRationale: Hormone levels can fluctuate throughout dayExamples\nCortisol: Highest morning, lowest night\nACTH: Highest morning, lowest night\nGrowth hormone: Secreted pulses\nCortisol: Highest morning, lowest nightACTH: Highest morning, lowest nightGrowth hormone: Secreted pulsesAction: Collect specimens specified time ensure accurate resultsStress: Stress can affect hormone levels\nRationale: Stress increases release cortisol, catecholamines, hormones\nAction: Minimize patient stress specimen collection\nRationale: Stress increases release cortisol, catecholamines, hormonesAction: Minimize patient stress specimen collectionMenstrual Cycle: women, phase menstrual cycle can affect sex hormone levels\nRationale: Estrogen progesterone levels vary throughout menstrual cycle\nAction: Collect specimens specified phase menstrual cycle\nRationale: Estrogen progesterone levels vary throughout menstrual cycleAction: Collect specimens specified phase menstrual cycle","code":""},{"path":"precautions-2.html","id":"specimen-collection-7","chapter":"Precautions","heading":"Specimen Collection","text":"Collection Tubes\nUse appropriate collection tubes hormone test\nRationale: Different tubes contain different anticoagulants additives can affect hormone stability assay performance\nExamples\nSerum separator tubes (SST): Commonly used many hormone tests\nEDTA tubes: Used ACTH, renin\nHeparin tubes: Used peptide hormones\n\n\nFollow manufacturer’s instructions tube selection\nUse appropriate collection tubes hormone test\nRationale: Different tubes contain different anticoagulants additives can affect hormone stability assay performance\nExamples\nSerum separator tubes (SST): Commonly used many hormone tests\nEDTA tubes: Used ACTH, renin\nHeparin tubes: Used peptide hormones\n\nRationale: Different tubes contain different anticoagulants additives can affect hormone stability assay performanceExamples\nSerum separator tubes (SST): Commonly used many hormone tests\nEDTA tubes: Used ACTH, renin\nHeparin tubes: Used peptide hormones\nSerum separator tubes (SST): Commonly used many hormone testsEDTA tubes: Used ACTH, reninHeparin tubes: Used peptide hormonesFollow manufacturer’s instructions tube selectionOrder Draw\nFollow correct order draw collecting multiple tubes\nRationale: Prevents cross-contamination tube additives\nAction: Consult CLSI guidelines correct order draw\n\nFollow correct order draw collecting multiple tubes\nRationale: Prevents cross-contamination tube additives\nAction: Consult CLSI guidelines correct order draw\nRationale: Prevents cross-contamination tube additivesAction: Consult CLSI guidelines correct order drawTechnique\nUse proper venipuncture technique\nRationale: Minimizes hemolysis contamination\nAction: Avoid prolonged tourniquet time use gentle technique\n\nUse proper venipuncture technique\nRationale: Minimizes hemolysis contamination\nAction: Avoid prolonged tourniquet time use gentle technique\nRationale: Minimizes hemolysis contaminationAction: Avoid prolonged tourniquet time use gentle techniqueLabeling\nLabel specimens immediately accurately\nRationale: Prevents misidentification errors\nAction: Use two patient identifiers (e.g., name date birth)\n\nLabel specimens immediately accurately\nRationale: Prevents misidentification errors\nAction: Use two patient identifiers (e.g., name date birth)\nRationale: Prevents misidentification errorsAction: Use two patient identifiers (e.g., name date birth)Volume\nCollect correct volume blood\nRationale: Insufficient volume can affect assay performance\nAction: Follow manufacturer’s instructions minimum volume requirements\n\nCollect correct volume blood\nRationale: Insufficient volume can affect assay performance\nAction: Follow manufacturer’s instructions minimum volume requirements\nRationale: Insufficient volume can affect assay performanceAction: Follow manufacturer’s instructions minimum volume requirements","code":""},{"path":"precautions-2.html","id":"specimen-processing-1","chapter":"Precautions","heading":"Specimen Processing","text":"Centrifugation\nCentrifuge specimens promptly collection\nRationale: Separates serum plasma cells\nAction: Follow manufacturer’s instructions centrifugation speed time\n\nCentrifuge specimens promptly collection\nRationale: Separates serum plasma cells\nAction: Follow manufacturer’s instructions centrifugation speed time\nRationale: Separates serum plasma cellsAction: Follow manufacturer’s instructions centrifugation speed timeSeparation\nSeparate serum plasma cells within specified time frame\nRationale: Prevents hemolysis degradation hormones\nAction: Follow manufacturer’s instructions separation time\n\nSeparate serum plasma cells within specified time frame\nRationale: Prevents hemolysis degradation hormones\nAction: Follow manufacturer’s instructions separation time\nRationale: Prevents hemolysis degradation hormonesAction: Follow manufacturer’s instructions separation timeAliquotting\nAliquot specimens appropriate containers\nRationale: Prevents contamination allows multiple tests\nAction: Use clean, dry containers\n\nAliquot specimens appropriate containers\nRationale: Prevents contamination allows multiple tests\nAction: Use clean, dry containers\nRationale: Prevents contamination allows multiple testsAction: Use clean, dry containersStorage\nStore specimens appropriate temperature\nRationale: Preserves hormone stability\nExamples\nRefrigeration (2-8°C): short-term storage\nFreezing (-20°C -80°C): long-term storage\n\n\nFollow manufacturer’s instructions storage conditions\nStore specimens appropriate temperature\nRationale: Preserves hormone stability\nExamples\nRefrigeration (2-8°C): short-term storage\nFreezing (-20°C -80°C): long-term storage\n\nRationale: Preserves hormone stabilityExamples\nRefrigeration (2-8°C): short-term storage\nFreezing (-20°C -80°C): long-term storage\nRefrigeration (2-8°C): short-term storageFreezing (-20°C -80°C): long-term storageFollow manufacturer’s instructions storage conditionsThawing\nThaw specimens properly testing\nRationale: Prevents degradation hormones\nAction: Thaw room temperature refrigerator, mix gently\n\nThaw specimens properly testing\nRationale: Prevents degradation hormones\nAction: Thaw room temperature refrigerator, mix gently\nRationale: Prevents degradation hormonesAction: Thaw room temperature refrigerator, mix gently","code":""},{"path":"precautions-2.html","id":"troubleshooting-15","chapter":"Precautions","heading":"Troubleshooting","text":"High Hormone Results\nPre-analytical\nPatient fasting\nSpecimen collected wrong time\nMedication interference\nStress collection\nImproper collection tube\nDelayed processing\nContamination specimen\n\nAnalytical\nIncorrect calibration\nReagent deterioration\nInterfering substances\nCross-reactivity\nNon-specific binding\n\nPre-analytical\nPatient fasting\nSpecimen collected wrong time\nMedication interference\nStress collection\nImproper collection tube\nDelayed processing\nContamination specimen\nPatient fastingSpecimen collected wrong timeMedication interferenceStress collectionImproper collection tubeDelayed processingContamination specimenAnalytical\nIncorrect calibration\nReagent deterioration\nInterfering substances\nCross-reactivity\nNon-specific binding\nIncorrect calibrationReagent deteriorationInterfering substancesCross-reactivityNon-specific bindingLow Hormone Results\nPre-analytical\nImproper collection tube\nDelayed processing\nImproper storage\nMedication interference\n\nAnalytical\nIncorrect calibration\nReagent deterioration\nInterfering substances\nAssay drift\n\nPre-analytical\nImproper collection tube\nDelayed processing\nImproper storage\nMedication interference\nImproper collection tubeDelayed processingImproper storageMedication interferenceAnalytical\nIncorrect calibration\nReagent deterioration\nInterfering substances\nAssay drift\nIncorrect calibrationReagent deteriorationInterfering substancesAssay driftInconsistent Results\nPre-analytical\nPatient variability\nSpecimen handling errors\n\nAnalytical\nAssay variability\nInterfering substances\nCross-reactivity\n\nPost-analytical\nTranscription errors\nReporting errors\n\nPre-analytical\nPatient variability\nSpecimen handling errors\nPatient variabilitySpecimen handling errorsAnalytical\nAssay variability\nInterfering substances\nCross-reactivity\nAssay variabilityInterfering substancesCross-reactivityPost-analytical\nTranscription errors\nReporting errors\nTranscription errorsReporting errorsQuality Control Failures\nPre-analytical\nQC material improperly stored\nQC material expired\n\nAnalytical\nIncorrect calibration\nReagent deterioration\nInstrument malfunction\n\nAction: Investigate cause failure take corrective action\nPre-analytical\nQC material improperly stored\nQC material expired\nQC material improperly storedQC material expiredAnalytical\nIncorrect calibration\nReagent deterioration\nInstrument malfunction\nIncorrect calibrationReagent deteriorationInstrument malfunctionAction: Investigate cause failure take corrective action","code":""},{"path":"precautions-2.html","id":"interfering-substances-15","chapter":"Precautions","heading":"Interfering Substances","text":"Heterophile Antibodies\nInterference: Bind assay antibodies, causing falsely high low results\nMechanism: Non-specific binding assay components\nMitigation: Use blocking reagents heterophile antibody blocking tubes\nInterference: Bind assay antibodies, causing falsely high low resultsMechanism: Non-specific binding assay componentsMitigation: Use blocking reagents heterophile antibody blocking tubesBiotin\nInterference: High levels biotin can interfere biotin-streptavidin assays, causing falsely high low results\nMechanism: Biotin competes analyte binding streptavidin\nMitigation: Ask patients discontinue biotin supplements several days testing\nInterference: High levels biotin can interfere biotin-streptavidin assays, causing falsely high low resultsMechanism: Biotin competes analyte binding streptavidinMitigation: Ask patients discontinue biotin supplements several days testingHemolysis\nInterference: Releases intracellular components can interfere hormone assays\nMechanism: Interferes spectrophotometric immunoassay measurements\nMitigation: Avoid hemolysis collection processing\nInterference: Releases intracellular components can interfere hormone assaysMechanism: Interferes spectrophotometric immunoassay measurementsMitigation: Avoid hemolysis collection processingLipemia\nInterference: Turbidity high lipid concentrations can interfere spectrophotometric assays\nMechanism: Lipids scatter light, leading inaccurate absorbance measurements\nMitigation: Use lipemia clearing techniques consider methods less affected turbidity\nInterference: Turbidity high lipid concentrations can interfere spectrophotometric assaysMechanism: Lipids scatter light, leading inaccurate absorbance measurementsMitigation: Use lipemia clearing techniques consider methods less affected turbidityBilirubin\nInterference: High bilirubin levels can interfere spectrophotometric assays\nMechanism: Bilirubin absorbs light similar wavelengths, affecting absorbance readings\nMitigation: Use methods less susceptible bilirubin interference employ bilirubin correction techniques\nInterference: High bilirubin levels can interfere spectrophotometric assaysMechanism: Bilirubin absorbs light similar wavelengths, affecting absorbance readingsMitigation: Use methods less susceptible bilirubin interference employ bilirubin correction techniquesDrugs\nInterference: Certain drugs can directly affect hormone levels interfere hormone assays\nExamples\nOral contraceptives: Affect sex hormone levels\nCorticosteroids: Affect cortisol levels\nThyroid medications: Affect thyroid hormone levels\n\nMitigation: aware patient’s medication list\nInterference: Certain drugs can directly affect hormone levels interfere hormone assaysExamples\nOral contraceptives: Affect sex hormone levels\nCorticosteroids: Affect cortisol levels\nThyroid medications: Affect thyroid hormone levels\nOral contraceptives: Affect sex hormone levelsCorticosteroids: Affect cortisol levelsThyroid medications: Affect thyroid hormone levelsMitigation: aware patient’s medication listCross-Reactivity\nInterference: Assay antibodies may cross-react structurally similar compounds, leading inaccurate results\nMechanism: Antibodies bind unintended targets\nMitigation: Use highly specific antibodies aware potential cross-reactants\nInterference: Assay antibodies may cross-react structurally similar compounds, leading inaccurate resultsMechanism: Antibodies bind unintended targetsMitigation: Use highly specific antibodies aware potential cross-reactantsNon-Specific Binding\nInterference: Non-specific binding assay components solid phase can lead inaccurate results\nMechanism: Non-specific interactions assay components\nMitigation: Use blocking reagents optimize assay conditions\nInterference: Non-specific binding assay components solid phase can lead inaccurate resultsMechanism: Non-specific interactions assay componentsMitigation: Use blocking reagents optimize assay conditions","code":""},{"path":"precautions-2.html","id":"key-terms-60","chapter":"Precautions","heading":"Key Terms","text":"Pre-Analytical: Processes occur sample analyzedAnalytical: Processes involved analyzing samplePost-Analytical: Processes occur sample analyzedInterfering Substance: substance affects accuracy testHeterophile Antibodies: Antibodies bind multiple antigensCross-Reactivity: ability antibody bind multiple antigensHemolysis: breakdown red blood cellsLipemia: presence excess lipids bloodCalibration: Adjusting instrument ensure accurate readingsQuality Control: Samples used monitor accuracy precision test","code":""},{"path":"stimulationsuppression.html","id":"stimulationsuppression","chapter":"Stimulation/Suppression","heading":"Stimulation/Suppression","text":"Dynamic endocrine testing, stimulation suppression, helps assess gland function challenging normal feedback loops observing hormonal response","code":""},{"path":"stimulationsuppression.html","id":"principles-of-stimulationsuppression-testing","chapter":"Stimulation/Suppression","heading":"Principles of Stimulation/Suppression Testing","text":"Purpose: evaluate functional reserve endocrine gland assess autonomy hormone productionDynamic Assessment: Unlike static hormone measurements, tests measure gland’s response challengeTypes Tests\nStimulation Tests: Used assess hormone deficiency stimulating hormone release measuring gland’s capacity respond\nSuppression Tests: Used assess hormone excess suppressing hormone production measuring gland’s ability inhibited\nStimulation Tests: Used assess hormone deficiency stimulating hormone release measuring gland’s capacity respondSuppression Tests: Used assess hormone excess suppressing hormone production measuring gland’s ability inhibitedGeneral Procedure\nBaseline Sample Collection: One baseline blood samples collected measure initial hormone levels\nAdministration Stimulatory Suppressive Agent: specific agent administered stimulate suppress hormone production\nSerial Sample Collection: Blood samples collected specified intervals agent administered monitor hormone response\nInterpretation: Hormone levels measured compared established reference ranges determine endocrine gland functioning normally\nBaseline Sample Collection: One baseline blood samples collected measure initial hormone levelsAdministration Stimulatory Suppressive Agent: specific agent administered stimulate suppress hormone productionSerial Sample Collection: Blood samples collected specified intervals agent administered monitor hormone responseInterpretation: Hormone levels measured compared established reference ranges determine endocrine gland functioning normally","code":""},{"path":"stimulationsuppression.html","id":"common-stimulation-tests","chapter":"Stimulation/Suppression","heading":"Common Stimulation Tests","text":"","code":""},{"path":"stimulationsuppression.html","id":"acth-stimulation-test-cosyntropin-test","chapter":"Stimulation/Suppression","heading":"ACTH Stimulation Test (Cosyntropin Test)","text":"Purpose: assess adrenal gland function diagnose adrenal insufficiencyPrinciple: Synthetic ACTH (cosyntropin) administered stimulate cortisol production adrenal glandsProcedure\nBaseline cortisol level measured\nCosyntropin (250 μg) administered intravenously intramuscularly\nCortisol levels measured 30 60 minutes post-injection\nBaseline cortisol level measuredCosyntropin (250 μg) administered intravenously intramuscularlyCortisol levels measured 30 60 minutes post-injectionInterpretation\nNormal Response: Cortisol level increases least 20 μg/dL baseline reaches peak value least 20 μg/dL\nPrimary Adrenal Insufficiency: Minimal increase cortisol levels, indicating adrenal gland dysfunction\nSecondary Adrenal Insufficiency: Delayed subnormal response, indicating pituitary dysfunction\nNormal Response: Cortisol level increases least 20 μg/dL baseline reaches peak value least 20 μg/dLPrimary Adrenal Insufficiency: Minimal increase cortisol levels, indicating adrenal gland dysfunctionSecondary Adrenal Insufficiency: Delayed subnormal response, indicating pituitary dysfunctionSpecial Considerations\nPatient glucocorticoid medications prior test\nFalse-positive results can occur patients acute illness stress\nPatient glucocorticoid medications prior testFalse-positive results can occur patients acute illness stress","code":""},{"path":"stimulationsuppression.html","id":"insulin-tolerance-test-itt","chapter":"Stimulation/Suppression","heading":"Insulin Tolerance Test (ITT)","text":"Purpose: assess growth hormone (GH) ACTH reservePrinciple: Insulin-induced hypoglycemia stimulates release GH ACTHProcedure\nBaseline GH cortisol levels measured\nRegular insulin (0.05-0.15 U/kg) administered intravenously induce hypoglycemia\nGH cortisol levels measured 30, 60, 90 minutes post-injection\nBlood glucose levels monitored throughout test ensure adequate hypoglycemia (glucose < 40 mg/dL)\nBaseline GH cortisol levels measuredRegular insulin (0.05-0.15 U/kg) administered intravenously induce hypoglycemiaGH cortisol levels measured 30, 60, 90 minutes post-injectionBlood glucose levels monitored throughout test ensure adequate hypoglycemia (glucose < 40 mg/dL)Interpretation\nNormal GH Response: GH level increases least 5-10 ng/mL\nNormal Cortisol Response: Cortisol level increases least 7 μg/dL baseline reaches peak value least 20 μg/dL\nAbnormal Response: Failure achieve adequate hypoglycemia failure GH /cortisol increase appropriately\nNormal GH Response: GH level increases least 5-10 ng/mLNormal Cortisol Response: Cortisol level increases least 7 μg/dL baseline reaches peak value least 20 μg/dLAbnormal Response: Failure achieve adequate hypoglycemia failure GH /cortisol increase appropriatelySpecial Considerations\nITT contraindicated patients coronary artery disease, seizures, known adrenal insufficiency\nTest performed close medical supervision due risk severe hypoglycemia\nITT contraindicated patients coronary artery disease, seizures, known adrenal insufficiencyTest performed close medical supervision due risk severe hypoglycemia","code":""},{"path":"stimulationsuppression.html","id":"trh-stimulation-test","chapter":"Stimulation/Suppression","heading":"TRH Stimulation Test","text":"Purpose: assess pituitary TSH reserve diagnose thyroid disordersPrinciple: TRH (thyrotropin-releasing hormone) stimulates release TSH pituitary glandProcedure\nBaseline TSH level measured\nTRH (200-500 μg) administered intravenously\nTSH levels measured 30 60 minutes post-injection\nBaseline TSH level measuredTRH (200-500 μg) administered intravenouslyTSH levels measured 30 60 minutes post-injectionInterpretation\nNormal Response: TSH level increases least 5 μIU/mL baseline\nPrimary Hypothyroidism: Elevated baseline TSH exaggerated response TRH\nSecondary Hypothyroidism: Low normal baseline TSH blunted absent response TRH, indicating pituitary dysfunction\nTertiary Hypothyroidism: Low normal baseline TSH delayed response TRH, indicating hypothalamic dysfunction\nNormal Response: TSH level increases least 5 μIU/mL baselinePrimary Hypothyroidism: Elevated baseline TSH exaggerated response TRHSecondary Hypothyroidism: Low normal baseline TSH blunted absent response TRH, indicating pituitary dysfunctionTertiary Hypothyroidism: Low normal baseline TSH delayed response TRH, indicating hypothalamic dysfunctionSpecial Considerations\nPatient thyroid hormone medications prior test\nCertain medications (e.g., glucocorticoids, dopamine) can affect TSH secretion interfere test results\nPatient thyroid hormone medications prior testCertain medications (e.g., glucocorticoids, dopamine) can affect TSH secretion interfere test results","code":""},{"path":"stimulationsuppression.html","id":"common-suppression-tests","chapter":"Stimulation/Suppression","heading":"Common Suppression Tests","text":"","code":""},{"path":"stimulationsuppression.html","id":"dexamethasone-suppression-test-dst","chapter":"Stimulation/Suppression","heading":"Dexamethasone Suppression Test (DST)","text":"Purpose: diagnose Cushing’s syndrome differentiate causesPrinciple: Dexamethasone, synthetic glucocorticoid, suppresses ACTH production pituitary gland, turn suppresses cortisol production adrenal glandsTypes DST\nLow-Dose DST: Used screen Cushing’s syndrome\nHigh-Dose DST: Used differentiate pituitary-dependent Cushing’s disease ectopic ACTH-secreting tumors\nLow-Dose DST: Used screen Cushing’s syndromeHigh-Dose DST: Used differentiate pituitary-dependent Cushing’s disease ectopic ACTH-secreting tumorsProcedure\nLow-Dose DST\nBaseline cortisol level measured\nDexamethasone (1 mg) administered orally 11 PM\nCortisol level measured 8 following morning\n\nHigh-Dose DST\nBaseline cortisol ACTH levels measured\nDexamethasone (8 mg) administered orally 11 PM\nCortisol ACTH levels measured 8 following morning\n\nLow-Dose DST\nBaseline cortisol level measured\nDexamethasone (1 mg) administered orally 11 PM\nCortisol level measured 8 following morning\nBaseline cortisol level measuredDexamethasone (1 mg) administered orally 11 PMCortisol level measured 8 following morningHigh-Dose DST\nBaseline cortisol ACTH levels measured\nDexamethasone (8 mg) administered orally 11 PM\nCortisol ACTH levels measured 8 following morning\nBaseline cortisol ACTH levels measuredDexamethasone (8 mg) administered orally 11 PMCortisol ACTH levels measured 8 following morningInterpretation\nLow-Dose DST\nNormal Suppression: Cortisol level suppressed < 1.8 μg/dL\nLack Suppression: Cortisol level remains elevated, indicating Cushing’s syndrome\n\nHigh-Dose DST\nPituitary-Dependent Cushing’s Disease: Cortisol level suppressed least 50% baseline\nEctopic ACTH-Secreting Tumor: Cortisol level suppressed\nAdrenal Tumor: Cortisol level suppressed\n\nLow-Dose DST\nNormal Suppression: Cortisol level suppressed < 1.8 μg/dL\nLack Suppression: Cortisol level remains elevated, indicating Cushing’s syndrome\nNormal Suppression: Cortisol level suppressed < 1.8 μg/dLLack Suppression: Cortisol level remains elevated, indicating Cushing’s syndromeHigh-Dose DST\nPituitary-Dependent Cushing’s Disease: Cortisol level suppressed least 50% baseline\nEctopic ACTH-Secreting Tumor: Cortisol level suppressed\nAdrenal Tumor: Cortisol level suppressed\nPituitary-Dependent Cushing’s Disease: Cortisol level suppressed least 50% baselineEctopic ACTH-Secreting Tumor: Cortisol level suppressedAdrenal Tumor: Cortisol level suppressedSpecial Considerations\nCertain medications (e.g., phenytoin, carbamazepine) can increase metabolism dexamethasone interfere test results\nFalse-positive results can occur patients depression, alcoholism, chronic stress\nCertain medications (e.g., phenytoin, carbamazepine) can increase metabolism dexamethasone interfere test resultsFalse-positive results can occur patients depression, alcoholism, chronic stress","code":""},{"path":"stimulationsuppression.html","id":"oral-glucose-suppression-test","chapter":"Stimulation/Suppression","heading":"Oral Glucose Suppression Test","text":"Purpose: diagnose acromegalyPrinciple: Glucose normally suppresses growth hormone (GH) secretionProcedure\nBaseline GH level measured\nPatient drinks standard glucose solution (75 g)\nGH levels measured 30, 60, 90, 120 minutes post-ingestion\nBaseline GH level measuredPatient drinks standard glucose solution (75 g)GH levels measured 30, 60, 90, 120 minutes post-ingestionInterpretation\nNormal Suppression: GH level suppressed < 1 ng/mL\nLack Suppression: GH level remains elevated, indicating autonomous GH secretion characteristic acromegaly\nNormal Suppression: GH level suppressed < 1 ng/mLLack Suppression: GH level remains elevated, indicating autonomous GH secretion characteristic acromegalySpecial Considerations\nCertain medications (e.g., beta-blockers) can interfere test results\nFalse-positive results can occur patients renal failure liver disease\nCertain medications (e.g., beta-blockers) can interfere test resultsFalse-positive results can occur patients renal failure liver disease","code":""},{"path":"stimulationsuppression.html","id":"general-precautions-and-considerations","chapter":"Stimulation/Suppression","heading":"General Precautions and Considerations","text":"Patient Selection: Ensure patient appropriate candidate test contraindicationsMedication Review: Review patient’s medication list determine medications need withheld prior testInformed Consent: Obtain informed consent patient explaining purpose, procedure, potential risks testAdverse Reactions: prepared manage potential adverse reactions stimulatory suppressive agentStandardized Procedures: Follow standardized procedures test administration, sample collection, hormone measurementQuality Control: Implement rigorous quality control procedures ensure accuracy reliability hormone measurementsReference Ranges: Use appropriate reference ranges specific test patient populationClinical Correlation: Interpret test results context patient’s clinical presentation laboratory findings","code":""},{"path":"stimulationsuppression.html","id":"key-terms-61","chapter":"Stimulation/Suppression","heading":"Key Terms","text":"Stimulation Test: test used assess hormone deficiency stimulating hormone releaseSuppression Test: test used assess hormone excess suppressing hormone productionACTH Stimulation Test: test used assess adrenal gland functionInsulin Tolerance Test (ITT): test used assess growth hormone ACTH reserveTRH Stimulation Test: test used assess pituitary TSH reserveDexamethasone Suppression Test (DST): test used diagnose Cushing’s syndromeOral Glucose Suppression Test: test used diagnose acromegalyDynamic Testing: Assessing endocrine function measuring response challengeBaseline Sample: blood sample collected prior administration stimulatory suppressive agentReference Range: range values found healthy individuals","code":""},{"path":"result-interpretation-7.html","id":"result-interpretation-7","chapter":"Result Interpretation","heading":"Result Interpretation","text":"Interpreting endocrine test results requires careful consideration various factors, including patient’s clinical presentation, reference intervals, potential interfering substances","code":""},{"path":"result-interpretation-7.html","id":"general-principles-of-test-result-interpretation","chapter":"Result Interpretation","heading":"General Principles of Test Result Interpretation","text":"Reference Intervals\nUse appropriate reference intervals specific assay patient population\nReference intervals can vary based age, sex, ethnicity, geographic location\nUse appropriate reference intervals specific assay patient populationReference intervals can vary based age, sex, ethnicity, geographic locationClinical Context\nInterpret test results context patient’s clinical history, physical examination findings, laboratory data\nConsider patient’s symptoms, medications, coexisting medical conditions\nInterpret test results context patient’s clinical history, physical examination findings, laboratory dataConsider patient’s symptoms, medications, coexisting medical conditionsMultiple Tests\nOften, single hormone measurement insufficient diagnosis; multiple tests dynamic tests may necessary\nAssess pattern hormone levels rather relying single value\nOften, single hormone measurement insufficient diagnosis; multiple tests dynamic tests may necessaryAssess pattern hormone levels rather relying single valueInterfering Substances\naware potential interfering substances can affect hormone measurements (e.g., heterophile antibodies, biotin, medications)\nConsider repeating test using different method interference suspected\naware potential interfering substances can affect hormone measurements (e.g., heterophile antibodies, biotin, medications)Consider repeating test using different method interference suspectedAssay Limitations\nUnderstand limitations specific assay used, including sensitivity, specificity, potential cross-reactivity\nConsult laboratory manufacturer guidance test interpretation\nUnderstand limitations specific assay used, including sensitivity, specificity, potential cross-reactivityConsult laboratory manufacturer guidance test interpretation","code":""},{"path":"result-interpretation-7.html","id":"pituitary-hormone-interpretation","chapter":"Result Interpretation","heading":"Pituitary Hormone Interpretation","text":"","code":""},{"path":"result-interpretation-7.html","id":"growth-hormone-gh","chapter":"Result Interpretation","heading":"Growth Hormone (GH)","text":"Normal\nBasal GH: < 5 ng/mL (may vary assay)\nSuppression glucose load: < 1 ng/mL\nBasal GH: < 5 ng/mL (may vary assay)Suppression glucose load: < 1 ng/mLElevated GH\nAcromegaly (adults): Enlargement hands, feet, facial features; joint pain; excessive sweating; glucose intolerance\nGigantism (children): Excessive growth height\nPituitary adenoma: Confirmed imaging studies (MRI)\nAcromegaly (adults): Enlargement hands, feet, facial features; joint pain; excessive sweating; glucose intoleranceGigantism (children): Excessive growth heightPituitary adenoma: Confirmed imaging studies (MRI)Suppressed GH\nGrowth hormone deficiency (GHD): Short stature children, fatigue, decreased muscle mass, increased body fat adults\nHypopituitarism: May associated deficiencies pituitary hormones\nEvaluate stimulation testing (e.g., insulin tolerance test)\nGrowth hormone deficiency (GHD): Short stature children, fatigue, decreased muscle mass, increased body fat adultsHypopituitarism: May associated deficiencies pituitary hormonesEvaluate stimulation testing (e.g., insulin tolerance test)","code":""},{"path":"result-interpretation-7.html","id":"adrenocorticotropic-hormone-acth","chapter":"Result Interpretation","heading":"Adrenocorticotropic Hormone (ACTH)","text":"Normal\nMorning ACTH: 10-50 pg/mL (may vary assay)\nMorning ACTH: 10-50 pg/mL (may vary assay)Elevated ACTH\nCushing’s disease: Pituitary adenoma causing excessive ACTH production\nEctopic ACTH syndrome: ACTH-secreting tumor outside pituitary (e.g., small cell lung cancer)\nPrimary adrenal insufficiency: Lack negative feedback cortisol\nCushing’s disease: Pituitary adenoma causing excessive ACTH productionEctopic ACTH syndrome: ACTH-secreting tumor outside pituitary (e.g., small cell lung cancer)Primary adrenal insufficiency: Lack negative feedback cortisolSuppressed ACTH\nSecondary adrenal insufficiency: Pituitary hypothalamic dysfunction\nExogenous glucocorticoid use: Suppression hypothalamic-pituitary-adrenal (HPA) axis\nDifferentiate causes stimulation suppression testing (e.g., dexamethasone suppression test)\nSecondary adrenal insufficiency: Pituitary hypothalamic dysfunctionExogenous glucocorticoid use: Suppression hypothalamic-pituitary-adrenal (HPA) axisDifferentiate causes stimulation suppression testing (e.g., dexamethasone suppression test)","code":""},{"path":"result-interpretation-7.html","id":"thyroid-stimulating-hormone-tsh","chapter":"Result Interpretation","heading":"Thyroid-Stimulating Hormone (TSH)","text":"Normal\nTSH: 0.4-4.0 μIU/mL (may vary assay)\nTSH: 0.4-4.0 μIU/mL (may vary assay)Elevated TSH\nPrimary hypothyroidism: Thyroid gland failure\nHashimoto’s thyroiditis: Autoimmune destruction thyroid gland\nSymptoms: Fatigue, weight gain, cold intolerance, constipation\nPrimary hypothyroidism: Thyroid gland failureHashimoto’s thyroiditis: Autoimmune destruction thyroid glandSymptoms: Fatigue, weight gain, cold intolerance, constipationSuppressed TSH\nHyperthyroidism: Excessive thyroid hormone production\nGraves’ disease: Autoimmune stimulation thyroid gland\nToxic nodular goiter: Overactive thyroid nodules\nSymptoms: Weight loss, anxiety, heat intolerance, palpitations\nCentral hypothyroidism: Pituitary hypothalamic dysfunction\nEvaluate free T4 T3 measurements\nHyperthyroidism: Excessive thyroid hormone productionGraves’ disease: Autoimmune stimulation thyroid glandToxic nodular goiter: Overactive thyroid nodulesSymptoms: Weight loss, anxiety, heat intolerance, palpitationsCentral hypothyroidism: Pituitary hypothalamic dysfunctionEvaluate free T4 T3 measurements","code":""},{"path":"result-interpretation-7.html","id":"prolactin","chapter":"Result Interpretation","heading":"Prolactin","text":"Normal\nProlactin: < 20 ng/mL (may vary assay)\nProlactin: < 20 ng/mL (may vary assay)Elevated Prolactin (Hyperprolactinemia)\nProlactinoma: Pituitary tumor secreting prolactin\nMedications: Antipsychotics, antidepressants, drugs\nPregnancy: Physiological increase prolactin\nHypothyroidism: Elevated TSH can stimulate prolactin secretion\nSymptoms: Galactorrhea (milk production), amenorrhea (absence menstruation), infertility, sexual dysfunction\nProlactinoma: Pituitary tumor secreting prolactinMedications: Antipsychotics, antidepressants, drugsPregnancy: Physiological increase prolactinHypothyroidism: Elevated TSH can stimulate prolactin secretionSymptoms: Galactorrhea (milk production), amenorrhea (absence menstruation), infertility, sexual dysfunctionSuppressed Prolactin\nHypopituitarism: May associated deficiencies pituitary hormones\nRarely clinically significant\nHypopituitarism: May associated deficiencies pituitary hormonesRarely clinically significant","code":""},{"path":"result-interpretation-7.html","id":"luteinizing-hormone-lh-and-follicle-stimulating-hormone-fsh","chapter":"Result Interpretation","heading":"Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH)","text":"Normal\nVaries depending sex menstrual cycle phase women\nVaries depending sex menstrual cycle phase womenElevated LH FSH\nPrimary hypogonadism: Gonadal failure (e.g., Klinefelter syndrome men, Turner syndrome women)\nPolycystic ovary syndrome (PCOS): Elevated LH/FSH ratio\nPrimary hypogonadism: Gonadal failure (e.g., Klinefelter syndrome men, Turner syndrome women)Polycystic ovary syndrome (PCOS): Elevated LH/FSH ratioSuppressed LH FSH\nSecondary hypogonadism: Pituitary hypothalamic dysfunction\nAnabolic steroid use: Suppression hypothalamic-pituitary-gonadal (HPG) axis\nSymptoms: Infertility, sexual dysfunction, decreased secondary sexual characteristics\nSecondary hypogonadism: Pituitary hypothalamic dysfunctionAnabolic steroid use: Suppression hypothalamic-pituitary-gonadal (HPG) axisSymptoms: Infertility, sexual dysfunction, decreased secondary sexual characteristics","code":""},{"path":"result-interpretation-7.html","id":"thyroid-hormone-interpretation","chapter":"Result Interpretation","heading":"Thyroid Hormone Interpretation","text":"","code":""},{"path":"result-interpretation-7.html","id":"free-thyroxine-free-t4","chapter":"Result Interpretation","heading":"Free Thyroxine (Free T4)","text":"Normal\nFree T4: 0.8-1.8 ng/dL (may vary assay)\nFree T4: 0.8-1.8 ng/dL (may vary assay)Elevated Free T4\nHyperthyroidism: Excessive thyroid hormone production\nGraves’ disease: Autoimmune stimulation thyroid gland\nToxic nodular goiter: Overactive thyroid nodules\nHyperthyroidism: Excessive thyroid hormone productionGraves’ disease: Autoimmune stimulation thyroid glandToxic nodular goiter: Overactive thyroid nodulesSuppressed Free T4\nHypothyroidism: Thyroid gland failure\nHashimoto’s thyroiditis: Autoimmune destruction thyroid gland\nCentral hypothyroidism: Pituitary hypothalamic dysfunction\nEvaluate conjunction TSH\nHypothyroidism: Thyroid gland failureHashimoto’s thyroiditis: Autoimmune destruction thyroid glandCentral hypothyroidism: Pituitary hypothalamic dysfunctionEvaluate conjunction TSH","code":""},{"path":"result-interpretation-7.html","id":"free-triiodothyronine-free-t3","chapter":"Result Interpretation","heading":"Free Triiodothyronine (Free T3)","text":"Normal\nFree T3: 2.3-4.2 pg/mL (may vary assay)\nFree T3: 2.3-4.2 pg/mL (may vary assay)Elevated Free T3\nHyperthyroidism: Excessive thyroid hormone production\nT3 toxicosis: Selective elevation T3\nHyperthyroidism: Excessive thyroid hormone productionT3 toxicosis: Selective elevation T3Suppressed Free T3\nHypothyroidism: Thyroid gland failure\nNon-thyroidal illness: Decreased conversion T4 T3\nEvaluate conjunction TSH free T4\nHypothyroidism: Thyroid gland failureNon-thyroidal illness: Decreased conversion T4 T3Evaluate conjunction TSH free T4","code":""},{"path":"result-interpretation-7.html","id":"thyroid-antibodies","chapter":"Result Interpretation","heading":"Thyroid Antibodies","text":"Thyroid Peroxidase Antibody (TPO Ab)\nElevated Hashimoto’s thyroiditis Graves’ disease\nElevated Hashimoto’s thyroiditis Graves’ diseaseThyroglobulin Antibody (Tg Ab)\nElevated Hashimoto’s thyroiditis Graves’ disease\nElevated Hashimoto’s thyroiditis Graves’ diseaseTSH Receptor Antibody (TRAb)\nElevated Graves’ disease\nConfirms diagnosis autoimmune thyroid disease\nElevated Graves’ diseaseConfirms diagnosis autoimmune thyroid disease","code":""},{"path":"result-interpretation-7.html","id":"adrenal-hormone-interpretation","chapter":"Result Interpretation","heading":"Adrenal Hormone Interpretation","text":"","code":""},{"path":"result-interpretation-7.html","id":"cortisol-1","chapter":"Result Interpretation","heading":"Cortisol","text":"Normal\nMorning cortisol: 5-25 μg/dL (may vary assay)\nEvening cortisol: < 5 μg/dL\nMorning cortisol: 5-25 μg/dL (may vary assay)Evening cortisol: < 5 μg/dLElevated Cortisol\nCushing’s syndrome: Excessive cortisol production\nCushing’s disease: Pituitary adenoma causing excessive ACTH production\nEctopic ACTH syndrome: ACTH-secreting tumor outside pituitary\nAdrenal tumor: Cortisol-secreting tumor adrenal gland\nExogenous glucocorticoid use: Iatrogenic Cushing’s syndrome\nEvaluate dexamethasone suppression test ACTH measurement\nCushing’s syndrome: Excessive cortisol productionCushing’s disease: Pituitary adenoma causing excessive ACTH productionEctopic ACTH syndrome: ACTH-secreting tumor outside pituitaryAdrenal tumor: Cortisol-secreting tumor adrenal glandExogenous glucocorticoid use: Iatrogenic Cushing’s syndromeEvaluate dexamethasone suppression test ACTH measurementSuppressed Cortisol\nAdrenal insufficiency: Insufficient cortisol production\nPrimary adrenal insufficiency: Addison’s disease (adrenal gland failure)\nSecondary adrenal insufficiency: Pituitary hypothalamic dysfunction\nEvaluate ACTH stimulation test\nAdrenal insufficiency: Insufficient cortisol productionPrimary adrenal insufficiency: Addison’s disease (adrenal gland failure)Secondary adrenal insufficiency: Pituitary hypothalamic dysfunctionEvaluate ACTH stimulation test","code":""},{"path":"result-interpretation-7.html","id":"aldosterone","chapter":"Result Interpretation","heading":"Aldosterone","text":"Normal\nVaries depending sodium intake posture\nVaries depending sodium intake postureElevated Aldosterone\nPrimary hyperaldosteronism: Aldosterone-secreting tumor adrenal gland (Conn’s syndrome)\nSecondary hyperaldosteronism: Increased renin production due kidney disease heart failure\nHypertension, hypokalemia, metabolic alkalosis\nPrimary hyperaldosteronism: Aldosterone-secreting tumor adrenal gland (Conn’s syndrome)Secondary hyperaldosteronism: Increased renin production due kidney disease heart failureHypertension, hypokalemia, metabolic alkalosisSuppressed Aldosterone\nAdrenal insufficiency: Adrenal gland failure\nCongenital adrenal hyperplasia: Genetic defect cortisol synthesis leading increased androgens decreased aldosterone\nEvaluate conjunction renin measurement\nAdrenal insufficiency: Adrenal gland failureCongenital adrenal hyperplasia: Genetic defect cortisol synthesis leading increased androgens decreased aldosteroneEvaluate conjunction renin measurement","code":""},{"path":"result-interpretation-7.html","id":"catecholamines-epinephrine-norepinephrine-dopamine","chapter":"Result Interpretation","heading":"Catecholamines (Epinephrine, Norepinephrine, Dopamine)","text":"Elevated Catecholamines\nPheochromocytoma: Tumor adrenal medulla produces excessive catecholamines\nSymptoms: Hypertension, palpitations, sweating, headaches\nEvaluate urine metanephrines catecholamines\nPheochromocytoma: Tumor adrenal medulla produces excessive catecholaminesSymptoms: Hypertension, palpitations, sweating, headachesEvaluate urine metanephrines catecholamines","code":""},{"path":"result-interpretation-7.html","id":"parathyroid-hormone-pth-interpretation","chapter":"Result Interpretation","heading":"Parathyroid Hormone (PTH) Interpretation","text":"Normal\nPTH: 10-65 pg/mL (may vary assay)\nPTH: 10-65 pg/mL (may vary assay)Elevated PTH\nPrimary hyperparathyroidism: Parathyroid adenoma hyperplasia causing excessive PTH production hypercalcemia\nSecondary hyperparathyroidism: Increased PTH production due chronic kidney disease vitamin D deficiency\nPrimary hyperparathyroidism: Parathyroid adenoma hyperplasia causing excessive PTH production hypercalcemiaSecondary hyperparathyroidism: Increased PTH production due chronic kidney disease vitamin D deficiencySuppressed PTH\nHypoparathyroidism: Insufficient PTH production leading hypocalcemia\nSurgical removal autoimmune destruction parathyroid glands\nEvaluate conjunction calcium vitamin D measurements\nHypoparathyroidism: Insufficient PTH production leading hypocalcemiaSurgical removal autoimmune destruction parathyroid glandsEvaluate conjunction calcium vitamin D measurements","code":""},{"path":"result-interpretation-7.html","id":"gonadal-hormone-interpretation","chapter":"Result Interpretation","heading":"Gonadal Hormone Interpretation","text":"","code":""},{"path":"result-interpretation-7.html","id":"testosterone","chapter":"Result Interpretation","heading":"Testosterone","text":"Normal\nVaries depending age sex\nAdult males: 300-1000 ng/dL\nAdult females: 15-70 ng/dL\nVaries depending age sexAdult males: 300-1000 ng/dLAdult females: 15-70 ng/dLElevated Testosterone\nPolycystic ovary syndrome (PCOS) women: Hirsutism, acne, menstrual irregularities\nTesticular tumor men: Rare\nCongenital adrenal hyperplasia (CAH): Genetic defect cortisol synthesis\nPolycystic ovary syndrome (PCOS) women: Hirsutism, acne, menstrual irregularitiesTesticular tumor men: RareCongenital adrenal hyperplasia (CAH): Genetic defect cortisol synthesisSuppressed Testosterone\nHypogonadism men: Sexual dysfunction, decreased muscle mass, fatigue\nKlinefelter syndrome: Genetic disorder males (XXY)\nPituitary hypothalamic dysfunction: Secondary hypogonadism\nAnabolic steroid use: Suppression endogenous testosterone production\nHypogonadism men: Sexual dysfunction, decreased muscle mass, fatigueKlinefelter syndrome: Genetic disorder males (XXY)Pituitary hypothalamic dysfunction: Secondary hypogonadismAnabolic steroid use: Suppression endogenous testosterone production","code":""},{"path":"result-interpretation-7.html","id":"estradiol-e2","chapter":"Result Interpretation","heading":"Estradiol (E2)","text":"Normal\nVaries depending sex menstrual cycle phase women\nAdult females: 30-400 pg/mL (varies cycle)\nAdult males: 10-40 pg/mL\nVaries depending sex menstrual cycle phase womenAdult females: 30-400 pg/mL (varies cycle)Adult males: 10-40 pg/mLElevated Estradiol\nOvarian tumor women: Rare\nGynecomastia men: Enlargement breast tissue\nPrecocious puberty: Early onset puberty children\nOvarian tumor women: RareGynecomastia men: Enlargement breast tissuePrecocious puberty: Early onset puberty childrenSuppressed Estradiol\nHypogonadism women: Menopause Turner syndrome\nPituitary hypothalamic dysfunction: Secondary hypogonadism\nSymptoms: Amenorrhea, infertility, osteoporosis\nHypogonadism women: Menopause Turner syndromePituitary hypothalamic dysfunction: Secondary hypogonadismSymptoms: Amenorrhea, infertility, osteoporosis","code":""},{"path":"result-interpretation-7.html","id":"progesterone","chapter":"Result Interpretation","heading":"Progesterone","text":"Normal\nVaries depending menstrual cycle phase pregnancy\nVaries depending menstrual cycle phase pregnancyElevated Progesterone\nPregnancy: Physiological increase\nOvarian cyst tumor: Rare\nPregnancy: Physiological increaseOvarian cyst tumor: RareSuppressed Progesterone\nAnovulation: Failure ovulate\nLuteal phase defect: Inadequate progesterone production ovulation\nAnovulation: Failure ovulateLuteal phase defect: Inadequate progesterone production ovulation","code":""},{"path":"result-interpretation-7.html","id":"other-hormones","chapter":"Result Interpretation","heading":"Other Hormones","text":"","code":""},{"path":"result-interpretation-7.html","id":"insulin-1","chapter":"Result Interpretation","heading":"Insulin","text":"Normal\nFasting insulin: 3-17 μIU/mL (may vary assay)\nFasting insulin: 3-17 μIU/mL (may vary assay)Elevated Insulin\nInsulin resistance: Elevated insulin levels required maintain normal glucose levels\nInsulinoma: Insulin-secreting tumor pancreas\nType 2 diabetes: Early stages\nInsulin resistance: Elevated insulin levels required maintain normal glucose levelsInsulinoma: Insulin-secreting tumor pancreasType 2 diabetes: Early stagesSuppressed Insulin\nType 1 diabetes: Autoimmune destruction pancreatic beta cells\nPancreatic damage removal\nType 1 diabetes: Autoimmune destruction pancreatic beta cellsPancreatic damage removal","code":""},{"path":"result-interpretation-7.html","id":"c-peptide","chapter":"Result Interpretation","heading":"C-Peptide","text":"Normal\nC-peptide: 0.5-2.0 ng/mL (may vary assay)\nC-peptide: 0.5-2.0 ng/mL (may vary assay)Elevated C-Peptide\nInsulinoma: Insulin-secreting tumor pancreas\nInsulin resistance: Elevated insulin production\nType 2 diabetes: Early stages\nInsulinoma: Insulin-secreting tumor pancreasInsulin resistance: Elevated insulin productionType 2 diabetes: Early stagesSuppressed C-Peptide\nType 1 diabetes: Autoimmune destruction pancreatic beta cells\nExogenous insulin administration: Suppression endogenous insulin production\nFactitious hypoglycemia: Intentional insulin administration\nType 1 diabetes: Autoimmune destruction pancreatic beta cellsExogenous insulin administration: Suppression endogenous insulin productionFactitious hypoglycemia: Intentional insulin administration","code":""},{"path":"result-interpretation-7.html","id":"human-chorionic-gonadotropin-hcg","chapter":"Result Interpretation","heading":"Human Chorionic Gonadotropin (hCG)","text":"Normal\nNon-pregnant: < 5 mIU/mL\nPregnancy: Rapidly increases early pregnancy\nNon-pregnant: < 5 mIU/mLPregnancy: Rapidly increases early pregnancyElevated hCG\nPregnancy: Confirms pregnancy\nEctopic pregnancy: Elevated hCG, lower expected gestational age\nGestational trophoblastic disease (e.g., hydatidiform mole): Markedly elevated hCG levels\nTumor marker certain cancers (e.g., testicular cancer)\nPregnancy: Confirms pregnancyEctopic pregnancy: Elevated hCG, lower expected gestational ageGestational trophoblastic disease (e.g., hydatidiform mole): Markedly elevated hCG levelsTumor marker certain cancers (e.g., testicular cancer)Suppressed hCG\nNon-pregnant: Normal\nMiscarriage: Decreasing hCG levels\nNon-pregnant: NormalMiscarriage: Decreasing hCG levels","code":""},{"path":"result-interpretation-7.html","id":"key-terms-62","chapter":"Result Interpretation","heading":"Key Terms","text":"Reference Interval: range values found healthy individualsClinical Context: patient’s clinical history, physical examination findings, laboratory dataInterfering Substance: substance affects accuracy testAssay Limitation: limitations specific assay used, including sensitivity, specificity, potential cross-reactivityHormone Excess: Abnormally high hormone levelsHormone Deficiency: Abnormally low hormone levelsPrimary Endocrine Disorder: disorder originating endocrine gland itselfSecondary Endocrine Disorder: disorder resulting dysfunction pituitary hypothalamusTertiary Endocrine Disorder: disorder resulting dysfunction hypothalamusStimulation Test: test used assess hormone deficiency stimulating hormone releaseSuppression Test: test used assess hormone excess suppressing hormone production","code":""},{"path":"disease-correlation-7.html","id":"disease-correlation-7","chapter":"Disease Correlation","heading":"Disease Correlation","text":"Understanding correlation specific endocrine disorders characteristic laboratory findings crucial accurate diagnosis effective management","code":""},{"path":"disease-correlation-7.html","id":"pituitary-disorders-1","chapter":"Disease Correlation","heading":"Pituitary Disorders","text":"","code":""},{"path":"disease-correlation-7.html","id":"acromegalygigantism","chapter":"Disease Correlation","heading":"Acromegaly/Gigantism","text":"Definition\nAcromegaly: Chronic disorder resulting excessive secretion growth hormone (GH) adults, leading gradual enlargement bones hands, feet, face\nGigantism: Excessive GH secretion closure epiphyseal plates children, leading excessive linear growth\nAcromegaly: Chronic disorder resulting excessive secretion growth hormone (GH) adults, leading gradual enlargement bones hands, feet, faceGigantism: Excessive GH secretion closure epiphyseal plates children, leading excessive linear growthEtiology\nPituitary adenoma: common cause (GH-secreting tumor)\nEctopic GH secretion: Rare\nPituitary adenoma: common cause (GH-secreting tumor)Ectopic GH secretion: RareLaboratory Findings\nElevated GH levels: Random GH levels often elevated, single measurements unreliable due pulsatile secretion\nElevated Insulin-Like Growth Factor 1 (IGF-1): Provides stable measure GH activity\nLack GH suppression glucose load: Failure GH suppress < 1 ng/mL oral glucose suppression test\nPituitary adenoma: Confirmed imaging studies (MRI)\nElevated GH levels: Random GH levels often elevated, single measurements unreliable due pulsatile secretionElevated Insulin-Like Growth Factor 1 (IGF-1): Provides stable measure GH activityLack GH suppression glucose load: Failure GH suppress < 1 ng/mL oral glucose suppression testPituitary adenoma: Confirmed imaging studies (MRI)Disease State Correlation\nSymptoms: Enlargement hands, feet, facial features; joint pain; excessive sweating; headaches; visual field defects; glucose intolerance; hypertension; sleep apnea\nIncreased risk cardiovascular disease, diabetes mellitus, colon cancer\nSymptoms: Enlargement hands, feet, facial features; joint pain; excessive sweating; headaches; visual field defects; glucose intolerance; hypertension; sleep apneaIncreased risk cardiovascular disease, diabetes mellitus, colon cancerClinical Significance\nEarly diagnosis treatment essential prevent long-term complications\nTreatment options include surgery, radiation therapy, medications (e.g., somatostatin analogs, GH receptor antagonists)\nEarly diagnosis treatment essential prevent long-term complicationsTreatment options include surgery, radiation therapy, medications (e.g., somatostatin analogs, GH receptor antagonists)","code":""},{"path":"disease-correlation-7.html","id":"cushings-disease","chapter":"Disease Correlation","heading":"Cushing’s Disease","text":"Definition\nSpecific form Cushing’s syndrome caused pituitary adenoma secretes excessive adrenocorticotropic hormone (ACTH), leading overproduction cortisol adrenal glands\nSpecific form Cushing’s syndrome caused pituitary adenoma secretes excessive adrenocorticotropic hormone (ACTH), leading overproduction cortisol adrenal glandsEtiology\nPituitary adenoma: ACTH-secreting tumor\nPituitary adenoma: ACTH-secreting tumorLaboratory Findings\nElevated cortisol levels: Increased 24-hour urine free cortisol excretion\nElevated late-night salivary cortisol: Loss diurnal variation cortisol secretion\nElevated ACTH levels: Usually normal slightly elevated\nLack cortisol suppression low-dose dexamethasone: Failure suppress cortisol < 1.8 μg/dL low-dose dexamethasone suppression test\nSuppression cortisol high-dose dexamethasone: Cortisol suppression ≥ 50% high-dose dexamethasone suppression test (helps differentiate ectopic ACTH secretion)\nPituitary adenoma: Confirmed imaging studies (MRI)\nElevated cortisol levels: Increased 24-hour urine free cortisol excretionElevated late-night salivary cortisol: Loss diurnal variation cortisol secretionElevated ACTH levels: Usually normal slightly elevatedLack cortisol suppression low-dose dexamethasone: Failure suppress cortisol < 1.8 μg/dL low-dose dexamethasone suppression testSuppression cortisol high-dose dexamethasone: Cortisol suppression ≥ 50% high-dose dexamethasone suppression test (helps differentiate ectopic ACTH secretion)Pituitary adenoma: Confirmed imaging studies (MRI)Disease State Correlation\nSymptoms: Weight gain, moon face, buffalo hump, hypertension, muscle weakness, skin changes (e.g., striae, easy bruising), glucose intolerance, osteoporosis\nIncreased risk infections cardiovascular disease\nSymptoms: Weight gain, moon face, buffalo hump, hypertension, muscle weakness, skin changes (e.g., striae, easy bruising), glucose intolerance, osteoporosisIncreased risk infections cardiovascular diseaseClinical Significance\nEarly diagnosis treatment essential prevent long-term complications\nTreatment typically involves surgical removal pituitary adenoma\nEarly diagnosis treatment essential prevent long-term complicationsTreatment typically involves surgical removal pituitary adenoma","code":""},{"path":"disease-correlation-7.html","id":"hypopituitarism","chapter":"Disease Correlation","heading":"Hypopituitarism","text":"Definition\nCondition characterized partial complete loss pituitary hormone function\nCondition characterized partial complete loss pituitary hormone functionEtiology\nPituitary adenoma tumor: Mass effect normal pituitary tissue\nSurgery radiation therapy: Treatment pituitary tumors\nPituitary infarction: Sheehan’s syndrome (postpartum pituitary necrosis)\nTraumatic brain injury\nInfections inflammatory conditions\nPituitary adenoma tumor: Mass effect normal pituitary tissueSurgery radiation therapy: Treatment pituitary tumorsPituitary infarction: Sheehan’s syndrome (postpartum pituitary necrosis)Traumatic brain injuryInfections inflammatory conditionsLaboratory Findings\nDeficiencies one pituitary hormones: GH, ACTH, TSH, LH, FSH, prolactin\nLow levels target gland hormones: Cortisol, thyroid hormones, sex hormones\nAbnormal responses stimulation tests: Impaired GH response insulin tolerance test, impaired cortisol response ACTH stimulation test\nDeficiencies one pituitary hormones: GH, ACTH, TSH, LH, FSH, prolactinLow levels target gland hormones: Cortisol, thyroid hormones, sex hormonesAbnormal responses stimulation tests: Impaired GH response insulin tolerance test, impaired cortisol response ACTH stimulation testDisease State Correlation\nSymptoms depend hormones deficient\nGrowth hormone deficiency: Short stature children, fatigue, decreased muscle mass, increased body fat adults\nAdrenal insufficiency: Fatigue, weakness, weight loss, hypotension\nHypothyroidism: Fatigue, weight gain, cold intolerance\nHypogonadism: Infertility, sexual dysfunction, decreased libido\nDiabetes insipidus: Polyuria polydipsia due ADH deficiency\nSymptoms depend hormones deficientGrowth hormone deficiency: Short stature children, fatigue, decreased muscle mass, increased body fat adultsAdrenal insufficiency: Fatigue, weakness, weight loss, hypotensionHypothyroidism: Fatigue, weight gain, cold intoleranceHypogonadism: Infertility, sexual dysfunction, decreased libidoDiabetes insipidus: Polyuria polydipsia due ADH deficiencyClinical Significance\nHormone replacement therapy essential treat hormone deficiencies prevent complications\nHormone replacement therapy essential treat hormone deficiencies prevent complications","code":""},{"path":"disease-correlation-7.html","id":"thyroid-disorders-1","chapter":"Disease Correlation","heading":"Thyroid Disorders","text":"","code":""},{"path":"disease-correlation-7.html","id":"hyperthyroidism","chapter":"Disease Correlation","heading":"Hyperthyroidism","text":"Definition\nCondition characterized excessive thyroid hormone production hypermetabolism\nCondition characterized excessive thyroid hormone production hypermetabolismEtiology\nGraves’ disease: Autoimmune disorder thyroid-stimulating antibodies\nToxic nodular goiter: Overactive thyroid nodules\nThyroiditis: Inflammation thyroid gland\nExcessive thyroid hormone intake\nGraves’ disease: Autoimmune disorder thyroid-stimulating antibodiesToxic nodular goiter: Overactive thyroid nodulesThyroiditis: Inflammation thyroid glandExcessive thyroid hormone intakeLaboratory Findings\nSuppressed TSH: Often < 0.1 μIU/mL\nElevated free T4 /free T3\nElevated TSH receptor antibody (TRAb): Specific Graves’ disease\nRadioactive iodine uptake scan: Increased uptake Graves’ disease toxic nodular goiter\nSuppressed TSH: Often < 0.1 μIU/mLElevated free T4 /free T3Elevated TSH receptor antibody (TRAb): Specific Graves’ diseaseRadioactive iodine uptake scan: Increased uptake Graves’ disease toxic nodular goiterDisease State Correlation\nSymptoms: Weight loss, anxiety, irritability, palpitations, heat intolerance, sweating, tremor, goiter, exophthalmos (bulging eyes) Graves’ disease\nIncreased risk atrial fibrillation osteoporosis\nSymptoms: Weight loss, anxiety, irritability, palpitations, heat intolerance, sweating, tremor, goiter, exophthalmos (bulging eyes) Graves’ diseaseIncreased risk atrial fibrillation osteoporosisClinical Significance\nTreatment options include antithyroid medications, radioactive iodine therapy, surgery\nTreatment options include antithyroid medications, radioactive iodine therapy, surgery","code":""},{"path":"disease-correlation-7.html","id":"hypothyroidism","chapter":"Disease Correlation","heading":"Hypothyroidism","text":"Definition\nCondition characterized insufficient thyroid hormone production hypometabolism\nCondition characterized insufficient thyroid hormone production hypometabolismEtiology\nHashimoto’s thyroiditis: Autoimmune destruction thyroid gland\nIodine deficiency: Rare developed countries\nThyroidectomy: Surgical removal thyroid gland\nRadiation therapy: Damage thyroid gland\nCentral hypothyroidism: Pituitary hypothalamic dysfunction\nHashimoto’s thyroiditis: Autoimmune destruction thyroid glandIodine deficiency: Rare developed countriesThyroidectomy: Surgical removal thyroid glandRadiation therapy: Damage thyroid glandCentral hypothyroidism: Pituitary hypothalamic dysfunctionLaboratory Findings\nElevated TSH: > 4.0 μIU/mL (primary hypothyroidism)\nLow free T4\nElevated thyroid peroxidase antibody (TPO Ab): Suggests Hashimoto’s thyroiditis\nLow normal TSH: Central hypothyroidism\nElevated TSH: > 4.0 μIU/mL (primary hypothyroidism)Low free T4Elevated thyroid peroxidase antibody (TPO Ab): Suggests Hashimoto’s thyroiditisLow normal TSH: Central hypothyroidismDisease State Correlation\nSymptoms: Fatigue, weight gain, constipation, cold intolerance, dry skin, hair loss, cognitive impairment\nSevere hypothyroidism can lead myxedema coma, life-threatening condition\nSymptoms: Fatigue, weight gain, constipation, cold intolerance, dry skin, hair loss, cognitive impairmentSevere hypothyroidism can lead myxedema coma, life-threatening conditionClinical Significance\nTreatment involves thyroid hormone replacement therapy levothyroxine\nTreatment involves thyroid hormone replacement therapy levothyroxine","code":""},{"path":"disease-correlation-7.html","id":"adrenal-disorders-1","chapter":"Disease Correlation","heading":"Adrenal Disorders","text":"","code":""},{"path":"disease-correlation-7.html","id":"cushings-syndrome","chapter":"Disease Correlation","heading":"Cushing’s Syndrome","text":"Definition\nCondition characterized chronic exposure excessive glucocorticoids (cortisol)\nCondition characterized chronic exposure excessive glucocorticoids (cortisol)Etiology\nExogenous glucocorticoids: common cause (iatrogenic Cushing’s syndrome)\nCushing’s disease: Pituitary adenoma causing excessive ACTH production\nEctopic ACTH syndrome: ACTH-secreting tumor outside pituitary (e.g., small cell lung cancer)\nAdrenal tumor: Cortisol-secreting tumor adrenal gland\nExogenous glucocorticoids: common cause (iatrogenic Cushing’s syndrome)Cushing’s disease: Pituitary adenoma causing excessive ACTH productionEctopic ACTH syndrome: ACTH-secreting tumor outside pituitary (e.g., small cell lung cancer)Adrenal tumor: Cortisol-secreting tumor adrenal glandLaboratory Findings\nElevated cortisol levels: Increased 24-hour urine free cortisol excretion\nElevated late-night salivary cortisol: Loss diurnal variation cortisol secretion\nElevated fasting glucose: Increased glucose levels due insulin resistance\nACTH levels: Variable depending cause\nElevated Cushing’s disease ectopic ACTH syndrome\nSuppressed adrenal tumors exogenous glucocorticoid use\n\nAbnormal responses dexamethasone suppression tests\nElevated cortisol levels: Increased 24-hour urine free cortisol excretionElevated late-night salivary cortisol: Loss diurnal variation cortisol secretionElevated fasting glucose: Increased glucose levels due insulin resistanceACTH levels: Variable depending cause\nElevated Cushing’s disease ectopic ACTH syndrome\nSuppressed adrenal tumors exogenous glucocorticoid use\nElevated Cushing’s disease ectopic ACTH syndromeSuppressed adrenal tumors exogenous glucocorticoid useAbnormal responses dexamethasone suppression testsDisease State Correlation\nSymptoms: Weight gain, moon face, buffalo hump, hypertension, muscle weakness, skin changes (e.g., striae, easy bruising), glucose intolerance, osteoporosis\nIncreased risk infections cardiovascular disease\nSymptoms: Weight gain, moon face, buffalo hump, hypertension, muscle weakness, skin changes (e.g., striae, easy bruising), glucose intolerance, osteoporosisIncreased risk infections cardiovascular diseaseClinical Significance\nTreatment depends underlying cause may involve surgery, radiation therapy, medications\nTreatment depends underlying cause may involve surgery, radiation therapy, medications","code":""},{"path":"disease-correlation-7.html","id":"addisons-disease-primary-adrenal-insufficiency","chapter":"Disease Correlation","heading":"Addison’s Disease (Primary Adrenal Insufficiency)","text":"Definition\nCondition characterized destruction dysfunction adrenal glands, leading deficient cortisol aldosterone production\nCondition characterized destruction dysfunction adrenal glands, leading deficient cortisol aldosterone productionEtiology\nAutoimmune adrenalitis: common cause\nInfections: Tuberculosis, fungal infections\nHemorrhage: Adrenal hemorrhage\nMetastatic cancer\nAutoimmune adrenalitis: common causeInfections: Tuberculosis, fungal infectionsHemorrhage: Adrenal hemorrhageMetastatic cancerLaboratory Findings\nLow cortisol levels: Decreased morning cortisol\nElevated ACTH levels: Lack negative feedback cortisol\nLow aldosterone levels: Decreased serum aldosterone\nElevated plasma renin activity (PRA): Indicates volume depletion\nHyponatremia: Low serum sodium\nHyperkalemia: High serum potassium\nAbnormal response ACTH stimulation test: Minimal increase cortisol levels ACTH administration\nLow cortisol levels: Decreased morning cortisolElevated ACTH levels: Lack negative feedback cortisolLow aldosterone levels: Decreased serum aldosteroneElevated plasma renin activity (PRA): Indicates volume depletionHyponatremia: Low serum sodiumHyperkalemia: High serum potassiumAbnormal response ACTH stimulation test: Minimal increase cortisol levels ACTH administrationDisease State Correlation\nSymptoms: Fatigue, weakness, weight loss, anorexia, nausea, vomiting, abdominal pain, hyperpigmentation, hypotension, salt craving\nAdrenal crisis: life-threatening condition characterized severe hypotension, shock, electrolyte imbalances\nSymptoms: Fatigue, weakness, weight loss, anorexia, nausea, vomiting, abdominal pain, hyperpigmentation, hypotension, salt cravingAdrenal crisis: life-threatening condition characterized severe hypotension, shock, electrolyte imbalancesClinical Significance\nTreatment involves lifelong hormone replacement therapy glucocorticoids (e.g., hydrocortisone) mineralocorticoids (e.g., fludrocortisone)\nTreatment involves lifelong hormone replacement therapy glucocorticoids (e.g., hydrocortisone) mineralocorticoids (e.g., fludrocortisone)","code":""},{"path":"disease-correlation-7.html","id":"pheochromocytoma","chapter":"Disease Correlation","heading":"Pheochromocytoma","text":"Definition\nRare tumor adrenal medulla produces excessive catecholamines (epinephrine norepinephrine)\nRare tumor adrenal medulla produces excessive catecholamines (epinephrine norepinephrine)Etiology\nSporadic: common\nGenetic syndromes: Multiple endocrine neoplasia type 2 (MEN2), von Hippel-Lindau (VHL) disease\nSporadic: commonGenetic syndromes: Multiple endocrine neoplasia type 2 (MEN2), von Hippel-Lindau (VHL) diseaseLaboratory Findings\nElevated plasma metanephrines: Highly sensitive specific\nElevated 24-hour urine metanephrines: Alternative plasma metanephrines\nElevated plasma catecholamines: Less sensitive specific metanephrines\nImaging studies (CT MRI): localize tumor\nElevated plasma metanephrines: Highly sensitive specificElevated 24-hour urine metanephrines: Alternative plasma metanephrinesElevated plasma catecholamines: Less sensitive specific metanephrinesImaging studies (CT MRI): localize tumorDisease State Correlation\nSymptoms: Hypertension (often paroxysmal), palpitations, sweating, headaches, anxiety, tremor\nIncreased risk cardiovascular complications, stroke myocardial infarction\nSymptoms: Hypertension (often paroxysmal), palpitations, sweating, headaches, anxiety, tremorIncreased risk cardiovascular complications, stroke myocardial infarctionClinical Significance\nDiagnosis essential prevent life-threatening complications\nTreatment involves surgical removal tumor adequate alpha-adrenergic blockade\nDiagnosis essential prevent life-threatening complicationsTreatment involves surgical removal tumor adequate alpha-adrenergic blockade","code":""},{"path":"disease-correlation-7.html","id":"parathyroid-disorders-1","chapter":"Disease Correlation","heading":"Parathyroid Disorders","text":"","code":""},{"path":"disease-correlation-7.html","id":"primary-hyperparathyroidism","chapter":"Disease Correlation","heading":"Primary Hyperparathyroidism","text":"Definition\nCondition characterized excessive secretion parathyroid hormone (PTH), leading hypercalcemia\nCondition characterized excessive secretion parathyroid hormone (PTH), leading hypercalcemiaEtiology\nParathyroid adenoma: common cause\nParathyroid hyperplasia: Enlargement four parathyroid glands\nParathyroid carcinoma: Rare\nParathyroid adenoma: common causeParathyroid hyperplasia: Enlargement four parathyroid glandsParathyroid carcinoma: RareLaboratory Findings\nElevated serum calcium: Often > 10.5 mg/dL\nElevated PTH levels: Inappropriately normal elevated presence hypercalcemia\nLow serum phosphate: Due increased renal excretion phosphate\nElevated 24-hour urine calcium excretion: May used assess severity\nVitamin D levels: May low normal\nElevated serum calcium: Often > 10.5 mg/dLElevated PTH levels: Inappropriately normal elevated presence hypercalcemiaLow serum phosphate: Due increased renal excretion phosphateElevated 24-hour urine calcium excretion: May used assess severityVitamin D levels: May low normalDisease State Correlation\nSymptoms: Often asymptomatic\nHypercalcemia symptoms: Bone pain, kidney stones, abdominal pain, constipation, fatigue, cognitive impairment\nComplications: Osteoporosis, kidney stones, cardiovascular disease\nSymptoms: Often asymptomaticHypercalcemia symptoms: Bone pain, kidney stones, abdominal pain, constipation, fatigue, cognitive impairmentComplications: Osteoporosis, kidney stones, cardiovascular diseaseClinical Significance\nTreatment may involve surgical removal affected parathyroid gland(s)\nTreatment may involve surgical removal affected parathyroid gland(s)","code":""},{"path":"disease-correlation-7.html","id":"hypoparathyroidism","chapter":"Disease Correlation","heading":"Hypoparathyroidism","text":"Definition\nCondition characterized deficient secretion parathyroid hormone (PTH), leading hypocalcemia\nCondition characterized deficient secretion parathyroid hormone (PTH), leading hypocalcemiaEtiology\nSurgical removal parathyroid glands: common cause\nAutoimmune destruction parathyroid glands\nGenetic disorders: DiGeorge syndrome\nMagnesium deficiency: Can impair PTH secretion\nSurgical removal parathyroid glands: common causeAutoimmune destruction parathyroid glandsGenetic disorders: DiGeorge syndromeMagnesium deficiency: Can impair PTH secretionLaboratory Findings\nLow serum calcium: Often < 8.5 mg/dL\nLow PTH levels: Inappropriately low presence hypocalcemia\nElevated serum phosphate: Due decreased renal excretion phosphate\nVitamin D levels: May low normal\nLow serum calcium: Often < 8.5 mg/dLLow PTH levels: Inappropriately low presence hypocalcemiaElevated serum phosphate: Due decreased renal excretion phosphateVitamin D levels: May low normalDisease State Correlation\nSymptoms: Muscle cramps, tetany, paresthesias (tingling), seizures, cognitive impairment\nSevere hypocalcemia can lead life-threatening cardiac arrhythmias\nSymptoms: Muscle cramps, tetany, paresthesias (tingling), seizures, cognitive impairmentSevere hypocalcemia can lead life-threatening cardiac arrhythmiasClinical Significance\nTreatment involves calcium vitamin D supplementation\nTreatment involves calcium vitamin D supplementation","code":""},{"path":"disease-correlation-7.html","id":"gonadal-disorders-1","chapter":"Disease Correlation","heading":"Gonadal Disorders","text":"","code":""},{"path":"disease-correlation-7.html","id":"hypogonadism-in-males","chapter":"Disease Correlation","heading":"Hypogonadism in Males","text":"Definition\nCondition characterized deficient testosterone production impaired sperm production\nCondition characterized deficient testosterone production impaired sperm productionTypes\nPrimary hypogonadism: Testicular failure\nSecondary hypogonadism: Pituitary hypothalamic dysfunction\nPrimary hypogonadism: Testicular failureSecondary hypogonadism: Pituitary hypothalamic dysfunctionEtiology\nKlinefelter syndrome: Genetic disorder (XXY)\nTesticular trauma infection\nAging: Age-related decline testosterone production\nPituitary hypothalamic tumors\nMedications: Anabolic steroids, opioids\nKlinefelter syndrome: Genetic disorder (XXY)Testicular trauma infectionAging: Age-related decline testosterone productionPituitary hypothalamic tumorsMedications: Anabolic steroids, opioidsLaboratory Findings\nLow serum testosterone: normal range age\nElevated LH FSH: Primary hypogonadism\nLow normal LH FSH: Secondary hypogonadism\nSemen analysis: May show decreased sperm count motility\nLow serum testosterone: normal range ageElevated LH FSH: Primary hypogonadismLow normal LH FSH: Secondary hypogonadismSemen analysis: May show decreased sperm count motilityDisease State Correlation\nSymptoms: Decreased libido, erectile dysfunction, fatigue, decreased muscle mass, increased body fat, osteoporosis\nSymptoms: Decreased libido, erectile dysfunction, fatigue, decreased muscle mass, increased body fat, osteoporosisClinical Significance\nTreatment may involve testosterone replacement therapy\nTreatment may involve testosterone replacement therapy","code":""},{"path":"disease-correlation-7.html","id":"polycystic-ovary-syndrome-pcos","chapter":"Disease Correlation","heading":"Polycystic Ovary Syndrome (PCOS)","text":"Definition\nCommon hormonal disorder affecting women reproductive age, characterized hyperandrogenism, ovulatory dysfunction, polycystic ovaries\nCommon hormonal disorder affecting women reproductive age, characterized hyperandrogenism, ovulatory dysfunction, polycystic ovariesEtiology\nComplex interplay genetic environmental factors\nInsulin resistance hyperinsulinemia play central role\nComplex interplay genetic environmental factorsInsulin resistance hyperinsulinemia play central roleLaboratory Findings\nElevated serum testosterone: May mildly elevated\nElevated LH/FSH ratio: Often > 2:1\nElevated androstenedione DHEA-S: Adrenal androgens\nInsulin resistance: Elevated fasting insulin glucose levels\nLipid abnormalities: Elevated triglycerides low HDL cholesterol\nPelvic ultrasound: Polycystic ovaries\nElevated serum testosterone: May mildly elevatedElevated LH/FSH ratio: Often > 2:1Elevated androstenedione DHEA-S: Adrenal androgensInsulin resistance: Elevated fasting insulin glucose levelsLipid abnormalities: Elevated triglycerides low HDL cholesterolPelvic ultrasound: Polycystic ovariesDisease State Correlation\nSymptoms: Hirsutism, acne, menstrual irregularities, infertility, obesity\nIncreased risk type 2 diabetes, cardiovascular disease, endometrial cancer\nSymptoms: Hirsutism, acne, menstrual irregularities, infertility, obesityIncreased risk type 2 diabetes, cardiovascular disease, endometrial cancerClinical Significance\nManagement involves lifestyle modifications (diet, exercise), medications regulate menstrual cycles, fertility treatments\nManagement involves lifestyle modifications (diet, exercise), medications regulate menstrual cycles, fertility treatments","code":""},{"path":"disease-correlation-7.html","id":"key-terms-63","chapter":"Disease Correlation","heading":"Key Terms","text":"Pituitary Adenoma: tumor pituitary glandEctopic ACTH Secretion: ACTH production non-pituitary tumorAdrenal Insufficiency: condition adrenal glands produce enough cortisolHyperthyroidism: condition thyroid gland produces much thyroid hormoneHypothyroidism: condition thyroid gland produce enough thyroid hormonePheochromocytoma: tumor adrenal medulla produces excessive catecholaminesHyperparathyroidism: condition parathyroid glands produce much parathyroid hormoneHypoparathyroidism: condition parathyroid glands produce enough parathyroid hormoneHypogonadism: condition gonads produce enough sex hormonesPolycystic Ovary Syndrome (PCOS): common hormonal disorder affecting women reproductive ageTestosterone: primary male sex hormoneEstradiol: primary female sex hormoneProgesterone: female sex hormone involved menstrual cycle pregnancyInsulin: hormone produced pancreas regulates blood sugar levelsC-Peptide: byproduct insulin productionHuman Chorionic Gonadotropin (hCG): hormone produced pregnancyLaboratory Findings: results laboratory testsDisease State Correlation: relationship specific endocrine disorders characteristic laboratory findingsClinical Significance: importance early diagnosis treatment prevent long-term complicationsTreatment Options: various medical interventions used manage endocrine disorders","code":""},{"path":"vitamins-nutrition.html","id":"vitamins-nutrition","chapter":"Vitamins, Nutrition","heading":"Vitamins, Nutrition","text":"section covers vitamins nutrition special chemistry - biochemical theory, lab procedures, result interpretation, disease correlations","code":""},{"path":"vitamins-nutrition.html","id":"biochemical-theory-and-pathways-6","chapter":"Vitamins, Nutrition","heading":"Biochemical Theory and Pathways","text":"Vitamins Essential Nutrients\nOrganic compounds needed small amounts metabolic processes; body synthesize adequately\nClassified water-soluble (B vitamins, C) fat-soluble (, D, E, K)\nOrganic compounds needed small amounts metabolic processes; body synthesize adequatelyClassified water-soluble (B vitamins, C) fat-soluble (, D, E, K)General Functions\nAct coenzymes (assist enzymes), antioxidants (protect damage), regulators (influence gene expression)\nAct coenzymes (assist enzymes), antioxidants (protect damage), regulators (influence gene expression)Specific Roles\nB vitamins: Involved energy metabolism\nVitamin C: Antioxidant, collagen synthesis\nVitamin : Vision, cell differentiation\nVitamin D: Calcium phosphate regulation\nVitamin E: Antioxidant\nVitamin K: Blood clotting\nB vitamins: Involved energy metabolismVitamin C: Antioxidant, collagen synthesisVitamin : Vision, cell differentiationVitamin D: Calcium phosphate regulationVitamin E: AntioxidantVitamin K: Blood clottingMetabolic Pathways\nAbsorption: Occurs small intestine\nTransport: Via bloodstream, either freely bound proteins\nStorage: Fat-soluble vitamins stored liver/adipose tissue\nExcretion: Water-soluble vitamins excreted urine\nAbsorption: Occurs small intestineTransport: Via bloodstream, either freely bound proteinsStorage: Fat-soluble vitamins stored liver/adipose tissueExcretion: Water-soluble vitamins excreted urine","code":""},{"path":"vitamins-nutrition.html","id":"laboratory-test-procedures-8","chapter":"Vitamins, Nutrition","heading":"Laboratory Test Procedures","text":"Analytical Principles\nSpectrophotometry: Measures light absorbance\nFluorometry: Measures fluorescence\nImmunoassays: Uses antibody-antigen interactions (e.g., ELISA)\nChromatography: Separates compounds (e.g., HPLC, GC)\nMass Spectrometry: Measures mass--charge ratio (LC-MS)\nAtomic Absorption Spectrometry: Measures light absorption free atoms\nSpectrophotometry: Measures light absorbanceFluorometry: Measures fluorescenceImmunoassays: Uses antibody-antigen interactions (e.g., ELISA)Chromatography: Separates compounds (e.g., HPLC, GC)Mass Spectrometry: Measures mass--charge ratio (LC-MS)Atomic Absorption Spectrometry: Measures light absorption free atomsPre-analytical Considerations\nPatient Preparation: Fasting, medication/supplement restrictions\nSpecimen Collection: Proper tubes, order draw, technique\nSpecimen Processing: Timely centrifugation, separation, storage\nPatient Preparation: Fasting, medication/supplement restrictionsSpecimen Collection: Proper tubes, order draw, techniqueSpecimen Processing: Timely centrifugation, separation, storageQuality Control\nRun QC samples ensure accuracy precision\nCalibrate instruments regularly\nRun QC samples ensure accuracy precisionCalibrate instruments regularly","code":""},{"path":"vitamins-nutrition.html","id":"test-result-interpretation-8","chapter":"Vitamins, Nutrition","heading":"Test Result Interpretation","text":"Reference Intervals\nUse appropriate reference ranges based age, sex, population\nUse appropriate reference ranges based age, sex, populationClinical Context\nInterpret results patient history, symptoms, lab data\nInterpret results patient history, symptoms, lab dataInterpreting Vitamin Levels\nEvaluate whether vitamin high, low, within range\nConsider test limitations: Assay specificity, interfering substances\nEvaluate whether vitamin high, low, within rangeConsider test limitations: Assay specificity, interfering substancesInfluencing Factors\nMedications, diet, malabsorption, lifestyle\nMedications, diet, malabsorption, lifestyle","code":""},{"path":"vitamins-nutrition.html","id":"disease-state-correlation-8","chapter":"Vitamins, Nutrition","heading":"Disease State Correlation","text":"Deficiency Disorders\nVitamin B1 (Thiamin): Beriberi, Wernicke-Korsakoff Syndrome\nVitamin B2 (Riboflavin): Ariboflavinosis\nVitamin B3 (Niacin): Pellagra\nVitamin B6 (Pyridoxine): Neurological symptoms, dermatitis\nVitamin B9 (Folate): Megaloblastic anemia, neural tube defects\nVitamin B12 (Cobalamin): Megaloblastic anemia, neurological problems\nVitamin C (Ascorbic Acid): Scurvy\nVitamin : Night blindness, xerophthalmia, immune dysfunction\nVitamin D: Rickets/osteomalacia\nVitamin E: Neurological symptoms, hemolytic anemia\nVitamin K: Bleeding disorders\nVitamin B1 (Thiamin): Beriberi, Wernicke-Korsakoff SyndromeVitamin B2 (Riboflavin): AriboflavinosisVitamin B3 (Niacin): PellagraVitamin B6 (Pyridoxine): Neurological symptoms, dermatitisVitamin B9 (Folate): Megaloblastic anemia, neural tube defectsVitamin B12 (Cobalamin): Megaloblastic anemia, neurological problemsVitamin C (Ascorbic Acid): ScurvyVitamin : Night blindness, xerophthalmia, immune dysfunctionVitamin D: Rickets/osteomalaciaVitamin E: Neurological symptoms, hemolytic anemiaVitamin K: Bleeding disordersToxicities\nVitamin : Liver damage, birth defects\nVitamin D: Hypercalcemia, kidney stones\nVitamin E: Increased bleeding risk\nNiacin: Flushing, liver damage\nVitamin : Liver damage, birth defectsVitamin D: Hypercalcemia, kidney stonesVitamin E: Increased bleeding riskNiacin: Flushing, liver damageOther Disease Correlations\nChronic diseases: CV disease, cancer, diabetes\nMalabsorption syndromes: Affect vitamin/mineral absorption\nChronic diseases: CV disease, cancer, diabetesMalabsorption syndromes: Affect vitamin/mineral absorptionKey Biochemical Tests\nVitamin levels (serum plasma)\nRed blood cell folate\nHomocysteine methylmalonic acid (B12 status)\n25-hydroxyvitamin D (Vitamin D status)\nProthrombin time (Vitamin K status)\nVitamin levels (serum plasma)Red blood cell folateHomocysteine methylmalonic acid (B12 status)25-hydroxyvitamin D (Vitamin D status)Prothrombin time (Vitamin K status)","code":""},{"path":"vitamins-nutrition.html","id":"key-terms-64","chapter":"Vitamins, Nutrition","heading":"Key Terms","text":"Vitamin: Essential organic compoundCoenzyme: Assists enzymesAntioxidant: Protects free radicalsMalnutrition: Imbalance inadequate/excessive intakeDeficiency: Inadequate nutrient levelsToxicity: Excessive nutrient levelsReference Interval: Normal range lab testPre-analytical: Processes analysisAnalytical: Processes analysisPost-analytical: Processes analysis","code":""},{"path":"biochemicals-6.html","id":"biochemicals-6","chapter":"Biochemicals","heading":"Biochemicals","text":"section covers key aspects vitamins nutrition - biochemical roles, metabolic pathways, associated normal abnormal states, fundamental properties","code":""},{"path":"biochemicals-6.html","id":"biochemical-theory-and-pathways-7","chapter":"Biochemicals","heading":"Biochemical Theory and Pathways","text":"Essential Nutrients: Vitamins organic compounds required small amounts various biochemical processes, synthesized adequately bodyClassification: Vitamins classified either water-soluble (B vitamins, vitamin C) fat-soluble (vitamins , D, E, K)General Metabolic Functions\nCoenzymes: Act coenzymes, essential enzyme activity metabolic reactions\nAntioxidants: Protect cells damage caused free radicals\nHormone-Like Functions: hormone-like effects, regulating gene expression\nCoenzymes: Act coenzymes, essential enzyme activity metabolic reactionsAntioxidants: Protect cells damage caused free radicalsHormone-Like Functions: hormone-like effects, regulating gene expressionMetabolic Pathways Actions\nThiamin (B1): Coenzyme carbohydrate metabolism\nRiboflavin (B2): Coenzyme redox reactions\nNiacin (B3): Coenzyme redox reactions\nPantothenic Acid (B5): Component Coenzyme \nPyridoxine (B6): Coenzyme amino acid metabolism\nBiotin (B7): Coenzyme carboxylation reactions\nFolate (B9): Coenzyme one-carbon transfer reactions\nCobalamin (B12): Coenzyme methionine synthase methylmalonyl-CoA mutase\nAscorbic Acid (Vitamin C): Antioxidant, collagen synthesis\nVitamin : Vision, cell differentiation, immune function\nVitamin D: Calcium phosphate metabolism\nVitamin E: Antioxidant\nVitamin K: Blood clotting, bone metabolism\nThiamin (B1): Coenzyme carbohydrate metabolismRiboflavin (B2): Coenzyme redox reactionsNiacin (B3): Coenzyme redox reactionsPantothenic Acid (B5): Component Coenzyme APyridoxine (B6): Coenzyme amino acid metabolismBiotin (B7): Coenzyme carboxylation reactionsFolate (B9): Coenzyme one-carbon transfer reactionsCobalamin (B12): Coenzyme methionine synthase methylmalonyl-CoA mutaseAscorbic Acid (Vitamin C): Antioxidant, collagen synthesisVitamin : Vision, cell differentiation, immune functionVitamin D: Calcium phosphate metabolismVitamin E: AntioxidantVitamin K: Blood clotting, bone metabolismAbsorption, Transport, Storage, Excretion\nWater-soluble: Absorbed directly bloodstream, stored significantly, excreted urine\nFat-soluble: Absorbed dietary fats, stored liver adipose tissue, excreted bile\nWater-soluble: Absorbed directly bloodstream, stored significantly, excreted urineFat-soluble: Absorbed dietary fats, stored liver adipose tissue, excreted bile","code":""},{"path":"biochemicals-6.html","id":"normal-and-abnormal-states-5","chapter":"Biochemicals","heading":"Normal and Abnormal States","text":"Normal Nutritional States\nAdequate dietary intake essential nutrients\nNormal absorption utilization nutrients\nMaintenance nutrient levels within normal reference ranges\nAdequate dietary intake essential nutrientsNormal absorption utilization nutrientsMaintenance nutrient levels within normal reference rangesMalnutrition: Imbalance resulting inadequate excessive nutrient intake\nUndernutrition: Deficiency one essential nutrients due inadequate intake, impaired absorption, increased requirements\nOvernutrition: Excessive intake nutrients, leading nutrient toxicity adverse health effects\nUndernutrition: Deficiency one essential nutrients due inadequate intake, impaired absorption, increased requirementsOvernutrition: Excessive intake nutrients, leading nutrient toxicity adverse health effectsSpecific Disorders\nVitamin Deficiencies: Scurvy (C), rickets (D), beriberi (B1), pellagra (B3)\nVitamin Toxicity: Liver damage (), hypercalcemia (D), increased bleeding risk (E)\nVitamin Deficiencies: Scurvy (C), rickets (D), beriberi (B1), pellagra (B3)Vitamin Toxicity: Liver damage (), hypercalcemia (D), increased bleeding risk (E)Assessment\nDietary assessment, anthropometric measurements, biochemical tests, clinical assessment used determine nutritional status\nDietary assessment, anthropometric measurements, biochemical tests, clinical assessment used determine nutritional status","code":""},{"path":"biochemicals-6.html","id":"properties-6","chapter":"Biochemicals","heading":"Properties","text":"Water-Soluble Vitamins\nSoluble water\nstored body\nLess risk toxicity\nServe coenzymes metabolism\nSoluble waterNot stored bodyLess risk toxicityServe coenzymes metabolismFat-Soluble Vitamins\nSoluble lipids\nStored body\nRisk toxicity\nInvolved vision, bone metabolism, antioxidant functions\nSoluble lipidsStored bodyRisk toxicityInvolved vision, bone metabolism, antioxidant functionsKey Chemical Characteristics\nVaried chemical structures influencing solubility, stability, interactions compounds\nVaried chemical structures influencing solubility, stability, interactions compoundsStability Reactivity\nSusceptible degradation heat, light, air, pH\nSusceptible degradation heat, light, air, pHActive Forms\nConverted specific coenzymes active forms exert biochemical functions\nConverted specific coenzymes active forms exert biochemical functions","code":""},{"path":"biochemicals-6.html","id":"clinical-significance-9","chapter":"Biochemicals","heading":"Clinical Significance","text":"Understanding concepts vital \nDiagnosing managing nutritional disorders effectively\nProviding personalized dietary recommendations\nDeveloping public health strategies prevent deficiencies toxicities\nInterpreting laboratory test results related vitamin nutrient status\nDiagnosing managing nutritional disorders effectivelyProviding personalized dietary recommendationsDeveloping public health strategies prevent deficiencies toxicitiesInterpreting laboratory test results related vitamin nutrient status","code":""},{"path":"metabolic-8.html","id":"metabolic-8","chapter":"Metabolic","heading":"Metabolic","text":"Understanding biochemical roles vitamins metabolic pathways critical appreciating impact health disease","code":""},{"path":"metabolic-8.html","id":"general-principles-of-vitamin-metabolism","chapter":"Metabolic","heading":"General Principles of Vitamin Metabolism","text":"Vitamins Essential Nutrients\nVitamins organic compounds essential human health synthesized sufficient quantities body\nmust obtained dietary sources supplements\nVitamins organic compounds essential human health synthesized sufficient quantities bodyThey must obtained dietary sources supplementsClassification Vitamins\nWater-Soluble Vitamins: B vitamins (thiamin, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folate, cobalamin) vitamin C\nFat-Soluble Vitamins: Vitamins , D, E, K\nWater-Soluble Vitamins: B vitamins (thiamin, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folate, cobalamin) vitamin CFat-Soluble Vitamins: Vitamins , D, E, KGeneral Metabolic Functions\nCoenzymes: Many vitamins act coenzymes, essential activity enzymes involved metabolic reactions\nAntioxidants: vitamins act antioxidants, protecting cells damage caused free radicals\nHormone-Like Functions: vitamins hormone-like functions, regulating gene expression cell differentiation\nFunctions: vitamins involved vision, blood clotting, immune function\nCoenzymes: Many vitamins act coenzymes, essential activity enzymes involved metabolic reactionsAntioxidants: vitamins act antioxidants, protecting cells damage caused free radicalsHormone-Like Functions: vitamins hormone-like functions, regulating gene expression cell differentiationOther Functions: vitamins involved vision, blood clotting, immune functionAbsorption Transport\nWater-Soluble Vitamins: Absorbed directly bloodstream\nFat-Soluble Vitamins: Absorbed along dietary fats, requiring bile acids pancreatic enzymes\nTransport: Vitamins transported bloodstream either freely bound carrier proteins\nWater-Soluble Vitamins: Absorbed directly bloodstreamFat-Soluble Vitamins: Absorbed along dietary fats, requiring bile acids pancreatic enzymesTransport: Vitamins transported bloodstream either freely bound carrier proteinsStorage Excretion\nWater-Soluble Vitamins: stored body significant extent; excess excreted urine\nFat-Soluble Vitamins: Stored liver adipose tissue; excess can lead toxicity\nWater-Soluble Vitamins: stored body significant extent; excess excreted urineFat-Soluble Vitamins: Stored liver adipose tissue; excess can lead toxicityDeficiency Toxicity\nVitamin Deficiency: Occurs intake inadequate, leading impaired metabolic functions specific deficiency symptoms\nVitamin Toxicity: Occurs intake excessive, leading adverse effects\nVitamin Deficiency: Occurs intake inadequate, leading impaired metabolic functions specific deficiency symptomsVitamin Toxicity: Occurs intake excessive, leading adverse effects","code":""},{"path":"metabolic-8.html","id":"water-soluble-vitamins","chapter":"Metabolic","heading":"Water-Soluble Vitamins","text":"","code":""},{"path":"metabolic-8.html","id":"thiamin-vitamin-b1","chapter":"Metabolic","heading":"Thiamin (Vitamin B1)","text":"Metabolism\nAbsorption: Absorbed small intestine\nConversion Active Form: Converted thiamin pyrophosphate (TPP) thiamin pyrophosphokinase\nAbsorption: Absorbed small intestineConversion Active Form: Converted thiamin pyrophosphate (TPP) thiamin pyrophosphokinaseBiochemical Actions\nCoenzyme Carbohydrate Metabolism: TPP coenzyme several key enzymes carbohydrate metabolism\nPyruvate dehydrogenase complex: Converts pyruvate acetyl-CoA\nα-Ketoglutarate dehydrogenase complex: Part citric acid cycle\nTransketolase: Part pentose phosphate pathway\n\nCoenzyme Carbohydrate Metabolism: TPP coenzyme several key enzymes carbohydrate metabolism\nPyruvate dehydrogenase complex: Converts pyruvate acetyl-CoA\nα-Ketoglutarate dehydrogenase complex: Part citric acid cycle\nTransketolase: Part pentose phosphate pathway\nPyruvate dehydrogenase complex: Converts pyruvate acetyl-CoAα-Ketoglutarate dehydrogenase complex: Part citric acid cycleTransketolase: Part pentose phosphate pathwayDeficiency\nBeriberi: Characterized neurological cardiovascular symptoms\nWernicke-Korsakoff Syndrome: Neurological disorder associated chronic alcohol abuse\nBeriberi: Characterized neurological cardiovascular symptomsWernicke-Korsakoff Syndrome: Neurological disorder associated chronic alcohol abuseToxicity\nRare\nRare","code":""},{"path":"metabolic-8.html","id":"riboflavin-vitamin-b2","chapter":"Metabolic","heading":"Riboflavin (Vitamin B2)","text":"Metabolism\nAbsorption: Absorbed small intestine\nConversion Active Forms: Converted flavin mononucleotide (FMN) flavin adenine dinucleotide (FAD)\nAbsorption: Absorbed small intestineConversion Active Forms: Converted flavin mononucleotide (FMN) flavin adenine dinucleotide (FAD)Biochemical Actions\nCoenzyme Redox Reactions: FMN FAD coenzymes numerous oxidoreductase enzymes involved energy metabolism\nComplex Complex II electron transport chain\nSuccinate dehydrogenase: Part citric acid cycle\nFatty acyl-CoA dehydrogenase: Involved fatty acid oxidation\n\nCoenzyme Redox Reactions: FMN FAD coenzymes numerous oxidoreductase enzymes involved energy metabolism\nComplex Complex II electron transport chain\nSuccinate dehydrogenase: Part citric acid cycle\nFatty acyl-CoA dehydrogenase: Involved fatty acid oxidation\nComplex Complex II electron transport chainSuccinate dehydrogenase: Part citric acid cycleFatty acyl-CoA dehydrogenase: Involved fatty acid oxidationDeficiency\nAriboflavinosis: Characterized cheilosis (cracking corners mouth), glossitis (inflammation tongue), dermatitis\nAriboflavinosis: Characterized cheilosis (cracking corners mouth), glossitis (inflammation tongue), dermatitisToxicity\nRare\nRare","code":""},{"path":"metabolic-8.html","id":"niacin-vitamin-b3","chapter":"Metabolic","heading":"Niacin (Vitamin B3)","text":"Metabolism\nAbsorption: Absorbed small intestine\nSynthesis: Can synthesized tryptophan, process inefficient\nConversion Active Forms: Converted nicotinamide adenine dinucleotide (\\(NAD^+\\)) nicotinamide adenine dinucleotide phosphate (\\(NADP^+\\))\nAbsorption: Absorbed small intestineSynthesis: Can synthesized tryptophan, process inefficientConversion Active Forms: Converted nicotinamide adenine dinucleotide (\\(NAD^+\\)) nicotinamide adenine dinucleotide phosphate (\\(NADP^+\\))Biochemical Actions\nCoenzyme Redox Reactions: NAD+ NADP+ coenzymes numerous dehydrogenase enzymes involved energy metabolism biosynthesis\nGlycolysis, citric acid cycle, fatty acid oxidation, pentose phosphate pathway\n\nCoenzyme Redox Reactions: NAD+ NADP+ coenzymes numerous dehydrogenase enzymes involved energy metabolism biosynthesis\nGlycolysis, citric acid cycle, fatty acid oxidation, pentose phosphate pathway\nGlycolysis, citric acid cycle, fatty acid oxidation, pentose phosphate pathwayDeficiency\nPellagra: Characterized “three Ds”: dermatitis, diarrhea, dementia\nPellagra: Characterized “three Ds”: dermatitis, diarrhea, dementiaToxicity\nNiacin Flush: Skin flushing itching high doses\nLiver damage\nNiacin Flush: Skin flushing itching high dosesLiver damage","code":""},{"path":"metabolic-8.html","id":"pantothenic-acid-vitamin-b5","chapter":"Metabolic","heading":"Pantothenic Acid (Vitamin B5)","text":"Metabolism\nAbsorption: Absorbed small intestine\nConversion Active Form: Used synthesize coenzyme (\\(CoA\\))\nAbsorption: Absorbed small intestineConversion Active Form: Used synthesize coenzyme (\\(CoA\\))Biochemical Actions\nComponent Coenzyme (CoA): \\(CoA\\) essential numerous metabolic reactions\nAcetyl-CoA: Involved citric acid cycle, fatty acid synthesis, fatty acid oxidation\nAcyl carrier protein (ACP): Involved fatty acid synthesis\n\nComponent Coenzyme (CoA): \\(CoA\\) essential numerous metabolic reactions\nAcetyl-CoA: Involved citric acid cycle, fatty acid synthesis, fatty acid oxidation\nAcyl carrier protein (ACP): Involved fatty acid synthesis\nAcetyl-CoA: Involved citric acid cycle, fatty acid synthesis, fatty acid oxidationAcyl carrier protein (ACP): Involved fatty acid synthesisDeficiency\nRare due widespread occurrence foods\nRare due widespread occurrence foodsToxicity\nRare\nRare","code":""},{"path":"metabolic-8.html","id":"pyridoxine-vitamin-b6","chapter":"Metabolic","heading":"Pyridoxine (Vitamin B6)","text":"Metabolism\nAbsorption: Absorbed small intestine\nConversion Active Form: Converted pyridoxal phosphate (\\(PLP\\))\nAbsorption: Absorbed small intestineConversion Active Form: Converted pyridoxal phosphate (\\(PLP\\))Biochemical Actions\nCoenzyme Amino Acid Metabolism: \\(PLP\\) coenzyme numerous enzymes involved amino acid metabolism\nTransaminases: Transfer amino groups amino acids keto acids\nDecarboxylases: Remove carboxyl groups amino acids form neurotransmitters\nGlycogen phosphorylase: Involved glycogen breakdown\n\nCoenzyme Amino Acid Metabolism: \\(PLP\\) coenzyme numerous enzymes involved amino acid metabolism\nTransaminases: Transfer amino groups amino acids keto acids\nDecarboxylases: Remove carboxyl groups amino acids form neurotransmitters\nGlycogen phosphorylase: Involved glycogen breakdown\nTransaminases: Transfer amino groups amino acids keto acidsDecarboxylases: Remove carboxyl groups amino acids form neurotransmittersGlycogen phosphorylase: Involved glycogen breakdownDeficiency\nNeurological symptoms, dermatitis, anemia\nNeurological symptoms, dermatitis, anemiaToxicity\nPeripheral neuropathy\nPeripheral neuropathy","code":""},{"path":"metabolic-8.html","id":"biotin-vitamin-b7","chapter":"Metabolic","heading":"Biotin (Vitamin B7)","text":"Metabolism\nAbsorption: Absorbed small intestine\nSynthesis: Can synthesized intestinal bacteria\nAbsorption: Absorbed small intestineSynthesis: Can synthesized intestinal bacteriaBiochemical Actions\nCoenzyme Carboxylation Reactions: Biotin coenzyme several carboxylase enzymes\nPyruvate carboxylase: Converts pyruvate oxaloacetate gluconeogenesis\nAcetyl-CoA carboxylase: Converts acetyl-CoA malonyl-CoA fatty acid synthesis\nPropionyl-CoA carboxylase: Involved metabolism odd-chain fatty acids branched-chain amino acids\n\nCoenzyme Carboxylation Reactions: Biotin coenzyme several carboxylase enzymes\nPyruvate carboxylase: Converts pyruvate oxaloacetate gluconeogenesis\nAcetyl-CoA carboxylase: Converts acetyl-CoA malonyl-CoA fatty acid synthesis\nPropionyl-CoA carboxylase: Involved metabolism odd-chain fatty acids branched-chain amino acids\nPyruvate carboxylase: Converts pyruvate oxaloacetate gluconeogenesisAcetyl-CoA carboxylase: Converts acetyl-CoA malonyl-CoA fatty acid synthesisPropionyl-CoA carboxylase: Involved metabolism odd-chain fatty acids branched-chain amino acidsDeficiency\nRare, can occur excessive consumption raw egg whites (contains avidin, binds biotin)\nRare, can occur excessive consumption raw egg whites (contains avidin, binds biotin)Toxicity\nRare\nRare","code":""},{"path":"metabolic-8.html","id":"folate-vitamin-b9","chapter":"Metabolic","heading":"Folate (Vitamin B9)","text":"Metabolism\nAbsorption: Absorbed small intestine\nConversion Active Form: Converted tetrahydrofolate (THF) folate coenzymes\nAbsorption: Absorbed small intestineConversion Active Form: Converted tetrahydrofolate (THF) folate coenzymesBiochemical Actions\nCoenzyme One-Carbon Transfer Reactions: THF coenzyme numerous enzymes involved one-carbon transfer reactions\nDNA synthesis: Required synthesis purines pyrimidines\nAmino acid metabolism: Involved interconversion serine glycine\n\nCoenzyme One-Carbon Transfer Reactions: THF coenzyme numerous enzymes involved one-carbon transfer reactions\nDNA synthesis: Required synthesis purines pyrimidines\nAmino acid metabolism: Involved interconversion serine glycine\nDNA synthesis: Required synthesis purines pyrimidinesAmino acid metabolism: Involved interconversion serine glycineDeficiency\nMegaloblastic anemia, neural tube defects developing fetuses\nMegaloblastic anemia, neural tube defects developing fetusesToxicity\nCan mask vitamin B12 deficiency\nCan mask vitamin B12 deficiency","code":""},{"path":"metabolic-8.html","id":"cobalamin-vitamin-b12","chapter":"Metabolic","heading":"Cobalamin (Vitamin B12)","text":"Metabolism\nAbsorption: Requires intrinsic factor, secreted parietal cells stomach\nConversion Active Forms: Converted methylcobalamin adenosylcobalamin\nAbsorption: Requires intrinsic factor, secreted parietal cells stomachConversion Active Forms: Converted methylcobalamin adenosylcobalaminBiochemical Actions\nCoenzyme Two Important Enzymes\nMethionine synthase: Converts homocysteine methionine\nMethylmalonyl-CoA mutase: Involved metabolism odd-chain fatty acids branched-chain amino acids\n\nCoenzyme Two Important Enzymes\nMethionine synthase: Converts homocysteine methionine\nMethylmalonyl-CoA mutase: Involved metabolism odd-chain fatty acids branched-chain amino acids\nMethionine synthase: Converts homocysteine methionineMethylmalonyl-CoA mutase: Involved metabolism odd-chain fatty acids branched-chain amino acidsDeficiency\nPernicious anemia (due lack intrinsic factor), neurological symptoms\nPernicious anemia (due lack intrinsic factor), neurological symptomsToxicity\nRare\nRare","code":""},{"path":"metabolic-8.html","id":"ascorbic-acid-vitamin-c","chapter":"Metabolic","heading":"Ascorbic Acid (Vitamin C)","text":"Metabolism\nAbsorption: Absorbed small intestine\nAbsorption: Absorbed small intestineBiochemical Actions\nAntioxidant: Scavenges free radicals protects oxidative damage\nCollagen Synthesis: Required hydroxylation proline lysine collagen\nIron Absorption: Enhances absorption non-heme iron\nNeurotransmitter Synthesis: Involved synthesis norepinephrine\nAntioxidant: Scavenges free radicals protects oxidative damageCollagen Synthesis: Required hydroxylation proline lysine collagenIron Absorption: Enhances absorption non-heme ironNeurotransmitter Synthesis: Involved synthesis norepinephrineDeficiency\nScurvy: Characterized bleeding gums, poor wound healing, anemia\nScurvy: Characterized bleeding gums, poor wound healing, anemiaToxicity\nGastrointestinal distress, kidney stones\nGastrointestinal distress, kidney stones","code":""},{"path":"metabolic-8.html","id":"fat-soluble-vitamins","chapter":"Metabolic","heading":"Fat-Soluble Vitamins","text":"","code":""},{"path":"metabolic-8.html","id":"vitamin-a","chapter":"Metabolic","heading":"Vitamin A","text":"Metabolism\nAbsorption: Absorbed along dietary fats\nTransport: Transported bloodstream bound retinol-binding protein (RBP)\nStorage: Stored liver\nAbsorption: Absorbed along dietary fatsTransport: Transported bloodstream bound retinol-binding protein (RBP)Storage: Stored liverBiochemical Actions\nVision: Retinal component rhodopsin, light-sensitive pigment retina\nCell Differentiation: Retinoic acid regulates gene expression cell differentiation\nImmune Function: Supports immune system\nVision: Retinal component rhodopsin, light-sensitive pigment retinaCell Differentiation: Retinoic acid regulates gene expression cell differentiationImmune Function: Supports immune systemDeficiency\nNight blindness, xerophthalmia (dry eyes), impaired immune function\nNight blindness, xerophthalmia (dry eyes), impaired immune functionToxicity\nLiver damage, bone abnormalities, birth defects\nLiver damage, bone abnormalities, birth defects","code":""},{"path":"metabolic-8.html","id":"vitamin-d","chapter":"Metabolic","heading":"Vitamin D","text":"Metabolism\nSynthesis: Can synthesized skin upon exposure sunlight\nActivation: Requires hydroxylation liver kidneys form active form, calcitriol (1,25-dihydroxyvitamin D)\nSynthesis: Can synthesized skin upon exposure sunlightActivation: Requires hydroxylation liver kidneys form active form, calcitriol (1,25-dihydroxyvitamin D)Biochemical Actions\nCalcium Phosphate Metabolism: Calcitriol regulates calcium phosphate absorption intestine, bone remodeling, kidney reabsorption\nCalcium Phosphate Metabolism: Calcitriol regulates calcium phosphate absorption intestine, bone remodeling, kidney reabsorptionDeficiency\nRickets (children), osteomalacia (adults), osteoporosis\nRickets (children), osteomalacia (adults), osteoporosisToxicity\nHypercalcemia, kidney stones, soft tissue calcification\nHypercalcemia, kidney stones, soft tissue calcification","code":""},{"path":"metabolic-8.html","id":"vitamin-e","chapter":"Metabolic","heading":"Vitamin E","text":"Metabolism\nAbsorption: Absorbed along dietary fats\nTransport: Transported bloodstream lipoproteins\nStorage: Stored adipose tissue\nAbsorption: Absorbed along dietary fatsTransport: Transported bloodstream lipoproteinsStorage: Stored adipose tissueBiochemical Actions\nAntioxidant: Protects cell membranes lipid peroxidation\nAntioxidant: Protects cell membranes lipid peroxidationDeficiency\nRare, can occur individuals fat malabsorption\nNeurological symptoms hemolytic anemia\nRare, can occur individuals fat malabsorptionNeurological symptoms hemolytic anemiaToxicity\nIncreased risk bleeding\nIncreased risk bleeding","code":""},{"path":"metabolic-8.html","id":"vitamin-k","chapter":"Metabolic","heading":"Vitamin K","text":"Metabolism\nAbsorption: Absorbed along dietary fats\nSynthesis: Can synthesized intestinal bacteria\nAbsorption: Absorbed along dietary fatsSynthesis: Can synthesized intestinal bacteriaBiochemical Actions\nBlood Clotting: Required carboxylation glutamate residues several clotting factors (II, VII, IX, X)\nBone Metabolism: Involved bone mineralization\nBlood Clotting: Required carboxylation glutamate residues several clotting factors (II, VII, IX, X)Bone Metabolism: Involved bone mineralizationDeficiency\nBleeding disorders\nBleeding disordersToxicity\nRare, can interfere anticoagulant medications\nRare, can interfere anticoagulant medications","code":""},{"path":"metabolic-8.html","id":"summary-table-of-vitamins","chapter":"Metabolic","heading":"Summary Table of Vitamins","text":"","code":""},{"path":"metabolic-8.html","id":"clinical-significance-10","chapter":"Metabolic","heading":"Clinical Significance","text":"Nutritional Deficiencies: Vitamin deficiencies can lead wide range health problems, including anemia, neurological disorders, immune dysfunctionChronic Diseases: Vitamins play role prevention management chronic diseases, cardiovascular disease, cancer, diabetesDietary Supplements: Vitamin supplements can beneficial individuals inadequate dietary intake specific health conditions, excessive supplementation can harmfulPersonalized Nutrition: Understanding individual’s vitamin status genetic factors can help optimize dietary recommendations supplement use","code":""},{"path":"metabolic-8.html","id":"key-terms-65","chapter":"Metabolic","heading":"Key Terms","text":"Vitamin: organic compound essential human healthCoenzyme: substance required activity enzymeAntioxidant: substance protects cells damage caused free radicalsFree Radical: unstable molecule can damage cellsMetabolism: sum chemical reactions occur living organismAbsorption: process nutrients taken digestive tract bloodstreamTransport: process nutrients carried bloodstream tissues organsStorage: process nutrients stored bodyExcretion: process waste products eliminated bodyDeficiency: condition body enough particular nutrientToxicity: condition body much particular nutrient","code":""},{"path":"physiology-8.html","id":"physiology-8","chapter":"Physiology","heading":"Physiology","text":"Understanding normal abnormal states associated vitamin nutrient metabolism crucial identifying managing nutritional disorders","code":""},{"path":"physiology-8.html","id":"general-principles-of-nutritional-status","chapter":"Physiology","heading":"General Principles of Nutritional Status","text":"Nutritional Requirements\nbody requires balanced intake macronutrients (carbohydrates, fats, proteins) micronutrients (vitamins, minerals) optimal health\nNutritional requirements vary based age, sex, activity level, physiological state (e.g., pregnancy, lactation)\nbody requires balanced intake macronutrients (carbohydrates, fats, proteins) micronutrients (vitamins, minerals) optimal healthNutritional requirements vary based age, sex, activity level, physiological state (e.g., pregnancy, lactation)Dietary Intake Absorption\nAdequate dietary intake essential meeting nutritional requirements\nFactors affecting absorption: Digestive function, intestinal health, interactions nutrients medications\nAdequate dietary intake essential meeting nutritional requirementsFactors affecting absorption: Digestive function, intestinal health, interactions nutrients medicationsMetabolic Processes\nNutrients undergo various metabolic processes (digestion, absorption, transport, storage, utilization)\nEnzymes, hormones, factors regulate processes\nNutrients undergo various metabolic processes (digestion, absorption, transport, storage, utilization)Enzymes, hormones, factors regulate processesAssessment Nutritional Status\nDietary Assessment: Evaluation dietary intake eating habits\nAnthropometric Measurements: Height, weight, body mass index (BMI), body composition\nBiochemical Tests: Measurement nutrient levels related metabolites blood, urine, tissues\nClinical Assessment: Physical examination identify signs symptoms nutritional deficiencies excesses\nDietary Assessment: Evaluation dietary intake eating habitsAnthropometric Measurements: Height, weight, body mass index (BMI), body compositionBiochemical Tests: Measurement nutrient levels related metabolites blood, urine, tissuesClinical Assessment: Physical examination identify signs symptoms nutritional deficiencies excesses","code":""},{"path":"physiology-8.html","id":"normal-nutritional-states","chapter":"Physiology","heading":"Normal Nutritional States","text":"Adequate Dietary Intake\nConsumption balanced diet meets body’s nutritional requirements\nIncludes variety foods different food groups (fruits, vegetables, grains, protein sources, dairy)\nConsumption balanced diet meets body’s nutritional requirementsIncludes variety foods different food groups (fruits, vegetables, grains, protein sources, dairy)Normal Absorption Utilization\nEfficient digestion absorption nutrients gastrointestinal tract\nNormal metabolic processes nutrient utilization cells tissues\nEfficient digestion absorption nutrients gastrointestinal tractNormal metabolic processes nutrient utilization cells tissuesOptimal Nutrient Levels\nMaintenance nutrient levels within normal reference ranges\nAdequate storage mobilization nutrients needed\nMaintenance nutrient levels within normal reference rangesAdequate storage mobilization nutrients needed","code":""},{"path":"physiology-8.html","id":"abnormal-nutritional-states","chapter":"Physiology","heading":"Abnormal Nutritional States","text":"Malnutrition\nstate nutritional imbalance resulting inadequate excessive intake nutrients, impaired nutrient utilization\nIncludes undernutrition overnutrition\nstate nutritional imbalance resulting inadequate excessive intake nutrients, impaired nutrient utilizationIncludes undernutrition overnutritionUndernutrition\nDefinition: Deficiency one essential nutrients\nCauses\nInadequate dietary intake: Poverty, food insecurity, eating disorders, fad diets\nImpaired absorption: Malabsorption syndromes, gastrointestinal disorders\nIncreased nutrient requirements: Pregnancy, lactation, chronic diseases\nIncreased nutrient losses: Diarrhea, vomiting, kidney disease\n\nTypes Undernutrition\nProtein-energy malnutrition (PEM): Deficiency protein calories\nMicronutrient deficiencies: Deficiency vitamins minerals\n\nDefinition: Deficiency one essential nutrientsCauses\nInadequate dietary intake: Poverty, food insecurity, eating disorders, fad diets\nImpaired absorption: Malabsorption syndromes, gastrointestinal disorders\nIncreased nutrient requirements: Pregnancy, lactation, chronic diseases\nIncreased nutrient losses: Diarrhea, vomiting, kidney disease\nInadequate dietary intake: Poverty, food insecurity, eating disorders, fad dietsImpaired absorption: Malabsorption syndromes, gastrointestinal disordersIncreased nutrient requirements: Pregnancy, lactation, chronic diseasesIncreased nutrient losses: Diarrhea, vomiting, kidney diseaseTypes Undernutrition\nProtein-energy malnutrition (PEM): Deficiency protein calories\nMicronutrient deficiencies: Deficiency vitamins minerals\nProtein-energy malnutrition (PEM): Deficiency protein caloriesMicronutrient deficiencies: Deficiency vitamins mineralsOvernutrition\nDefinition: Excessive intake nutrients, leading nutrient toxicity adverse health effects\nCauses\nExcessive dietary intake: Overeating, consumption nutrient-dense foods\nExcessive supplementation: High doses vitamin mineral supplements\n\nTypes Overnutrition\nObesity: Excessive accumulation body fat\nVitamin toxicity: Excessive intake fat-soluble vitamins (, D, E, K)\n\nDefinition: Excessive intake nutrients, leading nutrient toxicity adverse health effectsCauses\nExcessive dietary intake: Overeating, consumption nutrient-dense foods\nExcessive supplementation: High doses vitamin mineral supplements\nExcessive dietary intake: Overeating, consumption nutrient-dense foodsExcessive supplementation: High doses vitamin mineral supplementsTypes Overnutrition\nObesity: Excessive accumulation body fat\nVitamin toxicity: Excessive intake fat-soluble vitamins (, D, E, K)\nObesity: Excessive accumulation body fatVitamin toxicity: Excessive intake fat-soluble vitamins (, D, E, K)Specific Nutritional Disorders\nVitamin Deficiencies: Scurvy, rickets, beriberi, pellagra\nMineral Deficiencies: Iron deficiency anemia, iodine deficiency, calcium deficiency\nEating Disorders: Anorexia nervosa, bulimia nervosa\nObesity: Excessive accumulation body fat\nMetabolic Syndrome: cluster conditions increase risk heart disease, stroke, diabetes\nVitamin Deficiencies: Scurvy, rickets, beriberi, pellagraMineral Deficiencies: Iron deficiency anemia, iodine deficiency, calcium deficiencyEating Disorders: Anorexia nervosa, bulimia nervosaObesity: Excessive accumulation body fatMetabolic Syndrome: cluster conditions increase risk heart disease, stroke, diabetesBiochemical Markers Nutritional Status\nProtein Status: Serum albumin, prealbumin, transferrin, retinol-binding protein\nVitamin Status: Serum vitamin levels, urinary excretion vitamin metabolites\nMineral Status: Serum mineral levels, red blood cell mineral levels\nIron Status: Serum iron, transferrin saturation, ferritin, hemoglobin, hematocrit\nLipid Status: Cholesterol, triglycerides, HDL cholesterol, LDL cholesterol\nGlucose Status: Fasting glucose, HbA1c, oral glucose tolerance test\nProtein Status: Serum albumin, prealbumin, transferrin, retinol-binding proteinVitamin Status: Serum vitamin levels, urinary excretion vitamin metabolitesMineral Status: Serum mineral levels, red blood cell mineral levelsIron Status: Serum iron, transferrin saturation, ferritin, hemoglobin, hematocritLipid Status: Cholesterol, triglycerides, HDL cholesterol, LDL cholesterolGlucose Status: Fasting glucose, HbA1c, oral glucose tolerance test","code":""},{"path":"physiology-8.html","id":"water-soluble-vitamin-disorders","chapter":"Physiology","heading":"Water-Soluble Vitamin Disorders","text":"","code":""},{"path":"physiology-8.html","id":"thiamin-vitamin-b1-1","chapter":"Physiology","heading":"Thiamin (Vitamin B1)","text":"Normal State: Adequate dietary intake thiamin\nSources: Whole grains, meat, fish\nRequirements: 1.2 mg/day men, 1.1 mg/day women\nSources: Whole grains, meat, fishRequirements: 1.2 mg/day men, 1.1 mg/day womenAbnormal State: Thiamin Deficiency\nCauses\nInadequate dietary intake: Common alcoholics individuals poor nutrition\nImpaired absorption: Gastrointestinal disorders\nIncreased requirements: Pregnancy, lactation\n\nDisorders\nBeriberi: Neurological cardiovascular symptoms\nWernicke-Korsakoff Syndrome: Neurological disorder associated chronic alcohol abuse\n\nBiochemical Findings\nDecreased erythrocyte transketolase activity\nElevated blood pyruvate lactate levels\n\nCauses\nInadequate dietary intake: Common alcoholics individuals poor nutrition\nImpaired absorption: Gastrointestinal disorders\nIncreased requirements: Pregnancy, lactation\nInadequate dietary intake: Common alcoholics individuals poor nutritionImpaired absorption: Gastrointestinal disordersIncreased requirements: Pregnancy, lactationDisorders\nBeriberi: Neurological cardiovascular symptoms\nWernicke-Korsakoff Syndrome: Neurological disorder associated chronic alcohol abuse\nBeriberi: Neurological cardiovascular symptomsWernicke-Korsakoff Syndrome: Neurological disorder associated chronic alcohol abuseBiochemical Findings\nDecreased erythrocyte transketolase activity\nElevated blood pyruvate lactate levels\nDecreased erythrocyte transketolase activityElevated blood pyruvate lactate levels","code":""},{"path":"physiology-8.html","id":"riboflavin-vitamin-b2-1","chapter":"Physiology","heading":"Riboflavin (Vitamin B2)","text":"Normal State: Adequate dietary intake riboflavin\nSources: Milk, eggs, meat, green vegetables\nRequirements: 1.3 mg/day men, 1.1 mg/day women\nSources: Milk, eggs, meat, green vegetablesRequirements: 1.3 mg/day men, 1.1 mg/day womenAbnormal State: Riboflavin Deficiency\nCauses\nInadequate dietary intake: Common individuals poor nutrition\nImpaired absorption: Gastrointestinal disorders\nIncreased requirements: Pregnancy, lactation\n\nDisorders\nAriboflavinosis: Characterized cheilosis, glossitis, dermatitis\n\nBiochemical Findings\nDecreased erythrocyte glutathione reductase activity\nDecreased urinary excretion riboflavin\n\nCauses\nInadequate dietary intake: Common individuals poor nutrition\nImpaired absorption: Gastrointestinal disorders\nIncreased requirements: Pregnancy, lactation\nInadequate dietary intake: Common individuals poor nutritionImpaired absorption: Gastrointestinal disordersIncreased requirements: Pregnancy, lactationDisorders\nAriboflavinosis: Characterized cheilosis, glossitis, dermatitis\nAriboflavinosis: Characterized cheilosis, glossitis, dermatitisBiochemical Findings\nDecreased erythrocyte glutathione reductase activity\nDecreased urinary excretion riboflavin\nDecreased erythrocyte glutathione reductase activityDecreased urinary excretion riboflavin","code":""},{"path":"physiology-8.html","id":"niacin-vitamin-b3-1","chapter":"Physiology","heading":"Niacin (Vitamin B3)","text":"Normal State: Adequate dietary intake niacin\nSources: Meat, fish, poultry, enriched grains\nRequirements: 16 mg/day men, 14 mg/day women\nSources: Meat, fish, poultry, enriched grainsRequirements: 16 mg/day men, 14 mg/day womenAbnormal State: Niacin Deficiency\nCauses\nInadequate dietary intake: Common individuals poor nutrition\nImpaired absorption: Gastrointestinal disorders\nDecreased conversion tryptophan niacin\n\nDisorders\nPellagra: Characterized dermatitis, diarrhea, dementia\n\nBiochemical Findings\nDecreased urinary excretion niacin metabolites\nDecreased erythrocyte nicotinamide adenine dinucleotide (NAD) levels\n\nCauses\nInadequate dietary intake: Common individuals poor nutrition\nImpaired absorption: Gastrointestinal disorders\nDecreased conversion tryptophan niacin\nInadequate dietary intake: Common individuals poor nutritionImpaired absorption: Gastrointestinal disordersDecreased conversion tryptophan niacinDisorders\nPellagra: Characterized dermatitis, diarrhea, dementia\nPellagra: Characterized dermatitis, diarrhea, dementiaBiochemical Findings\nDecreased urinary excretion niacin metabolites\nDecreased erythrocyte nicotinamide adenine dinucleotide (NAD) levels\nDecreased urinary excretion niacin metabolitesDecreased erythrocyte nicotinamide adenine dinucleotide (NAD) levelsAbnormal State: Niacin Toxicity\nCauses\nExcessive intake niacin supplements\n\nDisorders\nNiacin Flush: Characterized skin flushing itching\nLiver Damage: Elevated liver enzymes\n\nCauses\nExcessive intake niacin supplements\nExcessive intake niacin supplementsDisorders\nNiacin Flush: Characterized skin flushing itching\nLiver Damage: Elevated liver enzymes\nNiacin Flush: Characterized skin flushing itchingLiver Damage: Elevated liver enzymes","code":""},{"path":"physiology-8.html","id":"pyridoxine-vitamin-b6-1","chapter":"Physiology","heading":"Pyridoxine (Vitamin B6)","text":"Normal State: Adequate dietary intake pyridoxine\nSources: Meat, fish, poultry, whole grains\nRequirements: 1.3 mg/day adults\nSources: Meat, fish, poultry, whole grainsRequirements: 1.3 mg/day adultsAbnormal State: Pyridoxine Deficiency\nCauses\nInadequate dietary intake: Common alcoholics\nDrug interactions: Certain medications can interfere pyridoxine metabolism\n\nDisorders\nNeurological Symptoms: Seizures, depression, peripheral neuropathy\nDermatitis: Skin rash\nAnemia: Microcytic anemia\n\nBiochemical Findings\nDecreased plasma pyridoxal phosphate (PLP) levels\nElevated urinary xanthurenic acid excretion tryptophan load\n\nCauses\nInadequate dietary intake: Common alcoholics\nDrug interactions: Certain medications can interfere pyridoxine metabolism\nInadequate dietary intake: Common alcoholicsDrug interactions: Certain medications can interfere pyridoxine metabolismDisorders\nNeurological Symptoms: Seizures, depression, peripheral neuropathy\nDermatitis: Skin rash\nAnemia: Microcytic anemia\nNeurological Symptoms: Seizures, depression, peripheral neuropathyDermatitis: Skin rashAnemia: Microcytic anemiaBiochemical Findings\nDecreased plasma pyridoxal phosphate (PLP) levels\nElevated urinary xanthurenic acid excretion tryptophan load\nDecreased plasma pyridoxal phosphate (PLP) levelsElevated urinary xanthurenic acid excretion tryptophan loadAbnormal State: Pyridoxine Toxicity\nCauses\nExcessive intake pyridoxine supplements\n\nDisorders\nPeripheral Neuropathy: Nerve damage, causing numbness tingling extremities\n\nCauses\nExcessive intake pyridoxine supplements\nExcessive intake pyridoxine supplementsDisorders\nPeripheral Neuropathy: Nerve damage, causing numbness tingling extremities\nPeripheral Neuropathy: Nerve damage, causing numbness tingling extremities","code":""},{"path":"physiology-8.html","id":"folate-vitamin-b9-1","chapter":"Physiology","heading":"Folate (Vitamin B9)","text":"Normal State: Adequate dietary intake folate\nSources: Green leafy vegetables, fruits, fortified grains\nRequirements: 400 mcg/day adults, 600 mcg/day pregnant women\nSources: Green leafy vegetables, fruits, fortified grainsRequirements: 400 mcg/day adults, 600 mcg/day pregnant womenAbnormal State: Folate Deficiency\nCauses\nInadequate dietary intake: Common individuals poor nutrition\nImpaired absorption: Malabsorption syndromes\nDrug interactions: Certain medications can interfere folate metabolism\n\nDisorders\nMegaloblastic Anemia: Characterized large, abnormal red blood cells\nNeural Tube Defects: Birth defects affecting brain spinal cord developing fetuses\nIncreased risk cardiovascular disease\n\nBiochemical Findings\nDecreased serum red blood cell folate levels\nElevated homocysteine levels\n\nCauses\nInadequate dietary intake: Common individuals poor nutrition\nImpaired absorption: Malabsorption syndromes\nDrug interactions: Certain medications can interfere folate metabolism\nInadequate dietary intake: Common individuals poor nutritionImpaired absorption: Malabsorption syndromesDrug interactions: Certain medications can interfere folate metabolismDisorders\nMegaloblastic Anemia: Characterized large, abnormal red blood cells\nNeural Tube Defects: Birth defects affecting brain spinal cord developing fetuses\nIncreased risk cardiovascular disease\nMegaloblastic Anemia: Characterized large, abnormal red blood cellsNeural Tube Defects: Birth defects affecting brain spinal cord developing fetusesIncreased risk cardiovascular diseaseBiochemical Findings\nDecreased serum red blood cell folate levels\nElevated homocysteine levels\nDecreased serum red blood cell folate levelsElevated homocysteine levelsAbnormal State: Folate Toxicity\nCauses\nExcessive intake folate supplements\n\nDisorders\nMasking Vitamin B12 Deficiency: High folate intake can mask symptoms vitamin B12 deficiency, leading irreversible neurological damage\n\nCauses\nExcessive intake folate supplements\nExcessive intake folate supplementsDisorders\nMasking Vitamin B12 Deficiency: High folate intake can mask symptoms vitamin B12 deficiency, leading irreversible neurological damage\nMasking Vitamin B12 Deficiency: High folate intake can mask symptoms vitamin B12 deficiency, leading irreversible neurological damage","code":""},{"path":"physiology-8.html","id":"cobalamin-vitamin-b12-1","chapter":"Physiology","heading":"Cobalamin (Vitamin B12)","text":"Normal State: Adequate dietary intake cobalamin\nSources: Meat, fish, poultry, dairy products\nRequirements: 2.4 mcg/day adults\nSources: Meat, fish, poultry, dairy productsRequirements: 2.4 mcg/day adultsAbnormal State: Cobalamin Deficiency\nCauses\nInadequate dietary intake: Common vegans vegetarians\nImpaired absorption: Pernicious anemia (lack intrinsic factor), malabsorption syndromes\n\nDisorders\nMegaloblastic Anemia: Characterized large, abnormal red blood cells\nNeurological Symptoms: Peripheral neuropathy, cognitive impairment\nIncreased risk cardiovascular disease\n\nBiochemical Findings\nDecreased serum vitamin B12 levels\nElevated homocysteine methylmalonic acid (MMA) levels\n\nCauses\nInadequate dietary intake: Common vegans vegetarians\nImpaired absorption: Pernicious anemia (lack intrinsic factor), malabsorption syndromes\nInadequate dietary intake: Common vegans vegetariansImpaired absorption: Pernicious anemia (lack intrinsic factor), malabsorption syndromesDisorders\nMegaloblastic Anemia: Characterized large, abnormal red blood cells\nNeurological Symptoms: Peripheral neuropathy, cognitive impairment\nIncreased risk cardiovascular disease\nMegaloblastic Anemia: Characterized large, abnormal red blood cellsNeurological Symptoms: Peripheral neuropathy, cognitive impairmentIncreased risk cardiovascular diseaseBiochemical Findings\nDecreased serum vitamin B12 levels\nElevated homocysteine methylmalonic acid (MMA) levels\nDecreased serum vitamin B12 levelsElevated homocysteine methylmalonic acid (MMA) levels","code":""},{"path":"physiology-8.html","id":"ascorbic-acid-vitamin-c-1","chapter":"Physiology","heading":"Ascorbic Acid (Vitamin C)","text":"Normal State: Adequate dietary intake ascorbic acid\nSources: Fruits vegetables, especially citrus fruits berries\nRequirements: 90 mg/day men, 75 mg/day women\nSources: Fruits vegetables, especially citrus fruits berriesRequirements: 90 mg/day men, 75 mg/day womenAbnormal State: Ascorbic Acid Deficiency\nCauses\nInadequate dietary intake: Common individuals limited access fresh fruits vegetables\n\nDisorders\nScurvy: Characterized bleeding gums, poor wound healing, anemia\n\nBiochemical Findings\nDecreased serum ascorbic acid levels\n\nCauses\nInadequate dietary intake: Common individuals limited access fresh fruits vegetables\nInadequate dietary intake: Common individuals limited access fresh fruits vegetablesDisorders\nScurvy: Characterized bleeding gums, poor wound healing, anemia\nScurvy: Characterized bleeding gums, poor wound healing, anemiaBiochemical Findings\nDecreased serum ascorbic acid levels\nDecreased serum ascorbic acid levels","code":""},{"path":"physiology-8.html","id":"fat-soluble-vitamin-disorders","chapter":"Physiology","heading":"Fat-Soluble Vitamin Disorders","text":"","code":""},{"path":"physiology-8.html","id":"vitamin-a-1","chapter":"Physiology","heading":"Vitamin A","text":"Normal State: Adequate dietary intake vitamin \nSources: Liver, dairy products, eggs, orange yellow fruits vegetables\nRequirements: 900 mcg/day men, 700 mcg/day women\nSources: Liver, dairy products, eggs, orange yellow fruits vegetablesRequirements: 900 mcg/day men, 700 mcg/day womenAbnormal State: Vitamin Deficiency\nCauses\nInadequate dietary intake: Common developing countries\nImpaired absorption: Fat malabsorption syndromes\n\nDisorders\nNight Blindness: Impaired vision low light conditions\nXerophthalmia: Dryness damage cornea\nImpaired Immune Function: Increased susceptibility infections\n\nBiochemical Findings\nDecreased serum retinol levels\n\nCauses\nInadequate dietary intake: Common developing countries\nImpaired absorption: Fat malabsorption syndromes\nInadequate dietary intake: Common developing countriesImpaired absorption: Fat malabsorption syndromesDisorders\nNight Blindness: Impaired vision low light conditions\nXerophthalmia: Dryness damage cornea\nImpaired Immune Function: Increased susceptibility infections\nNight Blindness: Impaired vision low light conditionsXerophthalmia: Dryness damage corneaImpaired Immune Function: Increased susceptibility infectionsBiochemical Findings\nDecreased serum retinol levels\nDecreased serum retinol levelsAbnormal State: Vitamin Toxicity\nCauses\nExcessive intake vitamin supplements\n\nDisorders\nAcute Toxicity: Nausea, vomiting, headache, dizziness\nChronic Toxicity: Liver damage, bone pain, birth defects\n\nBiochemical Findings\nElevated serum retinol levels\n\nCauses\nExcessive intake vitamin supplements\nExcessive intake vitamin supplementsDisorders\nAcute Toxicity: Nausea, vomiting, headache, dizziness\nChronic Toxicity: Liver damage, bone pain, birth defects\nAcute Toxicity: Nausea, vomiting, headache, dizzinessChronic Toxicity: Liver damage, bone pain, birth defectsBiochemical Findings\nElevated serum retinol levels\nElevated serum retinol levels","code":""},{"path":"physiology-8.html","id":"vitamin-d-1","chapter":"Physiology","heading":"Vitamin D","text":"Normal State: Adequate vitamin D status\nSources: Sunlight exposure, fortified foods, supplements\nRequirements: 600 IU/day adults, 800 IU/day adults 70\nSources: Sunlight exposure, fortified foods, supplementsRequirements: 600 IU/day adults, 800 IU/day adults 70Abnormal State: Vitamin D Deficiency\nCauses\nInadequate sunlight exposure: Limited outdoor activities, dark skin pigmentation\nInadequate dietary intake: Limited consumption vitamin D-rich foods\nImpaired absorption: Fat malabsorption syndromes\nKidney liver disorders: Impaired conversion active form\n\nDisorders\nRickets: Bone deformities children\nOsteomalacia: Softening bones adults\nOsteoporosis: Decreased bone density, increasing risk fractures\n\nBiochemical Findings\nDecreased serum 25-hydroxyvitamin D [25(OH)D] levels\nElevated parathyroid hormone (PTH) levels response hypocalcemia\n\nCauses\nInadequate sunlight exposure: Limited outdoor activities, dark skin pigmentation\nInadequate dietary intake: Limited consumption vitamin D-rich foods\nImpaired absorption: Fat malabsorption syndromes\nKidney liver disorders: Impaired conversion active form\nInadequate sunlight exposure: Limited outdoor activities, dark skin pigmentationInadequate dietary intake: Limited consumption vitamin D-rich foodsImpaired absorption: Fat malabsorption syndromesKidney liver disorders: Impaired conversion active formDisorders\nRickets: Bone deformities children\nOsteomalacia: Softening bones adults\nOsteoporosis: Decreased bone density, increasing risk fractures\nRickets: Bone deformities childrenOsteomalacia: Softening bones adultsOsteoporosis: Decreased bone density, increasing risk fracturesBiochemical Findings\nDecreased serum 25-hydroxyvitamin D [25(OH)D] levels\nElevated parathyroid hormone (PTH) levels response hypocalcemia\nDecreased serum 25-hydroxyvitamin D [25(OH)D] levelsElevated parathyroid hormone (PTH) levels response hypocalcemiaAbnormal State: Vitamin D Toxicity\nCauses\nExcessive intake vitamin D supplements\n\nDisorders\nHypercalcemia: Elevated serum calcium levels\nKidney Stones: Calcium deposits kidneys\nSoft Tissue Calcification: Calcium deposits soft tissues\n\nBiochemical Findings\nElevated serum 25(OH)D calcium levels\n\nCauses\nExcessive intake vitamin D supplements\nExcessive intake vitamin D supplementsDisorders\nHypercalcemia: Elevated serum calcium levels\nKidney Stones: Calcium deposits kidneys\nSoft Tissue Calcification: Calcium deposits soft tissues\nHypercalcemia: Elevated serum calcium levelsKidney Stones: Calcium deposits kidneysSoft Tissue Calcification: Calcium deposits soft tissuesBiochemical Findings\nElevated serum 25(OH)D calcium levels\nElevated serum 25(OH)D calcium levels","code":""},{"path":"physiology-8.html","id":"vitamin-e-1","chapter":"Physiology","heading":"Vitamin E","text":"Normal State: Adequate dietary intake vitamin E\nSources: Vegetable oils, nuts, seeds, green leafy vegetables\nRequirements: 15 mg/day adults\nSources: Vegetable oils, nuts, seeds, green leafy vegetablesRequirements: 15 mg/day adultsAbnormal State: Vitamin E Deficiency\nCauses\nFat malabsorption syndromes: Cystic fibrosis, celiac disease\nGenetic disorders: Abetalipoproteinemia\n\nDisorders\nNeurological Symptoms: Peripheral neuropathy, ataxia\nHemolytic Anemia: Damage red blood cells\n\nBiochemical Findings\nDecreased serum alpha-tocopherol levels\n\nCauses\nFat malabsorption syndromes: Cystic fibrosis, celiac disease\nGenetic disorders: Abetalipoproteinemia\nFat malabsorption syndromes: Cystic fibrosis, celiac diseaseGenetic disorders: AbetalipoproteinemiaDisorders\nNeurological Symptoms: Peripheral neuropathy, ataxia\nHemolytic Anemia: Damage red blood cells\nNeurological Symptoms: Peripheral neuropathy, ataxiaHemolytic Anemia: Damage red blood cellsBiochemical Findings\nDecreased serum alpha-tocopherol levels\nDecreased serum alpha-tocopherol levelsAbnormal State: Vitamin E Toxicity\nCauses\nExcessive intake vitamin E supplements\n\nDisorders\nIncreased Risk Bleeding: Interferes blood clotting\n\nCauses\nExcessive intake vitamin E supplements\nExcessive intake vitamin E supplementsDisorders\nIncreased Risk Bleeding: Interferes blood clotting\nIncreased Risk Bleeding: Interferes blood clotting","code":""},{"path":"physiology-8.html","id":"vitamin-k-1","chapter":"Physiology","heading":"Vitamin K","text":"Normal State: Adequate vitamin K status\nSources: Green leafy vegetables synthesized intestinal bacteria\nRequirements: 120 mcg/day men, 90 mcg/day women\nSources: Green leafy vegetables synthesized intestinal bacteriaRequirements: 120 mcg/day men, 90 mcg/day womenAbnormal State: Vitamin K Deficiency\nCauses\nInadequate dietary intake: Rare\nMalabsorption Syndromes: Cystic fibrosis, celiac disease\nAntibiotic Use: Kills intestinal bacteria\nNewborns: Lack intestinal bacteria limited placental transfer\n\nDisorders\nBleeding Disorders: Impaired blood clotting\n\nBiochemical Findings\nProlonged Prothrombin Time (PT) International Normalized Ratio (INR)\n\nPoor bone health\nCauses\nInadequate dietary intake: Rare\nMalabsorption Syndromes: Cystic fibrosis, celiac disease\nAntibiotic Use: Kills intestinal bacteria\nNewborns: Lack intestinal bacteria limited placental transfer\nInadequate dietary intake: RareMalabsorption Syndromes: Cystic fibrosis, celiac diseaseAntibiotic Use: Kills intestinal bacteriaNewborns: Lack intestinal bacteria limited placental transferDisorders\nBleeding Disorders: Impaired blood clotting\nBleeding Disorders: Impaired blood clottingBiochemical Findings\nProlonged Prothrombin Time (PT) International Normalized Ratio (INR)\nProlonged Prothrombin Time (PT) International Normalized Ratio (INR)Poor bone healthAbnormal State: Vitamin K Toxicity\nCauses\nExcessive intake synthetic vitamin K (menadione)\n\nDisorders\nRare, can cause hemolytic anemia liver damage infants\n\nCauses\nExcessive intake synthetic vitamin K (menadione)\nExcessive intake synthetic vitamin K (menadione)Disorders\nRare, can cause hemolytic anemia liver damage infants\nRare, can cause hemolytic anemia liver damage infants","code":""},{"path":"physiology-8.html","id":"summary-table-of-nutritional-disorders","chapter":"Physiology","heading":"Summary Table of Nutritional Disorders","text":"","code":""},{"path":"physiology-8.html","id":"clinical-significance-11","chapter":"Physiology","heading":"Clinical Significance","text":"Diagnosis Management\nAccurate assessment nutritional status essential diagnosing managing nutritional disorders\nAccurate assessment nutritional status essential diagnosing managing nutritional disordersPublic Health Interventions\nAddressing nutritional deficiencies populations food fortification supplementation programs\nAddressing nutritional deficiencies populations food fortification supplementation programsPersonalized Nutrition\nTailoring dietary recommendations supplement use based individual’s nutritional status genetic factors\nTailoring dietary recommendations supplement use based individual’s nutritional status genetic factors","code":""},{"path":"physiology-8.html","id":"key-terms-66","chapter":"Physiology","heading":"Key Terms","text":"Malnutrition: Nutritional imbalance resulting inadequate excessive intake nutrientsUndernutrition: Deficiency one essential nutrientsOvernutrition: Excessive intake nutrients, leading nutrient toxicityScurvy: Vitamin C deficiencyRickets: Vitamin D deficiency childrenBeriberi: Thiamin deficiencyPellagra: Niacin deficiencyMegaloblastic Anemia: Anemia characterized large, abnormal red blood cells, often due folate vitamin B12 deficiencyOsteomalacia: Softening bones adultsOsteoporosis: Decreased bone density, increasing risk fracturesBiochemical Marker: measurable substance blood, urine, tissues reflects nutritional status","code":""},{"path":"properties-7.html","id":"properties-7","chapter":"Properties","heading":"Properties","text":"Understanding physical chemical properties vitamins nutrients crucial comprehending absorption, transport, storage, biological activities","code":""},{"path":"properties-7.html","id":"general-properties-of-vitamins","chapter":"Properties","heading":"General Properties of Vitamins","text":"Organic Compounds\nVitamins organic compounds essential human health\nVitamins organic compounds essential human healthDietary Requirements\nrequired small amounts diet body synthesize adequately\nrequired small amounts diet body synthesize adequatelyClassification\nVitamins classified two groups based solubility: water-soluble fat-soluble\nVitamins classified two groups based solubility: water-soluble fat-soluble","code":""},{"path":"properties-7.html","id":"water-soluble-vitamins-1","chapter":"Properties","heading":"Water-Soluble Vitamins","text":"General Characteristics\nSoluble water\nAbsorbed directly bloodstream\nstored body significant extent\nExcess excreted urine\nLess risk toxicity compared fat-soluble vitamins\nAct coenzymes various metabolic reactions\nSoluble waterAbsorbed directly bloodstreamNot stored body significant extentExcess excreted urineLess risk toxicity compared fat-soluble vitaminsAct coenzymes various metabolic reactions","code":""},{"path":"properties-7.html","id":"thiamin-vitamin-b1-2","chapter":"Properties","heading":"Thiamin (Vitamin B1)","text":"Chemical Name: ThiaminStructure: Contains pyrimidine ring thiazole ring connected methylene bridgeSolubility: Soluble waterStability: Unstable heat, especially alkaline solutionsActive Form: Thiamin pyrophosphate (\\(TPP\\))Biochemical Functions\nCoenzyme pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, transketolase\nInvolved carbohydrate metabolism energy production\nCoenzyme pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, transketolaseInvolved carbohydrate metabolism energy production","code":""},{"path":"properties-7.html","id":"riboflavin-vitamin-b2-2","chapter":"Properties","heading":"Riboflavin (Vitamin B2)","text":"Chemical Names: RiboflavinStructure: Consists flavin ring system attached ribitol (sugar alcohol)Solubility: Slightly soluble waterStability: Unstable light, especially alkaline solutionsActive Forms: Flavin mononucleotide (\\(FMN\\)) flavin adenine dinucleotide (\\(FAD\\))Biochemical Functions\nCoenzymes oxidoreductase enzymes\nInvolved energy metabolism, electron transport, antioxidant defense\nCoenzymes oxidoreductase enzymesInvolved energy metabolism, electron transport, antioxidant defense","code":""},{"path":"properties-7.html","id":"niacin-vitamin-b3-2","chapter":"Properties","heading":"Niacin (Vitamin B3)","text":"Chemical Names: Nicotinic acid, nicotinamideStructure: Pyridine derivativeSolubility: Soluble waterStability: Stable heat, light, airActive Forms: Nicotinamide adenine dinucleotide (\\(NAD^+\\)) nicotinamide adenine dinucleotide phosphate (\\(NADP^+\\))Biochemical Functions\nCoenzymes numerous dehydrogenase enzymes\nInvolved energy metabolism, DNA repair, cell signaling\nCoenzymes numerous dehydrogenase enzymesInvolved energy metabolism, DNA repair, cell signaling","code":""},{"path":"properties-7.html","id":"pantothenic-acid-vitamin-b5-1","chapter":"Properties","heading":"Pantothenic Acid (Vitamin B5)","text":"Chemical Name: Pantothenic acidStructure: Consists β-alanine pantoic acid linked peptide bondSolubility: Soluble waterStability: Unstable heat, especially acidic alkaline solutionsActive Form: Coenzyme (\\(CoA\\))Biochemical Functions\nComponent coenzyme (\\(CoA\\))\nInvolved fatty acid synthesis oxidation, citric acid cycle, synthesis cholesterol steroid hormones\nComponent coenzyme (\\(CoA\\))Involved fatty acid synthesis oxidation, citric acid cycle, synthesis cholesterol steroid hormones","code":""},{"path":"properties-7.html","id":"pyridoxine-vitamin-b6-2","chapter":"Properties","heading":"Pyridoxine (Vitamin B6)","text":"Chemical Names: Pyridoxine, pyridoxal, pyridoxamineStructure: Pyridine derivative different functional groupsSolubility: Soluble waterStability: Unstable heat, light, alkaline solutionsActive Form: Pyridoxal phosphate (\\(PLP\\))Biochemical Functions\nCoenzyme numerous enzymes involved amino acid metabolism\nInvolved neurotransmitter synthesis, heme synthesis, glycogen metabolism\nCoenzyme numerous enzymes involved amino acid metabolismInvolved neurotransmitter synthesis, heme synthesis, glycogen metabolism","code":""},{"path":"properties-7.html","id":"biotin-vitamin-b7-1","chapter":"Properties","heading":"Biotin (Vitamin B7)","text":"Chemical Name: BiotinStructure: Consists ureido ring fused tetrahydrothiophene ringSolubility: Slightly soluble waterStability: Stable heat air, unstable strong acids basesActive Form: Biotin covalently bound carboxylase enzymesBiochemical Functions\nCoenzyme carboxylation enzymes\nInvolved fatty acid synthesis, gluconeogenesis, amino acid catabolism\nCoenzyme carboxylation enzymesInvolved fatty acid synthesis, gluconeogenesis, amino acid catabolism","code":""},{"path":"properties-7.html","id":"folate-vitamin-b9-2","chapter":"Properties","heading":"Folate (Vitamin B9)","text":"Chemical Names: Folic acid, pteroylglutamic acidStructure: Consists pteridine ring, p-aminobenzoic acid (\\(PABA\\)), glutamic acidSolubility: Slightly soluble waterStability: Unstable heat, light, acidic solutionsActive Form: Tetrahydrofolate (\\(THF\\))Biochemical Functions\nCoenzyme one-carbon transfer reactions\nInvolved DNA synthesis, amino acid metabolism, homocysteine metabolism\nCoenzyme one-carbon transfer reactionsInvolved DNA synthesis, amino acid metabolism, homocysteine metabolism","code":""},{"path":"properties-7.html","id":"cobalamin-vitamin-b12-2","chapter":"Properties","heading":"Cobalamin (Vitamin B12)","text":"Chemical Names: CobalaminStructure: Contains corrin ring system central cobalt atomSolubility: Soluble waterStability: Stable heat, unstable light, strong acids, basesActive Forms: Methylcobalamin adenosylcobalaminBiochemical Functions\nCoenzyme methionine synthase methylmalonyl-CoA mutase\nInvolved homocysteine metabolism, DNA synthesis, nerve function\nCoenzyme methionine synthase methylmalonyl-CoA mutaseInvolved homocysteine metabolism, DNA synthesis, nerve function","code":""},{"path":"properties-7.html","id":"ascorbic-acid-vitamin-c-2","chapter":"Properties","heading":"Ascorbic Acid (Vitamin C)","text":"Chemical Name: Ascorbic acidStructure: six-carbon lactone ringSolubility: Soluble waterStability: Unstable heat, light, air; easily oxidizedActive Form: Ascorbic acidBiochemical Functions\nAntioxidant\nRequired collagen synthesis, carnitine synthesis, neurotransmitter synthesis\nEnhances iron absorption\nAntioxidantRequired collagen synthesis, carnitine synthesis, neurotransmitter synthesisEnhances iron absorption","code":""},{"path":"properties-7.html","id":"fat-soluble-vitamins-1","chapter":"Properties","heading":"Fat-Soluble Vitamins","text":"General Characteristics\nSoluble lipids\nAbsorbed along dietary fats\nStored liver adipose tissue\nRisk toxicity excessive intake\nInvolved various physiological functions, vision, bone metabolism, antioxidant defense\nSoluble lipidsAbsorbed along dietary fatsStored liver adipose tissueRisk toxicity excessive intakeInvolved various physiological functions, vision, bone metabolism, antioxidant defense","code":""},{"path":"properties-7.html","id":"vitamin-a-2","chapter":"Properties","heading":"Vitamin A","text":"Chemical Names: Retinol, retinal, retinoic acid, beta-carotene (provitamin)Structure: Consists beta-ionone ring isoprenoid chainSolubility: Soluble lipidsStability: Unstable heat, light, airActive Forms: Retinol, retinal, retinoic acidBiochemical Functions\nVision (retinal)\nCell differentiation gene expression (retinoic acid)\nImmune function\nVision (retinal)Cell differentiation gene expression (retinoic acid)Immune function","code":""},{"path":"properties-7.html","id":"vitamin-d-2","chapter":"Properties","heading":"Vitamin D","text":"Chemical Names: Cholecalciferol (Vitamin D3), ergocalciferol (Vitamin D2)Structure: Steroid derivativeSolubility: Soluble lipidsStability: Stable heat air, unstable lightActive Form: Calcitriol (1,25-dihydroxyvitamin D)Biochemical Functions\nCalcium phosphate metabolism\nBone health\nCell growth differentiation\nCalcium phosphate metabolismBone healthCell growth differentiationActivation\nCholecalciferol ergocalciferol require two hydroxylation steps activation\n25-hydroxylation liver forms calcidiol (25-hydroxyvitamin D)\n1α-hydroxylation kidney forms calcitriol (1,25-dihydroxyvitamin D)\n\nCholecalciferol ergocalciferol require two hydroxylation steps activation\n25-hydroxylation liver forms calcidiol (25-hydroxyvitamin D)\n1α-hydroxylation kidney forms calcitriol (1,25-dihydroxyvitamin D)\n25-hydroxylation liver forms calcidiol (25-hydroxyvitamin D)1α-hydroxylation kidney forms calcitriol (1,25-dihydroxyvitamin D)","code":""},{"path":"properties-7.html","id":"vitamin-e-2","chapter":"Properties","heading":"Vitamin E","text":"Chemical Names: Tocopherols, tocotrienolsStructure: Consists chromanol ring isoprenoid side chainSolubility: Soluble lipidsStability: Unstable heat, light, air, alkaline conditionsActive Form: Alpha-tocopherolBiochemical Functions\nAntioxidant\nProtects cell membranes lipid peroxidation\nAntioxidantProtects cell membranes lipid peroxidation","code":""},{"path":"properties-7.html","id":"vitamin-k-2","chapter":"Properties","heading":"Vitamin K","text":"Chemical Names: Phylloquinone (Vitamin K1), menaquinone (Vitamin K2), menadione (synthetic form)Structure: Consists quinone ring isoprenoid side chainSolubility: Soluble lipidsStability: Unstable light alkaline solutionsActive Forms: Phylloquinone menaquinoneBiochemical Functions\nBlood clotting\nBone metabolism\nBlood clottingBone metabolismAction\nActs coenzyme gamma-glutamyl carboxylase, carboxylates glutamate residues clotting factors II, VII, IX, X\nActs coenzyme gamma-glutamyl carboxylase, carboxylates glutamate residues clotting factors II, VII, IX, X","code":""},{"path":"properties-7.html","id":"properties-and-functions-summary","chapter":"Properties","heading":"Properties and Functions Summary","text":"","code":""},{"path":"properties-7.html","id":"clinical-significance-12","chapter":"Properties","heading":"Clinical Significance","text":"Understanding Properties Aids \nPredicting absorption, transport, storage vitamins within body\nDesigning appropriate dietary recommendations supplementation strategies\nDeveloping analytical methods measuring vitamin levels biological samples\nExplaining mechanisms vitamin deficiencies toxicities\nPredicting absorption, transport, storage vitamins within bodyDesigning appropriate dietary recommendations supplementation strategiesDeveloping analytical methods measuring vitamin levels biological samplesExplaining mechanisms vitamin deficiencies toxicities","code":""},{"path":"properties-7.html","id":"key-terms-67","chapter":"Properties","heading":"Key Terms","text":"Vitamins: Essential organic compounds required small amounts human healthWater-Soluble Vitamins: Vitamins soluble water readily excretedFat-Soluble Vitamins: Vitamins soluble lipids stored bodyCoenzyme: substance required activity enzymeAntioxidant: substance protects cells damage caused free radicalsAbsorption: process nutrients taken digestive tract bloodstreamTransport: process nutrients carried bloodstream tissues organsStorage: process nutrients stored bodyExcretion: process waste products eliminated bodyDeficiency: condition body enough particular nutrientToxicity: condition body much particular nutrientRetinoids: class chemical compounds related vitamin ATocopherols: class chemical compounds related vitamin EQuinones: class chemical compounds related vitamin K","code":""},{"path":"procedures-8.html","id":"procedures-8","chapter":"Procedures","heading":"Procedures","text":"section covers laboratory analysis vitamins nutrients","code":""},{"path":"procedures-8.html","id":"general-principles-of-vitamin-and-nutrient-analysis","chapter":"Procedures","heading":"General Principles of Vitamin and Nutrient Analysis","text":"Purpose: measure levels vitamins nutrients biological samples assessment nutritional statusAnalytical Techniques\nSpectrophotometry\nFluorometry\nImmunoassays (ELISA, CLIA)\nChromatography (HPLC, GC, TLC)\nLiquid Chromatography-Mass Spectrometry (LC-MS)\nAtomic Absorption Spectrometry (AAS)\nInductively Coupled Plasma Mass Spectrometry (ICP-MS)\nPoint--Care Testing (POCT)\nSpectrophotometryFluorometryImmunoassays (ELISA, CLIA)Chromatography (HPLC, GC, TLC)Liquid Chromatography-Mass Spectrometry (LC-MS)Atomic Absorption Spectrometry (AAS)Inductively Coupled Plasma Mass Spectrometry (ICP-MS)Point--Care Testing (POCT)","code":""},{"path":"procedures-8.html","id":"special-precautions-12","chapter":"Procedures","heading":"Special Precautions","text":"Patient Preparation\nFasting: Required tests\nMedications: drugs interfere nutrient tests\nSupplements: Avoid testing\nAlcohol Consumption: Affects absorption metabolism\nTiming: Important due diurnal variations\nFasting: Required testsMedications: drugs interfere nutrient testsSupplements: Avoid testingAlcohol Consumption: Affects absorption metabolismTiming: Important due diurnal variationsSpecimen Collection\nUse appropriate collection tubes\nFollow correct order draw\nUse proper venipuncture technique\nLabel specimens immediately accurately\nCollect correct volume blood\nUse appropriate collection tubesFollow correct order drawUse proper venipuncture techniqueLabel specimens immediately accuratelyCollect correct volume bloodSpecimen Processing\nCentrifuge promptly collection\nSeparate serum plasma cells within specified time frame\nAliquot specimens appropriate containers\nStore specimens appropriate temperature\nThaw specimens properly testing\nLight Protection: Especially important certain vitamins\nCentrifuge promptly collectionSeparate serum plasma cells within specified time frameAliquot specimens appropriate containersStore specimens appropriate temperatureThaw specimens properly testingLight Protection: Especially important certain vitamins","code":""},{"path":"procedures-8.html","id":"troubleshooting-16","chapter":"Procedures","heading":"Troubleshooting","text":"High Nutrient Results\nPre-analytical: Patient fasting, recent supplement intake, medication interference, improper collection tube, delayed processing, contamination specimen\nAnalytical: Incorrect calibration, reagent deterioration, interfering substances, cross-reactivity, non-specific binding\nPre-analytical: Patient fasting, recent supplement intake, medication interference, improper collection tube, delayed processing, contamination specimenAnalytical: Incorrect calibration, reagent deterioration, interfering substances, cross-reactivity, non-specific bindingLow Nutrient Results\nPre-analytical: Improper collection tube, delayed processing, improper storage, medication interference\nAnalytical: Incorrect calibration, reagent deterioration, interfering substances, assay drift\nPre-analytical: Improper collection tube, delayed processing, improper storage, medication interferenceAnalytical: Incorrect calibration, reagent deterioration, interfering substances, assay driftInconsistent Results\nPre-analytical: Patient variability, specimen handling errors\nAnalytical: Assay variability, interfering substances, cross-reactivity\nPost-analytical: Transcription errors, reporting errors\nPre-analytical: Patient variability, specimen handling errorsAnalytical: Assay variability, interfering substances, cross-reactivityPost-analytical: Transcription errors, reporting errorsQuality Control Failures\nPre-analytical: QC material improperly stored, QC material expired\nAnalytical: Incorrect calibration, reagent deterioration, instrument malfunction\nAction: Investigate cause failure take corrective action\nPre-analytical: QC material improperly stored, QC material expiredAnalytical: Incorrect calibration, reagent deterioration, instrument malfunctionAction: Investigate cause failure take corrective action","code":""},{"path":"procedures-8.html","id":"interfering-substances-16","chapter":"Procedures","heading":"Interfering Substances","text":"Hemolysis: Releases intracellular componentsLipemia: Interferes spectrophotometric assaysBilirubin: Interferes spectrophotometric assaysDrugs: Directly affect nutrient levels interfere assaysHeterophile Antibodies: Cause falsely high low resultsCross-Reactivity: Antibodies may cross-react structurally similar compoundsBiotin: Interferes biotin-streptavidin assaysAscorbic Acid: Interferes certain assays acting reducing agentHomocysteine: Interferes folate vitamin B12 assays","code":""},{"path":"procedures-8.html","id":"key-terms-68","chapter":"Procedures","heading":"Key Terms","text":"Pre-Analytical: Processes sample analysisAnalytical: Processes involved sample analysisPost-Analytical: Processes sample analysisInterfering Substance: Affects test accuracyCalibration: Adjusting instrument accurate readingsQuality Control: Measures ensure test accuracy precisionHemolysis: Breakdown red blood cellsLipemia: Excess lipids blood","code":""},{"path":"principles-8.html","id":"principles-8","chapter":"Principles","heading":"Principles","text":"Analyzing vitamins nutrients requires range sophisticated laboratory techniques. procedures fundamental assessing nutritional status diagnosing deficiencies excesses","code":""},{"path":"principles-8.html","id":"general-principles-of-nutrient-analysis","chapter":"Principles","heading":"General Principles of Nutrient Analysis","text":"Sample Preparation: Sample preparation crucial accurate nutrient analysis. involves extraction, purification, concentration stepsQuality Control: Quality control measures essential ensure accuracy reliability resultsStandardization: Standardization methods use reference materials necessary minimize variability laboratories","code":""},{"path":"principles-8.html","id":"common-analytical-techniques","chapter":"Principles","heading":"Common Analytical Techniques","text":"","code":""},{"path":"principles-8.html","id":"spectrophotometry","chapter":"Principles","heading":"Spectrophotometry","text":"Principle: Measures absorbance transmission light solutionApplication: Used measuring vitamins characteristic absorption spectra ultraviolet (UV) visible regionProcedure\nSample Preparation: Extract vitamin sample dissolve suitable solvent\nSpectrophotometric Measurement: Measure absorbance solution specific wavelength\nQuantification: Compare absorbance standard curve determine vitamin concentration\nSample Preparation: Extract vitamin sample dissolve suitable solventSpectrophotometric Measurement: Measure absorbance solution specific wavelengthQuantification: Compare absorbance standard curve determine vitamin concentrationAdvantages: Simple, inexpensive, widely availableLimitations: Can subject interference compounds sampleExamples\nVitamin : Measurement retinol serum plasma\nVitamin C: Measurement ascorbic acid serum plasma\nVitamin : Measurement retinol serum plasmaVitamin C: Measurement ascorbic acid serum plasma","code":""},{"path":"principles-8.html","id":"fluorometry","chapter":"Principles","heading":"Fluorometry","text":"Principle: Measures fluorescence emitted molecule absorbs light specific wavelengthApplication: Used vitamins exhibit fluorescence propertiesProcedure\nSample Preparation: Extract vitamin sample dissolve suitable solvent\nFluorometric Measurement: Excite sample light specific wavelength measure emitted fluorescence\nQuantification: Compare fluorescence intensity standard curve determine vitamin concentration\nSample Preparation: Extract vitamin sample dissolve suitable solventFluorometric Measurement: Excite sample light specific wavelength measure emitted fluorescenceQuantification: Compare fluorescence intensity standard curve determine vitamin concentrationAdvantages: sensitive spectrophotometryLimitations: Susceptible interference fluorescent compounds sampleExamples\nRiboflavin (Vitamin B2): Measurement serum urine\nThiamin (Vitamin B1): Measurement blood\nRiboflavin (Vitamin B2): Measurement serum urineThiamin (Vitamin B1): Measurement blood","code":""},{"path":"principles-8.html","id":"immunoassays-1","chapter":"Principles","heading":"Immunoassays","text":"Principle: Based specific binding antibodies target analyte (vitamin nutrient)Types\nEnzyme-Linked Immunosorbent Assay (ELISA): Uses enzyme-labeled antibody detect analyte\nChemiluminescent Immunoassay (CLIA): Uses chemiluminescent label detect analyte\nEnzyme-Linked Immunosorbent Assay (ELISA): Uses enzyme-labeled antibody detect analyteChemiluminescent Immunoassay (CLIA): Uses chemiluminescent label detect analyteProcedure\nSample Preparation: Prepare sample remove interfering substances\nAntibody Binding: Add sample microplate coated specific antibody\nEnzyme-Labeled Antibody: Add enzyme-labeled antibody binds analyte\nSubstrate Addition: Add substrate reacts enzyme produce detectable signal\nSignal Measurement: Measure signal (absorbance, fluorescence, luminescence)\nQuantification: Compare signal standard curve determine analyte concentration\nSample Preparation: Prepare sample remove interfering substancesAntibody Binding: Add sample microplate coated specific antibodyEnzyme-Labeled Antibody: Add enzyme-labeled antibody binds analyteSubstrate Addition: Add substrate reacts enzyme produce detectable signalSignal Measurement: Measure signal (absorbance, fluorescence, luminescence)Quantification: Compare signal standard curve determine analyte concentrationAdvantages: High sensitivity specificityLimitations: Can subject interference heterophile antibodies matrix effectsExamples\nVitamin B12: Measurement serum plasma\nFolate: Measurement serum red blood cells\nVitamin B12: Measurement serum plasmaFolate: Measurement serum red blood cells","code":""},{"path":"principles-8.html","id":"chromatography-1","chapter":"Principles","heading":"Chromatography","text":"Principle: Separates compounds based physical chemical propertiesTypes\nHigh-Performance Liquid Chromatography (HPLC): Uses high pressure force sample column stationary phase\nApplications: Water-soluble fat-soluble vitamins, amino acids, fatty acids\n\nGas Chromatography (GC): Separates volatile compounds based boiling points\nApplications: Fatty acids, volatile organic compounds\n\nThin-Layer Chromatography (TLC): Separates compounds thin layer adsorbent material\nApplications: Screening aminoacidopathies, lipid analysis\n\nHigh-Performance Liquid Chromatography (HPLC): Uses high pressure force sample column stationary phase\nApplications: Water-soluble fat-soluble vitamins, amino acids, fatty acids\nApplications: Water-soluble fat-soluble vitamins, amino acids, fatty acidsGas Chromatography (GC): Separates volatile compounds based boiling points\nApplications: Fatty acids, volatile organic compounds\nApplications: Fatty acids, volatile organic compoundsThin-Layer Chromatography (TLC): Separates compounds thin layer adsorbent material\nApplications: Screening aminoacidopathies, lipid analysis\nApplications: Screening aminoacidopathies, lipid analysisDetection Methods\nUV-Vis Detection: Measures absorbance compounds specific wavelengths\nFluorescence Detection: Measures fluorescence compounds excitation light\nElectrochemical Detection: Measures oxidation reduction compounds\nMass Spectrometry (MS): Measures mass--charge ratio compounds\nUV-Vis Detection: Measures absorbance compounds specific wavelengthsFluorescence Detection: Measures fluorescence compounds excitation lightElectrochemical Detection: Measures oxidation reduction compoundsMass Spectrometry (MS): Measures mass--charge ratio compoundsProcedure\nSample Preparation: Extract analytes sample dissolve suitable solvent\nChromatographic Separation: Inject sample chromatography system separate compounds based properties\nDetection: Detect separated compounds using appropriate detection method\nQuantification: Compare peak areas heights standard curve determine analyte concentrations\nSample Preparation: Extract analytes sample dissolve suitable solventChromatographic Separation: Inject sample chromatography system separate compounds based propertiesDetection: Detect separated compounds using appropriate detection methodQuantification: Compare peak areas heights standard curve determine analyte concentrationsAdvantages: High resolution sensitivity; can separate quantify multiple compounds simultaneouslyLimitations: Requires specialized equipment skilled operatorsExamples\nVitamin D: Measurement 25-hydroxyvitamin D 1,25-dihydroxyvitamin D\nVitamin E: Measurement tocopherols tocotrienols\nAmino Acids: Measurement serum urine\nFatty Acids: Measurement plasma tissues\nVitamin D: Measurement 25-hydroxyvitamin D 1,25-dihydroxyvitamin DVitamin E: Measurement tocopherols tocotrienolsAmino Acids: Measurement serum urineFatty Acids: Measurement plasma tissues","code":""},{"path":"principles-8.html","id":"liquid-chromatography-mass-spectrometry-lc-ms","chapter":"Principles","heading":"Liquid Chromatography-Mass Spectrometry (LC-MS)","text":"Principle: Combines separation capabilities liquid chromatography detection power mass spectrometryTypes\nLC-MS: Liquid chromatography coupled single mass spectrometer\nLC-MS/MS: Liquid chromatography coupled tandem mass spectrometry (sensitive specific)\nLC-MS: Liquid chromatography coupled single mass spectrometerLC-MS/MS: Liquid chromatography coupled tandem mass spectrometry (sensitive specific)Procedure\nSample Preparation: Extract analytes sample dissolve suitable solvent\nChromatographic Separation: Inject sample liquid chromatography system separate compounds based properties\nMass Spectrometry Detection: Ionize separated compounds measure mass--charge ratio using mass spectrometer\nQuantification: Compare peak areas standard curve determine analyte concentrations\nSample Preparation: Extract analytes sample dissolve suitable solventChromatographic Separation: Inject sample liquid chromatography system separate compounds based propertiesMass Spectrometry Detection: Ionize separated compounds measure mass--charge ratio using mass spectrometerQuantification: Compare peak areas standard curve determine analyte concentrationsAdvantages: High sensitivity, specificity, throughput; can quantify multiple compounds simultaneouslyLimitations: Requires expensive equipment highly skilled operatorsExamples\nVitamin D: Measurement 25-hydroxyvitamin D 1,25-dihydroxyvitamin D\nVitamin K: Measurement phylloquinone menaquinones\nAmino Acids: Measurement serum urine\nFatty Acids: Measurement plasma tissues\nVitamin D: Measurement 25-hydroxyvitamin D 1,25-dihydroxyvitamin DVitamin K: Measurement phylloquinone menaquinonesAmino Acids: Measurement serum urineFatty Acids: Measurement plasma tissues","code":""},{"path":"principles-8.html","id":"atomic-absorption-spectrometry-aas","chapter":"Principles","heading":"Atomic Absorption Spectrometry (AAS)","text":"Principle: Measures absorption light free atoms gaseous stateApplication: Used measuring minerals, calcium, magnesium, iron, zincProcedure\nSample Preparation: Digest sample release minerals\nAtomization: Convert minerals free atoms flame graphite furnace\nAtomic Absorption Measurement: Pass light atomized sample measure absorption light specific wavelength\nQuantification: Compare absorbance standard curve determine mineral concentration\nSample Preparation: Digest sample release mineralsAtomization: Convert minerals free atoms flame graphite furnaceAtomic Absorption Measurement: Pass light atomized sample measure absorption light specific wavelengthQuantification: Compare absorbance standard curve determine mineral concentrationAdvantages: High sensitivity specificity mineral analysisLimitations: Requires specialized equipment can subject matrix effectsExamples\nCalcium: Measurement serum urine\nMagnesium: Measurement serum red blood cells\nIron: Measurement serum\nCalcium: Measurement serum urineMagnesium: Measurement serum red blood cellsIron: Measurement serum","code":""},{"path":"principles-8.html","id":"inductively-coupled-plasma-mass-spectrometry-icp-ms","chapter":"Principles","heading":"Inductively Coupled Plasma Mass Spectrometry (ICP-MS)","text":"Principle: Measures mass--charge ratio ions produced inductively coupled plasmaApplication: Used measuring trace elements minerals various samplesProcedure\nSample Preparation: Digest sample release elements\nPlasma Generation: Introduce sample inductively coupled plasma, ionizes elements\nMass Spectrometry Detection: Pass ions mass spectrometer, separates based mass--charge ratio\nQuantification: Compare ion intensities standard curve determine element concentrations\nSample Preparation: Digest sample release elementsPlasma Generation: Introduce sample inductively coupled plasma, ionizes elementsMass Spectrometry Detection: Pass ions mass spectrometer, separates based mass--charge ratioQuantification: Compare ion intensities standard curve determine element concentrationsAdvantages: High sensitivity, multi-element analysis, isotope ratio measurementsLimitations: Requires specialized equipment can subject matrix effectsExamples\nTrace Elements: Measurement serum, urine, tissues\nMineral Analysis: Measurement foods dietary supplements\nTrace Elements: Measurement serum, urine, tissuesMineral Analysis: Measurement foods dietary supplements","code":""},{"path":"principles-8.html","id":"point-of-care-testing-poct","chapter":"Principles","heading":"Point-of-Care Testing (POCT)","text":"Principle: Involves rapid, portable testing performed near patientApplications: Screening nutritional deficiencies, monitoring nutrient status clinical settingsMethods\nLateral Flow Immunoassays: Used rapid detection vitamins minerals\nElectrochemical Sensors: Used measuring glucose, electrolytes, analytes\nLateral Flow Immunoassays: Used rapid detection vitamins mineralsElectrochemical Sensors: Used measuring glucose, electrolytes, analytesAdvantages: Rapid turnaround time, ease use, portabilityLimitations: Lower accuracy precision compared laboratory-based methods","code":""},{"path":"principles-8.html","id":"summary-table-of-analytical-techniques","chapter":"Principles","heading":"Summary Table of Analytical Techniques","text":"","code":""},{"path":"principles-8.html","id":"key-terms-69","chapter":"Principles","heading":"Key Terms","text":"Spectrophotometry: technique measures absorbance transmission light solutionFluorometry: technique measures fluorescence emitted molecule absorbs lightImmunoassay: technique uses antibodies detect quantify specific substancesChromatography: technique separates compounds based physical chemical propertiesLiquid Chromatography-Mass Spectrometry (LC-MS): technique combines liquid chromatography mass spectrometryAtomic Absorption Spectrometry (AAS): technique measures absorption light free atomsInductively Coupled Plasma Mass Spectrometry (ICP-MS): technique measures mass--charge ratio ions produced inductively coupled plasmaPoint--Care Testing (POCT): Testing performed near patientStandard Curve: graph plots known concentrations substance corresponding instrument readingsQuality Control: Measures taken ensure accuracy reliability test resultsMatrix Effects: effect sample matrix analytical measurement","code":""},{"path":"precautions-3.html","id":"precautions-3","chapter":"Precautions","heading":"Precautions","text":"Ensuring accuracy reliability vitamin nutrient analyses requires meticulous attention pre-analytical factors, proper specimen handling, awareness potential interferences","code":""},{"path":"precautions-3.html","id":"special-precautions-13","chapter":"Precautions","heading":"Special Precautions","text":"Patient Preparation\nFasting: nutrient tests require patients fast specified period (e.g., 8-12 hours) specimen collection\nRationale: Fasting minimizes effects recent food intake nutrient levels\nExamples: Lipid profiles, glucose, iron studies\n\nMedications: Certain medications can interfere nutrient tests\nRationale: Medications can affect nutrient absorption, metabolism, excretion\nExamples\nOral contraceptives: Affect vitamin B6 folate levels\nMetformin: Affect vitamin B12 levels\nCholestyramine: Affect fat-soluble vitamin absorption\n\nAction: Inquire medications supplements patient taking\n\nSupplements: Inform patients avoid taking vitamin mineral supplements specified period testing\nRationale: Supplements can falsely elevate nutrient levels\nAction: Follow laboratory’s guidelines supplement restrictions\n\nAlcohol Consumption: Alcohol can affect nutrient absorption metabolism\nRationale: Chronic alcohol consumption can lead deficiencies thiamin, folate, nutrients\nAction: Instruct patients avoid alcohol consumption 24-48 hours testing\n\nTiming: nutrients, timing specimen collection can important due diurnal variations postprandial changes\nRationale: Iron levels vary throughout day; lipid profiles affected recent food intake\nAction: Collect specimens specified time\n\nFasting: nutrient tests require patients fast specified period (e.g., 8-12 hours) specimen collection\nRationale: Fasting minimizes effects recent food intake nutrient levels\nExamples: Lipid profiles, glucose, iron studies\nRationale: Fasting minimizes effects recent food intake nutrient levelsExamples: Lipid profiles, glucose, iron studiesMedications: Certain medications can interfere nutrient tests\nRationale: Medications can affect nutrient absorption, metabolism, excretion\nExamples\nOral contraceptives: Affect vitamin B6 folate levels\nMetformin: Affect vitamin B12 levels\nCholestyramine: Affect fat-soluble vitamin absorption\n\nAction: Inquire medications supplements patient taking\nRationale: Medications can affect nutrient absorption, metabolism, excretionExamples\nOral contraceptives: Affect vitamin B6 folate levels\nMetformin: Affect vitamin B12 levels\nCholestyramine: Affect fat-soluble vitamin absorption\nOral contraceptives: Affect vitamin B6 folate levelsMetformin: Affect vitamin B12 levelsCholestyramine: Affect fat-soluble vitamin absorptionAction: Inquire medications supplements patient takingSupplements: Inform patients avoid taking vitamin mineral supplements specified period testing\nRationale: Supplements can falsely elevate nutrient levels\nAction: Follow laboratory’s guidelines supplement restrictions\nRationale: Supplements can falsely elevate nutrient levelsAction: Follow laboratory’s guidelines supplement restrictionsAlcohol Consumption: Alcohol can affect nutrient absorption metabolism\nRationale: Chronic alcohol consumption can lead deficiencies thiamin, folate, nutrients\nAction: Instruct patients avoid alcohol consumption 24-48 hours testing\nRationale: Chronic alcohol consumption can lead deficiencies thiamin, folate, nutrientsAction: Instruct patients avoid alcohol consumption 24-48 hours testingTiming: nutrients, timing specimen collection can important due diurnal variations postprandial changes\nRationale: Iron levels vary throughout day; lipid profiles affected recent food intake\nAction: Collect specimens specified time\nRationale: Iron levels vary throughout day; lipid profiles affected recent food intakeAction: Collect specimens specified time","code":""},{"path":"precautions-3.html","id":"specimen-collection-8","chapter":"Precautions","heading":"Specimen Collection","text":"Collection Tubes\nUse appropriate collection tubes nutrient test\nRationale: Different tubes contain different anticoagulants additives can affect nutrient stability assay performance\nExamples\nEDTA tubes: Commonly used vitamin B12, folate, iron studies\nSerum separator tubes (SST): Used fat-soluble vitamins\nLight-protected tubes: Used light-sensitive vitamins (e.g., vitamin , vitamin B6)\n\n\nFollow manufacturer’s instructions tube selection\nUse appropriate collection tubes nutrient test\nRationale: Different tubes contain different anticoagulants additives can affect nutrient stability assay performance\nExamples\nEDTA tubes: Commonly used vitamin B12, folate, iron studies\nSerum separator tubes (SST): Used fat-soluble vitamins\nLight-protected tubes: Used light-sensitive vitamins (e.g., vitamin , vitamin B6)\n\nRationale: Different tubes contain different anticoagulants additives can affect nutrient stability assay performanceExamples\nEDTA tubes: Commonly used vitamin B12, folate, iron studies\nSerum separator tubes (SST): Used fat-soluble vitamins\nLight-protected tubes: Used light-sensitive vitamins (e.g., vitamin , vitamin B6)\nEDTA tubes: Commonly used vitamin B12, folate, iron studiesSerum separator tubes (SST): Used fat-soluble vitaminsLight-protected tubes: Used light-sensitive vitamins (e.g., vitamin , vitamin B6)Follow manufacturer’s instructions tube selectionOrder Draw\nFollow correct order draw collecting multiple tubes\nRationale: Prevents cross-contamination tube additives\nAction: Consult CLSI guidelines correct order draw\n\nFollow correct order draw collecting multiple tubes\nRationale: Prevents cross-contamination tube additives\nAction: Consult CLSI guidelines correct order draw\nRationale: Prevents cross-contamination tube additivesAction: Consult CLSI guidelines correct order drawTechnique\nUse proper venipuncture technique\nRationale: Minimizes hemolysis contamination\nAction: Avoid prolonged tourniquet time use gentle technique\n\nUse proper venipuncture technique\nRationale: Minimizes hemolysis contamination\nAction: Avoid prolonged tourniquet time use gentle technique\nRationale: Minimizes hemolysis contaminationAction: Avoid prolonged tourniquet time use gentle techniqueLabeling\nLabel specimens immediately accurately\nRationale: Prevents misidentification errors\nAction: Use two patient identifiers (e.g., name date birth)\n\nLabel specimens immediately accurately\nRationale: Prevents misidentification errors\nAction: Use two patient identifiers (e.g., name date birth)\nRationale: Prevents misidentification errorsAction: Use two patient identifiers (e.g., name date birth)Volume\nCollect correct volume blood\nRationale: Insufficient volume can affect assay performance\nAction: Follow manufacturer’s instructions minimum volume requirements\n\nCollect correct volume blood\nRationale: Insufficient volume can affect assay performance\nAction: Follow manufacturer’s instructions minimum volume requirements\nRationale: Insufficient volume can affect assay performanceAction: Follow manufacturer’s instructions minimum volume requirements","code":""},{"path":"precautions-3.html","id":"specimen-processing-2","chapter":"Precautions","heading":"Specimen Processing","text":"Centrifugation\nCentrifuge specimens promptly collection\nRationale: Separates serum plasma cells\nAction: Follow manufacturer’s instructions centrifugation speed time\n\nCentrifuge specimens promptly collection\nRationale: Separates serum plasma cells\nAction: Follow manufacturer’s instructions centrifugation speed time\nRationale: Separates serum plasma cellsAction: Follow manufacturer’s instructions centrifugation speed timeSeparation\nSeparate serum plasma cells within specified time frame\nRationale: Prevents hemolysis degradation nutrients\nAction: Follow manufacturer’s instructions separation time\n\nSeparate serum plasma cells within specified time frame\nRationale: Prevents hemolysis degradation nutrients\nAction: Follow manufacturer’s instructions separation time\nRationale: Prevents hemolysis degradation nutrientsAction: Follow manufacturer’s instructions separation timeAliquotting\nAliquot specimens appropriate containers\nRationale: Prevents contamination allows multiple tests\nAction: Use clean, dry containers\n\nAliquot specimens appropriate containers\nRationale: Prevents contamination allows multiple tests\nAction: Use clean, dry containers\nRationale: Prevents contamination allows multiple testsAction: Use clean, dry containersStorage\nStore specimens appropriate temperature\nRationale: Preserves nutrient stability\nExamples\nRefrigeration (2-8°C): short-term storage\nFreezing (-20°C -80°C): long-term storage\n\n\nFollow manufacturer’s instructions storage conditions\nStore specimens appropriate temperature\nRationale: Preserves nutrient stability\nExamples\nRefrigeration (2-8°C): short-term storage\nFreezing (-20°C -80°C): long-term storage\n\nRationale: Preserves nutrient stabilityExamples\nRefrigeration (2-8°C): short-term storage\nFreezing (-20°C -80°C): long-term storage\nRefrigeration (2-8°C): short-term storageFreezing (-20°C -80°C): long-term storageFollow manufacturer’s instructions storage conditionsThawing\nThaw specimens properly testing\nRationale: Prevents degradation nutrients\nAction: Thaw room temperature refrigerator, mix gently\n\nThaw specimens properly testing\nRationale: Prevents degradation nutrients\nAction: Thaw room temperature refrigerator, mix gently\nRationale: Prevents degradation nutrientsAction: Thaw room temperature refrigerator, mix gentlyLight Protection\nProtect light-sensitive vitamins light exposure collection, processing, storage\nRationale: Light can degrade certain vitamins (e.g., vitamin , vitamin B6, folate)\nAction: Use amber-colored tubes wrap clear tubes aluminum foil\n\nProtect light-sensitive vitamins light exposure collection, processing, storage\nRationale: Light can degrade certain vitamins (e.g., vitamin , vitamin B6, folate)\nAction: Use amber-colored tubes wrap clear tubes aluminum foil\nRationale: Light can degrade certain vitamins (e.g., vitamin , vitamin B6, folate)Action: Use amber-colored tubes wrap clear tubes aluminum foil","code":""},{"path":"precautions-3.html","id":"troubleshooting-17","chapter":"Precautions","heading":"Troubleshooting","text":"High Nutrient Results\nPre-analytical\nPatient fasting\nRecent supplement intake\nMedication interference\nImproper collection tube\nDelayed processing\nContamination specimen\n\nAnalytical\nIncorrect calibration\nReagent deterioration\nInterfering substances\nCross-reactivity\nNon-specific binding\n\nPre-analytical\nPatient fasting\nRecent supplement intake\nMedication interference\nImproper collection tube\nDelayed processing\nContamination specimen\nPatient fastingRecent supplement intakeMedication interferenceImproper collection tubeDelayed processingContamination specimenAnalytical\nIncorrect calibration\nReagent deterioration\nInterfering substances\nCross-reactivity\nNon-specific binding\nIncorrect calibrationReagent deteriorationInterfering substancesCross-reactivityNon-specific bindingLow Nutrient Results\nPre-analytical\nImproper collection tube\nDelayed processing\nImproper storage\nMedication interference\n\nAnalytical\nIncorrect calibration\nReagent deterioration\nInterfering substances\nAssay drift\n\nPre-analytical\nImproper collection tube\nDelayed processing\nImproper storage\nMedication interference\nImproper collection tubeDelayed processingImproper storageMedication interferenceAnalytical\nIncorrect calibration\nReagent deterioration\nInterfering substances\nAssay drift\nIncorrect calibrationReagent deteriorationInterfering substancesAssay driftInconsistent Results\nPre-analytical\nPatient variability\nSpecimen handling errors\n\nAnalytical\nAssay variability\nInterfering substances\nCross-reactivity\n\nPost-analytical\nTranscription errors\nReporting errors\n\nPre-analytical\nPatient variability\nSpecimen handling errors\nPatient variabilitySpecimen handling errorsAnalytical\nAssay variability\nInterfering substances\nCross-reactivity\nAssay variabilityInterfering substancesCross-reactivityPost-analytical\nTranscription errors\nReporting errors\nTranscription errorsReporting errorsQuality Control Failures\nPre-analytical\nQC material improperly stored\nQC material expired\n\nAnalytical\nIncorrect calibration\nReagent deterioration\nInstrument malfunction\n\nAction: Investigate cause failure take corrective action\nPre-analytical\nQC material improperly stored\nQC material expired\nQC material improperly storedQC material expiredAnalytical\nIncorrect calibration\nReagent deterioration\nInstrument malfunction\nIncorrect calibrationReagent deteriorationInstrument malfunctionAction: Investigate cause failure take corrective action","code":""},{"path":"precautions-3.html","id":"interfering-substances-17","chapter":"Precautions","heading":"Interfering Substances","text":"Hemolysis\nInterference: Releases intracellular components can interfere nutrient assays\nMechanism: Interferes spectrophotometric immunoassay measurements\nMitigation: Avoid hemolysis collection processing\nInterference: Releases intracellular components can interfere nutrient assaysMechanism: Interferes spectrophotometric immunoassay measurementsMitigation: Avoid hemolysis collection processingLipemia\nInterference: Turbidity high lipid concentrations can interfere spectrophotometric assays\nMechanism: Lipids scatter light, leading inaccurate absorbance measurements\nMitigation: Use lipemia clearing techniques consider methods less affected turbidity\nInterference: Turbidity high lipid concentrations can interfere spectrophotometric assaysMechanism: Lipids scatter light, leading inaccurate absorbance measurementsMitigation: Use lipemia clearing techniques consider methods less affected turbidityBilirubin\nInterference: High bilirubin levels can interfere spectrophotometric assays\nMechanism: Bilirubin absorbs light similar wavelengths, affecting absorbance readings\nMitigation: Use methods less susceptible bilirubin interference employ bilirubin correction techniques\nInterference: High bilirubin levels can interfere spectrophotometric assaysMechanism: Bilirubin absorbs light similar wavelengths, affecting absorbance readingsMitigation: Use methods less susceptible bilirubin interference employ bilirubin correction techniquesDrugs\nInterference: Certain drugs can directly affect nutrient levels interfere nutrient assays\nExamples\nMetformin: Affects vitamin B12 levels\nCholestyramine: Affects fat-soluble vitamin absorption\nOral contraceptives: Affect vitamin B6 folate levels\n\nMitigation: aware patient’s medication list\nInterference: Certain drugs can directly affect nutrient levels interfere nutrient assaysExamples\nMetformin: Affects vitamin B12 levels\nCholestyramine: Affects fat-soluble vitamin absorption\nOral contraceptives: Affect vitamin B6 folate levels\nMetformin: Affects vitamin B12 levelsCholestyramine: Affects fat-soluble vitamin absorptionOral contraceptives: Affect vitamin B6 folate levelsMitigation: aware patient’s medication listHeterophile Antibodies\nInterference: Bind assay antibodies, causing falsely high low results\nMechanism: Non-specific binding assay components\nMitigation: Use blocking reagents heterophile antibody blocking tubes\nInterference: Bind assay antibodies, causing falsely high low resultsMechanism: Non-specific binding assay componentsMitigation: Use blocking reagents heterophile antibody blocking tubesCross-Reactivity\nInterference: Assay antibodies may cross-react structurally similar compounds, leading inaccurate results\nMechanism: Antibodies bind unintended targets\nMitigation: Use highly specific antibodies aware potential cross-reactants\nInterference: Assay antibodies may cross-react structurally similar compounds, leading inaccurate resultsMechanism: Antibodies bind unintended targetsMitigation: Use highly specific antibodies aware potential cross-reactantsBiotin\nInterference: High levels biotin can interfere biotin-streptavidin assays, causing falsely high low results\nMechanism: Biotin competes analyte binding streptavidin\nMitigation: Ask patients discontinue biotin supplements several days testing\nInterference: High levels biotin can interfere biotin-streptavidin assays, causing falsely high low resultsMechanism: Biotin competes analyte binding streptavidinMitigation: Ask patients discontinue biotin supplements several days testingAscorbic Acid (Vitamin C)\nInterference: Can interfere certain assays acting reducing agent\nMitigation: Use methods less susceptible ascorbic acid interference\nInterference: Can interfere certain assays acting reducing agentMitigation: Use methods less susceptible ascorbic acid interferenceHomocysteine\nInterference: Elevated homocysteine levels can interfere folate vitamin B12 assays\nMitigation: Consider measuring homocysteine levels separately\nInterference: Elevated homocysteine levels can interfere folate vitamin B12 assaysMitigation: Consider measuring homocysteine levels separately","code":""},{"path":"precautions-3.html","id":"key-terms-70","chapter":"Precautions","heading":"Key Terms","text":"Pre-Analytical: Processes occur sample analyzedAnalytical: Processes involved analyzing samplePost-Analytical: Processes occur sample analyzedInterfering Substance: substance affects accuracy testHemolysis: breakdown red blood cellsLipemia: presence excess lipids bloodCalibration: Adjusting instrument ensure accurate readingsQuality Control: Samples used monitor accuracy precision testHeterophile Antibodies: Antibodies bind multiple antigensCross-Reactivity: ability antibody bind multiple antigensFasting: Abstaining food drink specified periodSupplement: product taken orally contains one ingredients intended supplement diet","code":""},{"path":"result-interpretation-8.html","id":"result-interpretation-8","chapter":"Result Interpretation","heading":"Result Interpretation","text":"Interpreting vitamin nutrient test results effectively requires thorough understanding reference intervals, clinical context, potential influencing factors","code":""},{"path":"result-interpretation-8.html","id":"general-principles-of-test-result-interpretation-1","chapter":"Result Interpretation","heading":"General Principles of Test Result Interpretation","text":"Reference Intervals\nUse appropriate reference intervals specific assay patient population\nReference intervals can vary based age, sex, ethnicity, geographic location\nUse appropriate reference intervals specific assay patient populationReference intervals can vary based age, sex, ethnicity, geographic locationClinical Context\nInterpret test results context patient’s clinical history, physical examination findings, laboratory data\nConsider patient’s symptoms, medications, coexisting medical conditions\nInterpret test results context patient’s clinical history, physical examination findings, laboratory dataConsider patient’s symptoms, medications, coexisting medical conditionsMultiple Tests\nOften, single nutrient measurement insufficient diagnosis; assess multiple markers provide comprehensive assessment\nEvaluate pattern nutrient levels rather relying single value\nOften, single nutrient measurement insufficient diagnosis; assess multiple markers provide comprehensive assessmentEvaluate pattern nutrient levels rather relying single valueInterfering Substances\naware potential interfering substances can affect nutrient measurements (e.g., heterophile antibodies, biotin, medications)\nConsider repeating test using different method interference suspected\naware potential interfering substances can affect nutrient measurements (e.g., heterophile antibodies, biotin, medications)Consider repeating test using different method interference suspectedAssay Limitations\nUnderstand limitations specific assay used, including sensitivity, specificity, potential cross-reactivity\nConsult laboratory manufacturer guidance test interpretation\nUnderstand limitations specific assay used, including sensitivity, specificity, potential cross-reactivityConsult laboratory manufacturer guidance test interpretationDynamic Testing\ncases, dynamic tests may necessary assess nutrient status metabolic function (e.g., vitamin D stimulation test)\ncases, dynamic tests may necessary assess nutrient status metabolic function (e.g., vitamin D stimulation test)","code":""},{"path":"result-interpretation-8.html","id":"water-soluble-vitamin-interpretation","chapter":"Result Interpretation","heading":"Water-Soluble Vitamin Interpretation","text":"","code":""},{"path":"result-interpretation-8.html","id":"thiamin-vitamin-b1-3","chapter":"Result Interpretation","heading":"Thiamin (Vitamin B1)","text":"Normal\nErythrocyte transketolase activity: Within reference range\nErythrocyte transketolase activity: Within reference rangeDeficiency\nDecreased erythrocyte transketolase activity\nElevated blood pyruvate lactate levels\nClinical Correlation: Suspect patients alcohol abuse, malnutrition, Wernicke-Korsakoff syndrome\nDecreased erythrocyte transketolase activityElevated blood pyruvate lactate levelsClinical Correlation: Suspect patients alcohol abuse, malnutrition, Wernicke-Korsakoff syndrome","code":""},{"path":"result-interpretation-8.html","id":"riboflavin-vitamin-b2-3","chapter":"Result Interpretation","heading":"Riboflavin (Vitamin B2)","text":"Normal\nErythrocyte glutathione reductase activity: Within reference range\nUrinary excretion riboflavin: Within reference range\nErythrocyte glutathione reductase activity: Within reference rangeUrinary excretion riboflavin: Within reference rangeDeficiency\nDecreased erythrocyte glutathione reductase activity\nDecreased urinary excretion riboflavin\nClinical Correlation: Suspect patients ariboflavinosis, malnutrition, malabsorption\nDecreased erythrocyte glutathione reductase activityDecreased urinary excretion riboflavinClinical Correlation: Suspect patients ariboflavinosis, malnutrition, malabsorption","code":""},{"path":"result-interpretation-8.html","id":"niacin-vitamin-b3-3","chapter":"Result Interpretation","heading":"Niacin (Vitamin B3)","text":"Normal\nUrinary excretion niacin metabolites: Within reference range\nErythrocyte nicotinamide adenine dinucleotide (NAD) levels: Within reference range\nUrinary excretion niacin metabolites: Within reference rangeErythrocyte nicotinamide adenine dinucleotide (NAD) levels: Within reference rangeDeficiency\nDecreased urinary excretion niacin metabolites\nDecreased erythrocyte NAD levels\nClinical Correlation: Suspect patients pellagra, alcohol abuse, malabsorption\nDecreased urinary excretion niacin metabolitesDecreased erythrocyte NAD levelsClinical Correlation: Suspect patients pellagra, alcohol abuse, malabsorption","code":""},{"path":"result-interpretation-8.html","id":"pyridoxine-vitamin-b6-3","chapter":"Result Interpretation","heading":"Pyridoxine (Vitamin B6)","text":"Normal\nPlasma pyridoxal phosphate (PLP) levels: Within reference range\nUrinary xanthurenic acid excretion tryptophan load: Within reference range\nPlasma pyridoxal phosphate (PLP) levels: Within reference rangeUrinary xanthurenic acid excretion tryptophan load: Within reference rangeDeficiency\nDecreased plasma PLP levels\nElevated urinary xanthurenic acid excretion tryptophan load\nClinical Correlation: Suspect patients neurological symptoms, dermatitis, anemia\nDecreased plasma PLP levelsElevated urinary xanthurenic acid excretion tryptophan loadClinical Correlation: Suspect patients neurological symptoms, dermatitis, anemia","code":""},{"path":"result-interpretation-8.html","id":"folate-vitamin-b9-3","chapter":"Result Interpretation","heading":"Folate (Vitamin B9)","text":"Normal\nSerum folate levels: Within reference range\nRed blood cell (RBC) folate levels: Within reference range\nHomocysteine levels: Within reference range\nSerum folate levels: Within reference rangeRed blood cell (RBC) folate levels: Within reference rangeHomocysteine levels: Within reference rangeDeficiency\nDecreased serum RBC folate levels\nElevated homocysteine levels\nClinical Correlation: Suspect patients megaloblastic anemia neural tube defects\nDecreased serum RBC folate levelsElevated homocysteine levelsClinical Correlation: Suspect patients megaloblastic anemia neural tube defectsLimitations\nSerum folate affected recent dietary intake\nRBC folate better indicator long-term folate status\nSerum folate affected recent dietary intakeRBC folate better indicator long-term folate status","code":""},{"path":"result-interpretation-8.html","id":"cobalamin-vitamin-b12-3","chapter":"Result Interpretation","heading":"Cobalamin (Vitamin B12)","text":"Normal\nSerum vitamin B12 levels: Within reference range\nHomocysteine levels: Within reference range\nMethylmalonic acid (MMA) levels: Within reference range\nSerum vitamin B12 levels: Within reference rangeHomocysteine levels: Within reference rangeMethylmalonic acid (MMA) levels: Within reference rangeDeficiency\nDecreased serum vitamin B12 levels\nElevated homocysteine MMA levels\nClinical Correlation: Suspect patients megaloblastic anemia, neurological symptoms, malabsorption\nDecreased serum vitamin B12 levelsElevated homocysteine MMA levelsClinical Correlation: Suspect patients megaloblastic anemia, neurological symptoms, malabsorptionLimitations\nSerum vitamin B12 always reliable\nElevated MMA sensitive indicator B12 deficiency\nSerum vitamin B12 always reliableElevated MMA sensitive indicator B12 deficiency","code":""},{"path":"result-interpretation-8.html","id":"ascorbic-acid-vitamin-c-3","chapter":"Result Interpretation","heading":"Ascorbic Acid (Vitamin C)","text":"Normal\nSerum ascorbic acid levels: Within reference range\nSerum ascorbic acid levels: Within reference rangeDeficiency\nDecreased serum ascorbic acid levels\nClinical Correlation: Suspect patients scurvy, poor wound healing, bleeding gums\nDecreased serum ascorbic acid levelsClinical Correlation: Suspect patients scurvy, poor wound healing, bleeding gums","code":""},{"path":"result-interpretation-8.html","id":"fat-soluble-vitamin-interpretation","chapter":"Result Interpretation","heading":"Fat-Soluble Vitamin Interpretation","text":"","code":""},{"path":"result-interpretation-8.html","id":"vitamin-a-3","chapter":"Result Interpretation","heading":"Vitamin A","text":"Normal\nSerum retinol levels: Within reference range\nSerum retinol levels: Within reference rangeDeficiency\nDecreased serum retinol levels\nClinical Correlation: Suspect patients night blindness, xerophthalmia, impaired immune function\nDecreased serum retinol levelsClinical Correlation: Suspect patients night blindness, xerophthalmia, impaired immune functionToxicity\nElevated serum retinol levels\nClinical Correlation: Liver damage, bone abnormalities, birth defects\nElevated serum retinol levelsClinical Correlation: Liver damage, bone abnormalities, birth defects","code":""},{"path":"result-interpretation-8.html","id":"vitamin-d-3","chapter":"Result Interpretation","heading":"Vitamin D","text":"Normal\nSerum 25-hydroxyvitamin D [25(OH)D] levels: Within reference range\nParathyroid hormone (PTH) levels: Within reference range\nSerum 25-hydroxyvitamin D [25(OH)D] levels: Within reference rangeParathyroid hormone (PTH) levels: Within reference rangeDeficiency\nDecreased serum 25(OH)D levels\nElevated PTH levels\nClinical Correlation: Suspect patients rickets, osteomalacia, osteoporosis\nDecreased serum 25(OH)D levelsElevated PTH levelsClinical Correlation: Suspect patients rickets, osteomalacia, osteoporosisToxicity\nElevated serum 25(OH)D calcium levels\nClinical Correlation: Hypercalcemia, kidney stones, soft tissue calcification\nElevated serum 25(OH)D calcium levelsClinical Correlation: Hypercalcemia, kidney stones, soft tissue calcification","code":""},{"path":"result-interpretation-8.html","id":"vitamin-e-3","chapter":"Result Interpretation","heading":"Vitamin E","text":"Normal\nSerum alpha-tocopherol levels: Within reference range\nSerum alpha-tocopherol levels: Within reference rangeDeficiency\nDecreased serum alpha-tocopherol levels\nClinical Correlation: Suspect patients neurological symptoms hemolytic anemia\nDecreased serum alpha-tocopherol levelsClinical Correlation: Suspect patients neurological symptoms hemolytic anemia","code":""},{"path":"result-interpretation-8.html","id":"vitamin-k-3","chapter":"Result Interpretation","heading":"Vitamin K","text":"Normal\nProthrombin time (PT) International Normalized Ratio (INR): Within reference range\nProthrombin time (PT) International Normalized Ratio (INR): Within reference rangeDeficiency\nProlonged PT INR\nClinical Correlation: Suspect patients bleeding disorders\nProlonged PT INRClinical Correlation: Suspect patients bleeding disorders","code":""},{"path":"result-interpretation-8.html","id":"general-factors-affecting-interpretation","chapter":"Result Interpretation","heading":"General Factors Affecting Interpretation","text":"Age\nReference intervals may vary age\nReference intervals may vary ageSex\nReference intervals may vary sex\nReference intervals may vary sexPregnancy\nNutrient requirements reference intervals change pregnancy\nNutrient requirements reference intervals change pregnancyUnderlying Medical Conditions\nKidney disease, liver disease, malabsorption syndromes, conditions can affect nutrient status\nKidney disease, liver disease, malabsorption syndromes, conditions can affect nutrient statusMedications\nCertain medications can affect nutrient absorption, metabolism, excretion\nCertain medications can affect nutrient absorption, metabolism, excretionSupplements\nRecent supplement intake can falsely elevate nutrient levels\nRecent supplement intake can falsely elevate nutrient levelsLifestyle Factors\nDietary habits, alcohol consumption, smoking can affect nutrient status\nDietary habits, alcohol consumption, smoking can affect nutrient status","code":""},{"path":"result-interpretation-8.html","id":"key-terms-71","chapter":"Result Interpretation","heading":"Key Terms","text":"Reference Interval: range values found healthy individualsClinical Context: patient’s clinical history, physical examination findings, laboratory dataInterfering Substance: substance affects accuracy testAssay Limitation: limitations specific assay used, including sensitivity, specificity, potential cross-reactivityNutrient Deficiency: condition body enough particular nutrientNutrient Toxicity: condition body much particular nutrientHomocysteine: amino acid elevated folate vitamin B12 deficienciesMethylmalonic Acid (MMA): organic acid elevated vitamin B12 deficiencyAlbumin: protein blood can affect calcium levelsTotal Iron-Binding Capacity (TIBC): measure blood’s capacity bind ironTransferrin Saturation: percentage transferrin saturated ironFerritin: protein stores ironHypochromic: Pertaining red blood cells reduced colorMicrocytic: Pertaining small red blood cellsMacrocytic: Pertaining large red blood cells","code":""},{"path":"disease-correlation-8.html","id":"disease-correlation-8","chapter":"Disease Correlation","heading":"Disease Correlation","text":"Understanding connections specific disease states abnormalities vitamin nutrient levels critical effective diagnosis management","code":""},{"path":"disease-correlation-8.html","id":"vitamin-and-mineral-deficiencies-general-considerations","chapter":"Disease Correlation","heading":"Vitamin and Mineral Deficiencies: General Considerations","text":"Etiology: Inadequate dietary intake, impaired absorption, increased nutrient requirements, drug interactions common causes vitamin mineral deficienciesPopulations Risk: Certain populations higher risk nutrient deficiencies, including infants, children, pregnant women, elderly individuals, chronic diseases poor dietary habitsClinical Manifestations: Nutrient deficiencies can lead wide range symptoms, including fatigue, weakness, neurological problems, skin changes, impaired immune functionDiagnosis: Diagnosis based dietary assessment, clinical evaluation, laboratory testingTreatment: Treatment involves dietary modifications, supplementation, addressing underlying causes","code":""},{"path":"disease-correlation-8.html","id":"water-soluble-vitamin-deficiencies","chapter":"Disease Correlation","heading":"Water-Soluble Vitamin Deficiencies","text":"","code":""},{"path":"disease-correlation-8.html","id":"thiamin-vitamin-b1-deficiency","chapter":"Disease Correlation","heading":"Thiamin (Vitamin B1) Deficiency","text":"Disorder: Beriberi Wernicke-Korsakoff SyndromeEtiology\nAlcohol abuse\nMalnutrition\nMalabsorption\nAlcohol abuseMalnutritionMalabsorptionLaboratory Findings\nDecreased erythrocyte transketolase activity\nElevated blood pyruvate lactate levels\nDecreased erythrocyte transketolase activityElevated blood pyruvate lactate levelsDisease State Correlation\nBeriberi: Cardiovascular (wet beriberi) neurological (dry beriberi) symptoms\nWernicke-Korsakoff Syndrome: Confusion, ataxia, nystagmus, memory impairment\nBeriberi: Cardiovascular (wet beriberi) neurological (dry beriberi) symptomsWernicke-Korsakoff Syndrome: Confusion, ataxia, nystagmus, memory impairment","code":""},{"path":"disease-correlation-8.html","id":"riboflavin-vitamin-b2-deficiency","chapter":"Disease Correlation","heading":"Riboflavin (Vitamin B2) Deficiency","text":"Disorder: AriboflavinosisEtiology\nMalnutrition\nMalabsorption\nCertain medications\nMalnutritionMalabsorptionCertain medicationsLaboratory Findings\nDecreased erythrocyte glutathione reductase activity\nDecreased urinary excretion riboflavin\nDecreased erythrocyte glutathione reductase activityDecreased urinary excretion riboflavinDisease State Correlation\nCheilosis (cracking corners mouth)\nGlossitis (inflammation tongue)\nDermatitis\nCheilosis (cracking corners mouth)Glossitis (inflammation tongue)Dermatitis","code":""},{"path":"disease-correlation-8.html","id":"niacin-vitamin-b3-deficiency","chapter":"Disease Correlation","heading":"Niacin (Vitamin B3) Deficiency","text":"Disorder: PellagraEtiology\nInadequate dietary intake\nMalabsorption\nCertain medications\nHartnup disease\nInadequate dietary intakeMalabsorptionCertain medicationsHartnup diseaseLaboratory Findings\nDecreased urinary excretion niacin metabolites\nDecreased erythrocyte nicotinamide adenine dinucleotide (NAD) levels\nDecreased urinary excretion niacin metabolitesDecreased erythrocyte nicotinamide adenine dinucleotide (NAD) levelsDisease State Correlation\nDermatitis (photosensitive)\nDiarrhea\nDementia\nDermatitis (photosensitive)DiarrheaDementia","code":""},{"path":"disease-correlation-8.html","id":"pyridoxine-vitamin-b6-deficiency","chapter":"Disease Correlation","heading":"Pyridoxine (Vitamin B6) Deficiency","text":"Disorder: Pyridoxine DeficiencyEtiology\nAlcohol abuse\nDrug interactions (isoniazid, penicillamine)\nMalabsorption\nAlcohol abuseDrug interactions (isoniazid, penicillamine)MalabsorptionLaboratory Findings\nDecreased plasma pyridoxal phosphate (PLP) levels\nElevated urinary xanthurenic acid excretion tryptophan load\nDecreased plasma pyridoxal phosphate (PLP) levelsElevated urinary xanthurenic acid excretion tryptophan loadDisease State Correlation\nNeurological symptoms (seizures, depression, peripheral neuropathy)\nDermatitis\nAnemia (microcytic)\nNeurological symptoms (seizures, depression, peripheral neuropathy)DermatitisAnemia (microcytic)","code":""},{"path":"disease-correlation-8.html","id":"folate-vitamin-b9-deficiency","chapter":"Disease Correlation","heading":"Folate (Vitamin B9) Deficiency","text":"Disorder: Folate DeficiencyEtiology\nInadequate dietary intake\nMalabsorption\nDrug interactions (methotrexate)\nPregnancy\nInadequate dietary intakeMalabsorptionDrug interactions (methotrexate)PregnancyLaboratory Findings\nDecreased serum red blood cell folate levels\nElevated homocysteine levels\nDecreased serum red blood cell folate levelsElevated homocysteine levelsDisease State Correlation\nMegaloblastic anemia\nNeural tube defects developing fetuses\nIncreased risk cardiovascular disease\nMegaloblastic anemiaNeural tube defects developing fetusesIncreased risk cardiovascular disease","code":""},{"path":"disease-correlation-8.html","id":"cobalamin-vitamin-b12-deficiency","chapter":"Disease Correlation","heading":"Cobalamin (Vitamin B12) Deficiency","text":"Disorder: Cobalamin DeficiencyEtiology\nInadequate dietary intake (vegans)\nPernicious anemia (lack intrinsic factor)\nMalabsorption (Crohn’s disease, celiac disease)\nGastrectomy\nInadequate dietary intake (vegans)Pernicious anemia (lack intrinsic factor)Malabsorption (Crohn’s disease, celiac disease)GastrectomyLaboratory Findings\nDecreased serum vitamin B12 levels\nElevated homocysteine methylmalonic acid (MMA) levels\nDecreased serum vitamin B12 levelsElevated homocysteine methylmalonic acid (MMA) levelsDisease State Correlation\nMegaloblastic anemia\nNeurological symptoms (peripheral neuropathy, cognitive impairment)\nIncreased risk cardiovascular disease\nMegaloblastic anemiaNeurological symptoms (peripheral neuropathy, cognitive impairment)Increased risk cardiovascular disease","code":""},{"path":"disease-correlation-8.html","id":"ascorbic-acid-vitamin-c-deficiency","chapter":"Disease Correlation","heading":"Ascorbic Acid (Vitamin C) Deficiency","text":"Disorder: ScurvyEtiology\nInadequate dietary intake\nAlcohol abuse\nInadequate dietary intakeAlcohol abuseLaboratory Findings\nDecreased serum ascorbic acid levels\nDecreased serum ascorbic acid levelsDisease State Correlation\nBleeding gums\nPoor wound healing\nAnemia\nBleeding gumsPoor wound healingAnemia","code":""},{"path":"disease-correlation-8.html","id":"fat-soluble-vitamin-deficiencies","chapter":"Disease Correlation","heading":"Fat-Soluble Vitamin Deficiencies","text":"","code":""},{"path":"disease-correlation-8.html","id":"vitamin-a-deficiency","chapter":"Disease Correlation","heading":"Vitamin A Deficiency","text":"Disorder: Vitamin DeficiencyEtiology\nInadequate dietary intake\nFat malabsorption\nInadequate dietary intakeFat malabsorptionLaboratory Findings\nDecreased serum retinol levels\nDecreased serum retinol levelsDisease State Correlation\nNight blindness\nXerophthalmia (dry eyes)\nImpaired immune function\nNight blindnessXerophthalmia (dry eyes)Impaired immune function","code":""},{"path":"disease-correlation-8.html","id":"vitamin-d-deficiency","chapter":"Disease Correlation","heading":"Vitamin D Deficiency","text":"Disorder: Vitamin D DeficiencyEtiology\nInadequate sunlight exposure\nInadequate dietary intake\nFat malabsorption\nKidney liver disorders\nInadequate sunlight exposureInadequate dietary intakeFat malabsorptionKidney liver disordersLaboratory Findings\nDecreased serum 25-hydroxyvitamin D [25(OH)D] levels\nElevated parathyroid hormone (PTH) levels\nDecreased serum 25-hydroxyvitamin D [25(OH)D] levelsElevated parathyroid hormone (PTH) levelsDisease State Correlation\nRickets (children)\nOsteomalacia (adults)\nOsteoporosis\nIncreased risk falls fractures\nRickets (children)Osteomalacia (adults)OsteoporosisIncreased risk falls fractures","code":""},{"path":"disease-correlation-8.html","id":"vitamin-e-deficiency","chapter":"Disease Correlation","heading":"Vitamin E Deficiency","text":"Disorder: Vitamin E DeficiencyEtiology\nFat malabsorption\nGenetic disorders (abetalipoproteinemia)\nFat malabsorptionGenetic disorders (abetalipoproteinemia)Laboratory Findings\nDecreased serum alpha-tocopherol levels\nDecreased serum alpha-tocopherol levelsDisease State Correlation\nNeurological symptoms (peripheral neuropathy, ataxia)\nHemolytic anemia\nNeurological symptoms (peripheral neuropathy, ataxia)Hemolytic anemia","code":""},{"path":"disease-correlation-8.html","id":"vitamin-k-deficiency","chapter":"Disease Correlation","heading":"Vitamin K Deficiency","text":"Disorder: Vitamin K DeficiencyEtiology\nInadequate dietary intake\nFat malabsorption\nAntibiotic use\nNewborns (lack intestinal bacteria)\nInadequate dietary intakeFat malabsorptionAntibiotic useNewborns (lack intestinal bacteria)Laboratory Findings\nProlonged Prothrombin Time (PT) International Normalized Ratio (INR)\nProlonged Prothrombin Time (PT) International Normalized Ratio (INR)Disease State Correlation\nBleeding disorders\nBleeding disorders","code":""},{"path":"disease-correlation-8.html","id":"general-notes-on-interpretation","chapter":"Disease Correlation","heading":"General Notes on Interpretation","text":"Influence Assay Methodology: Different analytical methods measuring vitamins nutrients can varying sensitivities specificitiesPatient Population: Consider age, sex, physiological state (e.g., pregnancy), coexisting medical conditionsClinical Correlation: Always interpret test results context patient’s overall health clinical presentation","code":""},{"path":"disease-correlation-8.html","id":"key-terms-72","chapter":"Disease Correlation","heading":"Key Terms","text":"Vitamin: organic compound essential human healthDeficiency: condition body enough particular nutrientToxicity: condition body much particular nutrientMalnutrition: state nutritional imbalanceMegaloblastic Anemia: type anemia characterized large, abnormal red blood cellsHomocysteine: amino acid elevated folate vitamin B12 deficienciesClinical Correlation: Considering patient’s clinical history, physical examination, test results interpreting laboratory data","code":""},{"path":"therapeutic-drug-monitoring.html","id":"therapeutic-drug-monitoring","chapter":"Therapeutic Drug Monitoring","heading":"Therapeutic Drug Monitoring","text":"section provides comprehensive overview TDM","code":""},{"path":"therapeutic-drug-monitoring.html","id":"pharmacokinetics-pk","chapter":"Therapeutic Drug Monitoring","heading":"Pharmacokinetics (PK)","text":"Definition: study body affects drug administration (ADME)ADME Processes\nAbsorption: Entry drug bloodstream\nDistribution: Transport drug tissues\nMetabolism: Chemical alteration drug\nExcretion: Elimination drug metabolites\nAbsorption: Entry drug bloodstreamDistribution: Transport drug tissuesMetabolism: Chemical alteration drugExcretion: Elimination drug metabolitesKey PK Parameters\nBioavailability: Fraction drug reaching systemic circulation\nVolume Distribution (Vd): Apparent space body available contain drug\nClearance (CL): Rate drug removal body\nHalf-Life (t1/2): Time drug concentration decrease half\nBioavailability: Fraction drug reaching systemic circulationVolume Distribution (Vd): Apparent space body available contain drugClearance (CL): Rate drug removal bodyHalf-Life (t1/2): Time drug concentration decrease halfTherapeutic Range\nrange drug concentrations associated optimal therapeutic effect minimal toxicity\nrange drug concentrations associated optimal therapeutic effect minimal toxicityTherapeutic States\nSubtherapeutic: therapeutic range\nTherapeutic: Within therapeutic range\nToxic: therapeutic range\nSupratherapeutic: therapeutic range\nSubtherapeutic: therapeutic rangeTherapeutic: Within therapeutic rangeToxic: therapeutic rangeSupratherapeutic: therapeutic range","code":""},{"path":"therapeutic-drug-monitoring.html","id":"chemical-and-physical-properties","chapter":"Therapeutic Drug Monitoring","heading":"Chemical and Physical Properties","text":"Importance: Properties influence ADME, mechanism action, analytical methodsKey Properties\nSolubility: Affects absorption excretion\nIonization: Influences absorption, distribution, renal excretion\nProtein Binding: Affects distribution free drug concentration\nPartition Coefficient (Log P): Affects membrane permeability\nSolubility: Affects absorption excretionIonization: Influences absorption, distribution, renal excretionProtein Binding: Affects distribution free drug concentrationPartition Coefficient (Log P): Affects membrane permeabilityDrug Classes Properties\nAminoglycosides: Water-soluble, polycationic\nCardioactive Drugs: Variable properties\nAnticonvulsants: Lipid-soluble\nAntidepressants: Variable properties\nImmunosuppressants: Lipid-soluble, highly protein-bound\nAminoglycosides: Water-soluble, polycationicCardioactive Drugs: Variable propertiesAnticonvulsants: Lipid-solubleAntidepressants: Variable propertiesImmunosuppressants: Lipid-soluble, highly protein-bound","code":""},{"path":"therapeutic-drug-monitoring.html","id":"laboratory-test-procedures-9","chapter":"Therapeutic Drug Monitoring","heading":"Laboratory Test Procedures","text":"Analytical Principles\nImmunoassays: Antibody-antigen binding\nChromatography: Separates compounds\nMass Spectrometry: Measures mass--charge ratio\nImmunoassays: Antibody-antigen bindingChromatography: Separates compoundsMass Spectrometry: Measures mass--charge ratioSpecimen Collection Handling\nTiming Dose: Trough, peak\nCollection Tubes: Correct type minimize interference\nProcessing: Centrifugation, separation, storage\nTiming Dose: Trough, peakCollection Tubes: Correct type minimize interferenceProcessing: Centrifugation, separation, storageQuality Control\nUse QC samples validate accuracy\nCalibrate instruments routinely\nUse QC samples validate accuracyCalibrate instruments routinely","code":""},{"path":"therapeutic-drug-monitoring.html","id":"test-result-interpretation-9","chapter":"Therapeutic Drug Monitoring","heading":"Test Result Interpretation","text":"Reference Intervals\nUse appropriate reference ranges\nUse appropriate reference rangesClinical Context\nPatient history, symptoms, medication list\nPatient history, symptoms, medication listInfluence Variables\nDrug-drug interactions\nAge, Weight, etc\nDrug-drug interactionsAge, Weight, etcCommon Findings\nDrug level results , , within therapeutic range\nDrug level results , , within therapeutic rangeLimitations\nConsider test specificity\nConsider test specificity","code":""},{"path":"therapeutic-drug-monitoring.html","id":"disease-state-correlation-9","chapter":"Therapeutic Drug Monitoring","heading":"Disease State Correlation","text":"Renal Disease: Affects excretionLiver Disease: Affects metabolismHeart Failure: Affects distributionGastrointestinal Disorders: Affects absorptionObesity: Alters distributionPregnancy: Alters ADME phasesOther Correlations\ndiseases conditions may alter distribution, metabolization, excretion\ndiseases conditions may alter distribution, metabolization, excretion","code":""},{"path":"pharmacokinetics.html","id":"pharmacokinetics","chapter":"Pharmacokinetics","heading":"Pharmacokinetics","text":"section presents key aspects pharmacokinetics TDM, including therapeutic toxic states, processes metabolism excretion","code":""},{"path":"pharmacokinetics.html","id":"pharmacokinetics-in-therapeutic-drug-monitoring-tdm","chapter":"Pharmacokinetics","heading":"Pharmacokinetics in Therapeutic Drug Monitoring (TDM)","text":"Definition: study body affects drug administration, including absorption, distribution, metabolism, excretion (ADME)Importance TDM: Understanding pharmacokinetics essential optimizing drug therapy maintaining drug concentrations within specific therapeutic range","code":""},{"path":"pharmacokinetics.html","id":"therapeutic-states","chapter":"Pharmacokinetics","heading":"Therapeutic States","text":"Therapeutic Range: range drug concentrations associated high probability desired therapeutic effect low probability adverse effectsSubtherapeutic State\nDefinition: Drug concentration therapeutic range, resulting inadequate therapeutic effect\nCauses: Inadequate dose, poor adherence, drug interactions, rapid metabolism, increased clearance, malabsorption\nManagement: Increase dose, improve adherence, adjust dosing interval, avoid/manage drug interactions, use alternative drug\nDefinition: Drug concentration therapeutic range, resulting inadequate therapeutic effectCauses: Inadequate dose, poor adherence, drug interactions, rapid metabolism, increased clearance, malabsorptionManagement: Increase dose, improve adherence, adjust dosing interval, avoid/manage drug interactions, use alternative drugTherapeutic State\nDefinition: Drug concentration within therapeutic range, achieving desired therapeutic effect minimal adverse effects\nGoal TDM: maintain drug concentrations within therapeutic range\nManagement: Monitor drug concentrations regularly, adjust dose needed, monitor adverse effects, educate patient\nDefinition: Drug concentration within therapeutic range, achieving desired therapeutic effect minimal adverse effectsGoal TDM: maintain drug concentrations within therapeutic rangeManagement: Monitor drug concentrations regularly, adjust dose needed, monitor adverse effects, educate patientToxic State\nDefinition: Drug concentration therapeutic range, increasing risk adverse effects\nCauses: Excessive dose, decreased clearance, drug interactions, overdose\nConsequences: Adverse effects, organ damage, life-threatening conditions\nManagement: Reduce dose, discontinue drug, administer antidote, provide supportive care\nDefinition: Drug concentration therapeutic range, increasing risk adverse effectsCauses: Excessive dose, decreased clearance, drug interactions, overdoseConsequences: Adverse effects, organ damage, life-threatening conditionsManagement: Reduce dose, discontinue drug, administer antidote, provide supportive careSupratherapeutic State\nDefinition: Drug concentration therapeutic range may intentional certain situations\nManagement: Monitor patients closely adverse effects adjust dose accordingly\nDefinition: Drug concentration therapeutic range may intentional certain situationsManagement: Monitor patients closely adverse effects adjust dose accordingly","code":""},{"path":"pharmacokinetics.html","id":"toxic-states","chapter":"Pharmacokinetics","heading":"Toxic States","text":"Causes Toxic States\nExcessive dosage\nImpaired Elimination: Renal hepatic impairment\nDrug Interactions: Enzyme inhibition induction\nPatient-Specific Factors: Age, genetics, disease states\nExcessive dosageImpaired Elimination: Renal hepatic impairmentDrug Interactions: Enzyme inhibition inductionPatient-Specific Factors: Age, genetics, disease statesCommonly Monitored Drugs Toxic Effects\nDigoxin, Lithium, Theophylline, Aminoglycosides, Vancomycin, Phenytoin, Valproic Acid, Methotrexate, Cyclosporine/Tacrolimus, Tricyclic Antidepressants, Salicylates, Acetaminophen\nDigoxin, Lithium, Theophylline, Aminoglycosides, Vancomycin, Phenytoin, Valproic Acid, Methotrexate, Cyclosporine/Tacrolimus, Tricyclic Antidepressants, Salicylates, AcetaminophenSymptoms Clinical Presentation\nGastrointestinal, Neurological, Cardiovascular, Renal, Hepatic, Hematological, Dermatological\nGastrointestinal, Neurological, Cardiovascular, Renal, Hepatic, Hematological, DermatologicalLaboratory Tests Monitoring Toxicity\nTherapeutic Drug Monitoring (TDM), Renal Function Tests, Hepatic Function Tests, Electrolyte Monitoring, Cardiac Monitoring, Hematological Tests\nTherapeutic Drug Monitoring (TDM), Renal Function Tests, Hepatic Function Tests, Electrolyte Monitoring, Cardiac Monitoring, Hematological TestsManagement\nDiscontinue drug, provide supportive care, consider decontamination, enhance elimination, administer antidotes\nDiscontinue drug, provide supportive care, consider decontamination, enhance elimination, administer antidotesPrevention\nAppropriate Prescribing, Patient Education, Therapeutic Drug Monitoring, Medication Reconciliation, Electronic Prescribing, Pharmacist Involvement\nAppropriate Prescribing, Patient Education, Therapeutic Drug Monitoring, Medication Reconciliation, Electronic Prescribing, Pharmacist Involvement","code":""},{"path":"pharmacokinetics.html","id":"metabolism-and-excretion","chapter":"Pharmacokinetics","heading":"Metabolism and Excretion","text":"Drug Metabolism\nDefinition: process body chemically alters drug\nPrimary Site: Liver\nPurpose: Convert drugs water-soluble forms elimination, inactivate drugs, activate prodrugs\nPhases Metabolism: Phase (oxidation, reduction, hydrolysis), Phase II (conjugation)\nCytochrome P450 (CYP) Enzymes: Key enzymes involved drug metabolism\nFactors Affecting Drug Metabolism: Genetic factors, age, disease states, drug interactions, diet\nDefinition: process body chemically alters drugPrimary Site: LiverPurpose: Convert drugs water-soluble forms elimination, inactivate drugs, activate prodrugsPhases Metabolism: Phase (oxidation, reduction, hydrolysis), Phase II (conjugation)Cytochrome P450 (CYP) Enzymes: Key enzymes involved drug metabolismFactors Affecting Drug Metabolism: Genetic factors, age, disease states, drug interactions, dietDrug Excretion\nDefinition: process body eliminates drug metabolites\nPrimary Routes: Kidneys (urine), Liver (bile)\nRenal Excretion: Glomerular filtration, tubular secretion, tubular reabsorption\nBiliary Excretion: Excretion bile eliminated feces\nClearance (CL): Measure body’s efficiency eliminating drug\nDefinition: process body eliminates drug metabolitesPrimary Routes: Kidneys (urine), Liver (bile)Renal Excretion: Glomerular filtration, tubular secretion, tubular reabsorptionBiliary Excretion: Excretion bile eliminated fecesClearance (CL): Measure body’s efficiency eliminating drugClinical Significance\nDrug-Drug Interactions (DDIs): Knowledge metabolic pathways crucial\nPharmacogenomics: Genetic testing personalized dosing\nDosage Adjustments: Adjustments patients renal/hepatic impairment\nTherapeutic Drug Monitoring (TDM): Monitoring optimize drug therapy\nDrug-Drug Interactions (DDIs): Knowledge metabolic pathways crucialPharmacogenomics: Genetic testing personalized dosingDosage Adjustments: Adjustments patients renal/hepatic impairmentTherapeutic Drug Monitoring (TDM): Monitoring optimize drug therapy","code":""},{"path":"therapeutic-states-1.html","id":"therapeutic-states-1","chapter":"Therapeutic States","heading":"Therapeutic States","text":"Understanding interplay drug pharmacokinetics therapeutic states essential effective therapeutic drug monitoring (TDM)","code":""},{"path":"therapeutic-states-1.html","id":"pharmacokinetics-the-bodys-effect-on-drugs","chapter":"Therapeutic States","heading":"Pharmacokinetics: The Body’s Effect on Drugs","text":"Definition: study body affects drug administration, including processes absorption, distribution, metabolism, excretion (ADME)","code":""},{"path":"therapeutic-states-1.html","id":"absorption","chapter":"Therapeutic States","heading":"Absorption","text":"Definition: process drug enters bloodstream site administrationFactors Affecting Absorption\nRoute Administration: Oral, intravenous, intramuscular, subcutaneous, transdermal, etc\nDrug Formulation: Tablet, capsule, solution, etc\nPhysicochemical Properties Drug: Solubility, ionization, molecular size\nPhysiological Factors: Gastric emptying time, intestinal motility, blood flow, pH\nFirst-Pass Metabolism: Metabolism drug liver reaches systemic circulation (orally administered drugs)\nRoute Administration: Oral, intravenous, intramuscular, subcutaneous, transdermal, etcDrug Formulation: Tablet, capsule, solution, etcPhysicochemical Properties Drug: Solubility, ionization, molecular sizePhysiological Factors: Gastric emptying time, intestinal motility, blood flow, pHFirst-Pass Metabolism: Metabolism drug liver reaches systemic circulation (orally administered drugs)Bioavailability: fraction administered dose drug reaches systemic circulation unchanged\nIntravenous administration: Bioavailability 100%\nOral administration: Bioavailability often less 100% due incomplete absorption first-pass metabolism\nIntravenous administration: Bioavailability 100%Oral administration: Bioavailability often less 100% due incomplete absorption first-pass metabolism","code":""},{"path":"therapeutic-states-1.html","id":"distribution","chapter":"Therapeutic States","heading":"Distribution","text":"Definition: process drug transported bloodstream various tissues organs bodyFactors Affecting Distribution\nBlood Flow: Highly perfused organs (brain, heart, liver, kidneys) receive drug rapidly\nTissue Permeability: Ability drug cross cell membranes enter tissues\nLipid-soluble drugs can easily cross cell membranes\nWater-soluble drugs may require transport proteins\n\nProtein Binding: Binding drugs plasma proteins (albumin, alpha-1-acid glycoprotein)\nunbound (free) drug can exert pharmacological effects\nDrugs high protein binding limited distribution\n\nVolume Distribution (Vd): measure apparent space body available contain drug\nVd = Dose / Plasma Concentration\nHigh Vd: Indicates extensive tissue distribution\nLow Vd: Indicates limited tissue distribution\n\nBlood Flow: Highly perfused organs (brain, heart, liver, kidneys) receive drug rapidlyTissue Permeability: Ability drug cross cell membranes enter tissues\nLipid-soluble drugs can easily cross cell membranes\nWater-soluble drugs may require transport proteins\nLipid-soluble drugs can easily cross cell membranesWater-soluble drugs may require transport proteinsProtein Binding: Binding drugs plasma proteins (albumin, alpha-1-acid glycoprotein)\nunbound (free) drug can exert pharmacological effects\nDrugs high protein binding limited distribution\nunbound (free) drug can exert pharmacological effectsDrugs high protein binding limited distributionVolume Distribution (Vd): measure apparent space body available contain drug\nVd = Dose / Plasma Concentration\nHigh Vd: Indicates extensive tissue distribution\nLow Vd: Indicates limited tissue distribution\nVd = Dose / Plasma ConcentrationHigh Vd: Indicates extensive tissue distributionLow Vd: Indicates limited tissue distribution","code":""},{"path":"therapeutic-states-1.html","id":"metabolism","chapter":"Therapeutic States","heading":"Metabolism","text":"Definition: process body chemically alters drug, usually make water-soluble easier excretePrimary Site: LiverPhases Metabolism\nPhase Reactions: Introduce expose functional group drug molecule\nOxidation, reduction, hydrolysis\nEnzymes: Cytochrome P450 (CYP) enzymes, flavin-containing monooxygenases (FMOs)\n\nPhase II Reactions: Conjugate polar molecule drug molecule\nGlucuronidation, sulfation, acetylation, glutathione conjugation\nEnzymes: UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs)\n\nPhase Reactions: Introduce expose functional group drug molecule\nOxidation, reduction, hydrolysis\nEnzymes: Cytochrome P450 (CYP) enzymes, flavin-containing monooxygenases (FMOs)\nOxidation, reduction, hydrolysisEnzymes: Cytochrome P450 (CYP) enzymes, flavin-containing monooxygenases (FMOs)Phase II Reactions: Conjugate polar molecule drug molecule\nGlucuronidation, sulfation, acetylation, glutathione conjugation\nEnzymes: UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs)\nGlucuronidation, sulfation, acetylation, glutathione conjugationEnzymes: UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs)Enzyme Induction Inhibition\nEnzyme Inducers: Increase activity metabolizing enzymes, leading decreased drug levels\nExamples: Rifampin, carbamazepine\n\nEnzyme Inhibitors: Decrease activity metabolizing enzymes, leading increased drug levels\nExamples: Ketoconazole, erythromycin\n\nEnzyme Inducers: Increase activity metabolizing enzymes, leading decreased drug levels\nExamples: Rifampin, carbamazepine\nExamples: Rifampin, carbamazepineEnzyme Inhibitors: Decrease activity metabolizing enzymes, leading increased drug levels\nExamples: Ketoconazole, erythromycin\nExamples: Ketoconazole, erythromycinProdrugs: Drugs inactive administered form must metabolized active metabolites exert effects\n* Examples: Codeine, prednisone","code":""},{"path":"therapeutic-states-1.html","id":"excretion","chapter":"Therapeutic States","heading":"Excretion","text":"Definition: process body eliminates drugPrimary Routes\nKidneys: drugs excreted urine\nGlomerular filtration, tubular secretion, tubular reabsorption\n\nLiver: drugs excreted bile eliminated feces\nRoutes: Lungs, sweat, saliva, breast milk\nKidneys: drugs excreted urine\nGlomerular filtration, tubular secretion, tubular reabsorption\nGlomerular filtration, tubular secretion, tubular reabsorptionLiver: drugs excreted bile eliminated fecesOther Routes: Lungs, sweat, saliva, breast milkFactors Affecting Excretion\nRenal Function: Glomerular filtration rate (GFR), tubular secretion, tubular reabsorption affect renal drug excretion\nLiver Function: Bile flow hepatic metabolism affect biliary drug excretion\nDrug Properties: Molecular size, ionization, protein binding affect excretion\nRenal Function: Glomerular filtration rate (GFR), tubular secretion, tubular reabsorption affect renal drug excretionLiver Function: Bile flow hepatic metabolism affect biliary drug excretionDrug Properties: Molecular size, ionization, protein binding affect excretionClearance (CL): measure body’s ability eliminate drug\nCL = Rate Elimination / Plasma Concentration\nHigh CL: Indicates rapid drug elimination\nLow CL: Indicates slow drug elimination\nCL = Rate Elimination / Plasma ConcentrationHigh CL: Indicates rapid drug eliminationLow CL: Indicates slow drug elimination","code":""},{"path":"therapeutic-states-1.html","id":"therapeutic-states-in-tdm","chapter":"Therapeutic States","heading":"Therapeutic States in TDM","text":"Objective TDM: optimize drug therapy maintaining drug concentrations within specific therapeutic rangeTherapeutic Range: range drug concentrations associated high probability desired therapeutic effect low probability adverse effectsFactors Influencing Therapeutic Range\nDrug Properties: Potency, selectivity, therapeutic index\nPatient Factors: Age, sex, weight, genetics, disease state, concurrent medications\nDrug Properties: Potency, selectivity, therapeutic indexPatient Factors: Age, sex, weight, genetics, disease state, concurrent medicationsTherapeutic States\nSubtherapeutic: Drug concentration therapeutic range, resulting inadequate therapeutic effect\nTherapeutic: Drug concentration within therapeutic range, achieving desired therapeutic effect minimal adverse effects\nToxic: Drug concentration therapeutic range, increasing risk adverse effects\nSupratherapeutic: Drug concentration therapeutic range, necessarily associated toxicity\nSupratherapeutic levels may intentional certain situations (e.g., antibiotic dosing severe infections)\n\nSubtherapeutic: Drug concentration therapeutic range, resulting inadequate therapeutic effectTherapeutic: Drug concentration within therapeutic range, achieving desired therapeutic effect minimal adverse effectsToxic: Drug concentration therapeutic range, increasing risk adverse effectsSupratherapeutic: Drug concentration therapeutic range, necessarily associated toxicity\nSupratherapeutic levels may intentional certain situations (e.g., antibiotic dosing severe infections)\nSupratherapeutic levels may intentional certain situations (e.g., antibiotic dosing severe infections)","code":""},{"path":"therapeutic-states-1.html","id":"subtherapeutic-state","chapter":"Therapeutic States","heading":"Subtherapeutic State","text":"Definition: Drug concentration therapeutic range, resulting inadequate therapeutic effectCauses\nInadequate Dose: prescribed dose low\nPoor Adherence: patient taking medication prescribed\nDrug Interactions: medications substances decreasing drug levels\nRapid Metabolism: patient metabolizing drug quickly\nIncreased Clearance: patient’s kidneys eliminating drug quickly\nMalabsorption: Drug adequately absorbed GI tract\nInadequate Dose: prescribed dose lowPoor Adherence: patient taking medication prescribedDrug Interactions: medications substances decreasing drug levelsRapid Metabolism: patient metabolizing drug quicklyIncreased Clearance: patient’s kidneys eliminating drug quicklyMalabsorption: Drug adequately absorbed GI tractConsequences\nLack therapeutic effect: drug effectively treating condition\nDisease progression: condition may worsen due lack treatment\nDevelopment resistance: case antibiotics, subtherapeutic levels can promote development drug-resistant bacteria\nLack therapeutic effect: drug effectively treating conditionDisease progression: condition may worsen due lack treatmentDevelopment resistance: case antibiotics, subtherapeutic levels can promote development drug-resistant bacteriaManagement\nIncrease dose\nImprove adherence patient education support\nAdjust dosing interval\nAvoid manage drug interactions\nUse alternative drug\nIncrease doseImprove adherence patient education supportAdjust dosing intervalAvoid manage drug interactionsUse alternative drug","code":""},{"path":"therapeutic-states-1.html","id":"therapeutic-state","chapter":"Therapeutic States","heading":"Therapeutic State","text":"Definition: Drug concentration within therapeutic range, achieving desired therapeutic effect minimal adverse effectsGoal TDM: maintain drug concentrations within therapeutic rangeFactors Influencing Therapeutic Range\nIndividual variability drug metabolism response\nPatient-specific factors (age, weight, genetics, disease state)\nDrug interactions\nIndividual variability drug metabolism responsePatient-specific factors (age, weight, genetics, disease state)Drug interactionsManagement\nMonitor drug concentrations regularly\nAdjust dose dosing interval needed\nMonitor adverse effects\nEducate patient importance adherence potential drug interactions\nMonitor drug concentrations regularlyAdjust dose dosing interval neededMonitor adverse effectsEducate patient importance adherence potential drug interactions","code":""},{"path":"therapeutic-states-1.html","id":"toxic-state","chapter":"Therapeutic States","heading":"Toxic State","text":"Definition: Drug concentration therapeutic range, increasing risk adverse effectsCauses\nExcessive Dose: prescribed dose high\nDecreased Clearance: patient’s kidneys liver eliminating drug efficiently\nDrug Interactions: medications substances increasing drug levels\nOverdose: Intentional accidental ingestion much drug\nExcessive Dose: prescribed dose highDecreased Clearance: patient’s kidneys liver eliminating drug efficientlyDrug Interactions: medications substances increasing drug levelsOverdose: Intentional accidental ingestion much drugConsequences\nAdverse effects: drug causes unwanted side effects\nOrgan damage: drug damages organs, liver kidneys\nLife-threatening conditions: drug causes serious complications, arrhythmias seizures\nAdverse effects: drug causes unwanted side effectsOrgan damage: drug damages organs, liver kidneysLife-threatening conditions: drug causes serious complications, arrhythmias seizuresManagement\nReduce dose\nIncrease dosing interval\nDiscontinue drug\nAdminister antidote, available\nProvide supportive care\nReduce doseIncrease dosing intervalDiscontinue drugAdminister antidote, availableProvide supportive care","code":""},{"path":"therapeutic-states-1.html","id":"supratherapeutic-state","chapter":"Therapeutic States","heading":"Supratherapeutic State","text":"Definition: Drug concentration therapeutic range, necessarily associated toxicityIntentional Supratherapeutic Levels\nCertain situations may require supratherapeutic levels achieve desired effect (e.g., antibiotic dosing severe infections, chemotherapy)\nMonitor patients closely adverse effects\nCertain situations may require supratherapeutic levels achieve desired effect (e.g., antibiotic dosing severe infections, chemotherapy)Monitor patients closely adverse effectsUnintentional Supratherapeutic Levels\nMay occur due errors dosing, drug interactions, impaired drug elimination\nMonitor patients adverse effects adjust dose accordingly\nMay occur due errors dosing, drug interactions, impaired drug eliminationMonitor patients adverse effects adjust dose accordingly","code":""},{"path":"therapeutic-states-1.html","id":"summary-table-of-therapeutic-states","chapter":"Therapeutic States","heading":"Summary Table of Therapeutic States","text":"","code":""},{"path":"therapeutic-states-1.html","id":"key-terms-73","chapter":"Therapeutic States","heading":"Key Terms","text":"Pharmacokinetics: study body affects drug (ADME)Absorption: process drug enters bloodstreamDistribution: process drug transported tissuesMetabolism: process body chemically alters drugExcretion: process body eliminates drugTherapeutic Range: range drug concentrations associated optimal therapeutic effect minimal toxicitySubtherapeutic: Drug concentration therapeutic rangeTherapeutic: Drug concentration within therapeutic rangeToxic: Drug concentration therapeutic rangeSupratherapeutic: Drug concentration therapeutic range, necessarily toxicClearance: measure body’s ability eliminate drugBioavailability: fraction drug reaching systemic circulationVolume Distribution: Apparent space body available contain drugProtein Binding: Binding drugs plasma proteins reducing distribution","code":""},{"path":"toxic-states-1.html","id":"toxic-states-1","chapter":"Toxic States","heading":"Toxic States","text":"Delving toxic states within therapeutic drug monitoring (TDM) crucial understanding factors lead toxic drug concentrations subsequent adverse effects","code":""},{"path":"toxic-states-1.html","id":"toxic-states-in-tdm","chapter":"Toxic States","heading":"Toxic States in TDM","text":"Definition: toxic state occurs concentration drug body exceeds therapeutic range, leading increased risk adverse effects potential organ damageImportance Understanding Toxic States\nPrevents iatrogenic harm\nEnsures patient safety\nOptimizes drug therapy identifying managing factors contributing toxicity\nPrevents iatrogenic harmEnsures patient safetyOptimizes drug therapy identifying managing factors contributing toxicity","code":""},{"path":"toxic-states-1.html","id":"causes-of-toxic-states","chapter":"Toxic States","heading":"Causes of Toxic States","text":"Excessive Dosage\nPrescription Errors: Incorrect dose prescribed physician\nPatient Non-Adherence: Taking prescribed dose, either intentionally unintentionally\nMedication Errors: Dispensing errors pharmacy\nPrescription Errors: Incorrect dose prescribed physicianPatient Non-Adherence: Taking prescribed dose, either intentionally unintentionallyMedication Errors: Dispensing errors pharmacyImpaired Elimination\nRenal Impairment: Reduced kidney function decreases renal clearance, leading drug accumulation\nHepatic Impairment: Liver disease decreases hepatic metabolism, resulting higher drug concentrations\nHeart Failure: Reduced blood flow kidneys liver impairs drug elimination\nRenal Impairment: Reduced kidney function decreases renal clearance, leading drug accumulationHepatic Impairment: Liver disease decreases hepatic metabolism, resulting higher drug concentrationsHeart Failure: Reduced blood flow kidneys liver impairs drug eliminationDrug Interactions\nEnzyme Inhibition: drugs inhibit metabolism drugs, leading increased drug levels\nProtein Binding Displacement: Drugs can displace drugs plasma proteins, increasing concentration free (active) drug\nReduced Absorption: Drugs can increase absorption leading supratherapeutic levels\nEnzyme Inhibition: drugs inhibit metabolism drugs, leading increased drug levelsProtein Binding Displacement: Drugs can displace drugs plasma proteins, increasing concentration free (active) drugReduced Absorption: Drugs can increase absorption leading supratherapeutic levelsPatient-Specific Factors\nAge: Infants elderly individuals susceptible toxicity due immature declining organ function\nGenetics: Genetic variations drug-metabolizing enzymes can affect drug levels\nDisease States: Certain diseases can affect drug metabolism elimination\nPregnancy: Physiological changes pregnancy can affect drug pharmacokinetics\nAge: Infants elderly individuals susceptible toxicity due immature declining organ functionGenetics: Genetic variations drug-metabolizing enzymes can affect drug levelsDisease States: Certain diseases can affect drug metabolism eliminationPregnancy: Physiological changes pregnancy can affect drug pharmacokinetics","code":""},{"path":"toxic-states-1.html","id":"commonly-monitored-drugs-and-their-toxic-effects","chapter":"Toxic States","heading":"Commonly Monitored Drugs and Their Toxic Effects","text":"","code":""},{"path":"toxic-states-1.html","id":"symptoms-and-clinical-presentation-of-drug-toxicity","chapter":"Toxic States","heading":"Symptoms and Clinical Presentation of Drug Toxicity","text":"Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain, loss appetiteNeurological: Headache, dizziness, confusion, tremor, seizures, ataxia, visual disturbances, altered mental statusCardiovascular: Arrhythmias, hypotension, hypertension, bradycardia, tachycardiaRenal: Decreased urine output, elevated creatinine BUN, electrolyte imbalancesHepatic: Jaundice, abdominal pain, elevated liver enzymes (AST, ALT)Hematological: Bleeding, bruising, fatigue, infectionDermatological: Rash, itching, hives","code":""},{"path":"toxic-states-1.html","id":"laboratory-tests-for-monitoring-drug-toxicity","chapter":"Toxic States","heading":"Laboratory Tests for Monitoring Drug Toxicity","text":"Therapeutic Drug Monitoring (TDM): Measurement drug concentrations serum plasma\nAssays used: Immunoassays, chromatography (HPLC, LC-MS/MS)\nAssays used: Immunoassays, chromatography (HPLC, LC-MS/MS)Renal Function Tests\nSerum creatinine\nBlood urea nitrogen (BUN)\nCreatinine clearance\nUrinalysis\nSerum creatinineBlood urea nitrogen (BUN)Creatinine clearanceUrinalysisHepatic Function Tests\nAlanine aminotransferase (ALT)\nAspartate aminotransferase (AST)\nAlkaline phosphatase (ALP)\nBilirubin\nAlbumin\nProthrombin time (PT)/INR\nAlanine aminotransferase (ALT)Aspartate aminotransferase (AST)Alkaline phosphatase (ALP)BilirubinAlbuminProthrombin time (PT)/INRElectrolyte Monitoring\nSodium\nPotassium\nChloride\nBicarbonate\nSodiumPotassiumChlorideBicarbonateCardiac Monitoring\nElectrocardiogram (ECG): detect arrhythmias\nCardiac enzymes: Troponin, CK-MB (cardiac damage suspected)\nElectrocardiogram (ECG): detect arrhythmiasCardiac enzymes: Troponin, CK-MB (cardiac damage suspected)Hematological Tests\nComplete blood count (CBC): monitor bone marrow suppression bleeding abnormalities\nComplete blood count (CBC): monitor bone marrow suppression bleeding abnormalitiesSpecific Drug Toxicity Tests\nSalicylate levels\nAcetaminophen levels\nDigoxin levels\nLithium levels\nSalicylate levelsAcetaminophen levelsDigoxin levelsLithium levels","code":""},{"path":"toxic-states-1.html","id":"management-of-drug-toxicity","chapter":"Toxic States","heading":"Management of Drug Toxicity","text":"Immediate Actions\nDiscontinue drug: Stop drug administration\nSupportive care: Maintain vital functions (airway, breathing, circulation)\nMonitor vital signs: Blood pressure, heart rate, respiratory rate\nAssess mental status: Level consciousness, orientation\nDiscontinue drug: Stop drug administrationSupportive care: Maintain vital functions (airway, breathing, circulation)Monitor vital signs: Blood pressure, heart rate, respiratory rateAssess mental status: Level consciousness, orientationDecontamination (applicable)\nActivated charcoal: prevent absorption drug gastrointestinal tract (drug ingested recently)\nGastric lavage: remove drug stomach (rarely used)\nActivated charcoal: prevent absorption drug gastrointestinal tract (drug ingested recently)Gastric lavage: remove drug stomach (rarely used)Enhance Elimination\nForced diuresis: Administer intravenous fluids diuretics increase urine output enhance renal elimination drug\nHemodialysis: Remove drug blood using dialysis machine (drugs readily dialyzable)\nHemoperfusion: Remove drug blood passing cartridge containing adsorbent material\nUrine alkalinization: Increase urine pH enhance renal elimination certain acidic drugs (e.g., salicylates)\nForced diuresis: Administer intravenous fluids diuretics increase urine output enhance renal elimination drugHemodialysis: Remove drug blood using dialysis machine (drugs readily dialyzable)Hemoperfusion: Remove drug blood passing cartridge containing adsorbent materialUrine alkalinization: Increase urine pH enhance renal elimination certain acidic drugs (e.g., salicylates)Administer Antidotes (available)\nN-acetylcysteine (NAC) acetaminophen overdose\nDigoxin-specific antibody fragments (Digibind) digoxin toxicity\nNaloxone opioid overdose\nFlumazenil benzodiazepine overdose\nN-acetylcysteine (NAC) acetaminophen overdoseDigoxin-specific antibody fragments (Digibind) digoxin toxicityNaloxone opioid overdoseFlumazenil benzodiazepine overdoseSymptomatic Treatment\nManage specific symptoms appropriate medications (e.g., antiemetics nausea, anticonvulsants seizures)\nManage specific symptoms appropriate medications (e.g., antiemetics nausea, anticonvulsants seizures)Consult Toxicology Experts\nContact regional poison control center medical toxicologist guidance management drug toxicity\nContact regional poison control center medical toxicologist guidance management drug toxicity","code":""},{"path":"toxic-states-1.html","id":"prevention-of-drug-toxicity","chapter":"Toxic States","heading":"Prevention of Drug Toxicity","text":"Appropriate Prescribing\nConsider patient-specific factors (age, weight, renal function, liver function, drug interactions) prescribing medications\nStart low dose titrate gradually\nConsider patient-specific factors (age, weight, renal function, liver function, drug interactions) prescribing medicationsStart low dose titrate graduallyPatient Education\nEducate patients importance adherence, potential side effects, drug interactions\nEncourage patients report unusual symptoms healthcare provider\nEducate patients importance adherence, potential side effects, drug interactionsEncourage patients report unusual symptoms healthcare providerTherapeutic Drug Monitoring (TDM)\nMonitor drug concentrations patients receiving medications narrow therapeutic range\nMonitor drug concentrations patients receiving medications narrow therapeutic rangeMedication Reconciliation\nReview patient’s medication list regularly identify potential drug interactions\nReview patient’s medication list regularly identify potential drug interactionsElectronic Prescribing\nUse electronic prescribing systems built-safety alerts prevent medication errors\nUse electronic prescribing systems built-safety alerts prevent medication errorsPharmacist Involvement\nPharmacists can play key role preventing drug toxicity reviewing prescriptions, educating patients, monitoring drug interactions\nPharmacists can play key role preventing drug toxicity reviewing prescriptions, educating patients, monitoring drug interactions","code":""},{"path":"toxic-states-1.html","id":"key-terms-74","chapter":"Toxic States","heading":"Key Terms","text":"Therapeutic Drug Monitoring (TDM): Measurement drug concentrations optimize therapyToxic State: Drug concentration therapeutic range, increasing risk adverse effectsEnzyme Inhibition: Decreased activity drug-metabolizing enzymesProtein Binding Displacement: Displacement drug plasma proteins, increasing free drug concentrationRenal Clearance: rate drug removed body kidneysHepatic Metabolism: process liver chemically alters drugAntidote: substance counteracts effects poison drug overdoseActivated Charcoal: substance used prevent absorption drug gastrointestinal tractHemodialysis: procedure removes waste products excess fluid blood using dialysis machineNephrotoxicity: Kidney damageOtotoxicity: Hearing loss vertigoHepatotoxicity: Liver damageMyelosuppression: Bone marrow suppression","code":""},{"path":"metabolism-excretion.html","id":"metabolism-excretion","chapter":"Metabolism, Excretion","heading":"Metabolism, Excretion","text":"Understanding drug metabolism excretion processes critical therapeutic drug monitoring (TDM)","code":""},{"path":"metabolism-excretion.html","id":"drug-metabolism","chapter":"Metabolism, Excretion","heading":"Drug Metabolism","text":"Definition: process body chemically alters drug, often facilitate eliminationPrimary Site Metabolism: LiverOther Sites: Kidneys, intestines, lungs, plasmaPurpose Metabolism\nConvert lipid-soluble drugs water-soluble metabolites, facilitating excretion urine\nInactivate drugs terminate pharmacological effects\nActivate prodrugs active metabolites\nConvert lipid-soluble drugs water-soluble metabolites, facilitating excretion urineInactivate drugs terminate pharmacological effectsActivate prodrugs active metabolitesPhases Metabolism\nPhase Reactions: Introduce expose functional group drug molecule oxidation, reduction, hydrolysis\nPhase II Reactions: Conjugate polar molecule drug molecule, glucuronic acid, sulfate, glutathione\nPhase Reactions: Introduce expose functional group drug molecule oxidation, reduction, hydrolysisPhase II Reactions: Conjugate polar molecule drug molecule, glucuronic acid, sulfate, glutathione","code":""},{"path":"metabolism-excretion.html","id":"phase-i-metabolism","chapter":"Metabolism, Excretion","heading":"Phase I Metabolism","text":"Oxidation\nAddition oxygen removal hydrogen atoms drug molecule\nEnzymes involved: Cytochrome P450 (CYP) enzymes\nExamples reactions: Hydroxylation, epoxidation, N-oxidation, S-oxidation\nAddition oxygen removal hydrogen atoms drug moleculeEnzymes involved: Cytochrome P450 (CYP) enzymesExamples reactions: Hydroxylation, epoxidation, N-oxidation, S-oxidationReduction\nAddition hydrogen atoms electrons drug molecule\nEnzymes involved: Reductases\nExamples reactions: Reduction nitro groups, azo groups, carbonyl groups\nAddition hydrogen atoms electrons drug moleculeEnzymes involved: ReductasesExamples reactions: Reduction nitro groups, azo groups, carbonyl groupsHydrolysis\nAddition water break chemical bond\nEnzymes involved: Esterases, amidases, peptidases\nExamples reactions: Hydrolysis esters, amides, peptides\nAddition water break chemical bondEnzymes involved: Esterases, amidases, peptidasesExamples reactions: Hydrolysis esters, amides, peptides","code":""},{"path":"metabolism-excretion.html","id":"phase-ii-metabolism","chapter":"Metabolism, Excretion","heading":"Phase II Metabolism","text":"Glucuronidation\nAddition glucuronic acid drug molecule\nEnzymes involved: UDP-glucuronosyltransferases (UGTs)\nResults highly water-soluble metabolites easily excreted urine\nAddition glucuronic acid drug moleculeEnzymes involved: UDP-glucuronosyltransferases (UGTs)Results highly water-soluble metabolites easily excreted urineSulfation\nAddition sulfate group drug molecule\nEnzymes involved: Sulfotransferases (SULTs)\nResults water-soluble metabolites easily excreted urine\nAddition sulfate group drug moleculeEnzymes involved: Sulfotransferases (SULTs)Results water-soluble metabolites easily excreted urineAcetylation\nAddition acetyl group drug molecule\nEnzymes involved: N-acetyltransferases (NATs)\nGenetic polymorphisms NAT enzymes can affect drug metabolism\nAddition acetyl group drug moleculeEnzymes involved: N-acetyltransferases (NATs)Genetic polymorphisms NAT enzymes can affect drug metabolismGlutathione Conjugation\nAddition glutathione drug molecule\nEnzymes involved: Glutathione S-transferases (GSTs)\nImportant detoxifying reactive metabolites\nAddition glutathione drug moleculeEnzymes involved: Glutathione S-transferases (GSTs)Important detoxifying reactive metabolitesMethylation\nAddition methyl group drug molecule\nEnzymes involved: Methyltransferases\nCan either activate inactivate drugs\nAddition methyl group drug moleculeEnzymes involved: MethyltransferasesCan either activate inactivate drugs","code":""},{"path":"metabolism-excretion.html","id":"cytochrome-p450-cyp-enzymes","chapter":"Metabolism, Excretion","heading":"Cytochrome P450 (CYP) Enzymes","text":"Definition: superfamily heme-containing monooxygenases catalyze oxidation many drugs endogenous compoundsLocation: Primarily liver, also present tissuesImportance Drug Metabolism: Responsible metabolism approximately 75% clinically used drugsKey CYP Enzymes\nCYP3A4: Metabolizes largest number drugs\nCYP2D6: Metabolizes many psychiatric cardiovascular drugs\nCYP2C9: Metabolizes nonsteroidal anti-inflammatory drugs (NSAIDs) warfarin\nCYP2C19: Metabolizes proton pump inhibitors (PPIs) clopidogrel\nCYP1A2: Metabolizes caffeine theophylline\nCYP3A4: Metabolizes largest number drugsCYP2D6: Metabolizes many psychiatric cardiovascular drugsCYP2C9: Metabolizes nonsteroidal anti-inflammatory drugs (NSAIDs) warfarinCYP2C19: Metabolizes proton pump inhibitors (PPIs) clopidogrelCYP1A2: Metabolizes caffeine theophylline","code":""},{"path":"metabolism-excretion.html","id":"factors-affecting-drug-metabolism","chapter":"Metabolism, Excretion","heading":"Factors Affecting Drug Metabolism","text":"Genetic Factors\nGenetic polymorphisms drug-metabolizing enzymes can affect drug metabolism\nIndividuals can classified poor metabolizers, intermediate metabolizers, extensive metabolizers, ultra-rapid metabolizers\nGenetic polymorphisms drug-metabolizing enzymes can affect drug metabolismIndividuals can classified poor metabolizers, intermediate metabolizers, extensive metabolizers, ultra-rapid metabolizersAge\nInfants immature metabolic enzyme systems\nElderly individuals may decreased liver function reduced enzyme activity\nInfants immature metabolic enzyme systemsElderly individuals may decreased liver function reduced enzyme activityDisease States\nLiver disease: Reduces metabolic enzyme activity\nKidney disease: Affects drug clearance can lead drug accumulation\nHeart failure: Reduces blood flow liver kidneys, impairing drug metabolism excretion\nLiver disease: Reduces metabolic enzyme activityKidney disease: Affects drug clearance can lead drug accumulationHeart failure: Reduces blood flow liver kidneys, impairing drug metabolism excretionDrug Interactions\nEnzyme Inducers: Increase activity metabolizing enzymes, leading decreased drug levels\nEnzyme Inhibitors: Decrease activity metabolizing enzymes, leading increased drug levels\nEnzyme Inducers: Increase activity metabolizing enzymes, leading decreased drug levelsEnzyme Inhibitors: Decrease activity metabolizing enzymes, leading increased drug levelsDiet Environmental Factors\nGrapefruit juice: Inhibits CYP3A4\nSmoking: Induces CYP1A2\nAlcohol: Can induce inhibit certain enzymes\nGrapefruit juice: Inhibits CYP3A4Smoking: Induces CYP1A2Alcohol: Can induce inhibit certain enzymesGender\nDifferences hormone levels body composition can affect drug metabolism\nDifferences hormone levels body composition can affect drug metabolism","code":""},{"path":"metabolism-excretion.html","id":"drug-excretion","chapter":"Metabolism, Excretion","heading":"Drug Excretion","text":"Definition: process body eliminates drug metabolitesPrimary Routes Excretion\nKidneys: drugs excreted urine\nLiver: drugs excreted bile eliminated feces\nKidneys: drugs excreted urineLiver: drugs excreted bile eliminated fecesOther Routes: Lungs, sweat, saliva, breast milkRenal Excretion\nGlomerular Filtration: Drugs small molecules filtered blood renal tubules\nunbound (free) drug can filtered\n\nTubular Secretion: Active transport drugs blood renal tubules\nCan affected drug interactions\n\nTubular Reabsorption: Passive active transport drugs renal tubules back blood\nLipid-soluble drugs readily reabsorbed\nUrine pH can affect reabsorption weak acids bases\n\nGlomerular Filtration: Drugs small molecules filtered blood renal tubules\nunbound (free) drug can filtered\nunbound (free) drug can filteredTubular Secretion: Active transport drugs blood renal tubules\nCan affected drug interactions\nCan affected drug interactionsTubular Reabsorption: Passive active transport drugs renal tubules back blood\nLipid-soluble drugs readily reabsorbed\nUrine pH can affect reabsorption weak acids bases\nLipid-soluble drugs readily reabsorbedUrine pH can affect reabsorption weak acids basesBiliary Excretion\nDrugs metabolites transported liver bile\nBile secreted small intestine eliminated feces\ndrugs undergo enterohepatic circulation, reabsorbed intestine back blood\nDrugs metabolites transported liver bileBile secreted small intestine eliminated fecesSome drugs undergo enterohepatic circulation, reabsorbed intestine back bloodClearance (CL)\nmeasure body’s efficiency eliminating drug body\nTotal Clearance: Sum clearance pathways (renal, hepatic, )\nRenal Clearance: volume plasma drug completely removed kidneys per unit time\nHepatic Clearance: volume plasma drug completely removed liver per unit time\nmeasure body’s efficiency eliminating drug bodyTotal Clearance: Sum clearance pathways (renal, hepatic, )Renal Clearance: volume plasma drug completely removed kidneys per unit timeHepatic Clearance: volume plasma drug completely removed liver per unit timeFactors Affecting Excretion\nRenal Function: Glomerular filtration rate (GFR), tubular secretion, tubular reabsorption affect renal drug excretion\nLiver Function: Bile flow hepatic metabolism affect biliary drug excretion\nDrug Properties: Molecular size, ionization, protein binding affect excretion\nDrug Interactions: drugs can affect excretion drugs\nRenal Function: Glomerular filtration rate (GFR), tubular secretion, tubular reabsorption affect renal drug excretionLiver Function: Bile flow hepatic metabolism affect biliary drug excretionDrug Properties: Molecular size, ionization, protein binding affect excretionDrug Interactions: drugs can affect excretion drugs","code":""},{"path":"metabolism-excretion.html","id":"clinical-significance-13","chapter":"Metabolism, Excretion","heading":"Clinical Significance","text":"Drug-Drug Interactions (DDIs)\nKnowledge metabolic pathways drug excretion mechanisms crucial predicting managing DDIs\nEnzyme inducers inhibitors can significantly alter drug levels, leading therapeutic failure toxicity\nKnowledge metabolic pathways drug excretion mechanisms crucial predicting managing DDIsEnzyme inducers inhibitors can significantly alter drug levels, leading therapeutic failure toxicityPharmacogenomics\nGenetic testing can identify individuals variations drug-metabolizing enzymes\nPersonalized dosing recommendations can made based individual’s genotype\nGenetic testing can identify individuals variations drug-metabolizing enzymesPersonalized dosing recommendations can made based individual’s genotypeDosage Adjustments Patients Renal Hepatic Impairment\nPatients impaired renal hepatic function may require lower doses less frequent dosing avoid drug accumulation toxicity\nPatients impaired renal hepatic function may require lower doses less frequent dosing avoid drug accumulation toxicityTherapeutic Drug Monitoring (TDM)\nTDM used optimize drug therapy monitoring drug concentrations adjusting doses based individual patient factors\nTDM can help ensure drug levels within therapeutic range minimize risk toxicity\nTDM used optimize drug therapy monitoring drug concentrations adjusting doses based individual patient factorsTDM can help ensure drug levels within therapeutic range minimize risk toxicity","code":""},{"path":"metabolism-excretion.html","id":"key-terms-75","chapter":"Metabolism, Excretion","heading":"Key Terms","text":"Drug Metabolism: process body chemically alters drugEnzyme Induction: Increased activity drug-metabolizing enzymesEnzyme Inhibition: Decreased activity drug-metabolizing enzymesCytochrome P450 (CYP) Enzymes: superfamily heme-containing monooxygenasesProdrug: inactive drug metabolized active metaboliteDrug Excretion: process body eliminates drug metabolitesGlomerular Filtration: process drugs small molecules filtered blood renal tubulesTubular Secretion: active transport drugs blood renal tubulesTubular Reabsorption: transport drugs renal tubules back bloodBiliary Excretion: excretion drugs metabolites liver bileEnterohepatic Circulation: reabsorption drugs intestine back bloodClearance (CL): measure body’s efficiency eliminating drug bodyDrug-Drug Interactions (DDIs): interactions two drugs can affect absorption, distribution, metabolism, excretionPharmacogenomics: study genes affect person’s response drugsTherapeutic Drug Monitoring (TDM): Measurement drug concentrations optimize therapyGenetic Polymorphism: Variation DNA sequence among individuals","code":""},{"path":"properties-8.html","id":"properties-8","chapter":"Properties","heading":"Properties","text":"section outlines chemical physical properties key drug classes monitored TDM","code":""},{"path":"properties-8.html","id":"general-overview-of-chemical-and-physical-properties-in-tdm","chapter":"Properties","heading":"General Overview of Chemical and Physical Properties in TDM","text":"Importance: Understanding chemical physical properties drugs critical comprehending ADME processes, mechanism action, analytical methods, TDMProperties Influencing ADME\nSolubility: Affects absorption excretion\nIonization: Impacts absorption, distribution, renal excretion\nProtein Binding: Influences distribution free drug concentration\nPartition Coefficient (Log P): Affects membrane permeability distribution\nSolubility: Affects absorption excretionIonization: Impacts absorption, distribution, renal excretionProtein Binding: Influences distribution free drug concentrationPartition Coefficient (Log P): Affects membrane permeability distribution","code":""},{"path":"properties-8.html","id":"drug-classes-and-properties","chapter":"Properties","heading":"Drug Classes and Properties","text":"","code":""},{"path":"properties-8.html","id":"aminoglycosides-e.g.-gentamicin","chapter":"Properties","heading":"Aminoglycosides (e.g., Gentamicin)","text":"Definition: Antibiotics used treat bacterial infectionsChemical Structure: Amino-modified glycosides (sugars)Molecular Weight: 400-600 DaSolubility: Highly water-soluble due multiple polar amino hydroxyl groupsIonization: Polycationic physiological pHProtein Binding: Low protein binding (< 30%)Pharmacokinetic Implications: Poor oral absorption, limited distribution, renal excretionAnalytical Methods: Immunoassays, chromatography, mass spectrometry","code":""},{"path":"properties-8.html","id":"cardioactive-drugs-e.g.-digoxin","chapter":"Properties","heading":"Cardioactive Drugs (e.g., Digoxin)","text":"Definition: Used treat heart failure arrhythmiasChemical Structure: Steroid nucleus linked lactone ring sugar moleculesMolecular Weight: Approximately 780 g/molSolubility: Slightly soluble waterIonization: Variable, depends functional groupsProtein Binding: Moderate protein binding (20-30%)Pharmacokinetic Implications: Oral bioavailability varies, distributes widely, renal excretionAnalytical Methods: Immunoassays, chromatography","code":""},{"path":"properties-8.html","id":"anticonvulsants-e.g.-phenobarbital","chapter":"Properties","heading":"Anticonvulsants (e.g., Phenobarbital)","text":"Definition: Used prevent control seizuresChemical Structure: BarbiturateMolecular Weight: Approximately 232 g/molSolubility: Slightly soluble waterIonization: Weakly acidicProtein Binding: Moderate protein binding (45-60%)Pharmacokinetic Implications: Oral bioavailability, extensive metabolism liver, renal excretion (pH-dependent)Analytical Methods: Immunoassays, chromatography","code":""},{"path":"properties-8.html","id":"antidepressants-e.g.-lithium","chapter":"Properties","heading":"Antidepressants (e.g., Lithium)","text":"Definition: Used treat depression mood disordersChemical Structure: Simplest structure antidepressents, single chargeMolecular Weight: Approximately 7 g/molSolubility: Lithium salts soluble waterIonization: Exists monovalent cation (\\(Li^+\\)) solutionProtein Binding: Negligible protein bindingPharmacokinetic Implications: Rapid complete oral absorption, distributes throughout total body water, renal excretionAnalytical Methods: Flame Emission Spectrophotometry (FES), Ion-Selective Electrode (ISE), Atomic Absorption Spectrometry (AAS)","code":""},{"path":"properties-8.html","id":"immunosuppressants-e.g.-tacrolimus","chapter":"Properties","heading":"Immunosuppressants (e.g., Tacrolimus)","text":"Definition: Used prevent organ rejection treat autoimmune diseasesChemical Structure: Macrolide lactoneMolecular Weight: Approximately 804 g/molSolubility: Practically insoluble waterIonization: applicableProtein Binding: Highly protein-bound (approximately 99%)Pharmacokinetic Implications: Low variable oral bioavailability, extensive metabolism liver, biliary excretionAnalytical Methods: Immunoassays, chromatography (LC-MS/MS)","code":""},{"path":"properties-8.html","id":"summary-table-of-chemical-and-physical-properties","chapter":"Properties","heading":"Summary Table of Chemical and Physical Properties","text":"","code":""},{"path":"properties-8.html","id":"clinical-significance-14","chapter":"Properties","heading":"Clinical Significance","text":"properties influence drug absorbed, distributed, metabolized, excreted (ADME)Affects choice analytical methodKnowledge drug properties can change due disease states, concomitant disease drug interactions","code":""},{"path":"aminoglycosides.html","id":"aminoglycosides","chapter":"Aminoglycosides","heading":"Aminoglycosides","text":"Understanding chemical physical properties aminoglycosides like gentamicin essential comprehending pharmacokinetic behavior, mechanism action, analytical methods used therapeutic drug monitoring (TDM)","code":""},{"path":"aminoglycosides.html","id":"chemical-properties-of-aminoglycosides","chapter":"Aminoglycosides","heading":"Chemical Properties of Aminoglycosides","text":"Definition: Aminoglycosides class antibiotics composed amino-modified glycosides (sugars) linked glycosidic bondsStructure: aminoglycoside molecule consists aminocyclitol ring (usually 2-deoxystreptamine) connected various amino sugarsFunctional Groups: Multiple amino hydroxyl groups, giving strong basic propertiesMolecular Weight: Typically ranges 400 600 DaChemical Stability: Generally stable aqueous solutions, can affected pH temperature","code":""},{"path":"aminoglycosides.html","id":"physical-properties-of-aminoglycosides","chapter":"Aminoglycosides","heading":"Physical Properties of Aminoglycosides","text":"Appearance: White -white powdersSolubility: Highly water-soluble due presence multiple polar amino hydroxyl groupsPartition Coefficient (Log P): Low Log P values indicate poor lipid solubilityIonization: Aminoglycosides polycationic physiological pH, meaning multiple positive chargesHygroscopicity: aminoglycosides hygroscopic, meaning readily absorb moisture air","code":""},{"path":"aminoglycosides.html","id":"specific-chemical-and-physical-properties-of-gentamicin","chapter":"Aminoglycosides","heading":"Specific Chemical and Physical Properties of Gentamicin","text":"Structure: Gentamicin mixture closely related aminoglycoside antibiotics, primarily gentamicin C1, C1a, C2Molecular Formula\nGentamicin C1: \\(C_{21}H_{43}N_5O_7\\)\nGentamicin C1a: \\(C_{20}H_{41}N_5O_7\\)\nGentamicin C2: \\(C_{20}H_{41}N_5O_6\\)\nGentamicin C1: \\(C_{21}H_{43}N_5O_7\\)Gentamicin C1a: \\(C_{20}H_{41}N_5O_7\\)Gentamicin C2: \\(C_{20}H_{41}N_5O_6\\)Molecular Weight: Approximately 477.60 g/mol gentamicin C1Appearance: White -white powderSolubility: Highly soluble water, slightly soluble ethanol, practically insoluble chloroform etherpKa Values: Gentamicin multiple pKa values due presence several amino groupsPartition Coefficient (Log P): Low Log P value indicates poor lipid solubility","code":""},{"path":"aminoglycosides.html","id":"pharmacokinetic-implications","chapter":"Aminoglycosides","heading":"Pharmacokinetic Implications","text":"Absorption: Poor oral absorption due high polarity charge\nPrimarily administered intravenously intramuscularly\nPrimarily administered intravenously intramuscularlyDistribution: Limited distribution tissues body fluids\nLow volume distribution (Vd)\nreadily cross blood-brain barrier\nLow volume distribution (Vd)readily cross blood-brain barrierProtein Binding: Low protein binding (less 30%)\ndrug exists free, active form plasma\ndrug exists free, active form plasmaMetabolism: Minimal metabolism\nPrimarily excreted unchanged urine\nPrimarily excreted unchanged urineExcretion: Primarily eliminated glomerular filtration kidneys\nRenal impairment significantly affects drug clearance\nRenal impairment significantly affects drug clearance","code":""},{"path":"aminoglycosides.html","id":"mechanism-of-action-and-structure-activity-relationship-sar","chapter":"Aminoglycosides","heading":"Mechanism of Action and Structure-Activity Relationship (SAR)","text":"Mechanism Action: Aminoglycosides inhibit bacterial protein synthesis binding 30S ribosomal subunit\nbinding interferes mRNA translation causes misreading genetic code\nbinding interferes mRNA translation causes misreading genetic codeStructure-Activity Relationship (SAR)\npresence multiple amino groups crucial binding negatively charged ribosomal RNA\nspecific arrangement amino sugars aminocyclitol ring determines spectrum activity susceptibility bacterial resistance mechanisms\npresence multiple amino groups crucial binding negatively charged ribosomal RNAThe specific arrangement amino sugars aminocyclitol ring determines spectrum activity susceptibility bacterial resistance mechanisms","code":""},{"path":"aminoglycosides.html","id":"analytical-considerations-in-tdm","chapter":"Aminoglycosides","heading":"Analytical Considerations in TDM","text":"Analytical Methods\nImmunoassays: Commonly used routine TDM due ease use high throughput\nChromatography: HPLC UV fluorescence detection can used separate quantify individual gentamicin components\nMass Spectrometry: LC-MS/MS provides high sensitivity specificity gentamicin quantification\nImmunoassays: Commonly used routine TDM due ease use high throughputChromatography: HPLC UV fluorescence detection can used separate quantify individual gentamicin componentsMass Spectrometry: LC-MS/MS provides high sensitivity specificity gentamicin quantificationSample Preparation\nProtein precipitation solid-phase extraction (SPE) may used remove interfering substances sample\nProtein precipitation solid-phase extraction (SPE) may used remove interfering substances sampleCalibration Quality Control\nUse appropriate calibrators quality control materials ensure accurate reliable results\nUse appropriate calibrators quality control materials ensure accurate reliable resultsInterferences\nantibiotics drugs can interfere aminoglycoside assays\nHemolysis lipemia can also affect assay performance\nCross reactivity can occur aminoglycosides within certain immunoassays\nantibiotics drugs can interfere aminoglycoside assaysHemolysis lipemia can also affect assay performanceCross reactivity can occur aminoglycosides within certain immunoassays","code":""},{"path":"aminoglycosides.html","id":"clinical-significance-in-tdm","chapter":"Aminoglycosides","heading":"Clinical Significance in TDM","text":"Therapeutic Drug Monitoring (TDM)\nTDM essential optimizing aminoglycoside therapy minimizing risk toxicity\nAminoglycosides narrow therapeutic index, meaning therapeutic toxic concentrations close together\nTDM used monitor peak trough concentrations:\nPeak Concentrations: Reflect maximum drug level body associated efficacy\nTrough Concentrations: Reflect minimum drug level body associated toxicity\n\nTDM essential optimizing aminoglycoside therapy minimizing risk toxicityAminoglycosides narrow therapeutic index, meaning therapeutic toxic concentrations close togetherTDM used monitor peak trough concentrations:\nPeak Concentrations: Reflect maximum drug level body associated efficacy\nTrough Concentrations: Reflect minimum drug level body associated toxicity\nPeak Concentrations: Reflect maximum drug level body associated efficacyTrough Concentrations: Reflect minimum drug level body associated toxicityDosage Adjustments\nDosage adjustments based TDM results patient-specific factors, renal function infection severity\nDosage adjustments based TDM results patient-specific factors, renal function infection severityMonitoring Toxicity\nAssess renal function (serum creatinine, creatinine clearance)\nMonitor ototoxicity (hearing loss, tinnitus, vertigo)\nAssess renal function (serum creatinine, creatinine clearance)Monitor ototoxicity (hearing loss, tinnitus, vertigo)Specific considerations\nAminoglycoside concentrations can higher patients ascites\nHigh doses can effective treat infection, must balance risk nephrotoxicity ototoxicity\nAminoglycoside concentrations can higher patients ascitesHigh doses can effective treat infection, must balance risk nephrotoxicity ototoxicity","code":""},{"path":"aminoglycosides.html","id":"key-terms-76","chapter":"Aminoglycosides","heading":"Key Terms","text":"Aminoglycosides: class antibiotics composed amino-modified glycosidesGentamicin: aminoglycoside antibiotic used treat bacterial infectionsTherapeutic Drug Monitoring (TDM): Measurement drug concentrations optimize therapyPeak Concentration: maximum drug level body administrationTrough Concentration: minimum drug level body next dosePharmacokinetics: study body affects drug (ADME)Mechanism Action: way drug produces therapeutic effectStructure-Activity Relationship (SAR): relationship chemical structure drug biological activityNephrotoxicity: Kidney damageOtotoxicity: Hearing loss vertigoHydrophilic: affinity water; water-lovingHydrophobic: Lacking affinity water; water-fearingTherapeutic index: Ratio drug’s toxic level level provides therapeutic benefits","code":""},{"path":"cardioactive.html","id":"cardioactive","chapter":"Cardioactive","heading":"Cardioactive","text":"Understanding chemical physical properties cardioactive drugs like digoxin essential comprehending pharmacokinetic behavior, mechanism action, analytical methods used therapeutic drug monitoring (TDM)","code":""},{"path":"cardioactive.html","id":"chemical-properties-of-cardioactive-drugs","chapter":"Cardioactive","heading":"Chemical Properties of Cardioactive Drugs","text":"Definition: Cardioactive drugs diverse group medications used treat various cardiovascular conditions, including heart failure, arrhythmias, hypertensionStructural Diversity: class drugs exhibits significant structural diversity, including steroids, alkaloids, synthetic compoundsFunctional Groups: contain various functional groups, hydroxyl, amino, carbonyl, ether groups, influence solubility, binding properties, metabolismStereochemistry: Stereochemistry plays crucial role activityChemical Stability: Varies widely depending specific drug formulation; storage conditions can affect stability","code":""},{"path":"cardioactive.html","id":"physical-properties-of-cardioactive-drugs","chapter":"Cardioactive","heading":"Physical Properties of Cardioactive Drugs","text":"Appearance: Crystalline solids powdersSolubility: Varies depending specific drug chemical structurePartition Coefficient (Log P): Indicates relative affinity drug lipid aqueous phasesIonization: Acidic basic properties influence absorption, distribution, excretionProtein Binding: Binding plasma proteins (albumin, alpha-1-acid glycoprotein)Melting Point: Characteristic property identification purity assessmentHygroscopicity: cardioactive drugs hygroscopic, absorbing moisture air","code":""},{"path":"cardioactive.html","id":"specific-chemical-and-physical-properties-of-digoxin","chapter":"Cardioactive","heading":"Specific Chemical and Physical Properties of Digoxin","text":"Definition: Digoxin cardiac glycoside used treat heart failure atrial fibrillationChemical Structure: Consists steroid nucleus linked lactone ring three sugar molecules (digitoxose)Molecular Formula: \\(C_{41}H_{64}O_{14}\\)Molecular Weight: 780.94 g/molAppearance: White -white crystalline powderSolubility: Slightly soluble water, soluble diluted alcohol, practically insoluble chloroform etherpKa Values: Digoxin several pKa values due presence hydroxyl groups sugar moleculesPartition Coefficient (Log P): Approximately 0.9, indicating moderate lipid solubilityProtein Binding: Approximately 20-30% bound plasma proteins, primarily albumin","code":""},{"path":"cardioactive.html","id":"pharmacokinetic-implications-1","chapter":"Cardioactive","heading":"Pharmacokinetic Implications","text":"Absorption\nOral bioavailability varies 70-85%, depending formulation patient factors\nAbsorption can affected gastrointestinal motility, pH, drug interactions\nOral bioavailability varies 70-85%, depending formulation patient factorsAbsorption can affected gastrointestinal motility, pH, drug interactionsDistribution\nDistributes widely throughout body, large volume distribution (Vd) approximately 7 L/kg\nConcentrates heart, kidneys, skeletal muscle\nCrosses blood-brain barrier limited extent\nDistributes widely throughout body, large volume distribution (Vd) approximately 7 L/kgConcentrates heart, kidneys, skeletal muscleCrosses blood-brain barrier limited extentProtein Binding\nModerate protein binding (20-30%)\nChanges protein binding can affect free (active) drug concentration\nModerate protein binding (20-30%)Changes protein binding can affect free (active) drug concentrationMetabolism\nLimited metabolism; primarily excreted unchanged urine\nsmall fraction undergoes metabolism liver hydrolysis oxidation\nLimited metabolism; primarily excreted unchanged urineA small fraction undergoes metabolism liver hydrolysis oxidationExcretion\nPrimarily eliminated glomerular filtration kidneys\nRenal impairment significantly affects drug clearance\nPrimarily eliminated glomerular filtration kidneysRenal impairment significantly affects drug clearance","code":""},{"path":"cardioactive.html","id":"mechanism-of-action-and-structure-activity-relationship-sar-1","chapter":"Cardioactive","heading":"Mechanism of Action and Structure-Activity Relationship (SAR)","text":"Mechanism Action: Digoxin inhibits \\(Na^+/K^+-ATPase\\) pump myocardial cells, leading increased intracellular sodium calcium concentrations\nresults increased cardiac contractility (positive inotropic effect) slowed atrioventricular (AV) conduction\nresults increased cardiac contractility (positive inotropic effect) slowed atrioventricular (AV) conductionStructure-Activity Relationship (SAR)\nsteroid nucleus essential binding \\(Na^+/K^+-ATPase\\) pump\nlactone ring important activity\nsugar molecules enhance water solubility affect pharmacokinetic properties\nsteroid nucleus essential binding \\(Na^+/K^+-ATPase\\) pumpThe lactone ring important activityThe sugar molecules enhance water solubility affect pharmacokinetic properties","code":""},{"path":"cardioactive.html","id":"analytical-considerations-in-tdm-1","chapter":"Cardioactive","heading":"Analytical Considerations in TDM","text":"Analytical Methods\nImmunoassays: commonly used routine TDM due ease use high throughput\nEnzyme-multiplied immunoassay technique (EMIT)\nFluorescence polarization immunoassay (FPIA)\nChemiluminescent microparticle immunoassay (CMIA)\n\nChromatography: HPLC UV mass spectrometry detection can used specific sensitive measurements\nLiquid chromatography-tandem mass spectrometry (LC-MS/MS)\n\nImmunoassays: commonly used routine TDM due ease use high throughput\nEnzyme-multiplied immunoassay technique (EMIT)\nFluorescence polarization immunoassay (FPIA)\nChemiluminescent microparticle immunoassay (CMIA)\nEnzyme-multiplied immunoassay technique (EMIT)Fluorescence polarization immunoassay (FPIA)Chemiluminescent microparticle immunoassay (CMIA)Chromatography: HPLC UV mass spectrometry detection can used specific sensitive measurements\nLiquid chromatography-tandem mass spectrometry (LC-MS/MS)\nLiquid chromatography-tandem mass spectrometry (LC-MS/MS)Sample Preparation\nDirect immunoassays can performed serum plasma without extensive sample preparation\nchromatographic methods, sample preparation may involve protein precipitation solid-phase extraction (SPE)\nDirect immunoassays can performed serum plasma without extensive sample preparationFor chromatographic methods, sample preparation may involve protein precipitation solid-phase extraction (SPE)Calibration Quality Control\nUse appropriate calibrators quality control materials ensure accurate reliable results\nUse appropriate calibrators quality control materials ensure accurate reliable resultsInterferences\nEndogenous digoxin-like immunoreactive substances (DLIS) can interfere digoxin immunoassays, leading falsely elevated results\nSpironolactone, quinidine, amiodarone can increase digoxin concentrations inhibiting renal clearance\nHyperkalemia can decrease digoxin’s therapeutic effect\nEndogenous digoxin-like immunoreactive substances (DLIS) can interfere digoxin immunoassays, leading falsely elevated resultsSpironolactone, quinidine, amiodarone can increase digoxin concentrations inhibiting renal clearanceHyperkalemia can decrease digoxin’s therapeutic effect","code":""},{"path":"cardioactive.html","id":"clinical-significance-in-tdm-1","chapter":"Cardioactive","heading":"Clinical Significance in TDM","text":"Therapeutic Drug Monitoring (TDM)\nTDM essential optimizing digoxin therapy due narrow therapeutic index\nDigoxin narrow therapeutic range (0.5-2.0 ng/mL), toxicity can occur levels slightly range\nTDM used monitor serum digoxin concentrations adjust dose accordingly\nTDM essential optimizing digoxin therapy due narrow therapeutic indexDigoxin narrow therapeutic range (0.5-2.0 ng/mL), toxicity can occur levels slightly rangeTDM used monitor serum digoxin concentrations adjust dose accordinglyDosage Adjustments\nDosage adjustments based TDM results patient-specific factors, renal function, age, concurrent medications\nDosage adjustments based TDM results patient-specific factors, renal function, age, concurrent medicationsMonitoring Toxicity\nMonitor signs symptoms digoxin toxicity, nausea, vomiting, diarrhea, visual disturbances, cardiac arrhythmias, altered mental status\nAssess renal function (serum creatinine, creatinine clearance) electrolyte levels (potassium, magnesium)\nMonitor signs symptoms digoxin toxicity, nausea, vomiting, diarrhea, visual disturbances, cardiac arrhythmias, altered mental statusAssess renal function (serum creatinine, creatinine clearance) electrolyte levels (potassium, magnesium)Interpreting Digoxin Levels\nSample timing: Digoxin measured least 6 hours previous dose allow distribution\nCheck Digoxin-Like Immunoreactive Substances (DLIS): DLIS can interfere cause false high reading\nSample timing: Digoxin measured least 6 hours previous dose allow distributionCheck Digoxin-Like Immunoreactive Substances (DLIS): DLIS can interfere cause false high readingOther cardioactive drugs\nCardiac function cardioactive drugs important factors consider interpreting results\nCardiac function cardioactive drugs important factors consider interpreting results","code":""},{"path":"cardioactive.html","id":"key-terms-77","chapter":"Cardioactive","heading":"Key Terms","text":"Cardioactive Drugs: Medications used treat cardiovascular conditionsDigoxin: cardiac glycoside used treat heart failure atrial fibrillationTherapeutic Drug Monitoring (TDM): Measurement drug concentrations optimize therapyVolume Distribution: Apparent space body available contain drugProtein Binding: degree drug binds plasma proteinsBioavailability: fraction administered dose drug reaches systemic circulationMechanism Action: way drug produces therapeutic effectStructure-Activity Relationship (SAR): relationship chemical structure drug biological activityRenal Clearance: rate drug removed body kidneysHepatic Metabolism: process liver chemically alters drug\\(Na^+/K^+-ATPase\\) Pump: enzyme maintains sodium potassium gradients across cell membranesPositive Inotropic Effect: Increased cardiac contractilityAtrioventricular (AV) Conduction: transmission electrical impulses atria ventricles heartDigoxin-Like Immunoreactive Substances (DLIS): Endogenous substances can interfere digoxin immunoassays","code":""},{"path":"anticonvulsants.html","id":"anticonvulsants","chapter":"Anticonvulsants","heading":"Anticonvulsants","text":"Understanding chemical physical properties anticonvulsant drugs like phenobarbital crucial comprehending pharmacokinetic behavior, mechanism action, analytical methods used therapeutic drug monitoring (TDM)","code":""},{"path":"anticonvulsants.html","id":"chemical-properties-of-anticonvulsants","chapter":"Anticonvulsants","heading":"Chemical Properties of Anticonvulsants","text":"Definition: Anticonvulsants, also known antiepileptic drugs (AEDs), diverse group medications used prevent control seizures individuals epilepsyStructural Diversity: Anticonvulsants exhibit significant structural diversity, encompassing wide range chemical classes barbiturates, hydantoins, iminostilbenes, valproic acid derivativesFunctional Groups: contain various functional groups, hydroxyl, amino, carbonyl, amide groups, influence solubility, binding properties, metabolismChirality: anticonvulsants chiral molecules, existing enantiomers diastereomers differing pharmacological activitiesChemical Stability: Varies widely depending specific drug formulation; storage conditions can affect stability","code":""},{"path":"anticonvulsants.html","id":"physical-properties-of-anticonvulsants","chapter":"Anticonvulsants","heading":"Physical Properties of Anticonvulsants","text":"Appearance: Crystalline solids powdersSolubility: Varies depending specific drug chemical structurePartition Coefficient (Log P): Indicates relative affinity drug lipid aqueous phasesIonization: Acidic basic properties influence absorption, distribution, excretionProtein Binding: Binding plasma proteins (albumin, alpha-1-acid glycoprotein)Melting Point: Characteristic property identification purity assessmentHygroscopicity: anticonvulsants hygroscopic, absorbing moisture air","code":""},{"path":"anticonvulsants.html","id":"specific-chemical-and-physical-properties-of-phenobarbital","chapter":"Anticonvulsants","heading":"Specific Chemical and Physical Properties of Phenobarbital","text":"Definition: Phenobarbital barbiturate anticonvulsant used treat various types seizuresChemical Structure: 5-ethyl-5-phenylbarbituric acidMolecular Formula: \\(C_{12}H_{12}N_2O_3\\)Molecular Weight: 232.24 g/molAppearance: White -white crystalline powder colorless crystalsSolubility: Slightly soluble water (1 g 1000 mL), soluble alcohol, ether, chloroformpKa Value: Approximately 7.3Partition Coefficient (Log P): Approximately 1.4, indicating moderate lipid solubilityProtein Binding: Approximately 45-60% bound plasma proteins, primarily albuminMelting Point: 174-178°C","code":""},{"path":"anticonvulsants.html","id":"pharmacokinetic-implications-2","chapter":"Anticonvulsants","heading":"Pharmacokinetic Implications","text":"Absorption\nOral bioavailability approximately 70-90%\nAbsorption relatively slow can affected gastric pH food intake\nOral bioavailability approximately 70-90%Absorption relatively slow can affected gastric pH food intakeDistribution\nDistributes widely throughout body, including brain\nCrosses blood-brain barrier\nDistributes widely throughout body, including brainCrosses blood-brain barrierProtein Binding\nModerate protein binding (45-60%)\nChanges protein binding can affect free (active) drug concentration\nModerate protein binding (45-60%)Changes protein binding can affect free (active) drug concentrationMetabolism\nExtensively metabolized liver CYP2C9, CYP2C19, CYP2E1\nMetabolites include para-hydroxyphenobarbital glucuronide conjugates\nExtensively metabolized liver CYP2C9, CYP2C19, CYP2E1Metabolites include para-hydroxyphenobarbital glucuronide conjugatesExcretion\nPrimarily excreted urine metabolites unchanged drug\nRenal elimination pH-dependent; alkaline urine promotes excretion phenobarbital\nPrimarily excreted urine metabolites unchanged drugRenal elimination pH-dependent; alkaline urine promotes excretion phenobarbitalHalf-life\nLong half-life approximately 50-120 hours\nLong half-life approximately 50-120 hours","code":""},{"path":"anticonvulsants.html","id":"mechanism-of-action-and-structure-activity-relationship-sar-2","chapter":"Anticonvulsants","heading":"Mechanism of Action and Structure-Activity Relationship (SAR)","text":"Mechanism Action: Phenobarbital enhances effects GABA (gamma-aminobutyric acid), main inhibitory neurotransmitter brain\nbinds \\(GABA_A\\) receptor, increasing duration chloride channel opening, leading hyperpolarization decreased neuronal excitability\nbinds \\(GABA_A\\) receptor, increasing duration chloride channel opening, leading hyperpolarization decreased neuronal excitabilityStructure-Activity Relationship (SAR)\nbarbituric acid ring essential activity\nSubstitutions 5-position barbiturate ring influence potency duration action\nbarbituric acid ring essential activitySubstitutions 5-position barbiturate ring influence potency duration action","code":""},{"path":"anticonvulsants.html","id":"analytical-considerations-in-tdm-2","chapter":"Anticonvulsants","heading":"Analytical Considerations in TDM","text":"Analytical Methods\nImmunoassays: Commonly used routine TDM due ease use high throughput\nEnzyme-multiplied immunoassay technique (EMIT)\nFluorescence polarization immunoassay (FPIA)\nChemiluminescent microparticle immunoassay (CMIA)\n\nChromatography: HPLC UV mass spectrometry detection can used specific sensitive measurements\nLiquid chromatography-tandem mass spectrometry (LC-MS/MS)\n\nImmunoassays: Commonly used routine TDM due ease use high throughput\nEnzyme-multiplied immunoassay technique (EMIT)\nFluorescence polarization immunoassay (FPIA)\nChemiluminescent microparticle immunoassay (CMIA)\nEnzyme-multiplied immunoassay technique (EMIT)Fluorescence polarization immunoassay (FPIA)Chemiluminescent microparticle immunoassay (CMIA)Chromatography: HPLC UV mass spectrometry detection can used specific sensitive measurements\nLiquid chromatography-tandem mass spectrometry (LC-MS/MS)\nLiquid chromatography-tandem mass spectrometry (LC-MS/MS)Sample Preparation\nDirect immunoassays can performed serum plasma without extensive sample preparation\nchromatographic methods, sample preparation may involve protein precipitation liquid-liquid extraction\nDirect immunoassays can performed serum plasma without extensive sample preparationFor chromatographic methods, sample preparation may involve protein precipitation liquid-liquid extractionCalibration Quality Control\nUse appropriate calibrators quality control materials ensure accurate reliable results\nUse appropriate calibrators quality control materials ensure accurate reliable resultsInterferences\nbarbiturates drugs can interfere phenobarbital assays\nHigh bilirubin levels can interfere spectrophotometric assays\nbarbiturates drugs can interfere phenobarbital assaysHigh bilirubin levels can interfere spectrophotometric assaysFree Phenobarbital Measurement\nFree (unbound) phenobarbital concentrations may clinically relevant total concentrations, especially patients altered protein binding (e.g., renal failure, liver disease)\nUltrafiltration equilibrium dialysis can used separate free bound phenobarbital\nFree (unbound) phenobarbital concentrations may clinically relevant total concentrations, especially patients altered protein binding (e.g., renal failure, liver disease)Ultrafiltration equilibrium dialysis can used separate free bound phenobarbital","code":""},{"path":"anticonvulsants.html","id":"clinical-significance-in-tdm-2","chapter":"Anticonvulsants","heading":"Clinical Significance in TDM","text":"Therapeutic Drug Monitoring (TDM)\nTDM used optimize phenobarbital therapy due narrow therapeutic index potential drug interactions\nPhenobarbital therapeutic range 15-40 μg/mL, toxicity can occur levels range\nTDM used monitor serum phenobarbital concentrations adjust dose accordingly\nTDM used optimize phenobarbital therapy due narrow therapeutic index potential drug interactionsPhenobarbital therapeutic range 15-40 μg/mL, toxicity can occur levels rangeTDM used monitor serum phenobarbital concentrations adjust dose accordinglyDosage Adjustments\nDosage adjustments based TDM results patient-specific factors, age, liver function, concurrent medications\nDosage adjustments based TDM results patient-specific factors, age, liver function, concurrent medicationsMonitoring Toxicity\nMonitor signs symptoms phenobarbital toxicity, sedation, ataxia, nystagmus, respiratory depression, cognitive impairment\nMonitor signs symptoms phenobarbital toxicity, sedation, ataxia, nystagmus, respiratory depression, cognitive impairmentDrug Interactions\nPhenobarbital CYP enzyme inducer can affect metabolism drugs\nMonitor potential drug interactions adjust doses accordingly\nPhenobarbital CYP enzyme inducer can affect metabolism drugsMonitor potential drug interactions adjust doses accordinglyPatient-Specific Factors\nElderly patients may sensitive effects phenobarbital\nPatients liver disease may require lower doses due impaired metabolism\nElderly patients may sensitive effects phenobarbitalPatients liver disease may require lower doses due impaired metabolism","code":""},{"path":"anticonvulsants.html","id":"key-terms-78","chapter":"Anticonvulsants","heading":"Key Terms","text":"Anticonvulsants: Medications used prevent control seizuresPhenobarbital: barbiturate anticonvulsantTherapeutic Drug Monitoring (TDM): Measurement drug concentrations optimize therapyBioavailability: fraction administered dose drug reaches systemic circulationVolume Distribution: Apparent space body available contain drugProtein Binding: degree drug binds plasma proteinsMetabolism: process body chemically alters drugExcretion: process body eliminates drug metabolitesHalf-Life: time takes concentration drug body reduced one-halfGABA: Gamma-aminobutyric acid, main inhibitory neurotransmitter brainSedation: state decreased alertness responsiveness stimuliAtaxia: Loss coordinationNystagmus: Involuntary eye movementsCYP Enzymes: Cytochrome P450 enzymes involved drug metabolismpH: measure acidity alkalinity solution","code":""},{"path":"antidepressants.html","id":"antidepressants","chapter":"Antidepressants","heading":"Antidepressants","text":"Understanding chemical physical properties antidepressants like lithium essential comprehending pharmacokinetic behavior, mechanism action, analytical methods used therapeutic drug monitoring (TDM)","code":""},{"path":"antidepressants.html","id":"chemical-properties-of-antidepressants","chapter":"Antidepressants","heading":"Chemical Properties of Antidepressants","text":"Definition: Antidepressants diverse group medications used treat depression mood disordersStructural Diversity: Antidepressants exhibit significant structural diversity, encompassing wide range chemical classes selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs)Functional Groups: contain various functional groups, hydroxyl, amino, methyl, halogen groups, influence solubility, binding properties, metabolismChirality: antidepressants chiral molecules, existing enantiomers diastereomers differing pharmacological activitiesChemical Stability: Varies widely depending specific drug formulation; storage conditions can affect stability","code":""},{"path":"antidepressants.html","id":"physical-properties-of-antidepressants","chapter":"Antidepressants","heading":"Physical Properties of Antidepressants","text":"Appearance: Crystalline solids powdersSolubility: Varies depending specific drug chemical structurePartition Coefficient (Log P): Indicates relative affinity drug lipid aqueous phasesIonization: Acidic basic properties influence absorption, distribution, excretionProtein Binding: Binding plasma proteins (albumin, alpha-1-acid glycoprotein)Melting Point: Characteristic property identification purity assessmentHygroscopicity: antidepressants hygroscopic, absorbing moisture air","code":""},{"path":"antidepressants.html","id":"specific-chemical-and-physical-properties-of-lithium","chapter":"Antidepressants","heading":"Specific Chemical and Physical Properties of Lithium","text":"Definition: Lithium mood-stabilizing drug used primarily treatment bipolar disorderChemical Structure: Simplest structure antidepressants consisting single positive chargeMolecular Formula: LiMolecular Weight: 6.94 g/molAppearance: Soft, silver-white metalSolubility: Lithium salts (e.g., lithium carbonate, lithium citrate) soluble waterIonization: Exists monovalent cation (\\(Li^+\\)) solutionProtein Binding: Negligible protein binding","code":""},{"path":"antidepressants.html","id":"pharmacokinetic-implications-3","chapter":"Antidepressants","heading":"Pharmacokinetic Implications","text":"Absorption\nRapid complete absorption oral administration\nAbsorption significantly affected food\nRapid complete absorption oral administrationAbsorption significantly affected foodDistribution\nDistributes throughout total body water\nbind plasma proteins\nEnters cells slowly via sodium channels\nDistributes throughout total body waterDoes bind plasma proteinsEnters cells slowly via sodium channelsProtein Binding\nNegligible protein binding\nExists primarily free, ionized form\nNegligible protein bindingExists primarily free, ionized formMetabolism\nLithium metabolized body\nLithium metabolized bodyExcretion\nPrimarily excreted unchanged kidneys\nRenal excretion affected sodium balance\nSodium depletion increases lithium reabsorption, leading increased lithium levels\nSodium loading decreases lithium reabsorption, leading decreased lithium levels\n\nThiazide diuretics, NSAIDs, ACE inhibitors can reduce lithium clearance\nPrimarily excreted unchanged kidneysRenal excretion affected sodium balance\nSodium depletion increases lithium reabsorption, leading increased lithium levels\nSodium loading decreases lithium reabsorption, leading decreased lithium levels\nSodium depletion increases lithium reabsorption, leading increased lithium levelsSodium loading decreases lithium reabsorption, leading decreased lithium levelsThiazide diuretics, NSAIDs, ACE inhibitors can reduce lithium clearanceHalf-life\nHalf-life approximately 24 hours\nHalf-life approximately 24 hours","code":""},{"path":"antidepressants.html","id":"mechanism-of-action-and-structure-activity-relationship-sar-3","chapter":"Antidepressants","heading":"Mechanism of Action and Structure-Activity Relationship (SAR)","text":"Mechanism Action: exact mechanism action lithium fully understood, believed involve multiple effects neuronal signaling pathways\nInhibition inositol monophosphatase: Disrupts phosphatidylinositol signaling pathway\nInhibition glycogen synthase kinase-3 (GSK-3): Affects various cellular processes, including apoptosis inflammation\nModulation neurotransmitter release: Affects release dopamine, serotonin, glutamate\nInhibition inositol monophosphatase: Disrupts phosphatidylinositol signaling pathwayInhibition glycogen synthase kinase-3 (GSK-3): Affects various cellular processes, including apoptosis inflammationModulation neurotransmitter release: Affects release dopamine, serotonin, glutamateStructure-Activity Relationship (SAR)\nsmall size positive charge lithium ion critical interaction cellular targets\nLithium mimics sodium ions can interfere sodium transport\nsmall size positive charge lithium ion critical interaction cellular targetsLithium mimics sodium ions can interfere sodium transport","code":""},{"path":"antidepressants.html","id":"analytical-considerations-in-tdm-3","chapter":"Antidepressants","heading":"Analytical Considerations in TDM","text":"Analytical Methods\nFlame Emission Spectrophotometry (FES): Measures light emitted lithium atoms flame\nIon-Selective Electrode (ISE): Measures concentration lithium ions solution\nAtomic Absorption Spectrometry (AAS): Measures absorption light lithium atoms\nFlame Emission Spectrophotometry (FES): Measures light emitted lithium atoms flameIon-Selective Electrode (ISE): Measures concentration lithium ions solutionAtomic Absorption Spectrometry (AAS): Measures absorption light lithium atomsSample Preparation\nTypically, sample preparation required lithium measurements\nSerum plasma can analyzed directly\nTypically, sample preparation required lithium measurementsSerum plasma can analyzed directlyCalibration Quality Control\nUse appropriate calibrators quality control materials ensure accurate reliable results\nUse appropriate calibrators quality control materials ensure accurate reliable resultsInterferences\nSodium potassium can interfere lithium assays\nHemolysis can also affect assay performance\nSodium potassium can interfere lithium assaysHemolysis can also affect assay performance","code":""},{"path":"antidepressants.html","id":"clinical-significance-in-tdm-3","chapter":"Antidepressants","heading":"Clinical Significance in TDM","text":"Therapeutic Drug Monitoring (TDM)\nTDM essential optimizing lithium therapy due narrow therapeutic index potential toxicity\nLithium therapeutic range 0.6-1.2 mEq/L acute mania 0.6-0.8 mEq/L maintenance therapy, values can vary among individuals\nTDM used monitor serum lithium concentrations adjust dose accordingly\nTDM essential optimizing lithium therapy due narrow therapeutic index potential toxicityLithium therapeutic range 0.6-1.2 mEq/L acute mania 0.6-0.8 mEq/L maintenance therapy, values can vary among individualsTDM used monitor serum lithium concentrations adjust dose accordinglyDosage Adjustments\nDosage adjustments based TDM results patient-specific factors, renal function, age, concurrent medications\nDosage adjustments based TDM results patient-specific factors, renal function, age, concurrent medicationsMonitoring Toxicity\nMonitor signs symptoms lithium toxicity, nausea, vomiting, diarrhea, tremor, ataxia, confusion, seizures, renal dysfunction\nAssess renal function (serum creatinine, creatinine clearance) thyroid function (TSH, free T4)\nMonitor signs symptoms lithium toxicity, nausea, vomiting, diarrhea, tremor, ataxia, confusion, seizures, renal dysfunctionAssess renal function (serum creatinine, creatinine clearance) thyroid function (TSH, free T4)Timing Sample Collection\nLithium levels drawn 12 hours last dose ensure accurate trough concentrations\nLithium levels drawn 12 hours last dose ensure accurate trough concentrations","code":""},{"path":"antidepressants.html","id":"key-terms-79","chapter":"Antidepressants","heading":"Key Terms","text":"Antidepressants: Medications used treat depression mood disordersLithium: mood-stabilizing drug used primarily treatment bipolar disorderTherapeutic Drug Monitoring (TDM): Measurement drug concentrations optimize therapyBioavailability: fraction administered dose drug reaches systemic circulationVolume Distribution: Apparent space body available contain drugProtein Binding: degree drug binds plasma proteinsMetabolism: process body chemically alters drugExcretion: process body eliminates drug metabolitesHalf-Life: time takes concentration drug body reduced one-halfTDM: monitor drug ensure therapeutic range bloodSerotonin: neurotransmitter involved mood regulationNorepinephrine: neurotransmitter involved mood regulation stress responseGABA: Gamma-aminobutyric acid, main inhibitory neurotransmitter brainLithium Toxicity: condition level lithium blood becomes high","code":""},{"path":"immunosuppressants.html","id":"immunosuppressants","chapter":"Immunosuppressants","heading":"Immunosuppressants","text":"Understanding chemical physical properties immunosuppressant drugs like tacrolimus essential comprehending pharmacokinetic behavior, mechanism action, analytical methods used therapeutic drug monitoring (TDM)","code":""},{"path":"immunosuppressants.html","id":"chemical-properties-of-immunosuppressants","chapter":"Immunosuppressants","heading":"Chemical Properties of Immunosuppressants","text":"Definition: Immunosuppressants diverse group medications used suppress immune system order prevent organ rejection transplantation treat autoimmune diseasesStructural Diversity: Immunosuppressants exhibit significant structural diversity, encompassing wide range chemical classes calcineurin inhibitors, mTOR inhibitors, antiproliferative agents, antibodiesFunctional Groups: contain various functional groups, hydroxyl, amino, carbonyl, ether groups, influence solubility, binding properties, metabolismCyclic Structure: Many immunosuppressants large cyclic structuresChirality: immunosuppressants chiral molecules, existing enantiomers diastereomers differing pharmacological activitiesChemical Stability: Varies widely depending specific drug formulation; storage conditions can affect stability","code":""},{"path":"immunosuppressants.html","id":"physical-properties-of-immunosuppressants","chapter":"Immunosuppressants","heading":"Physical Properties of Immunosuppressants","text":"Appearance: Crystalline solids powdersSolubility: Varies depending specific drug chemical structurePartition Coefficient (Log P): Indicates relative affinity drug lipid aqueous phasesIonization: Acidic basic properties influence absorption, distribution, excretionProtein Binding: Binding plasma proteins (albumin, alpha-1-acid glycoprotein)Melting Point: Characteristic property identification purity assessmentHygroscopicity: immunosuppressants hygroscopic, absorbing moisture air","code":""},{"path":"immunosuppressants.html","id":"specific-chemical-and-physical-properties-of-tacrolimus","chapter":"Immunosuppressants","heading":"Specific Chemical and Physical Properties of Tacrolimus","text":"Definition: Tacrolimus (also known FK506) calcineurin inhibitor used prevent organ rejection transplantationChemical Structure: macrolide lactone complex cyclic structureMolecular Formula: \\(C_{44}H_{69}NO_{12}\\)Molecular Weight: 804.02 g/molAppearance: White crystalline powderSolubility: Practically insoluble water, freely soluble ethanol chloroformpKa Value: significant ionizable groupsPartition Coefficient (Log P): Approximately 3.7, indicating high lipid solubilityProtein Binding: Highly protein-bound (approximately 99%) plasma, primarily albumin alpha-1-acid glycoprotein","code":""},{"path":"immunosuppressants.html","id":"pharmacokinetic-implications-4","chapter":"Immunosuppressants","heading":"Pharmacokinetic Implications","text":"Absorption\nOral bioavailability low variable, typically ranging 5-67%\nAbsorption affected gastrointestinal motility, pH, drug interactions\nFood decreases rate extent absorption\nOral bioavailability low variable, typically ranging 5-67%Absorption affected gastrointestinal motility, pH, drug interactionsFood decreases rate extent absorptionDistribution\nDistributes widely throughout body, large volume distribution (Vd) approximately 1.3-3.0 L/kg\nConcentrates red blood cells, liver, kidneys, spleen\nDistributes widely throughout body, large volume distribution (Vd) approximately 1.3-3.0 L/kgConcentrates red blood cells, liver, kidneys, spleenProtein Binding\nHighly protein-bound (approximately 99%)\nChanges protein binding can significantly affect free (active) drug concentration\nHighly protein-bound (approximately 99%)Changes protein binding can significantly affect free (active) drug concentrationMetabolism\nExtensively metabolized liver CYP3A4 CYP3A5\nMetabolites little immunosuppressant activity\nExtensively metabolized liver CYP3A4 CYP3A5Metabolites little immunosuppressant activityExcretion\nPrimarily excreted bile eliminated feces\nMinimal renal excretion\nUndergoes enterohepatic recirculation\nPrimarily excreted bile eliminated fecesMinimal renal excretionUndergoes enterohepatic recirculationHalf-life\nHalf-life approximately 12 hours (range 4-40 hours)\nHalf-life approximately 12 hours (range 4-40 hours)","code":""},{"path":"immunosuppressants.html","id":"mechanism-of-action-and-structure-activity-relationship-sar-4","chapter":"Immunosuppressants","heading":"Mechanism of Action and Structure-Activity Relationship (SAR)","text":"Mechanism Action: Tacrolimus inhibits T-cell activation binding intracellular protein called FKBP12 (FK506-binding protein)\ntacrolimus-FKBP12 complex inhibits calcineurin, phosphatase enzyme essential T-cell activation\nInhibition calcineurin prevents dephosphorylation NFAT (nuclear factor activated T-cells), required transcription interleukin-2 (IL-2) cytokines\ntacrolimus-FKBP12 complex inhibits calcineurin, phosphatase enzyme essential T-cell activationInhibition calcineurin prevents dephosphorylation NFAT (nuclear factor activated T-cells), required transcription interleukin-2 (IL-2) cytokinesStructure-Activity Relationship (SAR)\nmacrolide lactone ring essential binding FKBP12\nSpecific functional groups molecule influence binding affinity immunosuppressant activity\nmacrolide lactone ring essential binding FKBP12Specific functional groups molecule influence binding affinity immunosuppressant activity","code":""},{"path":"immunosuppressants.html","id":"analytical-considerations-in-tdm-4","chapter":"Immunosuppressants","heading":"Analytical Considerations in TDM","text":"Analytical Methods\nImmunoassays: Used routine TDM due ease use high throughput\nMicroparticle enzyme immunoassay (MEIA)\nChemiluminescent microparticle immunoassay (CMIA)\n\nChromatography: HPLC mass spectrometry detection used specific sensitive measurements\nLiquid chromatography-tandem mass spectrometry (LC-MS/MS)\n\nImmunoassays: Used routine TDM due ease use high throughput\nMicroparticle enzyme immunoassay (MEIA)\nChemiluminescent microparticle immunoassay (CMIA)\nMicroparticle enzyme immunoassay (MEIA)Chemiluminescent microparticle immunoassay (CMIA)Chromatography: HPLC mass spectrometry detection used specific sensitive measurements\nLiquid chromatography-tandem mass spectrometry (LC-MS/MS)\nLiquid chromatography-tandem mass spectrometry (LC-MS/MS)Sample Preparation\nWhole blood preferred sample matrix due high intracellular concentration tacrolimus\nSample preparation involves protein precipitation extraction release tacrolimus red blood cells\nWhole blood preferred sample matrix due high intracellular concentration tacrolimusSample preparation involves protein precipitation extraction release tacrolimus red blood cellsCalibration Quality Control\nUse appropriate calibrators quality control materials ensure accurate reliable results\nUse appropriate calibrators quality control materials ensure accurate reliable resultsInterferences\nimmunosuppressants drugs can interfere tacrolimus assays\nHigh hematocrit levels can affect assay performance\nimmunosuppressants drugs can interfere tacrolimus assaysHigh hematocrit levels can affect assay performanceHPLC-MS/MS\nHPLC-MS/MS preferred analytical test since accurate precise\nsensitive enough able measure tacrolimus low concentrations\nHPLC-MS/MS preferred analytical test since accurate preciseIs sensitive enough able measure tacrolimus low concentrationsImportance Consistent Method\nAssays switched patient due variations\nAssays switched patient due variations","code":""},{"path":"immunosuppressants.html","id":"clinical-significance-in-tdm-4","chapter":"Immunosuppressants","heading":"Clinical Significance in TDM","text":"Therapeutic Drug Monitoring (TDM)\nTDM essential optimizing tacrolimus therapy due narrow therapeutic index significant interpatient variability pharmacokinetics\nTarget trough concentrations vary depending type transplant, time since transplantation, presence immunosuppressants\nTDM used monitor whole blood tacrolimus concentrations adjust dose accordingly\nTDM essential optimizing tacrolimus therapy due narrow therapeutic index significant interpatient variability pharmacokineticsTarget trough concentrations vary depending type transplant, time since transplantation, presence immunosuppressantsTDM used monitor whole blood tacrolimus concentrations adjust dose accordinglyDosage Adjustments\nDosage adjustments based TDM results patient-specific factors, renal function, liver function, concurrent medications\nDosage adjustments based TDM results patient-specific factors, renal function, liver function, concurrent medicationsMonitoring Toxicity\nMonitor signs symptoms tacrolimus toxicity, nephrotoxicity, neurotoxicity, hypertension, glucose intolerance, tremor\nAssess renal function (serum creatinine, creatinine clearance), electrolyte levels (potassium, magnesium), glucose levels\nMonitor signs symptoms tacrolimus toxicity, nephrotoxicity, neurotoxicity, hypertension, glucose intolerance, tremorAssess renal function (serum creatinine, creatinine clearance), electrolyte levels (potassium, magnesium), glucose levelsDrug Interactions\nTacrolimus metabolized CYP3A4 subject numerous drug interactions\nCYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase tacrolimus levels\nCYP3A4 inducers (e.g., rifampin, phenytoin) can decrease tacrolimus levels\nTacrolimus metabolized CYP3A4 subject numerous drug interactionsCYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase tacrolimus levelsCYP3A4 inducers (e.g., rifampin, phenytoin) can decrease tacrolimus levels","code":""},{"path":"immunosuppressants.html","id":"key-terms-80","chapter":"Immunosuppressants","heading":"Key Terms","text":"Immunosuppressants: Medications used suppress immune systemTacrolimus: calcineurin inhibitor used prevent organ rejectionTherapeutic Drug Monitoring (TDM): Measurement drug concentrations optimize therapyVolume Distribution: Apparent space body available contain drugProtein Binding: degree drug binds plasma proteinsBioavailability: fraction administered dose drug reaches systemic circulationMetabolism: process body chemically alters drugExcretion: process body eliminates drug metabolitesHalf-Life: time takes concentration drug body reduced one-halfCalcineurin: phosphatase enzyme essential T-cell activationFKBP12: FK506-binding protein, intracellular protein binds tacrolimusImmunosuppression: Suppression immune systemNephrotoxicity: Kidney damageNeurotoxicity: Nerve damage","code":""},{"path":"procedures-9.html","id":"procedures-9","chapter":"Procedures","heading":"Procedures","text":"section covers various facets laboratory test procedures TDM","code":""},{"path":"procedures-9.html","id":"general-principles-of-tdm-laboratory-test-procedures","chapter":"Procedures","heading":"General Principles of TDM Laboratory Test Procedures","text":"Purpose: accurately measure drug concentrations biological samples optimize therapy minimize toxicityAnalytical Methods\nImmunoassays: Based antibody-antigen binding\nChromatography: Separates quantifies drugs based properties\nImmunoassays: Based antibody-antigen bindingChromatography: Separates quantifies drugs based propertiesSample Types\nSerum, plasma, whole blood (depending drug)\nSerum, plasma, whole blood (depending drug)Reporting Units\nng/mL, μg/mL, mg/L, etc\nng/mL, μg/mL, mg/L, etc","code":""},{"path":"procedures-9.html","id":"immunoassay-methods-1","chapter":"Procedures","heading":"Immunoassay Methods","text":"Principle\nUtilizes specific antibodies bind drug measured\nantibody-drug complex detected quantified\nUtilizes specific antibodies bind drug measuredThe antibody-drug complex detected quantifiedTypes\nCompetitive Immunoassays: Drug sample competes labeled drug\nNon-Competitive Immunoassays: Antibody binds directly drug\nHomogeneous Immunoassays: separation steps\nHeterogeneous Immunoassays: Require separation steps\nCompetitive Immunoassays: Drug sample competes labeled drugNon-Competitive Immunoassays: Antibody binds directly drugHomogeneous Immunoassays: separation stepsHeterogeneous Immunoassays: Require separation stepsExamples\nEnzyme-Multiplied Immunoassay Technique (EMIT)\nFluorescence Polarization Immunoassay (FPIA)\nChemiluminescent Microparticle Immunoassay (CMIA)\nEnzyme-Multiplied Immunoassay Technique (EMIT)Fluorescence Polarization Immunoassay (FPIA)Chemiluminescent Microparticle Immunoassay (CMIA)Advantages: High throughput, ease use, automationLimitations: Potential cross-reactivity, matrix effects, interference heterophile antibodies","code":""},{"path":"procedures-9.html","id":"chromatographic-methods","chapter":"Procedures","heading":"Chromatographic Methods","text":"Principle\nSeparates drugs metabolites based physical chemical properties\nQuantifies separated compounds using various detectors\nSeparates drugs metabolites based physical chemical propertiesQuantifies separated compounds using various detectorsTypes\nHigh-Performance Liquid Chromatography (HPLC)\nLiquid Chromatography-Mass Spectrometry (LC-MS/MS)\nGas Chromatography (GC)\nHigh-Performance Liquid Chromatography (HPLC)Liquid Chromatography-Mass Spectrometry (LC-MS/MS)Gas Chromatography (GC)Detectors\nUV-Vis, fluorescence, mass spectrometry\nUV-Vis, fluorescence, mass spectrometryAdvantages: High specificity sensitivity, ability measure multiple drugs/metabolites simultaneouslyLimitations: complex, requires skilled operators, expensive immunoassays","code":""},{"path":"procedures-9.html","id":"special-precautions-14","chapter":"Procedures","heading":"Special Precautions","text":"Patient Preparation\nTiming dose: Collect samples appropriate times (trough, peak)\nMedication history: Document medications supplements\nFasting requirements: May needed tests\nTiming dose: Collect samples appropriate times (trough, peak)Medication history: Document medications supplementsFasting requirements: May needed testsSample Collection\nUse correct collection tubes\nFollow correct order draw\nProper venipuncture technique minimize hemolysis\nLabel specimens immediately accurately\nUse correct collection tubesFollow correct order drawProper venipuncture technique minimize hemolysisLabel specimens immediately accuratelySample Handling\nProcess promptly\nAliquot correctly\nStore correct temperature\nProtect light necessary\nProcess promptlyAliquot correctlyStore correct temperatureProtect light necessary","code":""},{"path":"procedures-9.html","id":"specimen-collection-and-processing-1","chapter":"Procedures","heading":"Specimen Collection and Processing","text":"Specimen Types: Serum, plasma, whole bloodCollection Tubes: SST, EDTA, heparinCentrifugation: Centrifuge promptly collectionSeparation: Separate serum plasma cells within specified time frameStorage: Refrigerate freeze samples recommended temperatures","code":""},{"path":"procedures-9.html","id":"troubleshooting-18","chapter":"Procedures","heading":"Troubleshooting","text":"High Drug Results\nPre-analytical: Wrong collection time, medication administration error, contamination\nAnalytical: Incorrect calibration, reagent issues, interferences\nPre-analytical: Wrong collection time, medication administration error, contaminationAnalytical: Incorrect calibration, reagent issues, interferencesLow Drug Results\nPre-analytical: Wrong collection time, degradation, improper storage\nAnalytical: Calibration issues, reagent problems, interferences\nPre-analytical: Wrong collection time, degradation, improper storageAnalytical: Calibration issues, reagent problems, interferencesInconsistent Results\nPre-analytical: Patient variability, handling errors\nAnalytical: Assay variability, interferences\nPre-analytical: Patient variability, handling errorsAnalytical: Assay variability, interferencesQuality Control (QC) Failures\nPre-analytical: QC improperly stored expired\nAnalytical: Calibration errors, reagent issues, instrument malfunction\nInvestigate correct source error\nPre-analytical: QC improperly stored expiredAnalytical: Calibration errors, reagent issues, instrument malfunctionInvestigate correct source error","code":""},{"path":"procedures-9.html","id":"interfering-substances-18","chapter":"Procedures","heading":"Interfering Substances","text":"Hemolysis: Can interfere immunoassaysLipemia: Can cause turbidity affect spectrophotometric assaysBilirubin: Can interfere spectrophotometric assaysDrugs: drugs can interfere assay affect drug levelsHeterophile Antibodies: Can cause falsely high low resultsCross-Reactivity: Antibodies may bind substancesMatrix Effects: Components sample matrix can affect results","code":""},{"path":"principles-9.html","id":"principles-9","chapter":"Principles","heading":"Principles","text":"Understanding analytical principles behind immunoassays chromatography essential accurate reliable therapeutic drug monitoring (TDM)","code":""},{"path":"principles-9.html","id":"immunoassays-in-tdm","chapter":"Principles","heading":"Immunoassays in TDM","text":"Principle: Immunoassays rely specific binding antibody target antigen (drug measured)Types Immunoassays\nCompetitive Immunoassay: Unlabeled drug sample competes labeled drug binding limited number antibodies\nNon-Competitive Immunoassay: Antibodies excess, amount antibody-drug complex formed directly proportional drug concentration\nHomogeneous Immunoassay: Antibody-antigen binding directly alters signal without need separation steps\nHeterogeneous Immunoassay: Requires separation bound unbound antibody-antigen complexes signal detection\nCompetitive Immunoassay: Unlabeled drug sample competes labeled drug binding limited number antibodiesNon-Competitive Immunoassay: Antibodies excess, amount antibody-drug complex formed directly proportional drug concentrationHomogeneous Immunoassay: Antibody-antigen binding directly alters signal without need separation stepsHeterogeneous Immunoassay: Requires separation bound unbound antibody-antigen complexes signal detectionComponents\nAntibody: protein produced immune system specifically binds target drug (antigen)\nAntigen (Drug): drug measured sample\nLabel: molecule attached antibody antigen allow detection\nDetection System: Measures amount label bound antibody-antigen complex\nAntibody: protein produced immune system specifically binds target drug (antigen)Antigen (Drug): drug measured sampleLabel: molecule attached antibody antigen allow detectionDetection System: Measures amount label bound antibody-antigen complexCommon Immunoassay Formats TDM\nEnzyme-Multiplied Immunoassay Technique (EMIT): homogeneous competitive immunoassay\nFluorescence Polarization Immunoassay (FPIA): homogeneous competitive immunoassay measures changes polarized light\nChemiluminescent Microparticle Immunoassay (CMIA): heterogeneous non-competitive immunoassay using chemiluminescent labels\nEnzyme-Multiplied Immunoassay Technique (EMIT): homogeneous competitive immunoassayFluorescence Polarization Immunoassay (FPIA): homogeneous competitive immunoassay measures changes polarized lightChemiluminescent Microparticle Immunoassay (CMIA): heterogeneous non-competitive immunoassay using chemiluminescent labelsApplications TDM\nMeasurement wide range drugs, including antibiotics, anticonvulsants, cardioactive drugs, immunosuppressants, antidepressants\nMeasurement wide range drugs, including antibiotics, anticonvulsants, cardioactive drugs, immunosuppressants, antidepressants","code":""},{"path":"principles-9.html","id":"enzyme-multiplied-immunoassay-technique-emit","chapter":"Principles","heading":"Enzyme-Multiplied Immunoassay Technique (EMIT)","text":"Principle: homogeneous competitive immunoassay uses enzyme labelProcedure\nAntibody Enzyme-Labeled Drug: fixed amount antibody specific drug fixed amount drug labeled active enzyme mixed patient sample\nCompetition: drug present patient sample, competes enzyme-labeled drug binding antibody\nEnzyme Activity: amount enzyme-labeled drug binds antibody inversely proportional concentration drug patient sample. enzyme activity measured adding substrate converted detectable product\nAntibody Enzyme-Labeled Drug: fixed amount antibody specific drug fixed amount drug labeled active enzyme mixed patient sampleCompetition: drug present patient sample, competes enzyme-labeled drug binding antibodyEnzyme Activity: amount enzyme-labeled drug binds antibody inversely proportional concentration drug patient sample. enzyme activity measured adding substrate converted detectable productAdvantages: Rapid, simple, automated, cost-effectiveLimitations: Less sensitive specific compared chromatographic methods; susceptible interferences","code":""},{"path":"principles-9.html","id":"fluorescence-polarization-immunoassay-fpia","chapter":"Principles","heading":"Fluorescence Polarization Immunoassay (FPIA)","text":"Principle: homogeneous competitive immunoassay measures changes polarized lightProcedure\nAntibody Fluorescently-Labeled Drug: fixed amount antibody specific drug fixed amount drug labeled fluorophore mixed patient sample\nPolarization: labeled drug free solution, rotates rapidly, resulting low polarization emitted light. labeled drug binds antibody, resulting complex rotates slowly, resulting increased polarization emitted light\nPolarization Measurement: degree polarization inversely proportional concentration drug patient sample\nAntibody Fluorescently-Labeled Drug: fixed amount antibody specific drug fixed amount drug labeled fluorophore mixed patient samplePolarization: labeled drug free solution, rotates rapidly, resulting low polarization emitted light. labeled drug binds antibody, resulting complex rotates slowly, resulting increased polarization emitted lightPolarization Measurement: degree polarization inversely proportional concentration drug patient sampleAdvantages: Automated, relatively high throughput, less susceptible interferences compared EMITLimitations: Lower sensitivity specificity compared chromatographic methods","code":""},{"path":"principles-9.html","id":"chemiluminescent-microparticle-immunoassay-cmia","chapter":"Principles","heading":"Chemiluminescent Microparticle Immunoassay (CMIA)","text":"Principle: heterogeneous non-competitive immunoassay using chemiluminescent labelsProcedure\nAntibody-Coated Microparticles: patient sample incubated antibody-coated microparticles capture drug\nWashing: Unbound substances washed away\nChemiluminescent-Labeled Antibody: chemiluminescent-labeled antibody specific drug added, binds drug captured microparticles\nChemiluminescent Reaction: chemiluminescent substrate added, emitted light measured\nAntibody-Coated Microparticles: patient sample incubated antibody-coated microparticles capture drugWashing: Unbound substances washed awayChemiluminescent-Labeled Antibody: chemiluminescent-labeled antibody specific drug added, binds drug captured microparticlesChemiluminescent Reaction: chemiluminescent substrate added, emitted light measuredAdvantages: High sensitivity specificity, automated, relatively high throughputLimitations: complex homogeneous immunoassays requires separation steps","code":""},{"path":"principles-9.html","id":"chromatography-in-tdm","chapter":"Principles","heading":"Chromatography in TDM","text":"Principle: Chromatography separation technique used separate quantify individual compounds complex mixture based physical chemical propertiesTypes Chromatography\nHigh-Performance Liquid Chromatography (HPLC): Uses liquid mobile phase solid stationary phase separate compounds\nGas Chromatography (GC): Uses gaseous mobile phase solid liquid stationary phase separate volatile compounds\nLiquid Chromatography-Mass Spectrometry (LC-MS): Combines separation capabilities HPLC detection power mass spectrometry\nGas Chromatography-Mass Spectrometry (GC-MS): Combines separation capabilities GC detection power mass spectrometry\nHigh-Performance Liquid Chromatography (HPLC): Uses liquid mobile phase solid stationary phase separate compoundsGas Chromatography (GC): Uses gaseous mobile phase solid liquid stationary phase separate volatile compoundsLiquid Chromatography-Mass Spectrometry (LC-MS): Combines separation capabilities HPLC detection power mass spectrometryGas Chromatography-Mass Spectrometry (GC-MS): Combines separation capabilities GC detection power mass spectrometryComponents\nMobile Phase: liquid gas carries sample chromatography system\nStationary Phase: solid liquid material interacts sample components, causing separate\nColumn: Contains stationary phase\nDetector: Detects separated compounds elute column\nMobile Phase: liquid gas carries sample chromatography systemStationary Phase: solid liquid material interacts sample components, causing separateColumn: Contains stationary phaseDetector: Detects separated compounds elute columnDetection Methods\nUV-Vis Detection: Measures absorbance compounds specific wavelengths\nFluorescence Detection: Measures fluorescence compounds excitation light\nElectrochemical Detection: Measures oxidation reduction compounds\nMass Spectrometry (MS): Measures mass--charge ratio compounds\nUV-Vis Detection: Measures absorbance compounds specific wavelengthsFluorescence Detection: Measures fluorescence compounds excitation lightElectrochemical Detection: Measures oxidation reduction compoundsMass Spectrometry (MS): Measures mass--charge ratio compoundsApplications TDM\nMeasurement drugs easily measured immunoassays\nSeparation quantification multiple drugs metabolites single sample\nConfirmation immunoassay results\nDetection drug metabolites\nAccurate measurement Free Drug (HPLC-UF)\nMeasurement drugs easily measured immunoassaysSeparation quantification multiple drugs metabolites single sampleConfirmation immunoassay resultsDetection drug metabolitesAccurate measurement Free Drug (HPLC-UF)","code":""},{"path":"principles-9.html","id":"high-performance-liquid-chromatography-hplc-1","chapter":"Principles","heading":"High-Performance Liquid Chromatography (HPLC)","text":"Principle: Separates compounds based interactions liquid mobile phase solid stationary phase high pressureProcedure\nSample Preparation: Extract drug sample dissolve suitable solvent\nInjection: Inject sample HPLC system\nSeparation: sample components separated based interactions mobile stationary phases\nDetection: separated compounds detected using UV-Vis detector, fluorescence detector, electrochemical detector\nQuantification: peak areas heights compared standard curve determine drug concentrations\nSample Preparation: Extract drug sample dissolve suitable solventInjection: Inject sample HPLC systemSeparation: sample components separated based interactions mobile stationary phasesDetection: separated compounds detected using UV-Vis detector, fluorescence detector, electrochemical detectorQuantification: peak areas heights compared standard curve determine drug concentrationsAdvantages: Versatile, can separate wide range compounds, high resolutionLimitations: Requires skilled operators, expensive instrumentation, can time-consuming","code":""},{"path":"principles-9.html","id":"liquid-chromatography-mass-spectrometry-lc-ms-1","chapter":"Principles","heading":"Liquid Chromatography-Mass Spectrometry (LC-MS)","text":"Principle: Combines separation capabilities liquid chromatography detection power mass spectrometryProcedure\nSample Preparation: Extract drug sample dissolve suitable solvent\nChromatographic Separation: Inject sample liquid chromatography system separate compounds based interactions mobile stationary phases\nMass Spectrometry Detection: separated compounds ionized passed mass spectrometer, measures mass--charge ratio\nQuantification: peak areas compared standard curve determine drug concentrations\nSample Preparation: Extract drug sample dissolve suitable solventChromatographic Separation: Inject sample liquid chromatography system separate compounds based interactions mobile stationary phasesMass Spectrometry Detection: separated compounds ionized passed mass spectrometer, measures mass--charge ratioQuantification: peak areas compared standard curve determine drug concentrationsAdvantages: High sensitivity, specificity, throughput; can quantify multiple compounds simultaneouslyLimitations: Requires highly skilled operators expensive instrumentation","code":""},{"path":"principles-9.html","id":"gas-chromatography-gc","chapter":"Principles","heading":"Gas Chromatography (GC)","text":"Principle: Separates volatile compounds based boiling pointsSample Requirement: must volatile able derivatized volatileProcedure\nSample Preparation: Extract drug sample dissolve suitable solvent\nInjection: Inject sample GC system\nSeparation: sample components vaporized separated based boiling points\nDetection: separated compounds detected using flame ionization detector (FID) mass spectrometer\nQuantification: peak areas compared standard curve determine drug concentrations\nSample Preparation: Extract drug sample dissolve suitable solventInjection: Inject sample GC systemSeparation: sample components vaporized separated based boiling pointsDetection: separated compounds detected using flame ionization detector (FID) mass spectrometerQuantification: peak areas compared standard curve determine drug concentrationsAdvantages: High resolution sensitivity volatile compoundsLimitations: Limited volatile compounds; requires derivatization non-volatile compounds","code":""},{"path":"principles-9.html","id":"comparison-of-immunoassays-and-chromatography","chapter":"Principles","heading":"Comparison of Immunoassays and Chromatography","text":"","code":""},{"path":"principles-9.html","id":"key-terms-81","chapter":"Principles","heading":"Key Terms","text":"Immunoassay: assay based specific binding antibodies antigensChromatography: separation technique used separate quantify individual compounds complex mixtureAntibody: protein produced immune system specifically binds antigenAntigen: molecule binds antibodyCompetitive Immunoassay: immunoassay unlabeled antigen competes labeled antigen antibody bindingNon-Competitive Immunoassay: immunoassay labeled antibody binds antigenHomogeneous Immunoassay: immunoassay signal directly altered antibody-antigen bindingHeterogeneous Immunoassay: immunoassay requires separation bound unbound complexes signal detectionLabel: molecule attached antibody antigen allow detectionHPLC: High-performance liquid chromatographyGC: Gas chromatographyLC-MS: Liquid chromatography-mass spectrometryGC-MS: Gas chromatography-mass spectrometryMobile Phase: liquid gas carries sample chromatography systemStationary Phase: solid liquid material interacts sample componentsRetention Time: time takes compound elute chromatography columnElute: remove washing solventDetector: device detects separated compounds elute chromatography columnSensitivity: ability assay detect small amounts substanceSpecificity: ability assay measure substance interestThroughput: number samples can analyzed given periodMatrix Effects: effect sample matrix analytical measurementAccuracy: closeness measurement true valuePrecision: reproducibility measurement","code":""},{"path":"precautions-4.html","id":"precautions-4","chapter":"Precautions","heading":"Precautions","text":"ensure reliability TDM, ’s essential address pre-analytical analytical factors, including special precautions, specimen handling, interfering substances","code":""},{"path":"precautions-4.html","id":"special-precautions-15","chapter":"Precautions","heading":"Special Precautions","text":"Patient Identification\nAccurate patient identification essential prevent errors\nUse two unique identifiers (e.g., name date birth)\nAccurate patient identification essential prevent errorsUse two unique identifiers (e.g., name date birth)Timing Specimen Collection\nCollect specimens correct time relative drug administration schedule\nTrough levels: Collected immediately next dose\nPeak levels: Collected specific time drug administration\n\nRecord date time drug administration specimen collection\nCollect specimens correct time relative drug administration schedule\nTrough levels: Collected immediately next dose\nPeak levels: Collected specific time drug administration\nTrough levels: Collected immediately next dosePeak levels: Collected specific time drug administrationRecord date time drug administration specimen collectionMedication History\nObtain complete medication history patient\nDocument prescription --counter medications, well herbal supplements\nObtain complete medication history patientDocument prescription --counter medications, well herbal supplementsClinical Information\nGather relevant clinical information, patient’s age, weight, renal function, liver function, concurrent medical conditions\nGather relevant clinical information, patient’s age, weight, renal function, liver function, concurrent medical conditionsChain Custody\nMaintain clear chain custody specimens\nDocument date, time, initials person handling specimen\nMaintain clear chain custody specimensDocument date, time, initials person handling specimenInformed Consent\nObtain informed consent patient collecting specimens TDM\nObtain informed consent patient collecting specimens TDMSafety Precautions\nFollow standard safety precautions handling blood biological specimens\nWear gloves, gowns, eye protection\nFollow standard safety precautions handling blood biological specimensWear gloves, gowns, eye protection","code":""},{"path":"precautions-4.html","id":"specimen-collection-9","chapter":"Precautions","heading":"Specimen Collection","text":"Specimen Type\nSerum plasma commonly used TDM\nWhole blood used immunosuppressant drugs (e.g., tacrolimus, cyclosporine)\nSerum plasma commonly used TDMWhole blood used immunosuppressant drugs (e.g., tacrolimus, cyclosporine)Collection Tubes\nUse appropriate collection tubes drug\nSerum separator tubes (SST)\nEDTA tubes\nHeparin tubes\n\nFollow manufacturer’s instructions tube selection\nUse appropriate collection tubes drug\nSerum separator tubes (SST)\nEDTA tubes\nHeparin tubes\nSerum separator tubes (SST)EDTA tubesHeparin tubesFollow manufacturer’s instructions tube selectionOrder Draw\nFollow correct order draw prevent cross-contamination\nConsult CLSI guidelines correct order draw\nFollow correct order draw prevent cross-contaminationConsult CLSI guidelines correct order drawCollection Technique\nUse proper venipuncture technique minimize hemolysis\nAvoid prolonged tourniquet time\nUse proper venipuncture technique minimize hemolysisAvoid prolonged tourniquet timeSpecimen Volume\nCollect sufficient volume perform assay allow repeat testing\nFollow laboratory’s guidelines minimum volume requirements\nCollect sufficient volume perform assay allow repeat testingFollow laboratory’s guidelines minimum volume requirementsLabeling\nLabel specimens immediately accurately patient information, date, time collection\nLabel specimens immediately accurately patient information, date, time collection","code":""},{"path":"precautions-4.html","id":"specimen-processing-3","chapter":"Precautions","heading":"Specimen Processing","text":"Centrifugation\nCentrifuge specimens promptly collection\nFollow manufacturer’s instructions centrifugation speed time\nCentrifuge specimens promptly collectionFollow manufacturer’s instructions centrifugation speed timeSeparation\nSeparate serum plasma cells within specified time frame\nPrevent hemolysis\nSeparate serum plasma cells within specified time framePrevent hemolysisAliquotting\nAliquot specimens appropriate containers\nUse clean, dry containers\nAliquot specimens appropriate containersUse clean, dry containersStorage\nStore specimens appropriate temperature\nRefrigeration (2-8°C): short-term storage\nFreezing (-20°C -80°C): long-term storage\n\nFollow manufacturer’s instructions storage conditions\nStore specimens appropriate temperature\nRefrigeration (2-8°C): short-term storage\nFreezing (-20°C -80°C): long-term storage\nRefrigeration (2-8°C): short-term storageFreezing (-20°C -80°C): long-term storageFollow manufacturer’s instructions storage conditionsThawing\nThaw specimens properly testing\nThaw room temperature refrigerator, mix gently\nThaw specimens properly testingThaw room temperature refrigerator, mix gently","code":""},{"path":"precautions-4.html","id":"troubleshooting-19","chapter":"Precautions","heading":"Troubleshooting","text":"High Drug Results\nPre-analytical: Specimen collected wrong time, medication administration error, contamination\nAnalytical: Incorrect calibration, reagent deterioration, interfering substances, cross-reactivity\nPre-analytical: Specimen collected wrong time, medication administration error, contaminationAnalytical: Incorrect calibration, reagent deterioration, interfering substances, cross-reactivityLow Drug Results\nPre-analytical: Specimen collected wrong time, improper storage, medication error, dilution\nAnalytical: Incorrect calibration, reagent deterioration, interfering substances, assay drift\nPre-analytical: Specimen collected wrong time, improper storage, medication error, dilutionAnalytical: Incorrect calibration, reagent deterioration, interfering substances, assay driftInconsistent Results\nPre-analytical: Patient variability, specimen handling errors, timing errors\nAnalytical: Assay variability, interfering substances, cross-reactivity\nPre-analytical: Patient variability, specimen handling errors, timing errorsAnalytical: Assay variability, interfering substances, cross-reactivityQuality Control Failures\nPre-analytical: QC material improperly stored, QC material expired\nAnalytical: Incorrect calibration, reagent deterioration, instrument malfunction\nAction: Investigate cause failure take corrective action\nPre-analytical: QC material improperly stored, QC material expiredAnalytical: Incorrect calibration, reagent deterioration, instrument malfunctionAction: Investigate cause failure take corrective action","code":""},{"path":"precautions-4.html","id":"interfering-substances-19","chapter":"Precautions","heading":"Interfering Substances","text":"Hemolysis\nInterference: Releases intracellular components can interfere immunoassays\nMitigation: Avoid hemolysis collection processing\nInterference: Releases intracellular components can interfere immunoassaysMitigation: Avoid hemolysis collection processingLipemia\nInterference: Turbidity high lipid concentrations can interfere spectrophotometric assays\nMitigation: Use lipemia clearing techniques consider methods less affected turbidity\nInterference: Turbidity high lipid concentrations can interfere spectrophotometric assaysMitigation: Use lipemia clearing techniques consider methods less affected turbidityBilirubin\nInterference: High bilirubin levels can interfere spectrophotometric assays\nMitigation: Use methods less susceptible bilirubin interference\nInterference: High bilirubin levels can interfere spectrophotometric assaysMitigation: Use methods less susceptible bilirubin interferenceDrugs\nInterference: drugs can directly interfere assays affect drug levels\nMitigation: aware patient’s medication list potential drug interactions\nInterference: drugs can directly interfere assays affect drug levelsMitigation: aware patient’s medication list potential drug interactionsHeterophile Antibodies\nInterference: Bind assay antibodies, causing falsely high low results\nMitigation: Use blocking reagents heterophile antibody blocking tubes\nInterference: Bind assay antibodies, causing falsely high low resultsMitigation: Use blocking reagents heterophile antibody blocking tubesCross-Reactivity\nInterference: Assay antibodies may cross-react structurally similar compounds\nMitigation: Use highly specific antibodies aware potential cross-reactants\nInterference: Assay antibodies may cross-react structurally similar compoundsMitigation: Use highly specific antibodies aware potential cross-reactantsMatrix Effects\nInterference: Components sample matrix can affect assay results\nMitigation: Use matrix-matched calibrators quality control materials\nInterference: Components sample matrix can affect assay resultsMitigation: Use matrix-matched calibrators quality control materialsEndogenous Substances\nInterference: Digoxin-like immunoreactive substances (DLIS) can interfere digoxin assays\nMitigation: Use methods less susceptible DLIS interference\nInterference: Digoxin-like immunoreactive substances (DLIS) can interfere digoxin assaysMitigation: Use methods less susceptible DLIS interference","code":""},{"path":"precautions-4.html","id":"factors-specific-to-different-drug-classes","chapter":"Precautions","heading":"Factors Specific to Different Drug Classes","text":"Aminoglycosides\nRenal function: Monitor serum creatinine creatinine clearance\nInterfering antibiotics: Certain penicillins can inactivate aminoglycosides vitro\nRenal function: Monitor serum creatinine creatinine clearanceInterfering antibiotics: Certain penicillins can inactivate aminoglycosides vitroCardioactive Drugs\nElectrolyte levels: Monitor potassium, magnesium, calcium\nCardiac function: Assess ECG arrhythmias\nDigoxin-like immunoreactive substances (DLIS): Especially neonates patients renal failure\nElectrolyte levels: Monitor potassium, magnesium, calciumCardiac function: Assess ECG arrhythmiasDigoxin-like immunoreactive substances (DLIS): Especially neonates patients renal failureAnticonvulsants\nProtein binding: Monitor free drug levels patients altered protein binding\nDrug interactions: Phenobarbital CYP enzyme inducer\nProtein binding: Monitor free drug levels patients altered protein bindingDrug interactions: Phenobarbital CYP enzyme inducerAntidepressants\nCYP2D6 genotype: Consider genetic testing predict drug metabolism\nDrug interactions: Many antidepressants CYP enzyme inhibitors\nCYP2D6 genotype: Consider genetic testing predict drug metabolismDrug interactions: Many antidepressants CYP enzyme inhibitorsImmunosuppressants\nHematocrit levels: Use whole blood specimens correct hematocrit\nCalcineurin inhibitors: Monitor renal function blood pressure\nDrug interactions: Many drugs can affect CYP3A4-mediated metabolism\nHematocrit levels: Use whole blood specimens correct hematocritCalcineurin inhibitors: Monitor renal function blood pressureDrug interactions: Many drugs can affect CYP3A4-mediated metabolism","code":""},{"path":"precautions-4.html","id":"key-terms-82","chapter":"Precautions","heading":"Key Terms","text":"Pre-Analytical: Processes sample analysisAnalytical: Processes sample analysisPost-Analytical: Processes sample analysisInterfering Substance: Affects test accuracyCalibration: Adjusting instrument accurate readingsQuality Control: Measures ensure test accuracy precisionHomogenous assay: Assay antigen/antibody reaction measured without separation stepHeterogenous assay: Assay antigen/antibody reaction measured separation stepHemolysis: Breakdown red blood cellsLipemia: Excess lipids blood","code":""},{"path":"result-interpretation-9.html","id":"result-interpretation-9","chapter":"Result Interpretation","heading":"Result Interpretation","text":"Interpreting therapeutic drug monitoring (TDM) results requires comprehensive approach considers patient’s clinical status, dosing history, potential influencing factors","code":""},{"path":"result-interpretation-9.html","id":"general-principles-of-test-result-interpretation-2","chapter":"Result Interpretation","heading":"General Principles of Test Result Interpretation","text":"Reference Ranges\nUse appropriate therapeutic ranges specific drug patient population\naware therapeutic ranges guidelines may need individualized\nUse appropriate therapeutic ranges specific drug patient populationBe aware therapeutic ranges guidelines may need individualizedClinical Context\nInterpret test results context patient’s clinical history, physical examination findings, laboratory data\nConsider patient’s symptoms, medications, coexisting medical conditions, response therapy\nInterpret test results context patient’s clinical history, physical examination findings, laboratory dataConsider patient’s symptoms, medications, coexisting medical conditions, response therapyDosing History\nReview patient’s dosing history, including dose, route administration, timing doses\nCheck adherence prescribed regimen\nReview patient’s dosing history, including dose, route administration, timing dosesCheck adherence prescribed regimenSample Timing\nEnsure specimen collected appropriate time relative drug administration schedule (trough, peak, random)\nEnsure specimen collected appropriate time relative drug administration schedule (trough, peak, random)Drug Interactions\naware potential drug interactions can affect drug concentrations\nCheck enzyme inducers, enzyme inhibitors, drugs can alter absorption, distribution, metabolism, excretion\naware potential drug interactions can affect drug concentrationsCheck enzyme inducers, enzyme inhibitors, drugs can alter absorption, distribution, metabolism, excretionAnalytical Considerations\nUnderstand limitations specific assay used, including sensitivity, specificity, potential cross-reactivity\nConsider repeating test using different method interference suspected\nUnderstand limitations specific assay used, including sensitivity, specificity, potential cross-reactivityConsider repeating test using different method interference suspectedSteady-State Concentrations\nEnsure patient reached steady-state concentrations interpreting drug levels\nSteady state typically achieved 5-7 half-lives\nEnsure patient reached steady-state concentrations interpreting drug levelsSteady state typically achieved 5-7 half-livesPatient-Specific Factors\nConsider factors age, weight, renal function, liver function, genetics can affect drug pharmacokinetics\nAdjust therapeutic range based factors\nConsider factors age, weight, renal function, liver function, genetics can affect drug pharmacokineticsAdjust therapeutic range based factors","code":""},{"path":"result-interpretation-9.html","id":"key-concepts-in-tdm-interpretation","chapter":"Result Interpretation","heading":"Key Concepts in TDM Interpretation","text":"Therapeutic Range\nrange drug concentrations associated optimal therapeutic effect minimal toxicity\nVaries depending drug, indication, individual patient\nrange drug concentrations associated optimal therapeutic effect minimal toxicityVaries depending drug, indication, individual patientTrough Level\nlowest drug concentration, typically measured immediately next dose\nUsed assess adequate drug exposure minimize toxicity\nlowest drug concentration, typically measured immediately next doseUsed assess adequate drug exposure minimize toxicityPeak Level\nhighest drug concentration, typically measured specific time drug administration\nUsed assess drug efficacy avoid excessive concentrations\nhighest drug concentration, typically measured specific time drug administrationUsed assess drug efficacy avoid excessive concentrationsArea Curve (AUC)\nmeasure total drug exposure specific time interval\nProvides comprehensive assessment drug exposure single-point measurements\nmeasure total drug exposure specific time intervalProvides comprehensive assessment drug exposure single-point measurementsVolume Distribution (Vd)\nmeasure apparent space body available contain drug\nInfluences peak concentration dose\nmeasure apparent space body available contain drugInfluences peak concentration doseClearance (CL)\nmeasure body’s efficiency eliminating drug\nInfluences steady-state concentration\nmeasure body’s efficiency eliminating drugInfluences steady-state concentrationHalf-Life (t1/2)\ntime takes concentration drug body reduced one-half\nDetermines time reach steady-state dosing interval\ntime takes concentration drug body reduced one-halfDetermines time reach steady-state dosing interval","code":""},{"path":"result-interpretation-9.html","id":"general-interpretation-guidelines","chapter":"Result Interpretation","heading":"General Interpretation Guidelines","text":"Levels Therapeutic Range\nConsider increasing dose decreasing dosing interval\nAssess patient adherence drug interactions\nConsider using loading dose achieve therapeutic concentrations rapidly\nConsider increasing dose decreasing dosing intervalAssess patient adherence drug interactionsConsider using loading dose achieve therapeutic concentrations rapidlyLevels Within Therapeutic Range\nContinue current therapy monitor efficacy toxicity\nAssess patient adherence drug interactions\nMay need adjust dose based clinical response\nContinue current therapy monitor efficacy toxicityAssess patient adherence drug interactionsMay need adjust dose based clinical responseLevels Therapeutic Range\nConsider reducing dose increasing dosing interval\nAssess drug interactions renal/hepatic impairment\nMonitor signs symptoms toxicity\ncases, temporary discontinuation drug may necessary\nConsider reducing dose increasing dosing intervalAssess drug interactions renal/hepatic impairmentMonitor signs symptoms toxicityIn cases, temporary discontinuation drug may necessaryUnexpected Results\nRepeat test confirm result\nCheck analytical errors interferences\nReview patient’s medical history medication list\nConsider alternative analytical methods\nRepeat test confirm resultCheck analytical errors interferencesReview patient’s medical history medication listConsider alternative analytical methods","code":""},{"path":"result-interpretation-9.html","id":"specific-considerations-for-different-drug-classes","chapter":"Result Interpretation","heading":"Specific Considerations for Different Drug Classes","text":"","code":""},{"path":"result-interpretation-9.html","id":"aminoglycosides-e.g.-gentamicin-1","chapter":"Result Interpretation","heading":"Aminoglycosides (e.g., Gentamicin)","text":"Target Concentrations\nTrough: < 1-2 μg/mL\nPeak: 5-10 μg/mL (depending infection)\nTrough: < 1-2 μg/mLPeak: 5-10 μg/mL (depending infection)Interpretation\nElevated trough levels: Increased risk nephrotoxicity ototoxicity\nLow peak levels: May indicate inadequate dosing resistance\nAdjust dosing interval based trough levels renal function\nElevated trough levels: Increased risk nephrotoxicity ototoxicityLow peak levels: May indicate inadequate dosing resistanceAdjust dosing interval based trough levels renal functionFactors Consider\nRenal function: Adjust dose based creatinine clearance\nInfection severity: Higher peak levels may needed serious infections\nConcurrent nephrotoxic medications: Avoid use possible\nRenal function: Adjust dose based creatinine clearanceInfection severity: Higher peak levels may needed serious infectionsConcurrent nephrotoxic medications: Avoid use possible","code":""},{"path":"result-interpretation-9.html","id":"cardioactive-drugs-e.g.-digoxin-1","chapter":"Result Interpretation","heading":"Cardioactive Drugs (e.g., Digoxin)","text":"Target Concentrations\n0.5-2.0 ng/mL (heart failure)\n0.8-1.2 ng/mL (atrial fibrillation)\n0.5-2.0 ng/mL (heart failure)0.8-1.2 ng/mL (atrial fibrillation)Interpretation\nElevated levels: Increased risk cardiac arrhythmias, nausea, vomiting, visual disturbances\nLow levels: May indicate inadequate control heart failure atrial fibrillation\nAssess potassium levels: Hypokalemia increases digoxin toxicity\nElevated levels: Increased risk cardiac arrhythmias, nausea, vomiting, visual disturbancesLow levels: May indicate inadequate control heart failure atrial fibrillationAssess potassium levels: Hypokalemia increases digoxin toxicityFactors Consider\nRenal function: Adjust dose based creatinine clearance\nElectrolyte imbalances: Correct potassium magnesium deficiencies\nDrug interactions: Quinidine, amiodarone, verapamil can increase digoxin levels\nRenal function: Adjust dose based creatinine clearanceElectrolyte imbalances: Correct potassium magnesium deficienciesDrug interactions: Quinidine, amiodarone, verapamil can increase digoxin levels","code":""},{"path":"result-interpretation-9.html","id":"anticonvulsants-e.g.-phenobarbital-1","chapter":"Result Interpretation","heading":"Anticonvulsants (e.g., Phenobarbital)","text":"Target Concentrations\n15-40 μg/mL (seizure control)\n15-40 μg/mL (seizure control)Interpretation\nElevated levels: Sedation, ataxia, nystagmus, respiratory depression\nLow levels: May indicate inadequate seizure control\nAdjust dosing interval based half-life clinical response\nElevated levels: Sedation, ataxia, nystagmus, respiratory depressionLow levels: May indicate inadequate seizure controlAdjust dosing interval based half-life clinical responseFactors Consider\nProtein binding: Monitor free drug levels patients altered protein binding (e.g., renal failure, liver disease)\nDrug interactions: Phenobarbital CYP enzyme inducer can affect metabolism drugs\nProtein binding: Monitor free drug levels patients altered protein binding (e.g., renal failure, liver disease)Drug interactions: Phenobarbital CYP enzyme inducer can affect metabolism drugs","code":""},{"path":"result-interpretation-9.html","id":"antidepressants-e.g.-lithium-1","chapter":"Result Interpretation","heading":"Antidepressants (e.g., Lithium)","text":"Target Concentrations\n0.6-1.2 mEq/L (acute mania)\n0.6-0.8 mEq/L (maintenance)\n0.6-1.2 mEq/L (acute mania)0.6-0.8 mEq/L (maintenance)Interpretation\nElevated levels: Tremor, ataxia, confusion, seizures, renal toxicity\nLow levels: May indicate inadequate mood stabilization\nMonitor side effects: Polyuria, polydipsia, thyroid dysfunction\nElevated levels: Tremor, ataxia, confusion, seizures, renal toxicityLow levels: May indicate inadequate mood stabilizationMonitor side effects: Polyuria, polydipsia, thyroid dysfunctionFactors Consider\nRenal function: Adjust dose based creatinine clearance\nSodium balance: Sodium depletion increases lithium levels\nDrug interactions: Thiazide diuretics, NSAIDs, ACE inhibitors can increase lithium levels\nRenal function: Adjust dose based creatinine clearanceSodium balance: Sodium depletion increases lithium levelsDrug interactions: Thiazide diuretics, NSAIDs, ACE inhibitors can increase lithium levels","code":""},{"path":"result-interpretation-9.html","id":"immunosuppressants-e.g.-tacrolimus-1","chapter":"Result Interpretation","heading":"Immunosuppressants (e.g., Tacrolimus)","text":"Target Concentrations\nVary depending type transplant, time since transplantation, presence immunosuppressants\nConsult transplant center guidelines specific target ranges\nVary depending type transplant, time since transplantation, presence immunosuppressantsConsult transplant center guidelines specific target rangesInterpretation\nElevated levels: Nephrotoxicity, neurotoxicity, hypertension, glucose intolerance, tremor\nLow levels: Increased risk organ rejection\nMonitor renal function, electrolytes, glucose levels\nElevated levels: Nephrotoxicity, neurotoxicity, hypertension, glucose intolerance, tremorLow levels: Increased risk organ rejectionMonitor renal function, electrolytes, glucose levelsFactors Consider\nHematocrit: Use whole blood specimens correct hematocrit\nCYP3A4 inhibitors inducers: Numerous drug interactions\nGastrointestinal motility: Diarrhea can affect absorption\nHematocrit: Use whole blood specimens correct hematocritCYP3A4 inhibitors inducers: Numerous drug interactionsGastrointestinal motility: Diarrhea can affect absorptionTrough level timing validity\nLevels taken absorptive phase invalidate results\nLevels taken absorptive phase invalidate results","code":""},{"path":"result-interpretation-9.html","id":"key-terms-83","chapter":"Result Interpretation","heading":"Key Terms","text":"Therapeutic Range: Optimal drug concentration rangeTrough Level: Minimum concentration next dosePeak Level: Maximum concentration doseAUC: Total drug exposure timeVolume Distribution: Apparent space drug distributionClearance: Rate drug eliminationHalf-Life: Time concentration decrease halfSteady State: Equilibrium drug input outputToxicity: Harmful drug effectsAdherence: Taking medication prescribedDrug Interactions: Effects substances drug levels","code":""},{"path":"disease-correlation-9.html","id":"disease-correlation-9","chapter":"Disease Correlation","heading":"Disease Correlation","text":"Understanding connections specific disease states alterations drug pharmacokinetics essential effective therapeutic drug monitoring (TDM). Different diseases can significantly impact drug absorption, distribution, metabolism, excretion (ADME), thereby influencing drug concentrations therapeutic outcomes","code":""},{"path":"disease-correlation-9.html","id":"general-principles-of-disease-state-correlation-in-tdm","chapter":"Disease Correlation","heading":"General Principles of Disease State Correlation in TDM","text":"Impact ADME Processes: Disease states can alter drug absorption, distribution, metabolism, excretion, leading changes drug concentrations therapeutic responseIndividual Variability: Disease states can introduce significant variability drug pharmacokinetics among patientsDose Adjustments: Dosage adjustments may necessary maintain drug concentrations within therapeutic range patients certain diseasesMonitoring Toxicity: Patients altered drug pharmacokinetics may increased risk drug toxicityImportance Clinical Assessment: TDM always interpreted context patient’s clinical status laboratory data","code":""},{"path":"disease-correlation-9.html","id":"renal-disease","chapter":"Disease Correlation","heading":"Renal Disease","text":"Mechanism Impact\nReduced glomerular filtration rate (GFR)\nImpaired tubular secretion\nDecreased drug clearance\nIncreased drug half-life\nAltered protein binding\nReduced glomerular filtration rate (GFR)Impaired tubular secretionDecreased drug clearanceIncreased drug half-lifeAltered protein bindingDrugs Commonly Affected\nAminoglycosides (gentamicin, tobramycin)\nVancomycin\nLithium\nMethotrexate\nDigoxin\nAminoglycosides (gentamicin, tobramycin)VancomycinLithiumMethotrexateDigoxinTDM Considerations\nMonitor renal function (serum creatinine, creatinine clearance)\nReduce drug doses /extend dosing intervals\nMonitor drug levels frequently\nMonitor renal function (serum creatinine, creatinine clearance)Reduce drug doses /extend dosing intervalsMonitor drug levels frequentlyDisease Examples\nChronic Kidney Disease (CKD)\nAcute Kidney Injury (AKI)\nNephrotic Syndrome\nChronic Kidney Disease (CKD)Acute Kidney Injury (AKI)Nephrotic Syndrome","code":""},{"path":"disease-correlation-9.html","id":"liver-disease","chapter":"Disease Correlation","heading":"Liver Disease","text":"Mechanism Impact\nReduced hepatic blood flow\nImpaired hepatic metabolism\nDecreased drug clearance\nIncreased drug half-life\nAltered protein binding\nReduced hepatic blood flowImpaired hepatic metabolismDecreased drug clearanceIncreased drug half-lifeAltered protein bindingDrugs Commonly Affected\nMany drugs metabolized CYP enzymes (e.g., phenytoin, warfarin, theophylline, cyclosporine, tacrolimus)\nMany drugs metabolized CYP enzymes (e.g., phenytoin, warfarin, theophylline, cyclosporine, tacrolimus)TDM Considerations\nMonitor liver function (AST, ALT, bilirubin, albumin, INR)\nReduce drug doses /extend dosing intervals\nMonitor drug levels frequently\nMonitor liver function (AST, ALT, bilirubin, albumin, INR)Reduce drug doses /extend dosing intervalsMonitor drug levels frequentlyDisease Examples\nCirrhosis\nHepatitis\nLiver Failure\nCirrhosisHepatitisLiver Failure","code":""},{"path":"disease-correlation-9.html","id":"heart-failure","chapter":"Disease Correlation","heading":"Heart Failure","text":"Mechanism Impact\nReduced cardiac output\nDecreased blood flow kidneys liver\nImpaired drug absorption, distribution, metabolism, excretion\nEdema can increase volume distribution\nReduced cardiac outputDecreased blood flow kidneys liverImpaired drug absorption, distribution, metabolism, excretionEdema can increase volume distributionDrugs Commonly Affected\nDigoxin\nDiuretics\nAntiarrhythmics\nDigoxinDiureticsAntiarrhythmicsTDM Considerations\nMonitor cardiac function (ejection fraction, heart rate)\nAdjust doses based clinical response drug levels\naware potential electrolyte imbalances\nMonitor cardiac function (ejection fraction, heart rate)Adjust doses based clinical response drug levelsBe aware potential electrolyte imbalancesRelevant Disease Examples\nCongestive Heart Failure (CHF)\nCardiomyopathy\nCongestive Heart Failure (CHF)Cardiomyopathy","code":""},{"path":"disease-correlation-9.html","id":"gastrointestinal-disorders","chapter":"Disease Correlation","heading":"Gastrointestinal Disorders","text":"Mechanism Impact\nAltered gastric pH\nChanges gastrointestinal motility\nMalabsorption\nChanges gut flora\nAltered gastric pHChanges gastrointestinal motilityMalabsorptionChanges gut floraDrugs Commonly Affected\nDrugs pH-dependent absorption\nDrugs undergo enterohepatic recirculation\nDrugs metabolized gut bacteria\nDrugs pH-dependent absorptionDrugs undergo enterohepatic recirculationDrugs metabolized gut bacteriaTDM Considerations\nMonitor symptoms malabsorption (diarrhea, weight loss)\nAdjust doses based drug levels clinical response\nConsider alternative routes administration (e.g., intravenous)\nMonitor symptoms malabsorption (diarrhea, weight loss)Adjust doses based drug levels clinical responseConsider alternative routes administration (e.g., intravenous)Disease Examples\nCrohn’s Disease\nUlcerative Colitis\nCeliac Disease\nGastric Bypass Surgery\nCrohn’s DiseaseUlcerative ColitisCeliac DiseaseGastric Bypass Surgery","code":""},{"path":"disease-correlation-9.html","id":"obesity","chapter":"Disease Correlation","heading":"Obesity","text":"Mechanism Impact\nIncreased volume distribution lipophilic drugs\nAltered drug metabolism\nChanges renal function\nIncreased volume distribution lipophilic drugsAltered drug metabolismChanges renal functionDrugs Commonly Affected\nLipophilic drugs (e.g., antidepressants, benzodiazepines)\nLipophilic drugs (e.g., antidepressants, benzodiazepines)TDM Considerations\nUse ideal body weight adjusted body weight calculate doses\nMonitor drug levels adjust doses accordingly\nUse ideal body weight adjusted body weight calculate dosesMonitor drug levels adjust doses accordinglyRelevant Disease Examples\nMorbid Obesity\nMorbid Obesity","code":""},{"path":"disease-correlation-9.html","id":"pregnancy","chapter":"Disease Correlation","heading":"Pregnancy","text":"Mechanism Impact\nIncreased blood volume\nIncreased cardiac output\nIncreased glomerular filtration rate\nAltered drug metabolism\nChanges protein binding\nIncreased blood volumeIncreased cardiac outputIncreased glomerular filtration rateAltered drug metabolismChanges protein bindingDrugs Commonly Affected\nAnticonvulsants\nAntibiotics\nAntiretrovirals\nAnticonvulsantsAntibioticsAntiretroviralsTDM Considerations\nMonitor drug levels frequently\nAdjust doses needed maintain therapeutic concentrations\naware potential risks fetus\nMonitor drug levels frequentlyAdjust doses needed maintain therapeutic concentrationsBe aware potential risks fetusPhysiological Changes\nIncreased blood volume\nIncreased cardiac output\nIncreased glomerular filtration rate\nIncreased blood volumeIncreased cardiac outputIncreased glomerular filtration ratePlacental Transfer\ndrugs can cross placenta affect fetus\nWeigh benefits risks drug therapy pregnancy\ndrugs can cross placenta affect fetusWeigh benefits risks drug therapy pregnancy","code":""},{"path":"disease-correlation-9.html","id":"hypoalbuminemia","chapter":"Disease Correlation","heading":"Hypoalbuminemia","text":"Mechanism Impact\nDecreased protein binding\nIncreased free drug concentration\nIncreased risk toxicity\nDecreased protein bindingIncreased free drug concentrationIncreased risk toxicityDrugs Commonly Affected\nHighly protein-bound drugs (e.g., phenytoin, warfarin, valproic acid)\nHighly protein-bound drugs (e.g., phenytoin, warfarin, valproic acid)TDM Considerations\nMonitor albumin levels\nMeasure free drug concentrations, available\nAdjust doses based free drug levels clinical response\nMonitor albumin levelsMeasure free drug concentrations, availableAdjust doses based free drug levels clinical responseRelevant Disease Examples\nNephrotic Syndrome\nLiver Disease\nMalnutrition\nNephrotic SyndromeLiver DiseaseMalnutrition","code":""},{"path":"disease-correlation-9.html","id":"cystic-fibrosis","chapter":"Disease Correlation","heading":"Cystic Fibrosis","text":"Mechanism Impact\nIncreased drug clearance\nAltered volume distribution\nMalabsorption\nIncreased drug clearanceAltered volume distributionMalabsorptionDrugs Commonly Affected\nAminoglycosides\nBeta-lactam antibiotics\nAminoglycosidesBeta-lactam antibioticsTDM Considerations\nHigher doses may required achieve therapeutic concentrations\nMonitor drug levels frequently\nHigher doses may required achieve therapeutic concentrationsMonitor drug levels frequently","code":""},{"path":"disease-correlation-9.html","id":"drug-interactions","chapter":"Disease Correlation","heading":"Drug Interactions","text":"Mechanism Impact\nEnzyme induction\nEnzyme inhibition\nAltered drug transport\nDisplacement protein binding\nEnzyme inductionEnzyme inhibitionAltered drug transportDisplacement protein bindingDrugs Commonly Affected\nDrugs metabolized CYP enzymes (e.g., warfarin, phenytoin, cyclosporine, tacrolimus)\nDrugs substrates inhibitors drug transporters (e.g., P-glycoprotein)\nDrugs metabolized CYP enzymes (e.g., warfarin, phenytoin, cyclosporine, tacrolimus)Drugs substrates inhibitors drug transporters (e.g., P-glycoprotein)TDM Considerations\naware potential drug interactions\nMonitor drug levels starting stopping interacting medications\nAdjust doses needed\naware potential drug interactionsMonitor drug levels starting stopping interacting medicationsAdjust doses needed","code":""},{"path":"disease-correlation-9.html","id":"genetics","chapter":"Disease Correlation","heading":"Genetics","text":"Mechanism Impact\nGenetic polymorphisms drug-metabolizing enzymes drug transporters\nAltered drug metabolism response\nGenetic polymorphisms drug-metabolizing enzymes drug transportersAltered drug metabolism responseDrugs Commonly Affected\nDrugs metabolized CYP2C9, CYP2C19, CYP2D6, polymorphic enzymes\nDrugs metabolized CYP2C9, CYP2C19, CYP2D6, polymorphic enzymesTDM Considerations\nConsider pharmacogenetic testing personalize drug therapy\nAdjust doses based genotype\nConsider pharmacogenetic testing personalize drug therapyAdjust doses based genotype","code":""},{"path":"disease-correlation-9.html","id":"summary-table-of-disease-state-correlation","chapter":"Disease Correlation","heading":"Summary Table of Disease State Correlation","text":"","code":""},{"path":"disease-correlation-9.html","id":"key-terms-84","chapter":"Disease Correlation","heading":"Key Terms","text":"Pharmacokinetics: study body affects drug (ADME)Therapeutic Drug Monitoring (TDM): Measurement drug concentrations optimize therapyDisease State: specific medical condition disorderDrug Interaction: interaction two drugs can affect ADMERenal Clearance: rate drug removed body kidneysHepatic Metabolism: process liver chemically alters drugVolume Distribution (Vd): Apparent space body available contain drugProtein Binding: degree drug binds plasma proteinsGenetic Polymorphism: Variation DNA sequence among individualsCytochrome P450 (CYP) Enzymes: superfamily heme-containing monooxygenasesMalabsorption: Impaired absorption nutrients gastrointestinal tract","code":""},{"path":"toxicology.html","id":"toxicology","chapter":"Toxicology","heading":"Toxicology","text":"section covers key components toxicology","code":""},{"path":"toxicology.html","id":"biochemical-theory-and-pathways-8","chapter":"Toxicology","heading":"Biochemical Theory and Pathways","text":"Toxicokinetics: body handles toxins (ADME processes)\nAbsorption: Entry body\nDistribution: Transport tissues\nMetabolism: Chemical alteration (detoxification bioactivation)\nExcretion: Elimination body\nAbsorption: Entry bodyDistribution: Transport tissuesMetabolism: Chemical alteration (detoxification bioactivation)Excretion: Elimination bodyMechanisms Toxicity\nCellular damage, enzyme inhibition, oxidative stress, etc\nCellular damage, enzyme inhibition, oxidative stress, etcTarget Organs\nSpecific organs vulnerable certain toxins\nLiver, kidneys, brain, lungs, heart\nSpecific organs vulnerable certain toxinsLiver, kidneys, brain, lungs, heartDose-Response Relationship\nHigher doses generally cause severe effects\nHigher doses generally cause severe effects","code":""},{"path":"toxicology.html","id":"laboratory-test-procedures-10","chapter":"Toxicology","heading":"Laboratory Test Procedures","text":"Analytical Principles\nImmunoassays: Antibody-antigen binding screening\nChromatography: Separates compounds\nMass Spectrometry: Identifies compounds mass\nAtomic Absorption Spectrometry: Measures light absorption atoms\nImmunoassays: Antibody-antigen binding screeningChromatography: Separates compoundsMass Spectrometry: Identifies compounds massAtomic Absorption Spectrometry: Measures light absorption atomsCommon Assays\nDrugs abuse screens\nAlcohol levels\nHeavy metal analysis\nSpecific drug assays\nDrugs abuse screensAlcohol levelsHeavy metal analysisSpecific drug assaysSpecial Precautions\nChain custody, proper storage, quality control\nChain custody, proper storage, quality control","code":""},{"path":"toxicology.html","id":"test-result-interpretation-10","chapter":"Toxicology","heading":"Test Result Interpretation","text":"Quantitative vs. Qualitative Results\nQualitative: Positive/negative\nQuantitative: Numerical concentration\nQualitative: Positive/negativeQuantitative: Numerical concentrationCutoff Values\nThreshold positive results\nThreshold positive resultsReference Intervals\nLimited toxicology (therapeutic ranges drugs)\nLimited toxicology (therapeutic ranges drugs)Analytical Considerations\nCross-reactivity, interfering substances\nCross-reactivity, interfering substancesClinical Correlation\nPatient history, symptoms, medications\nPatient history, symptoms, medications","code":""},{"path":"toxicology.html","id":"disease-state-correlation-10","chapter":"Toxicology","heading":"Disease State Correlation","text":"Liver Disease: Impairs metabolismRenal Disease: Impairs excretionHeart Failure: Alters distributionPulmonary Disease: Affects inhalationNutritional Deficiencies: Increases susceptibilityGenetic Factors: Influence metabolism","code":""},{"path":"toxicokinetics.html","id":"toxicokinetics","chapter":"Toxicokinetics","heading":"Toxicokinetics","text":"section covers key components toxicokinetics","code":""},{"path":"toxicokinetics.html","id":"toxicokinetics-1","chapter":"Toxicokinetics","heading":"Toxicokinetics","text":"Definition: study kinetics toxic substances body, focusing ADME processesPurpose: understand body handles toxic substances, predict distribution effects, guide treatment strategies","code":""},{"path":"toxicokinetics.html","id":"toxic-effects-signs-and-symptoms","chapter":"Toxicokinetics","heading":"Toxic Effects, Signs, and Symptoms","text":"Dose-Response Relationship\nDescribes relationship amount exposure toxic substance severity effects\nDescribes relationship amount exposure toxic substance severity effectsTarget Organs\ntoxins selectively target specific organs\ntoxins selectively target specific organsMechanisms Toxicity\nCellular necrosis, apoptosis, oxidative stress, mitochondrial dysfunction, inflammation, neurotoxicity, carcinogenesis, teratogenesis\nCellular necrosis, apoptosis, oxidative stress, mitochondrial dysfunction, inflammation, neurotoxicity, carcinogenesis, teratogenesisSigns Symptoms\nVary based substance, exposure route, individual factors\nVary based substance, exposure route, individual factorsCommon Toxic Syndromes (Toxidromes)\nCholinergic, anticholinergic, sympathomimetic, opioid, sedative-hypnotic\nCholinergic, anticholinergic, sympathomimetic, opioid, sedative-hypnotic","code":""},{"path":"toxicokinetics.html","id":"metabolism-and-excretion-1","chapter":"Toxicokinetics","heading":"Metabolism and Excretion","text":"Metabolism (Biotransformation)\nProcess body chemically alters toxins\nPrimary site: Liver\nPurpose: Detoxification (convert less harmful) bioactivation (convert harmful)\nPhases:\nPhase : Oxidation, reduction, hydrolysis (CYP enzymes)\nPhase II: Conjugation (glucuronidation, sulfation, etc.)\n\nFactors Affecting Metabolism:\nGenetics, age, liver kidney function, drug interactions\n\nProcess body chemically alters toxinsPrimary site: LiverPurpose: Detoxification (convert less harmful) bioactivation (convert harmful)Phases:\nPhase : Oxidation, reduction, hydrolysis (CYP enzymes)\nPhase II: Conjugation (glucuronidation, sulfation, etc.)\nPhase : Oxidation, reduction, hydrolysis (CYP enzymes)Phase II: Conjugation (glucuronidation, sulfation, etc.)Factors Affecting Metabolism:\nGenetics, age, liver kidney function, drug interactions\nGenetics, age, liver kidney function, drug interactionsExcretion\nProcess body eliminates toxins\nPrimary Routes:\nKidneys (urine)\nLiver (bile)\n\nRenal Excretion:\nGlomerular filtration, tubular secretion, tubular reabsorption\n\nFactors Affecting Excretion:\nRenal liver function, pH\n\nProcess body eliminates toxinsPrimary Routes:\nKidneys (urine)\nLiver (bile)\nKidneys (urine)Liver (bile)Renal Excretion:\nGlomerular filtration, tubular secretion, tubular reabsorption\nGlomerular filtration, tubular secretion, tubular reabsorptionFactors Affecting Excretion:\nRenal liver function, pH\nRenal liver function, pH","code":""},{"path":"toxicokinetics.html","id":"clinical-significance-15","chapter":"Toxicokinetics","heading":"Clinical Significance","text":"Understanding Toxicokinetics Helps \nPredicting toxicity substances\nAssessing individual susceptibility toxic effects\nDeveloping effective treatments poisoning\nDesigning strategies preventing exposure toxic substances\nPredicting toxicity substancesAssessing individual susceptibility toxic effectsDeveloping effective treatments poisoningDesigning strategies preventing exposure toxic substances","code":""},{"path":"toxic-effects.html","id":"toxic-effects","chapter":"Toxic Effects","heading":"Toxic Effects","text":"Understanding relationship toxicokinetics toxic effects, signs, symptoms crucial effective clinical toxicology. Toxicokinetics describes substance moves body, understanding clinical manifestations toxicity aids diagnosis treatment","code":""},{"path":"toxic-effects.html","id":"toxicokinetics-what-the-body-does-to-the-toxin","chapter":"Toxic Effects","heading":"Toxicokinetics: What the Body Does to the Toxin","text":"Definition: study movement toxic substances within body, encompassing absorption, distribution, metabolism, excretion (ADME)Relationship Pharmacokinetics: Toxicokinetics essentially study pharmacokinetics applied toxic substances, providing insights body handles compounds","code":""},{"path":"toxic-effects.html","id":"absorption-1","chapter":"Toxic Effects","heading":"Absorption","text":"Definition: process toxic substance enters bodyRoutes Exposure\nIngestion: Oral intake toxic substance\nInhalation: Breathing toxic gases, vapors, particulate matter\nDermal Absorption: Absorption skin\nInjection: Introduction directly bloodstream tissues\nMucosal Absorption: Absorption mucous membranes (e.g., nasal, oral, rectal)\nIngestion: Oral intake toxic substanceInhalation: Breathing toxic gases, vapors, particulate matterDermal Absorption: Absorption skinInjection: Introduction directly bloodstream tissuesMucosal Absorption: Absorption mucous membranes (e.g., nasal, oral, rectal)Factors Affecting Absorption\nRoute Exposure: Intravenous (IV) exposure 100% bioavailability\nPhysicochemical Properties\nMolecular weight, lipophilicity, ionization affect ease substance crosses biological membranes\n\nConcentration: Higher concentrations increase absorption rates\nSurface Area: Larger surface areas (e.g., lungs, small intestine) enhance absorption\nBlood Flow: Increased blood flow absorption site increases absorption rates\nPhysiological Factors: Gastric emptying time, intestinal motility, skin integrity influence absorption rates\nRoute Exposure: Intravenous (IV) exposure 100% bioavailabilityPhysicochemical Properties\nMolecular weight, lipophilicity, ionization affect ease substance crosses biological membranes\nMolecular weight, lipophilicity, ionization affect ease substance crosses biological membranesConcentration: Higher concentrations increase absorption ratesSurface Area: Larger surface areas (e.g., lungs, small intestine) enhance absorptionBlood Flow: Increased blood flow absorption site increases absorption ratesPhysiological Factors: Gastric emptying time, intestinal motility, skin integrity influence absorption rates","code":""},{"path":"toxic-effects.html","id":"distribution-1","chapter":"Toxic Effects","heading":"Distribution","text":"Definition: process toxic substance transported bloodstream various tissues organs bodyFactors Affecting Distribution\nBlood Flow: Highly perfused organs (brain, heart, liver, kidneys) receive toxic substance rapidly\nTissue Permeability\nLipid-soluble substances can easily cross cell membranes\nWater-soluble substances may require transport proteins\n\nProtein Binding: Binding toxic substances plasma proteins (albumin, alpha-1-acid glycoprotein)\nunbound (free) substance can exert toxic effects\nSubstances high protein binding limited distribution\n\nVolume Distribution (Vd): measure apparent space body available contain toxic substance\nVd = Amount Substance Body / Plasma Concentration\nHigh Vd: Indicates extensive tissue distribution\nLow Vd: Indicates limited tissue distribution\n\nTissue Binding: Accumulation toxic substances specific tissues (e.g., lead bone, DDT adipose tissue)\nBlood Flow: Highly perfused organs (brain, heart, liver, kidneys) receive toxic substance rapidlyTissue Permeability\nLipid-soluble substances can easily cross cell membranes\nWater-soluble substances may require transport proteins\nLipid-soluble substances can easily cross cell membranesWater-soluble substances may require transport proteinsProtein Binding: Binding toxic substances plasma proteins (albumin, alpha-1-acid glycoprotein)\nunbound (free) substance can exert toxic effects\nSubstances high protein binding limited distribution\nunbound (free) substance can exert toxic effectsSubstances high protein binding limited distributionVolume Distribution (Vd): measure apparent space body available contain toxic substance\nVd = Amount Substance Body / Plasma Concentration\nHigh Vd: Indicates extensive tissue distribution\nLow Vd: Indicates limited tissue distribution\nVd = Amount Substance Body / Plasma ConcentrationHigh Vd: Indicates extensive tissue distributionLow Vd: Indicates limited tissue distributionTissue Binding: Accumulation toxic substances specific tissues (e.g., lead bone, DDT adipose tissue)Barriers Distribution\nBlood-Brain Barrier (BBB): Protects brain many toxic substances\nPlacental Barrier: Protects fetus , , toxic substances\nBlood-Brain Barrier (BBB): Protects brain many toxic substancesPlacental Barrier: Protects fetus , , toxic substances","code":""},{"path":"toxic-effects.html","id":"metabolism-1","chapter":"Toxic Effects","heading":"Metabolism","text":"Definition: process body chemically alters toxic substance, often facilitate eliminationPrimary Site: LiverOther Sites: Kidneys, intestines, lungs, plasmaPhases Metabolism\nPhase Reactions: Introduce expose functional group toxic substance molecule\nOxidation, reduction, hydrolysis\nEnzymes: Cytochrome P450 (CYP) enzymes, flavin-containing monooxygenases (FMOs)\n\nPhase II Reactions: Conjugate polar molecule toxic substance molecule\nGlucuronidation, sulfation, acetylation, glutathione conjugation\nEnzymes: UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs)\n\nPhase Reactions: Introduce expose functional group toxic substance molecule\nOxidation, reduction, hydrolysis\nEnzymes: Cytochrome P450 (CYP) enzymes, flavin-containing monooxygenases (FMOs)\nOxidation, reduction, hydrolysisEnzymes: Cytochrome P450 (CYP) enzymes, flavin-containing monooxygenases (FMOs)Phase II Reactions: Conjugate polar molecule toxic substance molecule\nGlucuronidation, sulfation, acetylation, glutathione conjugation\nEnzymes: UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs)\nGlucuronidation, sulfation, acetylation, glutathione conjugationEnzymes: UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs)Activation vs. Detoxification\nDetoxification: Metabolism can convert toxic substances less harmful metabolites\nActivation: Metabolism can convert relatively harmless substances toxic metabolites (bioactivation)\nDetoxification: Metabolism can convert toxic substances less harmful metabolitesActivation: Metabolism can convert relatively harmless substances toxic metabolites (bioactivation)Factors Affecting Metabolism\nGenetic Factors: Genetic polymorphisms drug-metabolizing enzymes can affect rate metabolism\nAge: Infants elderly individuals may reduced metabolic capacity\nDisease States: Liver disease can impair metabolism\nDrug Interactions: Enzyme inducers inhibitors can affect metabolism substances\nGenetic Factors: Genetic polymorphisms drug-metabolizing enzymes can affect rate metabolismAge: Infants elderly individuals may reduced metabolic capacityDisease States: Liver disease can impair metabolismDrug Interactions: Enzyme inducers inhibitors can affect metabolism substances","code":""},{"path":"toxic-effects.html","id":"excretion-1","chapter":"Toxic Effects","heading":"Excretion","text":"Definition: process body eliminates toxic substance metabolitesPrimary Routes\nKidneys: toxic substances excreted urine\nGlomerular filtration, tubular secretion, tubular reabsorption\n\nLiver: toxic substances excreted bile eliminated feces\nKidneys: toxic substances excreted urine\nGlomerular filtration, tubular secretion, tubular reabsorption\nGlomerular filtration, tubular secretion, tubular reabsorptionLiver: toxic substances excreted bile eliminated fecesOther Routes: Lungs, sweat, saliva, breast milkFactors Affecting Excretion\nRenal Function: Glomerular filtration rate (GFR), tubular secretion, tubular reabsorption affect renal excretion\nLiver Function: Bile flow hepatic metabolism affect biliary excretion\nSubstance Properties: Molecular size, ionization, protein binding affect excretion\nUrine pH: Can affect excretion weak acids bases\nRenal Function: Glomerular filtration rate (GFR), tubular secretion, tubular reabsorption affect renal excretionLiver Function: Bile flow hepatic metabolism affect biliary excretionSubstance Properties: Molecular size, ionization, protein binding affect excretionUrine pH: Can affect excretion weak acids basesClearance (CL): measure body’s ability eliminate toxic substance\nCL = Rate Elimination / Plasma Concentration\nCL = Rate Elimination / Plasma Concentration","code":""},{"path":"toxic-effects.html","id":"toxic-effects-signs-and-symptoms-what-the-toxin-does-to-the-body","chapter":"Toxic Effects","heading":"Toxic Effects, Signs, and Symptoms: What the Toxin Does to the Body","text":"Dose-Response Relationship: severity toxic effects generally related dose toxic substanceTarget Organs: Toxic substances can selectively target specific organs tissues (e.g., liver, kidneys, brain)Mechanisms Toxicity: Toxic substances can cause damage various mechanisms, including:\nCellular Necrosis: Cell death\nApoptosis: Programmed cell death\nOxidative Stress: Damage caused free radicals\nMitochondrial Dysfunction: Disruption energy production\nInflammation: Activation immune system\nNeurotoxicity: Damage nervous system\nCarcinogenesis: Cancer development\nTeratogenesis: Birth defects\nCellular Necrosis: Cell deathApoptosis: Programmed cell deathOxidative Stress: Damage caused free radicalsMitochondrial Dysfunction: Disruption energy productionInflammation: Activation immune systemNeurotoxicity: Damage nervous systemCarcinogenesis: Cancer developmentTeratogenesis: Birth defectsSigns Symptoms: clinical manifestations toxicity vary depending toxic substance, dose, route exposure, individual factorsCommon Toxic Syndromes (Toxidromes): group signs symptoms associated particular class toxic substances\nCholinergic Toxidrome: Associated exposure organophosphates, carbamates, cholinergic agents\nSymptoms: Salivation, lacrimation, urination, defecation, gastrointestinal distress, emesis (SLUDGE)\n\nAnticholinergic Toxidrome: Associated exposure anticholinergic medications plants\nSymptoms: Dry mouth, blurred vision, dilated pupils, urinary retention, constipation, tachycardia, delirium\n\nSympathomimetic Toxidrome: Associated exposure stimulants cocaine, amphetamines, caffeine\nSymptoms: Tachycardia, hypertension, diaphoresis, agitation, tremor, seizures\n\nOpioid Toxidrome: Associated exposure opioid medications\nSymptoms: Respiratory depression, miosis (pinpoint pupils), altered mental status\n\nSedative-Hypnotic Toxidrome: Associated exposure benzodiazepines, barbiturates, sedatives\nSymptoms: Sedation, altered mental status, slurred speech, ataxia, respiratory depression\n\nCholinergic Toxidrome: Associated exposure organophosphates, carbamates, cholinergic agents\nSymptoms: Salivation, lacrimation, urination, defecation, gastrointestinal distress, emesis (SLUDGE)\nSymptoms: Salivation, lacrimation, urination, defecation, gastrointestinal distress, emesis (SLUDGE)Anticholinergic Toxidrome: Associated exposure anticholinergic medications plants\nSymptoms: Dry mouth, blurred vision, dilated pupils, urinary retention, constipation, tachycardia, delirium\nSymptoms: Dry mouth, blurred vision, dilated pupils, urinary retention, constipation, tachycardia, deliriumSympathomimetic Toxidrome: Associated exposure stimulants cocaine, amphetamines, caffeine\nSymptoms: Tachycardia, hypertension, diaphoresis, agitation, tremor, seizures\nSymptoms: Tachycardia, hypertension, diaphoresis, agitation, tremor, seizuresOpioid Toxidrome: Associated exposure opioid medications\nSymptoms: Respiratory depression, miosis (pinpoint pupils), altered mental status\nSymptoms: Respiratory depression, miosis (pinpoint pupils), altered mental statusSedative-Hypnotic Toxidrome: Associated exposure benzodiazepines, barbiturates, sedatives\nSymptoms: Sedation, altered mental status, slurred speech, ataxia, respiratory depression\nSymptoms: Sedation, altered mental status, slurred speech, ataxia, respiratory depression","code":""},{"path":"toxic-effects.html","id":"specific-examples-of-toxic-substances-and-their-effects","chapter":"Toxic Effects","heading":"Specific Examples of Toxic Substances and Their Effects","text":"","code":""},{"path":"toxic-effects.html","id":"key-terms-85","chapter":"Toxic Effects","heading":"Key Terms","text":"Toxicokinetics: study toxic substance moves body (ADME)Absorption: process toxic substance enters bodyDistribution: process toxic substance transported tissuesMetabolism: process body chemically alters toxic substanceExcretion: process body eliminates toxic substanceVolume Distribution (Vd): measure apparent space body available contain toxic substanceClearance (CL): measure body’s efficiency eliminating toxic substanceToxidrome: group signs symptoms associated particular class toxic substancesDose-Response Relationship: relationship dose toxic substance severity effectsTarget Organ: organ tissue affected toxic substanceMechanism Toxicity: way toxic substance causes damageSigns: Objective evidence disease conditionSymptoms: Subjective evidence disease conditionCellular Necrosis: Cell deathApoptosis: Programmed cell deathOxidative Stress: Damage caused free radicalsMitochondrial Dysfunction: Disruption energy productionInflammation: Activation immune systemNeurotoxicity: Damage nervous systemCarcinogenesis: Cancer developmentTeratogenesis: Birth defectsBioactivation: Metabolic activation substance become toxic","code":""},{"path":"metabolism-excretion-1.html","id":"metabolism-excretion-1","chapter":"Metabolism, Excretion","heading":"Metabolism, Excretion","text":"Understanding processes metabolism excretion crucial toxicology","code":""},{"path":"metabolism-excretion-1.html","id":"drug-metabolism-1","chapter":"Metabolism, Excretion","heading":"Drug Metabolism","text":"Definition: process body chemically alters toxic substance, often facilitate eliminationPrimary Site Metabolism: LiverOther Sites: Kidneys, intestines, lungs, plasmaPurpose Metabolism\nConvert lipid-soluble toxic substances water-soluble metabolites, facilitating excretion urine\nDetoxify converting toxic substances less harmful metabolites\nBioactivation: Convert relatively harmless substances toxic metabolites\nConvert lipid-soluble toxic substances water-soluble metabolites, facilitating excretion urineDetoxify converting toxic substances less harmful metabolitesBioactivation: Convert relatively harmless substances toxic metabolitesPhases Metabolism\nPhase Reactions: Introduce expose functional group toxic substance molecule oxidation, reduction, hydrolysis\nPhase II Reactions: Conjugate polar molecule toxic substance molecule, glucuronic acid, sulfate, glutathione\nPhase Reactions: Introduce expose functional group toxic substance molecule oxidation, reduction, hydrolysisPhase II Reactions: Conjugate polar molecule toxic substance molecule, glucuronic acid, sulfate, glutathione","code":""},{"path":"metabolism-excretion-1.html","id":"phase-i-metabolism-1","chapter":"Metabolism, Excretion","heading":"Phase I Metabolism","text":"Oxidation\nAddition oxygen removal hydrogen atoms toxic substance molecule\nEnzymes involved: Cytochrome P450 (CYP) enzymes\nExamples reactions: Hydroxylation, epoxidation, N-oxidation, S-oxidation\nAddition oxygen removal hydrogen atoms toxic substance moleculeEnzymes involved: Cytochrome P450 (CYP) enzymesExamples reactions: Hydroxylation, epoxidation, N-oxidation, S-oxidationReduction\nAddition hydrogen atoms electrons toxic substance molecule\nEnzymes involved: Reductases\nExamples reactions: Reduction nitro groups, azo groups, carbonyl groups\nAddition hydrogen atoms electrons toxic substance moleculeEnzymes involved: ReductasesExamples reactions: Reduction nitro groups, azo groups, carbonyl groupsHydrolysis\nAddition water break chemical bond\nEnzymes involved: Esterases, amidases, peptidases\nExamples reactions: Hydrolysis esters, amides, peptides\nAddition water break chemical bondEnzymes involved: Esterases, amidases, peptidasesExamples reactions: Hydrolysis esters, amides, peptides","code":""},{"path":"metabolism-excretion-1.html","id":"phase-ii-metabolism-1","chapter":"Metabolism, Excretion","heading":"Phase II Metabolism","text":"Glucuronidation\nAddition glucuronic acid toxic substance molecule\nEnzymes involved: UDP-glucuronosyltransferases (UGTs)\nResults highly water-soluble metabolites easily excreted urine\nAddition glucuronic acid toxic substance moleculeEnzymes involved: UDP-glucuronosyltransferases (UGTs)Results highly water-soluble metabolites easily excreted urineSulfation\nAddition sulfate group toxic substance molecule\nEnzymes involved: Sulfotransferases (SULTs)\nResults water-soluble metabolites easily excreted urine\nAddition sulfate group toxic substance moleculeEnzymes involved: Sulfotransferases (SULTs)Results water-soluble metabolites easily excreted urineAcetylation\nAddition acetyl group toxic substance molecule\nEnzymes involved: N-acetyltransferases (NATs)\nGenetic polymorphisms NAT enzymes can affect metabolism toxic substances\nAddition acetyl group toxic substance moleculeEnzymes involved: N-acetyltransferases (NATs)Genetic polymorphisms NAT enzymes can affect metabolism toxic substancesGlutathione Conjugation\nAddition glutathione toxic substance molecule\nEnzymes involved: Glutathione S-transferases (GSTs)\nImportant detoxifying reactive metabolites, formed acetaminophen metabolism\nAddition glutathione toxic substance moleculeEnzymes involved: Glutathione S-transferases (GSTs)Important detoxifying reactive metabolites, formed acetaminophen metabolismMethylation\nAddition methyl group toxic substance molecule\nEnzymes involved: Methyltransferases\nCan either activate inactivate drugs\nAddition methyl group toxic substance moleculeEnzymes involved: MethyltransferasesCan either activate inactivate drugs","code":""},{"path":"metabolism-excretion-1.html","id":"cytochrome-p450-cyp-enzymes-1","chapter":"Metabolism, Excretion","heading":"Cytochrome P450 (CYP) Enzymes","text":"Definition: superfamily heme-containing monooxygenases catalyze oxidation many drugs, toxins, endogenous compoundsLocation: Primarily liver, also present tissuesImportance Toxicology: Responsible metabolism many toxic substancesKey CYP Enzymes\nCYP3A4: Metabolizes largest number drugs toxins\nCYP2D6: Metabolizes many psychiatric cardiovascular drugs\nCYP2C9: Metabolizes nonsteroidal anti-inflammatory drugs (NSAIDs) warfarin\nCYP2E1: Metabolizes ethanol, acetaminophen, volatile organic compounds\nCYP3A4: Metabolizes largest number drugs toxinsCYP2D6: Metabolizes many psychiatric cardiovascular drugsCYP2C9: Metabolizes nonsteroidal anti-inflammatory drugs (NSAIDs) warfarinCYP2E1: Metabolizes ethanol, acetaminophen, volatile organic compounds","code":""},{"path":"metabolism-excretion-1.html","id":"factors-affecting-drug-metabolism-1","chapter":"Metabolism, Excretion","heading":"Factors Affecting Drug Metabolism","text":"Genetic Factors\nGenetic polymorphisms drug-metabolizing enzymes can affect rate metabolism\nIndividuals can classified poor metabolizers, intermediate metabolizers, extensive metabolizers, ultra-rapid metabolizers\nGenetic polymorphisms drug-metabolizing enzymes can affect rate metabolismIndividuals can classified poor metabolizers, intermediate metabolizers, extensive metabolizers, ultra-rapid metabolizersAge\nInfants immature metabolic enzyme systems\nElderly individuals may decreased liver function reduced enzyme activity\nInfants immature metabolic enzyme systemsElderly individuals may decreased liver function reduced enzyme activityDisease States\nLiver disease: Reduces metabolic enzyme activity\nKidney disease: Affects drug clearance can lead drug accumulation\nLiver disease: Reduces metabolic enzyme activityKidney disease: Affects drug clearance can lead drug accumulationDrug Interactions\nEnzyme Inducers: Increase activity metabolizing enzymes, leading decreased levels toxicant\nEnzyme Inhibitors: Decrease activity metabolizing enzymes, leading increased levels toxicant\nEnzyme Inducers: Increase activity metabolizing enzymes, leading decreased levels toxicantEnzyme Inhibitors: Decrease activity metabolizing enzymes, leading increased levels toxicantDiet Environmental Factors\nGrapefruit juice: Inhibits CYP3A4\nSmoking: Induces CYP1A2\nGrapefruit juice: Inhibits CYP3A4Smoking: Induces CYP1A2Gender\nDifferences hormone levels body composition can affect drug metabolism\nDifferences hormone levels body composition can affect drug metabolism","code":""},{"path":"metabolism-excretion-1.html","id":"excretion-2","chapter":"Metabolism, Excretion","heading":"Excretion","text":"Definition: process body eliminates toxic substance metabolitesPrimary Routes Excretion\nKidneys: toxic substances excreted urine\nLiver: toxic substances excreted bile eliminated feces\nKidneys: toxic substances excreted urineLiver: toxic substances excreted bile eliminated fecesOther Routes: Lungs, sweat, saliva, breast milkRenal Excretion\nGlomerular Filtration: Toxic substances small molecules filtered blood renal tubules\nunbound (free) substance can filtered\n\nTubular Secretion: Active transport toxic substances blood renal tubules\nCan affected drug interactions\n\nTubular Reabsorption: Passive active transport toxic substances renal tubules back blood\nLipid-soluble toxic substances readily reabsorbed\nUrine pH can affect reabsorption weak acids bases\n\nGlomerular Filtration: Toxic substances small molecules filtered blood renal tubules\nunbound (free) substance can filtered\nunbound (free) substance can filteredTubular Secretion: Active transport toxic substances blood renal tubules\nCan affected drug interactions\nCan affected drug interactionsTubular Reabsorption: Passive active transport toxic substances renal tubules back blood\nLipid-soluble toxic substances readily reabsorbed\nUrine pH can affect reabsorption weak acids bases\nLipid-soluble toxic substances readily reabsorbedUrine pH can affect reabsorption weak acids basesBiliary Excretion\nToxic substances metabolites transported liver bile\nBile secreted small intestine eliminated feces\ntoxic substances undergo enterohepatic circulation, reabsorbed intestine back blood\nToxic substances metabolites transported liver bileBile secreted small intestine eliminated fecesSome toxic substances undergo enterohepatic circulation, reabsorbed intestine back bloodClearance (CL)\nmeasure body’s efficiency eliminating toxic substance body\nTotal Clearance: Sum clearance pathways (renal, hepatic, )\nRenal Clearance: volume plasma toxic substance completely removed kidneys per unit time\nHepatic Clearance: volume plasma toxic substance completely removed liver per unit time\nmeasure body’s efficiency eliminating toxic substance bodyTotal Clearance: Sum clearance pathways (renal, hepatic, )Renal Clearance: volume plasma toxic substance completely removed kidneys per unit timeHepatic Clearance: volume plasma toxic substance completely removed liver per unit timeFactors Affecting Excretion\nRenal Function: Glomerular filtration rate (GFR), tubular secretion, tubular reabsorption affect renal excretion\nLiver Function: Bile flow hepatic metabolism affect biliary excretion\nSubstance Properties: Molecular size, ionization, protein binding affect excretion\nDrug Interactions: drugs can affect excretion substances\nUrine pH: Can influence excretion weak acids bases\nRenal Function: Glomerular filtration rate (GFR), tubular secretion, tubular reabsorption affect renal excretionLiver Function: Bile flow hepatic metabolism affect biliary excretionSubstance Properties: Molecular size, ionization, protein binding affect excretionDrug Interactions: drugs can affect excretion substancesUrine pH: Can influence excretion weak acids bases","code":""},{"path":"metabolism-excretion-1.html","id":"clinical-significance-16","chapter":"Metabolism, Excretion","heading":"Clinical Significance","text":"Understanding Metabolism Excretion Crucial \nPredicting toxicity substances\nAssessing individual susceptibility toxic effects\nDeveloping effective treatments poisoning\nDesigning strategies preventing exposure toxic substances\nPredicting toxicity substancesAssessing individual susceptibility toxic effectsDeveloping effective treatments poisoningDesigning strategies preventing exposure toxic substancesAltered Drug Metabolism Can Affect Toxicity\n* Enzyme inducers can decrease toxicant concentrations\n* Enzyme inhibitors can increase toxicant concentrationsPharmacogenomics\nGenetic testing can determine specific treatment detox remove substance system\nGenetic testing can determine specific treatment detox remove substance systemDosage Adjustments Patients Renal Hepatic Impairment\n* Knowing kidney liver capabilities allow proper dosage adjustmentsTherapeutic Drug Monitoring (TDM)\n* drugs may used treatments","code":""},{"path":"metabolism-excretion-1.html","id":"key-terms-86","chapter":"Metabolism, Excretion","heading":"Key Terms","text":"Drug Metabolism: process body chemically alters drugEnzyme Induction: Increased activity drug-metabolizing enzymesEnzyme Inhibition: Decreased activity drug-metabolizing enzymesCytochrome P450 (CYP) Enzymes: superfamily heme-containing monooxygenasesProdrug: inactive drug metabolized active metaboliteDrug Excretion: process body eliminates drug metabolitesGlomerular Filtration: process drugs small molecules filtered blood renal tubulesTubular Secretion: active transport drugs blood renal tubulesTubular Reabsorption: transport drugs renal tubules back bloodBiliary Excretion: excretion drugs metabolites liver bileEnterohepatic Circulation: reabsorption drugs intestine back bloodClearance (CL): measure body’s efficiency eliminating drug bodyDrug-Drug Interactions (DDIs): interactions two drugs can affect absorption, distribution, metabolism, excretionPharmacogenomics: study genes affect person’s response drugsGenetic Polymorphism: Variation DNA sequence among individualsBioactivation: Metabolic activation substance become toxic","code":""},{"path":"properties-9.html","id":"properties-9","chapter":"Properties","heading":"Properties","text":"section covers chemical physical properties key substance classes toxicology","code":""},{"path":"properties-9.html","id":"alcohols","chapter":"Properties","heading":"Alcohols","text":"Definition: Organic compounds characterized one hydroxyl (-OH) groupsExamples: Methanol, ethanol, isopropanol, ethylene glycol, propylene glycolKey Properties\nPolarity: hydroxyl group makes alcohols polar\nSolubility: Short-chain alcohols miscible water; solubility decreases increasing carbon chain length\nBoiling Point: Increases increasing molecular weight hydrogen bonding\nFlammability: Alcohols flammable\nPolarity: hydroxyl group makes alcohols polarSolubility: Short-chain alcohols miscible water; solubility decreases increasing carbon chain lengthBoiling Point: Increases increasing molecular weight hydrogen bondingFlammability: Alcohols flammableToxicokinetics\nRapid absorption\nMetabolism: Alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH)\nExcretion: Urine lungs\nRapid absorptionMetabolism: Alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH)Excretion: Urine lungsToxic Effects\nCNS depression, metabolic acidosis, organ damage\nCNS depression, metabolic acidosis, organ damage","code":""},{"path":"properties-9.html","id":"heavy-metals-e.g.-lead","chapter":"Properties","heading":"Heavy Metals (e.g., Lead)","text":"Definition: Metallic elements relatively high densities toxic low concentrationsExamples: Lead (Pb), mercury (Hg), arsenic (), cadmium (Cd)Key Properties\nMetallic Bonding: Good electrical thermal conductivity\nVariable Oxidation States: Can exist multiple oxidation states\nComplex Formation: Tendency form complexes biological molecules\nHigh Density\nMetallic Bonding: Good electrical thermal conductivityVariable Oxidation States: Can exist multiple oxidation statesComplex Formation: Tendency form complexes biological moleculesHigh DensityToxicokinetics\nAbsorption: Varies based metal route\nDistribution: Accumulation specific tissues (e.g., bone, kidneys)\nMetabolism: undergo biotransformation\nExcretion: Primarily urine feces\nAbsorption: Varies based metal routeDistribution: Accumulation specific tissues (e.g., bone, kidneys)Metabolism: undergo biotransformationExcretion: Primarily urine fecesToxic Effects\nEnzyme inhibition, oxidative stress, organ damage, neurological effects\nEnzyme inhibition, oxidative stress, organ damage, neurological effects","code":""},{"path":"properties-9.html","id":"analgesics-e.g.-acetaminophen","chapter":"Properties","heading":"Analgesics (e.g., Acetaminophen)","text":"Definition: Medications used relieve painExamples: Acetaminophen, NSAIDs, OpioidsKey Properties\nStructural Diversity: Wide range chemical classes\nFunctional Groups: Hydroxyl, amino, carbonyl, carboxyl\nSolubility: Varies depending specific drug\nAcidic Basic Character\nStructural Diversity: Wide range chemical classesFunctional Groups: Hydroxyl, amino, carbonyl, carboxylSolubility: Varies depending specific drugAcidic Basic CharacterToxicokinetics\nVariable absorption distribution\nMetabolism: Liver (CYP enzymes)\nExcretion: Urine\nVariable absorption distributionMetabolism: Liver (CYP enzymes)Excretion: UrineToxic Effects\nLiver damage, gastrointestinal effects, respiratory depression\nLiver damage, gastrointestinal effects, respiratory depression","code":""},{"path":"properties-9.html","id":"drugs-of-abuse","chapter":"Properties","heading":"Drugs of Abuse","text":"Definition: Substances used non-medical purposes, often psychoactive effects, can lead dependence addictionExamples: Opioids, stimulants, cannabinoids, hallucinogens, depressantsKey Properties\nStructural Diversity: Wide range chemical classes\nPsychoactive Effects: Alter mood, perception, cognition\nLipophilicity: Many lipophilic\nSolubility: Variable\nStructural Diversity: Wide range chemical classesPsychoactive Effects: Alter mood, perception, cognitionLipophilicity: Many lipophilicSolubility: VariableToxicokinetics\nVariable absorption, distribution, metabolism, excretion depending drug\nVariable absorption, distribution, metabolism, excretion depending drugToxic Effects\nDependence, addiction, organ damage, neurological cardiovascular effects |\nDependence, addiction, organ damage, neurological cardiovascular effects |","code":""},{"path":"properties-9.html","id":"clinical-significance-17","chapter":"Properties","heading":"Clinical Significance","text":"Analytical Method Selection: Physical chemical properties influence choice analytical methodsToxic Effects: properties influence substances absorbed, distributed, metabolized, excreted, interact biological systems, ultimately affecting toxicitySample Preparation: Understanding properties helps optimize sample preparationExposure Assessment Risk Evaluation: Knowing sources fate chemicals important assessing exposure risks","code":""},{"path":"alcohols-1.html","id":"alcohols-1","chapter":"Alcohols","heading":"Alcohols","text":"Understanding chemical physical properties alcohols crucial toxicology","code":""},{"path":"alcohols-1.html","id":"general-properties-of-alcohols","chapter":"Alcohols","heading":"General Properties of Alcohols","text":"Definition: Organic compounds characterized presence one hydroxyl (\\(-OH\\)) groups attached carbon atomNomenclature: Named adding suffix “-ol” parent alkane name (e.g., methanol, ethanol)Classification: Alcohols can classified primary, secondary, tertiary, depending number carbon atoms bonded carbon atom bearing hydroxyl groupHydrogen Bonding: presence hydroxyl group allows alcohols form hydrogen bonds molecules, including water","code":""},{"path":"alcohols-1.html","id":"chemical-properties-of-alcohols","chapter":"Alcohols","heading":"Chemical Properties of Alcohols","text":"Polarity: hydroxyl group makes alcohols polar moleculesAcidity: Alcohols weakly acidic due ability hydroxyl group donate proton (\\(H^+\\))Reactivity: Alcohols undergo various chemical reactions, including:\nOxidation: Alcohols can oxidized aldehydes, ketones, carboxylic acids, depending alcohol oxidizing agent\nEsterification: Alcohols react carboxylic acids form esters\nDehydration: Alcohols can dehydrated form alkenes\nEther Formation: Alcohols react alcohols form ethers\nOxidation: Alcohols can oxidized aldehydes, ketones, carboxylic acids, depending alcohol oxidizing agentEsterification: Alcohols react carboxylic acids form estersDehydration: Alcohols can dehydrated form alkenesEther Formation: Alcohols react alcohols form ethersFlammability: Alcohols flammable","code":""},{"path":"alcohols-1.html","id":"physical-properties-of-alcohols","chapter":"Alcohols","heading":"Physical Properties of Alcohols","text":"Appearance: Alcohols can liquids solids room temperature, depending molecular weightBoiling Point: Boiling points increase increasing molecular weight hydrogen bondingSolubility: Alcohols short carbon chains miscible water due hydrogen bonding. Solubility decreases carbon chain length increases, influence nonpolar part molecule increasesViscosity: Alcohols tend viscous alkanes similar molecular weights due hydrogen bonding","code":""},{"path":"alcohols-1.html","id":"specific-alcohols-of-toxicological-significance","chapter":"Alcohols","heading":"Specific Alcohols of Toxicological Significance","text":"","code":""},{"path":"alcohols-1.html","id":"methanol-methyl-alcohol","chapter":"Alcohols","heading":"Methanol (Methyl Alcohol)","text":"Chemical Formula: \\(CH_3OH\\)Molecular Weight: 32.04 g/molAppearance: Colorless, volatile liquidBoiling Point: 64.7°CSolubility: Miscible water many organic solventsToxicokinetics\nRapidly absorbed ingestion inhalation\nWidely distributed throughout body\nMetabolized alcohol dehydrogenase (ADH) aldehyde dehydrogenase (ALDH) formaldehyde formic acid, highly toxic\nExcreted urine carbon dioxide via lungs\nRapidly absorbed ingestion inhalationWidely distributed throughout bodyMetabolized alcohol dehydrogenase (ADH) aldehyde dehydrogenase (ALDH) formaldehyde formic acid, highly toxicExcreted urine carbon dioxide via lungsToxicity\nVisual disturbances: Blurred vision, decreased visual acuity, blindness\nMetabolic acidosis: Due accumulation formic acid\nNeurological symptoms: Headache, dizziness, confusion, seizures, coma\nVisual disturbances: Blurred vision, decreased visual acuity, blindnessMetabolic acidosis: Due accumulation formic acidNeurological symptoms: Headache, dizziness, confusion, seizures, comaAnalytical Methods: Gas chromatography (GC), enzymatic assays","code":""},{"path":"alcohols-1.html","id":"ethanol-ethyl-alcohol","chapter":"Alcohols","heading":"Ethanol (Ethyl Alcohol)","text":"Chemical Formula: \\(C_2H_5OH\\)Molecular Weight: 46.07 g/molAppearance: Colorless, volatile liquidBoiling Point: 78.37°CSolubility: Miscible water many organic solventsToxicokinetics\nRapidly absorbed ingestion\nWidely distributed throughout body\nMetabolized alcohol dehydrogenase (ADH) aldehyde dehydrogenase (ALDH) acetaldehyde acetic acid\nExcreted urine carbon dioxide via lungs\nRapidly absorbed ingestionWidely distributed throughout bodyMetabolized alcohol dehydrogenase (ADH) aldehyde dehydrogenase (ALDH) acetaldehyde acetic acidExcreted urine carbon dioxide via lungsToxicity\nCentral nervous system (CNS) depression: Impaired judgment, slurred speech, ataxia, coma\nLiver damage: Cirrhosis, hepatitis\nGastrointestinal problems: Gastritis, pancreatitis\nWithdrawal syndrome: Tremors, anxiety, seizures, delirium tremens\nCentral nervous system (CNS) depression: Impaired judgment, slurred speech, ataxia, comaLiver damage: Cirrhosis, hepatitisGastrointestinal problems: Gastritis, pancreatitisWithdrawal syndrome: Tremors, anxiety, seizures, delirium tremensAnalytical Methods: Gas chromatography (GC), enzymatic assays","code":""},{"path":"alcohols-1.html","id":"isopropanol-isopropyl-alcohol","chapter":"Alcohols","heading":"Isopropanol (Isopropyl Alcohol)","text":"Chemical Formula: \\((CH_3)_2CHOH\\)Molecular Weight: 60.10 g/molAppearance: Colorless liquidBoiling Point: 82.4°CSolubility: Miscible water many organic solventsToxicokinetics\nRapidly absorbed ingestion inhalation\nWidely distributed throughout body\nMetabolized alcohol dehydrogenase (ADH) acetone\nExcreted urine acetone via lungs\nRapidly absorbed ingestion inhalationWidely distributed throughout bodyMetabolized alcohol dehydrogenase (ADH) acetoneExcreted urine acetone via lungsToxicity\nCNS depression: Drowsiness, confusion, coma\nGastrointestinal irritation: Nausea, vomiting, abdominal pain\nPulmonary edema\nCNS depression: Drowsiness, confusion, comaGastrointestinal irritation: Nausea, vomiting, abdominal painPulmonary edemaAnalytical Methods: Gas chromatography (GC)","code":""},{"path":"alcohols-1.html","id":"ethylene-glycol","chapter":"Alcohols","heading":"Ethylene Glycol","text":"Chemical Formula: \\(C_2H_6O_2\\)Molecular Weight: 62.07 g/molAppearance: Colorless, odorless liquidBoiling Point: 197.3°CSolubility: Miscible water many organic solventsToxicokinetics\nRapidly absorbed ingestion\nWidely distributed throughout body\nMetabolized alcohol dehydrogenase (ADH) aldehyde dehydrogenase (ALDH) glycoaldehyde, glycolic acid, glyoxylic acid, oxalic acid, highly toxic\nExcreted urine\nRapidly absorbed ingestionWidely distributed throughout bodyMetabolized alcohol dehydrogenase (ADH) aldehyde dehydrogenase (ALDH) glycoaldehyde, glycolic acid, glyoxylic acid, oxalic acid, highly toxicExcreted urineToxicity\nStage 1 (0.5-12 hours): CNS depression, nausea, vomiting\nStage 2 (12-24 hours): Cardiopulmonary effects, tachycardia, hypertension, pulmonary edema\nStage 3 (24-72 hours): Renal failure, flank pain, oliguria\nCalcium oxalate crystals urine\nStage 1 (0.5-12 hours): CNS depression, nausea, vomitingStage 2 (12-24 hours): Cardiopulmonary effects, tachycardia, hypertension, pulmonary edemaStage 3 (24-72 hours): Renal failure, flank pain, oliguriaCalcium oxalate crystals urineAnalytical Methods: Gas chromatography (GC), enzymatic assays, osmolal gap calculation","code":""},{"path":"alcohols-1.html","id":"propylene-glycol","chapter":"Alcohols","heading":"Propylene Glycol","text":"Chemical Formula: \\(C_3H_8O_2\\)Molecular Weight: 76.09 g/molAppearance: Colorless, odorless liquidBoiling Point: 188.2°CSolubility: Miscible water many organic solventsToxicokinetics\nRapidly absorbed ingestion\nWidely distributed throughout body\nMetabolized lactic acid pyruvic acid\nExcreted urine\nRapidly absorbed ingestionWidely distributed throughout bodyMetabolized lactic acid pyruvic acidExcreted urineToxicity\nGenerally considered less toxic ethylene glycol\nHigh concentrations can cause CNS depression, lactic acidosis, hyperosmolality\nGenerally considered less toxic ethylene glycolHigh concentrations can cause CNS depression, lactic acidosis, hyperosmolalityAnalytical Methods: Gas chromatography (GC)","code":""},{"path":"alcohols-1.html","id":"summary-table-of-alcohols","chapter":"Alcohols","heading":"Summary Table of Alcohols","text":"","code":""},{"path":"alcohols-1.html","id":"analytical-significance","chapter":"Alcohols","heading":"Analytical Significance","text":"Selection Analytical Method: Physical chemical properties guide selection appropriate analytical methodsSample Preparation: Solubility stability determine optimal sample preparation techniquesInterpretation Results: Understanding metabolism excretion helps interpret analytical results assess severity poisoning","code":""},{"path":"alcohols-1.html","id":"clinical-significance-18","chapter":"Alcohols","heading":"Clinical Significance","text":"Accurate Diagnosis: Prompt accurate identification ingested alcohol crucial appropriate treatmentAssessment Severity: Measurement alcohol concentrations helps assess severity poisoning guide clinical managementMonitoring Treatment: Serial measurements alcohol concentrations used monitor effectiveness treatment guide interventions","code":""},{"path":"alcohols-1.html","id":"key-terms-87","chapter":"Alcohols","heading":"Key Terms","text":"Alcohol: organic compound containing one hydroxyl (\\(-OH\\)) groupsMethanol: Methyl alcohol, highly toxic alcoholEthanol: Ethyl alcohol, alcohol found alcoholic beveragesIsopropanol: Isopropyl alcohol, common disinfectantEthylene Glycol: toxic alcohol found antifreezePropylene Glycol: less toxic alcohol used various productsToxicokinetics: study movement toxic substances within bodyMetabolism: process body chemically alters substanceExcretion: process body eliminates substanceAlcohol Dehydrogenase (ADH): enzyme involved metabolism alcoholsAldehyde Dehydrogenase (ALDH): enzyme involved metabolism aldehydesOsmolal Gap: difference measured osmolality calculated osmolality serum plasma","code":""},{"path":"heavy-metals.html","id":"heavy-metals","chapter":"Heavy Metals","heading":"Heavy Metals","text":"Heavy metals group metallic elements relatively high densities, atomic weights, atomic numbers toxic poisonous low concentrations\n* Characteristics\n* Naturally occurring elements\n* Persistent environment\n* Non-biodegradable\n* Can accumulate living organisms\n* Sources Exposure\n* Occupational (mining, manufacturing)\n* Environmental (contaminated soil, water, air)\n* Dietary (food, beverages)\n* Household (lead-based paint, plumbing)","code":""},{"path":"heavy-metals.html","id":"general-chemical-properties-of-heavy-metals","chapter":"Heavy Metals","heading":"General Chemical Properties of Heavy Metals","text":"Metallic Bonding: Exhibit metallic bonding, resulting good electrical thermal conductivityVariable Oxidation States: Can exist multiple oxidation states, influencing chemical behavior toxicityComplex Formation: Tendency form complexes various ligands, proteins, enzymes, DNAReactivity: React biological molecules, disrupting structure function","code":""},{"path":"heavy-metals.html","id":"general-physical-properties-of-heavy-metals","chapter":"Heavy Metals","heading":"General Physical Properties of Heavy Metals","text":"Appearance: Typically metallic lusterDensity: Relatively high densities compared elementsMelting Boiling Points: Varies depending specific metalSolubility: Solubility metal compounds varies widely depending specific compound solventConductivity: Good electrical thermal conductivity","code":""},{"path":"heavy-metals.html","id":"specific-heavy-metals-of-toxicological-significance","chapter":"Heavy Metals","heading":"Specific Heavy Metals of Toxicological Significance","text":"","code":""},{"path":"heavy-metals.html","id":"lead-pb","chapter":"Heavy Metals","heading":"Lead (\\(Pb\\))","text":"Definition: naturally occurring heavy metal toxic even low concentrationsSources Exposure\nLead-based paint\nContaminated soil dust\nDrinking water lead pipes\nOccupational exposure (mining, manufacturing)\nLead-based paintContaminated soil dustDrinking water lead pipesOccupational exposure (mining, manufacturing)Chemical Properties\nAtomic Number: 82\nAtomic Weight: 207.2 g/mol\nOxidation States: +2 (common), +4\nForms complexes various ligands, including proteins, enzymes, DNA\nAtomic Number: 82Atomic Weight: 207.2 g/molOxidation States: +2 (common), +4Forms complexes various ligands, including proteins, enzymes, DNAPhysical Properties\nAppearance: Soft, gray-blue metal\nDensity: 11.34 g/cm³\nMelting Point: 327.5°C\nBoiling Point: 1749°C\nSolubility: Insoluble water, lead compounds (e.g., lead acetate, lead nitrate) soluble\nAppearance: Soft, gray-blue metalDensity: 11.34 g/cm³Melting Point: 327.5°CBoiling Point: 1749°CSolubility: Insoluble water, lead compounds (e.g., lead acetate, lead nitrate) solubleToxicokinetics\nAbsorption:\nInhalation: Rapidly absorbed bloodstream\nIngestion: Absorption varies depending form lead presence food stomach\nDermal: Minimal absorption intact skin\n\nDistribution:\nDistributed throughout body\nAccumulates bone (90%), blood (1-2%), soft tissues (5-8%)\nCrosses blood-brain barrier placenta\n\nMetabolism:\nmetabolized\n\nExcretion:\nPrimarily excreted urine feces\nExcretion slow, leading accumulation body\n\nAbsorption:\nInhalation: Rapidly absorbed bloodstream\nIngestion: Absorption varies depending form lead presence food stomach\nDermal: Minimal absorption intact skin\nInhalation: Rapidly absorbed bloodstreamIngestion: Absorption varies depending form lead presence food stomachDermal: Minimal absorption intact skinDistribution:\nDistributed throughout body\nAccumulates bone (90%), blood (1-2%), soft tissues (5-8%)\nCrosses blood-brain barrier placenta\nDistributed throughout bodyAccumulates bone (90%), blood (1-2%), soft tissues (5-8%)Crosses blood-brain barrier placentaMetabolism:\nmetabolized\nmetabolizedExcretion:\nPrimarily excreted urine feces\nExcretion slow, leading accumulation body\nPrimarily excreted urine fecesExcretion slow, leading accumulation bodyMechanism Toxicity\nInterferes various enzymatic processes\nInhibits heme synthesis, leading anemia\nDisrupts calcium homeostasis\nCauses oxidative stress\nAffects nervous system, kidneys, reproductive system\nInterferes various enzymatic processesInhibits heme synthesis, leading anemiaDisrupts calcium homeostasisCauses oxidative stressAffects nervous system, kidneys, reproductive systemSigns Symptoms Lead Poisoning\nNeurological:\nAdults: Headache, irritability, memory loss, peripheral neuropathy\nChildren: Developmental delays, learning disabilities, seizures, coma\n\nGastrointestinal: Abdominal pain, constipation, nausea, vomiting\nHematological: Anemia (microcytic, hypochromic)\nRenal: Kidney damage\nNeurological:\nAdults: Headache, irritability, memory loss, peripheral neuropathy\nChildren: Developmental delays, learning disabilities, seizures, coma\nAdults: Headache, irritability, memory loss, peripheral neuropathyChildren: Developmental delays, learning disabilities, seizures, comaGastrointestinal: Abdominal pain, constipation, nausea, vomitingHematological: Anemia (microcytic, hypochromic)Renal: Kidney damageAnalytical Methods\nAtomic Absorption Spectrometry (AAS)\nInductively Coupled Plasma Mass Spectrometry (ICP-MS)\nAnodic Stripping Voltammetry (ASV)\nAtomic Absorption Spectrometry (AAS)Inductively Coupled Plasma Mass Spectrometry (ICP-MS)Anodic Stripping Voltammetry (ASV)","code":""},{"path":"heavy-metals.html","id":"mercury-hg","chapter":"Heavy Metals","heading":"Mercury (\\(Hg\\))","text":"Definition: naturally occurring heavy metal exists various forms, different toxicological propertiesForms Mercury\nElemental Mercury (Hg⁰): Liquid room temperature\nInorganic Mercury (Hg⁺, Hg²⁺): Mercury salts\nOrganic Mercury: Methylmercury, ethylmercury\nElemental Mercury (Hg⁰): Liquid room temperatureInorganic Mercury (Hg⁺, Hg²⁺): Mercury saltsOrganic Mercury: Methylmercury, ethylmercurySources Exposure\nOccupational (mining, manufacturing)\nDental amalgams\nContaminated fish (methylmercury)\nIndustrial waste\nOccupational (mining, manufacturing)Dental amalgamsContaminated fish (methylmercury)Industrial wasteChemical Properties\nAtomic Number: 80\nAtomic Weight: 200.59 g/mol\nOxidation States: 0, +1, +2\nForms complexes sulfur, selenium, elements\nAtomic Number: 80Atomic Weight: 200.59 g/molOxidation States: 0, +1, +2Forms complexes sulfur, selenium, elementsPhysical Properties\nAppearance: Silver-white liquid metal\nDensity: 13.534 g/cm³ (dense)\nMelting Point: -38.83°C\nBoiling Point: 356.7°C\nSolubility: Insoluble water, mercury compounds soluble\nAppearance: Silver-white liquid metalDensity: 13.534 g/cm³ (dense)Melting Point: -38.83°CBoiling Point: 356.7°CSolubility: Insoluble water, mercury compounds solubleToxicokinetics\nElemental Mercury:\nInhalation: Rapidly absorbed bloodstream\nIngestion: Poorly absorbed\n\nInorganic Mercury:\nIngestion: Poorly absorbed\n\nOrganic Mercury (Methylmercury):\nRapidly completely absorbed gastrointestinal tract\nCrosses blood-brain barrier placenta\n\nDistribution:\nElemental Mercury: Accumulates brain kidneys\nInorganic Mercury: Accumulates kidneys\nOrganic Mercury: Distributed throughout body, including brain fetus\n\nMetabolism:\nElemental Mercury: Oxidized inorganic mercury\nOrganic Mercury: Demethylated inorganic mercury\n\nExcretion:\nPrimarily excreted urine feces\nExcretion slow, leading accumulation body\n\nElemental Mercury:\nInhalation: Rapidly absorbed bloodstream\nIngestion: Poorly absorbed\nInhalation: Rapidly absorbed bloodstreamIngestion: Poorly absorbedInorganic Mercury:\nIngestion: Poorly absorbed\nIngestion: Poorly absorbedOrganic Mercury (Methylmercury):\nRapidly completely absorbed gastrointestinal tract\nCrosses blood-brain barrier placenta\nRapidly completely absorbed gastrointestinal tractCrosses blood-brain barrier placentaDistribution:\nElemental Mercury: Accumulates brain kidneys\nInorganic Mercury: Accumulates kidneys\nOrganic Mercury: Distributed throughout body, including brain fetus\nElemental Mercury: Accumulates brain kidneysInorganic Mercury: Accumulates kidneysOrganic Mercury: Distributed throughout body, including brain fetusMetabolism:\nElemental Mercury: Oxidized inorganic mercury\nOrganic Mercury: Demethylated inorganic mercury\nElemental Mercury: Oxidized inorganic mercuryOrganic Mercury: Demethylated inorganic mercuryExcretion:\nPrimarily excreted urine feces\nExcretion slow, leading accumulation body\nPrimarily excreted urine fecesExcretion slow, leading accumulation bodyMechanism Toxicity\nBinds sulfhydryl groups proteins enzymes, disrupting function\nCauses oxidative stress\nAffects nervous system, kidneys, immune system\nBinds sulfhydryl groups proteins enzymes, disrupting functionCauses oxidative stressAffects nervous system, kidneys, immune systemSigns Symptoms Mercury Poisoning\nNeurological: Tremor, memory loss, irritability, numbness, tingling\nRenal: Kidney damage, proteinuria\nGastrointestinal: Nausea, vomiting, abdominal pain\nDermatological: Skin rash\nMinamata Disease (methylmercury poisoning): Neurological syndrome ataxia, sensory disturbances, cognitive impairment\nNeurological: Tremor, memory loss, irritability, numbness, tinglingRenal: Kidney damage, proteinuriaGastrointestinal: Nausea, vomiting, abdominal painDermatological: Skin rashMinamata Disease (methylmercury poisoning): Neurological syndrome ataxia, sensory disturbances, cognitive impairmentAnalytical Methods\nCold Vapor Atomic Absorption Spectrometry (CVAAS)\nInductively Coupled Plasma Mass Spectrometry (ICP-MS)\nCold Vapor Atomic Absorption Spectrometry (CVAAS)Inductively Coupled Plasma Mass Spectrometry (ICP-MS)","code":""},{"path":"heavy-metals.html","id":"arsenic-as","chapter":"Heavy Metals","heading":"Arsenic (\\(As\\))","text":"Definition: naturally occurring metalloid toxic inorganic organic formsSources Exposure\nContaminated drinking water\nFood (seafood, rice)\nPesticides\nIndustrial processes (smelting, wood preservation)\nContaminated drinking waterFood (seafood, rice)PesticidesIndustrial processes (smelting, wood preservation)Chemical Properties\nAtomic Number: 33\nAtomic Weight: 74.92 g/mol\nOxidation States: -3, 0, +3, +5\nForms compounds oxygen, sulfur, elements\nAtomic Number: 33Atomic Weight: 74.92 g/molOxidation States: -3, 0, +3, +5Forms compounds oxygen, sulfur, elementsPhysical Properties\nAppearance: Gray, metallic solid\nDensity: 5.727 g/cm³\nMelting Point: 817°C (28 atm)\nBoiling Point: Sublimes 615°C\nSolubility: Insoluble water, arsenic compounds soluble\nAppearance: Gray, metallic solidDensity: 5.727 g/cm³Melting Point: 817°C (28 atm)Boiling Point: Sublimes 615°CSolubility: Insoluble water, arsenic compounds solubleToxicokinetics\nAbsorption:\nInorganic Arsenic: Well-absorbed gastrointestinal tract lungs\nOrganic Arsenic: Less well-absorbed\n\nDistribution:\nDistributed throughout body\nAccumulates liver, kidneys, spleen, skin\n\nMetabolism:\nInorganic arsenic methylated monomethylarsonic acid (MMA) dimethylarsinic acid (DMA)\nMethylation detoxification pathway, intermediates may toxic\n\nExcretion:\nPrimarily excreted urine inorganic arsenic methylated metabolites\nExcretion half-life varies depending form arsenic\n\nAbsorption:\nInorganic Arsenic: Well-absorbed gastrointestinal tract lungs\nOrganic Arsenic: Less well-absorbed\nInorganic Arsenic: Well-absorbed gastrointestinal tract lungsOrganic Arsenic: Less well-absorbedDistribution:\nDistributed throughout body\nAccumulates liver, kidneys, spleen, skin\nDistributed throughout bodyAccumulates liver, kidneys, spleen, skinMetabolism:\nInorganic arsenic methylated monomethylarsonic acid (MMA) dimethylarsinic acid (DMA)\nMethylation detoxification pathway, intermediates may toxic\nInorganic arsenic methylated monomethylarsonic acid (MMA) dimethylarsinic acid (DMA)Methylation detoxification pathway, intermediates may toxicExcretion:\nPrimarily excreted urine inorganic arsenic methylated metabolites\nExcretion half-life varies depending form arsenic\nPrimarily excreted urine inorganic arsenic methylated metabolitesExcretion half-life varies depending form arsenicMechanism Toxicity\nInhibits enzyme function\nCauses oxidative stress\nDisrupts DNA repair\nInhibits enzyme functionCauses oxidative stressDisrupts DNA repairSigns Symptoms Arsenic Poisoning\nAcute:\nGastrointestinal: Nausea, vomiting, abdominal pain, diarrhea\nCardiovascular: Hypotension, arrhythmias\nNeurological: Encephalopathy, seizures\n\nChronic:\nDermatological: Hyperpigmentation, palmar-plantar hyperkeratosis (Mees’ lines nails)\nNeurological: Peripheral neuropathy\nCardiovascular: Increased risk cardiovascular disease\nCancer: Increased risk skin, lung, bladder cancer\n\nAcute:\nGastrointestinal: Nausea, vomiting, abdominal pain, diarrhea\nCardiovascular: Hypotension, arrhythmias\nNeurological: Encephalopathy, seizures\nGastrointestinal: Nausea, vomiting, abdominal pain, diarrheaCardiovascular: Hypotension, arrhythmiasNeurological: Encephalopathy, seizuresChronic:\nDermatological: Hyperpigmentation, palmar-plantar hyperkeratosis (Mees’ lines nails)\nNeurological: Peripheral neuropathy\nCardiovascular: Increased risk cardiovascular disease\nCancer: Increased risk skin, lung, bladder cancer\nDermatological: Hyperpigmentation, palmar-plantar hyperkeratosis (Mees’ lines nails)Neurological: Peripheral neuropathyCardiovascular: Increased risk cardiovascular diseaseCancer: Increased risk skin, lung, bladder cancerAnalytical Methods\nHydride Generation Atomic Absorption Spectrometry (HGAAS)\nInductively Coupled Plasma Mass Spectrometry (ICP-MS)\nHydride Generation Atomic Absorption Spectrometry (HGAAS)Inductively Coupled Plasma Mass Spectrometry (ICP-MS)","code":""},{"path":"heavy-metals.html","id":"analytical-significance-1","chapter":"Heavy Metals","heading":"Analytical Significance","text":"Selection Analytical Method: Physical chemical properties guide selection appropriate analytical methodsSample Preparation: Solubility stability determine optimal sample preparation techniquesInterpretation Results: Understanding metabolism excretion helps interpret analytical results assess severity poisoning","code":""},{"path":"heavy-metals.html","id":"clinical-significance-19","chapter":"Heavy Metals","heading":"Clinical Significance","text":"Accurate Diagnosis: Prompt accurate identification ingested heavy metal crucial appropriate treatmentAssessment Severity: Measurement heavy metal concentrations helps assess severity poisoning guide clinical managementMonitoring Treatment: Serial measurements heavy metal concentrations used monitor effectiveness treatment guide interventions","code":""},{"path":"heavy-metals.html","id":"key-terms-88","chapter":"Heavy Metals","heading":"Key Terms","text":"Heavy Metal: metallic element relatively high density toxic low concentrationsLead: naturally occurring heavy metalMercury: heavy metal exists various forms, different toxicological propertiesArsenic: metalloid toxic inorganic organic formsToxicokinetics: study movement toxic substances within bodyMetabolism: process body chemically alters substanceExcretion: process body eliminates substanceChelation Therapy: use chelating agents bind heavy metals facilitate excretionAtomic Absorption Spectrometry (AAS): analytical technique used measure concentration elements sampleInductively Coupled Plasma Mass Spectrometry (ICP-MS): analytical technique used measure concentration elements sampleHydride Generation Atomic Absorption Spectrometry (HGAAS): analytical technique used measure concentration arsenic sampleCold Vapor Atomic Absorption Spectrometry (CVAAS): analytical technique used measure concentration mercury sampleChelating Agent: molecule binds metal ionsMetalloid: element properties intermediate metal nonmetal","code":""},{"path":"analgesics.html","id":"analgesics","chapter":"Analgesics","heading":"Analgesics","text":"Analyzing analgesics hinges understanding chemical nature. section gives overview analgesics","code":""},{"path":"analgesics.html","id":"general-properties-of-analgesics","chapter":"Analgesics","heading":"General Properties of Analgesics","text":"Definition: Analgesics medications used relieve painClassification: Analgesics can classified several categories based mechanism action:\nOpioids: Bind opioid receptors central nervous system (e.g., morphine, codeine, oxycodone)\nNonsteroidal Anti-Inflammatory Drugs (NSAIDs): Inhibit cyclooxygenase (COX) enzymes (e.g., ibuprofen, naproxen, aspirin)\nAcetaminophen: centrally acting analgesic antipyretic properties\nOthers: Atypical analgesics various mechanisms action (e.g., gabapentin, pregabalin, tramadol)\nOpioids: Bind opioid receptors central nervous system (e.g., morphine, codeine, oxycodone)Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Inhibit cyclooxygenase (COX) enzymes (e.g., ibuprofen, naproxen, aspirin)Acetaminophen: centrally acting analgesic antipyretic propertiesOthers: Atypical analgesics various mechanisms action (e.g., gabapentin, pregabalin, tramadol)Common Properties\nAnalgesic Effect: Relieve pain\nAnti-Inflammatory Effect: May reduce inflammation (NSAIDs)\nAntipyretic Effect: May reduce fever (acetaminophen, NSAIDs)\nAnalgesic Effect: Relieve painAnti-Inflammatory Effect: May reduce inflammation (NSAIDs)Antipyretic Effect: May reduce fever (acetaminophen, NSAIDs)","code":""},{"path":"analgesics.html","id":"chemical-properties-of-analgesics","chapter":"Analgesics","heading":"Chemical Properties of Analgesics","text":"Structural Diversity: Analgesics exhibit significant structural diversity, encompassing wide range chemical classesFunctional Groups: contain various functional groups, hydroxyl, amino, carbonyl, carboxyl groups, influence solubility, binding properties, metabolismAcidic Basic Character: Acidic (NSAIDs) basic (opioids) properties influence behavior biological systemsChirality: analgesics chiral molecules, existing enantiomers diastereomers differing pharmacological activitiesChemical Stability: Varies widely depending specific drug formulation; storage conditions can affect stability","code":""},{"path":"analgesics.html","id":"physical-properties-of-analgesics","chapter":"Analgesics","heading":"Physical Properties of Analgesics","text":"Appearance: Crystalline solids powdersSolubility: Varies depending specific drug chemical structurePartition Coefficient (Log P): Indicates relative affinity drug lipid aqueous phasesIonization: Acidic basic properties influence absorption, distribution, excretionProtein Binding: Binding plasma proteins (albumin, alpha-1-acid glycoprotein)Melting Point: Characteristic property identification purity assessmentHygroscopicity: analgesics hygroscopic, absorbing moisture air","code":""},{"path":"analgesics.html","id":"specific-analgesic-acetaminophen","chapter":"Analgesics","heading":"Specific Analgesic: Acetaminophen","text":"Definition: Acetaminophen (also known paracetamol) widely used --counter analgesic antipyretic drugChemical Structure: N-acetyl-p-aminophenolMolecular Formula: \\(C_8H_9NO_2\\)Molecular Weight: 151.16 g/molAppearance: White crystalline powderSolubility: Slightly soluble water (1.4 g/100 mL 22°C), soluble ethanol methanolpKa Value: 9.5 (weakly acidic)Partition Coefficient (Log P): Approximately 0.46, indicating moderate polarityProtein Binding: Relatively low protein binding (20-50%)Melting Point: 169-170.5°C","code":""},{"path":"analgesics.html","id":"pharmacokinetic-implications-5","chapter":"Analgesics","heading":"Pharmacokinetic Implications","text":"Absorption\nRapid almost complete absorption oral administration\nPeak plasma concentrations typically reached within 30-60 minutes\nAbsorption can affected gastric emptying rate food intake\nRapid almost complete absorption oral administrationPeak plasma concentrations typically reached within 30-60 minutesAbsorption can affected gastric emptying rate food intakeDistribution\nDistributes rapidly uniformly throughout body tissues fluids\nCrosses blood-brain barrier\nDistributes rapidly uniformly throughout body tissues fluidsCrosses blood-brain barrierProtein Binding\nRelatively low protein binding (20-50%)\nChanges protein binding usually clinically significant\nRelatively low protein binding (20-50%)Changes protein binding usually clinically significantMetabolism\nPrimarily metabolized liver :\nGlucuronidation (55-60%)\nSulfation (20-30%)\nCYP2E1-mediated oxidation reactive intermediate, N-acetyl-p-benzoquinone imine (NAPQI) (5-10%)\n\nPrimarily metabolized liver :\nGlucuronidation (55-60%)\nSulfation (20-30%)\nCYP2E1-mediated oxidation reactive intermediate, N-acetyl-p-benzoquinone imine (NAPQI) (5-10%)\nGlucuronidation (55-60%)Sulfation (20-30%)CYP2E1-mediated oxidation reactive intermediate, N-acetyl-p-benzoquinone imine (NAPQI) (5-10%)Excretion\nExcreted primarily urine glucuronide sulfate conjugates\nSmall amounts excreted unchanged\nExcreted primarily urine glucuronide sulfate conjugatesSmall amounts excreted unchangedHalf-Life\nHalf-life approximately 1.5-3 hours adults normal liver function\nHalf-life approximately 1.5-3 hours adults normal liver function","code":""},{"path":"analgesics.html","id":"mechanism-of-action-2","chapter":"Analgesics","heading":"Mechanism of Action","text":"exact mechanism action acetaminophen fully understood, believed involve:\nInhibition cyclooxygenase (COX) enzymes brain: Selectively inhibits COX-2 CNS, reducing prostaglandin synthesis pain/fever\nActivation descending inhibitory serotonergic pathway\nInhibition endocannabinoid system\nInhibition cyclooxygenase (COX) enzymes brain: Selectively inhibits COX-2 CNS, reducing prostaglandin synthesis pain/feverActivation descending inhibitory serotonergic pathwayInhibition endocannabinoid system","code":""},{"path":"analgesics.html","id":"structure-activity-relationship-sar","chapter":"Analgesics","heading":"Structure-Activity Relationship (SAR)","text":"acetamide group essential activityThe para-aminophenol structure important analgesic antipyretic effects","code":""},{"path":"analgesics.html","id":"analytical-considerations-in-tdm-5","chapter":"Analgesics","heading":"Analytical Considerations in TDM","text":"Analytical Methods\nSpectrophotometry: Historically used, less specific sensitive\nImmunoassays: Commonly used routine TDM due ease use high throughput\nEnzyme-multiplied immunoassay technique (EMIT)\nLatex agglutination inhibition assay (LIA)\n\nChromatography: HPLC UV mass spectrometry detection used specific sensitive measurements\nLiquid chromatography-tandem mass spectrometry (LC-MS/MS)\n\nSpectrophotometry: Historically used, less specific sensitiveImmunoassays: Commonly used routine TDM due ease use high throughput\nEnzyme-multiplied immunoassay technique (EMIT)\nLatex agglutination inhibition assay (LIA)\nEnzyme-multiplied immunoassay technique (EMIT)Latex agglutination inhibition assay (LIA)Chromatography: HPLC UV mass spectrometry detection used specific sensitive measurements\nLiquid chromatography-tandem mass spectrometry (LC-MS/MS)\nLiquid chromatography-tandem mass spectrometry (LC-MS/MS)Sample Preparation\nimmunoassays, serum plasma can analyzed directly simple dilution\nchromatographic methods, sample preparation may involve protein precipitation solid-phase extraction (SPE)\nimmunoassays, serum plasma can analyzed directly simple dilutionFor chromatographic methods, sample preparation may involve protein precipitation solid-phase extraction (SPE)Calibration Quality Control\nUse appropriate calibrators quality control materials ensure accurate reliable results\nUse appropriate calibrators quality control materials ensure accurate reliable resultsInterferences\nHigh bilirubin levels can interfere spectrophotometric assays\nN-acetylcysteine (NAC), antidote acetaminophen overdose, can interfere immunoassays\nHigh bilirubin levels can interfere spectrophotometric assaysN-acetylcysteine (NAC), antidote acetaminophen overdose, can interfere immunoassays","code":""},{"path":"analgesics.html","id":"clinical-significance-in-tdm-5","chapter":"Analgesics","heading":"Clinical Significance in TDM","text":"Therapeutic Drug Monitoring (TDM)\nTDM routinely used acetaminophen, relatively safe drug recommended doses\nTDM primarily used cases suspected overdose liver toxicity assess risk hepatotoxicity\nTDM routinely used acetaminophen, relatively safe drug recommended dosesTDM primarily used cases suspected overdose liver toxicity assess risk hepatotoxicityHepatotoxicity\nAcetaminophen overdose can lead severe liver damage liver failure\nNAPQI, toxic metabolite, normally detoxified glutathione, overdose, glutathione stores depleted, leading liver damage\nAcetaminophen overdose can lead severe liver damage liver failureNAPQI, toxic metabolite, normally detoxified glutathione, overdose, glutathione stores depleted, leading liver damageRumack-Matthew Nomogram\ngraph used assess risk hepatotoxicity based serum acetaminophen concentration time since ingestion\ngraph used assess risk hepatotoxicity based serum acetaminophen concentration time since ingestionTreatment Acetaminophen Overdose\nN-acetylcysteine (NAC): antidote replenishes glutathione stores detoxifies NAPQI\nN-acetylcysteine (NAC): antidote replenishes glutathione stores detoxifies NAPQIFactors Affecting Toxicity\nDose: Higher doses increase risk hepatotoxicity\nTime since ingestion: risk hepatotoxicity decreases time\nLiver function: Patients pre-existing liver disease higher risk\nDrug interactions: CYP2E1 inducers (e.g., alcohol, isoniazid) can increase NAPQI formation\nGlutathione levels: Malnutrition fasting can deplete glutathione stores\nDose: Higher doses increase risk hepatotoxicityTime since ingestion: risk hepatotoxicity decreases timeLiver function: Patients pre-existing liver disease higher riskDrug interactions: CYP2E1 inducers (e.g., alcohol, isoniazid) can increase NAPQI formationGlutathione levels: Malnutrition fasting can deplete glutathione storesNon-linearity Liver Function Tests (LFTs)\nSevere toxicity may underestimated LFTs repeated since elevation LFTs non-linear\nSevere toxicity may underestimated LFTs repeated since elevation LFTs non-linear","code":""},{"path":"analgesics.html","id":"key-terms-89","chapter":"Analgesics","heading":"Key Terms","text":"Analgesics: Medications used relieve painAcetaminophen: widely used --counter analgesic antipyretic drugTherapeutic Drug Monitoring (TDM): Measurement drug concentrations optimize therapyHepatotoxicity: Liver damageNAPQI: N-acetyl-p-benzoquinone imine, toxic metabolite acetaminophenGlutathione: antioxidant protects cells damageRumack-Matthew Nomogram: graph used assess risk hepatotoxicity acetaminophen overdoseN-acetylcysteine (NAC): antidote acetaminophen overdoseBioavailability: fraction administered dose drug reaches systemic circulationVolume Distribution: Apparent space body available contain drugProtein Binding: degree drug binds plasma proteinsMetabolism: process body chemically alters drugExcretion: process body eliminates drug metabolitesAnalgesic: medicine used relieve painAntipyretic: medicine used reduce fever","code":""},{"path":"drugs-of-abuse-1.html","id":"drugs-of-abuse-1","chapter":"Drugs of Abuse","heading":"Drugs of Abuse","text":"Studying drugs abuse toxicology calls understanding core properties. section, look properties drugs abuse","code":""},{"path":"drugs-of-abuse-1.html","id":"general-properties-of-drugs-of-abuse","chapter":"Drugs of Abuse","heading":"General Properties of Drugs of Abuse","text":"Definition: Drugs abuse substances used non-medical purposes, often psychoactive effects, can lead dependence, addiction, adverse health consequencesClassification: Drugs abuse can classified several categories based pharmacological effects:\nOpioids: Produce analgesia, euphoria, sedation (e.g., heroin, morphine, oxycodone)\nStimulants: Increase alertness, energy, euphoria (e.g., cocaine, amphetamines, methamphetamine)\nCannabinoids: Produce relaxation, altered perception, euphoria (e.g., marijuana, hashish)\nHallucinogens: Alter perception, thought, mood (e.g., LSD, psilocybin, MDMA)\nDepressants: Slow brain activity, producing relaxation sedation (e.g., alcohol, benzodiazepines, barbiturates)\nInhalants: Volatile substances produce psychoactive effects inhaled (e.g., solvents, aerosols, gases)\nOpioids: Produce analgesia, euphoria, sedation (e.g., heroin, morphine, oxycodone)Stimulants: Increase alertness, energy, euphoria (e.g., cocaine, amphetamines, methamphetamine)Cannabinoids: Produce relaxation, altered perception, euphoria (e.g., marijuana, hashish)Hallucinogens: Alter perception, thought, mood (e.g., LSD, psilocybin, MDMA)Depressants: Slow brain activity, producing relaxation sedation (e.g., alcohol, benzodiazepines, barbiturates)Inhalants: Volatile substances produce psychoactive effects inhaled (e.g., solvents, aerosols, gases)Common Properties\nPsychoactive Effects: Alter mood, perception, cognition\nReinforcing Effects: Produce pleasurable rewarding experiences promote continued use\nAddictive Potential: Can lead dependence addiction\nPsychoactive Effects: Alter mood, perception, cognitionReinforcing Effects: Produce pleasurable rewarding experiences promote continued useAddictive Potential: Can lead dependence addiction","code":""},{"path":"drugs-of-abuse-1.html","id":"chemical-properties-of-drugs-of-abuse","chapter":"Drugs of Abuse","heading":"Chemical Properties of Drugs of Abuse","text":"Structural Diversity: Drugs abuse exhibit significant structural diversity, encompassing wide range chemical classesFunctional Groups: contain various functional groups, hydroxyl, amino, carbonyl, ester, ether groups, influence solubility, binding properties, metabolismBasic Acidic Character: Many drugs abuse weak bases acidsChirality: drugs abuse chiral molecules, existing enantiomers diastereomers differing pharmacological activitiesChemical Stability: Varies widely depending specific drug formulation; storage conditions can affect stability","code":""},{"path":"drugs-of-abuse-1.html","id":"physical-properties-of-drugs-of-abuse","chapter":"Drugs of Abuse","heading":"Physical Properties of Drugs of Abuse","text":"Appearance: Crystalline solids, powders, liquids, plant materialsSolubility: Varies depending specific drug chemical structurePartition Coefficient (Log P): Indicates relative affinity drug lipid aqueous phasesIonization: Acidic basic properties influence absorption, distribution, excretionProtein Binding: Binding plasma proteins (albumin, alpha-1-acid glycoprotein)Melting Point: Characteristic property identification purity assessmentBoiling Point: Important volatile substancesHygroscopicity: drugs abuse hygroscopic, absorbing moisture air","code":""},{"path":"drugs-of-abuse-1.html","id":"specific-drugs-of-abuse","chapter":"Drugs of Abuse","heading":"Specific Drugs of Abuse","text":"","code":""},{"path":"drugs-of-abuse-1.html","id":"opioids-e.g.-morphine","chapter":"Drugs of Abuse","heading":"Opioids (e.g., Morphine)","text":"Definition: Opioids class drugs bind opioid receptors central nervous system, producing analgesia, euphoria, sedationExamples: Morphine, codeine, heroin, oxycodone, hydrocodone, fentanylChemical Structure: Complex alkaloids characteristic morphinan ring structureMolecular Weight: Varies depending specific opioid (e.g., morphine: 285.34 g/mol)Solubility: Varies depending specific opioid, generally soluble water alcoholIonization: Weak basesProtein Binding: Varies depending specific opioidPharmacokinetic Implications: Rapid absorption oral, intravenous, intramuscular administration; extensive metabolism liver; renal excretion","code":""},{"path":"drugs-of-abuse-1.html","id":"stimulants-e.g.-cocaine","chapter":"Drugs of Abuse","heading":"Stimulants (e.g., Cocaine)","text":"Definition: Stimulants class drugs increase alertness, energy, euphoria affecting central nervous systemExamples: Cocaine, amphetamine, methamphetamine, methylphenidateChemical Structure: Amphetamines derivatives phenethylamine; cocaine benzoylmethylecgonineMolecular Weight: Varies depending specific stimulant (e.g., cocaine: 303.36 g/mol)Solubility: Varies depending specific stimulant, generally soluble water alcoholIonization: Weak basesProtein Binding: Varies depending specific stimulantPharmacokinetic Implications: Rapid absorption various routes administration (oral, intranasal, intravenous, smoking); metabolized liver; excreted urine","code":""},{"path":"drugs-of-abuse-1.html","id":"cannabinoids-e.g.-thc","chapter":"Drugs of Abuse","heading":"Cannabinoids (e.g., THC)","text":"Definition: Cannabinoids class chemical compounds act cannabinoid receptors cells alter neurotransmitter release brainExamples: Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN)Chemical Structure: Tricyclic compounds characteristic dibenzopyran ring systemMolecular Weight: Varies depending specific cannabinoid (e.g., THC: 314.46 g/mol)Solubility: Highly lipophilic poorly soluble waterIonization: NeutralProtein Binding: Highly protein-boundPharmacokinetic Implications: Rapid absorption smoked vaporized; slow variable absorption oral administration; extensive metabolism liver; excreted feces urine","code":""},{"path":"drugs-of-abuse-1.html","id":"hallucinogens-e.g.-lsd","chapter":"Drugs of Abuse","heading":"Hallucinogens (e.g., LSD)","text":"Definition: Hallucinogens class drugs alter perception, thought, moodExamples: Lysergic acid diethylamide (LSD), psilocybin, mescaline, 3,4-methylenedioxymethamphetamine (MDMA)Chemical Structure: Highly variable, depending specific hallucinogenMolecular Weight: Varies depending specific hallucinogen (e.g., LSD: 328.43 g/mol)Solubility: Varies depending specific hallucinogenIonization: basic, neutralProtein Binding: Varies depending specific hallucinogenPharmacokinetic Implications: Rapid absorption oral administration; metabolized liver; excreted urine","code":""},{"path":"drugs-of-abuse-1.html","id":"depressants-e.g.-benzodiazepines","chapter":"Drugs of Abuse","heading":"Depressants (e.g., Benzodiazepines)","text":"Definition: Depressants class drugs slow brain activity, producing relaxation sedationExamples: Alcohol, benzodiazepines (diazepam, alprazolam, lorazepam), barbiturates (phenobarbital, secobarbital)Chemical Structure: Benzodiazepines contain benzene ring fused diazepine ring; barbiturates derivatives barbituric acidMolecular Weight: Varies depending specific depressantSolubility: Varies depending specific depressantIonization: Weak acids basesProtein Binding: Varies depending specific depressantPharmacokinetic Implications: Rapid absorption oral administration; metabolized liver; excreted urine","code":""},{"path":"drugs-of-abuse-1.html","id":"analytical-significance-2","chapter":"Drugs of Abuse","heading":"Analytical Significance","text":"Selection Analytical Method: Physical chemical properties guide selection appropriate analytical methodsSample Preparation: Solubility stability determine optimal sample preparation techniquesInterpretation Results: Understanding metabolism excretion helps interpret analytical results assess severity poisoning","code":""},{"path":"drugs-of-abuse-1.html","id":"clinical-significance-20","chapter":"Drugs of Abuse","heading":"Clinical Significance","text":"Accurate Diagnosis: Prompt accurate identification ingested drug crucial appropriate treatmentAssessment Severity: Measurement drug concentrations helps assess severity poisoning guide clinical managementMonitoring Treatment: Serial measurements drug concentrations used monitor effectiveness treatment guide interventions","code":""},{"path":"drugs-of-abuse-1.html","id":"summary-table-of-drugs-of-abuse-and-their-properties","chapter":"Drugs of Abuse","heading":"Summary Table of Drugs of Abuse and their properties","text":"","code":""},{"path":"drugs-of-abuse-1.html","id":"key-terms-90","chapter":"Drugs of Abuse","heading":"Key Terms","text":"Drugs Abuse: Substances used non-medical purposes can lead dependence addictionOpioids: Analgesic drugs bind opioid receptorsStimulants: Drugs increase alertness energyCannabinoids: Chemical compounds found cannabisHallucinogens: Drugs alter perception thoughtDepressants: Drugs slow brain activityToxicokinetics: study movement toxic substances within bodyMetabolism: process body chemically alters substanceExcretion: process body eliminates substanceAddiction: chronic, relapsing brain disease characterized compulsive drug seeking useDependence: state body adapted drug experiences withdrawal symptoms upon cessation useOverdose: toxic dose drug can lead serious health consequences deathAnalgesic: medicine used relieve painIllicit: Illegal activities","code":""},{"path":"procedures-10.html","id":"procedures-10","chapter":"Procedures","heading":"Procedures","text":"section covers various aspects toxicology lab procedures","code":""},{"path":"procedures-10.html","id":"general-principles-of-toxicology-laboratory-test-procedures","chapter":"Procedures","heading":"General Principles of Toxicology Laboratory Test Procedures","text":"Objective: identify quantify toxic substances biological samples clinical, forensic, environmental purposesScope: Encompasses wide range analytes, including drugs, poisons, heavy metals, environmental toxinsTypes Assays\nScreening Assays: Provide rapid, qualitative detection substances classes substances\nConfirmatory Assays: Provide quantitative identification confirmation specific substances\nScreening Assays: Provide rapid, qualitative detection substances classes substancesConfirmatory Assays: Provide quantitative identification confirmation specific substancesSample Types\nBlood, urine, gastric contents, tissues, hair, oral fluid, specimens\nBlood, urine, gastric contents, tissues, hair, oral fluid, specimens","code":""},{"path":"procedures-10.html","id":"analytical-principles-3","chapter":"Procedures","heading":"Analytical Principles","text":"Immunoassays (IAs)\nPrinciple: Based antibody-antigen binding\nTypes: ELISA, FPIA, CLIA\nAdvantages: High throughput, ease use\nLimitations: Cross-reactivity, limited quantitative accuracy\nPrinciple: Based antibody-antigen bindingTypes: ELISA, FPIA, CLIAAdvantages: High throughput, ease useLimitations: Cross-reactivity, limited quantitative accuracyChromatography (GC, HPLC)\nPrinciple: Separates compounds based physical chemical properties\nDetectors: UV-Vis, fluorescence, electrochemical, mass spectrometry (MS)\nAdvantages: High resolution, quantitative analysis\nLimitations: Requires skilled operators\nPrinciple: Separates compounds based physical chemical propertiesDetectors: UV-Vis, fluorescence, electrochemical, mass spectrometry (MS)Advantages: High resolution, quantitative analysisLimitations: Requires skilled operatorsMass Spectrometry (MS)\nPrinciple: Identifies quantifies compounds based mass--charge ratio\nTechniques: GC-MS, LC-MS/MS\nAdvantages: High sensitivity specificity, can identify unknowns\nLimitations: Requires expensive equipment highly skilled operators\nPrinciple: Identifies quantifies compounds based mass--charge ratioTechniques: GC-MS, LC-MS/MSAdvantages: High sensitivity specificity, can identify unknownsLimitations: Requires expensive equipment highly skilled operatorsAtomic Absorption Spectrometry (AAS)\nPrinciple: Measures light absorption free atoms\nApplication: Heavy metal analysis\nAdvantages: High sensitivity minerals\nLimitations: Requires specialized equipment, matrix effects\nPrinciple: Measures light absorption free atomsApplication: Heavy metal analysisAdvantages: High sensitivity mineralsLimitations: Requires specialized equipment, matrix effectsInductively Coupled Plasma Mass Spectrometry (ICP-MS)\nPrinciple: Measures mass--charge ratio ions plasma\nApplication: Trace elements, heavy metals\nAdvantages: High sensitivity, multi-element analysis\nLimitations: Requires specialized equipment, matrix effects\nPrinciple: Measures mass--charge ratio ions plasmaApplication: Trace elements, heavy metalsAdvantages: High sensitivity, multi-element analysisLimitations: Requires specialized equipment, matrix effects","code":""},{"path":"procedures-10.html","id":"special-precautions-16","chapter":"Procedures","heading":"Special Precautions","text":"Personnel Safety\nPersonal Protective Equipment (PPE)\nChemical Hygiene Plan\nFume Hood\nSpill Response\nPersonal Protective Equipment (PPE)Chemical Hygiene PlanFume HoodSpill ResponseSpecimen Handling\nChain Custody\nLabeling\nStorage\nChain CustodyLabelingStorageInstrumentation\nCalibration\nMaintenance\nQuality Control\nCalibrationMaintenanceQuality ControlWaste Disposal\nChemical Waste\nBiohazardous Waste\nChemical WasteBiohazardous WasteDocumentation\nProcedures, results, QC data, maintenance logs\nProcedures, results, QC data, maintenance logsSecurity\nControlled substances stored securely\nLimited access\nControlled substances stored securelyLimited access","code":""},{"path":"procedures-10.html","id":"specimen-collection-and-processing-2","chapter":"Procedures","heading":"Specimen Collection and Processing","text":"General Guidelines\nSample Integrity: Proper containers prevent contamination\nVolume: Collect adequate volume\nTimeliness: Process promptly\nSample Integrity: Proper containers prevent contaminationVolume: Collect adequate volumeTimeliness: Process promptlySpecific Specimen Types\nBlood: Gray-top alcohol, avoid hemolysis\nUrine: Random timed, preservatives needed\nGastric Contents: Collect soon possible\nTissues: Collect autopsy biopsy\nHair: Collect close scalp, wash segment\nOral Fluid: Use specialized collection devices\nBlood: Gray-top alcohol, avoid hemolysisUrine: Random timed, preservatives neededGastric Contents: Collect soon possibleTissues: Collect autopsy biopsyHair: Collect close scalp, wash segmentOral Fluid: Use specialized collection devices","code":""},{"path":"procedures-10.html","id":"troubleshooting-20","chapter":"Procedures","heading":"Troubleshooting","text":"Unexpected Results\nVerify patient ID\nRepeat test\nCheck interferences\nReview history\nConsider alternative methods\nVerify patient IDRepeat testCheck interferencesReview historyConsider alternative methodsQuality Control (QC) Failures\n--Range QC\nCalibration Issues\nReagent Problems\nInstrument Malfunction\nAction: Investigate correct source error\n--Range QCCalibration IssuesReagent ProblemsInstrument MalfunctionAction: Investigate correct source error","code":""},{"path":"procedures-10.html","id":"interfering-substances-20","chapter":"Procedures","heading":"Interfering Substances","text":"Endogenous Substances\nBilirubin\nLipids\nProteins\nBilirubinLipidsProteinsExogenous Substances\nMedications\nHerbal Supplements\nFood\nCleaning Agents\nMedicationsHerbal SupplementsFoodCleaning AgentsCollection/Handling Materials\nTube Additives\nContaminated Containers\nTube AdditivesContaminated ContainersSpecific Interferences\nCross-Reactivity\nMatrix Effects\nHeterophile Antibodies\nCross-ReactivityMatrix EffectsHeterophile AntibodiesStrategies Address Interferences\nDilution\nExtraction\nCleanup Procedures\nMasking Agents\nAlternate Methods\nInterference Checks\nDilutionExtractionCleanup ProceduresMasking AgentsAlternate MethodsInterference Checks","code":""},{"path":"principles-10.html","id":"principles-10","chapter":"Principles","heading":"Principles","text":"section covers common analytical principles toxicology lab procedures","code":""},{"path":"principles-10.html","id":"general-principles-of-toxicological-analysis","chapter":"Principles","heading":"General Principles of Toxicological Analysis","text":"Objective: identify quantify toxic substances biological samplesSample Types: Blood, urine, gastric contents, tissues, hair, specimensScreening vs. Confirmation\nScreening tests: Rapid, inexpensive, sensitive methods used detect presence substance class substances\nConfirmation tests: specific sensitive methods used confirm identity quantity substance\nScreening tests: Rapid, inexpensive, sensitive methods used detect presence substance class substancesConfirmation tests: specific sensitive methods used confirm identity quantity substanceQuality Control (QC): Essential ensure accuracy reliability","code":""},{"path":"principles-10.html","id":"common-analytical-techniques-1","chapter":"Principles","heading":"Common Analytical Techniques","text":"","code":""},{"path":"principles-10.html","id":"immunoassays-2","chapter":"Principles","heading":"Immunoassays","text":"Principle: Based specific binding antibodies target antigens (toxic substances)Types\nEnzyme-Linked Immunosorbent Assay (ELISA)\nRadioimmunoassay (RIA)\nFluorescence Polarization Immunoassay (FPIA)\nChemiluminescent Immunoassay (CLIA)\nEnzyme-Linked Immunosorbent Assay (ELISA)Radioimmunoassay (RIA)Fluorescence Polarization Immunoassay (FPIA)Chemiluminescent Immunoassay (CLIA)Procedure\nSample Preparation: May involve dilution extraction\nAntibody Binding: Add sample microplate coated antibodies\nEnzyme-Labeled Antibody: Add labeled antibodies bind target\nSignal Detection: Add substrate measure signal\nQuantification: Compare signal intensity standard curve\nSample Preparation: May involve dilution extractionAntibody Binding: Add sample microplate coated antibodiesEnzyme-Labeled Antibody: Add labeled antibodies bind targetSignal Detection: Add substrate measure signalQuantification: Compare signal intensity standard curveAdvantages\nHigh throughput\nEase use\nRelatively inexpensive\nHigh throughputEase useRelatively inexpensiveLimitations\nPotential cross-reactivity\nLimited quantitative accuracy\nSusceptible interferences\nPotential cross-reactivityLimited quantitative accuracySusceptible interferencesApplications\nScreening drugs abuse, therapeutic drugs, toxins\nScreening drugs abuse, therapeutic drugs, toxins","code":""},{"path":"principles-10.html","id":"chromatography-2","chapter":"Principles","heading":"Chromatography","text":"Principle: Separates compounds based physical chemical propertiesTypes\nThin-Layer Chromatography (TLC): Separates substances thin layer adsorbent material\nSimple, inexpensive, versatile\nUsed screening\n\nGas Chromatography (GC): Separates volatile compounds based boiling points\nSuitable volatile organic compounds\nRequires derivatization non-volatile compounds\n\nHigh-Performance Liquid Chromatography (HPLC): Separates compounds based interactions mobile stationary phases\nUsed non-volatile compounds\nVersatile, widely applicable\n\nThin-Layer Chromatography (TLC): Separates substances thin layer adsorbent material\nSimple, inexpensive, versatile\nUsed screening\nSimple, inexpensive, versatileUsed screeningGas Chromatography (GC): Separates volatile compounds based boiling points\nSuitable volatile organic compounds\nRequires derivatization non-volatile compounds\nSuitable volatile organic compoundsRequires derivatization non-volatile compoundsHigh-Performance Liquid Chromatography (HPLC): Separates compounds based interactions mobile stationary phases\nUsed non-volatile compounds\nVersatile, widely applicable\nUsed non-volatile compoundsVersatile, widely applicableDetectors\nUV-Vis Detection\nFluorescence Detection\nElectrochemical Detection\nMass Spectrometry (MS)\nUV-Vis DetectionFluorescence DetectionElectrochemical DetectionMass Spectrometry (MS)Procedure\nSample Preparation: Extract analytes sample\nSeparation: Inject sample chromatography system\nDetection: Detect separated compounds using appropriate detection method\nQuantification: Compare peak areas standard curve\nSample Preparation: Extract analytes sampleSeparation: Inject sample chromatography systemDetection: Detect separated compounds using appropriate detection methodQuantification: Compare peak areas standard curveAdvantages\nHigh resolution sensitivity\nCan separate complex mixtures\nQuantitative analysis\nHigh resolution sensitivityCan separate complex mixturesQuantitative analysisLimitations\nRequires specialized equipment\nSkilled operators\nTime-consuming\nRequires specialized equipmentSkilled operatorsTime-consumingApplications\nIdentification quantification drugs, pesticides, toxins\nIdentification quantification drugs, pesticides, toxins","code":""},{"path":"principles-10.html","id":"mass-spectrometry-ms","chapter":"Principles","heading":"Mass Spectrometry (MS)","text":"Principle: Identifies quantifies compounds based mass--charge ratioTypes\nGas Chromatography-Mass Spectrometry (GC-MS)\nCombines gas chromatography mass spectrometry analysis volatile compounds\n\nLiquid Chromatography-Mass Spectrometry (LC-MS)\nCombines liquid chromatography mass spectrometry analysis non-volatile compounds\n\nTandem Mass Spectrometry (MS/MS)\nsensitive specific single MS\nUsed quantifying low-level analytes confirming identity compounds\n\nGas Chromatography-Mass Spectrometry (GC-MS)\nCombines gas chromatography mass spectrometry analysis volatile compounds\nCombines gas chromatography mass spectrometry analysis volatile compoundsLiquid Chromatography-Mass Spectrometry (LC-MS)\nCombines liquid chromatography mass spectrometry analysis non-volatile compounds\nCombines liquid chromatography mass spectrometry analysis non-volatile compoundsTandem Mass Spectrometry (MS/MS)\nsensitive specific single MS\nUsed quantifying low-level analytes confirming identity compounds\nsensitive specific single MSUsed quantifying low-level analytes confirming identity compoundsProcedure\nSample Preparation: Extract analytes sample\nChromatographic Separation: Inject sample GC LC system\nIonization: Ionize separated compounds\nMass Analysis: Separate ions based mass--charge ratio\nDetection: Detect ions using mass spectrometer\nQuantification: Compare ion abundances standard curve\nSample Preparation: Extract analytes sampleChromatographic Separation: Inject sample GC LC systemIonization: Ionize separated compoundsMass Analysis: Separate ions based mass--charge ratioDetection: Detect ions using mass spectrometerQuantification: Compare ion abundances standard curveAdvantages\nHigh sensitivity specificity\nCan identify unknown compounds\nCan quantify multiple compounds simultaneously\nHigh sensitivity specificityCan identify unknown compoundsCan quantify multiple compounds simultaneouslyLimitations\nRequires expensive equipment\nHighly skilled operators\nRequires expensive equipmentHighly skilled operatorsApplications\nConfirmation quantification drugs toxins\nMetabolite identification\nForensic toxicology\nEnvironmental analysis\nConfirmation quantification drugs toxinsMetabolite identificationForensic toxicologyEnvironmental analysis","code":""},{"path":"principles-10.html","id":"atomic-absorption-spectrometry-aas-1","chapter":"Principles","heading":"Atomic Absorption Spectrometry (AAS)","text":"Principle: Measures absorption light free atoms gaseous stateProcedure\nSample Preparation: Digest sample release elements\nAtomization: Convert elements free atoms\nAbsorption Measurement: Pass light atomized sample measure absorption\nQuantification: Compare absorbance standard curve\nSample Preparation: Digest sample release elementsAtomization: Convert elements free atomsAbsorption Measurement: Pass light atomized sample measure absorptionQuantification: Compare absorbance standard curveAdvantages\nHigh sensitivity specificity mineral analysis\nHigh sensitivity specificity mineral analysisLimitations\nRequires specialized equipment\nMatrix effects\nRequires specialized equipmentMatrix effectsApplications\nMeasuring heavy metals (lead, mercury, cadmium) biological samples\nMeasuring heavy metals (lead, mercury, cadmium) biological samples","code":""},{"path":"principles-10.html","id":"inductively-coupled-plasma-mass-spectrometry-icp-ms-1","chapter":"Principles","heading":"Inductively Coupled Plasma Mass Spectrometry (ICP-MS)","text":"Principle: Measures mass--charge ratio ions produced inductively coupled plasmaProcedure\nSample Preparation: Digest sample release elements\nPlasma Generation: Introduce sample ICP, ionizes elements\nMass Analysis: Separate ions based mass--charge ratio\nDetection: Detect ions using mass spectrometer\nQuantification: Compare ion intensities standard curve\nSample Preparation: Digest sample release elementsPlasma Generation: Introduce sample ICP, ionizes elementsMass Analysis: Separate ions based mass--charge ratioDetection: Detect ions using mass spectrometerQuantification: Compare ion intensities standard curveAdvantages\nHigh sensitivity\nMulti-element analysis\nIsotope ratio measurements\nHigh sensitivityMulti-element analysisIsotope ratio measurementsLimitations\nRequires specialized equipment\nMatrix effects\nRequires specialized equipmentMatrix effectsApplications\nMeasuring trace elements heavy metals biological samples\nMeasuring trace elements heavy metals biological samples","code":""},{"path":"principles-10.html","id":"point-of-care-testing-poct-1","chapter":"Principles","heading":"Point-of-Care Testing (POCT)","text":"Principle: Rapid, portable testing performed near patientTypes\nLateral flow immunoassays\nElectrochemical sensors\nLateral flow immunoassaysElectrochemical sensorsAdvantages\nRapid turnaround time\nEase use\nPortability\nRapid turnaround timeEase usePortabilityLimitations\nLower accuracy precision\nLimited range analytes\nLower accuracy precisionLimited range analytesApplications\nScreening drugs abuse\nRapid detection certain toxins\nScreening drugs abuseRapid detection certain toxins","code":""},{"path":"principles-10.html","id":"summary-table-of-analytical-techniques-1","chapter":"Principles","heading":"Summary Table of Analytical Techniques","text":"","code":""},{"path":"principles-10.html","id":"key-terms-91","chapter":"Principles","heading":"Key Terms","text":"Analytical Sensitivity: ability assay detect small amounts substanceAnalytical Specificity: ability assay measure substance interestCross-Reactivity: ability antibody bind multiple antigensMatrix Effects: effect sample matrix analytical measurementCalibration: process adjusting analytical instrument ensure accurate measurementsQuality Control (QC): set procedures used monitor accuracy precision analytical measurementsDetection Limit: lowest amount substance can reliably detected assayQuantitation Limit: lowest amount substance can reliably quantified assayDynamic Range: range concentrations can accurately measured assaySample Preparation: process preparing sample analysisDerivatization: Altering chemical structure increase detection","code":""},{"path":"precautions-5.html","id":"precautions-5","chapter":"Precautions","heading":"Precautions","text":"Toxicology lab procedures highly sensitive. section gives full overview maximize accuracy safety","code":""},{"path":"precautions-5.html","id":"special-precautions-17","chapter":"Precautions","heading":"Special Precautions","text":"Personnel Safety\nPersonal Protective Equipment (PPE): Wear appropriate PPE, including gloves, lab coats, eye protection\nChemical Hygiene Plan: Follow laboratory’s chemical hygiene plan\nFume Hood: Work volatile organic compounds (VOCs) hazardous chemicals fume hood\nSpill Response: spill kits readily available follow proper spill response procedures\nPersonal Protective Equipment (PPE): Wear appropriate PPE, including gloves, lab coats, eye protectionChemical Hygiene Plan: Follow laboratory’s chemical hygiene planFume Hood: Work volatile organic compounds (VOCs) hazardous chemicals fume hoodSpill Response: spill kits readily available follow proper spill response proceduresSpecimen Handling\nChain Custody: Maintain strict chain custody specimens\nLabeling: Label specimens clearly accurately patient information, date, time collection\nStorage: Store specimens appropriate temperatures maintain stability\nChain Custody: Maintain strict chain custody specimensLabeling: Label specimens clearly accurately patient information, date, time collectionStorage: Store specimens appropriate temperatures maintain stabilityInstrumentation\nCalibration: Calibrate instruments regularly using appropriate standards\nMaintenance: Perform routine maintenance instruments ensure proper functioning\nQuality Control: Run quality control samples regular intervals monitor accuracy precision\nCalibration: Calibrate instruments regularly using appropriate standardsMaintenance: Perform routine maintenance instruments ensure proper functioningQuality Control: Run quality control samples regular intervals monitor accuracy precisionWaste Disposal\nChemical Waste: Dispose chemical waste according federal, state, local regulations\nBiohazardous Waste: Dispose biohazardous waste properly\nChemical Waste: Dispose chemical waste according federal, state, local regulationsBiohazardous Waste: Dispose biohazardous waste properlyDocumentation\nRecord procedures, results, quality control data accurately completely\nMaintain log instrument maintenance calibrations\nRecord procedures, results, quality control data accurately completelyMaintain log instrument maintenance calibrationsSecurity\nStore controlled substances securely\nLimit access toxicology laboratory\nStore controlled substances securelyLimit access toxicology laboratory","code":""},{"path":"precautions-5.html","id":"specimen-collection-and-processing-3","chapter":"Precautions","heading":"Specimen Collection and Processing","text":"General Considerations\nSample Integrity: Collect specimens appropriate containers prevent contamination degradation\nVolume: Collect adequate volume testing potential reanalysis\nTimeliness: Process specimens promptly minimize changes analyte concentrations\nSample Integrity: Collect specimens appropriate containers prevent contamination degradationVolume: Collect adequate volume testing potential reanalysisTimeliness: Process specimens promptly minimize changes analyte concentrationsSpecific Specimen Types\nBlood:\nCollect appropriate tubes (e.g., gray-top tubes alcohol analysis)\nAvoid hemolysis\nSeparate plasma serum cells promptly\n\nUrine:\nCollect random timed urine sample\nUse appropriate containers preservatives, necessary\n\nGastric Contents:\nCollect soon possible ingestion\nRecord volume appearance gastric contents\n\nTissues:\nCollect tissue samples autopsy biopsy\nStore appropriate containers -20°C -80°C\n\nHair:\nCollect hair samples close scalp\nWash segment hair analysis\n\nOral Fluid:\nCollect using specialized collection device\nFollow manufacturer’s instructions collection storage\n\nBlood:\nCollect appropriate tubes (e.g., gray-top tubes alcohol analysis)\nAvoid hemolysis\nSeparate plasma serum cells promptly\nCollect appropriate tubes (e.g., gray-top tubes alcohol analysis)Avoid hemolysisSeparate plasma serum cells promptlyUrine:\nCollect random timed urine sample\nUse appropriate containers preservatives, necessary\nCollect random timed urine sampleUse appropriate containers preservatives, necessaryGastric Contents:\nCollect soon possible ingestion\nRecord volume appearance gastric contents\nCollect soon possible ingestionRecord volume appearance gastric contentsTissues:\nCollect tissue samples autopsy biopsy\nStore appropriate containers -20°C -80°C\nCollect tissue samples autopsy biopsyStore appropriate containers -20°C -80°CHair:\nCollect hair samples close scalp\nWash segment hair analysis\nCollect hair samples close scalpWash segment hair analysisOral Fluid:\nCollect using specialized collection device\nFollow manufacturer’s instructions collection storage\nCollect using specialized collection deviceFollow manufacturer’s instructions collection storage","code":""},{"path":"precautions-5.html","id":"troubleshooting-21","chapter":"Precautions","heading":"Troubleshooting","text":"Unexpected Results\nVerify patient identification\nRepeat test confirm result\nCheck interfering substances\nReview patient’s medical history medication list\nConsider alternative analytical methods\nVerify patient identificationRepeat test confirm resultCheck interfering substancesReview patient’s medical history medication listConsider alternative analytical methodsQuality Control Failures\n--Range QC: Investigate correct cause failure\nCalibration Issues: Check calibration standards recalibrate instrument\nReagent Problems: Verify reagent integrity, storage conditions, expiration dates\nInstrument Malfunction: Troubleshoot repair instrument\n--Range QC: Investigate correct cause failureCalibration Issues: Check calibration standards recalibrate instrumentReagent Problems: Verify reagent integrity, storage conditions, expiration datesInstrument Malfunction: Troubleshoot repair instrumentInterferences\nIdentify interfering substance\nUse appropriate methods minimize eliminate interference\nConsider using alternative analytical method\nIdentify interfering substanceUse appropriate methods minimize eliminate interferenceConsider using alternative analytical method","code":""},{"path":"precautions-5.html","id":"common-interfering-substances","chapter":"Precautions","heading":"Common Interfering Substances","text":"Endogenous Substances\nBilirubin: Can interfere spectrophotometric assays\nLipids: Can cause turbidity affect immunoassays\nProteins: Can interfere chromatography mass spectrometry\nBilirubin: Can interfere spectrophotometric assaysLipids: Can cause turbidity affect immunoassaysProteins: Can interfere chromatography mass spectrometryExogenous Substances\nMedications: Many drugs can interfere toxicology assays\nHerbal Supplements: Can contain compounds interfere assays\nFood: Can affect absorption metabolism drugs\nCleaning Agents: Can contaminate specimens affect results\nMedications: Many drugs can interfere toxicology assaysHerbal Supplements: Can contain compounds interfere assaysFood: Can affect absorption metabolism drugsCleaning Agents: Can contaminate specimens affect resultsCollection Handling Materials\nTube Additives: Can interfere assays\nContaminated Containers: Can introduce interfering substances\nTube Additives: Can interfere assaysContaminated Containers: Can introduce interfering substancesSpecific Interferences\nCross-Reactivity: Antibodies may bind multiple compounds\nMatrix Effects: Components sample matrix can affect results\nHeterophile Antibodies: Can cause falsely high low results\nCross-Reactivity: Antibodies may bind multiple compoundsMatrix Effects: Components sample matrix can affect resultsHeterophile Antibodies: Can cause falsely high low results","code":""},{"path":"precautions-5.html","id":"specific-strategies-for-addressing-interferences","chapter":"Precautions","heading":"Specific Strategies for Addressing Interferences","text":"Dilution: Dilute sample reduce concentration interfering substanceExtraction: Use liquid-liquid extraction solid-phase extraction (SPE) remove interfering substancesCleanup Procedures: Employ cleanup procedures remove interfering substancesMasking Agents: Add masking agents bind interfering substances prevent interfering assayAlternate Methods: Use different analytical method less susceptible interferenceInterference Checks: Implement interference checks assess impact potential interfering substances","code":""},{"path":"precautions-5.html","id":"key-terms-92","chapter":"Precautions","heading":"Key Terms","text":"Calibration: Adjusting instrument ensure accurate readingsChain Custody: Documentation handling specimenControl: sample known result run reference pointHeterophile Antibodies: Human antibodies can bind animal antibodiesInterfering Substance: component affects test measurementsMatrix Effects: combined effect sample components analytePersonnel Protective Equipment (PPE): Provides safety laboratory staffPreservative: Chemical added maintain stabilityQuality Control (QC): Testing process results createdToxicology: Branch science concerned nature, effects, detection poisonsExtraction: process separating substance sample matrixMatrix Effects: components within sample affect resultsInterference Checks: Testing specific components can affect test results","code":""},{"path":"result-interpretation-10.html","id":"result-interpretation-10","chapter":"Result Interpretation","heading":"Result Interpretation","text":"Interpreting toxicology test results multifaceted. section describes steps follow order properly interpret","code":""},{"path":"result-interpretation-10.html","id":"general-principles-of-test-result-interpretation-3","chapter":"Result Interpretation","heading":"General Principles of Test Result Interpretation","text":"Quantitative vs. Qualitative Results\nQualitative: Indicates presence absence substance (e.g., positive negative)\nQuantitative: Provides numerical value concentration substance\nQualitative: Indicates presence absence substance (e.g., positive negative)Quantitative: Provides numerical value concentration substanceCutoff Values\nconcentration test considered positive\nCutoff values established based analytical sensitivity clinical relevance\nconcentration test considered positiveCutoff values established based analytical sensitivity clinical relevanceUnits Measurement\nfamiliar units measurement used laboratory (e.g., ng/mL, μg/mL, mg/L)\nfamiliar units measurement used laboratory (e.g., ng/mL, μg/mL, mg/L)Reference Intervals\nToxicology tests typically “normal” reference intervals, goal detect presence toxic substances\nHowever, therapeutic ranges may available drugs\nToxicology tests typically “normal” reference intervals, goal detect presence toxic substancesHowever, therapeutic ranges may available drugsChain Custody\nVerify chain custody ensure integrity validity specimen\nVerify chain custody ensure integrity validity specimenPositive Negative Controls\nEnsure positive negative controls within acceptable limits\nEnsure positive negative controls within acceptable limitsInterfering Substances\naware potential interfering substances can affect test results\naware potential interfering substances can affect test results","code":""},{"path":"result-interpretation-10.html","id":"factors-affecting-interpretation-4","chapter":"Result Interpretation","heading":"Factors Affecting Interpretation","text":"Patient History\nAge, sex, weight, medical conditions, medications, substance use history\nAge, sex, weight, medical conditions, medications, substance use historyTime Sample Collection\nTime since ingestion, inhalation, exposure\nTime since ingestion, inhalation, exposureRoute Exposure\nIngestion, inhalation, dermal, injection\nIngestion, inhalation, dermal, injectionMetabolism Elimination\nLiver kidney function\nGenetic factors affecting drug metabolism\nLiver kidney functionGenetic factors affecting drug metabolismDrug Interactions\nConcurrent use drugs\nConcurrent use drugsAnalytical Limitations\nCross-reactivity, sensitivity, specificity assay\nCross-reactivity, sensitivity, specificity assay","code":""},{"path":"result-interpretation-10.html","id":"step-by-step-approach-to-result-interpretation","chapter":"Result Interpretation","heading":"Step-by-Step Approach to Result Interpretation","text":"Verify Patient Information: Confirm patient’s identity demographic informationReview Analytical Data\n* Check QC results calibration data\n* Assess validity resultsAssess Qualitative Results\n* positive, proceed confirmation quantitative analysis\n* negative, consider possibility false-negative result due low concentration, interfering substances, limitations assayEvaluate Quantitative Results\n* Compare concentration cutoff values therapeutic ranges\n* Consider dose-response relationshipCorrelate Clinical Information\n* Interpret results context patient’s clinical presentation, medical history, laboratory dataConsider Interfering Factors\n* Assess potential drug interactions interfering substancesProvide Interpretation\n* Summarize findings provide concise interpretation results\n* Explain clinical significance results\n* Offer recommendations testing management","code":""},{"path":"result-interpretation-10.html","id":"specific-considerations-for-different-substance-classes","chapter":"Result Interpretation","heading":"Specific Considerations for Different Substance Classes","text":"","code":""},{"path":"result-interpretation-10.html","id":"alcohols-2","chapter":"Result Interpretation","heading":"Alcohols","text":"Typical Analytes: Ethanol, methanol, isopropanol, ethylene glycolReporting Units: mg/dL, g/dLCutoff Values: Vary depending substance legal clinical contextFactors Consider\nEthanol: Legal limits driving influence (DUI)\nMethanol ethylene glycol: Toxic metabolites can cause severe acidosis organ damage\nOsmolal Gap: difference measured calculated osmolality can suggest presence unmeasured alcohols\nEthanol: Legal limits driving influence (DUI)Methanol ethylene glycol: Toxic metabolites can cause severe acidosis organ damageOsmolal Gap: difference measured calculated osmolality can suggest presence unmeasured alcoholsClinical Significance: Intoxication, poisoning, differential diagnosis altered mental status","code":""},{"path":"result-interpretation-10.html","id":"heavy-metals-1","chapter":"Result Interpretation","heading":"Heavy Metals","text":"Typical Analytes: Lead, mercury, arsenic, cadmiumReporting Units: μg/dL, μg/LCutoff Values: Vary depending metal regulatory guidelinesFactors Consider\nLead: Elevated levels can cause neurological damage, developmental delays, anemia\nMercury: Different forms mercury (elemental, inorganic, organic) different toxicities\nArsenic: Acute chronic exposure can cause various health effects, including cancer\nLead: Elevated levels can cause neurological damage, developmental delays, anemiaMercury: Different forms mercury (elemental, inorganic, organic) different toxicitiesArsenic: Acute chronic exposure can cause various health effects, including cancerClinical Significance: Environmental occupational exposure, poisoning, chronic toxicity","code":""},{"path":"result-interpretation-10.html","id":"analgesics-1","chapter":"Result Interpretation","heading":"Analgesics","text":"Typical Analytes: Acetaminophen, salicylates, opioids, NSAIDsReporting Units: μg/mL, mg/LCutoff Values: Vary depending drug clinical contextFactors Consider\nAcetaminophen: Risk hepatotoxicity\nSalicylates: Risk metabolic acidosis respiratory alkalosis\nOpioids: Respiratory depression, altered mental status\nAcetaminophen: Risk hepatotoxicitySalicylates: Risk metabolic acidosis respiratory alkalosisOpioids: Respiratory depression, altered mental statusClinical Significance: Overdose, toxicity, monitoring therapeutic drug levels","code":""},{"path":"result-interpretation-10.html","id":"drugs-of-abuse-2","chapter":"Result Interpretation","heading":"Drugs of Abuse","text":"Typical Analytes: Amphetamines, cocaine, opiates, cannabinoids, benzodiazepines, barbiturates, etcReporting Units: ng/mL, μg/mLCutoff Values: Vary depending drug testing purpose (e.g., forensic, workplace, clinical)Factors Consider\nMetabolic pathways: Different metabolites may detected depending assay\nCross-reactivity: assays may cross-react structurally similar compounds\nMetabolic pathways: Different metabolites may detected depending assayCross-reactivity: assays may cross-react structurally similar compoundsClinical Significance: Drug abuse, overdose, monitoring drug treatment programs","code":""},{"path":"result-interpretation-10.html","id":"cardioactive-drugs-e.g.-digoxin-2","chapter":"Result Interpretation","heading":"Cardioactive Drugs (e.g., Digoxin)","text":"Typical Analytes: DigoxinReporting Units: ng/mLTherapeutic Range: 0.5 - 2.0 ng/mL (Varies based condition/patient)Factors Consider\nClinical picture: Underlying cardio condition additional meds\nElectrolyte levels: Potassium, Magnesium\nClinical picture: Underlying cardio condition additional medsElectrolyte levels: Potassium, MagnesiumClinical Significance: verify avoid toxic levels cause side effects","code":""},{"path":"result-interpretation-10.html","id":"anticonvulsants-e.g.-phenobarbital-2","chapter":"Result Interpretation","heading":"Anticonvulsants (e.g., Phenobarbital)","text":"Typical Analytes: PhenobarbitalReporting Units: μg/mLTherapeutic Range: 15 - 40 μg/mL (Varies based patient)Factors Consider\npatient’s additional meds\npatient’s liver/kidney function\npatient’s additional medsThe patient’s liver/kidney functionClinical Significance: maintain safe therapeutic levels","code":""},{"path":"result-interpretation-10.html","id":"limitations-in-interpretations","chapter":"Result Interpretation","heading":"Limitations in Interpretations","text":"Cut-Values: set specific testsDrugs included: drug panels test every single drugPatients can metabolize drugs differently: patient’s body disease states also affect drug metabolized","code":""},{"path":"result-interpretation-10.html","id":"key-terms-93","chapter":"Result Interpretation","heading":"Key Terms","text":"Cutoff Value: concentration test considered positiveReference Interval: range values found healthy individualsClinical Context: patient’s clinical history, physical examination findings, laboratory dataCross-Reactivity: ability antibody bind multiple antigensMetabolite: product drug metabolismDrug Interaction: effect one drug ADME another drugToxidrome: group signs symptoms associated particular class toxic substancesForensic Toxicology: application toxicology legal investigationsWorkplace Drug Testing: Testing employees drug useTherapeutic Range: Concentration range effects commonly observed","code":""},{"path":"disease-correlation-10.html","id":"disease-correlation-10","chapter":"Disease Correlation","heading":"Disease Correlation","text":"Understanding various disease states influence toxicological findings critical accurate interpretation effective patient management","code":""},{"path":"disease-correlation-10.html","id":"general-principles-of-disease-state-correlation-in-toxicology","chapter":"Disease Correlation","heading":"General Principles of Disease State Correlation in Toxicology","text":"Impact Toxicokinetics: Disease states can alter drug absorption, distribution, metabolism, excretion (ADME), leading changes toxic substance concentrationsIndividual Variability: Disease states can introduce significant variability individuals respond toxic substancesPre-Existing Conditions: Pre-existing conditions can increase susceptibility toxicityClinical Context: Always interpret toxicological results context patient’s clinical presentation medical historyDiagnostic Considerations: Knowledge common associations helps guide diagnostic evaluationManagement Strategies: Disease-specific considerations influence treatment decisions","code":""},{"path":"disease-correlation-10.html","id":"liver-disease-1","chapter":"Disease Correlation","heading":"Liver Disease","text":"Mechanism Impact\nImpaired hepatic metabolism\nDecreased production clotting factors\nAltered protein binding\nReduced bile flow\nImpaired hepatic metabolismDecreased production clotting factorsAltered protein bindingReduced bile flowCommonly Affected Substances\nAcetaminophen: Increased risk hepatotoxicity\nAlcohol: Increased susceptibility alcohol-related liver damage\nDrugs metabolized CYP enzymes (e.g., opioids, benzodiazepines)\nAcetaminophen: Increased risk hepatotoxicityAlcohol: Increased susceptibility alcohol-related liver damageDrugs metabolized CYP enzymes (e.g., opioids, benzodiazepines)Typical Laboratory Findings\nElevated liver enzymes (ALT, AST)\nIncreased bilirubin\nProlonged prothrombin time (PT/INR)\nDecreased albumin\nElevated liver enzymes (ALT, AST)Increased bilirubinProlonged prothrombin time (PT/INR)Decreased albuminToxicological Considerations\nIncreased sensitivity hepatotoxic substances\nImpaired clearance drugs, leading elevated drug levels\nHigher risk bleeding anticoagulants antiplatelet agents\nIncreased sensitivity hepatotoxic substancesImpaired clearance drugs, leading elevated drug levelsHigher risk bleeding anticoagulants antiplatelet agentsDisease Examples\nCirrhosis\nHepatitis\nLiver Failure\nCirrhosisHepatitisLiver Failure","code":""},{"path":"disease-correlation-10.html","id":"renal-disease-1","chapter":"Disease Correlation","heading":"Renal Disease","text":"Mechanism Impact\nReduced glomerular filtration rate (GFR)\nImpaired tubular secretion\nDecreased drug clearance\nAltered fluid electrolyte balance\nReduced glomerular filtration rate (GFR)Impaired tubular secretionDecreased drug clearanceAltered fluid electrolyte balanceCommonly Affected Substances\nDrugs primarily excreted kidneys (e.g., aminoglycosides, lithium, methotrexate)\nHeavy metals (e.g., lead, mercury)\nDrugs primarily excreted kidneys (e.g., aminoglycosides, lithium, methotrexate)Heavy metals (e.g., lead, mercury)Typical Laboratory Findings\nElevated serum creatinine blood urea nitrogen (BUN)\nDecreased creatinine clearance\nElectrolyte imbalances (e.g., hyperkalemia)\nElevated serum creatinine blood urea nitrogen (BUN)Decreased creatinine clearanceElectrolyte imbalances (e.g., hyperkalemia)Toxicological Considerations\nIncreased risk toxicity renally excreted substances\nReduced effectiveness antidotes\nIncreased risk toxicity renally excreted substancesReduced effectiveness antidotesDisease Examples\nChronic Kidney Disease (CKD)\nAcute Kidney Injury (AKI)\nNephrotic Syndrome\nChronic Kidney Disease (CKD)Acute Kidney Injury (AKI)Nephrotic Syndrome","code":""},{"path":"disease-correlation-10.html","id":"cardiovascular-disease","chapter":"Disease Correlation","heading":"Cardiovascular Disease","text":"Mechanism Impact\nReduced cardiac output\nImpaired drug distribution\nAltered hepatic renal blood flow\nReduced cardiac outputImpaired drug distributionAltered hepatic renal blood flowCommonly Affected Substances\nDigoxin\nAntiarrhythmics\nBeta-blockers\nDigoxinAntiarrhythmicsBeta-blockersTypical Laboratory Findings\nElevated cardiac enzymes (troponin, CK-MB)\nAbnormal electrocardiogram (ECG)\nElevated cardiac enzymes (troponin, CK-MB)Abnormal electrocardiogram (ECG)Toxicological Considerations\nIncreased sensitivity cardiotoxic substances\nAltered drug pharmacokinetics\nIncreased sensitivity cardiotoxic substancesAltered drug pharmacokineticsDisease Examples\nCongestive Heart Failure (CHF)\nIschemic Heart Disease\nCongestive Heart Failure (CHF)Ischemic Heart Disease","code":""},{"path":"disease-correlation-10.html","id":"pulmonary-disease","chapter":"Disease Correlation","heading":"Pulmonary Disease","text":"Mechanism Impact\nImpaired gas exchange\nReduced pulmonary clearance\nIncreased susceptibility respiratory irritants\nImpaired gas exchangeReduced pulmonary clearanceIncreased susceptibility respiratory irritantsCommonly Affected Substances\nInhaled toxins (e.g., carbon monoxide, smoke)\nDrugs cause pulmonary toxicity (e.g., amiodarone, bleomycin)\nInhaled toxins (e.g., carbon monoxide, smoke)Drugs cause pulmonary toxicity (e.g., amiodarone, bleomycin)Typical Laboratory Findings\nAbnormal arterial blood gases (ABGs)\nDecreased oxygen saturation\nAbnormal chest X-ray CT scan\nAbnormal arterial blood gases (ABGs)Decreased oxygen saturationAbnormal chest X-ray CT scanToxicological Considerations\nIncreased risk respiratory complications\nImpaired clearance inhaled toxins\nIncreased risk respiratory complicationsImpaired clearance inhaled toxinsDisease Examples\nChronic Obstructive Pulmonary Disease (COPD)\nAsthma\nPneumonia\nChronic Obstructive Pulmonary Disease (COPD)AsthmaPneumonia","code":""},{"path":"disease-correlation-10.html","id":"neurological-disorders","chapter":"Disease Correlation","heading":"Neurological Disorders","text":"Mechanism Impact\nIncreased permeability blood-brain barrier (BBB)\nAltered neurotransmitter function\nIncreased susceptibility neurotoxic substances\nIncreased permeability blood-brain barrier (BBB)Altered neurotransmitter functionIncreased susceptibility neurotoxic substancesCommonly Affected Substances\nDrugs affect central nervous system (CNS)\nNeurotoxins (e.g., heavy metals, organophosphates)\nDrugs affect central nervous system (CNS)Neurotoxins (e.g., heavy metals, organophosphates)Typical Laboratory Findings\nAbnormal neurological examination\nElevated intracranial pressure\nAbnormal brain imaging (CT MRI)\nAbnormal neurological examinationElevated intracranial pressureAbnormal brain imaging (CT MRI)Toxicological Considerations\nIncreased risk seizures, coma, neurological complications\nAltered response antidotes\nIncreased risk seizures, coma, neurological complicationsAltered response antidotesDisease Examples\nEpilepsy\nAlzheimer’s Disease\nParkinson’s Disease\nEpilepsyAlzheimer’s DiseaseParkinson’s Disease","code":""},{"path":"disease-correlation-10.html","id":"nutritional-deficiencies","chapter":"Disease Correlation","heading":"Nutritional Deficiencies","text":"Mechanism Impact\nImpaired detoxification pathways\nIncreased susceptibility oxidative stress\nAltered drug metabolism\nImpaired detoxification pathwaysIncreased susceptibility oxidative stressAltered drug metabolismCommonly Affected Substances\nAcetaminophen: Increased risk hepatotoxicity glutathione deficiency\nAlcohol: Increased susceptibility liver damage malnutrition\nAcetaminophen: Increased risk hepatotoxicity glutathione deficiencyAlcohol: Increased susceptibility liver damage malnutritionTypical Laboratory Findings\nLow serum levels vitamins minerals\nElevated homocysteine levels\nLow serum levels vitamins mineralsElevated homocysteine levelsToxicological Considerations\nIncreased vulnerability toxic effects various substances\nImpaired ability metabolize eliminate toxins\nIncreased vulnerability toxic effects various substancesImpaired ability metabolize eliminate toxinsDisease Examples\nMalnutrition\nVitamin Deficiencies\nMalnutritionVitamin Deficiencies","code":""},{"path":"disease-correlation-10.html","id":"genetic-factors","chapter":"Disease Correlation","heading":"Genetic Factors","text":"Mechanism Impact\nGenetic polymorphisms drug-metabolizing enzymes drug transporters\nAltered drug metabolism excretion\nGenetic polymorphisms drug-metabolizing enzymes drug transportersAltered drug metabolism excretionCommonly Affected Substances\nDrugs metabolized CYP2C9, CYP2C19, CYP2D6, polymorphic enzymes\nDrugs metabolized CYP2C9, CYP2C19, CYP2D6, polymorphic enzymesTypical Laboratory Findings\nPharmacogenetic testing can identify specific genotypes\nPharmacogenetic testing can identify specific genotypesToxicological Considerations\nIndividuals certain genotypes may susceptible toxicity altered responses antidotes\nIndividuals certain genotypes may susceptible toxicity altered responses antidotesExamples\nCYP2D6 polymorphisms affecting opioid metabolism\nNAT2 polymorphisms affecting isoniazid metabolism\nCYP2D6 polymorphisms affecting opioid metabolismNAT2 polymorphisms affecting isoniazid metabolism","code":""},{"path":"disease-correlation-10.html","id":"the-importance-of-history-and-exam","chapter":"Disease Correlation","heading":"The Importance of History and Exam","text":"proper assessment drug levels relate disease done :\n* Obtaining thorough history patient\n* Completing full physical examinationExamples\n* Asking patients taken additional pain fever reducers acetaminophen toxicity suspected can help guide treatment\n* Asking patients noticed visual halos digoxin toxicity suspectedThese factors overlooked properly assess toxicology results","code":""},{"path":"disease-correlation-10.html","id":"summary-table-of-disease-state-correlation-1","chapter":"Disease Correlation","heading":"Summary Table of Disease State Correlation","text":"","code":""},{"path":"disease-correlation-10.html","id":"key-terms-94","chapter":"Disease Correlation","heading":"Key Terms","text":"Pharmacokinetics: study body affects drug (ADME)Toxicokinetics: study toxic substance moves bodyDrug Interaction: effect one drug pharmacokinetics pharmacodynamics another drugGenotype: genetic makeup individualPhenotype: observable characteristics individual, resulting interaction genotype environmentEnzyme Induction: Increased activity drug-metabolizing enzymesEnzyme Inhibition: Decreased activity drug-metabolizing enzymesHalf-Life: time takes concentration drug body reduced one-halfClearance: measure body’s ability eliminate drug bodyVolume Distribution: Apparent space body available contain drugToxidrome: group signs symptoms consistently associated specific condition resulting exposure particular substanceMedical Toxicology: Branch medicine focused adverse effects chemicals drugs","code":""}]
